

STIC-Biotech/ChemLib

91802

From: Whiteman, Brian  
Sent: Friday, April 18, 2003 10:19 AM  
To: STIC-Biotech/ChemLib  
Subject: seq search

09/729,264 11/26/00 Welcher et al.

search seq id nos 1, 3, and 5 against us patent and us patent application databases.

search seq id nos 2, 4, and 6 against us patent and us patent application databases.

Thanks,  
Brian Whiteman, 11e12  
Patent Examiner - Art Unit 1635  
United States Patent and Trademark Office  
Crystal Mall 1, 11A16  
(703) 305-0775

Mary Jane Ruhl  
Tech. Info. Specialist, STIC  
TC-1600  
CM-1, Room 6A-06  
Phone: 605-1155

Searcher: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Location: \_\_\_\_\_  
Date Picked Up: \_\_\_\_\_  
Date Completed: 4/30/03  
Searcher Prep/Review: \_\_\_\_\_  
Clerical: \_\_\_\_\_  
Online time: \_\_\_\_\_

TYPE OF SEARCH:  
NA Sequences: \_\_\_\_\_  
AA Sequences: \_\_\_\_\_  
Structures: \_\_\_\_\_  
Bibliographic: \_\_\_\_\_  
Litigation: \_\_\_\_\_  
Full text: \_\_\_\_\_  
Patent Family: \_\_\_\_\_  
Other: \_\_\_\_\_

VENDOR/COST (where applic.)  
STN: \_\_\_\_\_  
DIALOG: \_\_\_\_\_  
Questel/Orbit: \_\_\_\_\_  
DRLink: \_\_\_\_\_  
Lexis/Nexis: \_\_\_\_\_  
Sequence Sys.: \_\_\_\_\_  
WWW/Internet: \_\_\_\_\_  
Other (specify): \_\_\_\_\_



Wed Apr 30 10:00:21 2003

us-09-729-264-2.rsp1

GenCore version 5.1.4-p5.4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 28, 2003, 16:24:32 ; Search time 36.7435 seconds  
(without alignments)  
2142.147 Million cell updates/sec

Title: US-09-729-264-2

Perfect score: 2059 1 MGIVFLHSGSGNEVIEGP.....HPQASEFNLAPEKYSNTTV 382

Sequence: BLOSUM62

Scoring table: Gapop 10.0, Gapext 0.5

Searched: 671580 seqs, 206047115 residues 671580

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

SPREMBL\_21:\*

- 1: sp\_archaea:\*
- 2: sp\_bacteria:\*
- 3: sp\_fungi:\*
- 4: sp\_human:\*
- 5: sp\_invertebrate:\*
- 6: sp\_mammal:\*
- 7: sp\_mhc:\*
- 8: sp\_organelle:\*
- 9: sp\_phage:\*
- 10: sp\_plant:\*
- 11: sp\_rodent:\*
- 12: sp\_virus:\*
- 13: sp\_vertebrate:\*
- 14: sp\_unclassified:\*
- 15: sp\_rvtnus:\*
- 16: sp\_bacteriopl:\*
- 17: sp\_archaeop:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1694	82.3	315	4 Q9NS15	Q9NS15 homo sapien
2	575.5	28.0	270	11 Q9DB62	Q9DB62 mus musculu
3	141	168	11	Q9DP92	Q9DP92 mus musculu
4	136.5	6.6	173	11 Q9D4K2	Q9D4K2 mus sapien
5	135	6.6	1496	4 Q92626	Q92626 xenopus lae
6	133	6.5	1427	13 Q91562	Q91562 gallus gall
7	132.5	6.4	344	13 Q9DF61	Q9DF61 mus musculu
8	131	6.4	697	11 Q9DBP0	Q9DBP0 mus musculu
9	131	6.4	697	11 Q92290	Q92290 mus musculu
10	129.5	6.3	315	5 Q22048	Q22048 caenorhabdi
11	127.5	6.2	315	13 Q9DP15	Q9DP15 mus musculu
12	127.5	6.2	344	11 Q99P10	Q99P10 mus musculu
13	127.5	6.2	344	13 Q93242	Q93242 gallus gall
14	127.5	6.2	871	11 Q61987	Q61987 mus musculu
15	127.5	6.2	881	11 Q61988	Q61988 mus musculu
16	127	6.2	197	5 Q17641	Q17641 caenorhabdi

17	127	6.2	1445	11	Q63155	Q15146 homo sapien
18	126.5	6.1	869	4	Q15146	Q15146 homo sapien
19	126	6.1	313	13	Q57596	Q57596 gallus gall
20	125.5	6.1	166	5	Q950Y1	Q950Y1 caenorhabdi
21	125.5	6.1	6632	5	Q01761	Q01761 caenorhabdi
22	123.5	6.0	344	4	Q9P121	Q9P121 homo sapien
23	123.5	6.0	6620	4	Q96AA2	Q96AA2 homo sapien
24	122.5	5.9	188	4	Q18238	Q18238 caenorhabdi
25	122.5	5.9	455	4	Q9NR0	Q9NR0 homo sapien
26	120	5.8	959	5	Q9N9Y9	Q9N9Y9 drosophila
27	120	5.8	968	5	Q9W4T9	Q9W4T9 drosophila
28	120	5.8	975	5	Q9J174	Q9J174 drosophila
29	119	5.8	695	11	Q9J008	Q9J109 rattus norv
30	118	5.7	275	11	Q9JK39	Q9JK39 mus musculus
31	117.5	5.7	390	4	Q9H1X9	Q9H1X9 homo sapien
32	117.5	5.7	5636	4	Q96RW7	Q96RW7 homo sapien
33	117.5	5.7	325	6	Q02838	Q02838 sus scrofa
34	116.5	5.7	2221	5	Q9W4U1	Q9W4U1 drosophila
35	116	5.6	345	5	Q9H3V5	Q9H3V5 homo sapien
36	116	5.6	4370	4	Q9H362	Q9H362 caenorhabdi
37	115	5.6	6632	5	Q17362	Q17362 caenorhabdi
38	115.5	5.6	196	4	Q9H0T1	Q9H0T1 homo sapien
39	114.5	5.6	152	5	Q9YVX3	Q9YVX3 caenorhabdi
40	114	5.5	46	4	Q16861	Q16861 homo sapien
41	114	5.5	327	4	Q96107	Q96107 homo sapien
42	114	5.5	569	11	Q920G3	Q920G3 mus musculu
43	114	5.5	1395	5	Q44924	Q44924 drosophila
44	114	5.5	1395	5	Q9W213	Q9W213 drosophila
45	114	5.5	2673	4	Q96SC3	Q96SC3 homo sapien

## ALIGNMENTS

RESULT	1	PRELIMINARY:	PRT:	315 AA.
Q9NS15	Q9NS15	Q9NS15		
AC	01-OCT-2000 (TREMBLrel. 15, Created)			
DT	01-OCT-2000 (TREMBLrel. 15, Last sequence update)			
DT	01-DEC-2001 (TREMBLrel. 19, Last annotation update)			
DE	IGSF5 protein (Fragment).			
GN	IGSF5.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RA	Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.S.,			
RA	Noyoda A., Ishii K., Totsuki Y., Choi D.K., Soeda E., Ohki M.,			
RA	Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A.,			
RA	Wenzel U., Delabar J., Rumpf K., Lehmann R., Patterson D.,			
RA	Reichwald K., Rump A., Schillabel M., Schudy A., Zimmermann W.,			
RA	Rosenthal A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,			
RA	Shintani A., Shimizu N., Nordlek G., Hornischer K., Brandt P.,			
RA	Minoshima S., Schoen O., Desario A., Reichelt J., Kauer G., Bloeker H.,			
RA	Scharfe M., Schenck A., Klages S., Hennig S., Rieselmann L., Dagand E.,			
RA	Kammer J., Beck A., Klages S., Gardiner K., Nizetic D., Francis F.,			
RA	Wehmer S., Borzym K., Gardiner K., Yaspo M.L.,			
RA	Lehrach H., Reinhardt R., Yaspo M.L.,			
RL	Submitted (MAY-2000) to the EMBL/GenBank/DBJ databases.			
DR	EMBL: AL163280; CAB90447.1;			
DR	InterPro: IPR000561; EGF-like.			
DR	InterPro: IPR003599; IGF.			
DR	InterPro: IPR003066; IGF-MHC.			
DR	Pfam: PF00047; IGF_2.			
DR	SMART: SM00409; IGF_1; UNKNOWN_1.			
DR	PROSITE: PS00022; EGF_1; UNKNOWN_1.			
FT	NON_TER	1		
FT	NON_TER	315		
FT	SEQUENCE	315 AA;	34599 MW;	B69DCB23570FA3D1 CRC64;

DR Interpro: IPR003599; Ig.  
 DR Interpro: IPR003006; Ig\_MHC.  
 DR SMART: SM00409; Ig; 1.  
 DR PROSITE: PS00290; Ig\_MHC; UNKNOWN.1.  
 SO SEQUENCE 270 AA; 29604 MW; A39C273DAA950DFE CRC64;  
 Query Match 28.0%; Score 575.5; DB 11; Length 270;  
 Best Local Similarity 35.1%; Pred. No. 2.3e-44;  
 Matches 136; Conservative 42; Mismatches 73; Indels 137; Gaps

QY 3 LVYF--LHSSGSQNEVIGPONATVYLGKSGARFCVTYSQSGKLTLMALSDMYLVSVRPME 60  
 DB 12 LVTLAQLTASGSSVQIIEGPPQNVTLKDSAEHFNCTYTHKTKLMTLQNMVYLSLTGG 71  
 QY 61 PIIITDRTISQRYDQGGNFTESEMIYHNVPSDSGNIRCSLQNSRLGSAVYLVQVWGELEF 120  
 DB 72 PIIITNRTYASYNSTDSFTSELIHDYQPSDSGVSQSLQNSHGSGSAFLSVQ----- 125  
 QY 121 IPSNVLYVAENEPEVYCLPSSHWRCLPDISWELGLVSHSYFVPEPSSDQSAVSIILAL 180  
 DB 126 ----- 125  
 QY 181 TPQSNGTITFCVATMKSLKARKSATVNLVYIRCPDPTGGGINIPGLVSLSPSGSLPTWG 240  
 DB 126 ----- 125  
 QY 241 KVGIGLAGTMTLPTCTLTIRCCCRRRCCGCCNCCRCCKRKGRIQFO---KKSE 297  
 DB 140 IILLAVPSLLILITLVIIIFCCC-----CASRKEKESTYQETIRKSA 184  
 QY 298 KEKTKK---ELETSGNENSGYNSDEOKTDPASLSPKSCESSDPQRNNSCGPPHORAD 354  
 DB 185 NMRTKKADEPKELKLSGKENGYSSDEAKAQTGSLSPKSAEVLSPKRSSSL--PYQELN 242  
 QY 355 QRPRPASHPOASFNLASPEKYSNTYV 382  
 DB 243 KHQPPATHPRVSEFDIASPQKVRNVILV 270

RESULT 3  
 09D912  
 ID 09D912 PRELIMINARY; PRT; 168 AA.  
 AC 09D912;  
 DT 01-JUN-2001 (Tremblrel. 17, Created)  
 DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)  
 DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
 DE 4931420D14Rik protein.  
 GN 4931420D14Rik.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 CX NCBI\_TaxId=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=TESTIS.  
 RX MEDLINE=1085660; PubMed=11217851;  
 RA Kawai T., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
 RA Arakawa T., Hara A., Fukunishi Y., Kono H., Adachi J., Fukuda S.,  
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaoka I.,  
 RA Kadota T., Okazaki Y., Gojobori T., Bono H., Kasuura T., Saito R.,  
 RA Fleitschmann W., Gaasterland T., Gissi C., Kiang B., Casavani T.,  
 RA Kuehl P., Lewis S., Matsuo Y., Nikido I., Pesole G., Quackenbush J.,  
 RA Schiomi L.M., Staudt F., Suzuki R., Tomita M., Wagner L., Washio T.,  
 RA Sakai K., Okido T., Futuno M., Anono H., Baldarelli R., Barsh G.,  
 RA Blake J., Botfield D., Boljuna N., Cantlinci P., de Bonaldo M.F.,  
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
 RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,  
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Saito K., Sasaki H., Sato K.,  
 RA Sasaki H., Sato K., Ringwald M., Rodriguez I., Saito K., Sasaki H., Sato K.,





FT NON\_TER 1 1  
 SQ SEQUENCE 1496 AA; 167209 MW; E9B9A7069BFLABFF CRC64;

Query Match  
 Best Local Similarity 25.08; Score 135; DB 4; Length 1496;  
 Matches 73; Conservative 36; Mismatches 127; Indels 56; Gaps 15;

QY 9 GSGSNEVIEGPNATVYKGSQAFNCTVS--QCGKLIMALLSDMVLSRPMELITNDR 67  
 DB 354 GSPARPEFVIOPTTEVLVAGESVTLBESATGHPRIISMTGRPLPDPFRNITPS-- 411  
 QY 68 FTSORYOGGNTSEMIIHNPESDSGNIRCSLONS--RLHGSAYLTVQMGELFLPSVN 125  
 DB 412 -----GG-----LTIQNVVQDSDGEYACASATNNIDSVHATFLIYQALQFVITPD 458  
 QY 126 LVVAENPECEVTLPSHMTRLPDISW--ELGLVSHSSYFVEPEPDSQANSIATLPQS 184  
 DB 459 RVVIEGQTVDFQC--EAKGNPPPIAMTKGSLSDVRHLVLSGTLR--ISGVALHDO- 514  
 QY 185 NGTLTCVATWKSARKSATVNLTV-----INCPDPT---GGGINIFVLSLPSL 232  
 DB 515 -GGYECQAV--NIGSQKVAHLTVQPRVTPYFASIPSDTVEVGANYQLP-----CSSQ 566  
 QY 233 GFSLP--TWGKVGGLI--AGTMLIPCTCTLT-----RCCGCRRCGC 271  
 DB 567 GEPERATWKNKDGVOYTESGKFKHISPEGFLITINDGADAGRYCVARNITG 618

RESULT 6

Q91562 PRELIMINARY; PRT; 1427 AA.

AC Q91562;  
 DT 01-NOV-1996 (TREMBLrel. 01, Created)  
 DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)  
 DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)  
 DE Tumor suppressor.  
 GN XCCA.  
 OS Xenopus laevis (African clawed frog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidea; Pipidae;  
 OC Xenopodidae; Xenopus.  
 OX NCBI\_Taxid=8355;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=95113183; PubMed=7813784;  
 RA Pierceall W.E.; Reale M.A.; Candia A.F.; Wright C.V.; Cho K.R.;  
 RA Featon E.R.;  
 RT "Expression of a homologue of the deleted in colorectal cancer (DCC)  
 gene in the nervous system of developing Xenopus embryos."  
 RL Dev. Biol. 166:654-665(1994).  
 DR EMBL; U10986; AAA70168.1;-.  
 DR HSSP; P40189; 180V.  
 DR InterPro; IPR003962; FNIII\_repeat.  
 DR InterPro; IPR003961; FN\_III.  
 DR InterPro; IPR003598; IG\_C2.  
 DR InterPro; IPR003600; IG\_1like.  
 DR InterPro; IPR003006; IG\_MHC.  
 DR Pfam; PF00047; fn3; 6.  
 DR PRINTS; PR00014; FNTYPEIIT.  
 DR SMART; SM00060; FN3; 6.  
 DR SMART; SM00408; IG\_C2; 3.  
 DR SMART; SM00410; IG\_1like; 2.  
 DR Immunoglobulin domain; Repeat.  
 KW SEQUENCE 1427 AA; 156533 MW; 61FEA12C8A674972 CRC64;

Query Match  
 Best Local Similarity 25.7%; Score 133; DB 13; Length 1427;  
 Matches 59; Conservative 33; Mismatches 90; Indels 48; Gaps 13;

QY 17 IESPNATVYKGSQAFNCTVSGW--KLIMALLSDMVLSRPMELITNDRFSORYD 74  
 DB 243 LQPSNVVAIEGDVAVLECAVS--GYPTPTIWMQD-----EPVPIRTR---KYS 288

QY 75 QGNETSEMIIHNPESDSGNIRC--SLONSRLHGSAYLTVQMGELFLPSVNLVAENE 132  
 DB 289 VLGG--SNLLISNTDDEACAYTCVAKNNTSFSADLTVMPPQFLHNPANLVAYESM 346  
 QY 133 PCEVTC---PSHMTRLPDISW--ELGLVSHSSYFVEPEPDSQANSIATLPQSGT 187  
 DB 347 DIEECVASKGPS---PTVKWTKNGEVYIPSDYQIYDGSNLR---ILGLVNSDEGY 397  
 QY 188 LTCVA-----TWKSLARKSATVNLVI--RCPDTEGGINIEGVLS 228  
 DB 398 YOCIAENENGIQTYAQILIPDPAVPSILPSADRV-----VPLVSS 442

RESULT 7

Q9DF61 PRELIMINARY; PRT; 344 AA.

AC Q9DF61;  
 DT 01-MAR-2001 (TREMBLrel. 16, Created)  
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)  
 DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)  
 DE OBKAM alpha 1 isoform.  
 GN OBKAM.  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 OX NCBI\_Taxid=9031;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX TISSUE-BRAIN.  
 RX MEDLINE=2049204; PubMed=11042360;  
 RA Lodge A.P.; Howard M.R.; McNamee C.J.; Moss D.J.;  
 RT "Co-localisation, heterophilic interactions and regulated expression  
 of Irgon family proteins in the chick nervous system."  
 RL Brain Res. Mol. Brain Res. 82:84-94(2000).  
 DR EMBL; AF292934; AAG01877.1;-.  
 DR InterPro; IPR003599; IG\_C2.  
 DR InterPro; IPR003598; IG\_1like.  
 DR InterPro; IPR003600; IG\_1like.  
 DR InterPro; IPR003006; IG\_MHC.  
 DR Pfam; PF00047; Ig; 3.  
 DR SMART; SM00409; IG; 3.  
 DR SMART; SM00408; IG\_C2; 3.  
 DR SMART; SM00410; IG\_1like; 2.  
 KW Immunoglobulin domain.  
 SQ SEQUENCE 344 AA; 37531 MW; 37FE6051CBF0E7B4 CRC64;

Query Match  
 Best Local Similarity 25.5%; Score 132.5; DB 13; Length 344;  
 Matches 70; Conservative 38; Mismatches 104; Indels 63; Gaps 16;

QY 4 VIFLHSG---SGNEVI--EGPNATVYKGSQAFNCTVSQCGKLIMALLSDMVLSRPMELITNDRFSORYD 74  
 DB 21 LFLVPAAGVPRSGDATFRAMDVITYRQGESATLCTYDDRVRAVA--LNSSTILYGN 79  
 QY 55 ---SVRPMELITNDRFSORYDQGNFTSEMIIHNPESDSGNIRCSLONS--RL 105  
 DB 80 DKMSIDNRVILSN---TKTY-----SIKIHVDYDGGPYTCGQDINHKTSTRV 128  
 QY 106 HGSAYLTVQMGELFLPSVNLVAENPECVCL---PSHMTRLPDISWELGLVSHSS 161  
 DB 129 H---LIVQVPQIVNISSDIYNESSSTVLMCLAFGRE---PVTWR---HLSGKG 176  
 QY 162 YFVPEPDSQANSIATLPQSGTLTCVATWKSARKSATVNLVI-----IRCPDPT 216  
 DB 177 QGVSDEDEYLE---ITGTREOSGEYECASAV--NDVAAPDVRAKRYVNYNPPYISNAKNT 231  
 QY 217 GGGINIPGVL-----SLPSLGSFLPTWKGVLGUA 247  
 DB 232 GASVGGKGILOCEASAVVAERQ---WFKEDTRLA 263

## RESULT 8

O9DBPO PRELIMINARY: PRT: 697 AA.

AC 09DBPO: 01-JUN-2001 (TREMBlrel. 17, Created)  
 DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)  
 DT 01-JUN-2002 (TREMBlrel. 21, Last annotation update)  
 DE Solute carrier family 34 (sodium phosphate), member 2.  
 GN SLC34A2.

OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 NCBI\_Taxid=10090;

RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=LUNG;  
 MEDLINE=21085660; PubMed=11217851;

RA Kawai J., Shingawa A., Shibata K., Yoshino M., Itoh M., Ishi Y.,  
 RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,  
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Imanaka I.,  
 RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,  
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
 RA Pleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,  
 RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,  
 RA Schirml L.M., Staudl F., Suzuki R., Tomita M., Wagner L., Washio T.,  
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,  
 RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,  
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
 RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,  
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
 RA Nordone P., Ring B., Ringwald C., Seye T., Shibata Y., Storch K.F.,  
 RA Sasaki H., Sato K., Schoenbach C., Seye T., Shibata Y., Storch K.F.,  
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whitaker C., Wilmink L.,  
 RA Wyszawski A., Yoshida K., Hasegawa Y., Kawaji H., Kotsuki S.,  
 RA Hayashizaki Y.;  
 RT "Functional annotation of a full-length mouse cDNA collection."  
 RL Nature 409:685-690(2001).  
 DR EMBL; AK004832; BAB33600.1;  
 DR MGD; MGI:1342284; Slc34a2.  
 DR InterPro; IPR003841; Na\_P1\_cotrans.  
 DR Pfam; PF02690; Na\_P1\_cotrans; 1.  
 DR Trifams; TIGR01013; 2a58; 1.  
 SQ SEQUENCE 697 AA; 76244 MW; 2A7B9384857EF16F CRC64;

Query Match 6.4%; Score 131; DB 11; Length 697;  
 Best Local Similarity 20.6%; Pred. No. 0.0028;  
 Matches 89; Conservative 51; Mismatches 123; Indels 168; Gaps 23;

OY 3 LVIFLHSGSGNEVIEGPONATVLK-----GSOARFNCVSG 40  
 DB 382 MYVLLGS-----VLRG-QVATVYIKKTLNTDPPFPAMLTGYLAILVAGMTEIYVSSSV 435  
 OY 41 WKLIKALSDMWVLSVRPEPIITNDRTSQRDQGNFTSEMIHNVPSDGNIRCSL 100  
 DB 436 FTSAMTPLLIGIVISIERAYPLTGSNI-----GTTTITAILALASGNT--LRSSL 485  
 OY 101 ONSRLGSAVLYQVVGELFIPSVNLVVAENPECVTCLPSHWTRLP-----DIS-- 150  
 DB 486 QIALCH-----FFFNISGI-----LWYPIPTRLPIRLAKGLGNISAK 524  
 OY 151 --WEIGLVSHSSYVVPESDQSAVSILALTPQNSGTLTCAVATKSLKARSAVNL 208  
 DB 525 YRW--FAVYLLFFEFVTP-----LTVRGLS-----LAGMVLVGVGPITILL 566  
 OY 209 VI-----RCPODGGGINIPGVL--SSPLSLGFSLPTWKGVLGLAGTMLLPTC 256  
 DB 567 LTVLCRLMLOFRCP-----ILPKLRDWNPLPLMWHSLKPMDNV-----ISLATTC 613  
 OY 257 TLTIRCCCCRRRCG-----CNC-CCRCCFCRCRRKRGFRIFQFKSKEKTNETIESG 310  
 DB 614 -FORRCCCCRCVCCVCCVCCGCKCCKCCKR-----DQG 648  
 OY 311 NENSGYNSDQKTTDTASLPPKSCSSDPEGRNSGCPPHORADORPPRASHQASFN 370

DB 649 EE-----EERKQD--IPVKASGAFDNAMAKREC-----QDEKQGVYV 685

OY 371 ASPEKVSNTTV 381  
 DB 686 LSMKALSTTV 696

## RESULT 9

O92290 PRELIMINARY: PRT: 697 AA.

AC 092290;  
 DT 01-MAY-1999 (TREMBlrel. 10, Created)  
 DT 01-MAY-1999 (TREMBlrel. 10, Last sequence update)  
 DT 01-JUN-2002 (TREMBlrel. 21, Last annotation update)  
 DE Type IIB Na/phosphate-cotransporter.  
 GN SLC34A2 OR NPT2B.

OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 NCBI\_Taxid=10090;

RP SEQUENCE FROM N.A.  
 RC STRAIN=NMRI; TISSUE=SMALL INTESTINE;  
 MEDLINE=99045724; PubMed=9826740.

RA Hilfinger H., Hattenhauer O., Traebert M., Forster I., Murer H.,  
 RA Biber J.;  
 RT "Characterization of a murine type II sodium-phosphate cotransporter  
 expressed in mammalian small intestine."  
 RL Proc. Natl. Acad. Sci. U.S.A. 95:14564-14569(1998).

DR EMBL; AF081499; AAC80007.1;  
 DR MGD; MGI:1342284; Slc34a2.  
 DR InterPro; IPR003841; Na\_P1\_cotrans.  
 DR Pfam; PF02690; Na\_P1\_cotrans; 1.  
 DR Trifams; TIGR01013; 2a58; 1.  
 SQ SEQUENCE 697 AA; 76286 MW; 839E5CCB0F565265 CRC64;

Query Match 6.4%; Score 131; DB 11; Length 697;  
 Best Local Similarity 20.6%; Pred. No. 0.0028;  
 Matches 89; Conservative 51; Mismatches 123; Indels 168; Gaps 23;

OY 3 LVIFLHSGSGNEVIEGPONATVLK-----GSOARFNCVSG 40  
 DB 382 MYVLLGS-----VLRG-QVATVYIKKTLNTDPPFPAMLTGYLAILVAGMTEIYVSSSV 435  
 OY 41 WKLIKALSDMWVLSVRPEPIITNDRTSQRDQGNFTSEMIHNVPSDGNIRCSL 100  
 DB 436 FTSAMTPLLIGIVISIERAYPLTGSNI-----GTTTITAILALASGNT--LRSSL 485  
 OY 101 ONSRLGSAVLYQVVGELFIPSVNLVVAENPECVTCLPSHWTRLP-----DIS-- 150  
 DB 486 QIALCH-----FFFNISGI-----LWYPIPTRLPIRLAKGLGNISAK 524  
 OY 151 --WEIGLVSHSSYVVPESDQSAVSILALTPQNSGTLTCAVATKSLKARSAVNL 208  
 DB 525 YRW--FAVYLLFFEFVTP-----LTVRGLS-----LAGMVLVGVGPITILL 566  
 OY 209 VI-----RCPODGGGINIPGVL--SSPLSLGFSLPTWKGVLGLAGTMLLPTC 256  
 DB 567 LTVLCRLMLOFRCP-----ILPKLRDWNPLPLMWHSLKPMDNV-----ISLATTC 613  
 OY 649 EE-----EERKQD--IPVKASGAFDNAMAKREC-----QDEKQGVYV 685  
 OY 371 ASPEKVSNTTV 381  
 DB 686 LSMKALSTTV 696

Query Match	6.2%	Score 127.5	DB 13	Length 315
Best Local Similarity	25.4%	Pred. No. 0.0021		
Matches 68	Conservative 41	Mismatches 98	Indels 61	Gaps 15
4 VITLHSGSG--SGNEVT-EGFQNAVLYKSGOARFCTVSO-----GW---KLIMALSD 50				
21 LELVLPVAGPVNSGDTTFPKRNDANTVQGSATLRCSDVDRYTRVAMLRSSILYAOND 80				
51 MVLVSRPEPIITNDRETSQRHYDGGNFTSEMIIHNVPEPDSGNINCSIQ-----NDR 104				
81 KWLIDLPRVVLNFTKQYSIQ-----IHDDVYIDSEPTFYCSVOTDNEHKTSR 127				
105 LHGSATVLTQVNGELFISVNIYVAENPECVYTLPSHMTRLPD--ISWELGLVSSSY 162				
128 VH---LIVVSPKTTETISDLSISINEGNVSLTIA--TGRDPTITWR--HISPKAV 177				
163 YEVPEPDSQSASVSLATLPQSNGLTNCVAAWKSILTKRKASATVNLIV-----TRCDPDG 217				
178 GFISEDEYLE---ITGITREGSGEYCSAS-NDVAPVYQKAKYIVNPPYISDAKSTG 232				
218 GGINIPGVY---SSLPSLGGSLPTWKG 241				
233 VEVGOKGILMCEASAVPSADFQ---WYK 257				
RESULT 12				
Q99PJ0 PRELIMINARY; PRT: 344 AA.				
Q99PJ0				
01-JUN-2001 (TREMBlrel. 17, Created)				
01-JUN-2001 (TREMBlrel. 17, Last sequence update)				
01-DEC-2001 (TREMBlrel. 19, Last annotation update)				
Neurotrophin.				
Mus musculus (Mouse).				
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.				
NCL_TaxId=10090;				
SEQUENCE FROM N.A.				
STRAIN=ICR; TISSUE=BRAIN;				
Kim T.H., Choi S.C., Kim J.W., Kim K.D., Lee S.H.;				
"Cloning and expression of mouse neurotrophin gene in the developing				
neurotic system."				
Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.				
EMBL, AF29236; AAK00276.1; ..				
InterPro: IPR003599; Ig.				
InterPro: IPR003598; Ig_C2.				
InterPro: IPR003600; Ig_Like.				
InterPro: IPR003006; Ig_MHC.				
Pfam: PF00047; Ig_3.				
SMART: SM00409; Ig_3.				
SMART: SM00408; ICG2; 3.				
SMART: SM00410; Ig_Like; 2.				
Immunoglobulin domain.				
SEQUENCE 344 AA; 37924 MW; 3EC6D5EB6C5C17D CRC64;				

QY 4 VIFLHSG-----SGNEVI-EGPONAIVLKSGSARFNCTVSQGMKILMALSDMYLVSVP 58  
 Db 21 LFLVPTGVPVRSRSDATPPKAMDNVTVROGESATLRCTIDNRVRYVAMLNSTI-----74  
 QY 59 MEPIITNDNF-TSORYDOGNFTSE--MIINVEPSDSGNIRCSIQ-----NSRLHGA 109  
 Db 75 --PYANDKWCMDPRVLLGNTOTQYSEIIONVDYDEGPTCSVQIDNHPKTSRVH---129  
 QY 110 YLVQVYMGELFIPSVMLVVAENEPCEVCLPSPHTRLPDISWELGLVSHSSYFVPEPS 169  
 Db 130 -LIVQVSPKIVELISDISINEGNISLTICIAGRE-PIVTRW---HISPKAVGEVSEDE 184  
 QY 170 DLSAVSIALATPQSGNGLTVCAVTKMSLKARSAVNLTVICP-----QDTGGGINLP 224  
 Db 185 YLQ-----IGITREQSEGEYECSSAS-NDVAAPVPRVKTVMNPPYSEAKGTGVVQKQ 239  
 QY 225 VL-----SLPSLGFSLPTWCK 241  
 Db 240 TLQCEASAVPSAEFO---WCK 257

## RESULT 13

093242 PRELIMINARY; PRT; 344 AA.  
 AC 093242  
 DT 01-NOV-1998 (TREMBLREL. 08, Created)  
 DT 01-NOV-1998 (TREMBLREL. 08, Last sequence update)  
 DT 01-DEC-2001 (TREMBLREL. 19, Last annotation update)  
 DE CEPU-1.  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 NCBI\_TaxID=9031;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Kiumura Y., Shirabe K., Fukushima M., Takeshita M., Tanaka H.;  
 RT "CEPU-1: an immunoglobulin Superfamily Molecule, Has Cell Adhesion  
 Activity and Shows Dynamic Expression Patterns in Chick Embryonic  
 RT Spinal Cord";  
 RL Submitted (MAR-1998) to the EMBL/Genbank/DBJ databases.  
 DR EMBL; AB011810; BAA31514.1; --  
 DR InterPro: IPR003398; I9\_C2.  
 DR InterPro: IPR003600; I9\_Like.  
 DR InterPro: IPR003006; I9\_MHC.  
 DR Pfam: PF00047; I9; 3.  
 DR SMART: SM00408; Igc2; 2.  
 DR SMART: SM00410; I9\_Like; 1.  
 DR Immunoglobulin domain.  
 KW SIGNAL; Transferrase.  
 FT SEQUENCE 344 AA; 37613 MW; 22CAAF526A857E CRC64;

Query Match 6.28; Score 127.5; DB 13; Length 344;  
 Best Local Similarity 25.44; Pred. No. 0.0023; Indels 61; Gaps 15;  
 Matches 68; Conservative 41; Mismatches 98;

QY 4 VIFLHSG-----SGNEVI-EGPONAIVLKSGSARFNCTVSQ-----GW---KLIMALSD 50  
 Db 21 LFLVPTGVPVRSRSDATPPKAMDNVTVROGESATLRCSVNRVRYVAMLNSTI-----NSR 104  
 QY 51 MYVLVSRMEPIITNDRTSQRYDOGNFTSEMIIHNEPSDSGNIRCSIQ-----NSR 162  
 Db 81 KMCCLDRVLLANTKTQYSIQ-----IHDDVYDEGPTCSVQIDNHPKTSR 127  
 QY 105 LHGSATLVQVNGELFIPSVNLVVAENEPCEVCLPSPHTRLPD--ISWELGLVSHSSY 162  
 Db 128 VH-----LIVQVSPKIVELISDISINEGNVSLTICIA--TGRPDTITWR---HISPKAV 177  
 QY 163 YFVPEPSDLSAVSIALATPQSGNGLTVCAVTKMSLKARSAVNLTV-----IRCPDPTG 217  
 Db 178 GFISEDEYLE-----IGITREQSEGEYECSSAS-NDVAAPVQVRYKTVNPPYISAKSTG 232  
 QY 218 GGINIGVL-----SLPSLGFSLPTWCK 241

Db 233 VEVGQGIIMCEASAVPSADFQ---WCK 257

## RESULT 14

061987 PRELIMINARY; PRT; 871 AA.  
 AC 061987  
 DT 01-NOV-1996 (TREMBLREL. 01, Created)  
 DT 01-NOV-1996 (TREMBLREL. 01, Last sequence update)  
 DT 01-MAR-2002 (TREMBLREL. 20, Last annotation update)  
 DE Nsk2 protein precursor.  
 GN MUSK OR NSK2.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE-MYOBLAST;  
 RA MEDLINE-9534951; PubMed-7624144;  
 RA Ganju P., Nalis E., Brennan J., Reith A.D.;  
 RT "Cloning and developmental expression of Nsk2, a novel receptor  
 RT tyrosine kinase implicated in skeletal myogenesis.";  
 RL Oncogene 11:281-290(1995).  
 CC -1-SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.  
 DR EMBL; X86444; CAA60165.1; --  
 DR HSP; P11362; IFGK.  
 DR MGP; MGI:103581; Musk.  
 DR InterPro: IPR002453; Beta.tubulin.  
 DR InterPro: IPR000719; Euk.pkinase.  
 DR InterPro: IPR000024; Fz\_domain.  
 DR InterPro: IPR003598; I9\_C2.  
 DR InterPro: IPR003600; I9\_Like.  
 DR InterPro: IPR003006; I9\_MHC.  
 DR InterPro: IPR002290; Ser\_thr\_pkinase.  
 DR InterPro: IPR001245; Tyr\_pkinase.  
 DR Pfam; PF001392; Fz; 1.  
 DR Pfam; PF00047; I9; 3.  
 DR Pfam; PF00069; pkinase; 1.  
 DR PRINTS; PR00109; TYRKINASE.  
 DR PRODOM; PD000001; Euk\_pkinase; 1.  
 DR SMART; SM00408; Igc2; 2.  
 DR SMART; SM00410; I9\_Like; 1.  
 DR SMART; SM00219; TYRK; 1.  
 DR PROSITE; PS50038; Fz; 1.  
 DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
 DR PROSITE; PS00108; PROTEIN\_KINASE\_DOM; 1.  
 DR PROSITE; PS00109; PROTEIN\_KINASE\_ST; 1.  
 DR PROSITE; PS00109; PROTEIN\_KINASE\_TYR; 1.  
 DR PROSITE; PS00228; TUBULIN\_B\_AUTOREG; 1.  
 DR APP-binding; Immunoglobulin domain; Serine/threonine-protein kinase;  
 KW SIGNAL; Transferrase.  
 FT SIGNAL 1 POTENTIAL.  
 FT SEQUENCE 871 AA; 97047 MW; F3C53DC6A6E702AB CRC64;

Query Match 6.28; Score 127.5; DB 11; Length 871;  
 Best Local Similarity 21.78; Pred. No. 0.0077;  
 Matches 70; Conservative 41; Mismatches 125; Indels 87; Gaps 16;

QY 15 EYIEGPONATVILKSGSARFNCTVSQGMK-ILMALSDMYLVSVRMEPIITNDRTSQRY 73  
 Db 122 KITRPINVKIKIEGLKAVLPCTMGNRPSPYSWTKG-----NALNENRIALAE 171  
 QY 74 DOGNFTSEMIIHNEPSDSGNIRCSLNSRLHGSAY-----LTVQVNGELFIPSVNLV 128  
 Db 172 -----SGSLRHNVQKEDAGYRCVAKNSL--GTAASKLVKLEVEVLGILRAPESHNV 223  
 QY 129 AENEPEVTC-----LPSPHTRLPDISW-ELGLVSHSSYVYVPEPSDLSAVSIALATPQ 183  
 Db 224 TRESFVLTCTELGIP-----VPTISWENGNVSSGSIQESVQKQRYIDSLQFLTKP- 277  
 QY 184 SNGTLTCVAT-----WKSILKARSAVNLTVIR-----CPDPTGGGINIFP-----V 225

RESULT	15
061988	
ID	061988
AC	061988;
DT	01-NOV-1996
DT	01-NOV-1996 (TREMBLERel_01, Created)
DT	01-MAR-2002 (TREMBLERel_01, Last sequence update)
DE	NSK2 protein precursor.
GN	MUSK OR NSK2.
OS	Mus musculus (Mouse).
OOS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus
NCBI_TaxID	10090;
NCBI_TaxID	10090;
PRELIMINARY;	PRT; 881 AA.

Query Match	6.2%;	Score 127.5;	DB 11;	Length 881;
Best Local Similarity	21.7%;	Pred No. 0.0078;		
Matches 70;	Conservative 41;	Mismatches 125;		

QY	15	EVIEGPNATVLKGSQARENCFTVSGWR-LIMMALSDVAVLSTVPMETITTDNDFTSQAR	73
		122 KITRPINVKIITGLKAAVLPCTTGMNPRPSVWIKG-----NALNENRIAALE	171
QY	74	DOGNFTSEMIHNEPDSGNIRCSLNSKLSAS-----LTVOYMGELFTPSVNLV	128

```

Dh 172 -----SGSRINWOKEDAGQYRCVANKSL--GTAYSKLYRLEVEVLGRILRAPESHNV 22
QY 129 AENECEVTC---LP$HWTRLPDISW-EL$LYSHSSXYFVPEPBDLOSAN$IALTPQ 183
Dh 224 TFG$FVTLRTEIGIP-----VPTIS$ENKNANVSSG$IOESKYDRV$IDSRLO$FTIKP- 277
QY 184 $NGITFCVAT---WMSUKARSATVNLITYIR-----CPQDTGGGINIPG-----V 225
Dh 278 --GLYICIN$K$HGE$FTAC$AAATV$IAEM$SKSDOGYACQYRG$EVLMOQ$PG$KML 335
QY 226 L$SL$PL$G$SLP-----TWK$GGLAGL$AMLL$PTQTL$TRRCC$CRRCC$GN-- 273
Dh 336 LV$EL$PT$SHRDEP$AOELL$HTANVEL-----KAV$SLC$P$AA$EALL$CYH$FL$E$SPG 388
QY 274 -----CCCRC-----FCCR 283
Dh 389 V$PT$P$P$IO$REYCLAV$KEL$FC$AK 411

```

Search completed: April 28, 2003, 21:07:34  
Job time : 42.7435 secs

GenCore version 5.1.4.p5.4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

# OM nucleic - nucleic search, using sw model

Run on: April 28, 2003, 23:25:03 ; Search time 3225.61 Seconds

(without alignments)  
10538.186 Million cell updates/sec

Title: US-09-729-264-3

Perfect score: 1 agtgcacatggtgcgcagagag.....gtatcacactgtagtag 1168

Sequence: IDENTITY\_NUC  
Gapop 10.0, Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 4109280

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database : GenEmbl:  
1: gb\_ba:\*  
2: gb\_hgt:\*  
3: gb\_in:\*  
4: gb\_om:\*  
5: gb\_ov:\*  
6: gb\_pac:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_sts:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vl:\*  
15: em\_ba:\*  
16: em\_fun:\*  
17: em\_hum:\*  
18: em\_in:\*  
19: em\_mu:\*  
20: em\_om:\*  
21: em\_or:\*  
22: em\_ov:\*  
23: em\_pat:\*  
24: em\_ph:\*  
25: em\_pl:\*  
26: em\_ro:\*  
27: em\_sts:\*  
28: em\_un:\*  
29: em\_vl:\*  
30: em\_hgt\_hum:\*  
31: em\_hgt\_inv:\*  
32: em\_hgt\_other:\*  
33: em\_hgt\_mus:\*  
34: em\_hgt\_pin:\*  
35: em\_hgt\_rod:\*  
36: em\_hgt\_mam:\*  
37: em\_hgt\_vit:\*  
38: em\_sy:\*  
39: em\_hgt\_hum:\*  
40: em\_hgt\_mus:\*  
41: em\_hgt\_other:\*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1168	100.0	1168	6	AX380398
2	1122.4	96.1	1175	6	AX380396
3	1119.6	95.9	2051	6	AK092516
4	1119	95.8	1240	6	AX380400
5	1102.8	94.4	1139	6	AX380402
6	378.4	32.4	1195	6	AX380404
7	326.6	28.0	142742	9	AF121782
8	326.6	28.0	340000	9	HS21C080
9	182.4	15.6	196900	2	AC020851
10	181.8	15.6	754	6	AX380408
11	181.8	15.6	895	6	AX380406
12	181.8	15.6	1556	10	BC004806
13	171.4	14.7	175861	2	AC120346
14	171.4	14.7	196900	2	AC120346
15	57.4	4.8	196900	2	AC020851
16	56.6	4.8	427	9	HS063332
17	55.4	4.7	53808	2	AC120145
18	55	4.7	1061	2	AC120346
19	54.8	4.7	175861	2	AC118358
20	53	4.5	138685	2	AC017582
21	52.8	4.5	166249	3	AC093502
22	52.8	4.5	185404	3	AC104703
23	52.8	4.5	185404	3	AC093502
24	52.8	4.5	341319	3	AE003536
25	51.8	4.4	397	6	BD010479
26	51.4	4.4	85584	2	AC099238
27	50.8	4.3	162971	2	AC103439
28	50.6	4.3	147185	9	AC020589
29	50.6	4.3	165675	2	AC113925
30	50.6	4.3	195460	2	AC129068
31	50	4.3	94674	2	AC128456
32	50	4.3	179494	2	AC113770
33	50	4.3	185487	2	AC108346
34	49.8	4.3	299	9	HS131896
35	49.8	4.3	161170	2	AC129166
36	49.4	4.2	49845	2	AC100974
37	49.4	4.2	160650	3	AC008188
38	49.4	4.2	160885	2	AC018184
39	49.4	4.2	162384	2	AC007840
40	49.4	4.2	172334	2	AC122602
41	49.4	4.2	173373	3	AC099016
42	49.4	4.2	306854	3	AE003797
43	49.4	4.2	312634	2	AC095096
44	49.4	4.2	313820	2	AC115350
45	49.2	4.2	233337	2	AC126948

## ALIGNMENTS

RESULT 1  
LOCUS AX380398 1168 bp DNA linear PAT 18-MAR-2002  
DEFINITION Sequence 3 from Patent WO0200710.  
ACCESSION AX380398  
VERSION AX380398.1 GI:19575328  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
AUTHORS 1  
TITLE Weicher, A.A., Sarmiento, U.M., Schultz, H.J. and Chute, H.T.  
JOURNAL B7-like molecules and uses thereof  
Patent: WO 0200710-A 3 03-JAN-2002;

Amgen, Inc. (US)  
 Location/Qualifiers  
 1. 1168  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 8. 1168  
 /note="unnamed protein product"  
 /codon\_start=1  
 /protein\_id="CAD28217.1"  
 /db\_xref="GI:19575329"  
 /translation="MAYAGMENRDPGSSGSENEVIEGPONAVLKGSOARENCYVSGK  
 KKLIMALSDMVLVSVREMEPLITNDRETSQRYDGGNTSEMIHNPSPDSGNIR  
 SLONSRLHGSALIVQVMEELIPSVNLVAENEBCEVCLPSHMTWLPDISELGL  
 VSHSYEVEPEPSDLSQSAVSIATLPQSNGLTCAVATKSKARSATVNLVTRCPD  
 DTGGINIPGVLSLPSLGEFSLPTWKGVLGAGMLLPCTLTIRCCCRRCGCC  
 NCCRCCECRKRKRGRIQFOFKSKSEKTKNETETESGENSGYNSDEKTDITSLP  
 PKSCSSPEQRNSCGPPHQRADORPPRPAASHQASFNILASPEKVSMTIVV"  
 BASE COUNT 299 a 302 c 288 g 279 t  
 ORIGIN

Query Match 100.0%; Score 1168; DB 6; Length 1168;  
 Best Local Similarity 100.0%; Pred. No. 2.4e-270;  
 Matches 1168; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTGATCATGTGGCGAGGAGCCATGGAATAGACCCACCGGTTGTGGCTGTAA 60  
 DB 1 AGTGATCATGTGGCGAGGAGCCATGGAATAGACCCACCGGTTGTGGCTGTAA 60  
 QY 61 TGAAGTCATAGAAAGGCCCCCAAAATGCAAGAGCTCGAAGGGCTCCAGGCTGTCA 120  
 DB 61 TGAAGTCATAGAAAGGCCCCCAAAATGCAAGAGCTCGAAGGGCTCCAGGCTGTCA 120  
 QY 121 CTGACACGCTCTCCAGAGGCTGGAAGCTCATGTGGGCTCTCACTGACATGGTGTCT 180  
 DB 121 CTGACACGCTCTCCAGAGGCTGGAAGCTCATGTGGGCTCTCACTGACATGGTGTCT 180  
 QY 181 AAGCGTCAGAGCCCATGAGACCCCATCATCAACCAATGACCCCTTCACTCAAGATGACA 240  
 DB 181 AAGCGTCAGAGCCCATGAGACCCCATCATCAACCAATGACCCCTTCACTCAAGATGACA 240  
 QY 241 CCAGGAGCGGGAATCTCACCTCGAGATGATCATCAATGTGAGAGCCAGTGGATCGGG 300  
 DB 241 CCAGGAGCGGGAATCTCACCTCGAGATGATCATCAATGTGAGAGCCAGTGGATCGGG 300  
 QY 301 GAACATCAGATCAGACCTTCCAGAAAGTGGCTGATGATGCTTACCTTACCGTCA 360  
 DB 301 GAACATCAGATCAGACCTTCCAGAAAGTGGCTGATGATGCTTACCTTACCGTCA 360  
 QY 361 AGTTATGGAGAGCTGTTCATCCAGTGTATCTTGTAGTGGCTGGAATGAACCTTG 420  
 DB 361 AGTTATGGAGAGCTGTTCATCCAGTGTATCTTGTAGTGGCTGGAATGAACCTTG 420  
 QY 421 TGAAGTACTTGTCTACCTCAGCTGAGACCTGGCTCCCGATATTCTCGGAGCTCG 480  
 DB 421 TGAAGTACTTGTCTACCTCAGCTGAGACCTGGCTCCCGATATTCTCGGAGCTCG 480  
 QY 481 TCTCTGTGAGCCATTAAGCTATATTGTTGTCGAGAGCCAGACCTTCAAGTGC 540  
 DB 481 TCTCTGTGAGCCATTAAGCTATATTGTTGTCGAGAGCCAGACCTTCAAGTGC 540  
 QY 541 AGTGAGCATCTGGCTGAGACCCACAGAGCAATGGACTTGAATTCGATGGCTACCG 600  
 DB 541 AGTGAGCATCTGGCTGAGACCCACAGAGCAATGGACTTGAATTCGATGGCTACCG 600  
 QY 601 GAAGAGCTGAAGGCCCCCAAGTGTGCAAGCTGAATCTGATGGTGGTCCCA 660  
 DB 601 GAAGAGCTGAAGGCCCCCAAGTGTGCAAGCTGAATCTGATGGTGGTCCCA 660  
 QY 661 AGACACTGAGAGTGTATTAATTCAGGTATTAATTCAGGTATTAATTCAGGTATTA 720  
 DB 661 AGACACTGAGAGTGTATTAATTCAGGTATTAATTCAGGTATTAATTCAGGTATTA 720  
 QY 721 TTCAATGCTACTTGGGCAAGTTGACTGATGACAGGACCATGCTTGTGAGCC 780

DB 721 TTCAATGCTACTTGGGCAAGTTGACTGATGACAGGACCATGCTTGTGAGCC 780  
 QY 781 GAGGTGACTCTTACATATACGCTGCTGCTCCGCCGCGTGTGTGGTGCATCACTG 840  
 DB 781 GAGGTGACTCTTACATATACGCTGCTGCTCCGCCGCGTGTGTGTGGTGCATCACTG 840  
 QY 841 CTGCTGCGGCTGT 900  
 DB 841 CTGCTGCGGCTGT 900  
 QY 901 GAATCTGAAAAGAGAGAACCAAGAAAGTGAAGACGAAAGGAAATGAAAAATC 960  
 DB 901 GAATCTGAAAAGAGAGAACCAAGAAAGTGAAGACGAAAGGAAATGAAAAATC 960  
 QY 961 CGGCTACATTCATGATGAACAAAAGACACACACCGCTTCTCTCTCCCAATCTG 1020  
 DB 961 CGGCTACATTCATGATGAACAAAAGACACACACCGCTTCTCTCTCCCAATCTG 1020  
 QY 1021 TGAATCCAGTATCTGATGAACAAAAGACACACACCGCTTCTCTCTCCCAATCTG 1080  
 DB 1021 TGAATCCAGTATCTGATGAACAAAAGACACACACCGCTTCTCTCTCCCAATCTG 1080  
 QY 1081 TCAAGCTCCAGCCAGGCGCAGCAAGTATCATCAGGCTCTTTTAAATCTGGCCAGTCTGA 1140  
 DB 1081 TCAAGCTCCAGCCAGGCGCAGCAAGTATCATCAGGCTCTTTTAAATCTGGCCAGTCTGA 1140  
 QY 1141 GAAGTCTAATTAATCACTGATGATAG 1168  
 DB 1141 GAAGTCTAATTAATCACTGATGATAG 1168

RESULT 2  
 AX380396 1175 bp DNA linear PAT 18-MAR-2002  
 LOCUS AX380396  
 DEFINITION Sequence 1 from Patent WO0200710.  
 ACCESSION AX380396  
 VERSION AX380396.1 GI:19575326  
 KEYWORDS  
 SOURCE  
 ORGANISM human.  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE  
 1  
 Weicher, A.A., Sarmiento, U.M., Schultz, H.J. and Chute, H.T.  
 B7-like molecules and uses thereof  
 Patent: WO 0200710-A 1 03-JAN-2002;  
 JOURNAL

FEATURES  
 Location/Qualifiers  
 1. 1175  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 27. 1175  
 /note="unnamed protein product"  
 /codon\_start=1  
 /protein\_id="CAD28216.1"  
 /db\_xref="GI:19575327"  
 /translation="MGLVIFLHSGSGSENEVIEGPONAVLKGSOARENCYVSGK  
 KKLIMALSDMVLVSVREMEPLITNDRETSQRYDGGNTSEMIHNPSPDSGNIR  
 SLONSRLHGSALIVQVMEELIPSVNLVAENEBCEVCLPSHMTWLPDISELGL  
 VSHSYEVEPEPSDLSQSAVSIATLPQSNGLTCAVATKSKARSATVNLVTRCPD  
 DTGGINIPGVLSLPSLGEFSLPTWKGVLGAGMLLPCTLTIRCCCRRCGCC  
 NCCRCCECRKRKRGRIQFOFKSKSEKTKNETETESGENSGYNSDEKTDITSLP  
 PKSCSSPEQRNSCGPPHQRADORPPRPAASHQASFNILASPEKVSMTIVV"  
 BASE COUNT 295 a 307 c 286 g 287 t  
 ORIGIN

Query Match 96.1%; Score 1122.4; DB 6; Length 1175;  
 Best Local Similarity 99.5%; Pred. No. 2.2e-259;  
 Matches 1126; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 37 CCCACCGGCTTGGGTGTGAATGAGTCATGAAGGCCCCCAAAATGCAAGAGTCT 96  
 || | |||||





OY	343	TCCTTAACCTTACCGTCCCAAGTTATGAGAGAGCTGTTCAATTCACAGTGTAAATCTGTTAGT	402
Db	502	TGCTTAACCTTACCGTCCCAAGTTATGAGAGAGCTGTTCAATTCACAGTGTAAATCTGTTAGT	561
OY	403	CGCTGAGATGAACTCTGTGAAATTACTGTGTACCCCTACACTGTGACTGGCTCCCGGA	462
Db	562	CGCTGAGATGAACTCTGTGAAATTACTGTGTACCCCTACACTGTGACTGGCTCCCGGA	621
OY	463	TATTTCCCTGGGAGCTCGGCTCTCTGGTCAAGCCATTAATATTTTGTTCGGAGCC	522
Db	622	TATTTCCCTGGGAGCTCGGCTCTCTGGTCAAGCCATTAATATTTTGTTCGGAGCC	681
OY	523	CAGGACCTTAAAGTGTGAGAGATCTGGCTGTGACCCACAGACCAATGGACATT	582
Db	682	CAGGACCTTAAAGTGTGAGAGATCTGGCTGTGACCCACAGACCAATGGACATT	741
OY	583	GACTTGGGTGGCTACCTTGAAAGAGCCGGAAGCCGCAAGTCTGCACTGTAAATCTCAC	642
Db	742	GACTTGGGTGGCTACCTTGAAAGAGCCGGAAGCCGCAAGTCTGCACTGTAAATCTCAC	801
OY	643	TGTATTCGGGTGGCTCCCAAGACACTGAGAGTGTATTAATTTCCAGGTGATTATCAAG	702
Db	802	TGTATTCGGGTGGCTCCCAAGACACTGAGAGTGTATTAATTTCCAGGTGATTATCAAG	861
OY	703	TTTACCGAGTTTAAAGTTTTTCATTGACCTACTTGGGGCAAAAGTTGGAGCTTGGACTACAGG	762
Db	862	TTTACCGAGTTTAAAGTTTTTCATTGACCTACTTGGGGCAAAAGTTGGAGCTTGGACTACAGG	921
OY	763	CACCATTCCTCTACAGCGCCGACAGTGTACTCTTACAAATACGTGCTGCTGCGCCGCTCG	822
Db	922	CACCATTCCTCTACAGCGCCGACAGTGTACTCTTACAAATACGTGCTGCTGCGCCGCTCG	981
OY	823	TGTGTGTGGCTGCAAGTGTGCTGCGGTTTGTGTTCTGCTGTAGAAAGAAAGAGATT	882
Db	982	TGTGTGTGGCTGCAAGTGTGCTGCGGTTTGTGTTCTGCTGTAGAAAGAAAGAGATT	1041
OY	883	TGCTATTCAATTTCAAAAGAAATCTGAAAAAGAAAGAACAAAGAAATAGAGACAGA	942
Db	1042	TGCTATTCAATTTCAAAAGAAATCTGAAAAAGAAAGAACAAAGAAATAGAGACAGA	1101
OY	943	AAGTGAATAATGAAAACCTCGGGCTACAAATTCAGATGAAACAAAAGACACAGACCGCTTTC	1002
Db	1102	AAGTGAATAATGAAAACCTCGGGCTACAAATTCAGATGAAACAAAAGACACAGACCGCTTTC	1161
OY	1003	TCTCCCTCCCAAAATCTGTGAATTCAGATGATCCTGAAACAAAGAACAGTAGCTGTGGCCC	1062
Db	1162	TCTCCCTCCCAAAATCTGTGAATTCAGATGATCCTGAAACAAAGAACAGTAGCTGTGGCCC	1221
OY	1063	TCCTCACACAGCGGGGATCAACAGTCCACCCAGGCGCAGAAATCATCCACAGGCTTCTTT	1122
Db	1222	TCCTCACACAGCGGGGATCAACAGTCCACCCAGGCGCAGAAATCATCCACAGGCTTCTTT	1281
OY	1123	TAAATCTGGCCAGTCTGTGAAAGGTAGTAATTCACACTGTAGATATAG	1168
Db	1282	TAAATCTGGCCAGTCTGTGAAAGGTAGTAATTCACACTGTAGATATAG	1327

RESULT 4					
AX380400					
LOCUS	AX380400	1240 bp	DNA	linear	PAT 18-MAR-2002
DEFINITION	Sequence 5 from Patent WO0200710.				
ACCESSION	AX380400				
VERSION	AX380400.1	GI:19575330			
KEYWORDS					
SOURCE	human.				
ORGANISM	Homo sapiens				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.				
REFERENCE	1				
AUTHORS	Welcher/A.A., Sarmiento,U.M., Schultz,H.J. and Chute,H.T.				
TITLE	B7-1-like molecules and uses thereof				
JOURNAL	Patent: WO 0200710-A 5 03-JAN-2002;				

FEATURES	Location/Qualifiers
source	1..1240
	/organism="Homo sapiens"
	/db_xref="taxon:9606"
CDS	80..1240
	/note="unnamed protein product"
	/codon_start=1
	/protein_id="CaD28218.1"
	/db_xref="GI:1957531"
	/translation="MERHLITVEAVSGSGNEVIEGPONATVLKGSQARPCVSGQ WKLIMALSDMNVLSVRPMBPIITNDRFISQYDQGNFSEMTIHHVPEPDSNTRC SLQSRHLSGSAVLTVQVMEELFSPYNIVVAENPECEVICPISHRIPLDLSWELGL VSHSRYFEVPEPDSLDQSAVSIILATPQSGNLTICVATKSLAKRASAVNLTIVRCPO DDGGINIPGVLSILPSLSPFSLPTMRKGLGAGMLLTLPCTLTIRCCQRRRCGCC NCCCRGFCFRRKRGRIQFOKKESEKINIKETTESENENSGNSDQKTTETVASLP PKCESSEDFQRNNSGCPHPHRADQRPPIPAHPASHQSPFNLASPEKVSNTIVV"
BASE COUNT	318 a 319 c 305 g 298 t
ORIGIN	
Query Match	95.8%; Score 1119; DB 6; Length 1240;
Best Local Similarity	99.1%; Pred. No. 1.5e-258;
Matches 1125; Conservative	0; Mismatches 10; Indels 0; Gaps 0;
Db	34 AGACCCACCCCGTTCTGGGCTGTGTAATGAAAGTCATGAAAGCCCCCAAAATGCAAGT 93
Db	106 AGAAGCGTAGAGTCTTGCTGTGTAATGAAAGTCATGAAAGCCCCCAAAATGCAAGT 165
Qy	94 CCTGAAGGGCTCCAGAGCTCGTTCAACGTGACACCGTCCTCCAGGGCTGAAAGCTCATCAT 153
Db	166 CCTGAAGGGCTCCAGAGCTCGTTCAACGTGACACCGTCCTCCAGGGCTGAAAGCTCATCAT 225
Qy	154 GTGGGCTCTCAGTGACATGAGTGGTGCTAAGCGTCAGGCCATGAGCCATCATACCAA 213
Db	226 GTGGGCTCTCAGTGACATGAGTGGTGCTAAGCGTCAGGCCATGAGCCATCATACCAA 285
Qy	214 TGACCGCTTCACTCTCAGAGGTACACACGAGGGGGGAACTTACCTCGGATGATCAT 273
Db	286 TGACCGCTTCACTCTCAGAGGTACACACGAGGGGGGAACTTACCTCGGATGATCAT 345
Qy	274 CCACATGTGAGAGCCCAAGTATTCGGGGAACTCAGATGACAGCTCCAGAAACATGCGCT 333
Db	346 CCACATGTGAGAGCCCAAGTATTCGGGGAACTCAGATGACAGCTCCAGAAACATGCGCT 405
Qy	334 GCATGATCTGCGTTACCTACCGTCCAGATTATGGAGAGCTGTTCAATCCAGGTGTTAA 393
Db	406 GCATGATCTGCGTTACCTACCGTCCAGATTATGGAGAGCTGTTCAATCCAGGTGTTAA 465
Qy	394 TCTTGTAGTGGCTGAGAAATGAACCTTGTGAAGTTACTTGTCTACCCACACTGGACCTG 453
Db	466 TCTTGTAGTGGCTGAGAAATGAACCTTGTGAAGTTACTTGTCTACCCACACTGGACCTG 525
Qy	454 GCTCCCGGATATTTCTGGGAGCTCGGTCTCTGGTACGCCATTCAGCTATTATTTGT 513
Db	526 GCTCCCGGATATTTCTGGGAGCTCGGTCTCTGGTACGCCATTCAGCTATTATTTGT 585
Qy	514 TCCGGAGCCAGCAAGCTTCAAAATGCAAGTACATCTGGGCTGTAACCCACAGAGCAA 573
Db	586 TCCGGAGCCAGCAAGCTTCAAAATGCAAGTACATCTGGGCTGTAACCCACAGAGCAA 645
Qy	574 TGGGACTTGTGACTTGGCTGCTACCTGTGAAGAGCGTGAAGCCCGCAAGTGTGCAACTGT 633
Db	646 TGGGACTTGTGACTTGGCTGCTACCTGTGAAGAGCGTGAAGCCCGCAAGTGTGCAACTGT 705
Qy	634 AAATTCACCTGATTTGGGTGCTCCCAAGACATGAGGTTGATTAATATTCAGGTGT 693
Db	706 AAATTCACCTGATTTGGGTGCTCCCAAGACATGAGGTTGATTAATATTCAGGTGT 765
Qy	694 ATTATTCAGTTTACCGAGTTTAGTTTTCATTTGCTACTTGGGGCAAAAGTTGGACTTGG 753
Db	766 ATTATTCAGTTTACCGAGTTTAGTTTTCATTTGCTACTTGGGGCAAAAGTTGGACTTGG 825
Qy	754 ACTGACGACCAATGCTTCTGTGACGCCGAGCGTGTACTTCAAAATAGACCTGCTGCTGTG 813

Db 826 ACTAGAGGACACCATGCTTGCAGCCCACTGACTTTCATACGCTGCTGCTG 885  
 QY 814 CCGCCGCTGTTGTTGGCTGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 873  
 Db 886 CCGCCGCTGTTGTTGGCTGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 945  
 QY 874 AAGAGATTTTCTGATTCATTTCAAGAAATCTGAAAAAGAGAACAAACAAAGAAC 933  
 Db 946 AAGAGATTTTCTGATTCATTTCAAGAAATCTGAAAAAGAGAACAAACAAAGAAC 1005  
 QY 934 TGAGACAGAAATGGAATGAAATGCGGCTGCAATTTAGTGAACAAAGACACAGA 993  
 Db 1006 TGAGACAGAAATGGAATGAAATGCGGCTGCAATTTAGTGAACAAAGACACAGA 1065  
 QY 994 CACCGCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1053  
 Db 1066 AACCGCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1125  
 QY 1054 CTGAGCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1113  
 Db 1126 CTGAGCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1185  
 QY 1114 GCGTCTTTTATCTGCGCAGTCTGAGAAAGTCAATATCAACTGATGATG 1168  
 Db 1186 GCGTCTTTTATCTGCGCAGTCTGAGAAAGTCAATATCAACTGATGATG 1240

RESULT 5  
 AX380402 1139 bp DNA linear PAT 18-MAR-2002  
 LOCUS AX380402 7 from Patent WO020710.  
 DEFINITION Sequence  
 AX380402  
 ACCESSION AX380402.1 GI:19575332  
 VERSION  
 KEYWORDS  
 SOURCE  
 ORGANISM

human.  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
 REFERENCE  
 AUTHORS Welcher, A.A., Sarmiento, U.M., Schultz, H.J. and Chute, H.T.  
 TITLE B7-like molecules and uses thereof  
 JOURNAL Patent: WO 020710-A 7 03-JAN-2002.  
 Amgen, Inc. (US)

FEATURES  
 source  
 1..1139  
 /location/Qualifiers  
 1..1139  
 /db\_xref="taxon:9606"  
 1..1134  
 /note="unnamed protein product"  
 /codon\_start=1  
 /protein\_id="CAD28219.1"  
 /db\_xref="GI:19575332"  
 /translation="MVAGAMENRDPSSGSGNEVIESPONARVLKSOARFNCVSOG  
 KLIIMMALSDVAVLVSVRPMETITNDRTSQRDQGNLTSEMIINVERSDGNIRC  
 SLONSRILGSAYLIVQVWGLFIPSVNLVAENRPECVTCIPLHMRRLDIPISLELL  
 VSHSRYVPEPSPDLQSAVSIILATPOSNGTLCVAIWKSLKARKSATVNLIVIRGPO  
 DRGGINIPVLISSLPGLFSLPTMGVGLGLACTMLTLPCTITTCGCCRRRCGC  
 NCCRCRCRCRRKRRKTRKTRKTRKTRKTRKTRKTRKTRKTRKTRKTRKTRKTRK  
 LNKETVAVALLTSLINVHVGQOVIHLLIIMVLRVSYQL"

CDS  
 1..1139  
 /db\_xref="taxon:9606"  
 1..1134  
 /note="unnamed protein product"  
 /codon\_start=1  
 /protein\_id="CAD28219.1"  
 /db\_xref="GI:19575332"  
 /translation="MVAGAMENRDPSSGSGNEVIESPONARVLKSOARFNCVSOG  
 KLIIMMALSDVAVLVSVRPMETITNDRTSQRDQGNLTSEMIINVERSDGNIRC  
 SLONSRILGSAYLIVQVWGLFIPSVNLVAENRPECVTCIPLHMRRLDIPISLELL  
 VSHSRYVPEPSPDLQSAVSIILATPOSNGTLCVAIWKSLKARKSATVNLIVIRGPO  
 DRGGINIPVLISSLPGLFSLPTMGVGLGLACTMLTLPCTITTCGCCRRRCGC  
 NCCRCRCRCRRKRRKTRKTRKTRKTRKTRKTRKTRKTRKTRKTRKTRKTRKTRK  
 LNKETVAVALLTSLINVHVGQOVIHLLIIMVLRVSYQL"

BASE COUNT 290 a 300 c 283 g 266 t  
 ORIGIN  
 Query Match 94.4%; Score 1102.8; DB 6; Length 1139;  
 Best Local Similarity 97.9%; Pred. No. 1.2e-254;  
 Matches 1136; Conservative 0; Mismatches 2; Indels 22; Gaps 1;  
 QY 8 ATGTGCGAGGAGCCATGAAATATAGAGACCCGCGTCTGCTGCTGATGAAGTC 67  
 Db 1 ATGTGCGAGGAGCCATGAAATATAGAGACCCGCGTCTGCTGCTGATGAAGTC 60  
 QY 68 ATAGAAGGCCCCAAATGCAAGATCTGTAAGGCTCCAGGCTGCTCACTGACAC 127

Db 61 ATAGAAGGCCCCAAATGCAAGATCTGTAAGGCTCCAGGCTGCTCACTGACAC 120  
 QY 128 GTCTCCAGGCGTGAAGCTCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 187  
 Db 121 GTCTCCAGGCGTGAAGCTCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 180  
 QY 188 AGGCCATGAGCCCATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 247  
 Db 181 AGGCCATGAGCCCATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240  
 QY 248 GGGAACTTCACTCGAGATGATCATCCACATGAGGAGCCAGATTCGGGAGATC 307  
 Db 241 GGGAACTTCACTCGAGATGATCATCCACATGAGGAGCCAGATTCGGGAGATC 300  
 QY 308 AGATGACGCTCCAGAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 367  
 Db 301 AGATGACGCTCCAGAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 360  
 QY 368 GAGAGCTGTTCAATCCAGTGTATCTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 427  
 Db 361 GAGAGCTGTTCAATCCAGTGTATCTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 420  
 QY 428 ACTTGTCTACCTGACACTGACCTGACCTGACCTGACCTGACCTGACCTGAC 487  
 Db 421 ACTTGTCTACCTGACACTGACCTGACCTGACCTGACCTGACCTGACCTGAC 480  
 QY 488 GTGACCAATGCAAGTATTTATTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 547  
 Db 481 GTGACCAATGCAAGTATTTATTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 540  
 QY 548 ATCTGCGCTGCTGACCCCAAGAGCAAGTGAATGGAATGGAATGGAATGGAATG 607  
 Db 541 ATCTGCGCTGCTGACCCCAAGAGCAAGTGAATGGAATGGAATGGAATGGAATG 600  
 QY 608 CTGAAAGCCCGCAAGTCTGCAACTGTAATCTGATGCTGATGCTGATGCTGATG 667  
 Db 601 CTGAAAGCCCGCAAGTCTGCAACTGTAATCTGATGCTGATGCTGATGCTGATG 660  
 QY 668 GAGAGCTGTTCAATCCAGTGTATCTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 727  
 Db 661 GAGAGCTGTTCAATCCAGTGTATCTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 720  
 QY 728 CCTACTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 787  
 Db 721 CCTACTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 780  
 QY 788 ACTGTTCAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 847  
 Db 781 ACTGTTCAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 840  
 QY 848 CTTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 907  
 Db 841 CTTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 907  
 QY 908 GAAAAAGAGAGCAAAAGCAAAAGCAAAAGCAAAAGCAAAAGCAAAAGCAAAAGCA 967  
 Db 879 GAAAAAGAGAGCAAAAGCAAAAGCAAAAGCAAAAGCAAAAGCAAAAGCAAAAGCA 938  
 QY 968 AATTGATGATGAAAGAAAGCAAGACACCGGCTTCTCCCTCCAAATCTGGAATCC 1027  
 Db 939 AATTGATGATGAAAGAAAGCAAGACACCGGCTTCTCCCTCCAAATCTGGAATCC 998  
 QY 1028 AGTGAATCTGAAACAAAGAAAGCAAGACACCGGCTTCTCCCTCCAAATCTGGAATCC 1058  
 Db 999 AGTGAATCTGAAACAAAGAAAGCAAGACACCGGCTTCTCCCTCCAAATCTGGAATCC 1058  
 QY 1088 CCACCCAGGCGACAGTATCCACAGGCTTCTTTTATCTGCGAGTCTGAGAGGTC 1147  
 Db 1059 CCACCCAGGCGACAGTATCCACAGGCTTCTTTTATCTGCGAGTCTGAGAGGTC 1118  
 QY 1148 AGTATACAACTGTATATA 1167  
 Db 1119 AGTATACAACTGTATATA 1138

RESULT 6  
AX380404  
LOCUS AX380404 1195 bp DNA Linear PAT 18-MAR-2002  
DEFINITION Sequence 9 from Patent WO0200710.  
ACCESSION AX380404  
VERSION AX380404.1 GI:19575334  
KEYWORDS  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
AUTHORS Melcher, A.A., Sarmiento, U.M., Schultze, H.J. and Chute, H.T.  
TITLE B7-like molecules and uses thereof  
JOURNAL Patent: WO 0200710-A 9 03-JAN-2002;  
Amgen, Inc. (US)

FEATURES  
source location/Qualifiers  
1..1195  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
53..1165  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="CAD28220.1"  
/db\_xref="GI:19575335"  
/translation="MEGSRDYLAVLVLAQITAGSSSYOIEGPNVYIKDSEAH  
DSGVCSQNSHSGSRAFLSVQMGITINISNLIYEGPCVTCYAVGMTSLDPI  
SWELEVPVSHSYNSFLFENFMVLSVLDLPLGNTLCVAVELIDQASKEITVNL  
TYVQPPDSIGEGEPALPTMAIILAVAFSLILILVILITTCASRREESTY  
ONEIKRSAMRNKADPEPTKLKSGKENYSSDPAKQAQASLPPSAEVSLEPKRSS  
SLPEQLNHQGPATHRVSEFSDIASPKVANTVLY"

BASE COUNT 313 a 304 c 291 g 287 t

Query Match 32.4%; Score 378.4; DB 6; Length 1195;  
Best Local Similarity 62.3%; Pred. No. 2.5e-80;  
Matches 701; Conservative 0; Mismatches 356; Indels 69; Gaps 4;

QY 42 CCGGCTCTGGCTGTGTGTAATGATCATAGAGCCCAAAATGCAAGAGTCTCTAAG 101  
DB 108 CAGCTTCGGATCCAGTTATCATGATCAGTAAGGCTCTCAAGATGATCAAGTCTTAAAG 167  
QY 102 GCTCCAGGCTGCTTCAACGACCCGCTCCAGGCTGGAAGCTCATCATGTGGGCTC 161  
DB 168 ACTCAGAGGCTACTTCACTGACCGCTGACTCAGCGCTGGAAGCTTCTCATGTGGACTC 227  
QY 162 TCAGTGAATGTGTGCTAAGCGTCAAGCCCATGAGCCATCATCATGACCGCT 221  
DB 228 TTAACCAATGTGTGCTGCTGCTGCTCAACCAAGACCCATCATCAACCAACCGCT 287  
QY 222 TCACCTCAGAGGTAGCAGCAGGCGGGAACCTCAGCTGAGATGATCATCCCAATG 281  
DB 288 TCACCTATGCCAGTTACACACAGCAGTCAAGCTTCACTCGGAGTTGATCATCATGATG 347  
QY 282 TGGAGCCCATGATGGGAGACATCAGATGAGCCCTCAGAGACGCTGCTCATGAT 341  
DB 348 TGCAGCCCAATGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 407  
QY 342 CTGCTACTTACCTGCTCAAGTTATGAGAGAGCTTATATTCACAGTTATATTTAG 401  
DB 408 CTGCTCTCTCTCAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCA 467  
QY 402 TCGCTAGATGACCTGTGTGATGATGATGATGATGATGATGATGATGATGATGATGAT 461  
DB 468 TCACTAGAGGTAGACCTGTATGATGATGATGATGATGATGATGATGATGATGATGAT 527  
QY 462 AATATTCCTGGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 521  
DB 528 AATATTCCTGGAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 587

QY 522 CCAGGACCTTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCA 581  
DB 588 CGGCACTTTATAGAGGTCTTGAGTCTCTGAGTCTCAACACCTGAGGCAAGGAGTCACT 647  
QY 582 TGACTTGGTGGTCTTCACTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 641  
DB 648 TGACTTGGTGGTCTTCACTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAG 707  
QY 642 CTGTGATTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 701  
DB 708 CTGTGATTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 744  
QY 702 GTTATCCGAGTTAGTTTTCATTCCTTACCTTACCTTACCTTACCTTACCTTACCTT 761  
DB 745 -----AGCCGACGACGACGACGACGACGACGACGACGACGACGACGACGACGAC 791  
QY 762 GCAACATGCTTCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAG 821  
DB 792 TTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 843  
QY 822 GTTGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 881  
DB 844 -----TTGCTCTCCAG 898  
QY 882 TTGCTATTCATTTCAAG 941  
DB 899 TCTGCAACATGAG 944  
QY 942 AAGTGAAG 1001  
DB 945 AAGTGAAG 1004  
QY 1002 CTCCTCCCTCCCAATTCCTGTAATTCAGTATCTGATCTGATCAAGAGAGAGAGAG 1061  
DB 1005 CTCCTCCCTCCCAATTCCTGTAATTCAGTATCTGATCTGATCAAGAGAGAGAGAG 1058  
QY 1062 CTCCTCCCAAGGCGGCTGATCAAGTCCAGGCTGATCAAGGCTGATCAAGGCTGAT 1121  
DB 1059 TTCTTATTCAG 1118  
QY 1122 TTAATCGGCGCTGCTGAGAGGCTGATCAAGTATCAAGTATCAAGTATCAAGTAT 1167  
DB 1119 TTAATCGGCGCTGCTGAGAGGCTGATCAAGTATCAAGTATCAAGTATCAAGTAT 1164

RESULT 7  
AF121782 142742 bp DNA Linear PRI 02-FEB-1999  
LOCUS Homo sapiens chromosome 21q22.3 PAC 206A10, complete sequence.  
DEFINITION AF121782  
ACCESSION AF121782.1 GI:4210991  
VERSION HTG.  
KEYWORDS  
SOURCE Homo sapiens.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
AUTHORS Taudien, S., Dagand, E., Hildmann, T., Nordtsick, G., Drescher, B.,  
Schaltevoy, R., Weber, J., Schilling, M., Menzel, U., Yaspo, M.L. and  
Rosenthal, A.  
TITLE Direct Submission  
JOURNAL Submitted (21-JAN-1999) Genome Analysis, Institute for Molecular  
Biotechnology, Beutenbergstrasse 11, Jena 07745, Germany  
FEATURES  
source location/Qualifiers  
1..142742  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="21"  
/map="21q22.3"  
/clone="PAC 206A10"  
3..118  
/evidence="not\_experimental"  
/rpe\_family="MIR"

repeat\_region

```

repeat_region complement(140..415)
/evidence-not_experimental
/rpt_family="MLT2E"
complement(668..881)
/evidence-not_experimental
/rpt_family="MER38A"
complement(1078..1162)
/exon /note="GRAIL, score = 86.000%, comment = excellent shadow"
/evidence-not_experimental
1114..1403
repeat_region /evidence-not_experimental
/rpt_family="MLT1I"
1481..1603
repeat_region /evidence-not_experimental
/rpt_family="L2"
1576..1710
/exon /note="MZE, score = 66.1%"
/evidence-not_experimental
1576..1710
/exon /note="GRAIL, score = 99.000%, comment = excellent"
/evidence-not_experimental
complement(1693..1741)
repeat_region /evidence-not_experimental
/rpt_family="MIR"
complement(1780..2326)
repeat_region /evidence-not_experimental
/rpt_family="MLT1E"
complement(1834..1955)
/exon /note="GRAIL, score = 50.000%, comment = good shadow"
/evidence-not_experimental
2629..2831
repeat_region /evidence-not_experimental
/rpt_family="ALUSX"
3012..3122
repeat_region /evidence-not_experimental
/rpt_family="MLT1J"
3123..3478
repeat_region /evidence-not_experimental
/rpt_family="THE1B"
3479..3618
repeat_region /evidence-not_experimental
/rpt_family="MLT1J"
complement(3502..3540)
/exon /note="GRAIL, score = 65.000%, comment = good shadow"
/evidence-not_experimental
4674..4781
/exon /note="GRAIL, score = 42.000%, comment = marginal"
/evidence-not_experimental
4712..4749
/exon /note="Xpound exon prediction, score = 70% (0%)"
repeat_region /evidence-not_experimental
5385..6104
repeat_region /evidence-not_experimental
/rpt_family="HERV1"
6682..6751
/exon /note="MZE, score = 95.1%"
/evidence-not_experimental
6746..6751
/exon /note="Genscan, score = 1.83%, comment = Initial_exon 6 bp
frame: 1 phase: 0"
/evidence-not_experimental
6901..7339
repeat_region /evidence-not_experimental
/rpt_family="MLT1C"
7347..7457
repeat_region /evidence-not_experimental
/rpt_family="LRR16C"
complement(7561..7696)
repeat_region /evidence-not_experimental
/rpt_family="MIR"
complement(7819..8220)
repeat_region /evidence-not_experimental
/rpt_family="MLT1J"

exon 8097..8119
/note="GRAIL, score = 45.000%, comment = marginal"
/evidence-not_experimental
complement(8738..9332)
repeat_region /evidence-not_experimental
/rpt_family="MLT1C"
complement(9273..9420)
/exon /note="GRAIL, score = 71.000%, comment = good"
/evidence-not_experimental
9290..9371
/exon /note="GRAIL, score = 81.000%, comment = excellent shadow"
/evidence-not_experimental
9966..10041
repeat_region /evidence-not_experimental
/note="homology = 100.00%, score = 38, counts = 2"
/evidence-not_experimental
/rpt_type=tandem
/rpt_unit=ctcttcgacactctctgtgagagcggttatcgc
10244..10664
repeat_region /evidence-not_experimental
/rpt_family="MLT1E"
10665..11028
repeat_region /evidence-not_experimental
/rpt_family="MLT1F"
11318..11417
repeat_region /evidence-not_experimental
/rpt_family="L1MC/D"
11503..11818
repeat_region /evidence-not_experimental
/rpt_family="ALUSg"
complement(11525..11777)
/exon /note="MZE, score = 79.4%"
/evidence-not_experimental
complement(12346..12827)
repeat_region /evidence-not_experimental
/rpt_family="MLT1C"
12902..13180
repeat_region /evidence-not_experimental
/rpt_family="ALUSg"
complement(13057..13161)
/exon /note="MZE, score = 76.1%"
/evidence-not_experimental
complement(13226..13364)
repeat_region /evidence-not_experimental
/rpt_family="L1MC2"
complement(13613..13908)
repeat_region /evidence-not_experimental
/rpt_family="ALUSX"
complement(14317..14614)
repeat_region /evidence-not_experimental
/rpt_family="LRR37A"
complement(14962..15036)
/exon /note="MZE, score = 93%"
/evidence-not_experimental
15255..15299
repeat_region /evidence-not_experimental
/rpt_family="L1PA6"
complement(15469..15497)
/exon /note="Xpound exon prediction, score = 62% (0%)"
/evidence-not_experimental
16045..16768
repeat_region /evidence-not_experimental
/rpt_family="MER21A"
complement(16555..16655)
/exon /note="GRAIL, score = 54.000%, comment = good"
/evidence-not_experimental
16823..16850
repeat_region /evidence-not_experimental
/rpt_family="MER34"
complement(16851..17208)
repeat_region /evidence-not_experimental
/rpt_family="THE1A"
17209..17632
repeat_region /evidence-not_experimental

```

```

repeat_region      /rpt_family="MER34"
                   complement(17633..17969)
                   /evidence=not_experimental
repeat_region      /rpt_family="AluSg1"
                   complement(18004..18334)
                   /evidence=not_experimental
repeat_region      /rpt_family="L1R17"
                   complement(18335..18632)
                   /evidence=not_experimental
exon               /rpt_family="HERV17"
                   complement(18352..18420)
                   /note="GRAIL score = 51.000%, comment = good shadow"
exon               /evidence=not_experimental
                   complement(18397..18584)
                   /note="GRAIL score = 66.000%, comment = good"
repeat_region      /evidence=not_experimental
                   complement(18643..24647)
                   /evidence=not_experimental
exon               /rpt_family="HERV17"
                   complement(19228..19361)
                   /note="MZF score = 92.8%"
exon               /evidence=not_experimental
                   complement(20900..21135)
                   /note="MZF score = 51.4%"
exon               /evidence=not_experimental
                   complement(21150..21275)
                   /note="Xpound exon prediction, score = 74% (0%)"
                   /evidence=not_experimental

```

```

Query Match      28.0% Score 326.6; DB 9; Length 142742;
Best Local Similarity 97.4%; Fred. No. 9.4e-68;
Matches 332; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

```

```

QY 27 AAAAAAGAACCCACCGGTTCTGGGCTGTGTAATGAAGTCATGAAGAGCCCAAAATG 86
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 44257 AATTGGCTACCTTCACAGTTCTGGGCTGTGTAATGAAGTCATGAAGAGCCCAAAATG 86
QY 87 CAAGAGTCCTGAAGGGCTCCAGGCTGCTTCAACTGCACCGTCTCCAGAGGCTGAAGC 146
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 44317 CAAGAGTCCTGAAGGGCTCCAGGCTGCTTCAACTGCACCGTCTCCAGAGGCTGAAGC 146
QY 147 TCATCATGTGGGCTCTCAAGTACATGTTGTTGTAAGCTCAGGCGCCATGAGAGCCCATCA 206
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 44377 TCATCATGTGGGCTCTCAAGTACATGTTGTTGTAAGCTCAGGCGCCATGAGAGCCCATCA 206
QY 207 TCACCAATGACCGCTTCACCTCTCAGAGGTAGACAGGCGGGAAGTCTCACTCGAGAGA 44436
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 44437 TCACCAATGACCGCTTCACCTCTCAGAGGTAGACAGGCGGGAAGTCTCACTCGAGAGA 44436
QY 267 TGATCATCCACATGTGAGAGCCCAAGTATCGGGAGACATGATGACGCTCCAGAGAGA 326
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 44497 TGATCATCCACATGTGAGAGCCCAAGTATCGGGAGACATGATGACGCTCCAGAGAGA 326
QY 327 GTGGCCTGCATGATCTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTAC 367
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 44557 GTGGCCTGCATGATCTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTAC 367

```

```

RESULT 8
LOCUS      HS21C080
DEFINITION Homo sapiens chromosome 21 segment HS21C080.
ACCESSION AL163280.2 GI:7717369
VERSION    AL163280.2 GI:7717369
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

```

```

REFERENCE 1 (bases 1 to 340000)
AUTHORS   Hattori,M., Fujiyama,A., Taylor,T.D., Matanabe,H., Yada,T.,
            Park,H.S., Toyoda,A., Ishii,K., Totoki,Y., Choi,D.K., Soeda,E.,
            Ohki,M., Takagi,T., Sakaki,Y., Iaudien,S., Blechschmidt,K.,

```

## TITLE

## JOURNAL

## COMMENT

Polley,A., Menzel,U., Delabar,J., Kumpf,K., Lehmann,R., Zimmerson,D., Reichwald,K., Rump,A., Schillhabel,M., Schudy,A., Zimmermann,W., Rosenthal,A., Kudoh,J., Shibuya,K., Kawasaki,K., Asakawa,S., Shintani,A., Sasaki,T., Negamine,K., Mitsuyma,S., Atonaekis,S.E., Minoshima,S., Shimizu,N., Nordsiek,G., Hornischer,K., Brandt,P., Schefe,M., Schoen,O., Desario,A., Reichelt,J., Kauer,G., Scherf,M., Schenck,J., Beck,A., Klages,S., Hennig,S., Riessmann,L., Dagand,E., Wehrmeyer,S., Borzym,K., Gardiner,K., Nizetic,D., Francis,F., Lehrach,H., Reinhardt,K. and Yaspo,M.L.

Submitted (05-MAY-2000) The Chromosome 21 Mapping and Sequencing Consortium: \* RIKEN Genomic Sciences Center, Human Genome Research Group \* Institute of Molecular Biotechnology, Genome Analysis \* Keio University School of Medicine, Dept. of Molecular Biology \* GBF, Dept. of Genome Analysis \* Max-Planck Institute for Molecular Genetics (addresses see below)

The Chromosome 21 Mapping and Sequencing Consortium consists of

\* RIKEN Genomic Sciences Center, Human Genome Research Group, \* Sagamiyama 228-8535, Japan,

\* e-mail: sakaki@gscc.riken.go.jp

\* URL: http://hnp.gscc.riken.go.jp/

and

\* Institute of Molecular Biotechnology, Genome Analysis, \* Beutenbergstrasse 11, D-07745 Jena, Germany,

\* e-mail: gscj-submit@genome.imb-jena.de

\* URL: http://genome.imb-jena.de/

and

\* Keio University School of Medicine, Dept. of Molecular Biology, \* Tokyo 160-8582, Japan,

\* e-mail: shimizu@med.keio.ac.jp

\* URL: http://adenine.dmb.med.keio.ac.jp/

and

\* GBF, Dept. of Genome Analysis, \* Mascheroder Weg 1, D-38124 Braunschweig, Germany, \* e-mail: info.genome@gbf.de

\* URL: http://genome.gbf.de/

and

\* Max-Planck Institute for Molecular Genetics, \* Ihnestrasse 73, D-14195 Berlin, Germany,

\* e-mail: info-chr21@molgen.mpg.de

\* URL: http://chr21.rz-berlin.mpg.de/

## FEATURES

## source

## source

## source

## source

## source

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="21"
/map="21q22.3"
<1..125946
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="21"
/map="21q22.3"
/clone="P16019, 5' partial"
/clone_lib="RPC11,3-5 PAC library"
/note="Accession No. AF121897"
73410..243533
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="21"
/map="21q22.3"
/clone="P70124"
/clone_lib="RPC11,3-5 PAC library"
/note="Accession No. AF064860"
224137..>340000
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="21"
/map="21q22.3"
/clone="P206A10, 3' partial"
/clone_lib="RPC11,3-5 PAC library"
/note="Accession No. AF121782"
286628..>340000

```

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="21"
/map="21q22.3"
/clone="BAC-29183, 3' partial"
/clone_lib="BAC library"
/note="Accession No. AF064857"
1088..1566
/note="L1M4"
/rpt_family="LINE/L1"
/rpt_type=DISPERSED
repeat_region
2398..2495
/note="(TCTA)n"
/rpt_family="Simple_repeat"
/rpt_type=TANDEM
complement(2496..2878)
/note="THE1C"
/rpt_family="LTR/MALR"
/rpt_type=DISPERSED
repeat_region
2879..2931
/note="(TCTA)n"
/rpt_family="Simple_repeat"
/rpt_type=TANDEM
2932..3004
/note="(TCCA)n"
/rpt_family="Simple_repeat"
/rpt_type=TANDEM
3005..3074
/note="(TCCA)n"
/rpt_family="Simple_repeat"
/rpt_type=TANDEM
repeat_region
3075..3157
/rpt_family="SH3BGR"
join(<3473..3565,12649..12678,15331..15460,18739..19157)
/note="SH3BGR"
join(3473..3565,12649..12678,15331..15426)
CDS
/partial
/gene="SH3BGR"
/note="Accession No. X93498"
/codon_start=1
/product="21-Glutamic Acid Rich protein 21-GARP"
/protein_id="CAB90445.1"
/db_xref="GI:7717370"
/translation="GSEKAEKGGTETAKRGSESDVGNLPKAEKNEEGTATETEE
IAMEGAEAEDEEETATGEPGEDEDS"
3473..3565
/gene="SH3BGR"
/number=4
repeat_region
5542..5829
/note="AluSx"
/rpt_family="SINE/Alu"
/rpt_type=DISPERSED
complement(6887..7067)
/note="L1MD3"
/rpt_family="LINE/L1"
/rpt_type=DISPERSED
repeat_region
complement(8482..8762)
/note="AluJo"
/rpt_family="SINE/Alu"
/rpt_type=DISPERSED
complement(8865..8964)
/note="L12"
/rpt_family="LINE/L12"
/rpt_type=DISPERSED
repeat_region
9131..9424
/note="AluSg"
/rpt_family="SINE/Alu"
/rpt_type=DISPERSED
complement(9723..9882)
/note="L12"
/rpt_family="LINE/L12"
/rpt_type=DISPERSED
complement(989..10077)

```

```

/note="L12"
/rpt_family="LINE/L12"
/rpt_type=DISPERSED
complement(10078..10429)
/note="THE1B"
/rpt_family="LTR/MALR"
/rpt_type=DISPERSED
complement(10430..10651)
/note="L12"
/rpt_family="LINE/L12"
/rpt_type=DISPERSED
repeat_region
10980..11000
/note="(TTTA)n"
/rpt_family="Simple_repeat"
/rpt_type=TANDEM
complement(11002..11282)
/note="AluSp"
/rpt_family="SINE/Alu"
/rpt_type=DISPERSED
complement(11315..11556)
/note="AluJo"
/rpt_family="SINE/Alu"
/rpt_type=DISPERSED
repeat_region
11702..11753
/note="MIR"
/rpt_family="SINE/MIR"
/rpt_type=DISPERSED
12649..12678
/gene="SH3BGR"
/number=5
complement(13115..13425)
/note="AluSx"
/rpt_family="SINE/Alu"
/rpt_type=DISPERSED
complement(13598..13892)
/note="AluY"
/rpt_family="SINE/Alu"
/rpt_type=DISPERSED
14013..14131
/note="(CA)n"
/rpt_family="Simple_repeat"

```

Query Match 28.0%; Score 326.6; DB 9; Length 340000;  
Best Local Similarity 97.4%; Pred. No. 9.8e-68;  
Matches 332; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 27	AAATATGAGACCCACCCGGTCTGCGTCTGGAATGAGATCATGAGAGCCCAAAATG	86
DB 268437	AAATGCTACTCTCCAGGTCTGGGTCTGTAATGAGTATGAGAGCCCAAAATG	268496
QY 87	CNAGAGTCTGAGAGGCTCCAGGCTCGCTCACTGACACCGTCTCCAGGGCTGGAAGC	146
DB 268497	CNAGAGTCTGAGAGGCTCCAGGCTCGCTCACTGACACCGTCTCCAGGGCTGGAAGC	268556
QY 147	TCATCATGTGGGCTCTCAGTGCAGATGATGGTGTAAAGCTCAGGCCATGAGCCATCA	206
DB 268557	TCATCATGTGGGCTCTCAGTGCAGATGATGGTGTAAAGCTCAGGCCATGAGCCATCA	268616
QY 207	TCACCAATGACCGCTTCACCTTCAGAGGTACGACGAGGCGGGAACCTTACCTGGGAGA	266
DB 268617	TCACCAATGACCGCTTCACCTTCAGAGGTACGACGAGGCGGGAACCTTACCTGGGAGA	268676
QY 267	TGATCATCCACCAATGTGAGAGCCAGTATTCGGGGGAACATCAGATCAGACCTCCAGAA	326
DB 268677	TGATCATCCACCAATGTGAGAGCCAGTATTCGGGGGAACATCAGATCAGACCTCCAGAA	268736
QY 327	GTCGCTCATGATGATGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCT	367
DB 268737	GTCGCTCATGATGATGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCT	268777

RESULT 9  
AC020851

LOCUS AC020851 196900 bp DNA linear HTG 15-JUL-2000  
 DEFINITION Mus musculus clone RP21-467L12, WORKING DRAFT SEQUENCE, 33  
 ACCESSION AC020851  
 VERSION AC020851.2 GI:9211212  
 KEYWORDS HTG; HTGS\_PHASE1; HTGS\_DRAFT.  
 SOURCE Mus musculus.  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE 1 (bases 1 to 196900)  
 AUTHORS DOE Joint Genome Institute.  
 TITLE Sequencing of Mouse  
 JOURNAL Unpublished  
 2 (bases 1 to 196900)  
 DIRECT SUBMISSION DOE Joint Genome Institute.  
 JOURNAL Submitted (10-JAN-2000) Production Sequencing Facility, DOE Joint  
 Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA  
 On Jul 15, 2000 this sequence version replaced gi:6686457.  
 COMMENT  
 Center: Joint Genome Institute  
 Center Code: JGI  
 Web site: <http://www.jgi.doe.gov>  
 Project Information  
 Center Project Name: 1437240  
 Center clone name: RP21-467L12

Summary Statistics  
 Consensus quality: 164618 bases at least Q40  
 Consensus quality: 180887 bases at least Q30  
 Consensus quality: 183777 bases at least Q20  
 Estimated insert size: 147000; pulse field gel estimation  
 Quality coverage: 5.67 in Q20 bases; sum-of-coverage estimation  
 Quality coverage: 4.3 in Q20 bases; pulse field gel estimation  
 NOTE: This is a 'working draft' sequence. It currently  
 consists of 33 contigs. The true order of the pieces  
 is not known and their order in this sequence record is  
 arbitrary. Gaps between the contigs are represented as  
 runs of N, but the exact sizes of the gaps are unknown.  
 This record will be updated with the finished sequence  
 as soon as it is available and the accession number will  
 be preserved.

1  
 1542 1541: contig of 1541 bp in length  
 1642 1641: gap of unknown length  
 3493 3492: contig of 1851 bp in length  
 3593 3592: gap of unknown length  
 4739 4738: contig of 1146 bp in length  
 4839 4838: gap of unknown length  
 7249 7248: contig of 2410 bp in length  
 7349 7348: gap of unknown length  
 9179 9178: contig of 1830 bp in length  
 9279 9278: gap of unknown length  
 11494 11493: contig of 2215 bp in length  
 11594 11593: gap of unknown length  
 13608 13607: contig of 2014 bp in length  
 13708 13707: gap of unknown length  
 15947 15946: contig of 2239 bp in length  
 16047 16046: gap of unknown length  
 18392 18392: contig of 2346 bp in length  
 18493 18492: gap of unknown length  
 21232 21231: contig of 2739 bp in length  
 21332 21331: gap of unknown length  
 24662 24662: contig of 3331 bp in length  
 24763 24762: gap of unknown length  
 27141 27140: contig of 2378 bp in length  
 27241 27240: gap of unknown length  
 29951 29950: contig of 2710 bp in length  
 30051 30050: gap of unknown length  
 32245 32245: contig of 2195 bp in length  
 32246 32245: gap of unknown length

32346 35688: contig of 3343 bp in length  
 35689 35788: gap of unknown length  
 35789 40387: contig of 4599 bp in length  
 40388 40487: gap of unknown length  
 40488 43580: contig of 3093 bp in length  
 43581 43680: gap of unknown length  
 43681 46437: contig of 2757 bp in length  
 46438 46537: gap of unknown length  
 46538 50184: contig of 3647 bp in length  
 50185 50284: gap of unknown length  
 50285 54572: contig of 4288 bp in length  
 54573 54672: gap of unknown length  
 54673 60327: contig of 5555 bp in length  
 60328 60327: gap of unknown length  
 60328 68024: contig of 7697 bp in length  
 68025 68124: gap of unknown length  
 68125 78610: contig of 10486 bp in length  
 78611 78710: gap of unknown length  
 78711 88151: contig of 9441 bp in length  
 88152 88251: gap of unknown length  
 88252 88251: gap of unknown length  
 88253 96258: contig of 8006 bp in length  
 96258 96358: gap of unknown length  
 96358 106327: contig of 9870 bp in length  
 106327 106327: gap of unknown length  
 106328 115795: contig of 9468 bp in length  
 115795 115895: gap of unknown length  
 115896 126363: contig of 10468 bp in length  
 126364 126463: gap of unknown length  
 126464 137189: contig of 10726 bp in length  
 137190 137289: gap of unknown length  
 137290 146378: contig of 9089 bp in length  
 146378 146478: gap of unknown length  
 146479 161686: contig of 15208 bp in length  
 161687 161786: gap of unknown length  
 161787 176149: contig of 14363 bp in length  
 176150 176249: gap of unknown length  
 176250 196900: contig of 20651 bp in length.

## FEATURES

1..196900  
 /organism="Mus musculus"  
 /db\_xref="taxon:10090"  
 /clone="RP21-467L12"  
 /clone.lib="RP21-467L12" mouse PAC library 21"

BASE COUNT 51456 a 43823 c 44608 g 53666 t 3347 others

Query Match 15.6%; Score 182.4; DB 2; Length 196900;  
 Best Local Similarity 72.3%; Pred. No. 4.8e-33;  
 Matches 237; Conservative 0; Mismatches 91; Indels 0; Gaps 0;

QY 37 CCCACCGGTTCTGGTCTGTAATGAAGTCATGAGGCCGCCCAAAATGACAGTCTCT 96  
 DB 67439 CCTTCTAGCTTCGGATCCAGTATCAGATCATGAAAGTCTCAGATTAACAGTCTT 96  
 QY 97 GAAGGCTCCCGAGCTCCCTTCACTGACCGTCTCCAGGGCTGGAAGTCAATGTTG 156  
 DB 67499 AAAGGACTCAGAGGCTCCTTCACTGACCGTCTCCAGGGCTGGAAGTCTTATGTC 156  
 QY 157 GCGTTCAGTACATATGTTGGTGTCTACGCTCAGGCGCATGAGCCATATCCACATATA 216  
 DB 67559 GACTTCTAACCAATGTTGGTGTCTACGCTCAGGCGCATGAGCCATATCCACATATA 216  
 QY 217 CCGCTTCACCTCTCAGAGGTCACGACCGTCCAGGGCGGAATTCCTCGAGATATATCA 276  
 DB 67619 CCGCTTCACCTCTCAGAGGTCACGACCGTCCAGGGCGGAATTCCTCGAGATATATCA 276  
 QY 277 CAATGTGAGGCCAGTATGTTGGGGAACATCAGATCAGCCCTCCAGACAGTCCCTGCA 336  
 DB 67679 TGATGTGAGGCCAGTATGTTGGGGAACATCAGATCAGCCCTCCAGACAGTCCCTGCA 336  
 QY 337 TGGATGTGCTTACCTTACGCTCCAGTT 364  
 DB 67739 TGGATGTGCTTACCTTACGCTCCAGTT 364



RESULT 10  
AX380408 754 bp DNA linear PAT 18-MAR-2002  
LOCUS  
DEFINITION Sequence 13 from Patent WO0200710.  
ACCESSION AX380408  
VERSION AX380408.1 GI:19575338  
KEYWORDS  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
1 Welcher, A.A., Sarmiento, U.M., Schultz, H.J. and Chute, H.T.  
AUTHORS B7-like molecules and uses thereof  
TITLE Patent: WO 0200710-A 13 03-JAN-2002;  
JOURNAL Amgen, Inc. (US)  
Location/Qualifiers

FEATURES  
source 1..754  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
53..724  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="CAD28222.1"  
/db\_xref="GI:19575338"  
/translation="MEGSRDYLAVLIIAOLTAAGSSVOIIEGPQNTYVTKDSEAH  
NCTVHGKMLMTLNMVYLSLTQGLITNNRFTYASYSSTDSFISELIHIDVPS  
DSGVSQCSLQNSHGFSAFLVSVDSTGEKPALEPMAIILAVAFSLILILVLI  
FCCCSARREKEESTYOMETIRKSNMTRKADDETKLSKSEKNGVSDPKAQAOTAS  
LPPKSAEVSLEPKRSSSLPYOELNKHOPGATPHRVSFDIASFOKRVNTLV"  
NYLV"

CDS  
15.6%; Score 181.8; DB 6; Length 754;  
Query Match Best Local Similarity 72.9%; Pred. No. 5.1e-33;  
Matches 234; Conservative 0; Mismatches 87; Indels 0; Gaps 0;

BASE COUNT 220 a 191 c 175 g 168 t  
ORIGIN

Query Match 15.6%; Score 181.8; DB 6; Length 754;  
Best Local Similarity 72.9%; Pred. No. 5.1e-33;  
Matches 234; Conservative 0; Mismatches 87; Indels 0; Gaps 0;

42 CCGGTTCTGGGTCTGTGAATGATAGTATAGAGGCCCAAAATGCAAGTCTCTGAAG 101  
108 CAGCTTCGGATCCAGTATACATAGAGGTCCTCAGAAATGTAAAGTCTTAAAG 167  
102 GCTCCAGGCTCGCTTCACTGACACCGTCCCGAGGCTGGAAGTCATCATGTGGGCTC 161  
168 ACTCAGAGGCTCACTTCAACGTCACCGGACTGACGGCTGGAAGCTTCTATGTGGACTC 227  
162 TCAGTGAATGGTGTGCTTAAGCGTCAGGCCCATGAGCCCATCATCACCATGACCGCT 221  
228 TTAACCAAAATGTGTGCTGCTGAGTCTCACACCAAGGACCATCATCACCACCAACCGCT 287  
222 TCACCTCTCAGAGTAGACAGCAGGGCGGAACTTCACTCGGAATATATATCCACATG 281  
288 TCACCTATCCAGTATACAAACAGCAGCTTCACTCGGAATATATATCCACATG 347  
282 TGAAGCCAGTATCGGGGAGCATCAGATGAGCGCTCCAAAGAGTCCGCTGATGAT 341  
348 TGAAGCCAGTATCGGGGAGCATCAGATGAGCGCTCCAAAGAGTCCGCTGATGAT 407  
342 CTGCTTACCTTACCGTCAAG 362  
408 CTGCTTCTCTCAGTCAAG 428

RESULT 11  
AX380406 895 bp DNA linear PAT 18-MAR-2002  
LOCUS  
DEFINITION Sequence 11 from Patent WO0200710.  
ACCESSION AX380406  
VERSION AX380406.1 GI:19575336  
KEYWORDS  
SOURCE house mouse.  
ORGANISM Mus musculus

REFERENCE  
1 Welcher, A.A., Sarmiento, U.M., Schultz, H.J. and Chute, H.T.  
AUTHORS B7-like molecules and uses thereof  
TITLE Patent: WO 0200710-A 11 03-JAN-2002;  
JOURNAL Amgen, Inc. (US)  
Location/Qualifiers

FEATURES  
source 1..895  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
53..865  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="CAD28221.1"  
/db\_xref="GI:19575337"  
/translation="MEGSRDYLAVLIIAOLTAAGSSVOIIEGPQNTYVTKDSEAH  
NCTVHGKMLMTLNMVYLSLTQGLITNNRFTYASYSSTDSFISELIHIDVPS  
DSGVSQCSLQNSHGFSAFLVSVDSTGEKPALEPMAIILAVAFSLILILVLI  
FCCCSARREKEESTYOMETIRKSNMTRKADDETKLSKSEKNGVSDPKAQAOTAS  
LPPKSAEVSLEPKRSSSLPYOELNKHOPGATPHRVSFDIASFOKRVNTLV"  
NYLV"

CDS  
15.6%; Score 181.8; DB 6; Length 895;  
Query Match Best Local Similarity 72.9%; Pred. No. 5.2e-33;  
Matches 224; Conservative 0; Mismatches 87; Indels 0; Gaps 0;

BASE COUNT 250 a 223 c 212 g 210 t  
ORIGIN

Query Match 15.6%; Score 181.8; DB 6; Length 895;  
Best Local Similarity 72.9%; Pred. No. 5.2e-33;  
Matches 224; Conservative 0; Mismatches 87; Indels 0; Gaps 0;

42 CCGGTTCTGGGTCTGTGAATGATAGTATAGAGGCCCAAAATGCAAGTCTCTGAAG 101  
108 CAGCTTCGGATCCAGTATACATAGAGGTCCTCAGAAATGTAAAGTCTTAAAG 167  
102 GCTCCAGGCTCGCTTCACTGACACCGTCCCGAGGCTGGAAGTCATCATGTGGGCTC 161  
168 ACTCAGAGGCTCACTTCAACGTCACCGGACTGACGGCTGGAAGCTTCTATGTGGACTC 227  
162 TCAGTGAATGGTGTGCTTAAGCGTCAGGCCCATGAGCCCATCATCACCATGACCGCT 221  
228 TTAACCAAAATGTGTGCTGCTGAGTCTCACACCAAGGACCATCATCACCACCAACCGCT 287  
222 TCACCTCTCAGAGTAGACAGCAGGGCGGAACTTCACTCGGAATATATATCCACATG 281  
288 TCACCTATCCAGTATACAAACAGCAGCTTCACTCGGAATATATATCCACATG 347  
282 TGAAGCCAGTATCGGGGAGCATCAGATGAGCGCTCCAAAGAGTCCGCTGATGAT 341  
348 TGAAGCCAGTATCGGGGAGCATCAGATGAGCGCTCCAAAGAGTCCGCTGATGAT 407  
342 CTGCTTACCTTACCGTCAAG 362  
408 CTGCTTCTCTCAGTCAAG 428

RESULT 12  
BC004806 1556 bp mRNA linear ROD 07-AUG-2002  
LOCUS  
DEFINITION Mus musculus, RIKEN cDNA 2010003D20 gene, clone MGC:7960  
IMAGE:3584645, mRNA, complete cds.  
ACCESSION BC004806  
VERSION BC004806.1 GI:13435932  
KEYWORDS  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
1 Strausberg, R.  
AUTHORS Direct Submission  
TITLE Submitted (21-MAR-2001) National Institutes of Health, Mammalian  
JOURNAL Gene Collection (MGC), Cancer Genomics Office, National Cancer  
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,  
USA  
MGC Project URL: <http://mgc.ncl.nih.gov>

## COMMENT

Contact: MGC help desk  
Email: cgaabs-remail.nih.gov  
Tissue Procurement: Gilbert Smith, Ph.D.  
cDNA Library Preparation: Life Technologies, Inc.  
DNA Sequencing by: The I.M.A.G.E. Consortium (LNL)  
Sequencing Center  
Center code: BCM-HGSC  
Web site: <http://www.hgsc.bcm.tmc.edu/cdna/>  
Contact: amg@bcm.tmc.edu  
Guanarone, P.H., Garcia, A.M., Lu, X., Huylk, S.W., Hale, S.M.,  
Yoon, V.S., Kowis, C.R., Lawrence, S., Martin, R.G., Muzny, D.M.,  
Richards, S., Gibbs, R.A.

Clone distribution: MGC clone distribution information can be found  
through the I.M.A.G.E. Consortium/LNL at: <http://image.lnl.gov>  
Series: IRK Plate: 10 Row: m Column: 23  
This clone was selected for full length sequencing because it  
passed the following selection criteria: Hexamer frequency ORF  
analysis.

## FEATURES

Location/Qualifiers  
1..1536  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
/map="FVB/N"  
/clone="MGC:7960 IMAGE:3584645"  
/tissue\_type="Mammary tumor. Metastatic/ontogen-TGF alpha  
model. 10 month old virgin mouse. Taken by biopsy."  
/clone\_id="NCL\_CGAP\_Mam1"  
/lab\_host="DH10B"  
/note="Vector: pCMV-SPORT6"  
55..867  
/codon\_start=1  
/product="Riken cDNA 2010003020 gene"  
/protein\_id="AAH04806.1"  
/db\_xref="GI:13435933"  
/db\_xref="LocusID:72058"  
/translation="MSSMRDLAVVLAQLAAGSSVOIEGPNVYAKDSAH  
NCVTHGKMLMTNOMVLSLTGPGITNNRPFYASNTSDSISLITLHDPS  
DSGVCSLONSHGFSAPLSVDSSTGGERPALPTAILLLVAESLLILITLII  
FCCCAARREESTYONETRKSNMRTKADETRLKSGKNGYSSDEAKAAQTAS  
LPRSAVSILPEKSSSLPQELNKHQPGPATPRVPSFDIASPOKRVNTLV"

## CDS

BASE COUNT 447 a 364 c 367 g 378 t  
ORIGIN

Query Match 15.6%; Score 181.8; DB 10; Length 1556;  
Best Local Similarity 72.9%; Pred. No. 5.3e-33;  
Matches 234; Conservative 0; Mismatches 87; Indels 0; Gaps 0;

42 CCGGTTGGGCTGCTATGAGTCTATAGAGCCCCCAAAATGCAAGATCCTGAAG 101  
110 CAGCTTCGGATCCATGATGATGATGATGATGATGATGATGATGATGATGAT 169  
102 GCTCCAGGCTCGCTTCACTGACGCTCCAGGCTGGAAGTCATCATCTGGCTC 161  
170 ACTGAGAGGCTCACTTCACTGACGCTTCACTGACGCTTCACTGACGCTC 229  
162 TCAGTGCATGAGTCTTCACTGAGGCTTCACTGAGGCTTCACTGAGGCTTCA 221  
230 TTAACCAATGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCT 289  
222 TCAGTGCATGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCT 281  
290 TCAGTGCATGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCT 349  
282 TGAAGCCAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAG 341  
350 TGAAGCCAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAGTCTGAG 409  
342 CTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTAC 362  
410 CTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTAC 430

## RESULT 13

AC120346/c

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

AC120346 175861 bp DNA linear HTG 09-MAY-2002  
Mus musculus clone RP23-147E11, WORKING DRAFT SEQUENCE, 22 ordered  
pieces.  
AC120346 GI:20514894  
HTG: HTGS PHASE2; HTGS\_DRAFT; HTGS\_FULLTOP.  
Mus musculus.  
Mus musculus.  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 175861)  
Birren, B., Linton, L., Nusbaum, C. and Lander, E.  
Mus musculus, clone RP23-147E11  
Unpublished  
2 (bases 1 to 175861)  
Birren, B., Linton, L., Nusbaum, C., Lander, E., Allen, N.,  
Anderson, S., Barna, N., Bastien, V., Bloom, T., Boguslavsky, L.,  
Boukhalter, B., Brown, A., Camarata, J., Campoliano, A., Chang, J.,  
Chazaro, B., Choepel, Y., Colangelo, M., Collins, S., Collymore, A.,  
Cook, A., Cooke, P., Dearellano, K., Dewar, K., Diaz, J.S., Dodge, S.,  
Faro, S., Ferreira, P., Fitzhugh, W., Gage, D., Galegan, J., Gardyna, S.,  
Ginde, S., Gord, S., Goyette, M., Hulme, W., Iliev, I., Johnson, R., Jones, C.,  
Kamat, A., Karatas, A., Kells, C., Lacroque, K., Lamazares, R.,  
Lander, T., Lehoczy, J., Levine, R., Lindblad-Toh, K., Liu, C.,  
Maclean, C., Macdonald, P., Major, J., Marguis, N., Matthews, C.,  
McCarthy, M., McEwan, P., McKernan, K., Meldrum, J., Menus, L.,  
Minova, T., Mienna, V., Murphy, T., Naylor, D., Nguyen, C., Nicol, R.,  
Oliver, J., Peterson, K., Phunkhang, P., Pletre, N., Pollara, V.,  
Raymond, C., Retta, R., Ribbeck, M., Riley, R., Rise, C., Rogov, P.,  
Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupack, R.,  
Seaman, S., Severy, P., Spencer, B., Stange-Thomann, N., Stojanovic, N.,  
Strauss, N., Subramanian, A., Talamas, J., Tesfaye, S., Theodore, J.,  
Tophan, K., Travers, M., Travis, N., Triggillo, J., Vassiliev, H.,  
Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W.D., Young, G.,  
Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.  
Direct Submission  
Submitted (06-MAY-2002) Whitehead Institute/MIT Center for Genome  
Research, 320 Charles Street, Cambridge, MA 02141, USA  
3 (bases 1 to 175861)  
Anderson, S., Linton, L., Nusbaum, C., Lander, E., Allen, N.,  
Boukhalter, B., Brown, A., Camarata, J., Campoliano, A., Chang, J.,  
Chazaro, B., Choepel, Y., Colangelo, M., Collins, S., Collymore, A.,  
Cook, A., Cooke, P., Dearellano, K., Dewar, K., Diaz, J.S., Dodge, S.,  
Faro, S., Ferreira, P., Fitzhugh, W., Gage, D., Galegan, J., Gardyna, S.,  
Ginde, S., Gord, S., Goyette, M., Hulme, W., Iliev, I., Johnson, R., Jones, C.,  
Kamat, A., Karatas, A., Kells, C., Lacroque, K., Lamazares, R.,  
Lander, T., Lehoczy, J., Levine, R., Lindblad-Toh, K., Liu, G.,  
Maclean, C., Macdonald, P., Major, J., Marguis, N., Matthews, C.,  
McCarthy, M., McEwan, P., McKernan, K., Meldrum, J., Menus, L.,  
Minova, T., Mienna, V., Murphy, T., Naylor, D., Nguyen, C., Nicol, R.,  
Oliver, J., Peterson, K., Phunkhang, P., Pletre, N., Pollara, V.,  
Raymond, C., Retta, R., Ribbeck, M., Riley, R., Rise, C., Rogov, P.,  
Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupack, R.,  
Seaman, S., Severy, P., Spencer, B., Stange-Thomann, N., Stojanovic, N.,  
Strauss, N., Subramanian, A., Talamas, J., Tesfaye, S., Theodore, J.,  
Tophan, K., Travers, M., Travis, N., Triggillo, J., Vassiliev, H.,  
Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W.D., Young, G.,  
Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.  
Direct Submission  
Submitted (09-MAY-2002) Whitehead Institute/MIT Center for Genome  
Research, 320 Charles Street, Cambridge, MA 02141, USA  
On May 9, 2002 this sequence version replaced gi:20503171.  
All repeats were identified using RepeatMasker:  
Smit, A.F.A. & Green, P. (1996-1997)  
<http://ftp.genome.washington.edu/RM/RepeatMasker.html>

```

source
1. .175861
/organism="Mus musculus"
/db_xref="taxon:10090"
/clone="RP23-147E11"
/clone_1db="RCI-23 Female Mouse BAC"
1. .28835
/note="assembly-fragment"
clone_end:SP6
vector_side:left"
28936..29562
/note="assembly-fragment"
29663..30328
/note="assembly-fragment"
30429..32005
/note="assembly-fragment"
32106..33128
/note="assembly-fragment"
33229..34512
/note="assembly-fragment"
34613..36079
/note="assembly-fragment"
36180..37483
/note="assembly-fragment"
37584..39166
/note="assembly-fragment"
39267..41065
/note="assembly-fragment"
41166..43203
/note="assembly-fragment"
43304..47489
/note="assembly-fragment"
47590..50604
/note="assembly-fragment"
50705..556370
/note="assembly-fragment"
556471..64079
/note="assembly-fragment"
64180..72619
/note="assembly-fragment"
72720..81566
/note="assembly-fragment"
81667..96774
/note="assembly-fragment"
96875..119647
/note="assembly-fragment"
119748..147772
/note="assembly-fragment"
147873..174557
/note="assembly-fragment"
174658..175861
/note="assembly-fragment"
clone_end:T7
vector_side:right"

BASE COUNT      48903 a   39540 c   39029 g   46286 t   2103 others
ORIGIN
Query Match      14.7%:   Score 171.4:   DB 2:   Length 175861:
Best Local Similarity 72.0%:   Pred. No. 2.1e-30:
Matches 237; Conservative 0; Mismatches 91; Indels 1; Gaps 1

OY      37  CCCACCCGGTCTGGGTGCTGTAATGAATCTATAAGGCCCCCAAAATGCACAGTCTCT 96
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 120535 CCTTCTAGCTTCGGATCCAGTTCATTAATCATATTAAGAAGTCTCTAGATGTAAACAGTCTT 120476

OY      97  GAAGGGCTCCAGGCTCGCTTCAATGCACCGT-CTCCAGAGGCTGGAAGCTCATCATGT 155
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 120475 AAAGGACTCAGAGGCTCACCTTCAACTGACCGCTGGGCTTCAGGGTGAAGCTTCTCATGT 120416

OY      156  GGGCTCTCAGTGACATCGTGCTGTCTAAAGGTGAGGCCATGAGGCCCATTCATCACCAATG 215
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 120415 GAGCTCTTAACCAATAGTGATGCTCAGTCTACCAACCAAGAACCATCATCACCAACA 120356

OY      216  ACCGCTTACACCTCTCAGAGGTACAGACAGGGCGGGAATTCACTCGGAGATGATCATCC 275

```

Db 120355 ACCGGTCACTAATGCGCAGTTACACAACAGCACTGCACACTCTTAATCTGGAACTTATATATCC 120296  
QY 276 ACAATGTGAGACCCAGTGATTCGGGGAAATCAATCAATGATCCAGCTCCCAAGAACATGTGGCTGC 335  
Db 120295 ATGATGTGCACACCCAGTGACATCGGGATCCCTGCAATGCACTCTGCAAGAACAGCATGGGT 120236  
QY 336 ATGGATCGCTTACTTACCTTAACGCTCCAAATT 364  
Db 120235 TTGGATCTGCTTCTCTCTCAATGCAAGGT 120207

RESULT 14

LOCUS	199665 bp	DNA	linear	PRI 23-JUN-1998
DEFINITION	Homo sapiens BAC derived from chromosome 21q22.3, complete sequence, containing PEP19 (PCP4) gene.			
ACCESSION	AF064857			
	AF064857			

VERSION	AF064857.1	GI:3171149
KEYWORDS	HTG.	
SOURCE	Homo sapiens.	
ORGANISM		

**REFERENCE**

Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.  
1 (bases 1 to 199665).

Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.  
1 (bases 1 to 199665).

Schattevoy, R. and Rosenthal, A.

**TITLE** Direct Submission  
**JOURNAL** Submitted (11-MAY-1998) Genome Analysis  
**Institute for Veterinary Medicine**

Biotechnology, Beutenbergstrasse 11, Jena 07745, Germany  
Location/Qualifiers

**source**

1. 199665

```
/organism="Homo sapiens"  
/db_xref="taxon:9606"
```

```
repeat_region /map="21q22.3"
complement(1. .383)
```

```
repeat_region      /rpt_family="L1"  
747.      .814
```

```
repeat_region      /LPL-family:="MIR"  
complement(1345.  .1500)
```

repeat_region	12pc_family- L1FA4
1499..1588	

```
repeat_region  
/rpt_family="L1PA2"  
complement(1584..2179)
```

```
repeat_region      /rpt_family="LIPAZ"
2174. .3405
```

```
repeat_region 3388. .3454 /4 pc_family="LIPAZ"
```

```
repeat_region
3968.4086
```

repeat_region	complement(6245, .6668)
1	1
2	1
3	1
4	1
5	1
6	1
7	1
8	1
9	1
10	1
11	1
12	1
13	1
14	1
15	1
16	1
17	1
18	1
19	1
20	1
21	1
22	1
23	1
24	1
25	1
26	1
27	1
28	1
29	1
30	1
31	1
32	1
33	1
34	1
35	1
36	1
37	1
38	1
39	1
40	1
41	1
42	1
43	1
44	1
45	1
46	1
47	1
48	1
49	1
50	1
51	1
52	1
53	1
54	1
55	1
56	1
57	1
58	1
59	1
60	1
61	1
62	1
63	1
64	1
65	1
66	1
67	1
68	1
69	1
70	1
71	1
72	1
73	1
74	1
75	1
76	1
77	1
78	1
79	1
80	1
81	1
82	1
83	1
84	1
85	1
86	1
87	1
88	1
89	1
90	1
91	1
92	1
93	1
94	1
95	1
96	1
97	1
98	1
99	1
100	1

repeat_region	6671	.6969
evidence	not	overestimated

```
repeat_region complement(7057. 7376)
/evidence=not experimental
```

```
repeat_region complement(7387. .7491)
/evidence=not experimental
```

```
repeat_region      /rpt_family="LIME3A"  
7781. .8020
```

```
/evidence=not_experimental
/rpt_family="MER58A"
repeat_region 8650 8823
```

```
repeat_region complement(10456. ,10720) /rpt_family="L1PA5"
```

```
repeat_region
/rt_family="L2"
complement(13514..13814)
```

```
repeat_region  
complement(13823, .14116)
```

```
repeat_region      /rpt_family="Alu0"  
complement(15662. 15785)  
/evidence=not experimental
```

```
repeat_region      complement(18994, .19347)
/evidence=not experimental
```

```
repeat_region 19378. 19470
/note="homology = 81.70%, s
```

```
repeat_region      /rpt_unit=agtatctattctgattc  
complement(20371..20556)
```

```
repeat_region 21213. 21500
```

```
repeat_region 22291. .22567
```

```
repeat_region
complement(22583..23201)
/ovidna.com-not available/
```

```
repeat_region 23202. 23471
/evidence=not exported
```

```
repeat_region 24223. 24454 /evidence=not_experimental
```

```
repeat_region 24455. 24889
/evidence=not_experimental
```

```
repeat_region complement(25434. .25767)
/evidence=not_experimental
```

```

repeatedly 25993. 26294
/evidence=not_experimental

```

```
2/222 : 2/2/205
/evidence=not_experimental
```

```
complement(20002:125555)
/evidence=not_experimental
```

```
/evidence=not_experimental
/ent_family=1000000000
```

```
/evidence=not_experimental
/ont_family="Mrna"
```

```
/evidence=not_experimental
/rnt_familyv="MT1A2"
```

```
/evidence=not_experimental
/rpt_family="MSTD"
```

```
repeat_region complement(32766..32980)
/evidence=not_experimental
```

Query Match	8.6%	Score 100;	DB 9;	Length 199665;
Best Local Similarity	100.0%;	Pred. No. 3.3e-13;		
Matches 100;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

OY	1069	CCAGCGGGCTATCAACGTCACCCAGGCAGCAGTATCACAGGGCTTTTAATCT	1128
Db	17555	CCAGCGGGCTATCAACGTCACCCAGGCAGCAGTATCACAGGGCTTTTAATCT	17614
OY	1129	GGCCAGTCTTGAGAAGTCACTAATACTAGTAGTAG	1168
Db	17615	GGCCAGTCTTGAGAAGTCACTAATACTAGTAGTAG	17654
RESULT 15			
AC020851/c			
LOCUS			
DEFINITION		Mus musculus clone RP21-467I12, WORKING DRAFT SEQUENCE, 33	
ACCESSION		AC020851	196900 bp DNA linear HTG 15-JUL-2000
VERSION		AC020851.2	
KEYWORDS		HTG; HTGS_PHASE1; HTGS_DRAFT.	
SOURCE		Mus musculus.	
ORGANISM		Mus musculus	
REFERENCE		Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
AUTHORS		Mammalia; Eutheria; Rodentia; Sclurognathii; Muridae; Murinae; Mus.	
TITLE		1 (bases 1 to 196900)	
JOURNAL		DOE Joint Genome Institute.	
REFERENCE		Sequencing of Mouse	
AUTHORS		Unpublished	
TITLE		2 (bases 1 to 196900)	
JOURNAL		DOE Joint Genome Institute.	
REFERENCE		Direct Submission	
AUTHORS		Submitted (10-JAN-2000) Production Sequencing Facility, DOE Joint	
TITLE		Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	
JOURNAL		On Jul 15, 2000 this sequence version replaced gi:5686457.	
COMMENT		-----Genome Center	
		Center: Joint Genome Institute	
		Center code: JGI	
		Web site: http://www.jgi.doe.gov	
		-----	
		Project Information	
		Center Project Name: 1437240	
		Center clone name: RPC1-21_467I12	
		-----	
		Summary Statistics	
		Consensus quality: 164618 bases at least Q40	
		Consensus quality: 180887 bases at least Q30	
		Consensus quality: 183777 bases at least Q20	
		Estimated insert size: 147000; pulse field gel estimation	
		Estimated insert size: 193700; sum-of-contigs estimation	
		Quality coverage: 5.67 in Q20 bases; pulse field gel estimation	
		Quality coverage: 4.3 in Q20 bases; sum-of-contigs estimation.	
		* NOTE: This is a 'working draft' sequence. It currently	
		* consists of 33 contigs. The true order of the pieces	
		* is not known and their order in this sequence record is	
		* arbitrary. Gaps between the contigs are represented as	
		* runs of N, but the exact sizes of the gaps are unknown.	
		* This record will be updated with the finished sequence	
		* as soon as it is available and the accession number will	
		* be preserved.	
*	1	1541: contig of 1541 bp in length	
*	1542	1641: gap of unknown length	
*	1642	3492: contig of 1851 bp in length	
*	3493	3592: gap of unknown length	
*	3593	4738: contig of 1146 bp in length	
*	4739	4838: gap of unknown length	
*	4839	7248: contig of 2410 bp in length	
*	7249	7348: gap of unknown length	
*	7349	9178: contig of 1830 bp in length	
*	9179	9278: gap of unknown length	
*	9279	11493: contig of 2215 bp in length	
*	11494	11593: gap of unknown length	
*	11594	13607: contig of 2014 bp in length	
*	13608	13707: gap of unknown length	
*	13708	15946: contig of 2239 bp in length	
*	15947	16046: gap of unknown length	
*	16047	18392: contig of 2346 bp in length	

Search completed: April 29, 2003, 14:30:21  
Job time : 4416.94 secs

```
* 18393 18492: gap of unknown length
* 18493 21231: contig of 2739 bp in length
* 21232 21331: gap of unknown length
* 21332 24662: contig of 3331 bp in length
* 24663 27140: contig of 2378 bp in length
* 27141 27240: gap of unknown length
* 27241 29950: contig of 2710 bp in length
* 29951 30050: gap of unknown length
* 30051 32245: contig of 2195 bp in length
* 32246 32345: gap of unknown length
* 32346 35688: contig of 3343 bp in length
* 35689 35788: gap of unknown length
* 35789 40387: contig of 4599 bp in length
* 40388 40487: gap of unknown length
* 40488 43580: contig of 3093 bp in length
* 43581 43680: gap of unknown length
* 43681 46437: contig of 2757 bp in length
* 46438 46537: gap of unknown length
* 46538 50184: contig of 3647 bp in length
* 50185 50284: gap of unknown length
* 50285 54572: contig of 4288 bp in length
* 54573 54672: gap of unknown length
* 54673 60227: contig of 5555 bp in length
* 60228 60327: gap of unknown length
* 60328 68024: contig of 7697 bp in length
* 68025 68124: gap of unknown length
* 68125 78610: contig of 10486 bp in length
* 78611 78710: gap of unknown length
* 78711 88151: contig of 9441 bp in length
* 88152 88251: gap of unknown length
* 88252 96257: contig of 8006 bp in length
* 96258 96357: gap of unknown length
* 96358 106227: contig of 9870 bp in length
* 106228 106327: gap of unknown length
* 106328 115795: contig of 9468 bp in length
* 115796 115895: gap of unknown length
* 115896 126363: contig of 10468 bp in length
* 126364 126463: gap of unknown length
* 126464 137189: contig of 10726 bp in length
* 137190 137289: gap of unknown length
* 137290 146378: contig of 9089 bp in length
* 146379 146478: gap of unknown length
* 146479 161686: contig of 15208 bp in length
* 161687 161786: gap of unknown length
* 161787 176149: contig of 14363 bp in length
* 176150 176249: gap of unknown length
* 176250 196900: contig of 20651 bp in length.
```

FEATURES  
source  
1. 196900  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
/clone="RP21-467L12"  
/clone\_lib="RP21 mouse PAC library 21"

BASE COUNT 51456 a 43823 c 44608 g 53666 t 3347 others  
ORIGIN

Query Match 4.9%; Score 57.4; DB 2; Length 196900;  
Best Local Similarity 66.7%; Pred. No. 0.0058;  
Matches 82; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

```
QY 1045 AACAGTAGCTGCGCCCTCCACGAGGCGGTGATCAAGTCACCGCCAGGCGCAG 1104
      |||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db 119051 ACACTGACCTTCTACCTTGTTACCAAGACATATAACATCACGCCGTCACAG 118992
      |||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
QY 1105 TCATCCACAGGCTTTTATCTGCGCAGTCTCTGAGAAAGTGTAGTAATACACTG 1164
      |||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
Db 118991 TCATCCACAGGCTTTCTTACATCGCCAGTCTCTCAGAAAGTGTAGTACTT 118932
      |||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
```

QY 1165 ATA 1167  
||  
Db 118931 GTA 118929

\* . . \*

GenCore version 5.1.4.p5.4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 28, 2003, 16:24:30 ; Search time 10.2617 Seconds  
(without alignments)  
1543.990 Million cell updates/sec

Title: US-09-729-264-2

Perfect score: 2059  
Sequence: 1 MGVIPLHSGSGSNEVIEGP.....HPOASFNLASPERKVSNTTVV 382

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database: SwissProt\_40.\*

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	147.5	7.2	404	1 RAGE_HUMAN	Q15109 homo sapien
2	131	6.4	337	1 G55A_CHICK	Q98892 gallus gall
3	129.5	6.3	344	1 MTR1_RAT	Q62718 rattus norv
4	128	6.2	353	1 CEPV_CHICK	Q90773 gallus gall
5	128	6.2	1447	1 DCC_HUMAN	P43146 homo sapien
6	128	6.2	1914	1 KMLS_HUMAN	O15746 homo sapien
7	127	6.2	1447	1 DCC_MOUSE	P70211 mus musculu
8	124	6.0	1070	1 PTK7_HUMAN	O13308 homo sapien
9	120	5.8	345	1 OPCM_HUMAN	Q14982 homo sapien
10	119	5.8	345	1 OPCM_BOVIN	P11834 bos taurus
11	118	5.7	345	1 OPCM_RAT	P32736 rattus norv
12	117.5	5.7	1443	1 NEOL_CHICK	Q90610 gallus gall
13	116	5.6	4393	1 PGBM_HUMAN	P98160 homo sapien
14	114.5	5.6	1461	1 NEOL_HUMAN	Q92859 homo sapien
15	113.5	5.5	416	1 RAGE_BOVIN	Q28173 bos taurus
16	113.5	5.5	1377	1 NEOL_RAT	P97603 rattus norv
17	112	5.4	764	1 ICCR_DROME	Q68180 dirosophila
18	110.5	5.4	524	1 BUTY_MOUSE	Q62556 mus musculu
19	110.5	5.4	620	1 SMP_COTIA	Q92154 coturnix co
20	109.5	5.3	249	1 CSF_DROME	Q92154 coturnix co
21	107	5.2	365	1 CXAR_HUMAN	P78310 homo sapien
22	107	5.2	3707	1 PGBM_MOUSE	Q05799 mus musculu
23	106.5	5.2	333	1 AMAL_DROME	P15364 dirosophila
24	106	5.1	319	1 A33_HUMAN	Q99799 homo sapien
25	106	5.1	862	1 NCAL_XENLA	P36333 xenopus lae
26	104.5	5.1	879	1 FRP_RAT	P35329 mus musculu
27	104.5	5.1	338	1 LAMP_CHICK	Q62786 rattus norv
28	103.5	5.0	890	1 TYO3_HUMAN	Q98919 gallus gall
29	103.5	5.0	344	1 CD2_MOUSE	Q06418 homo sapien
30	102.5	5.0	348	1 KIL0_RAT	P08921 rattus norv
31	102.5	5.0	365	1 CXAR_MOUSE	Q92018 rattus norv
32	102.5	5.0	2499	1 MPRL_BOVIN	P97792 mus musculu
33	102.5	5.0	2499	1 MPRL_BOVIN	P08169 bos taurus

34	102	5.0	880	1 TYO3_RAT	P55146 rattus norv
35	100.5	4.9	873	1 FAS2_DROME	P34082 dirosophila
36	100	4.9	1241	1 NPHN_HUMAN	O60500 homo sapien
37	99.5	4.8	261	1 KLR8_RAT	P36374 rattus norv
38	99.5	4.8	1260	1 CAML_MOUSE	P11627 mus musculu
39	99.5	4.8	1906	1 KMLS_CHICK	P11799 gallus gall
40	99.5	4.8	2481	1 UN52_CAEEL	O06561 caenorhabdi
41	99	4.8	338	1 LAMP_HUMAN	Q13449 homo sapien
42	99	4.8	359	1 LAMP_RAT	Q62813 rattus norv
43	99	4.8	830	1 LACH_DROME	Q24372 dirosophila
44	99	4.8	830	1 SREC_HUMAN	O14162 homo sapien
45	99	4.8	880	1 TYO3_MOUSE	P55144 mus musculu

## ALIGNMENTS

RESULT 1  
RAGE\_HUMAN STANDARD; PRT; 404 AA.  
ID RAGE\_HUMAN  
AC Q15109; Q15279; Q9Y3R3; Q9H2X7;  
DT 01-NOV-1997 (Rel. 35, Created)  
DT 01-NOV-1997 (Rel. 35, Last sequence update)  
DT 15-JUN-2002 (Rel. 41, Last annotation update)  
DE Advanced glycosylation end product-specific receptor precursor  
DE (Receptor for advanced glycosylation end products).  
GN AGER OR RAGE.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A. (ISOFORM 1).  
RC TISSUE=Lung;  
RX MEDLINE=92340547; PubMed=1378843;  
RA Neepser M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C.,  
RA Elliston K., Stern D., Shaw A.;  
RT "Cloning and expression of a cell surface receptor for advanced  
RT glycosylation end products of proteins.";  
RT J. Biol. Chem. 267:14998-15004(1992).  
RL [2]  
RN SEQUENCE FROM N.A. (ISOFORM 1).  
RP MEDLINE=95137587; PubMed=7835890;  
RX Suwaya K., Fukagawa T., Matsumoto K., Mita K., Takahashi E., Ando A.,  
RA Inoko H., Ikemura T.;  
RT "Three genes in the human MHC class III region near the junction with  
RT the class II gene for receptor of advanced glycosylation end  
RT products, PBX2 homeobox gene and a notch homolog, human counterpart  
RT of mouse mammary tumor gene int-3.";  
RT Genomics 23:408-419(1994).  
RL [3]  
RN SEQUENCE FROM N.A. (ISOFORM 1).  
RP Rowen L., Dankers C., Baskin D., Faust J., Loretz C., Ahearn M.E.,  
RA Banta A., Spies T., Hood L.;  
RL Submitted (Feb-1997) to the EMBL/GenBank/DBJ databases.  
RN [4]  
RP SEQUENCE FROM N.A. (ISOFORM 1), AND VARIANT ARG-100.  
RA Abeid M.J., Yonekura H., Migita H., Karasawa J., Yamamoto Y.;  
RL "Molecular heterogeneity of the receptor for advanced glycation  
RT endproducts.";  
RT Submitted (Jan-2000) to the EMBL/GenBank/DBJ databases.  
RL [5]  
RN SEQUENCE FROM N.A. (ISOFORM 2).  
RP Mallerbe P., Richards J., Galliard H., Thompson A., Diener C.,  
RA Schuler A., Huber G.;  
RT "CDNA cloning of a novel secreted isoform of the human Receptor for  
RT Advanced Glycation End products (RAGE) and characterization of cells  
RT co-expressing cell-surface scavenger receptors and Swedish mutant  
RT amyloid precursor protein.";  
RL Submitted (May-1999) to the EMBL/GenBank/DBJ databases.  
RN [6]  
RP SEQUENCE FROM N.A. (ISOFORM 1).

RC TISSUE-Lung;  
 RA Strausberg R.;  
 RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.  
 RN [7]  
 RP SEQUENCE OF 1-12 FROM N.A.  
 RA Hudson B.I., Futers T.S.;  
 RT "Novel polymorphisms in the receptor for advanced glycation  
 end-products (RAGE) gene."  
 RL Submitted (NOV-1999) to the EMBL/GenBank/DBJ databases.  
 CC -1- FUNCTION: MEDIATES INTERACTIONS OF ADVANCED GLYCOSYLATION END  
 PRODUCTS (AGE). THESE ARE NONENZYMATICALLY GLYCOSYLATED PROTEINS  
 WHICH ACCUMULATE IN VASCULAR TISSUE IN AGING AND AT AN ACCELERATED  
 RATE IN DIABETES.  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein (isoform 1).  
 CC -1- Secreted (isoform 2).  
 CC -1- ALTERNATIVE PRODUCTS: 2 ISOFORMS: 1 (SHOWN HERE) AND 2/RAGESEC;  
 CC ARE PRODUCED BY ALTERNATIVE SPLICING.  
 CC -1- TISSUE SPECIFICITY: ENDOTHELIAL CELLS.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.  
 CC -1- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.  
 CC -1- SIMILARITY: CONTAINS 2 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL Outstation  
 the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; M91211; AA03574.1; -  
 DR EMBL; D28769; BA05958.1; -  
 DR EMBL; U89336; AA04791.1; -  
 DR EMBL; AB036432; BA089369.1; -  
 DR EMBL; AJ133822; CAB43108.1; -  
 DR EMBL; BC020669; AA020669.1; -  
 DR EMBL; AF208289; AAG35728.1; -  
 DR Genbank; HGNC:320; AGER.  
 DR MIM; 600214; -  
 DR InterPro; IPR003006; Ig\_MHC.  
 DR InterPro; IPR003598; Ig\_C2.  
 DR InterPro; IPR003600; Ig\_Like.  
 DR Pfam; PF00047; Ig; 2.  
 DR SMART; SMO0410; Ig\_Like; 1.  
 DR SMART; SMO0408; IGG2; 1.  
 DR PROSITE; PS00290; Ig\_MHC; 1.  
 DR Immunoglobulin domain; Glycoprotein; Transmembrane; Repeat; Signal;  
 KW Alternative splicing; Polymorphism.  
 FT SIGNAL 1 22  
 FT CHAIN 23 404  
 FT -----  
 FT DOMAIN 23 342  
 FT TRANSMEM 343 363  
 FT DOMAIN 364 404  
 FT DOMAIN 31 106  
 FT DOMAIN 137 215  
 FT DOMAIN 252 308  
 FT DISULFID 38 99  
 FT DISULFID 144 208  
 FT DISULFID 259 301  
 FT CARBOHYD 25 25  
 FT CARBOHYD 81 81  
 FT DOMAIN 380 384  
 FT VARSPPLIC 54 67  
 FT VARSPPLIC 275 404  
 FT -----  
 FT VARIANT 100 100  
 FT CONFLICT 1 1  
 M -> G (IN REF. 1).  
 O -> R.  
 /FTID=VAR\_011338.  
 M -> G (IN REF. 1).

SQ SEQUENCE 404 AA: 42802 MW: 0D584C436C30CCE7 CRC64;  
 Query Match  
 Best Local Similarity 7.2%; Score 147.5; DB 1; Length 404;  
 Matches 85; Conservative 40; Mismatches 114; Indels 137; Gaps 18;  
 QY 15 EVIEGPNATVLKSGARFCVYSOG---WKIMMALSDMYVLSRPMPIITNDRTS- 70  
 DB 125 EIVDSASELTA--GVNKKGTGVSESGYPAGLTSLHLLG-----KPLVPEKGVSY 173  
 QY 71 ----QRYDGGNT--SEMIINVEPSDGNIR---CSLONSRLHGSAYLTVOVMGELE 120  
 DB 174 KEQTRRHHPETGFTLOSELN---VTPARGDPRPTFSCSFSPGLPRHRLATATIQRRW 230  
 QY 121 IP-----SVNLVAENRP-----CEVCLSHMTRLPDLSWEGLVSHSSV 162  
 DB 231 EAPVLEEVGLVY---EPREGANAPGQVTLVCEVPAQS-----PQIHMMD----- 274  
 QY 163 YVPEPSDLSQASVSLALTPQSGTGLTCVATWKSLSKRSATVNLTVRCPODTGGGINI 222  
 DB 275 -GVPLPSPVPLILPEIGPODQGYSCVATHSHSGPDSRAVSISIE-PEEG----- 327  
 QY 223 PGVLSLSLSIGSLPTMGKVGIGLAGTMLP-----PCTLTIRCCCRRCGCCNC 275  
 DB 328 -----PTASVSGSLGTLALALGILGLGTLALIGVILMQRR----- 366  
 QY 276 CACCCCRKRRKFRIFQFKSEKERT--NKELETESNGNSGVNSDEKTTDTASLPPKS 333  
 DB 367 -----ORGEERKAPENOEEERAEIN----- 389  
 QY 334 CESSDPEQNSCGPP 349  
 DB 390 -QSEPEAGSGSTGGP 404  
 RESULT 2  
 G55A\_CHICK STANDARD; PRT; 337 AA.  
 AC Q98892;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Neurite inhibitor GP35-A precursor (OBCAM protein gamma isoform).  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinoptera; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 OX NCBI\_TaxID=9031;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE-Brain;  
 RA Lodge A.P., Kim D.-S., Howard M.R., McNamee C.J., Smith N., Moss D.J.;  
 RT "Cloning of CEPU-8, a secreted isoform of CEPU-1, and OBCAM cDNAs from  
 chick: structural diversity of Iqon family proteins."  
 RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.  
 RN [2]  
 RP SEQUENCE OF 64-337 FROM N.A., AND PARTIAL SEQUENCE.  
 RC TISSUE-Brain;  
 RX MEDLINE=97157768; PubMed=9004047;  
 RA Wilson D.J.A., Kim D.-S., Clarke G.A., Marshall-Clarke S., Moss D.J.;  
 RT "A family of glycoproteins (GP55), which inhibit neurite outgrowth,  
 are members of the Ig superfamily and are related to OBCAM,  
 J. Cell Sci. 109:3129-3138(1996).  
 CC -1- FUNCTION: INHIBITS NEURITE OUTGROWTH.  
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.  
 CC -1- TISSUE SPECIFICITY: RESTRICTED TO THE NERVOUS SYSTEM.  
 CC -1- DEVELOPMENTAL STAGE: INCREASES DURING DEVELOPMENT FROM VERY LOW  
 CC LEVELS AT EMBRYONIC DAY 10 AND IS MOST ABUNDANT AFTER HATCHING.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGLON  
 CC SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.



DR	EMBL: Y08170; CAB41420.1;	-
DR	InterPro: IPR003006; IG_MHC.	
DR	InterPro: IPR003598; IG_c2.	
DR	InterPro: IPR003600; Ig_like.	
DR	Pfam: PF00047; Ig_3.	
DR	SMART: SM00410; IG_Like; 1.	
DR	SMART; SM00408; IGc2; 2.	
KW	Immunoglobulin domain; Cell adhesion; Glycoprotein; GPI-anchor;	
KW	Repeat; Signal.	
FT	SIGNAL	1 .. 20
FT	CHAIN	21 .. 317
FT	PROPEP	318 .. 337
FT	DOMAIN	43 .. 115
FT	DOMAIN	143 .. 201
FT	DOMAIN	229 .. 295
FT	DISELID	50 .. 108
FT	DISELID	150 .. 194
FT	DISELID	236 .. 288
FT	CARBOHYD	133 .. 133
FT	CARBOHYD	277 .. 277
FT	CARBOHYD	285 .. 285
FT	CARBOHYD	298 .. 298
SQ	SEQUENCE	337 AA; 36887 MW; BAE7155185651E CRC64;

Struyk A.F., Canoll P.D., Wolfgang M.J., Rosen C.L., D'Eustachio P., Salzer J.L.: "Cloning of neurotrophin defines a new subfamily of differentially expressed neural cell adhesion molecules." J. Neurosci. 15:2141-2156 (1995).

J. Neurosci. 15:2141-2156 (1995).

-1- FUNCTION: NEURAL CELL ADHESION MOLECULE.

-1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.

-1- TISSUE SPECIFICITY: CENTRAL NERVOUS SYSTEM.

-1- DEVELOPMENTAL STAGE: EXPRESSED AT HIGH LEVELS IN SEVERAL SUBPLATE, AND LOWER CORTICAL LAMINAE IN THE FOREBRAIN AND IN POSTNATAL NUCLEUS, CEREBELLAR GRANULE CELLS, AND POKKING CELLS IN THE HINDRAIN.

-1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGLON

SUPERFAMILY.

-1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.

-----

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as their content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.isb-sib.ch/announce/> or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).

-----

CC EMBL: U16845; AAA67445.1; -

DR InterPro: IPR003006; Iq\_MHC.

DR InterPro: IPR003598; Iq\_C2.

DR InterPro: IPR003600; Iq\_Like.

DR Pfam: PF00047; Iq; 3.

DR SMART: SM00410; Iq\_Like; 1.

DR SMART: SM00408; IqC2; 2.

DR Immunoglobulin domain; Cell adhesion; Glycoprotein; GPI-anchor;

KM Repeat; Signal 1 31

FM CHAIN 321

FM PROPEP 322

FM DOMAIN 50

FM DOMAIN 136

FM DISULFID 57

FM DISULFID 157

FM DISULFID 243

FM DISULFID 44

FM CARBOHYD 70

FM CARBOHYD 152

FM CARBOHYD 216

FM CARBOHYD 284

FM CARBOHYD 292

FM CARBOHYD 305

FM CARBOHYD 321

FM LIPID 321

FM SEQUENCE 344 AA; 37998 MW; CBB39BE5B3B224 CRC64;

Query Match

Best Local Similarity 24.2%; Score 129.5; DB 1; Length 344;

Matches 64; Conservative 43; Mismatches 104; Indels 53; Gaps 14;

QY 4 VIFLHSG-----SGNEVI-EGPONATVILGSOARNCVTSOGWKLIMWALSDAWVLS---55

DB 21 LILFIPVPGVPSRSDATFPKADNVTYRGGESALTRCTIDNRVTRVVALNISTILYVAND 80

QY 56 ---VRPMPEITNDRTSQRYYDGGNFTSBMIIHNVFSDSNINCSIO-----NSRLH 106

DB 81 KWCLDPRVLLVLSN---TQFY-----SIEIÖNVDDVDEDPYCSVOTDNHPTSVH 129

QY 107 GSAVITVOVQGEELFIPSVNLVVAENFCEVYTCPLSHMTFLPDIWSWELGLVSHSYIYVP 166

DB 130 ---LIVVPSKRIYELISDISINGNISILCLATGPE-PRVTVR---HISPKAVGVLS 181

QY 167 EPSDOSANVILATPQSGNTLTCVATWKSIIKARKATVNLVYIRP-----OTGGGGIN 221

DB 182 EDEYLF---IGCIRREGSGEYCSAS-NDVAAPVRRVAVTVNPPYISSEAKGIVPVG 236

```

FT CAROABD 282 282 N-LINKED (GLCNAC. . . ) (POTENTIAL).
FT CAROABD 290 290 N-LINKED (GLCNAC. . . ) (POTENTIAL).
FT CAROABD 303 303 N-LINKED (GLCNAC. . . ) (POTENTIAL).
FT LIPID 330 330 GPT-ANCHOR (POTENTIAL).
FT VARSPLIC 310 320 MISSING (IN MAJOR ISOFORM).
SQ SEQUENCE 353 AA; 38736 MW; 2550C48591EBBBA6 CRC64;

Query Match
Best Local Similarity 25.7%; Score 128; DB 1; Length 353;
Matches 63; Conservative 36; Mismatches 90; Indels 56; Gaps 13

QY 22 NATYLKSSQARENCVTSQ-----GW-----KLIMWALSDMVLVSVPMPPIITNDRTSQRY 73
Db 42 NVYRQGESATLRCSDVNDRTVRAMLNSLSILXAGNDKWCIDPPVVLANTKQYSIQ-- 99
QY 74 DQGNFTSEMIHINVEPDSGNIKRSIQ-----NSRLHGSAYLTVQVMGLFIPSVNLY 127
Db 100 -----IHDDVYDEGPPYTSVOTDNHPKTSRVH-----LIYQVSPKIRETSIDS 144
QY 128 VAENEPCVETCLPSHWTLRPD--ISMELGLIVSHSSYFVPEPDSIQSAVSIALTPQSN 185
Db 145 INGGVNSLTLCIA---TGPRDPTIWR---HISKANGFISEDEYLE---ITGILTRQES 194
QY 186 GILTCVATYKSKARKSAKSNVNLTV-----IRCPDQTGGGINIPGVL-----SSLPSLGFSL 236
Db 195 GEYECAS-NDVAALVYORAVKATVNPYPYISDAKSTGVPYQKGLIMCEASAVPEADNQ- 252
QY 237 PTMGK 241
Db 253 --WYK 255

RESULT 5
DCC_HUMAN
ID DCC_HUMAN STANDARD; PRT: 1447 AA.
AC P43146;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Tumor suppressor protein DCC precursor (Colorectal cancer suppressor).
GN DCC.
NC Cytosol.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homindaes; Homo.
OX NCBI_TaxID=9606;
RN 1;
RP SEQUENCE FROM N.A.
RX MEDLINE=95011532; PubMed=7926722;
RA Hedrick L., Cho K.R., Fearon E.R., Wu T.-C., Kinzler K.W.,
RA Vogelstein B.;
RT "The DCC gene product in cellular differentiation and colorectal
RT tumorigenesis.";
RL Genes Dev. 8:1174-1183(1994).
RN 12;
RP SEQUENCE OF 1-750 FROM N.A.
RX MEDLINE=90100559; PubMed=2294591;
RA Fearon E.R., Cho K.R., Nigro J.M., Kern S.E., Simons J.W.,
RA Ruppert J.M., Hamilton S.R., Preisinger A.C., Thomas G., Kinzler K.W.,
RA Vogelstein B.;
RT "Identification of a chromosome 10q gene that is altered in
RT colorectal cancers.";
RL Science 247:49-56(1990).
RN 13;
RP SEQUENCE OF 107-472 FROM N.A. (SCRAMBLED EXONS).
RX MEDLINE=91121517; PubMed=1991322;
RA Nigro J.M., Cho K.R., Fearon E.R., Kern S.E., Ruppert J.M.,
RA Oliner J.D., Kinzler K.W., Vogelstein B.;
RT "Scrambled exons.";
RL Cell 64:607-613(1991).
RN 14;
RP GENE STRUCTURE, AND VARIANTS CARCINOMA HIS-1375.
RX MEDLINE=94245241; PubMed=8188295;
RA Cho K.R., Oliner J.D., Simons J.W.,

```

Preisinger A.C., Hedge P., Silverman G.A., Vogelstein B.,  
 "The DCC gene: structural analysis and mutations in colorectal  
 carcinomas." *Cell* 58:287-292 (1989).  
 RT Genomics 19:525-531(1994).  
 [5]  
 RP VARIANT CARCINOMA THR-168, AND VARIANT GLY-201.  
 RX MEDLINE=94243823; PubMed=8187090;  
 RA Miyake S., Nagai K., Yoshino K., Ota M., Endo M., Yasa Y.,  
 "Point mutations and allelic deletion of tumor suppressor gene DCC in  
 human esophageal squamous cell carcinomas and their relation to  
 metastasis." *Cancer Res.* 54:3007-3010(1994).  
 RT Cancer Res. 54:3007-3010(1994).  
 CC -1- FUNCTION: IMPLICATED AS A TUMOR SUPPRESSOR GENE.  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.  
 CC -1- TISSUE SPECIFICITY: FOUND IN AXONS OF THE CENTRAL AND PERIPHERAL  
 CC NERVOUS SYSTEM AND IN DIFFERENTIATED CELL TYPES OF THE INTESTINE.  
 CC -1- DISEASE: COLORECTAL TUMORS THAT LOST THEIR CAPACITY TO  
 CC DIFFERENTIATE INTO MUCUS PRODUCING CELLS UNIFORMLY LACK DCC  
 CC EXPRESSION. INACTIVATION OF DCC DUE TO ALLELIC DELETION AND/OR  
 CC POINT MUTATIONS MAY CAUSE BOTH LYMPHATIC AND HEMATOGENOUS  
 CC METASTASIS OF OESOPHAGEAL SQUAMOUS CELL CARCINOMAS.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. DCC  
 CC SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 4 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -1- SIMILARITY: CONTAINS 6 FIBRONECTIN TYPE III-LIKE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
 CC -----  
 DR EMBL; X76132; CAAS3735.1; -  
 DR EMBL; M32292; AAA35751.1; -  
 DR EMBL; M32286; AAA52174.1; -  
 DR EMBL; M32288; AAA52175.1; ALT\_SEQ.  
 DR EMBL; M32290; AAA52176.1; -  
 DR EMBL; M32290; AAA52177.1; -  
 DR EMBL; M63700; AAA52178.1; -  
 DR EMBL; M63702; AAA52179.1; -  
 DR EMBL; M63718; AAA52180.1; -  
 DR EMBL; M63698; AAA52181.1; -  
 DR PIR; A54100; A54100.  
 DR PIR; A40098; A40098.  
 DR PIR; A38442; A38442.  
 DR HSSP; PS6276; 1TLK.  
 DR Genew; HGNC:2701; DCC.  
 DR MIM; 120470; -  
 DR InterPro; IPR003961; FN\_III.  
 DR InterPro; IPR003962; FNIII\_repeat.  
 DR InterPro; IPR003006; IG\_MHC.  
 DR InterPro; IPR003598; IG\_C2.  
 DR InterPro; IPR003600; IG\_II-like.  
 DR Pfam; PF00047; Ig\_4.  
 DR Pfam; PF00014; FMYPEIII.  
 DR PRINTS; PR00014; FMYPEIII.  
 DR SMART; SM00060; FN3; 6.  
 DR SMART; SM00410; IG\_II-like; 2.  
 DR SMART; SM00408; IGC2; 3.  
 DR Glycoprotein; Immunoglobulin domain; Transmembrane; Signal;  
 KW Repeat; Anti-oncogene; Disease mutation; Polymorphism.  
 KM SIGNAL; 1 25  
 FT CHAIN; 26 1447  
 FT DOMAIN; 26 1097  
 FT TRANSMEM; 1098 1122  
 FT DOMAIN; 1123 1447  
 FT DOMAIN; 54 124  
 FT DOMAIN; 154 219  
 FT DOMAIN; 254 317  
 FT DOMAIN; 345 407  
 FT DOMAIN; 426 522  
 FT FIBRONECTIN TYPE-III 1.

FT DOMAIN 525 618 FIBRONECTIN TYPE-III 2.  
 FT DOMAIN 619 716 FIBRONECTIN TYPE-III 3.  
 FT DOMAIN 722 816 FIBRONECTIN TYPE-III 4.  
 FT DOMAIN 840 940 FIBRONECTIN TYPE-III 5.  
 FT DOMAIN 941 1042 FIBRONECTIN TYPE-III 6.  
 FT DISULFID 61 117 BY SIMILARITY.  
 FT DISULFID 161 212 BY SIMILARITY.  
 FT DISULFID 261 310 BY SIMILARITY.  
 FT DISULFID 352 400 BY SIMILARITY.  
 FT CARBOHYD 94 94 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 299 299 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 318 318 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 478 478 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 628 628 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 702 702 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT VARIANT 168 168 M->T (IN OESOPHAGEAL CARCINOMA).  
 FT VARIANT 201 201 /FTID=VAR\_003909.  
 FT VARIANT 201 201 R->G.  
 FT VARIANT 1375 1375 /FTID=VAR\_003910.  
 FT VARIANT 138 138 P->H (IN A COLORECTAL CARCINOMA).  
 FT CONFLICT 233 329 /FTID=VAR\_003911.  
 FT CONFLICT 421 421 MISSING (IN REF. 3).  
 FT CONFLICT 421 421 MISSING (IN REF. 3).  
 SQ SEQUENCE 1447 AA; 158456 MW; 4A8612766ED0471F CRC64;  
 Query Match 6.2%; Score 128; DB 1; Length 1447;  
 Best Local Similarity 24.8%; Pred. No. 0.021; 99; Indels 50; Gaps 10;  
 Matches 60; Conservative 33; Mismatches 99;  
 QY 10 SSGSNEV-----IEGPNATVLSQARFNCVSGW--KLIMWLSDM 51  
 DB 220 SRTGNEARVRLSPGJHROLYFLQRPNSVVAIEGDVAIECCVS-GYPPSPFTWLRGEE 278  
 QY 52 VYLSVRPEPIITNDRTFSORYDGGNFTSEMIITHNVEPDSGNINC--SIQSRRLHSGA 109  
 DB 279 VI-----QLSKKRYSLGG--SNLISNTVDDSGWTCVYTKKENSASA 323  
 QY 110 VYTVQVGEELFIPSVNIVVAENPECEVTCPLPSHTRLPDISM-ELGLVSHSYTPPEP 168  
 DB 324 ELTVLPPEWFLNHPNSNLAYESMDIEFCYVS-GKPVPTVMMKMGDVPISDYFQIVGG 382  
 QY 169 SDIOSAVSITALTPQSNGLTFCVATWKLARKKSNVYLVYIRCPDPTGGINIPVLS 228  
 DB 383 SNIR---ILGVKSDDEGVCVAENEGANQTSQTLVPRKPAIPSSS-----VLPS 430  
 QY 229 LP 230  
 DB 431 AP 432  
 RESULT 6  
 KMLS\_HUMAN STANDARD; PRT; 1914 AA.  
 ID KMLS\_HUMAN Q15746; Q14844; Q16794; Q95796; Q95797; Q95798; Q95799; Q9UBG5;  
 AC Q9UT79;  
 DT 15-JUL-1998 (Rel. 36, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Myosin light chain kinase, smooth muscle and non-muscle isozymes  
 DE (EC 2.7.1.117) (MCK) [Contains: Telokin (kinase related protein)  
 DE (KRP)].  
 DE GN MYLK OR MLCK.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 CC Mammalia; Eutheria; Primates; Catarrhini; Homiinae; Homo.  
 RX NCBI\_Taxid=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A. (ISOFORM 1).  
 RC TISSUE=umbilical vein endothelial cells;  
 RX MEDLINE=97304466; PubMed=9160829;  
 RA Garcia J.G.N., Lazar V.L., Gilbert-McClain L.I., Gallagher P.J.,  
 Verin A.D.;



```

FT REPEAT 1004 1015 II-2.
FT REPEAT 1016 1027 II-3.
FT REPEAT 1028 1039 II-4.
FT REPEAT 1040 1051 II-5.
FT REPEAT 1052 1063 II-6.
FT VARSPLIC 437 506 VSGIPKPEVAMFEGTPVRROQSGIEYEDAGSHYLCLLKA
FT VARSPLIC 1433 1439 ISOFORM 2 AND ISOFORM 3B.
FT VARSPLIC 1473 1546 DEVEVD -> MKRRCOT (IN ISOFORM 3A,
ISOFORM 3B AND ISOFORM 4).
GKFGQVRLVETKTRKRWAGFEKRAISAKKENIROEISIM
NCLHHPKLVCCVDAFEERKANVWLEIVSGEL -> L
(IN ISOFORM 4).
MISSING (IN ISOFORM 3A AND ISOFORM 3B).
MISSING (IN ISOFORM DEL-1790).
V -> M (IN REF. 5). AAD15922.
S -> P (IN REF. 3). AAD15922.
P -> A (IN REF. 5).
KPM -> BAH (IN REF. 5). AAD15922/AAD15923.
P -> L (IN REF. 3). AAD15922/AAD15923.
L -> P (IN REF. 5).
E -> D (IN REF. 3). AAD15922/AAD15923.
M -> I (IN REF. 3). AAD15922/AAD15923.
AAD15924.
A -> G (IN REF. 5).
L -> S (IN REF. 5).
T -> S (IN REF. 5).
V -> C (IN REF. 5).
S -> T (IN REF. 3). AAD15922/AAD15923.
I -> T (IN REF. 5).
A -> P (IN REF. 5).
G -> R (IN REF. 5).
GY -> D (IN REF. 3). AAD15922/AAD15923/
AAD15924.

```

Query Match 6.2% Score 128; DB 1; Length 1914;  
 Best Local Similarity 20.3% Pred. No. 0.03;  
 Matches 86; Conservative 58; Mismatches 149; Indels 130; Gaps 19;

```

OY 20 PONATVLKSGQARFNCVSGM--KLIMWALSDMWLVSVPMETITNDFTSGRDGG 77
DB 39 PNLILKEGATKAFEGGRV-RGYPEPOVW- - - - -RNGOPTISGGRFL--LDCGI 85
OY 78 NTSSEITIHNVSPDSGNIRCSLNSRLHGSAYLTVOY- - - - -MGEL 119
DB 86 RGTFSLVIAHAEEDRGKTYCATNG--SGARQVVELTVEGSAKOLGCPVYSKTLGDR 143
OY 120 FI-----PSV-----NLVVAENE--PCEYTCPLPSHWRTRPDLSWELG- 154
DB 144 FMSAVETPRPSIMGECPPKFAIKLGRVYVKEQMGFRFSCKITGRPO--POYTWLKGN 198
OY 155 LLYVSHSYFFVPEPDLQASVSLALTPQSNGLTFCVATMKSLLKARKSA-----TVN 206
DB 199 VPLQPARVSVSEKNGMO-VLEIHGVNDQDVYTCIIVNNGSKGMSAEISIGLDSAN 257
OY 207 LTVIRCPDGTGGI-----NIPGVLSLPLSGFLPTWKGVLGAGMLLPTCTLTIR 261
DB 258 RSEYREKRNKANSVREKVTNVIKESKLDL-----288
OY 262 CCCRRRCGCCNCCRCPCGCRKRGFRIOFOKSEKTEKNETESNGEN--SGYNS 318
DB 289 -----EAAKSKNCSSPQGGSPPMANSSOPPP-RESKLESKDSDPRATAPCP 336
OY 319 DEOKTDTASLPKSCSSDPEQRNNSCGPPHQRADQ--PPRASHPOQSFNLASPE 374
DB 337 VLQTTSSITLQARVQ--PEPRAPGLAVLSPSGEERKRAPPRAPTEPTPQGLIGSD 393
OY 375 KVS 377
DB 394 VVS 396

```

RESULT 7

```

DCC_MOUSE ID DCC_MOUSE STANDARD; PRT; 1447 AA.
AC P70211;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Tumor suppressor protein DCC precursor.
DCC.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORMS A; B AND C).
RC STRAIN-BALB/c; TISSUE-Brain;
RX MEDLINE=96112625; PubMed=8570174;
RA Cooper H.M., Ames P., Brito J., Gad J., Wilks A.F.;
RT "Cloning of the mouse homologue of the deleted in colorectal cancer
RL gene (mdcc) and its expression in the developing mouse embryo.";
RN Oncogene 11:2243-2254(1995).
RP REVISIONS.
RC STRAIN-BALB/c; TISSUE-Brain;
RA Cooper H.M.;
RL Submitted (JUN-1996) to the EMBL/Genbank/DBJ databases.
CC -1- FUNCTION: IMPLICATED AS A TUMOR SUPPRESSOR GENE.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- ALTERNATIVE PRODUCTS: 2 isoforms; A (shown here) and B; are
CC produced by alternative splicing.
CC -1- TISSUE SPECIFICITY: IN THE EMBRYO, EXPRESSED AT HIGH LEVELS IN THE
CC DEVELOPING BRAIN AND NEURAL TUBE. IN ADULT, HIGHLY EXPRESSED IN
CC BRAIN WITH VERY LOW LEVELS FOUND IN TESTIS, HEART AND THYMUS.
CC ISOFORM C IS EXPRESSED ONLY IN THE EMBRYO.
CC -1- DEVELOPMENTAL STAGE: LOW LEVELS IN EARLY GESTATION, HIGHEST LEVELS
CC EXPRESSED DURING MID GESTATION. LEVELS DECREASE IN LATE GESTATION
CC AND REMAIN AT THIS LEVEL IN THE ADULT.
CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. DCC
CC SUBFAMILY.
CC -1- SIMILARITY: CONTAINS 4 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
CC -1- SIMILARITY: CONTAINS 6 FIBRONECTIN TYPE III-LIKE DOMAINS.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
DB EMBL: X85788; CAA59786.1; -.
DB HSSP: P56276; IFLK.
DB MGD: MGI:94869; Dcc.
DR InterPro: IPR003961; FN.III.
DR InterPro: IPR003962; FN.III.repeat.
DR InterPro: IPR003006; I9_MHC.
DR InterPro: IPR003598; I9_C2.
DR InterPro: IPR003600; I9_Like.
DR Pfam: PF00041; fn3; 6.
DR Pfam: PF00047; I9; 4.
DR PRINTS: PRO0014; FNTPETIII.
DR SMART: SM00060; FN3; 6.
DR SMART: SM00410; IG_Like; 2.
DR SMART: SM00408; IG_C2; 3.
DR GlycoProtein: Immunoglobulin domain; Transmembrane; Signal;
KW Repeat; Anti-oncogene; Alternative initiation; Alternative splicing.
FT SIGNAL 1 25
FT CHAIN 26 1447 TUMOR SUPPRESSOR PROTEIN DCC, ISOFORM A.
FT CHAIN 85 1447 TUMOR SUPPRESSOR PROTEIN DCC, ISOFORM B.
FT INT_MET 85 85 FOR ISOFORM B.
FT DOMAIN 26 1097 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 1098 1122 POTENTIAL.
FT DOMAIN 1123 1447 CYTOPLASMIC (POTENTIAL).

```

```

FT DOMAIN 54 124 IG-LIKE C2-TYPE DOMAIN 1.
FT DOMAIN 154 219 IG-LIKE C2-TYPE DOMAIN 2.
FT DOMAIN 254 317 IG-LIKE C2-TYPE DOMAIN 3.
FT DOMAIN 345 407 IG-LIKE C2-TYPE DOMAIN 4.
FT DOMAIN 426 522 FIBRONECTIN TYPE-III 1.
FT DOMAIN 525 618 FIBRONECTIN TYPE-III 2.
FT DOMAIN 619 716 FIBRONECTIN TYPE-III 3.
FT DOMAIN 722 816 FIBRONECTIN TYPE-III 4.
FT DOMAIN 840 940 FIBRONECTIN TYPE-III 5.
FT DOMAIN 941 1042 FIBRONECTIN TYPE-III 6.
FT DISULFID 61 117 BY SIMILARITY.
FT DISULFID 161 212 BY SIMILARITY.
FT DISULFID 261 310 BY SIMILARITY.
FT DISULFID 352 400 BY SIMILARITY.
FT CARBOHYD 60 60 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 94 94 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 299 299 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 318 318 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 478 478 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 628 628 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 702 702 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT VARSPIC 819 838 MISSING (IN ISOFORM C).
SQ SEQUENCE 1447 AA; 158298 MW; 0D1F1097C22D5B9F CRC64;

Query Match 6.2%; Score 127; DB 1; Length 1447;
Best Local Similarity 26.6%; Pred. No. 0.026;
Matches 51; Conservative 29; Mismatches 86; Indels 26; Gaps 8;

OY 17 IEGPQNAVYKSGARFPCVYSGW--KLIMWALSDWVLSVPRMEPIITNDRFTSORVD 74
DB 243 IORPSNVATIEKQDVLDCVVS-GYPPSPFWLGEIEV-----QLRSKRS 288
OY 75 OGNTSEMIHNEPDSGNIRC--SLONSRLHGSXLYVOVWGLFISVNLVAENE 132
DB 289 ILGG--SNLLSNTVDDSGTYTCTVYTKENISASALVLPVPLNHPMLVAYEES 346
OY 133 PCEVTCUPSHWTRLPDJSV-ELGLVSHSSYFVPEPSDQSAVSIATLPQSGNGLCV 191
DB 347 DIEECVAVS-GKPVPTVMKMGNDVLPSPDYFVGGSNLR-----ILGVKSGDEGYQCV 401
OY 192 ATWKSARKSA 203
DB 402 AENAGNAGSSA 413

RESULT 8
PRK7_HUMAN
ID PRK7_HUMAN STANDARD; PRT; 1070 AA.
AC Q13308; Q13417;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DE 15-JUN-2002 (Rel. 41, Last annotation update)
DE Tyrosine-protein kinase-like 7 precursor (Colon carcinoma kinase-4)
DE (CCK-4).
GN PRK7 OR CCK4.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_Taxid=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon carcinoma, and Placenta;
RX MEDLINE=96074849; PubMed=7478540;
RA Mossie K., Jallat B., Alves F., Sures I., Plozman G.D., Ullrich A.;
RT "Colon carcinoma kinase-4 defines a new subclass of the receptor
RT tyrosine kinase family.";
RL Oncogene 11:2179-2184(1995).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Fibroblast;
RX MEDLINE=97037064; PubMed=8882711;
RA Park S.-K., Lee H.-S., Lee S.-T.;
RT "Characterization of the human full-length PRK7 cDNA encoding a

```

```

FT receptor protein tyrosine kinase-like molecule closely related to
FT chick Klg.".
FT J. Biochem. 119:235-239(1996).
RN [3]
RP SEQUENCE FROM N.A., AND REVISION TO 834.
RA Lee S.-T., Park S.-K., Lee H.-S., Ji A.R., Jung J.W.;
RL Submitted (Nov-2001) to the EMBL/GenBank/DBJ databases.
CC FUNCTION: MAY FUNCTION AS A CELL ADHESION MOLECULE. LACKS PROBABLY
CC THE CATALYTIC ACTIVITY OF TYROSINE KINASE. MAY BE CONNECTED TO THE
CC PATHOPHYSIOLOGY OF COLON CARCINOMAS AND/OR MAY REPRESENT A TUMOR
CC PROGRESSION MARKER.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- TISSUE SPECIFICITY: HIGHLY EXPRESSED IN LUNG, LIVER, PANCREAS,
CC KIDNEY, PLACENTA AND MELANOCYTES. WEAKLY EXPRESSED IN THYROID
CC GLAND, OVARY, BRAIN, HEART AND SKELETAL MUSCLE. ALSO EXPRESSED IN
CC ERYTHROLEUKEMIA CELLS. BUT NOT EXPRESSED IN COLON.
CC -1- SIMILARITY: BELONGS TO THE TYR FAMILY OF PROTEIN KINASES. INSULIN
CC RECEPTOR SUBFAMILY.
CC -1- SIMILARITY: CONTAINS 7 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U33635; AAA87565.1; -
DR EMBL; U40271; AAC50484.2; -
DR EMBL; AF447157; AAL39062.1; -
DR EMBL; AF447157; AAL39062.1; JOINED.
DR EMBL; AF447158; AAL39062.1; JOINED.
DR EMBL; AF447162; AAL39062.1; JOINED.
DR EMBL; AF447164; AAL39062.1; JOINED.
DR EMBL; AF447170; AAL39062.1; JOINED.
DR EMBL; AF447171; AAL39062.1; JOINED.
DR EMBL; AF447173; AAL39062.1; JOINED.
DR EMBL; AF447174; AAL39062.1; JOINED.
DR EMBL; AF447175; AAL39062.1; JOINED.
DR HSSP; P08631; IADS.
DR Genew; HGNC; 9618; PRK7.
DR MTM; 601890; -
DR InterPro; IPR000719; Euk_pkinase.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003598; Ig_C2.
DR InterPro; IPR003600; Ig_Like.
DR InterPro; IPR002011; RtkinaseII.
DR InterPro; IPR001245; Tyr_pkinase.
DR Pfam; PF00047; Ig; 7.
DR Pfam; PF00069; pkinase; 1.
DR PRINTS; PR00109; TYRKINASE.
DR PRODOM; PD000001; Euk_pkinase; 1.
DR SMART; SM00410; IG_Like; 2.
DR SMART; SM00219; TyrcKc; 1.
DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00339; RECEPTOR_TYR_KIN_II; FALSE NEG.
KW Immunoglobulin domain; Repeat.
FT SIGNAL 1
FT CHAIN 31 1070 POTENTIAL.
FT DOMAIN 31 704 TYROSINE-PROTEIN KINASE-LIKE 7.
FT TRANSF 705 725 EXTRACELLULAR (POTENTIAL).
FT TRANSF 726 1070 POTENTIAL.
FT DOMAIN 143 108 CYTOPLASMIC (POTENTIAL).
FT DOMAIN 146 108 IG-LIKE C2-TYPE DOMAIN 1.
FT DOMAIN 239 308 IG-LIKE C2-TYPE DOMAIN 2.
FT DOMAIN 336 398 IG-LIKE C2-TYPE DOMAIN 3.
FT DOMAIN 426 488 IG-LIKE C2-TYPE DOMAIN 4.
FT DOMAIN 517 577 IG-LIKE C2-TYPE DOMAIN 5.
FT DOMAIN 517 577 IG-LIKE C2-TYPE DOMAIN 6.

```

FT DOMAIN 606 671 IG-LIKE C2-TYPE DOMAIN 7.  
 FT PROTEIN KINASE; INACTIVE.  
 FT DISULFID 796 1066  
 FT DISULFID 53 101  
 FT DISULFID 150 200 BY SIMILARITY.  
 FT DISULFID 246 301 BY SIMILARITY.  
 FT DISULFID 343 391 BY SIMILARITY.  
 FT DISULFID 433 481 BY SIMILARITY.  
 FT DISULFID 524 570 BY SIMILARITY.  
 FT DISULFID 613 664 BY SIMILARITY.  
 FT DISULFID 116 115 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 175 175 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 184 184 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 214 214 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 268 268 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 283 283 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 405 405 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 463 463 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 567 567 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 646 646 P -> R (IN REF. 2 AND 3).  
 FT CONFLICT 92 92 K -> T (IN REF. 2 AND 3).  
 FT CONFLICT 147 147 S -> G (IN REF. 2 AND 3).  
 FT CONFLICT 207 207 VL -> RV (IN REF. 2 AND 3).  
 FT CONFLICT 495 496 G -> E (IN REF. 2 AND 3).  
 FT CONFLICT 515 515 E -> G (IN REF. 2 AND 3).  
 FT CONFLICT 881 881 A -> P (IN REF. 2 AND 3).  
 FT CONFLICT 969 969 S -> F (IN REF. 2 AND 3).  
 FT CONFLICT 992 992  
 SQ SEQUENCE 1070 AA; 118260 MW; 47CDE258BE3698A5 CRC64;

Query Match  
 Best Local Similarity 25.0%; Score 124; DB 1; Length 1070;  
 Matches 58; Conservative 32; Mismatches 103; Indels 36; Gaps 10;

QY 16 VIEGQNFVTKSGARNCVTS-QGKLMALSDMVLVSREMEITDNRFTSQRD 74  
 DB 227 VVLAPODVVAYREAMHCQSPNSQPPSLQWLFEDERPIINRSPHRLATVFA--- 282  
 QY 75 QGNETSEMITHNEPSSGNIRCSLQNSR-----LHSAVLTVQVNGELFIPSVNLVVA 129  
 DB 283 -----NGSLITQVPRNRNAGIRCGIGQGPPILEATLHLAELFEDMPLFEPRTVAGS 337  
 QY 130 ENRPECVTCGLPSHWRLPLDISWE-LGL-LVSHSYFYFPEPSDQSAVSITALTPOSN-G 186  
 DB 338 EE---RVTCPLPKGLPEPSVWMEHAGVRLPTGRVY-----QKGHELVLANIAESDAG 387  
 QY 187 TLTCVATWKSILKARKSATVNLTV-----IRPOPTGGGINIPGLVSSL 229  
 DB 388 VYTCMAA-NLAGQRQDVNITVATVPWIKRPODSQLEEGKPGYLDCL 434

RESULT 9  
 OPMC\_HUMAN STANDARD; PRT; 345 AA.  
 ID OPMC\_HUMAN  
 AC 014982;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Opioid binding protein/cell adhesion molecule precursor (OB CAM)  
 DE (Opioid-binding cell adhesion molecule) (OPCML).  
 GN OPCML OR OB CAM.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.  
 NCBI\_TaxID=9606;  
 RX MEDLINE=95237612; PubMed=7721093;  
 RA "Cloning, sequencing and localization to chromosome 11 of a cDNA  
 RT encoding a human opioid-binding cell adhesion molecule (OB CAM)."  
 RL Gene 155:213-217(1995).  
 CC -FUNCTION: BINDS OPIOIDS IN THE PRESENCE OF ACIDIC LIPIDS; PROBABLY

INVOLVED IN CELL CONTACT  
 -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By similarity).  
 -1- SIMILARITY: BELONGS TO THE IMUNOGLOBULIN SUPERFAMILY. IGLON SUBFAMILY.  
 -1- SIMILARITY: CONTAINS 3 IMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 -----  
 This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation at the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 -----

DR EMBL; L34774; AAA6387.1; .  
 DR Genbank; HGNC:8143; OPCML.  
 DR MIM; 600632; .  
 DR InterPro; IPR003006; I9\_MHC.  
 DR InterPro; IPR003598; I9\_C2.  
 DR InterPro; IPR003600; I9\_Like.  
 DR Pfam; PF00047; I9\_3.  
 DR SMART; SM00408; I9C2; 2; I9\_Like; 1.  
 DR SMART; SM00410; I9\_Like; 1.  
 DR Immunoglobulin domain; Cell adhesion; Glycoprotein; GPI-anchor; Repeat; Signal.  
 FT SIGNAL 1 27  
 FT CHAIN 28 322  
 FT PROPEP 323 345  
 FT DOMAIN 50 122  
 FT DOMAIN 150 209  
 FT DOMAIN 237 303  
 FT DISULFID 57 115  
 FT DISULFID 157 202  
 FT DISULFID 244 296  
 FT CARBOHYD 44 44  
 FT CARBOHYD 70 70  
 FT CARBOHYD 140 140  
 FT CARBOHYD 285 285  
 FT CARBOHYD 293 293  
 FT CARBOHYD 306 306  
 FT LIPID 322 322  
 SQ SEQUENCE 345 AA; 38007 MW; E7AD17BE1AA3FE4 CRC64;

Query Match  
 Best Local Similarity 25.0%; Score 120; DB 1; Length 345;  
 Matches 71; Conservative 37; Mismatches 102; Indels 74; Gaps 18;

QY 4 VIFLAGSG-----SGNEVT-EGPQNAFVTKSGQARNCVTSQGMKLMALSDMVL----- 54  
 DB 21 LLEFLVPTGVPRSGDATFPKANDVTVRQGESATLRCITDDVTRVAM-LNRSTILVAGN 79  
 QY 55 ---SVRPEMEITDNRFTSQRYDQGNFTSEMITHNEPSSDGNIRCSLQ-----NSRL 105  
 DB 80 DKMSIDPRVILIVN---TPQY-----SIMQWVDYDDEGPTVCSQVDNHEKTSRV 128  
 QY 106 HGSAYLVTVQVNGELFIPSVNLVVAENPCRYNCL-----PSHMTRLPLDISWELGLVSHS 161  
 DB 129 H-----LTIQVPPQIMNISIDITVNEGSSVTLLCLAIGREP-----PTVIMR-----HLS 173  
 QY 162 YX-----FVPEPSDQSAVSITALTPOSNGTLCVATWKSILKARKSATVNLTV-----IRC 212  
 DB 174 VKEGGGEFSEBYLE-----ISDIRQDSGEYECNAL-NDVADADVKRVKITVNPYISK 228  
 QY 213 PQTGGGINIPGVL-----SLPSLGFSLTPWKG-----VGLAG 248  
 DB 229 AKNTGVSVGKGKILSCENSAVPMKAEFO---WFKETRLATGLDGS 269

RESULT 10  
 OPMC\_BOVIN STANDARD; PRT; 345 AA.  
 ID OPMC\_BOVIN

AC P11834;  
 DT 01-OCT-1989 (Rel. 12, Created)  
 DT 01-OCT-1989 (Rel. 12, Last sequence update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Opioid binding protein/cell adhesion molecule precursor (OB CAM)  
 DE (Opioid-binding protein/cell adhesion molecule precursor (OB CAM))  
 GN OPMCL OR OB CAM OR OCAM.  
 OS Bos taurus (Bovine).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Cetartiodactyla; Kuminantia; Pecora; Bovidea;  
 OC Bovidae; Bovinae; Bos.  
 OX NCBI\_Taxid-9913;  
 RN [1]  
 RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.  
 RC TISSUE-Brain;  
 RX MEDLINE-9251576; PubMed-2721489;  
 RA Schofield P.R., McFarland K.C., Hayflick J.S., Wilcox J.N.,  
 RA Cho T.M., Roy S., Lee N.M., Loh H.H., Seeburg P.H.;  
 RT Molecular characterization of a new immunoglobulin superfamily  
 RT protein with potential roles in opioid binding and cell contact."  
 RL EMBO J. 8:489-495(1989).  
 CC -1- FUNCTION: BINDS OPIOIDS IN THE PRESENCE OF ACIDIC LIPIDS; PROBABLY  
 CC INVOLVED IN CELL CONTACT.  
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By  
 CC similarity).  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGLON  
 CC SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL: X12672; CA31192.1; -  
 DR PIR: S03199; S03199; -  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR Pfam: PF00047; Ig; 3.  
 DR SMART: SM00410; Ig\_Like; 1.  
 DR SMART: SM00408; IgC2; 2.  
 KW Immunoglobulin domain; Cell adhesion; Glycoprotein; GPI-anchor;  
 KW Repeat; Signal.  
 FT SIGNAL 1 27  
 FT CHAIN 28 322  
 FT PROPEP 323 345  
 FT DOMAIN 50 122  
 FT DOMAIN 150 209  
 FT DOMAIN 237 303  
 FT DISULFID 57 115  
 FT DISULFID 157 202  
 FT DISULFID 244 296  
 FT CARBOHYD 44 44  
 FT CARBOHYD 70 70  
 FT CARBOHYD 140 140  
 FT CARBOHYD 285 285  
 FT CARBOHYD 293 293  
 FT CARBOHYD 306 306  
 FT LIPID 322 322  
 SO SEQUENCE 345 AA; 37914 MW; D1ECC8D9E7D8CB19 CRC64;  
 Query Match 5.88; Score 119; DB 1; Length 345;  
 Best Local Similarity 25.18; Pred. No. 0.02; Mismatches 103; Indels 70; Gaps 17;  
 Matches 70; Conservative 36;  
 4 VIPIHGS-SCNEVI-BEPONATV LKSGARFNCVSGKRLIMALSDMVV- 54  
 21 LFLVPTGVPRVSGDATPRAMNVTVROGESATLRCCTIDRTYTRAV-LNNSITLYAGN 79

OPCM RAT  
 ID OPCM RAT STANDARD. PRT: 345 AA.  
 DT P32736; 001654; P32735; Q01653;  
 DT 01-JUL-1993 (Rel. 26, Created)  
 DT 01-FEB-1996 (Rel. 33, Last sequence update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Opioid binding protein/cell adhesion molecule precursor (OB CAM)  
 DE (Opioid-binding protein/cell adhesion molecule precursor (OB CAM))  
 GN OPMCL OR OB CAM.  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_Taxid-10116;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE-Brain;  
 RX MEDLINE-92347701; PubMed-1339369;  
 RA Lipman D.A., Lee N.M., Loh H.H.;  
 RT "Opioid-binding cell adhesion molecule (OB CAM)-related clones from a  
 RT rat brain cDNA library."  
 RL Gene 117:249-254(1992).  
 RN [2]  
 RP SEQUENCE OF 195-214, AND GPI-ANCHOR.  
 RX MEDLINE-95198094; PubMed-7891157;  
 RA Struyk A.F., Canoll P.D., Wolfgang M.J., Rosen C.L., D'Eustachio P.,  
 RA Salzer J.L.;  
 RT "Cloning of neurotrophin defines a new subfamily of differentially  
 RT expressed neural cell adhesion molecules."  
 RL J. Neurosci. 15:2141-2156(1995).  
 CC -1- FUNCTION: BINDS OPIOIDS IN THE PRESENCE OF ACIDIC LIPIDS; PROBABLY  
 CC INVOLVED IN CELL CONTACT.  
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.  
 CC -1- ALTERNATIVE PRODUCTS: AT LEAST 2 ISOFORMS, 1 (SHOWN HERE) AND 2;  
 CC MAY BE PRODUCED BY ALTERNATIVE SPLICING.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGLON  
 CC SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL: M88710; AAA40859.1; -  
 DR EMBL: M88711; AAA40860.1; -  
 DR EMBL: M88709; AAA40858.1; -  
 DR PIR: J01239; J01239.  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR Pfam: PF00047; Ig; 3.  
 RESULT 11  
 OPCM RAT  
 ID OPCM RAT STANDARD. PRT: 345 AA.  
 DT P32736; 001654; P32735; Q01653;  
 DT 01-JUL-1993 (Rel. 26, Created)  
 DT 01-FEB-1996 (Rel. 33, Last sequence update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Opioid binding protein/cell adhesion molecule precursor (OB CAM)  
 DE (Opioid-binding protein/cell adhesion molecule precursor (OB CAM))  
 GN OPMCL OR OB CAM.  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_Taxid-10116;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE-Brain;  
 RX MEDLINE-92347701; PubMed-1339369;  
 RA Lipman D.A., Lee N.M., Loh H.H.;  
 RT "Opioid-binding cell adhesion molecule (OB CAM)-related clones from a  
 RT rat brain cDNA library."  
 RL Gene 117:249-254(1992).  
 RN [2]  
 RP SEQUENCE OF 195-214, AND GPI-ANCHOR.  
 RX MEDLINE-95198094; PubMed-7891157;  
 RA Struyk A.F., Canoll P.D., Wolfgang M.J., Rosen C.L., D'Eustachio P.,  
 RA Salzer J.L.;  
 RT "Cloning of neurotrophin defines a new subfamily of differentially  
 RT expressed neural cell adhesion molecules."  
 RL J. Neurosci. 15:2141-2156(1995).  
 CC -1- FUNCTION: BINDS OPIOIDS IN THE PRESENCE OF ACIDIC LIPIDS; PROBABLY  
 CC INVOLVED IN CELL CONTACT.  
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.  
 CC -1- ALTERNATIVE PRODUCTS: AT LEAST 2 ISOFORMS, 1 (SHOWN HERE) AND 2;  
 CC MAY BE PRODUCED BY ALTERNATIVE SPLICING.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGLON  
 CC SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL: M88710; AAA40859.1; -  
 DR EMBL: M88711; AAA40860.1; -  
 DR EMBL: M88709; AAA40858.1; -  
 DR PIR: J01239; J01239.  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR Pfam: PF00047; Ig; 3.  
 Db 55 ---SVREPEPIITNDRTSORYDOGNFTSEMIHHVPSDSGNICSLQ-----NSRL 105  
 Db 80 DKMSIDPRVILTVN---TPQY-----SIQNVNDVYDEEPYCSVQTNHPRKTSRV 128  
 Qy 106 HGSAYLVTVQMGELFIPISVNLVAENEPCEVTCL-----PSHMTRLPDISWELGLVSHSS 161  
 Db 129 H---LIVVPPQIMNTSSDVTVNEGSSVYLCLAGRE-----PYVWR-----HLS 173  
 Qy 162 YV---FVPEPSDLQSAVSIALTPQSNGLTLCVATWSLKRKATVNLVY-----TRC 212  
 Db 174 VKESGGVSEDEYLE---ISDIKRQSEYECSL-NDVAPDVKRVKIVTVNPPYISK 228  
 Qy 213 PDRTGGINIPGL-----SSLPSLGSLEPTWGRVIGLA 247  
 Db 229 AKRTGVSGQKGLSCENASAVPMARFO---WEKEDTRLA 264



DR SMART: SM00410; IG-like: 1.  
 DR SMART: SM00408; IGC2: 2.  
 KW Immunoglobulin domain; Cell adhesion; glycoprotein; GPI-anchor;  
 KW Repeat: Signal; Alternative splicing.  
 FT SIGNAL 1 27  
 FT CHAIN 28 322  
 FT PROPEP 323 345  
 FT DOMAIN 50 122  
 FT DOMAIN 150 209  
 FT DOMAIN 237 303  
 FT DISULFID 57 115  
 FT DISULFID 157 202  
 FT CARBOHYD 244 296  
 FT CARBOHYD 70 140  
 FT CARBOHYD 140 285  
 FT CARBOHYD 285 293  
 FT CARBOHYD 306 306  
 FT LIPID 322 322  
 FT VARSPLIC 1 27  
 SO SEQUENCE 345 AA; 38067 MW; A3181B0753F9658E CRC64;  
 Query Match 5.7%; Score 118; DB 1; Length 345;  
 Best Local Similarity 24.7%; Pred. No. 0.024;  
 Matches 71; Conservative 38; Mismatches 104; Indels 74; Gaps 18;  
 QY 4 VIFLHSG-----SGNEVI-EGPONAVYKGSQARFNCVSGQKLMWALSDWVLT-----54  
 DB 21 LFLVPTGVPVRSGDAPFKAMDVTVQGSATLRCITIDRYTRVAV-LNRSTIILACN 79  
 QY 55 ---SVRPEPITNRFORSQRDGNGNTSEMIITHNEPSDSGNIRCSLO-----NSRL 105  
 DB 80 DKMSIDPVIILVN---TPPTQ-----SIMIONDVDEGPTGCVQDNHPKTSRV 128  
 QY 106 HGSAYLVTVQMGELFIPSVNLVVAENEPEVTCV-----PSWTRLPDISMELGLVSHSS 161  
 DB 129 H-----LIVQVPPQIMNISDIIVNEISSVTLICLAGIRE-----PVTWTR-----HLS 173  
 QY 162 YV---FVPEPSDLSQSAVSIILATLPQSNGLTCVATWKSRLKRSATVNLTV-----IRC 212  
 DB 174 VKEGQFVSEDEYLE-----ISDKRDSQSEYECSSAL-NDVAPADVRKVIKIVNPPYISK 228  
 QY 213 PDDTGGGINIPGVL-----SLPSLGFSLPTWCK-----VGLGLAGTML 251  
 DB 229 AKNTGVSVGOKGILSCSAVPMAFEO---WEKEDTRLATGLDGVRI 272  
 RESULT 12  
 NEOL\_CHICK STANDARD; PRT; 1443 AA.  
 ID NEOL\_CHICK  
 AC 090610;  
 AC 16-OCT-2001 (Rel. 40, Created)  
 AC 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Neogenin (Fragment).  
 DE Gallus gallus (Chicken).  
 OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus  
 OX NCBI\_TaxID=9031;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=White Leghorn; TISSUE=Embryonic brain;  
 RX MEDLINE=95105243; PubMed=7806578;  
 RA Vlemler J., Roman J.M., Dreyer W.J.;  
 RT "Neogenin, an avian cell surface protein expressed during terminal  
 neuronal differentiation, is closely related to the human tumor  
 suppressor molecule deleted in colorectal cancer.";  
 RL J. Cell Biol. 127:2009-2020(1994).  
 CC -!- FUNCTION: MAY BE INVOLVED AS A REGULATORY PROTEIN IN THE

CC TRANSITION OF UNDIFFERENTIATED PROLIFERATING CELLS TO THEIR  
 CC DIFFERENTIATED STATE. MAY ALSO FUNCTION AS A CELL ADHESION  
 CC MOLECULE IN A BROAD SPECTRUM OF EMBRYONIC AND ADULT TISSUES.  
 CC -!- SUBCELLULAR LOCATION: Type 1 membrane protein.  
 CC -!- DEVELOPMENTAL STAGE: IN RETINA, EXPRESSED ON GANGLION CELL FIBERS.  
 CC AS SOON AS THEY BEGIN TO EXTEND THEIR AXONS.  
 CC -!- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. DCC  
 CC SUBFAMILY.  
 CC -!- SIMILARITY: CONTAINS 4 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -!- SIMILARITY: CONTAINS 6 FIBRONECTIN TYPE III-LIKE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC or send an email to license@sib.ch).  
 CC -----  
 CC EMBL: U07644; AAC59662.1; -.  
 CC HSSP: P11276; 2MFN.  
 DR InterPro: IPR003961; FN\_III.  
 DR InterPro: IPR003962; FNIII\_repeat.  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR Pfam: PF00041; fn3; 6.  
 DR Pfam: PF00047; Ig; 4.  
 DR PRINTS: PR00014; FNTYPEIII.  
 DR SMART: SM00408; IGC2, 2.  
 DR SMART: SM00410; IG-like: 2.  
 DR Transmembrane: 1  
 DR NON\_TER 1  
 FT DOMAIN 1091 1111  
 FT TRANSMEM 1091 1111  
 FT DOMAIN 1112 1443  
 FT DOMAIN 132 194  
 FT DOMAIN 229 293  
 FT DOMAIN 321 383  
 FT DOMAIN 422 519  
 FT DOMAIN 522 615  
 FT DOMAIN 616 714  
 FT DOMAIN 720 814  
 FT DOMAIN 835 935  
 FT DOMAIN 936 1037  
 FT DISULFID 40 95  
 FT DISULFID 139 187  
 FT DISULFID 236 286  
 FT DISULFID 328 376  
 FT CARBOHYD 39 39  
 FT CARBOHYD 176 176  
 FT CARBOHYD 292 292  
 FT CARBOHYD 456 456  
 FT CARBOHYD 475 475  
 FT CARBOHYD 625 625  
 FT CARBOHYD 700 700  
 FT CARBOHYD 894 894  
 SO SEQUENCE 1443 AA; 158050 MW; 558C6795579C0E26 CRC64;  
 Query Match 5.7%; Score 117.5; DB 1; Length 1443;  
 Best Local Similarity 26.2%; Pred. No. 0.15;  
 Matches 49; Conservative 26; Mismatches 73; Indels 37; Gaps 11;  
 QY 17 IEGPONATVYKGSQARFNCVSGW--KLIMWALSDWVLSVPRMEPIITNDRFTSQRY- 73  
 DB 218 VQPSLTKRVQGNANVFC-VAGGPPPYVKTNG-----EELIED--SERFA 264  
 QY 74 -DQGNFTSEMITHNEPSDSGNIRCC--SLNSRLHGSAYLVTVQMGELFIPSVNLVVAE 130  
 DB 265 LRAGGS-----LITSDVTEDEVYTYCIADNNENETLEAQELAVGVPPPEFLKRPANIYAE 320

QY 131 NE-----PCEVTCIPSHMTLPDISW-ELGLVSHSYFVEPESDLOSANSIALPQSN 185  
 Db 321 SMDIVECEVYTKPT-----PTVKNVKNQDVYIPSYDFKIVKEHNLQ-----VLGVKSD 371  
 QY 186 GTLTGVA 192  
 | | |  
 Db 372 GYQCIA 378

## RESULT 13

PGBM\_HUMAN

ID PGBM\_HUMAN STANDARD; PRT; 4393 AA.

AC P98160; 016287;

DT 01-OCT-1996 (Rel. 34, Created)

DT 01-OCT-1996 (Rel. 34, Last sequence update)

DE 15-JUN-2002 (Rel. 41, Last annotation update)

DE Basement membrane-specific heparan sulfate proteoglycan core protein precursor (HSPG) (Perlecan) (PLC).

GN HSPG2.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

OX NCBI\_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A. MEDLINE=92112994; PubMed=1730768;

RA Kallunki P., Tryggvason K.;

RT "Human basement membrane heparan sulfate proteoglycan core protein: a 467-kD protein containing multiple domains resembling elements of the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor.";

RL J. Cell Biol. 116:559-571(1992).

RN [2]

RP SEQUENCE FROM N.A. MEDLINE=92235084; PubMed=1569102;

RA Murdoch A.D., Dodge G.R., Cohen I., Tuan R.S., Iozzo R.V.;

RT "Primary structure of the human heparan sulfate proteoglycan from domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor.";

RL J. Biol. Chem. 267:8544-8557(1992).

RN [3]

RP SEQUENCE OF 1018-1472 FROM N.A. MEDLINE=91365376; PubMed=1679749;

RA Dodge G.R., Kovacs I., Chu M.L., Hassell J.R., McBride O.W.;

RT "Heparan sulfate proteoglycan of human colon: partial molecular cloning, cellular expression, and mapping of the gene (HSPG2) to the short arm of human chromosome 1.";

RL Genomics 10:673-680(1991).

RN [4]

RP SEQUENCE OF 892-1398 FROM N.A. MEDLINE=92120660; PubMed=1685141;

RA Kallunki P., Eddy R.L., Byers M.G., Kestila M., Shows T.B.;

RT "Cloning of human heparan sulfate proteoglycan core protein, assignment of the gene (HSPG2) to 1p36.1--p33 and identification of a BamHI restriction fragment length polymorphism.";

RL Genomics 11:389-396(1991).

RN [5]

RP SEQUENCE OF 1-21 FROM N.A. MEDLINE=94052171; PubMed=8234307;

RA Cohen I.R., Graessle S., Murdoch A.D., Iozzo R.V.;

RT "Structural characterization of the complete human perlecan gene and its promoter.";

RL Proc Natl. Acad. Sci. U.S.A. 90:10404-10408(1993).

RN [6]

RP SEQUENCE OF 1-21 FROM N.A. MEDLINE=94052171; PubMed=8234307;

RA Cohen I.R., Graessle S., Murdoch A.D., Iozzo R.V.;

RT "Structural characterization of the complete human perlecan gene and its promoter.";

RL Proc Natl. Acad. Sci. U.S.A. 90:10404-10408(1993).

RN [7]

RP SEQUENCE OF 1-21 FROM N.A. MEDLINE=94052171; PubMed=8234307;

RA Cohen I.R., Graessle S., Murdoch A.D., Iozzo R.V.;

RT "Structural characterization of the complete human perlecan gene and its promoter.";

RL Proc Natl. Acad. Sci. U.S.A. 90:10404-10408(1993).

RN [8]

RP SEQUENCE OF 1-21 FROM N.A. MEDLINE=94052171; PubMed=8234307;

RA Cohen I.R., Graessle S., Murdoch A.D., Iozzo R.V.;

RT "Structural characterization of the complete human perlecan gene and its promoter.";

RL Proc Natl. Acad. Sci. U.S.A. 90:10404-10408(1993).

RN [9]

RP SEQUENCE OF 1-21 FROM N.A. MEDLINE=94052171; PubMed=8234307;

RA Cohen I.R., Graessle S., Murdoch A.D., Iozzo R.V.;

RT "Structural characterization of the complete human perlecan gene and its promoter.";

RL Proc Natl. Acad. Sci. U.S.A. 90:10404-10408(1993).

CC -1- SUBUNIT: Purified perlecan has a strong tendency to aggregate in  
 CC dimers or stellate structures. It interacts with other basement  
 CC membrane components such as laminin, prolargin and collagen type  
 CC IV.

CC -1- SUBCELLULAR LOCATION: Extracellular.  
 CC -1- TISSUE SPECIFICITY: FOUND IN THE BASEMENT MEMBRANES.  
 CC AND O-LINKED OLIGOSACCHARIDES.

CC -1- SIMILARITY: CONTAINS 4 LDL-RECEPTOR CLASS A DOMAINS.  
 CC -1- SIMILARITY: CONTAINS 10.5 LAMININ EGF-LIKE DOMAINS.  
 CC -1- SIMILARITY: CONTAINS 22 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -1- SIMILARITY: CONTAINS 3 LAMININ G-LIKE DOMAINS.  
 CC -1- SIMILARITY: CONTAINS 1 SEA DOMAIN.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC or send an email to <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch).

CC EMBL: X62515; CA44373.1; -  
 CC EMBL: M85289; AA52700.1; -  
 CC EMBL: M64283; AA52699.1; -  
 CC EMBL: S76436; AA52121.2; -  
 CC EMBL: L22078; - NOT\_ANNOTATED\_CDS.  
 CC HSPG2: P00740; 1EDM.  
 CC Sienra-2DPAGE; P98160; -  
 CC GeneW: HGNC:5273; HSPG2.  
 CC MIM: 142461; -

DR InterPro: IPR000561; EGF-like.  
 DR InterPro: IPR000742; EGF\_2.  
 DR InterPro: IPR001438; EGF\_11.  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR002172; LDL\_recept\_A.  
 DR InterPro: IPR000034; Laminin\_B.  
 DR InterPro: IPR002049; Laminin\_EGF.  
 DR InterPro: IPR001791; Laminin\_G.  
 DR InterPro: IPR000082; SEA\_domain.  
 DR Pfam: PF00008; EGF\_4.  
 DR Pfam: PF00047; Ig\_22.  
 DR Pfam: PF00052; laminin\_B\_3.  
 DR Pfam: PF00053; laminin\_EGF\_7.  
 DR Pfam: PF00054; laminin\_G\_3.  
 DR Pfam: PF00057; ldl\_recept\_a; 4.  
 DR Pfam: PF01390; SEA\_1.  
 DR PRINTS: PR00010; EGFBLDOD.

DR PRODOM: PD003031; Laminin\_B\_3.  
 DR SMART: SM00180; EGF\_lam; 6.  
 DR SMART: SM00001; EGF\_like; 8.  
 DR SMART: SM00408; IGC2\_22.  
 DR SMART: SM00192; LDLa; 4.  
 DR SMART: SM00281; Lams; 3.  
 DR SMART: SM00282; Lams; 3.  
 DR SMART: SM00283; Lams; 3.  
 DR PROSITE: PS00022; EGF\_1; 9.  
 DR PROSITE: PS01186; EGF\_2; 5.  
 DR PROSITE: PS01248; LAMININ\_TYPE\_EGF; 11.  
 DR PROSITE: PS00025; LAM\_G\_DOMAIN; 3.  
 DR PROSITE: PS01209; LDLRA\_1; 4.  
 DR PROSITE: PS00068; LDLRA\_2; 4.  
 DR PROSITE: PS50024; SEA; 1.

DR Signal: Basement membrane: Proteoglycan; Repeat; Glycoprotein;  
 DR Heparan sulfate; laminin EGF-like domain; Immunoglobulin domain;  
 DR Extracellular matrix; EGF-like domain.  
 DR SIGTBL: 1 21  
 DR CHAIN 22 4393  
 DR DOMAIN 80 194

FT BASEMENT MEMBRANE-SPECIFIC HEPARAN  
 FT SULFATE PROTEOGLYCAN CORE PROTEIN.  
 FT SEA.

FT

FT

```

FT DOMAIN 197 236 LDL-RECEPTOR CLASS A 1.
FT 283 321 LDL-RECEPTOR CLASS A 2.
FT 323 361 LDL-RECEPTOR CLASS A 3.
FT 366 405 LDL-RECEPTOR CLASS A 4.
FT 405 506 IG-LIKE C2-TYPE DOMAIN 1.
FT 523 532 LAMININ EGF-LIKE 1 (N-TERMINAL).
FT 532 532 LAMININ DOMAIN IV.1 (DOMAIN III A).
FT 733 765 LAMININ EGF-LIKE 1 (C-TERMINAL).
FT 766 815 LAMININ EGF-LIKE 2.
FT 816 873 LAMININ EGF-LIKE 3.
FT 881 925 LAMININ EGF-LIKE 4 (INCOMPLETE).
FT 926 935 LAMININ EGF-LIKE 5 (N-TERMINAL).
FT 936 1127 LAMININ DOMAIN IV.2 (DOMAIN III B).
FT 1128 1160 LAMININ EGF-LIKE 5 (C-TERMINAL).
FT 1161 1210 LAMININ EGF-LIKE 6.
FT 1211 1267 LAMININ EGF-LIKE 8.
FT 1277 1326 LAMININ EGF-LIKE 9.
FT 1337 1336 LAMININ EGF-LIKE 9 (N-TERMINAL).
FT 1337 1336 LAMININ DOMAIN IV.3 (DOMAIN III C).
FT 1532 1564 LAMININ EGF-LIKE 9 (C-TERMINAL).
FT 1565 1614 LAMININ EGF-LIKE 10.
FT 1615 1672 LAMININ EGF-LIKE 11.
FT 1673 1773 IG-LIKE C2-TYPE DOMAIN 2.
FT 1774 1867 IG-LIKE C2-TYPE DOMAIN 3.
FT 1868 1957 IG-LIKE C2-TYPE DOMAIN 4.
FT 1958 2053 IG-LIKE C2-TYPE DOMAIN 5.
FT 2054 2153 IG-LIKE C2-TYPE DOMAIN 6.
FT 2154 2246 IG-LIKE C2-TYPE DOMAIN 7.
FT 2247 2342 IG-LIKE C2-TYPE DOMAIN 8.
FT 2343 2438 IG-LIKE C2-TYPE DOMAIN 9.
FT 2439 2535 IG-LIKE C2-TYPE DOMAIN 10.
FT 2536 2631 IG-LIKE C2-TYPE DOMAIN 11.
FT 2632 2728 IG-LIKE C2-TYPE DOMAIN 12.
FT 2729 2828 IG-LIKE C2-TYPE DOMAIN 13.
FT 2829 2926 IG-LIKE C2-TYPE DOMAIN 14.
FT 2927 3023 IG-LIKE C2-TYPE DOMAIN 15.
FT 3024 3114 IG-LIKE C2-TYPE DOMAIN 16.
FT 3115 3213 IG-LIKE C2-TYPE DOMAIN 17.
FT 3214 3300 IG-LIKE C2-TYPE DOMAIN 18.
FT 3301 3401 IG-LIKE C2-TYPE DOMAIN 19.
FT 3402 3490 IG-LIKE C2-TYPE DOMAIN 20.
FT 3491 3576 IG-LIKE C2-TYPE DOMAIN 21.
FT 3577 3664 IG-LIKE C2-TYPE DOMAIN 22.
FT 3665 3845 LAMININ G-LIKE 1.
FT 3846 3883 EGF-LIKE 1.
FT 3886 3924 EGF-LIKE 2.
FT 3930 4105 LAMININ G-LIKE 2.
FT 4106 4143 EGF-LIKE 3.
FT 4145 4178 EGF-LIKE 4.
FT 4203 4391 LAMININ G-LIKE 3.
FT 65 67 HEPARAN SULFATE (POTENTIAL).
FT 71 73 HEPARAN SULFATE (POTENTIAL).
FT 76 78 HEPARAN SULFATE (POTENTIAL).
FT 4151 4153 MEDIATES MOTOR NEURON ATTACHMENT.
FT SITE SITE (POTENTIAL).
FT 4301 4303 MEDIATES MOTOR NEURON ATTACHMENT.
FT DISULFID 199 212 BY SIMILARITY.
FT DISULFID 206 225 BY SIMILARITY.
FT DISULFID 219 234 BY SIMILARITY.
FT DISULFID 285 297 BY SIMILARITY.
FT DISULFID 292 310 BY SIMILARITY.
FT DISULFID 304 319 BY SIMILARITY.
FT DISULFID 325 337 BY SIMILARITY.
FT DISULFID 332 350 BY SIMILARITY.

Query Match 5.68; Score 116; DB 1; Length 4393;
Best Local Similarity 24.68; Pred. No. 0.77; Indexes 72; Gaps 10;
Matches 55; Conservative 25; Mismatches 72;

```

```

QY 20 PGNATVYSGQARFNCVTSQ-----WKLIMVALSDVVLVSVPMEPIITNDRTSQR 72
DB 3030 PPSSTVQGGQDASFKCLIHGDAPISELEKTRNOELEBNVAIS--PNSGSIIT----- 3079

```

```

QY 73 YDQGNFTSEMIIHNPESDGNIRC-----SLQNSRLHGSAYLVQVMEELFI- 121
DB 3080 -----IGTRPSNHNIGYRCASNAKGVQASVNLVSHGPPYVSLPECPVWVK 3127
QY 122 --PSVNL-VVAENPCEVTCPSHMTRLPDISWEL-----GLVSHSSVYVFEPSDDLS 173
DB 3128 VGKAVTLECVCAGEPRS-----SARWTRISSTPAKLEQRTYGLMDSH-----T 3170
QY 174 AVSIALTPQSGNGLTCVATKSLKARSAVNLTVLRCPQDNG 217
DB 3171 VLOISSAKPSDAGTYVCLAQNALGTAQKQVEVTV-----DTG 3207

RESULT 14
NEOL_HUMAN STANDARD; PRT; 1461 AA.
AC Q92859; Q00340;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Neogenin precursor.
GN NEOL OR NGN.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
RC TISSUE=Fetal brain;
RA Meyerhardt J.A., Look A.T., Bigner S.H., Fearon E.R.;
RT "Identification and characterization of neogenin, a DCC-related
RT gene."
RL Oncogene 14:1129-1136(1997).
RP [2]
RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
RC TISSUE=Fetal brain;
RA MEDLINE=97312699; PubMed=9169140;
RA Vielmetter J., Chen X.-N., Miskavich F., Lane R.P., Yamakawa K.,
RA Korenberg J.R., Dreyer W.J.;
RT "Molecular characterization of human neogenin, a DCC-related protein,
RT and the mapping of its gene (NEOL) to chromosomal position 15q22.3-
RT q23."
RL Genomics 41:414-421(1997).
CC -1- FUNCTION: MAY BE INVOLVED AS A REGULATORY PROTEIN IN THE
CC TRANSITION OF UNDIFFERENTIATED PROLIFERATING CELLS TO THEIR
CC DIFFERENTIATED STATE. MAY ALSO FUNCTION AS A CELL ADHESION
CC MOLECULE IN A BROAD SPECTRUM OF EMBRYONIC AND ADULT TISSUES.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- ALTERNATIVE PRODUCTS: At least 2 ISOFORMS; 1 (SHOWN HERE) AND 2;
CC ARE PRODUCED BY ALTERNATIVE SPLICING.
CC -1- TISSUE SPECIFICITY: WIDELY EXPRESSED AND ALSO IN CANCER CELL
CC LINES.
CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. DCC
CC SUBFAMILY.
CC -1- SIMILARITY: CONTAINS 4 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
CC -1- SIMILARITY: CONTAINS 6 FIBRONECTIN TYPE III-LIKE DOMAINS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: U61262; AAB17263.1; -
DR EMBL: U72391; AAC51287.1; -
DR HSRP: P02751; 197F.
DR GENE: HGNC:7754; NEOL.
DR MIM: 601907; -
DR InterPro: IPR003961; FN_III.

```

DR InterPro: IPR003962; FnIII repeat.  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR Pfam: PF00041; fn3; 6.  
 DR Pfam: PF00047; fn3; 6.  
 DR PRINTS: PR00014; FNTYPEIII.  
 DR SMART: SM00060; FN3; 6.  
 DR SMART: SM00410; Ig\_Like; 1.  
 DR SMART: SM00408; IgC2; 3.  
 KW Transmembrane; Immunoglobulin domain; Glycoprotein; Signal; Repeat;  
 KM Alternative splicing.  
 FT SIGNAL 1 33  
 FT CHAIN 34 1461  
 FT DOMAIN 34 1461  
 FT TRANSMEM 1106 1126  
 FT DOMAIN 1127 1461  
 FT DOMAIN 67 136  
 FT DOMAIN 166 228  
 FT DOMAIN 263 327  
 FT DOMAIN 353 417  
 FT DOMAIN 436 533  
 FT DOMAIN 536 629  
 FT DOMAIN 630 729  
 FT DOMAIN 735 829  
 FT DOMAIN 850 950  
 FT DOMAIN 951 1052  
 FT DOMAIN 1118 1121  
 FT DISULFID 1121 129  
 FT DISULFID 173 221  
 FT DISULFID 270 320  
 FT CARBOHYD 362 410  
 FT CARBOHYD 73 73  
 FT CARBOHYD 210 210  
 FT CARBOHYD 326 326  
 FT CARBOHYD 470 470  
 FT CARBOHYD 489 489  
 FT CARBOHYD 639 639  
 FT CARBOHYD 715 715  
 FT CARBOHYD 909 909  
 FT VARSPLIC 1248 1300  
 FT CONFLICT 168 168  
 SQ SEQUENCE 1461 AA; 159958 MW; 7AAE897E6953A21 CRC64;

Query Match 5.6%; Score 114.5; DB 1; Length 1461;  
 Best Local Similarity 24.4%; Pred. No. 0.27; Mismatches 107; Indels 73; Gaps 13;  
 Matches 68; Conservative 31; Mismatches 107; Indels 73; Gaps 13;

QY 12 SGENETEPONATVYKSGQARENCTVSQGWKLIMMALSDMVLVSRPMEPIITN-----65  
 DB 203 SGMVLT---SNAT---EGDGGIYRCVYESSGPP---KYSDEVELKVLDPDEVISDLVFLNQ 254  
 QY 66 -----DRETSQARD--OGNFTSEMIIHNV 88  
 DB 255 PSLPLRVIGQDVVLPVCAAGLPPTTIKMKNEALPTESSEKRLVLAGGS---LEISDV 310  
 QY 89 EPSDSGNIRCSLONS---LHGSAYLVYQVWGELEFIPSVNLYVAENP-----PCEVCLPSH 142  
 DB 311 TEDAGTYFCIADNGNETIQAQELVYQAPREFLKPNTIYAHESNDIYEEVEVTKPT- 369  
 QY 143 WTRLPDLSW-ELGLVSHSYFYVPEPSDQASVILALTPQSNGLTLCVATWKSILKAR 201  
 DB 370 ----PYKWKVNDWVIPSDFYKIVEKHNQ-----VLGLVKSDEGEFYQCIADENDGNQA 421  
 QY 202 SATVNLTVIRCPDGTGGIINIP-GVLSLPSISGFSPTM 239  
 DB 422 GAOL-TLLEHAFAPTGRLPSAPRDVAVSLVSTRFKLTW 459

RESULT 15  
 RAGE\_BOVIN  
 ID RAGE\_BOVIN STANDARD; PRT; 416 AA.  
 AC 028173;

DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Advanced glycosylation end product-specific receptor precursor  
 DE (receptor for advanced glycosylation end products).  
 GN AGER OR RAGE.  
 OS Bos taurus (Bovine).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidea;  
 OC Bovidae; Bovinae; Bos.  
 NX NCBI\_TaxId=9913;  
 RN [1]  
 RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.  
 RC TISSUE=Lung;  
 RX MEDLINE=92340547; PubMed=1378843;  
 RA Nepper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C.,  
 RA Elliston K., Stern D., Shaw A.;  
 RT Cloning and expression of a cell surface receptor for advanced  
 RT glycosylation end products of proteins.  
 RL J. Biol. Chem. 267:14998-15004(1992).  
 CC - FUNCTION: MEDIATES INTERACTIONS OF ADVANCED GLYCOSYLATION END  
 CC PRODUCTS (AGE). THESE ARE NONENZYMATICALLY GLYCOSYLATED PROTEINS  
 CC WHICH ACCUMULATE IN VASCULAR TISSUE IN AGING AND AT AN ACCELERATED  
 CC RATE IN DIABETES.  
 CC - SUBCELLULAR LOCATION: Type I membrane protein.  
 CC - TISSUE SPECIFICITY: ENDOTHELIAL CELLS.  
 CC - SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.  
 CC - SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.  
 CC - SIMILARITY: CONTAINS 2 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: M91212; AAA03575.1; -  
 CC InterPro: IPR003006; Ig\_MHC.  
 CC InterPro: IPR003598; Ig\_C2.  
 CC InterPro: IPR003600; Ig\_Like.  
 CC Pfam: PF00047; Ig; 2.  
 CC SMART: SM00410; Ig\_Like; 1.  
 CC SMART: SM00408; IgC2; 3.  
 CC PROSITE: PS00290; IG\_MHC; 1.  
 KW Immunoglobulin domain; Glycoprotein; Transmembrane; Repeat; Signal.  
 FT SIGNAL 1 22  
 FT CHAIN 23 416  
 FT DOMAIN 23 352  
 FT TRANSMEM 353 373  
 FT DOMAIN 374 416  
 FT DOMAIN 31 105  
 FT DOMAIN 136 214  
 FT DOMAIN 262 318  
 FT DISULFID 38 98  
 FT DISULFID 143 207  
 FT DISULFID 269 311  
 FT CARBOHYD 25 25  
 FT CARBOHYD 80 80  
 FT DOMAIN 391 396  
 SQ SEQUENCE 416 AA; 44182 MW; B70381573E767AE CRC64;

Query Match 5.5%; Score 113.5; DB 1; Length 416;  
 Best Local Similarity 23.1%; Pred. No. 0.069; Mismatches 87; Indels 127; Gaps 18;  
 Matches 75; Conservative 35; Mismatches 87; Indels 127; Gaps 18;

QY 70 SQRYDGGNFT--SEKTIHNPVSDSGNIR---CS-----LONSRLHGSAYLVYQVWGE- 118  
 DB 176 TKRHPKTIGLTILHSELM--VTPARGALHPTFSCSFPGLRRRAALHTAPIDQLRVSEH 232  
 QY 119 -----LFTPSVNLVVAENP-----CEVTCLPSS--HWTR---LP 147

Wed Apr '30 10:00:20 2003

us-09-729-264-2.rsp

Page 15

```
Db 233 RGGEGPNVDVAPLKEVOLV---EPEGAVAPGGTTLTCEADPQPPQTHWIKDGRPLP 289
QY 148 DISWELGLVSHSYFYFPEPSDQSAVSIALTPOSNGTLTCVATWKSILKARKSATVNL 207
Db 290 -----LPPGMILLPEVG-----PEDGTYSCVATHPSHQPOESRAVS 328
QY 208 TVIRCPD--TGGGINIPGVLSLPSLIGSLPTWKNVGLAGTMLLTPCTLIRCCC 265
Db 329 TIEGEBETAGSVEPG---LETLALTILGILG--GLG-----TVALLIGYIVW 373
QY 266 RRRCCGNCNCCCRKRRGRFIOFQKSKSEKTKNETETESGNENSGYNSDEOKTTD 325
Db 374 HRR-----RORNG-----QERKVPENQEEERERALENOPE----- 404
QY 326 TASLPPKSCSSDPEQRNSSCGPP 349
Db 405 -----EPEAASSTGAP 416
```

Search completed: April 28, 2003, 18:09:37  
Job time : 18.2617 secs

•  
•  
•

Wed Apr 30 10:00:19 2003

us-09-729-264-2.rpr

Page 1

GenCore version 5.1.4-p5.4578  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 28, 2003, 18:09:54 ; Search time 18.8683 Seconds  
(without alignments)  
1946.300 Million cell updates/sec

Title: US-09-729-264-2

Perfect score: 2059  
Sequence: 1 MGLVFLHSGSGNEVIEGP.....HPQASFLASPEKVSNTTV 382

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :  
1: p1r1:\*  
2: p1r2:\*  
3: p1r3:\*  
4: p1r4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	147.5	7.2	404	1	advanced glycosyla
2	133	6.5	1427	2	tumor suppressor -
3	129.5	6.3	164	2	hypothetical prote
4	129.5	6.3	344	2	neurotrophin - rat
5	128	6.2	1447	2	tumor suppressor p
6	127.5	6.2	871	1	protein-tyrosine k
7	127.5	6.1	881	1	protein-tyrosine k
8	125.5	6.1	6642	2	protein UNC-89 - C
9	124	6.0	1070	2	protein-tyrosine k
10	122.5	5.9	188	2	hypothetical prote
11	120	5.8	345	2	opitoid-binding pro
12	119	5.8	345	2	opitoid-binding pro
13	118	5.7	345	2	opitoid-binding pro
14	117.5	5.7	1443	2	neogennin - chicken
15	116.5	5.7	338	2	opitoid-binding pro
16	116.5	5.6	4391	2	perlecan precursor
17	114.5	5.6	152	2	hypothetical prote
18	113.5	5.5	416	1	advanced glycosyla
19	112	5.4	764	2	irregular chiasm C
20	111	5.4	693	2	sodium-dependent p
21	110.5	5.4	620	2	Schwann cell myeli
22	110.5	5.4	1177	2	hypothetical prote
23	109.5	5.3	2491	1	insulin-like growt
24	109	5.3	391	2	butyrophilin homol
25	108.5	5.3	487	2	receptor tyrosine
26	107	5.2	882	2	heparan sulfate pr
27	107	5.2	3707	2	hypothetical prote
28	106.5	5.2	662	2	protein-tyrosine k
29	106.5	5.2	802	2	mitogen and stress

30	106.5	5.2	946	1	A47299	for-related recept
31	106	5.1	1092	1	UN0635	neural cell adhesi
32	104.5	5.1	862	2	149583	differentiation an
33	104	5.1	2222	2	T13924	sdh protein - frui
34	104	5.1	5825	2	T12117	polyprotein - fava
35	103.5	5.0	890	1	A53743	protein-tyrosine k
36	102.5	5.0	423	2	A31923	amalgam protein pr
37	102.5	5.0	789	2	T28714	hypothetical prote
38	102.5	5.0	1273	2	T42405	hypothetical prote
39	102.5	5.0	1355	2	T28715	sax-3 protein - Ca
40	102.5	5.0	2499	1	A30788	hypothetical prote
41	102.5	5.0	365	2	JC7780	mannose 6-phosphat
42	102	5.0	721	2	T41530	coxsackie- and ade
43	102	5.0	868	2	A46512	hypothetical prote
44	102	5.0	880	1	JC4166	CD22 homolog/B-lym
45	102	5.0	880	1	JC4166	protein-tyrosine k

## ALIGNMENTS

### RESULT 1

161596 advanced glycosylation end-products receptor precursor - human

N:Alternate names: advanced glycosylation end product-binding protein, 35k, glycoprot

C:Species: Homo sapiens (man)

C:Date: 24-May-1996 #sequence\_revision 07-Feb-1997 #text\_change 16-Jul-1999

C:Accession: 161596; B42879; S27968

R:Snigaya, K., 408-419, 1994

Genomics, 23, 408-419, 1994

A:Title: Three genes in the human MHC class III region near the junction with the cla

nterpart of mouse mammary tumor gene int-3.

A:Reference number: A53562; MUID:95137587; PMID:7835890

A:Accession: 161596

A:Molecule type: DNA

A:Residues: 1-404 <RES>

A:Cross-references: GB:D8769; NID:9561657; PIDN:BA05958.1; PID:9561659

A:Note: sequence extracted from NCI backbone (NCBIP:109438)

A:Comment: Advanced glycosylation end products are heterogeneous nonenzymatically gly

cellular function, thus contributing to tissue lesions in diabetes.

C:Comment: This receptor appears also to mediate the effects of amyloid beta peptide

ates in the neurotoxic pathway that produces dementia in Alzheimer's disease.

C:Genetics:

A:Gene: GDB:ACER

A:Cross-references: GDB:306354; OMIM:600214

A:Map position: 6p21.3-6p21.1

A:Insertions: 18/1; 53/3; 119/1; 140/3; 170/1; 231/1; 274/3; 322/1; 331/1; 373/2

A:Deletion: 18/1; 53/3; 119/1; 140/3; 170/1; 231/1; 274/3; 322/1; 331/1; 373/2

C:Function: neuronal receptor for amphoterin, a DNA-binding protein involved in ne

C:Superfamily: advanced glycosylation end products receptor; immunoglobulin homology

C:Keywords: Alzheimer's disease; glycoprotein; receptor; transmembrane protein

Query Match

7.2%, Score 147.5; DB 1; Length 404;

Best Local Similarity 22.6%; Pred. No. 0.0019;  
Matches 85; Conservative 40; Mismatches 114; Indels 137; Gaps 18;

QY 15 EVIECPQNAVYKGSQARFNCTVSOG---KLMALMSDMVLSVRMEPIITNDRTS- 70  
Db 125 EIVDSASLTL- -GVPRKVCVSEGSYPAGTSLMHLG- - - - -RPLVNEKGVSV 173  
QY 71 ----QRDQGNFT--SEMIHNVPSDSGNIR---CSLONSRLHGSAYLVQVWGELEF 120  
Db 174 KEQTRRHETGELTLOSELN---VTPARGDPRPTSCSPSPOLPHNRALRTAPIQPRVW 230  
QY 121 IP---SVNLVVAENEP- - - - -CEVTLPSHWRLDPDISMELGLVSHSSY 162  
Db 231 EPVLEEVOLV- - - - -EPGGAAPAGCTVLTCEVPAQPS- - - - -PQIHMKD- - - - - 274  
QY 163 YFVPEPSDLOSASVIALTPQSNGLTCVATWKSILKARKSATVNLVTRCQDDGGGINTI 222  
Db 275 -GVPLEPPSPVILPEIGPODGTYSVATSHSGPQSRVASTITE-PEEG- - - - - 327  
QY 223 PGVLSLPSLGEFLPTWGVGVLGAGTMLT- - - - -PTCLTRCCCRRCGCCGCC 275  
Db 328 - - - - -PIAGSVGGSGGLTALALIGLGLTALILGVLIMQRR- - - - - 366  
QY 276 CRCCFCRRKRPRIOFOKSEKERT--NKETTESNGENSGYNSDEQKTDTASLPKS 333  
Db 367 - - - - - - - - - - -ORGERKAPENOEEERAEIN- - - - - 389  
QY 334 CESSDEORNSSCGPP 349  
Db 390 -QSEPEAGESSTGPR 404

## RESULT 2

151669  
tumor suppressor - African clawed frog  
C:Species: Xenopus laevis (African clawed frog)  
C>Date: 13-Sep-1996 #sequence\_revision 13-Sep-1996 #text\_change 21-Jul-2000  
C:Accession: 151669  
R:Pierceall, W.E.; Reale, M.A.; Candia, A.F.; Wright, C.V.; Cho, K.R.; Fearon, E.R.  
Dev. Biol. 166, 654-665, 1994  
A:Title: Expression of a homologue of the deleted in colorectal cancer (DCC) gene in the  
A:Reference number: 151668; MUID:95113183; PMID:7813784  
A:Accession: 151669  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-1427 <PIR>  
A:Cross-references: EMBL:U10986; NID:9606873; PIDN:AAA70168.1; PID:9606874  
A:Genetics: XDCCA

Query Match 6.5%; Score 133; DB 2; Length 1427;  
Best Local Similarity 25.7%; Pred. No. 0.088;  
Matches 59; Conservative 33; Mismatches 90; Indels 48; Gaps 13;

QY 17 IEQPNATVYKGSQARFNCTVSOG---KLMALMSDMVLSVRMEPIITNDRTSORDY 74  
Db 243 LDRPSNVAIEQDVLBCAAS-GYPTPIYWMGD- - - - -EPVLRTR- - - - -KYS 288  
QY 75 QGCFNTESEMIHNVPSDSGNIR- - - - -SLONSRLHGSAYLVQVWGELEFISVNLVAEN 132  
Db 289 YLGG---SMILISNVLDDAGAYTCVATYKNTSFSADLVWVPPQFLNPAIMLVYESW 346  
QY 133 PCEVYCL- - - - -PSHWRLPDISW-ELGLVSHSSYVFPPEPSDLOSASVIALTPQSN 187  
Db 347 DIEFCASVSKPS- - - - -PYKMTKNGEVYIPSDYQIVGSMNR- - - - -ILGLVSDSEY 397  
QY 188 LTCVA- - - - -TWKSLKARKSATVNLVTR-RCPODTGGGGINIPGVLS 228  
Db 398 YQCIAMENAGNIQYIADLIIPPAVSSSILPSAPRDV- - - - -VPVLVSS 442

## RESULT 3

T24272

hypothetical protein T01B7.8 - Caenorhabditis elegans  
C:Species: Caenorhabditis elegans  
C>Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 15-Oct-1999  
C:Accession: T24272  
R:Sim, M.

submitted to the EMBL Data Library, October 1995  
A:Reference number: 219867  
A:Accession: T24272  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: DNA  
A:Residues: 1-164 <WID>  
A:Cross-references: EMBL:266499; PIDN:CAA91301.1; GSPDB:GN00020; CESP:T01B7.8  
A:Experimental source: clone T01B7  
A:Genetics:  
A:Gene: CESP:T01B7.8  
A:Map position: 2  
A:Introns: 20/3; 90/2

Query Match 6.3%; Score 129.5; DB 2; Length 164;  
Best Local Similarity 32.1%; Pred. No. 0.015;  
Matches 43; Conservative 11; Mismatches 53; Indels 27; Gaps 6;

QY 153 LGLVSHSSYVFPPEPSDLOSASVIALTPQSNGLTCVATWKSILKARKSATVNLVTRC 212  
Db 6 LAILALIGTFLAV- - - - -SVOQAV- - - - -LPVSTELATVGTVDVSTALDTLGNSSRV 57  
QY 213 PDDTGGGINIPGVLSLPSLGFSPGWKVGVLGAGTMLTPTCTLIRCCCRRCGCC 272  
Db 58 KRQGGCGCGCGCGC- - - - -GCCGGCGGGGG- - - - -GCCGCCPRCCGCCRCCTC 101  
QY 273 - - - - -NCCG-RCRCRCR 283  
Db 102 CRCCCTRCRCRCR 115

## RESULT 4

156551  
neurotrophin - rat  
C:Species: Rattus norvegicus (Norway rat)  
C>Date: 26-Jul-1996 #sequence\_revision 26-Jul-1996 #text\_change 19-May-2000  
C:Accession: 156551  
R:Struyk, A.F.; Canoll, P.D.; Wolfgang, M.J.; Rosen, C.L.; D'Eustachio, P.; Salzer, J.  
J. Neurosci. 15, 2141-2156, 1995  
A:Title: Cloning of neurotrophin defines a new subfamily of differentially expressed n  
A:Reference number: 156551; MUID:95198094; PMID:7891157  
A:Accession: 156551  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-344 <RES>  
A:Cross-references: EMBL:U16845; NID:9755184; PIDN:AAA67445.1; PID:9755185  
C:Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amlno-ter

Query Match 6.3%; Score 129.5; DB 2; Length 344;  
Best Local Similarity 24.2%; Pred. No. 0.034;  
Matches 64; Conservative 43; Mismatches 104; Indels 53; Gaps 14;

QY 4 VIFLHSG- - - - -SGEYI-EGPNATVYKGSQARFNCTVSOGKLMALMSDMVLS- - - - - 55  
Db 21 LIFLVPTGVYRSGDAPPRKAMDMVTRQGESATLRCCTIDNRTVRAVNLNRSTILLACND 80  
QY 56 - - - - -VRMEPIITNDRTSORDGNTSEMIHNVPSDSGNIRCSLO- - - - -NSRLH 106  
Db 81 KWCIDPRVVLN- - - - -TQY- - - - -SIEIONDVYDEGPYCSVQTDNHPKTSRVH 129  
QY 107 GSAIVYQVWGELEFIPSVNLVAENEPCEVTLPSHWRLPDISMEGLVSHSSYTVR 166  
Db 130 - - - - -LIVQVSPKIVLEISDISINEGNISLTGLAIGRPE-PIVTR- - - - -HISPAKGVGS 181  
QY 167 EPSDLOSASVIALTPQSNGLTCVATWKSILKARKSATVNLVTRC- - - - -ODTGGGIN 221  
Db 182 EDEYLE- - - - -IGQITREGGTECSAS-NDVAPVRRVNTVNPYISBAKGGVPGV 236  
QY 222 IPGV- - - - -SLPSLGEFLPTWKG 241



Db 237 OKGTGOCASAVPSAFEPF---WPK 257

## RESULT 5

AS4100

tumor suppressor protein DCC precursor - human

N:Alternate names: colorectal cancer suppressor DCC

C:Species: Homo sapiens (Man)

C>Date: 02-Aug-1994 #sequence\_revision 02-Aug-1994 #text\_change 05-Nov-1999

C:Accession: A54100; A40098

R:Redick, L.; Cho, K.R.; Fearon, E.R.; Wu, T.C.; Kinzler, K.W.; Vogelstein, B.

Genes Dev. 8, 1174-1183, 1994

A:Title: The DCC gene product in cellular differentiation and colorectal tumorigenesis.

A:Reference number: A54100; MUID:95011532; PMID:7926722

A:Accession: A54100

A:Molecule type: mRNA

A:Residues: 1-1447 <HEP>

A:Cross-references: EMBL:X76132; NID:9453209; PIDN:CAA53735.1; PID:9453210

R:Pearson, E.R.; Cho, K.R.; Nigro, J.M.; Kern, S.E.; Simons, J.W.; Ruppert, J.M.; Hamilit

A:Title: Identification of a chromosome 18q gene that is altered in colorectal cancers.

A:Reference number: A40098; MUID:90100559; PMID:2294591

A:Accession: A40098

A:Molecule type: mRNA

A:Residues: 1-750 <FEA>

A:Cross-references: GB:M32292; NID:9181492; PIDN:AAA35751.1; PID:9181493

C:Genetics:

A:Gene: GDB:DC

A:Cross-references: GDB:119838; OMIM:120470

A:Map position: 18q21.1-18q21.1

C:Keywords: transmembrane protein; tumor suppressor

F:1-35/Domain: signal sequence #status predicted <SIG>

F:26-1447/Product: tumor suppressor protein DCC #status predicted <MAT>

Query Match

Best Local Similarity 24.8%; Pred. No. 0.21; Length 1447;

Matches 60; Conservative 33; Mismatches 99; Indels 50; Gaps 10;

10 SGGNGEV-----IEGPONATVTKGSOARFNCVTSQGW-KLIMMALSMD 51

Db 220 SRKGNAEVRILSDGLHQLYFLQRPSTVVAIEGKDAVLECVS-GYPSPFTWLKEE 278

QY 52 VLVSRMEPIITNDRFTSQRDQGNFSEMIHNVESDSGNTRC-SLONSRLHGA 109

Db 279 VI-----QIRSKKYSLLGG--SNLISNVDDDSGMYTCVYTKNENISASA 323

QY 110 YLVYVWGLFLIPSVNLIYVAENPECEVTCPLPSHMTLPDISW-ELGLVSHSYIFVPEP 168

Db 324 ELTVLVPFPLNHPNINLXAESMDIEFECTVS-GKPVPTVNMNMKNDVVIPSDYFOIVGG 382

QY 169 SDLOSASVILALPQSSNGTLTCVATKSLKARKSATVNLVIRCPDQDTGGGGINFGVLSS 228

Db 383 SNLR-----ILGVVKSDEGFYQVCAENAGNAQTSQQLIVPKPAIPSSS-----VLPS 430

QY 229 LP 230

Db 431 AP 432

## RESULT 6

148696

protein-tyrosine kinase (EC 2.7.1.112) nsk2 precursor, splice form 2 - mouse

N:Alternate names: receptor-type tyrosine kinase

C:Species: Mus musculus (house mouse)

C>Date: 19-May-2000 #sequence\_revision 19-May-2000 #text\_change 19-May-2000

C:Accession: 148696; S60738

R:Ganju, P.; Walls, E.; Brennan, J.; Reith, A.D.

Oncogene 11, 281-290, 1995

A:Title: Cloning and developmental expression of Nsk2, a novel receptor tyrosine kinase

A:Reference number: 148696; MUID:95349951; PMID:7624144

A:Status: nucleic acid sequence not shown; translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 1-871 <GAN1>

A:Cross-references: EMBL:X86444; NID:9929723; PIDN:CAA60165.1; PID:9929724

A:Experimental source: splice form 2

A:Accession: S60738

A:Molecule type: DNA

A:Residues: 1-456; A', 466-871 <GAN2>

A:Cross-references: EMBL:X86444; NID:9929723

A:Experimental source: splice form 4

C:Comment: For alternate splice forms see PIR:148697.

C:Genetics:

A:Gene: nsk2

A:Cross-references: MGI:103308

C:Superfamily: mouse for-related receptor; immunoglobulin homology; protein kinase ho

C:Keywords: ATP; glycoprotein; phosphotransferase; receptor; transmembrane protein; t

F:1-21/Domain: signal sequence #status predicted <SIG>

F:22-871/Product: protein-tyrosine kinase nsk2, splice form 2 #status predicted <MAT2

F:22-456; A', 466-871/Product: protein-tyrosine kinase nsk2, splice form 4 #status pre

F:42-101/Domain: immunoglobulin homology <IMM1>

F:42-192/Domain: immunoglobulin homology <IMM2>

F:226-284/Domain: immunoglobulin homology <IMM3>

F:498-518/Domain: transmembrane #status predicted <TRM>

F:575-865/Domain: protein kinase ATP-binding motif

F:583-591/Region: protein kinase ATP-binding motif

F:222,462/Binding site: carbohydrate (asn) (covalent) #status predicted

Query Match

Best Local Similarity 6.2%; Score 127.5; DB 1; Length 871;

Matches 70; Conservative 41; Mismatches 125; Indels 87; Gaps 16;

QY 15 EYIEGPONATVTKGSOARFNCVTSQGW-KLIMMALSMDVLSRPMPIITNDRFTSQRY 73

Db 122 KTRRPIPVKIKIEGKAVLPCTMGNRPYSWTKGD-----NALRENSRIALE 171

QY 74 DGGNFTSEMIHNVESDSGNTRC-SLONSRLHGSAY-----LVQVMEGLFIPSVNLVY 128

Db 172 -----SGSLRHHNVQKRDACQRCVAKNSL--GTAVSKLVKEVEVLGRLAPESHNV 223

QY 129 AENPECEVTC-----LPSHMTLPDISW-ELGLVSHSYIFVPEPSSDLOSASVILALTPQ 183

Db 224 TFGSEVTLTCTEIGP-----VPTISWENGNANVSSGSIQSVADRYLDSRLQLFITRP 277

QY 184 SNGTLTCVAT-----WKSLSKARKSATVNLTVIR-----CPQDTGGGINIPG-----V 225

Db 278 --GLYTCINATMKHGEKFSYAKAAATVSIAMSKSOKDSQGYCAQTRGCVLMQGPGEKML 335

QY 226 LSSLPSTLGSFP-----TWGVYGLAGTMLTPCTLTITRCCCRRCGCGN-- 273

Db 336 LVPLPTSHRDPDAQELLITRAMNEL-----KAVSPLCRPAEALICVHLECSFG 388

QY 274 -----CCCRCC-----FCCR 283

Db 389 VVPLPMPICREYCLAVKEIFCAK 411

## RESULT 7

148697

protein-tyrosine kinase (EC 2.7.1.112) nsk2 precursor, splice form 1 - mouse

N:Alternate names: receptor-type tyrosine kinase

C:Species: Mus musculus (house mouse)

C>Date: 19-May-2000 #sequence\_revision 19-May-2000 #text\_change 19-May-2000

C:Accession: 148697; S60740

R:Ganju, P.; Walls, E.; Brennan, J.; Reith, A.D.

Oncogene 11, 281-290, 1995

A:Title: Cloning and developmental expression of Nsk2, a novel receptor tyrosine kina

A:Reference number: 148697; MUID:95349951; PMID:7624144

A:Accession: 148697

A:Molecule type: DNA

A:Residues: 1-861 <GAN1>

A:Cross-references: EMBL:X86445; NID:9929725; PIDN:CAA60166.1; PID:9929726

A: Experimental source: splice form 1  
 A: Accession: S60740  
 A: Molecule type: DNA  
 A: Residues: 1-456, 'A', 466-881 <GAND>  
 A: Cross-references: EMBL:X86445; NID:9929725  
 A: Experimental source: splice form 3  
 C: Comment: For alternate splice forms see PIR:I48696.  
 C: Genetics:

A: Gene: nsk2  
 A: Cross-references: MGI:103308  
 C: Superfamily: mouse for-related receptor; immunoglobulin homology; protein kinase homol  
 C: Keywords: ATP; glycoprotein; phosphotransferase; receptor; transmembrane protein; tyro  
 F: 1-21/Domain: signal sequence #status predicted <Sig>  
 F: 22-881/Product: protein-tyrosine kinase nsk2, splice form 1 #status predicted <MAT1>  
 F: 22-456, 'A', 466-881/Product: protein-tyrosine kinase nsk2, splice form 3 #status predi  
 F: 42-101/Domain: immunoglobulin homology <IMM1>  
 F: 135-192/Domain: immunoglobulin homology <IMM2>  
 F: 236-284/Domain: immunoglobulin homology <IMM3>  
 F: 498-518/Domain: transmembrane #status predicted <TRM>  
 F: 575-865/Domain: protein kinase homology <KIN>  
 F: 583-591/Region: protein kinase ATP-binding motif  
 F: 222,462/Binding site: carbohydrate (asn) (covalent) #status predicted

## Query Match

Best Local Similarity 6.2%; Score 127.5; DB 1; Length 881;  
 Matches 70; Conservative 41; Mismatches 125; Indels 87; Gaps 16;

QY 15 EVIEGPNATVLKGSQARFNCVSGWK-LIMWALSDMVLSVRPMEPIITNDRFTSQRY 73  
 DB 122 KITRPINVKIIEGLKAVLPCTTKMNPSPVSWIRGD-----NALRNSRIALE- 171  
 QY 74 DOGNTSEMIITHNVEPSDSGNIRCSLONSRLHGSAY-----LTVQWGELEFIPSNLVY 128  
 DB 172 -----SSGLRIHNOQKEDAGQYRCVAKNSL--GTAVSKLVKLEVEVLGRILRAPESHNV 223  
 QY 129 AENPECEVTC-----LPSHWRLPDISW-ELGLVSHSYFVEPPSDLOSASVILALTPQ 183  
 DB 224 TFGSEVTLRCEIGIP-----VPIITSENGNAVSSGSIQSVKDRVIDRSLQITKRP- 277  
 QY 184 SNGTITLCVAT-----WKSIAKRSATVNLTVIR-----CPQDGGGGINING-----V 225  
 DB 278 --GLYTCTATKHKHEKSTAKAATVSIAMSKSQKSGCYCAQYGEVLMQGEKML 335  
 QY 226 LSLPSLGLFSLP-----TWGKVGGLAGTMTLTPCTLTTRCCCCRRCCGCN-- 273  
 DB 336 LVFLPTTSHRPEDAQGLLHTMANEL-----KAVSPICRPAAALCLYHLEFCSPG 388  
 QY 274 -----CCRCRC-----FCRC 283  
 DB 389 VVLPMPICREYCLAVKELEFCAR 411

## RESULT 8

129757

Protein UNC-89 - Caenorhabditis elegans  
 C: Species: Caenorhabditis elegans  
 C: Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 03-Dec-1999

C: Accession: T29757  
 R: Du, Z.; Le, T.T.; Wilson, R.  
 submitted to the EMBL Data Library, May 1997

A: Description: The sequence of C. elegans cosmid C09D1.  
 A: Reference number: 220679

A: Accession: T29757

A: Status: preliminary; translated from GB/EMBL/DBJ

A: Molecule type: DNA

A: Residues: 1-6642 <DND>

A: Cross-references: EMBL:AF003131; PTDN:AB54132.1; GSPDB:GN00019; CESP:unc-89

A: Experimental source: strain Bristol N2; clone C09D1

A: Gene: CESP:unc-89

A: Map position: 1

A: Introns: 17/2; 108/3; 154/2; 211/2; 265/3; 326/2; 352/3; 426/2; 454/1; 500/1; 537/1; 6

Query Match  
 Best Local Similarity 6.1%; Score 125.5; DB 2; Length 6642;  
 Matches 52; Conservative 39; Mismatches 92; Indels 35; Gaps 8;

QY 16 VIEGPNATVLKGSQARFNCVSGWK-LIMWALSDMVLSVRPMEPIITNDRFTSQRY 73  
 DB 2077 VVDPKSTVTEKTEETAEFKATIS--GEPAPVKTWIKETIVEESRTITTKTEDVY- 2131  
 QY 74 DOGNTSEMIITHNVEPSDSGNIRCSLONSRLHGSAYLTVQWGELEFIPSNLVY 128  
 DB 2132 -----LKSNAKIEQGTGVKTAQNASAGDSQADLKPEPVKAKERKSQLTDRVA 2182  
 QY 129 AENPECEVTC-----LPSHWRLPDISWEL-GLVSHSYFVEPPSDLOSASVILALTPQS 184  
 DB 2183 DEGEPLKMWNLDELDPSPGT-----EVSMLNGOPLRSDYVQVVDHGDGYHTVIAEKREM 2239  
 QY 185 NGTLTCAVATWKSIAKRSATVNLTV-----VIRCPQD 215  
 DB 2240 SGTITAKARNNAAGECTSAKVTYNGNKKPFEVQAPQN 2277

## RESULT 9

JC4593

protein-tyrosine kinase-related receptor PTK7 precursor - human  
 N: Alternate names: receptor protein tyrosine kinase-like protein (RPTK)  
 C: Date: 16-Apr-1996 #sequence\_revision 24-May-1996 #text\_change 24-Sep-1999

C: Accession: JC4593  
 R: Park, S.K.; Lee, H.S.; Lee, S.T.

J. Biochem. 119, 235-239, 1996

A: Title: Characterization of the human full-length PTK7 cDNA encoding a receptor prot

A: Reference number: JC4593; MUID:97037064; PMID:8882711

A: Accession: JC4593

A: Molecule type: mRNA

A: Residues: 1-1070 <PAR>

A: Cross-references: GB:J40371; NID:91322231; PTDN:AC50484.1; PID:91322232

C: Comment: This protein is a member of receptor protein tyrosine kinase family, but, p

C: Genetics:

A: Gene: GDB:PTK7

A: Cross-references: GDB:134760; OMIM:601890

A: Map position: 6p21.1-6p12.2

C: Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase hom

C: Keywords: cell adhesion; extracellular protein; glycoprotein; phosphotransferase; t

F: 1-30/Domain: signal sequence #status predicted <Sig>

F: 31-1070/Product: protein-tyrosine kinase 7 #status predicted <MAT>

F: 704-725/Domain: extracellular #status predicted <EXC>

F: 726-1070/Domain: transmembrane #status predicted <TRM>

F: 794-1065/Domain: intracellular #status predicted <INC>

F: 116,175,184,214,268,283,405,463,567,646/Binding site: carbohydrate (Asn) (covalent)

Query Match  
 Best Local Similarity 6.0%; Score 124; DB 2; Length 1070;  
 Matches 58; Conservative 32; Mismatches 103; Indels 36; Gaps 10;

QY 16 VIEGPNATVLKGSQARFNCVSGWK-LIMWALSDMVLSVRPMEPIITNDRFTSQRY 74  
 DB 227 VVLAQDDVAVVAYEFAMHCOFSAQPPSLQWLFEDEPITNRSRPHLRATVFA----- 282  
 QY 75 OGNFTSEMIITHNVEPSDSGNIRCSLONSRLHGSAYLTVQWGELEFIPSNLVY 129  
 DB 283 -----NGSLLLTVQRPNAGIYKICIGOGQKRPPILEATLHAEIDMDLFEPRVPTAAS 337  
 QY 130 ENPECEVTCLEPHTRLPDISWE-LGL-LVSHSYFVEPPSDLOSASVILALTPQSN-G 186  
 DB 338 EE---RVYTCLEPKGLPPSPVWMEHAGVRLPTGRVY-----QKHELVLANINAESDAG 387  
 QY 187 TLTCVATWKSIAKRSATVNLTV-----IRQDPTGGGINIPGVLSL 229  
 DB 388 VYTOHAM--NLACGRQDVAVITVATVPSWLKRPQDSLEBGRPGYLDCL 434

## RESULT 10

T15651

hypothetical protein C27A2.5 - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C:Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 20-Sep-1999

C:Accession: T15651

R:Nhan, M.

A:Submitted to the EMBL Data Library, May 1996

A:Description: The sequence of C. elegans cosmid C27A2.

A:Reference number: Z18382

A:Accession: T15651

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-188 &lt;NHA&gt;

A:Cross-references: EMBL:U58760; NID:q1330384; PID:q1330389; PIDN:AA00710.1; GSPDB:GN00

A:Experimental source: strain Bristol N2; clone C27A2

C:Genetics:

A:Gene: CESP:C27A2.5

A:Map position: 2

A:Introns: 19/3; 91/2

## Query Match

Best Local Similarity 61.3%; Pred. No. 0.059;

Matches 19; Conservative 1; Mismatches 8; Indels 3; Gaps 2;

OY 256 CTTTIRCCCRRCGCC--NCCC-RCCFCCR 283

Db 86 CCCPRKCCCRRCCTCCTCCTCCTCCTCCTC 116

## RESULT 11

JC4025

opioid-binding cell adhesion protein - human

C:Species: Homo sapiens (man)

C:Date: 13-Jun-1995 #sequence\_revision 14-Jul-1995 #text\_change 17-Mar-2000

C:Accession: JC4025

R:Shark, K.B.; Lee, N.M.

Gene 155, 213-317, 1995

A:Title: Cloning, sequencing and localization to chromosome 11 of a cDNA encoding a huma

A:Reference number: JC4025; M0ID:95237612; PMID:7721093

A:Accession: JC4025

A:Molecule type: mRNA

A:Residues: 1-345 &lt;SHA&gt;

A:Cross-references: GB:I34774; NID:q514373; PIDN:AAA36387.1; PID:q514374

A:Experimental source: brain

C:Comment: This protein binds opioid alkaloids in the presence of acidic lipids; exhibit

C:Genetics:

A:Gene: GDB:OPCM; OBCAM; OPCM

A:Cross-references: GDB:251677; OMIM:600632

A:Map position: 11pter-11qter

C:Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-termin

## Query Match

Best Local Similarity 25.0%; Pred. No. 0.17;

Matches 71; Conservative 37; Mismatches 102; Indels 74; Gaps 18;

OY 4 VIFLHSG---SGNEVI-EGPONATVVGKSGARFNCVSGQWKLIMWALSDMYVL-----54

Db 21 LFLVPTGVPRSGDATFPKAMDNVTVRQGESATLRCCTIDDRVTRVAV-LNRSTILVAGN 79

OY 55 ---SVRPMEPIITNDRTSORYDQGNFTSEMIHNEPSSDGNIRCSLQ-----NSRL 105

Db 80 DKMSIDPRVILLV---TPQY-----SIMIONVDVDEGPTCSVOQDNHPTKSRV 128

OY 106 HGSATLVYQWNGELFIPSVNLVVAENEPCEVYTCL-----PSHWTLPLDISMELGLVSHSS 161

Db 129 H-----LIVQVPPQIMNISDVTVNEGSSVTLCLAIQRP-----PYVTR-----HLS 173

OY 162 YX-----FVPEPSDLOSASVILATPQSNGLTVCAATWKSILKARKSATVNLTV-----IRC 212

Db 174 VKEGGFGVSEDEYLE-----ISDIKRDQSGEYECAL-NDVAAPDVRRKVKITLVNPPYISK 228

OY 213 PDGTGGGINIPGVL-----SLPISLGFSLPTWKG-----VGLAGL 248

## RESULT 12

S03199

opioid-binding protein OPCAM precursor - bovine

C:Species: Bos primigenius taurus (cattle)

C:Date: 04-Dec-1992 #sequence\_revision 04-Dec-1992 #text\_change 17-Mar-2000

C:Accession: S03199

R:Schofield, P.R.; McFarland, K.C.; Hayflick, J.S.; Wilcox, J.N.; Cho, T.M.; Roy, S.;

EMBO J. 8, 489-495, 1989

A:Title: Molecular characterization of a new immunoglobulin superfamily protein with

A:Reference number: S03199; M0ID:89251576; PMID:2721489

A:Accession: S03199

A:Molecule type: mRNA

A:Residues: 1-345 &lt;SCH&gt;

A:Cross-references: EMBL:X12672; NID:q585; PIDN:CAA31192.1; PID:q586

C:Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-ter

C:Keywords: transmembrane protein

F:1-27/Domain: signal sequence #status predicted &lt;SIG&gt;

F:28-345/Product: opioid-binding protein OPCAM #status predicted &lt;MAT&gt;

## Query Match

Best Local Similarity 25.1%; Pred. No. 0.2;

Matches 70; Conservative 36; Mismatches 103; Indels 70; Gaps 17;

OY 4 VIFLHSG---SGNEVI-EGPONATVVGKSGARFNCVSGQWKLIMWALSDMYVL-----54

Db 21 LFLVPTGVPRSGDATFPKAMDNVTVRQGESATLRCCTIDDRVTRVAV-LNRSTILVAGN 79

OY 55 ---SVRPMEPIITNDRTSORYDQGNFTSEMIHNEPSSDGNIRCSLQ-----NSRL 105

Db 80 DKMSIDPRVILLV---TPQY-----SIMIONVDVDEGPTCSVOQDNHPTKSRV 128

OY 106 HGSATLVYQWNGELFIPSVNLVVAENEPCEVYTCL-----PSHWTLPLDISMELGLVSHSS 161

Db 129 H-----LIVQVPPQIMNISDVTVNEGSSVTLCLAIQRP-----PYVTR-----HLS 173

OY 162 YX-----FVPEPSDLOSASVILATPQSNGLTVCAATWKSILKARKSATVNLTV-----IRC 212

Db 174 VKEGGFGVSEDEYLE-----ISDIKRDQSGEYECAL-NDVAAPDVRRKVKITLVNPPYISK 228

OY 213 PDGTGGGINIPGVL-----SLPISLGFSLPTWKGVLGLA 247

Db 229 AKNTGVSQKGLISCEASAVPMAEFQ---WKEEDTRLA 264

## RESULT 13

JC1239

opioid-binding protein (clones SG8 and SG13) - rat

C:Species: Rattus norvegicus (Norway rat)

C:Date: 03-May-1994 #sequence\_revision 03-May-1994 #text\_change 19-May-2000

C:Accession: JC1239

R:Lippman, D.A.; Lee, N.M.; Loh, H.H.

Gene 117, 249-254, 1992

A:Title: Opioid-binding cell adhesion molecule (ORCAM)-related clones from a rat brat

A:Reference number: JC1238; M0ID:92347701; PMID:1339369

A:Accession: JC1239

A:Molecule type: mRNA

A:Residues: 1-345 &lt;LIP&gt;

A:Cross-references: GB:M88710; NID:q203247; PIDN:AAA40859.1; PID:q203248; GB:M88711;

C:Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-ter

C:Keywords: transmembrane protein

## Query Match

Best Local Similarity 24.7%; Pred. No. 0.24;

Matches 71; Conservative 38; Mismatches 104; Indels 74; Gaps 18;

OY 4 VIFLHSG---SGNEVI-EGPONATVVGKSGARFNCVSGQWKLIMWALSDMYVL-----54

Db 21 LFLVPTGVPRSGDATFPKAMDNVTVRQGESATLRCCTIDDRVTRVAV-LNRSTILVAGN 79

QY 55 ---SVRPEPIITNDRTSQRVDGNGFTSEMIHNVPSDSGNIRCSLQ-----NSRL 105  
 Db 80 DKMSIDRVLITLVN---TPQY-----SIMIQNVDDYDEGPTCSVQTDHNPRTSRV 128  
 QY 106 HGSAYLVQVWGELEFISVINIYVAENPECEVTCL---PSHWRLPDISLWELVSHSS 161  
 Db 129 H---LIVQVPPQIMNITSSDITVNEISSVTLICLAIGRPE-----PIVTWR-----HLS 173  
 QY 162 YV---FVPEPSDLSQAVSIALTPQSNGLTCVATWKSILKARKSAVNLTV-----IRC 212  
 Db 174 VKEGQGVSPDEYLE-----ISDIKROSGEYECGSL-NDVAAPDVKRYKITVNPYPIYSK 228  
 QY 213 PQTGGGINIPGVL---SSLPISGSLPTWGR---VGLGLAGTML 251  
 Db 229 AKNTGVSVGQKGIISCASAVPMAEFQ---WFKEDTRLATGLDGVR 272

## RESULT 14

150600  
 neogenin - chicken (fragment)  
 C:Species: Gallus gallus (chicken)  
 C:Date: 13-Sep-1996 #sequence\_revision 13-Sep-1996 #text\_change 21-Jul-2000  
 C:Accession: 150600  
 R:Veiometer: J. Kayem, J.F.; Roman, J.M.; Dreyer, W.J.  
 J. Cell Biol. 127, 2003-2020, 1994  
 A:Title: Neogenin, an avian cell surface protein expressed during terminal neuronal diff  
 A:Reference number: A55193; MUID:95105243; PMID:7806578  
 A:Accession: 150600  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: mRNA  
 A:Residues: 1-1443 <VIR>  
 A:Cross-references: EMBL:U07644; NID:9641965; PIDN:AAC59662.1; PID:9641966

## Query Match

Best Local Similarity 5.7%; Score 117.5; DB 2; Length 1443;  
 Matches 49; Conservative 28; Mismatches 73; Indels 37; Gaps 11;

QY 17 IEQPNATVKGSGARFNCTVSGW--KLIMALSDMVLVSRPEPIITNDRTSQRV- 73  
 Db 218 VROPSSLTITVTCQNAVFPc-VAGGEPPTVVRTKNG-----EELITED---SERFA 264  
 QY 74 -DOGNFTSEMIHNVPSDSGNIRc--SLQNSRLHGSAYLVQVWGELEFISVNLVVAE 130  
 Db 265 LRAGGS---LISDYTEEDVCTYCINDNENETEAQAEALAVQVPEFLKRPANITYAHE 320  
 QY 131 NE---PCVATCLPSHWRLPDISW-ELGLVSHSSYFVPEPSDLSQAVSIALTPQSN 185  
 Db 321 SMDIYFECVETGKPT---PTVKWVKNGDVVIPSDFYFKIVEHNIQ---VLGLVKSDE 371  
 QY 186 GTLTGVA 192  
 Db 372 GFYQCIA 378

## RESULT 15

JC1238

opioid-binding protein (clone DU21) - rat

C:Species: Rattus norvegicus (Norway rat)

C:Date: 03-May-1994 #sequence\_revision 03-May-1994 #text\_change 19-May-2000

C:Accession: JC1238

R:Lippman, D.A.; Lee, N.M.; Loh, H.H.

Gene 117, 249-254, 1992

A:Title: Opioid-binding cell adhesion molecule (OBCAM)-related clones from a rat brain c

A:Reference number: JC1238; MUID:92347701; PMID:1339369

A:Accession: JC1238

A:Molecule type: mRNA

A:Residues: 1-338 &lt;LIP&gt;

A:Cross-references: GB:M8709; NID:g203245; PIDN:AAA40858.1; PID:g203246

C:Genetics:

A:Gene: OBCAM

C:Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-termin

Query Match 5.7%; Score 116.5; DB 2; Length 338;  
 Best Local Similarity 25.0%; Pred. No. 0.31;  
 Matches 66; Conservative 33; Mismatches 96; Indels 69; Gaps 16;

QY 22 NATVLKGSQARFNCTVSGQWKLIMALSDMVL-----SVRPEPIITNDRTSQRVD 74  
 Db 37 NTVAGGESATITRCTIIDDVTRVAVN-LNRSTILVAGNDKMSIDPREVITLVN---TPQY- 91  
 QY 75 QGNFTSEMIHNVPSDSGNIRCSLQ-----NSRLHGSAYLVQVWGELEFISVNLV 128  
 Db 92 -----SIMIQNVDDYDEGPTCSVQTDHNPRTSRV---LIVQVPPQIMNITSSDITV 140  
 QY 129 AENPECEVTCL---PSHWRLPDISWELGLVSHSSY---FVPEPSDLSQAVSIAL 180  
 Db 141 NEISSVTLICLAIGRPE-----PIVTWR-----HLSVKEGQGVSPDEYLE-----ISDI 185  
 QY 181 TPQSNGLTCVATWKSILKARKSAVNLTV-----IRCPDQTGGGINIPGVL---SSLP 231  
 Db 186 KRDQSGEYECGSL-NDVAAPDVKRYKITVNPYISRAKNTGVSVGQKGIISCASAVPM 244  
 QY 232 LGFSLPTWGR---VGLGLAGTML 251  
 Db 245 AEFQ---WFKEDTRLATGLDGVR 265

Search completed: April 28, 2003, 21:08:48  
 Job time : 26.8683 secs



Db 329 -----PTAGSVGGSGLTALALIGLGTALLIGVLMOR----- 367  
QY 275 CCRCCFCCRRKRGRIQFOKSEKKT--NKETETESGNGNSGYSDQKTTDTASLPK 332  
Db 368 -----ORGERKAPENOEERELN----- 390  
QY 333 SCSSDEQRNNSCGPP 349  
Db 391 ---QSEPEAGESSTGCP 405

## RESULT 2

US-10-184-644-559  
; Sequence 559, Application US/10184644  
; Publication No. US20030044930A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Chen, Jian  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Pan, James  
; APPLICANT: Smith, Victoria  
; APPLICANT: Watanabe, Colin K.  
; APPLICANT: Wood, William I.  
; APPLICANT: Zhang, Zemin  
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
; FILE REFERENCE: P3430RIC227  
; CURRENT APPLICATION NUMBER: US/10/184,644  
; PRIOR APPLICATION REMOVED - See File Wrapper or Palm  
; NUMBER OF SEQ ID NOS: 612  
; SEQ ID NO 559  
; LENGTH: 2473  
; TYPE: DNA  
; ORGANISM: Homo Sapien  
US-10-184-644-559

Query Match  
Best Local Similarity 29.5%; Score 138.5; DB 9; Length 2473;  
Matches 31; Conservative 3; Mismatches 36; Indels 35; Gaps 2;  
QY 179 ALTPQSNGLTCVATWKSLSKRSATVNLVIRCPDGTGGINIRPVLSLSLFSLEPT 238  
Db 2274 AATGAGATTTCATTAATAATTATATGTTTC----- 2307  
QY 239 GKGVLGAGTMTLTPCTLTIRCCCR--RCCGCNCCRCGCC 282  
Db 2308 -----ATTCCATCGCCACCCACCCGCCGCCGCCACCC 2344

## RESULT 3

US-10-184-634-559  
; Sequence 559, Application US/10184634  
; Publication No. US20030068684A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Chen, Jian  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Pan, James  
; APPLICANT: Smith, Victoria  
; APPLICANT: Watanabe, Colin K.  
; APPLICANT: Wood, William I.  
; APPLICANT: Zhang, Zemin  
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
; FILE REFERENCE: P3430RIC217  
; CURRENT APPLICATION NUMBER: US/10/184,634

; CURRENT FILING DATE: 2002-06-28  
; PRIOR APPLICATION REMOVED - See File Wrapper or Palm  
; NUMBER OF SEQ ID NOS: 612  
; SEQ ID NO 559  
; LENGTH: 2473  
; TYPE: DNA  
; ORGANISM: Homo Sapien  
US-10-184-634-559

## Query Match

US-10-174-590-584  
; Sequence 584, Application US/10174590  
; Publication No. US2003008352A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Chen, Jian  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Pan, James  
; APPLICANT: Smith, Victoria  
; APPLICANT: Watanabe, Colin K.  
; APPLICANT: Wood, William I.  
; APPLICANT: Zhang, Zemin  
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
; FILE REFERENCE: P3430RIC42  
; CURRENT APPLICATION NUMBER: US/10/174,590  
; PRIOR APPLICATION REMOVED - See File Wrapper or Palm  
; NUMBER OF SEQ ID NOS: 612  
; SEQ ID NO 584  
; LENGTH: 708  
; TYPE: PRT  
; ORGANISM: Homo Sapien  
US-10-174-590-584

## RESULT 4

US-10-174-590-584  
; Sequence 584, Application US/10174590  
; Publication No. US2003008352A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Chen, Jian  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Pan, James  
; APPLICANT: Smith, Victoria  
; APPLICANT: Watanabe, Colin K.  
; APPLICANT: Wood, William I.  
; APPLICANT: Zhang, Zemin  
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
; FILE REFERENCE: P3430RIC42  
; CURRENT APPLICATION NUMBER: US/10/174,590  
; PRIOR APPLICATION REMOVED - See File Wrapper or Palm  
; NUMBER OF SEQ ID NOS: 612  
; SEQ ID NO 584  
; LENGTH: 708  
; TYPE: PRT  
; ORGANISM: Homo Sapien  
US-10-174-590-584

Query Match  
Best Local Similarity 23.8%; Score 136; DB 9; Length 708;  
Matches 55; Conservative 40; Mismatches 106; Indels 30; Gaps 10;

QY 3 LVIFLHSGSGNEVEGQNTVYKSGQARENCTVSQWKLIMWALSMDVLSVRMEPI 62  
Db 13 LFCFRAGRPSPHFLQOEDLVLLGEARLPCALGAYWGLVMTSGLAGSOR----- 67  
QY 63 ITNDRFTSQRYDQGNFTS--EWIHHNVPDSGNIRCSLONSRLHG--SAVLTV----- 113  
Db 68 ---DLPGRWYISGNAANGHDLHTRPVELLEBASIEQATQAGLRSPADLVLPPE 124  
QY 114 --QVMELEFIPSVNLVYAENEPCEVTCPSHWTR-LPDISW-ELGLVSHSXY--FVPE 167  
Db 125 APQVLGG--PVSILVA--GVPAHLTCRSGDARPPPELIMFRDGVLLDGAFFHOTLKE 179  
QY 168 --PSDLOSANVSIATLPQSNGLTCVATWKSLSKRSATVNLVIRCPDGT 216  
Db 180 GTPGSVESTLTLPFSHHDGATFVCRASQALPTGRDVAITLSTLOYPREVT 230

## RESULT 5

[illegible]

RESULT 7  
 US-10-173-706-584  
 Sequence 584, Application US/10173706  
 Publication No. US2003002293A1  
 GENERAL INFORMATION:  
 APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zhenlin  
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 TITLE OF INVENTION: ACIDS ENCODING THE SAME  
 FILE REFERENCE: P3430R1C7  
 CURRENT APPLICATION NUMBER: US/10/173,706  
 CURRENT FILING DATE: 2002-06-17  
 Prior Application removed - See File Wrapper or Palm  
 NUMBER OF SEQ ID NOS: 612

[illegible]

Db 180 GTPGSVESTLTLPFSHDDGATFVCARARSQALPTGRDTAITSLOYPEVT 230

## RESULT 8

US-10-175-738-584  
 ; Sequence 584, Application US/10175738  
 ; Publication No. US20030022294A1  
 ; GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin  
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 FILE REFERENCE: P3430R1C45  
 CURRENT APPLICATION NUMBER: US/10/175,738  
 PRIOR FILING DATE: 2002-06-19  
 NUMBER OF SEQ ID NOS: 612  
 SEQ ID NO 584  
 LENGTH: 708  
 TYPE: PRT  
 ORGANISM: Homo Sapien  
 US-10-175-738-584

Query Match  
 Best Local Similarity 6.6%; Score 136; DB 9; Length 708;  
 Matches 55; Conservative 40; Mismatches 106; Indels 30; Gaps 10;

QY 3 LVIFLHSGSGNEVIEGPONATVYKGSQARFNCTVSQGWKLIMALSDMVLSVRPMEPI 62  
 Db 13 LFCFRGRAGSPHFLQDPEDLVLLGEARLPCALGAYGVLQWTKSGIALGGR----- 67  
 QY 63 ITNDRFTSQRYDQGNFTS---EMIIHNEPDSGNIRCSLQNSRLHG-SAYLTV----- 113  
 Db 68 ---DLPGMSRYWISGMNANGOHDLHTRPELEDEASVECCQATQAGLRSPAQHLVLPPE 124  
 QY 114 --QVMEGLFIPSNLVVAENEPCEVTCLSHWR-LPDISW-ELGLVSHSSY--FVPE 167  
 Db 125 APQVLGG---PSVSLVA--GVPANLTCRSGDARPTPELLMFRDGVLLDGAFTFHQLKE 179  
 QY 168 --PSDLOSASVILALTPQSNCTLCVATWKSLSKARKSATVNLTVIRCPDPT 216  
 Db 180 GTPGSVESTLTLPFSHDDGATFVCARARSQALPTGRDTAITSLOYPEVT 230

## RESULT 9

US-10-175-752-584  
 ; Sequence 584, Application US/10175752  
 ; Publication No. US20030022295A1  
 ; GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin  
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 FILE REFERENCE: P3430R1C60  
 CURRENT APPLICATION NUMBER: US/10/175,752

;; CURRENT FILING DATE: 2002-06-19

;; Prior Application removed - See File Wrapper or Palm

;; NUMBER OF SEQ ID NOS: 612

;; SEQ ID NO 584

;; LENGTH: 708

;; TYPE: PRT

;; ORGANISM: Homo Sapien

US-10-175-752-584

Query Match  
 Best Local Similarity 6.6%; Score 136; DB 9; Length 708;  
 Matches 55; Conservative 40; Mismatches 106; Indels 30; Gaps 10;

QY 3 LVIFLHSGSGNEVIEGPONATVYKGSQARFNCTVSQGWKLIMALSDMVLSVRPMEPI 62  
 Db 13 LFCFRGRAGSPHFLQDPEDLVLLGEARLPCALGAYGVLQWTKSGIALGGR----- 67  
 QY 63 ITNDRFTSQRYDQGNFTS---EMIIHNEPDSGNIRCSLQNSRLHG-SAYLTV----- 113  
 Db 68 ---DLPGMSRYWISGMNANGOHDLHTRPELEDEASVECCQATQAGLRSPAQHLVLPPE 124  
 QY 114 --QVMEGLFIPSNLVVAENEPCEVTCLSHWR-LPDISW-ELGLVSHSSY--FVPE 167  
 Db 125 APQVLGG---PSVSLVA--GVPANLTCRSGDARPTPELLMFRDGVLLDGAFTFHQLKE 179  
 QY 168 --PSDLOSASVILALTPQSNCTLCVATWKSLSKARKSATVNLTVIRCPDPT 216  
 Db 180 GTPGSVESTLTLPFSHDDGATFVCARARSQALPTGRDTAITSLOYPEVT 230

## RESULT 10

US-10-176-482-584  
 ; Sequence 584, Application US/10176482  
 ; Publication No. US20030022296A1  
 ; GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin  
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 FILE REFERENCE: P3430R1C70  
 CURRENT APPLICATION NUMBER: US/10/176,482  
 PRIOR FILING DATE: 2002-06-20  
 NUMBER OF SEQ ID NOS: 612  
 SEQ ID NO 584  
 LENGTH: 708  
 TYPE: PRT  
 ORGANISM: Homo Sapien  
 US-10-176-482-584

Query Match  
 Best Local Similarity 6.6%; Score 136; DB 9; Length 708;  
 Matches 55; Conservative 40; Mismatches 106; Indels 30; Gaps 10;

QY 3 LVIFLHSGSGNEVIEGPONATVYKGSQARFNCTVSQGWKLIMALSDMVLSVRPMEPI 62  
 Db 13 LFCFRGRAGSPHFLQDPEDLVLLGEARLPCALGAYGVLQWTKSGIALGGR----- 67  
 QY 63 ITNDRFTSQRYDQGNFTS---EMIIHNEPDSGNIRCSLQNSRLHG-SAYLTV----- 113  
 Db 68 ---DLPGMSRYWISGMNANGOHDLHTRPELEDEASVECCQATQAGLRSPAQHLVLPPE 124  
 QY 114 --QVMEGLFIPSNLVVAENEPCEVTCLSHWR-LPDISW-ELGLVSHSSY--FVPE 167



Db 125 APQVLGG---PSVSLVA--GVPANLTCRSRGDARPTPELLMFRDGVLLDGAATFHQTLKE 179  
 QY 168 --PSSDQSAVSIALTPQSNGLTLCVATKMSLKARSAIVNLVIRCPDPT 216  
 Db 180 GTPGSVESTLTLTPFSHDDGATFVCARSAQLPTGRDIAITLSIQYPEVT 230

# RESULT 11 US-10-176-757-584

Sequence 584, Application US/10176757  
 Publication No. US20030022297A1  
 GENERAL INFORMATION:  
 APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin  
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 FILE OF INVENTION: ACIDS ENCODING THE SAME  
 FILE REFERENCE: P3430R1C86  
 CURRENT APPLICATION NUMBER: US/10/176,757  
 CURRENT FILING DATE: 2002-06-20  
 Prior Application removed - See file wrapper or Palm  
 NUMBER OF SEQ ID NOS: 612  
 SEQ ID NO 584  
 LENGTH: 708  
 TYPE: PRT  
 ORGANISM: Homo Sapien  
 US-10-176-757-584

Query Match 6.6%; Score 136; DB 9; Length 708;  
 Best Local Similarity 23.8%; Pred. No. 0.026;  
 Matches 55; Conservative 40; Mismatches 106; Indels 30; Gaps 10;

QY 3 LVIFLHSGSGNEVIEGPONATVYLGKSGARFNCVSGQKLMALSDMVYLSVRPMEPI 62  
 Db 13 LFCFRGAGSPSPHFLQOPEDLVLLGEARLPCALGAYWGLVQWTKSGIALGGOR----- 67  
 QY 63 ITNDRFTSORYDQGNFTS---EMITHNVEPSDSGNIRCSLQNSRLHG-SAYLTV----- 113  
 Db 68 ---DLPGMSRYWISGNANQGHDLHRLPYELDEASVYEQATQAGLRSPAQHLVLPPE 124  
 QY 114 --QVMGELETPSVNLVVAENEPCVTCPLPSHWTR-LPDISW-ELGLVSHSSY--FVPE 167  
 Db 125 APQVLGG---PSVSLVA--GVPANLTCRSRGDARPTPELLMFRDGVLLDGAATFHQTLKE 179  
 QY 168 --PSSDQSAVSIALTPQSNGLTLCVATKMSLKARSAIVNLVIRCPDPT 216  
 Db 180 GTPGSVESTLTLTPFSHDDGATFVCARSAQLPTGRDIAITLSIQYPEVT 230

# RESULT 12 US-10-176-913-584

Sequence 584, Application US/10176913  
 Publication No. US20030022298A1  
 GENERAL INFORMATION:  
 APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin

;; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 ;; FILE OF INVENTION: ACIDS ENCODING THE SAME  
 ;; FILE REFERENCE: P3430R1C86  
 ;; CURRENT APPLICATION NUMBER: US/10/176,913  
 ;; CURRENT FILING DATE: 2002-06-20  
 ;; Prior Application removed - See file wrapper or Palm  
 ;; NUMBER OF SEQ ID NOS: 612  
 ;; SEQ ID NO 584  
 ;; LENGTH: 708  
 ;; TYPE: PRT  
 ;; ORGANISM: Homo Sapien  
 US-10-176-913-584

Query Match 6.6%; Score 136; DB 9; Length 708;  
 Best Local Similarity 23.8%; Pred. No. 0.026;  
 Matches 55; Conservative 40; Mismatches 106; Indels 30; Gaps 10;

QY 3 LVIFLHSGSGNEVIEGPONATVYLGKSGARFNCVSGQKLMALSDMVYLSVRPMEPI 62  
 Db 13 LFCFRGAGSPSPHFLQOPEDLVLLGEARLPCALGAYWGLVQWTKSGIALGGOR----- 67  
 QY 63 ITNDRFTSORYDQGNFTS---EMITHNVEPSDSGNIRCSLQNSRLHG-SAYLTV----- 113  
 Db 68 ---DLPGMSRYWISGNANQGHDLHRLPYELDEASVYEQATQAGLRSPAQHLVLPPE 124  
 QY 114 --QVMGELETPSVNLVVAENEPCVTCPLPSHWTR-LPDISW-ELGLVSHSSY--FVPE 167  
 Db 125 APQVLGG---PSVSLVA--GVPANLTCRSRGDARPTPELLMFRDGVLLDGAATFHQTLKE 179  
 QY 168 --PSSDQSAVSIALTPQSNGLTLCVATKMSLKARSAIVNLVIRCPDPT 216  
 Db 180 GTPGSVESTLTLTPFSHDDGATFVCARSAQLPTGRDIAITLSIQYPEVT 230

# RESULT 13 US-10-180-552-584

Sequence 584, Application US/10180552  
 Publication No. US20030022300A1  
 GENERAL INFORMATION:  
 APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin  
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 FILE OF INVENTION: ACIDS ENCODING THE SAME  
 FILE REFERENCE: P3430R1C153  
 CURRENT APPLICATION NUMBER: US/10/180,552  
 CURRENT FILING DATE: 2002-06-25  
 Prior Application removed - See file wrapper or Palm  
 NUMBER OF SEQ ID NOS: 612  
 SEQ ID NO 584  
 LENGTH: 708  
 TYPE: PRT  
 ORGANISM: Homo Sapien  
 US-10-180-552-584

Query Match 6.6%; Score 136; DB 9; Length 708;  
 Best Local Similarity 23.8%; Pred. No. 0.026;  
 Matches 55; Conservative 40; Mismatches 106; Indels 30; Gaps 10;

QY 3 LVIFLHSGSGNEVIEGPONATVYLGKSGARFNCVSGQKLMALSDMVYLSVRPMEPI 62  
 Db 13 LFCFRGAGSPSPHFLQOPEDLVLLGEARLPCALGAYWGLVQWTKSGIALGGOR----- 67  
 QY 63 ITNDRFTSORYDQGNFTS---EMITHNVEPSDSGNIRCSLQNSRLHG-SAYLTV----- 113

100

[REDACTED]

GenCore version 5.1.4-p5\_4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 28, 2003, 18:14:43 ; Search time 13.9029 Seconds  
(without alignments)  
808.430 Million cell updates/sec

Title: US-09-729-264-2

Perfect score: 2059  
Sequence: 1 MGLVIFLHGSGSGNEVIEGP.....HPQASFLNAPSEKYSNTTV 382

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database :  
1: /cgn2\_6/ptodata/1/1aa/5A.COMB.pep.\*  
2: /cgn2\_6/ptodata/1/1aa/5B.COMB.pep.\*  
3: /cgn2\_6/ptodata/1/1aa/5C.COMB.pep.\*  
4: /cgn2\_6/ptodata/1/1aa/5D.COMB.pep.\*  
5: /cgn2\_6/ptodata/1/1aa/5E.COMB.pep.\*  
6: /cgn2\_6/ptodata/1/1aa/5F.COMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	128.5	6.2	1345	2	US-08-977-767-3
2	128	6.2	1447	4	US-09-041-886-25
3	128	6.2	1447	5	PCT-US94-05277-2
4	126.5	6.1	869	1	US-08-374-834-16
5	126.5	6.1	869	2	US-08-644-271-29
6	126.5	6.1	869	4	US-09-077-955-33
7	123.5	6.0	332	4	US-09-062-365-1
8	122.5	5.9	340	4	US-09-651-200-2
9	122.5	5.9	441	4	US-09-651-200-6
10	121.5	5.9	534	4	US-09-651-200-24
11	121.5	5.9	534	2	US-08-633-148-4
12	118.5	5.8	340	2	US-08-633-148-2
13	118.5	5.8	340	2	US-08-633-148-2
14	117	5.7	325	4	US-09-540-245A-15
15	114	5.5	1395	4	US-08-374-834-1
16	112	5.4	868	2	US-08-644-271-1
17	112	5.4	868	2	US-09-077-955-1
18	112	5.4	868	4	US-09-499-964-1
19	110	5.3	478	5	PCT-US95-08493-15
20	109.5	5.3	860	5	PCT-US95-08493-19
21	109.5	5.3	868	5	PCT-US95-08493-21
22	107.5	5.2	362	1	US-08-415-751-6
23	107.5	5.2	362	1	US-08-979-424-3
24	107	5.2	365	4	US-09-272-496-2
25	106.5	5.2	946	5	PCT-US95-08493-13
26	106	5.1	319	1	US-08-597-495B-22
27					

28	106	5.1	319	4	US-09-068-051A-22	Sequence 22, Appl
29	106	5.1	319	4	US-09-336-536-67	Sequence 67, Appl
30	106	5.1	319	4	US-09-254-465A-6	Sequence 6, Appl
31	106	5.1	801	1	US-07-906-349A-6	Sequence 6, Appl
32	105	5.1	285	3	US-08-482-085B-20	Sequence 20, Appl
33	105	5.1	1297	4	US-09-540-245A-17	Sequence 17, Appl
34	105	5.1	1381	4	US-09-540-245A-16	Sequence 16, Appl
35	104.5	5.1	879	1	US-08-554-612C-1	Sequence 1, Appl
36	104	5.1	421	2	US-08-659-984A-1	Sequence 1, Appl
37	104	5.1	421	2	US-08-659-984A-1	Sequence 1, Appl
38	104	5.1	444	2	US-08-659-984A-5	Sequence 5, Appl
39	104	5.1	444	2	US-08-659-984A-5	Sequence 5, Appl
40	103.5	5.0	890	4	US-08-445-640-2	Sequence 2, Appl
41	103.5	5.0	890	3	US-08-445-640-2	Sequence 2, Appl
42	103.5	5.0	890	3	US-08-170-558-2	Sequence 2, Appl
43	103.5	5.0	890	3	US-08-447-314-2	Sequence 2, Appl
44	103.5	5.0	911	3	US-08-445-461-2	Sequence 2, Appl
45	103.5	5.0	911	2	US-08-286-305A-1	Sequence 1, Appl
					US-08-441-104A-1	Sequence 1, Appl

## ALIGNMENTS

RESULT 1  
US-08-977-767-3  
Sequence 3, Application US/08977767  
Patent No. 5972684  
GENERAL INFORMATION:  
APPLICANT: Bandman, Olga  
APPLICANT: Yee, Henry  
APPLICANT: Greenwald, Sara  
APPLICANT: Corley, Neil C.  
TITLE OF INVENTION: CARBONIC ANHYDRASE VIII  
NUMBER OF SEQUENCES: 3  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Incyte Pharmaceuticals, Inc.  
STREET: 3174 Porter Drive  
CITY: Palo Alto  
STATE: CA  
COUNTRY: USA  
ZIP: 94304  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FASTSEQ for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/977,767  
CLASSIFICATION: 424  
FILING DATE: Herewith  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Billings, Lucy J.  
REGISTRATION NUMBER: 36,749  
REFERENCE/DOCKET NUMBER: PF-0423 US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 650-855-0555  
TELEFAX: 650-845-4166  
TELEX:  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1345 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
LIBRARY: GenBank  
CLONE: 1532042  
US-08-977-767-3  
Query Match 6.2% Score 128.5; DB 2; Length 1345;

Best Local Similarity 33.0%; Pred. No. 0.0095;  
Matches 37; Conservative 1; Mismatches 41; Indels 33; Gaps 5;

QY 186 GTTCVATWKS LKARKSATVNLVIRCPDGTGGI-----NIPGVLSLPSLGFSLPTWGR 241  
Db 414 GTCTCTGT-----GC-CGTGGAGCGTCAGAGCCCGCTGGATGTGA 455  
QY 242 VGLGIACTMLLT-PTCTLTTRCCCRRCGCCGCCRC-----CFCC 282  
Db 456 CGTGAGAGGGCTCTCTATGACCCCTTCCCTGCCCTCTGAGACTGACGACC 507

## RESULT 2

US-09-041-886-25  
Sequence 25, Application US/09041886  
Patent No. 6235872

## GENERAL INFORMATION:

APPLICANT: Bredesen, Dale E.  
APPLICANT: Rabizadeh, Sharoz  
TITLE OF INVENTION: Proapoptotic Peptides, Dependence  
NUMBER OF SEQUENCES: 72  
CORRESPONDENCE ADDRESS:  
ADDRESSER: Campbell & Flores LLP  
STREET: 4370 La Jolla Village Drive, Suite 700  
CITY: San Diego  
STATE: California  
COUNTRY: United States  
ZIP: 92122

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/041, 886

FILING DATE:  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Campbell, Cathryn A.  
REGISTRATION NUMBER: 31, 815  
REFERENCE/DOCKET NUMBER: P-LJ 2626  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (619) 535-9001  
TELEFAX: (619) 535-8949  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1447 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein

US-09-041-886-25

Query Match  
Best Local Similarity 24.8%; Score 128; DB 4; Length 1447;  
Matches 60; Conservative 33; Mismatches 99; Indels 50; Gaps 10;

QY 10 SGSGNEV-----IEGPNATVLRGSAFNCVSGW-KLIMNALSDM 51  
Db 220 SRTGNEAEVRLSDPGIHRQLYFLQRPNSVVAIEGDAVLECCVS-GYPPPSFTWIRGE 278  
QY 52 VLVSVRMEPIITNDRTSQRYDOGGNFTSEMIINHVPSDSGNIRC--SIQNSRLHGSA 109  
Db 279 VI-----QIRSKKYSILGG--SNLISNVTDGSGMTVCVYTKNENISASA 323  
QY 110 YLVQVAGELFISVNLVVAENPECEVTCIPSHWTRLPDISW-ELGLVSHSYFYFVEP 168  
Db 324 ELTVLVPWFLNPSNLVYAESMDIEFECTVS-GKPVPTVMNMKGVDVIRPSDYFOIVGG 382  
QY 169 SDIQASVSIATLPQSGNGLTCVATWKS LKARKSATVNLVIRCPDGTGGGINTIPGVLS 228  
Db 383 SNLR-----ILGVKSDGEFYQCAVAREAGNAGTSAQLIVPRPAIPSSS-----VLPS 430

QY 229 LP 230  
Db 431 AP 432

## RESULT 3

PCT-US94-05277-2

Sequence 2, Application PC/TUS9405277

## GENERAL INFORMATION:

APPLICANT: Bruskin, Arthur  
APPLICANT: Jarosz, David E.  
APPLICANT: Johnson, Karen  
APPLICANT: Kinzler, Kenneth W.  
APPLICANT: Vogelstein, Bert  
APPLICANT: Zabrucky, James R.  
TITLE OF INVENTION: Antibodies Specific for DCC Gene Product  
NUMBER OF SEQUENCES: 2  
CORRESPONDENCE ADDRESS:  
ADDRESSER: Banner, Birch, McKie & Beckett  
STREET: 1001 G Street, N.W.  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20001

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
OPERATING SYSTEM: IBM PC compatible  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US94/05277  
FILING DATE:  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Kagan, Sarah A.  
REGISTRATION NUMBER: 32, 141  
REFERENCE/DOCKET NUMBER: 01107, 42709  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202.508.9100  
TELEFAX: 202.508.9299  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1447 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
PCT-US94-05277-2

Query Match  
Best Local Similarity 6.2%; Score 128; DB 5; Length 1447;  
Matches 60; Conservative 33; Mismatches 99; Indels 50; Gaps 10;

QY 10 SGSGNEV-----IEGPNATVLRGSAFNCVSGW-KLIMNALSDM 51  
Db 220 SRTGNEAEVRLSDPGIHRQLYFLQRPNSVVAIEGDAVLECCVS-GYPPPSFTWIRGE 278  
QY 52 VLVSVRMEPIITNDRTSQRYDOGGNFTSEMIINHVPSDSGNIRC--SIQNSRLHGSA 109  
Db 279 VI-----QIRSKKYSILGG--SNLISNVTDGSGMTVCVYTKNENISASA 323  
QY 110 YLVQVAGELFISVNLVVAENPECEVTCIPSHWTRLPDISW-ELGLVSHSYFYFVEP 168  
Db 324 ELTVLVPWFLNPSNLVYAESMDIEFECTVS-GKPVPTVMNMKGVDVIRPSDYFOIVGG 382  
QY 169 SDIQASVSIATLPQSGNGLTCVATWKS LKARKSATVNLVIRCPDGTGGGINTIPGVLS 228  
Db 383 SNLR-----ILGVKSDGEFYQCAVAREAGNAGTSAQLIVPRPAIPSSS-----VLPS 430  
QY 229 LP 230  
Db 431 AP 432

RESULT 4  
US-08-374-834-16  
Sequence 16, Application US/08374834  
Patent No. 5656473

GENERAL INFORMATION:  
APPLICANT: Valenzuela, et al.  
TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTOR  
NUMBER OF SEQUENCES: 17  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Regeneron Pharmaceuticals, Inc.  
STREET: 777 Old Saw Mill River Road  
CITY: Tarrytown  
STATE: New York  
COUNTRY: USA  
ZIP: 10591

COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/374,834  
FILING DATE: 19-JAN-1995  
CLASSIFICATION: 435  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US 08/095,658  
FILING DATE: 21-JUL-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: Cobert, Robert J.  
REGISTRATION NUMBER: 36,108  
REFERENCE/DOCKET NUMBER: REG 190A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (914) 345-7400  
TELEFAX: (914) 345-7721  
INFORMATION FOR SEQ ID NO: 16:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 869 amino acids  
TYPE: amino acid  
STRANDEDNESS:  
TOPOLOGY: unknown  
MOLECULE TYPE: protein

US-08-374-834-16

Query Match 6.1%; Score 126.5; DB 1; Length 869;  
Best Local Similarity 20.9%; Pred. No. 0.0078;  
Matches 86; Conservative 51; Mismatches 176; Indels 99; Gaps 19;

15 EVIEGPNATVLKGSORFNCYVSOGWK-LIMWALSDMYVLSVRPMEPIITNDRTSORY 73  
122 KITRPPIINVKIIEGKAVLPCTTMGNPKPSVWIKGD-----SPLRENSRLAVLE- 171  
74 DQGNFTSEMIHNVEPSDGNIRCSLONRLHGSAY-LTYOVGELFPVNLVVAENE 132  
172 -GSLRIHNWQKEDAGQRCYAKNSL--GTAISKYVKLEVEVFARILRAPESHV 223  
133 P-----CEVCLPSSHMTFLPDISW-ELGLVSHSSYYFVPEPSDLOSANSILALTPQ 183  
224 TFGSFVTLHCTATGIP-----VPIITWIENGNAVSSGSIQESYKDVYIDSRQLDFTTKP- 277  
184 SNGTLTCVAT-----WKSIAKRSATVNLITYRCQDITGG-----INIGVLSLP 230  
278 --GLTTCATATNKGKFKSTAKAAATISIAEWSKPKQKNGKCAQYRGVEVCNANVLADALV 335  
231 SLGFSL-----PTWGKVGGLAGTMLLPTCTLLITRCCCRRCGCCGN----- 273  
336 FLNTSYADPEEAQELLVHTANML-----KVVSPCRPAEALLCNHIFQECSPGVVP 388  
274 -----CCCRCC-----FCCRRKRGFRIOFKKSEKKTNETETESNGENSGVSDQKT 323  
389 TPLPICREGLAVKELFCAKE---WLVMEETKTRGLYRSMHLLSPECKLPSMMDP 444  
324 TDTASLPPKSCSSDPEQRNNSCGPPHQRADQRP-----PRPASHPOASFNLA 371

DB 445 TACARLP-----HLDYKNENIKTEPP--MTSSKPSVDIPNLPSSSSSSSEVS 489

RESULT 5  
US-08-644-271-29  
Sequence 29, Application US/08644271  
Patent No. 5814478

GENERAL INFORMATION:  
APPLICANT: Valenzuela, et al.  
TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTORS  
NUMBER OF SEQUENCES: 32  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Regeneron Pharmaceuticals, Inc.  
STREET: 777 Old Saw Mill Road  
CITY: Tarrytown  
STATE: NY  
COUNTRY: USA  
ZIP: 10591

COMPUTER READABLE FORM:  
MEDIUM TYPE: diskette  
COMPUTER: IBM compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FASTSEQ Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/644,271  
FILING DATE: 10-MAY-1996  
CLASSIFICATION: 435  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: USSN 60/008,657  
FILING DATE: 15-DEC-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Cobert, Robert J.  
REGISTRATION NUMBER: 36,108  
REFERENCE/DOCKET NUMBER: REG 195A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 914-345-7400  
TELEFAX: 914-345-7721

INFORMATION FOR SEQ ID NO: 29:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 869 amino acids  
TYPE: amino acid  
STRANDEDNESS:  
TOPOLOGY: unknown  
MOLECULE TYPE: protein

US-08-644-271-29

Query Match 6.1%; Score 126.5; DB 2; Length 869;  
Best Local Similarity 20.9%; Pred. No. 0.0078;  
Matches 86; Conservative 51; Mismatches 176; Indels 99; Gaps 19;

15 EVIEGPNATVLKGSORFNCYVSOGWK-LIMWALSDMYVLSVRPMEPIITNDRTSORY 73  
122 KITRPPIINVKIIEGKAVLPCTTMGNPKPSVWIKGD-----SPLRENSRLAVLE- 171  
74 DQGNFTSEMIHNVEPSDGNIRCSLONRLHGSAY-LTYOVGELFPVNLVVAENE 132  
172 -GSLRIHNWQKEDAGQRCYAKNSL--GTAISKYVKLEVEVFARILRAPESHV 223  
133 P-----CEVCLPSSHMTFLPDISW-ELGLVSHSSYYFVPEPSDLOSANSILALTPQ 183  
224 TFGSFVTLHCTATGIP-----VPIITWIENGNAVSSGSIQESYKDVYIDSRQLDFTTKP- 277  
184 SNGTLTCVAT-----WKSIAKRSATVNLITYRCQDITGG-----INIGVLSLP 230  
278 --GLTTCATATNKGKFKSTAKAAATISIAEWSKPKQKNGKCAQYRGVEVCNANVLADALV 335  
231 SLGFSL-----PTWGKVGGLAGTMLLPTCTLLITRCCCRRCGCCGN----- 273  
336 FLNTSYADPEEAQELLVHTANML-----KVVSPCRPAEALLCNHIFQECSPGVVP 388

QY 274 -----CCRC-----FCRRKRGFRIOFKSEKTEKNTETTESGNGSNDQOKT 323  
 Db 389 TPICREYCLAVKELCAKE-----WLVMEKTHRGLYSEMHLLSVPCSKLPSMHPD 444  
 QY 324 TDTASLPKCESSDPPQRNNSCGPPHQRADOP-----PRPASHPOASFNLA 371  
 Db 445 TACARLP-----HLDYKKNELKTFPP--MTSKPSVDIDINLPSSSSSSFSVS 489

## RESULT 6

US-09-077-955-33  
 ; Sequence 33, Application US/09077955A  
 ; Patent No. 6413740  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Valenzuela et al., David M.  
 ; TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTORS AND LIGANDS  
 ; FILE REFERENCE: REG195-B-PCT-US  
 ; CURRENT APPLICATION NUMBER: US/09/077,955A  
 ; EARLIER FILING DATE: 1998-09-10  
 ; EARLIER APPLICATION NUMBER: PCT/US96/20696  
 ; EARLIER FILING DATE: 1996-12-13  
 ; EARLIER APPLICATION NUMBER: 08/644,271  
 ; EARLIER FILING DATE: 1996-05-10  
 ; EARLIER APPLICATION NUMBER: 60/008,657  
 ; NUMBER OF SEQ ID NOS: 36  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO 33  
 ; LENGTH: 869  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 US-09-077-955-33

Query Match  
 Best Local Similarity 6.1%; Score 126.5; DB 4; Length 869;  
 Matches 86; Conservative 51; Mismatches 176; Indels 99; Gaps 19;

QY 15 EVIEGPONATVYLGSOARENCTVSOGWK-LIMWALSDMNVLSVRPEPIITNDRTSQRY 73  
 Db 122 KITRPPINVKRIIEGLKAVLPCTMGNPKPSVSIKGD-----SPRENSKRLAVLE- 171  
 QY 74 DGGNFTSEMIHNVEPPSGNIRCSLONSRLHGSNY-LTYQWKELEFPVNLVVAENE 132  
 Db 172 -----SGSLRHNVOKEADGQRCYAKNSL--GTAYSKVVKLEVEVFAIRILRAPESHNV 223  
 QY 133 P-----CEYICLPSSHTRLPDISW-ELGLVSHSSYVEFPEPSDQSAVSLALTPQ 183  
 Db 224 TRGSVTLHCTATGIP-----VPTTWIENGNAVSSGSIQESVDRVIDSLQJLFTKP- 277  
 QY 184 SNGTLTCVAT-----WKSILKARKSATVNLVIRCPQDTGGC-----INIPGVLSLP 230  
 Db 278 --GLYTCIATNKHGKFTAKAAATISIAEWSKPOKNGKCAQYRGECNAVLAKDALY 335  
 QY 231 SLGFSL-----PTWKGVLGLAGTMLTPTCTLLIRCCCRRCGCGN-----273  
 Db 336 FLNTSYADPEEAQELLVHTANNEL-----KVYSPVCPRAAEELLCNHLFQECSEGVVP 388  
 QY 274 -----CCRC-----FCRRKRGFRIOFKSEKTEKNTETTESGNGSNDQOKT 323  
 Db 389 TPICREYCLAVKELCAKE-----WLVMEKTHRGLYSEMHLLSVPCSKLPSMHPD 444  
 QY 324 TDTASLPKCESSDPPQRNNSCGPPHQRADOP-----PRPASHPOASFNLA 371  
 Db 445 TACARLP-----HLDYKKNELKTFPP--MTSKPSVDIDINLPSSSSSSFSVS 489

## RESULT 7

US-09-062-365-1  
 ; Sequence 1, Application US/09062365  
 ; Patent No. 6465422  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Schmidt, Ann Marie  
 ; APPLICANT: Stern, David

; TITLE OF INVENTION: METHOD FOR INHIBITING TUMOR INVASION OR SPREADING IN A  
 ; FILE REFERENCE: SUBJECT  
 ; CURRENT APPLICATION NUMBER: US/09/062,365  
 ; CURRENT FILING DATE: 1998-04-17  
 ; NUMBER OF SEQ ID NOS: 6  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 1  
 ; LENGTH: 332  
 ; TYPE: PRT  
 ; ORGANISM: Human  
 US-09-062-365-1

Query Match  
 Best Local Similarity 6.0%; Score 123.5; DB 4; Length 332;  
 Matches 65; Conservative 33; Mismatches 89; Indels 83; Gaps 14;

QY 15 EVIEGPONATVYLGSOARENCTVSOGWK-LIMWALSDMNVLSVRPEPIITNDRTSQRY 70  
 Db 103 EIVDSASELTA--GVPMKVGTCVSEGSTPAGTSLWHLDG-----KPLVNEKGVSV 151  
 QY 71 -----ORYOGGNET--SEMIHNVEPPSDGNIR-----CSLONSRLHGSAYLTYQWKELEF 120  
 Db 152 KEQTRRHPEGTGLFTLOSELM--VTPARGDPRPTFSCSPSPCLPRHRLKTRAPLQPRW 208  
 QY 121 IP-----SVNLVVAENEP-----CEYICLPSSHTRLPDISWELGLLVSHSSY 162  
 Db 209 EPVPLEEYOLVY--EPEGGAVAPGGIVTLTCEVPAQPS-----PQIHMKD-----252  
 QY 163 YFVPEPSDQSAVSLALTPQNSGTLTCVATWKSILKARKSATVNLVIRCPQDTGGGGINI 222  
 Db 253 -GVPLPPEPSPVILPEIGPODGYSCVATSHSHQPSRAVSIISIE-POEE-----305  
 QY 223 PGVLSLPSLGFSLPWTKGVGLIAGTMLL 252  
 Db 306 -----PTAGSVGSGGLCTLAL 321

## RESULT 8

US-09-651-200-2  
 ; Sequence 2, Application US/09651200  
 ; Patent No. 6429303  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Green et al  
 ; TITLE OF INVENTION: Polynucleotides Encoding Members of the Human B  
 ; TITLE OF INVENTION: Lymphocyte Activation Antigen B-7 Family and  
 ; FILE REFERENCE: 15966-362 (CURA-62)  
 ; CURRENT APPLICATION NUMBER: US/09/651,200  
 ; CURRENT FILING DATE: 2000-08-30  
 ; PRIOR APPLICATION NUMBER: 60/152383  
 ; PRIOR FILING DATE: 1999-09-03  
 ; PRIOR APPLICATION NUMBER: 60/172909  
 ; PRIOR FILING DATE: 1999-12-21  
 ; PRIOR APPLICATION NUMBER: 60/183578  
 ; NUMBER OF SEQ ID NOS: 25  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO 2  
 ; LENGTH: 340  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 US-09-651-200-2

Query Match  
 Best Local Similarity 5.9%; Score 122.5; DB 4; Length 340;  
 Matches 77; Conservative 50; Mismatches 128; Indels 109; Gaps 17;

QY 10 SGGNEVIEGPONATVYLGSOARENCTVS--QGWKL-----IMWALSDMNVLSVRPEPI 62  
 Db 48 SPFGAVEVQVPEPVVALGDTALHCSFSPGFSLTQLNLQIUDTQGLV-----100  
 QY 63 ITNDRTSQRYDOGNF-----TSEMIHNVEPPSGNIRCSLONSRLHGS 108

```

Db 101 ---HSFTBGR-DGGSAYANRTALEPDLAOGNASLRQRYVADGESFTCFV-SINDFGS 155
      || || || |
      | | | | |
Qy 109 AYLTVQWGELEFIPSVNLV-----VAENPECEVTCLPSHWTRLP--DISWELG---LVSH 159
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 156 AAVSLQVAAPYSKPSMTLEPNKDLRPGDVTITC--SSYRGYPAEYFMODGQVPLTGN 213
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 160 SSYYFVPEPSDLSQAVSIALTPQSNGLTCVATWKSILKARKSATVNLTVIRCP---QDT 216
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 214 VTTSQMANEGLEFDVHSVLRVVLGANGTYS-----LVARNVLOQDA 255
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 217 GGGINIPVLSLSLPSLGSFLPTWKGVLGAGTMLTPCTLTIRCCCCRRCCGNCNCC 276
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 256 HGSVTTTGQPMTPPEAL-----WTVYGLSVCLIALV----- 288
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 277 RCFCRRKRGFRIOFOKSEKTKETETESGNGNSGYNSDEOKTDTASLPKSCS 336
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 289 ALAFVCMRK-----IKSCSEENAGADODG-----EGGSKTALQPLKHS 331
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 337 SDPE 340
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 332 KEDD 335
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

```

RESULT 9  
US-09-651-200-4  
Sequence 4, Application US/09651200  
Patent No. 6429303

```

GENERAL INFORMATION:
APPLICANT: Green et al
TITLE OF INVENTION: Polynucleotides Encoding Members of the Human B
TITLE OF INVENTION: Lymphocyte Activation Antigen B-7 Family and
FILE REFERENCE: 15966-562 (CURA-62)
CURRENT APPLICATION NUMBER: US/09/651,200
CURRENT FILING DATE: 2000-08-30
PRIOR APPLICATION NUMBER: 60/152383
PRIOR FILING DATE: 1999-09-03
PRIOR APPLICATION NUMBER: 60/172909
PRIOR FILING DATE: 1999-12-21
PRIOR APPLICATION NUMBER: 60/183578
PRIOR FILING DATE: 2000-02-18
NUMBER OF SEQ ID NOS: 25
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 4
LENGTH: 441
TYPE: PRT
ORGANISM: Homo sapiens
US-09-651-200-4

```

Query Match 5.9%; Score 122.5; DB 4; Length 441;  
Best local similarity 21.2%; Pred. No. 0.007; Indels 109; Gaps 17;  
Matches 77; Conservative 50; Mismatches 128;

```

Qy 10 SGGSGNEVIEGPNATV-LKGSQARFNCTVS--QGKTL-----IMWALSMDNVLSVPMPEPI 62
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 149 SFGAVEVQVPEDPVALVGTDTATLHCSPFEGFSLQTLNLTQDLTDTKQLV----- 201
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 63 ITNDRFTSQRYDQGNF-----TSEMIIHNPESDSGNIKRSLSQNRHGS 108
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 202 ---HSFTBGR-DGGSAYANRTALEPDLAOGNASLRQRYVADGESFTCFV-SINDFGS 256
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 109 AYLTVQWGELEFIPSVNLV-----VAENPECEVTCLPSHWTRLP--DISWELG---LVSH 159
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 257 AAVSLQVAAPYSKPSMTLEPNKDLRPGDVTITC--SSYRGYPAEYFMODGQVPLTGN 314
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 160 SSYYFVPEPSDLSQAVSIALTPQSNGLTCVATWKSILKARKSATVNLTVIRCP---QDT 216
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 315 VTTSQMANEGLEFDVHSVLRVVLGANGTYS-----LVARNVLOQDA 356
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 217 GGGINIPVLSLSLPSLGSFLPTWKGVLGAGTMLTPCTLTIRCCCCRRCCGNCNCC 276
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 357 HGSVTTTGQPMTPPEAL-----WTVYGLSVCLIALV----- 389
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

```

```

Qy 277 RCFCRRKRGFRIOFOKSEKTKETETESGNGNSGYNSDEOKTDTASLPKSCS 336
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 390 ALAFVCMRK-----IKSCSEENAGADODG-----EGGSKTALQPLKHS 432
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 337 SDPE 340
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 433 KEDD 436
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

```

RESULT 10  
US-09-651-200-6  
Sequence 6, Application US/09651200  
Patent No. 6429303

```

GENERAL INFORMATION:
APPLICANT: Green et al
TITLE OF INVENTION: Polynucleotides Encoding Members of the Human B
TITLE OF INVENTION: Lymphocyte Activation Antigen B-7 Family and
FILE REFERENCE: 15966-562 (CURA-62)
CURRENT APPLICATION NUMBER: US/09/651,200
CURRENT FILING DATE: 2000-08-30
PRIOR APPLICATION NUMBER: 60/152383
PRIOR FILING DATE: 1999-09-03
PRIOR APPLICATION NUMBER: 60/172909
PRIOR FILING DATE: 1999-12-21
PRIOR APPLICATION NUMBER: 60/183578
PRIOR FILING DATE: 2000-02-18
NUMBER OF SEQ ID NOS: 25
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 6
LENGTH: 534
TYPE: PRT
ORGANISM: Homo sapiens
US-09-651-200-6

```

Query Match 5.9%; Score 121.5; DB 4; Length 534;  
Best local similarity 21.2%; Pred. No. 0.011; Indels 109; Gaps 17;  
Matches 77; Conservative 49; Mismatches 129;

```

Qy 10 SGGSGNEVIEGPNATV-LKGSQARFNCTVS--QGKTL-----IMWALSMDNVLSVPMPEPI 62
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 242 SFGAVEVQVPEDPVALVGTDTATLHCSPFEGFSLQTLNLTQDLTDTKQLV----- 294
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 63 ITNDRFTSQRYDQGNF-----TSEMIIHNPESDSGNIKRSLSQNRHGS 108
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 295 ---HSFTBGR-DGGSAYANRTALEPDLAOGNASLRQRYVADGESFTCFV-SINDFGS 349
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 109 AYLTVQWGELEFIPSVNLV-----VAENPECEVTCLPSHWTRLP--DISWELG---LVSH 159
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 350 AAVSLQVAAPYSKPSMTLEPNKDLRPGDVTITC--SSYRGYPAEYFMODGQVPLTGN 407
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 160 SSYYFVPEPSDLSQAVSIALTPQSNGLTCVATWKSILKARKSATVNLTVIRCP---QDT 216
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 408 VTTSQMANEGLEFDVHSVLRVVLGANGTYS-----LVARNVLOQDA 449
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 217 GGGINIPVLSLSLPSLGSFLPTWKGVLGAGTMLTPCTLTIRCCCCRRCCGNCNCC 276
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 450 HGSVTTTGQPMTPPEAL-----WTVYGLSVCLIALV----- 482
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 277 RCFCRRKRGFRIOFOKSEKTKETETESGNGNSGYNSDEOKTDTASLPKSCS 336
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 483 ALAFVCMRK-----IKSCSEENAGADODG-----EGGSKTALQPLKHS 525
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Qy 337 SDPE 340
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 526 KEDD 529
      | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

```

RESULT 11  
US-09-651-200-24  
Sequence 24, Application US/09651200  
Patent No. 6429303

GENERAL INFORMATION:  
 APPLICANT: Green et al  
 TITLE OF INVENTION: Polynucleotides Encoding Members of the Human B  
 TITLE OF INVENTION: Lymphocyte Activation Antigen B-7 Family and  
 TITLE OF INVENTION: Polypeptide Activation Encoded Thereby  
 FILE REFERENCE: 15966-562 (CURA-62)  
 CURRENT APPLICATION NUMBER: 05/09/651,200  
 PRIOR FILING DATE: 2000-08-30  
 PRIOR APPLICATION NUMBER: 60/152383  
 PRIOR FILING DATE: 1999-09-03  
 PRIOR APPLICATION NUMBER: 60/172909  
 PRIOR FILING DATE: 1999-12-21  
 PRIOR APPLICATION NUMBER: 60/183578  
 NUMBER OF SEQ ID NOS: 25  
 SOFTWARE: PatentIn Ver. 2.0  
 SEQ ID NO 24  
 LENGTH: 534  
 TYPE: PRT  
 ORGANISM: Unknown  
 FEATURE:  
 OTHER INFORMATION: Description of Unknown Organism: Sequence  
 US-09-651-200-24

Query Match  
 Best Local Similarity 5.9%; Score 121.5; DB 4; Length 534;  
 Matches 77; Conservative 49; Mismatches 129; Indels 109; Gaps 17;

QY 10 SSGSNEVEGPNATV-LKSGAARFNCVTS--GGWKL---IMWALSDMVVLSVRMEPI 62  
 DB 242 SPTGAVEQVPEDEPVVALVGDIDLRCFSFSPGFSLAOLNLTWOLTRKOLV----- 294  
 QY 63 ITNREFSORYDOGNF-----TSEMIHNVPEPDSGNINCSLQNSRLHS 108  
 DB 295 ---HSFTEGR-DOGSAYANRTALFPDLAQNASTLRQVRADESGFTCEV-STDRGS 349  
 QY 109 AYLTVQVWGELEFIPSVLV---VAENRCEVTCPSHMTRLP--DISWELGL---LVSH 159  
 DB 350 AAVSLQVAARYSRKPMLEPNKDLRGDVTYITC--SSYRGVPEAEVWQDQGVPLIGN 407  
 QY 160 SSVYFVEPESDLOSASVSIATLPQSNGLTCVATWKSLSKARSATVNLVIRCP---ODT 216  
 DB 408 VTTSQMANEGLDFDVHSHVLRVVLGANGTYSC-----LVANPVLQDDA 449  
 QY 217 GGGINIGVLSLPSLGFSLPTMGVGLAGTALLTPCTLTTRCCRRRCGCCNCCC 276  
 DB 450 HGSVTLTGQPMTFPEAL---WTVGLSVCLIALLV----- 482  
 QY 277 RCFCCRRRRGFRIDQFKKSEKTKETKESGENSGYNSDROKTDTSLPKSCGS 336  
 DB 483 ALAFVCMRK-----IKOSCEENAGADQDG-----EGEGSKTALQPLKHS 525  
 QY 337 SDPE 340  
 DB 526 KEDD 529

RESULT 12  
 US-08-633-148-4  
 Sequence 4, Application US/08633148  
 Patent No. 5864018  
 GENERAL INFORMATION:  
 APPLICANT: MORSE, MICHAEL J.  
 APPLICANT: NAGASHIMA, MARIKO  
 APPLICANT: HOLLANDER, DORIS A.  
 TITLE OF INVENTION: ANTIBODIES TO ADVANCED GLYCOSYLATION  
 TITLE OF INVENTION: END-PRODUCT RECEPTOR POLYPEPTIDES AND USES THEREFOR  
 NUMBER OF SEQUENCES: 23  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: TOWNSEND & TOWNSENT & CREW LLP  
 STREET: TWO EMBARCADERO CENTER, 8TH FLOOR  
 CITY: SAN FRANCISCO

STATE: CALIFORNIA  
 COUNTRY: U.S.A.  
 ZIP: 94111  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/633,148  
 FILING DATE: 16-APR-1996  
 CLASSIFICATION: 435  
 ATTORNEY/AGENT INFORMATION:  
 NAME: MURPHY ESQ., MATTHEW B.  
 REGISTRATION NUMBER: 39,787  
 REFERENCE/DOCKET NUMBER: 014618-005600US  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (415) 326-2400  
 TELEFAX: (415) 326-2422  
 INFORMATION FOR SEQ ID NO: 4:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 318 amino acids  
 TYPE: amino acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 US-08-633-148-4

Query Match  
 Best Local Similarity 5.8%; Score 118.5; DB 2; Length 318;  
 Matches 64; Conservative 32; Mismatches 88; Indels 83; Gaps 14;

QY 15 EVIEGPONATVVGQAARFNCVTSOG---WKLMAISDMVVLVSRMEPIITNDRFS- 70  
 DB 103 EIVDSASELTA--GVNKKGTQVSEBSYPAGTILSMHLDG-----KPLVNEKVS 151  
 QY 71 ---QRTDQGNFT--SEMIHNVPEPDSGNIR---CSLQNSRLHGSAYLTVQWGELEF 120  
 DB 152 KEQTRHHPETGELTLOSEL---VTPARGDPRPFSSCFSGPLRHNALRTAPLQPRW 208  
 QY 121 IP-----SVNLVAENRP-----CEVTCPSHMTRLPDISWELGLLVSHSY 162  
 DB 209 EPPVLEEVOLV---EPGGAAPGCVTLTCVPAOPS-----PQIHMKD----- 252  
 QY 163 YFVPEPESDLOSASVSIATLPQSNGLTCVATWKSLSKARSATVNLVIRCPDODTGGINI 222  
 DB 253 -GVPLPLPPSPVLLIPETIGPODQGYSCVATHSHGQESNAVSISITE-PGEG----- 305  
 QY 223 PGVLSLPSLGFSLPTMGVGLAGT 249  
 DB 306 -----PTAGSVGGSGLGT 318

RESULT 13  
 US-08-633-148-2  
 Sequence 2, Application US/08633148  
 Patent No. 5864018  
 GENERAL INFORMATION:  
 APPLICANT: MORSE, MICHAEL J.  
 APPLICANT: NAGASHIMA, MARIKO  
 APPLICANT: HOLLANDER, DORIS A.  
 TITLE OF INVENTION: ANTIBODIES TO ADVANCED GLYCOSYLATION  
 TITLE OF INVENTION: END-PRODUCT RECEPTOR POLYPEPTIDES AND USES THEREFOR  
 NUMBER OF SEQUENCES: 23  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: TOWNSEND & TOWNSENT & CREW LLP  
 STREET: TWO EMBARCADERO CENTER, 8TH FLOOR  
 CITY: SAN FRANCISCO  
 STATE: CALIFORNIA  
 COUNTRY: U.S.A.  
 ZIP: 94111  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk



COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patentin Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/633,148  
 FILING DATE: 16-APR-1996  
 CLASSIFICATION: 435  
 ATTORNEY/AGENT INFORMATION:  
 NAME: MORRIS ESO., MATTHEW B.  
 REGISTRATION NUMBER: 39,787  
 REFERENCE/DOCKET NUMBER: 014618-00560005  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (415) 326-2422  
 TELEFAX: (415) 326-2400  
 INFORMATION FOR SEQ ID NO: 2:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 340 amino acids  
 TYPE: amino acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 US-08-633-148-2

Query Match 5.8%; Score 118.5; DB 2; Length 340;  
 Best Local Similarity 24.0%; Pred. No. 0.011; Indels 83; Gaps 14;  
 Matches 64; Conservative 32; Mismatches 88;

QY 15 EVLEGPNATVLKSGAARFNCYVSG--WKLMALSDVVLVSRPMEPIITNDRTS- 70  
 DB 125 EIVDSASELTA--GVPRKAVTCYSEGSYPAGTILSMHLDG-----KPLVNEKGVSV 173  
 QY 71 ----QRYDGGNFT--SEMIHNVSPDSGNIR-----CSLQNSRLHGSAYLVQVMGELE 120  
 DB 174 KEQTRRRPELGLFLOGLSELM---VTPARGGDPPTFCSPGLPRHRLKTAPIOPRVW 230  
 QY 121 IP-----GVNLVVAENP-----CEVTCLEPSHWTFLPDISWELGLVSHSSY 162  
 DB 231 EPPLEEVQLVV---EPGGAVAPAGGVITLTCVPAQPS-----PQIHMKD----- 274  
 QY 163 YFVEPSDLSQAVSIILTPQNSGTLTCVATWMSLKARKSATVNLVIRCPQDTGGGINI 222  
 DB 275 -GVPLPPLPPSVLILPEIGPDQGTSCVATHSHSGPQESRAVSISITE-PGEEG----- 327  
 QY 223 PGVLSSLPISLGFSLPTWCKVGLAGT 249  
 DB 328 -----PTAGSVGGSLGT 340

RESULT 14  
 US-09-651-200-20  
 ; Sequence 20, Application US/09651200  
 ; Patent No. 6429303  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Green et al  
 ; TITLE OF INVENTION: Polynucleotides Encoding Members of the Human B  
 ; TITLE OF INVENTION: Lymphocyte Activation Antigen B-7 Family and  
 ; TITLE OF INVENTION: Polypeptides Encoded Thereby  
 ; FILE REFERENCE: 15966-562 (CURA-62)  
 ; CURRENT APPLICATION NUMBER: US/09/651,200  
 ; CURRENT FILING DATE: 2000-08-30  
 ; PRIOR APPLICATION NUMBER: 60/152383  
 ; PRIOR FILING DATE: 1999-09-03  
 ; PRIOR APPLICATION NUMBER: 60/172909  
 ; PRIOR FILING DATE: 1999-12-21  
 ; PRIOR APPLICATION NUMBER: 60/183578  
 ; PRIOR FILING DATE: 2000-02-18  
 ; NUMBER OF SEQ ID NOS: 25  
 ; SOFTWARE: Patentin Ver. 2.0  
 ; SEQ ID NO 20  
 ; LENGTH: 325  
 ; TYPE: PRT  
 ; ORGANISM: sus sp.  
 ; US-09-651-200-20

Query Match 5.7%; Score 117; DB 4; Length 325;  
 Best Local Similarity 22.9%; Pred. No. 0.014;  
 Matches 88; Conservative 39; Mismatches 126; Indels 132; Gaps 22;

QY 3 IVIFLHSGSGNEVEYEGPQNAVLKSGAARN-----C--TYSGCKL-----IMGLSD 50  
 DB 10 WVLILSGAAS-----LK-SQAFYENEGELPCHFTNSQNSLDELVIWQDOD 55  
 QY 51 MYVL--SVRPMF-PITTDRTSQ-RYDGGNFTSEMIHNVSPDSGNIRCSLQNSRLH 106  
 DB 56 NLVLELYRGQEPKPHNVSKTMGRSTFQDA---TWTLRLHNVQIKDGSYGCFIHKGP 112  
 QY 107 GSAVL-----TVQVMGELFIPSVLVV--AENECEVTCLEPSHWTFLPDISWELGLVSH 159  
 DB 113 GLVPIHOMSSDLSILANSQPEINLTHNTENSVINILTC----- 151  
 QY 160 SSVYFVPEPSDLSQAVSIILTPQNSGTLTCVATWMSLKARKSATVNLTV---IRCPQDT 216  
 DB 152 SSTQGYPEPQ-----RMVMLNTRNSTTEHDADMKKSQNNITELYNVSVSLPIPET 205  
 QY 217 GGGINIPGVLSLPS--LGFSLP-----TWKVGGLAGTMTLLPTCT 257  
 DB 206 --NVSTVCVQLQLEPSTLFLPCNIDAKPVQPVPPDHLM-----IALLVTVVVV 256  
 QY 258 LITRCCCCRRRCGCCGCCRCFCCHRRK-----GRIOFOKK-SEKERTNET 305  
 DB 257 -----CGWVSFVTLKRRKKQPGPSNECGETIKMKKASQTKNRAEV 299  
 QY 306 ETESGENSGYN-----SDEQRTTD 325  
 DB 300 HENSDDAQCDVNLILKTASDNDSTTD 324

RESULT 15  
 US-09-540-245A-15  
 ; Sequence 15, Application US/09540245A  
 ; Patent No. 6270984  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Goodman, Corey  
 ; APPLICANT: Kid, Thomas  
 ; APPLICANT: Brose, Katja  
 ; APPLICANT: Tessier-Lavigne, Marc  
 ; TITLE OF INVENTION: Modulating Robo: Ligand Interactions  
 ; FILE REFERENCE: B98-031-3  
 ; CURRENT APPLICATION NUMBER: US/09/540,245A  
 ; CURRENT FILING DATE: 2000-03-31  
 ; PRIOR APPLICATION NUMBER: 60/065,544  
 ; PRIOR FILING DATE: 1997-11-14  
 ; PRIOR APPLICATION NUMBER: 60/081,057  
 ; PRIOR FILING DATE: 1998-04-07  
 ; NUMBER OF SEQ ID NOS: 20  
 ; SOFTWARE: Patentin Ver. 2.0  
 ; SEQ ID NO 15  
 ; LENGTH: 1395  
 ; TYPE: PRT  
 ; ORGANISM: Drosophila melanogaster  
 ; US-09-540-245A-15

Query Match 5.5%; Score 114; DB 4; Length 1395;  
 Best Local Similarity 25.8%; Pred. No. 0.2; Indels 56; Gaps 15;  
 Matches 65; Conservative 29; Mismatches 102;

QY 20 PNQATVLKSGAARFNCYVSG--WKLMV-----ALSDVVLVSRPMEPIITNDRTSQ 72  
 DB 161 PKDTRAKAKETALLBEGPPKGIPEPTLVIKIDGVPLDDLKAMSGASSRV-----R 211  
 QY 73 YDGGNFTSEMIHNVSPDSGNIRCSLQNSRLHGSAYLVQVMGELEFIPSVNLVVA 129  
 DB 212 IYDGN-----LLISNVEPIDEGNTKCIQNLVGTRESSTAKLIYQYKPFKEPKDQV 267  
 QY 130 ENRP-----CEVTCLEPSHWTFLPDISW---ELGLVSHSSYFVPEPSDLSQAVSIILATP 182

Db 268 YGOTATFHCVSVDPP-----PKVLWKKEGNIPVSARILHD-----EKSLEISNITP 316  
QY 183 QSNGLTFCA--TWKSLKARKSATV----NLVIRCPQDPTGGGINIPGVLSLPSLGFSL 236  
Db 317 TDEGTVCFAHNNVGOISARASLIVHAPPFT--KRPSNRKVGLEN--GVV-OLPCMASGN 371  
QY 237 PT-----WGVGL 244  
Db 372 PPPSVFWTKEGV 383

Search completed: April 28, 2003, 21:12:14  
Job time : 18.9029 secs



XX WP1: 2002-130881/17.  
 DR N-PSDB; ABK13028.  
 XX  
 PT New B7-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 XX proliferative disorders, e.g. cancer and arteriosclerosis  
 PS  
 PS Claim 13: Fig 1; 135pp; English.  
 CC The invention relates to an isolated B7-Like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-Like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions, and for  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of human B7-L<sub>h1</sub>.  
 XX  
 SQ Sequence 382 AA:

Query Match 100.0%; Score 2059; DB 23; Length 382;  
 Best Local Similarity 100.0%; Pred. No. 5.5e-162;  
 Matches 382; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGLVIFLHSGSGNVEITGPNATVVLKGSQARENTVSQGMKLIMALSDMVVLSRPM 60  
 DB 1 MGLVIFLHSGSGNVEITGPNATVVLKGSQARENTVSQGMKLIMALSDMVVLSRPM 60  
 QY 61 PIIITNDRTSGRYDGGNFTSEMIHNVSPDSGNTKCSLONRLGSAVLYVQWGELE 120  
 DB 61 PIIITNDRTSGRYDGGNFTSEMIHNVSPDSGNTKCSLONRLGSAVLYVQWGELE 120  
 QY 121 IPSVNLVAEKEPEVCVCLPSHWTIRLPDISWELGLLVSHSSYFVEPEPDLQSAVSI 180  
 DB 121 IPSVNLVAEKEPEVCVCLPSHWTIRLPDISWELGLLVSHSSYFVEPEPDLQSAVSI 180  
 QY 181 TPOSNGTLTCVATWMSLKARKSATVNLVIYRCPDQDGGGINIPGVLSIPSGFSLPTWG 240  
 DB 181 TPOSNGTLTCVATWMSLKARKSATVNLVIYRCPDQDGGGINIPGVLSIPSGFSLPTWG 240  
 QY 241 KVGGLAGTMTLLPTCTLTIRCCCRRCGCCGCCRCFCRCRRGRGRIOFKKSEK 300  
 DB 241 KVGGLAGTMTLLPTCTLTIRCCCRRCGCCGCCRCFCRCRRGRGRIOFKKSEK 300

QY 301 TNKETESGNGNSGYNSDEOKTTDTASLPKSCSSPEQPNSSCGPPHROADQRP 360  
 DB 301 TNKETESGNGNSGYNSDEOKTTDTASLPKSCSSPEQPNSSCGPPHROADQRP 360  
 QY 361 ASHPQASPNLASPEKSNNTTV 382  
 DB 361 ASHPQASPNLASPEKSNNTTV 382

RESULT 2  
 AA075542  
 ID AA075542 standard; Protein; 386 AA.  
 XX  
 AC AA075542;  
 XX  
 DT 23-APR-2002 (first entry)  
 XX  
 DE Human B7-Like protein, B7-L<sub>h3</sub>.  
 XX

KW Human; B7-Like protein; B7-L; antifertility; gynaecological;  
 KW antitumour; cytostatic; immunosuppressive; antiarthritic; antineumatic;  
 KW antiinflammatory; dermatological; antipsoriatic; neuroprotective;  
 KW antidiabetic; haemostatic; antithyroid; anticancer; antiallergic;  
 KW antiasthmatic; nephrotropic; antibacterial; virocidic; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200200710-A2.  
 XX  
 PD 03-JAN-2002.

PF 28-JUN-2001; 2001WO-US20719.  
 XX  
 PR 28-JUN-2000; 2000US-214512P.  
 XX  
 PR 28-NOV-2000; 2000US-0729264.  
 XX

(AMGE-) AMGEN INC.

PI Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 XX  
 DR WP1: 2002-130881/17.  
 DR N-PSDB; ABK13030.

PT New B7-Like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 PS  
 PS Claim 13: Fig 3; 135pp; English.

CC The invention relates to an isolated B7-Like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-Like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as

inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitization due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions.  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of human B7-L-h3.

SO Sequence 386 AA;

Query Match 97.8%; Score 2014; DB 23; Length 386;  
 Best Local Similarity 99.7%; Pred. No. 2,9e-158;  
 Matches 373; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

9 GSGSGNVEYIEGPONATYVKGQARFNCYSGQKLMALSDMVYLSVRPMEPIITNDRF 68  
 13 GSGSGNVEYIEGPONATYVKGQARFNCYSGQKLMALSDMVYLSVRPMEPIITNDRF 72  
 69 TSORVDGNGFTSEMIHNVPSDSGNIRCSLONSRLHGSAYLTVQVMELEFIPSVNLVY 128  
 73 TSORVDGNGFTSEMIHNVPSDSGNIRCSLONSRLHGSAYLTVQVMELEFIPSVNLVY 132  
 129 AENEPEVTCPLPSHWTRLPDISMELGLVSHSSYFVEPEPSDQASVIALTPQSGNTL 188  
 133 AENEPEVTCPLPSHWTRLPDISMELGLVSHSSYFVEPEPSDQASVIALTPQSGNTL 192  
 189 TCVAATKSKARKSATVNLVIRCPDITGGTNGVLSLPSLGSFSLPTMCKVGLGLAG 248  
 193 TCVAATKSKARKSATVNLVIRCPDITGGTNGVLSLPSLGSFSLPTMCKVGLGLAG 252  
 249 TMLTPTCTLTTRCCCRRCGCCGCCRCRCRCRRGRFIOFOKSEKETE 308  
 253 TMLTPTCTLTTRCCCRRCGCCGCCRCRCRCRRGRFIOFOKSEKETE 312  
 309 SGNSGNSGNSDEQKTTDTASLPKSCSSPDEQRNCGPHQRADPRPASHPOASF 368  
 313 SGNSGNSGNSDEQKTTDTASLPKSCSSPDEQRNCGPHQRADPRPASHPOASF 372  
 369 NIASPEKVSNTTV 382  
 373 NIASPEKVSNTTV 386

RESULT 3  
 AA075541  
 ID AA075541 standard; Protein: 386 AA.

AA075541:

23-APR-2002 (first entry)

Human B7-1-like protein, B7-L-h2.

Human: B7-1-like protein; B7-L; anti-infectivity; gynaecological;  
 anti-tumour; cytostatic; immunosuppressive; anti-arthritic; anti-rheumatic;  
 anti-inflammatory; dermatologic; antiproliferative; neuroprotective;  
 anti-diabetic; haematologic; antithyroid; anticancer; antiallergic;  
 antiproliferative; nephrotropic; antibacterial; virucide; tumour; cancer;  
 reproductive disorder; graft versus host disease; autoimmune disease;  
 toxic shock syndrome; allergy; nephropathy; skin disorder;  
 endocrinopathy; lymphoproliferative disorder.

XX Homo sapiens.  
 OS  
 XX  
 PN WO200200710-A2.

03-JAN-2002.  
 28-JUN-2001; 2001WO-US20719.  
 28-JUN-2000; 2000US-214512P.  
 28-NOV-2000; 2000US-0729264.  
 (AMGE-) AMGEN INC.  
 Welcher AA, Samiento UM, Schultz HJ, Chute HT;  
 WPT, 2002-130881/17.  
 N-PSDB: ABR13029.  
 New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 for diagnosing, preventing and treating reproductive, immune and  
 proliferative disorders, e.g. cancer and arteriosclerosis -  
 Claim 13; Fig 2; 135pp; English.

The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).  
 The polypeptide, polynucleotide encoding it and antibody against (I) are  
 useful for treating B7-1-like polypeptide-related disease, disorders or  
 conditions including reproductive disorders (e.g. infertility) and  
 miscarriage, preterm labour and delivery and endometriosis) and  
 proliferative disorders. Antibodies, soluble proteins comprising  
 extracellular domains and other regulators of B7-L polypeptides are  
 useful for enhancing the immune response to tumours. (I) plays a role in  
 growth and maintenance of cancer cells based on the observation of  
 seminal vesicle hyperplasia in transgenic mice overexpressing B7-L.  
 polypeptide. Hence modulators of (I) are useful for the treatment of  
 cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 in allograft transplantation, graft versus host disease, T-cell  
 dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 molecules are useful for alleviating the symptoms associated with  
 diseases involving chronic immune cell dysfunction or to treat  
 autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 purpura and psoriasis, chronic inflammatory disease such as  
 inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 are also useful as immunosuppressive agents for bone marrow and organ  
 transplantation or to prolong graft survival. B7-L molecules are also  
 useful for diagnosis and treatment of diseases involving abnormal cell  
 proliferation, including arteriosclerosis and vascular restenosis.  
 Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 shock syndrome or allo sensitization due to blood transfusions, and for  
 treatment of allergy, asthma and hypersensitivity reactions.  
 nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 lymphoproliferative disorders such as multiple myeloma. The present  
 sequence represents the amino acid sequence of human B7-L-h2.

SO Sequence 386 AA;

Query Match 97.3%; Score 2004; DB 23; Length 386;  
 Best Local Similarity 99.5%; Pred. No. 2e-157;  
 Matches 372; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

9 GSGSGNVEYIEGPONATYVKGQARFNCYSGQKLMALSDMVYLSVRPMEPIITNDRF 68  
 13 GSGSGNVEYIEGPONATYVKGQARFNCYSGQKLMALSDMVYLSVRPMEPIITNDRF 72  
 69 TSORVDGNGFTSEMIHNVPSDSGNIRCSLONSRLHGSAYLTVQVMELEFIPSVNLVY 128  
 73 TSORVDGNGFTSEMIHNVPSDSGNIRCSLONSRLHGSAYLTVQVMELEFIPSVNLVY 132  
 129 AENEPEVTCPLPSHWTRLPDISMELGLVSHSSYFVEPEPSDQASVIALTPQSGNTL 188

RESULT 4	
AAU75543	
ID	AAU75543 standard; Protein; 377 AA.
XX	
XX	
AC	AAU75543;
XX	
XX	
DT	23-APR-2002 (first entry)
XX	
DE	
XX	Human B7-like protein, B7-L <sub>h</sub> .
XX	

Human: B7-like protein; B7-L; antiinfectility; gynaecological;  
antitumor; cytostatic; immunosuppressive; antiarthritis; antirheumatic;  
antiinflammatory; dermatological; antipsoriatic; neuroprotective;  
antiadipatic; haemostatic; antihypertic; antileuk; anti allergic;  
antistomatitic; nephrotoxic; antibacterial; vituicide; tumour; cancer;  
reproductive disorder; graft versus host disease; autoimmune disease;  
toxic shock syndrome; allergy; nephropathy; skin disorder;  
endocrinopathy; lymphoproliferative disorder.

US	Homo sapiens.
TX	
NN	MO200200710-A2.
XX	
DD	03-JAN-2002.
XX	
FF	28-JUN-2001; 2001WO-US20719.
XX	
RR	28-JUN-2000; 2000US-214512P.
RR	28-NOV-2000; 2000US-0729264.
XX	
AA	(AMGE-) AMGEN INC.

Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
WPI: 2002-130881/17.  
N-PSDB; ABL13031.

New B7-like polypeptides, polynucleotides and their modulators, useful  
for diagnosing, preventing and treating reproductive, immune and  
proliferative disorders, e.g. cancer and arteriosclerosis -  
Claim 13; Fig 4; 135pp: English.

The invention relates to an isolated B7-1-like (B7-L) polypeptide (I). The polypeptide, polynucleotide encoding it and antibody against (I) are useful for treating B7-1-like polypeptide-related disease, disorders or conditions including reproductive disorders (e.g. infertility, miscarriage, preterm labour and delivery and endometriosis) and proliferative disorders. Antibodies, soluble proteins comprising extracellular domains and other regulators of B7-L polypeptides are useful for enhancing the immune response to tumours. (I) plays a role in growth and maintenance of cancer cells based on the observation of seminal vesicle hyperplasia in transgenic mice overexpressing B7-L

polypeptide. Hence modulators of (I) are useful for the treatment of cancer including seminal vesicle cancer, lung, brain, breast, ovarian, testicular cancer and cancers of haematopoietic system. B7-L polypeptide can be manipulated to regulate cytotoxic T-lymphocyte response in allograft transplantation, graft versus host disease, T-cell dependent B-cell mediated diseases and autoimmune diseases. T-cell molecules are useful for alleviating the symptoms associated with diseases involving chronic immune cell dysfunction or to treat autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, diabetes, immune thrombocytopenic purpura and psoriasis, chronic inflammatory disease such as inflammatory bowel disease (Crohn's disease and ulcerative colitis), Grave's disease, Hashimoto's thyroiditis and diabetes mellitus). They are also useful as immunosuppressive agents for bone marrow and organ transplantation or to prolong graft survival. B7-L molecules are also useful for diagnosis and treatment of diseases involving abnormal cell proliferation, including arteriosclerosis and vascular restenosis. Antagonists of B7-L polypeptides are useful for alleviation of toxic shock syndrome or allosensitisation due to blood transfusions, and for treatment of allergy, asthma and hypersensitivity reactions, and for nephropathies (e.g. glomerulonephritis), skin disorders (pemphigoid), endocrinopathies (Grave's disease), various pneumopathies (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia, lymphocytopoenias, Guillain-Barre syndrome and myasthenia gravis, and lymphoproliferative disorders such as multiple myeloma. The present sequence represents the amino acid sequence of human B7-L<sub>H4</sub>.

Query Match	73.5%;	Score 1514;	DB 23;	Length 377;
Best Local Similarity	88.2%;	Pred. No 6.5e-117;		
Matches 284;	Conservative 12;	Mismatches 20;	Indels 6;	Gaps 2
QY	9	GSGSNGNEIEGPOVATLKSGQARFCTVYSQGMKLIMMALSDMVVLSVRMEPIITNDRF		
Db	13	GSGSNGNEIEGPOVARLKSGQARFCTVYSQGMKLIMMALSDMVVLSVRMEPIITNDRF		
QY	69	TSQRTDGGNFTSEMTIHNPVSDSNIRCLSNRSLHGSAYLTVOVGELETPSVNLV		
Db	73	TSQRTDGGNLTSEMTIHNPVSDSNIRCLSNRSLHGSAYLTVOVGELETPSVNLV		
QY	129	AENEPEVCVLPWHMRLEDISWELGLVSHSSYFVPEPDSLOSASVLTALTPQSNGL		
Db	133	AENEPEVCVLPWHMRLEDISWELGLVSHSSYFVPEPDSLOSASVLTALTPQSNGL		
QY	189	TCVATWMSLKARKSATVNLTVIRCPODGGGGINICVLSLPSLGFSLPTMGKVGSLAG		
Db	193	TCVATWMSLKARKSATVNLTVIRCQODGGGINIPGVLSLPSLGFSLPTMGKVGSLAG		
QY	249	TMLLPPTCTLTIRCCCGRRCCGCCGCCRCFCGRKRGFRIOQKSEKTKTAKETETE		
Db	253	TMLLPPTCTLTIRCCCGRRCCGCCGCCRCFCGRKRGFRIOQKSEKTKTAKETETE		
QY	309	SGNENSGYNSDEQKTTPTASLP 330		
Db	310	T---PATIOUMKRRQTPLELSLP 328		

RESULT 5	
ABG28169	
ID	ABG28169 standard; Protein; 463 AA.
XX	
XX	
AC	ABG28169;
XX	
DT	18-FEB-2002 (first entry)
XX	
DE	Novel human diagnostic protein #28160.
XX	
KW	Human; Chromosome mapping; gene mapping; forensic;
KW	food supplement; medical imaging; diagnostic;
XX	genetic disorder.
CS	Homo sapiens.
XX	
XX	



CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of mouse B7-L<sub>ML</sub>.

SO Sequence 370 AA:

Query Match 44.9%, Score 924.5; DB 23; Length 370;  
 Best Local Similarity 50.8%, Pred. No. 3.6e-66;  
 Matches 197; Conservative 50; Mismatches 104; Indels 37; Gaps 6;

QY 3 IVTF--LHGSGNGNVEYVTCVAVGWSLQSGAENFVTSOGKMLIMALSDMVLSVRPME 60  
 DB 12 LVIIAQLTASSSSQIIEGPNVTVLKDSEAHFNCTVTHGKMLMTLMQMVLSLTGOG 71  
 QY 61 PLTNDRTSORYDGGNFTSEMIINHVESDSGNTRCSLONSRLGSAVLVQVNGELF 120  
 DB 72 PLTNNRFTYASVNSTDSFTSELIHIVQPSDGSVQCSLQNSHGSAFLSVQVWGTLN 131  
 QY 121 IPSVNLVAENPECEVTCVLSHMTRLPDLSWEGLLVSHSYFVEPEPDLQSAVSIIL 180  
 DB 132 IPSNNLIVTEGECNVTCAVGMTSLPDISWELEVPVSHSYNSFLEPGNFRVLSTLDL 191  
 QY 181 TPDSNGITLVATWKSLSKRRKSAVNLVTRCPDPTGGGGINPVLSLPSLGSFLPTWG 240  
 DB 192 TPLNGSTLCVAMELKDQASKSLVNLVYQPPD-----SISGEGLALPTWA 239  
 QY 241 KVGGLAGTMLTLPCTLRCCCRKCCGCCGCCRCFCRRKGRIFQ---KSE 297  
 DB 240 ILLAAVAFSLILLIIVLITPCC-----CASRREKESTYQVEIKKSA 284  
 QY 298 KKKTKK---ETESGNGNSGYNDSDEKTDPTASLPKSCSSDPEDRNSCGEPHQRAD 354  
 DB 285 NKRITKADPEKRLKSGKENYGYSSDEAKAQTASLPKSAEVSLEPKRSSSL--PYOELN 342  
 QY 335 QRRPPASHPOASFNLASPEKVSNTTVY 382  
 DB 343 KHQEPATHPRVSPDIASPOKVRNVTLV 370

RESULT 7

AAU75547  
 XX ANU75547 standard; Protein; 631 AA.

AC AAU75547;

XX 23-APR-2002 (first entry)

DE Rat B7-like protein, B7-1.

KM Rat: B7-like protein; B7-L; antiinfectivity; gynecological;  
 KM antitumor; cytostatic; immunosuppressive; antiarthritic; antirheumatic;  
 KM antidiabetic; dermatologic; antipsoriatic; neuroprotective;  
 KM antiaesthetic; nephrotoxic; antihypertensive; antiallergic;  
 KM reproductive disorder; graft versus host disease; cancer;  
 KM toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KM endocrinopathy; lymphoproliferative disorder.

OS Rattus rattus.

XX W0200200710-A2.

XX 03-JAN-2002.

XX 28-JUN-2001; 2001MO-US20719.

XX 28-JUN-2000; 2000US-214512P.

XX 28-NOV-2000; 2000US-0729264.

XX (AMGE-) AMGEN INC.

PI Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 DR WPI; 2002-130881/17.

XX New B7-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 PS Disclosure; Fig 8; 135pp; English.

CC The invention relates to an isolated B7-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, chronic inflammatory disease such as  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular stenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allosensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions.  
 CC pemphigoid (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC thrombocytopenias), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of rat B7-1.

SO Sequence 631 AA:

Query Match 28.3%, Score 583.5; DB 23; Length 631;  
 Best Local Similarity 26.9%, Pred. No. 1.2e-39;  
 Matches 173; Conservative 43; Mismatches 111; Indels 317; Gaps 11;

QY 3 IVTF--LHGSGNGNVEYVTCVAVGWSLQSGAENFVTSOGKMLIMALSDMVLSVRPME 21  
 DB 12 LVIIAQLTASSSSQIIEGPNVTVLKDSEAHFNCTVTHGKMLMTLMQMVLSLTGOG 71  
 QY 22 -----NATVLKSGAENFVTSOGKMLIMALSDMVLSVRPMEPTITNDRF----- 68  
 DB 72 VGVSKSVRNVTYVKDSEAHFNCTVTHGKMLMTLMQMVLSLTGOGPIITNDRF 131  
 QY 69 -----TSORYDGGNFTSEMI 84  
 DB 132 LSCDYKFCSEQSIHRLTWCKHDKVLSVSGVPEWPKKRRNTYASVNSTDSFTSELI 191  
 QY 85 IHNVERSDSGNTRCSLQNSRLGSAVL----- 111  
 DB 192 IHDVQPSDGSVQCSLQNSHGSAFLSVQVYDIANNVSESLGLILSDRGTYCVQRY 251  
 QY 112 -----TVQVWGLFVTSVNLVVAENPECEVTCVLSHMTRLPDLSWEGLLVSHS 160  
 DB 252 EGSYVYKHLTIVEVWGLTINLIPSNLIVTEGECNVTCAVGMTSLPDISWELEVPVSHS 311



QY 161 -----SYFVPEPSDQ 172  
 DB 312 LSVRADEPTNITEYGNPSADIRITCFASGCGPKPRLSMLENGRELNSYNSFLEPGNFM 371  
 QY 173 SAVSIIALTPQSNCTELCVATWKSILKARKSATVNL----- 207  
 DB 372 RVLSVLDITFGNCTILCVALEMDQASKSLVNLGINTTISODPESELYTISQIDFNA 431  
 QY 208 -----TYRCQDPTGGGINIPGVLSLPSLGSFSLPTMGKVLGL 246  
 DB 432 TYDHTDCEIEYGDVAHVSONTVVQPPD-----SIEGSPALPTAIIILAV 479  
 QY 247 AGTML-----TPT 255  
 DB 480 AFSLLIIILVLIITFWVKKPPEDPEKQVFPAMGPDVAKALIFIAITVIAVIA 539  
 QY 256 CTLTTRCCGCRRCRCGCCRCRCRRKGFRIQO-KSEKRNK---ETERNESGN 311  
 DB 540 IAIIFCCCCASR-----REKEESTYQNEIRKSAMRTKADPETKLSGK 585  
 QY 312 EMSGYNDEQKTTDPAFLPKSCSSDEQORNSCGPPHORADQ 355  
 DB 586 ENYGSYSDCTIVKRRRCRRRANESRETNNIYIGVEAAEQ 629

RESULT 8  
 AAU75545  
 ID AAU75545 standard; Protein: 270 AA.  
 AC AAU75545;  
 XX  
 DT 23-APR-2002 (first entry)  
 DE Mouse B7-Like protein, B7-L<sub>m2</sub>.  
 XX  
 XX Mouse; B7-Like protein; B7-L; antiinfectility; gynaecological;  
 KW antitumor; cytostatic; immunosuppressive; antirheumatic; antineumatic;  
 KW antiinflammatory; dermatological; antiporiatic; neuroprotective;  
 KW antidiabetic; haemostatic; antihypoid; antilucer; antiallergic;  
 KW antistimatic; nephrotoxic; antibacterial; vitruclide; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder.  
 XX  
 OS Mus musculus.  
 XX  
 PN MO200200710-A2.  
 XX  
 PD 03-JAN-2002.  
 XX  
 PF 28-JUN-2001; 2001WO-US20719.  
 XX  
 PR 28-JUN-2000; 2000US-214512P.  
 XX  
 PR 28-NOV-2000; 2000US-0729264.  
 XX  
 PA (AMGE-) AMGEN INC.  
 XX  
 PI Weicher AA, Sarmiento UM, Schultz HU, Chute HT;  
 XX  
 DR WPI; 2002-130881/17.  
 XX  
 DR N-PSDB; ABK13033.  
 XX  
 PT New B7-Like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 XX  
 PS Claim 13; Fig 6; 135pp; English.  
 XX  
 CC The invention relates to an isolated B7-Like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-Like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and

CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or alloimmunisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of mouse B7-L<sub>m2</sub>.  
 XX  
 SQ Sequence 270 AA;  
 QY Query Match 28.0%; Score 575.5; DB 23; Length 270;  
 QY Best Local Similarity 35.1%; Pred. No. 1.8e-39;  
 QY Matches 136; Conservative 42; Mismatches 73; Indels 137; Gaps 6;

QY 3 LVTF--LHSGSGENEYIEGPQNTYVKGQARFCTVSGKLMALSDMYVLSVPRME 60  
 DB 12 LVTLAQLTASGSSQYIEEPQNTVYKQSEAHFNCTVHGKLLMTLQNVVLSLTQQG 71  
 QY 61 PTTNDEFTSORDOGNFTSEMIHNVEPDSGNTCSLQNSRLGSAVLYTVQMGLEF 120  
 DB 72 PTTNNEFTTASVNSDSFSLIHDVQPSDSGVSQSLQNSHGFSAFLSVQ----- 125  
 QY 121 IPSVNLVVAENEPECEVTCIPSHWTRLPDISWELGLVSHSYFYFPEPSDQSAVSLAL 180  
 DB 126 ----- 125  
 QY 181 TPQSNGLTCVATWKSILKARKSATVNLTVIRCPQDTGGGINIPGVLSLPSLGSFSLPTWG 240  
 DB 126 -----DSIEGSPALPTWA 139  
 QY 241 KVGGLAGTMLPPTCTLTTRCCGCRRCGCCRCRCRRKGFRIQO---KKSE 297  
 DB 140 IITLAVAFSLIIILVLIIFCC-----CASRREKEESTYQNEIRKA 184  
 QY 298 KEKTNK---ETERTSGNENSGYNSDEQKTTDPAFLPKSCSSDPPQORNSCGPPHORAD 354  
 DB 185 NMRTKADPETKLSGKENGYSDEKAQAOTSLPKSAEYSLPKRSSL--PYQELN 242  
 QY 355 QRPAPASHPOASFNLASPEKVSNTTVV 382  
 DB 243 KHQGPALHPVSPFDIASPQKVRNVTIV 270

RESULT 9  
 AAU75546  
 ID AAU75546 standard; Protein: 223 AA.  
 AC AAU75546;  
 XX

23-APR-2002 (first entry)  
 Mouse B7-1-like protein, B7-L<sub>m3</sub>.  
 Mouse: B7-1-like protein; B7-L; antiinfertility; gynaecological;  
 antitumour; cyrostatic; immunosuppressive; antiarthritic; antineumatic;  
 antiinflammatory; dermatologic; antiporiatic; neuroprotective;  
 antidiabetic; haemostatic; antithyroid; antileuc; antiallergic;  
 antistimatic; nephrotropic; antibacterial; vitruide; tumour; cancer;  
 reproductive disorder; graft versus host disease; autoimmune disease;  
 toxic shock syndrome; allergy; nephropathy; skin disorder;  
 endocrinopathy; lymphoproliferative disorder.  
 Mus musculus.  
 WO200200710-A2.  
 03-JAN-2002.  
 28-JUN-2001; 2001WO-US20719.  
 28-JUN-2000; 2000US-214512P.  
 28-NOV-2000; 2000US-0729264.  
 (AMGE-) AMGEN INC.  
 Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 WPI: 2002-130881/17.  
 N-PSDB: ABK1034.  
 New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 for diagnosing, preventing and treating reproductive, immune and  
 proliferative disorders, e.g. cancer and arteriosclerosis  
 Claim 13; Fig 7; 135pp: English.  
 The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).  
 The polypeptide, polynucleotide encoding it and antibody against (I) are  
 useful for treating B7-1-like polypeptide-related disease, disorders or  
 conditions including reproductive disorders (e.g. infertility,  
 miscarriage, preterm labour and delivery and endometriosis) and  
 proliferative disorders. Antibodies, soluble proteins comprising  
 extracellular domains and other regulators of B7-L polypeptides are  
 useful for enhancing the immune response to tumours. (I) plays a role in  
 growth and maintenance of cancer cells based on the observation of  
 seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 polypeptide. Hence modulators of (I) are useful for the treatment of  
 cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 in allograft transplantation, graft versus host disease, T-cell  
 dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 molecules are useful for alleviating the symptoms associated with  
 diseases involving chronic immune cell dysfunction or to treat  
 autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 purpura and psoriasis, chronic inflammatory disease such as  
 inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 are also useful as immunosuppressive agents for bone marrow and organ  
 transplantation or to prolong graft survival. B7-L molecules are also  
 useful for diagnosis and treatment of diseases involving abnormal cell  
 proliferation, including arteriosclerosis and vascular restenosis.  
 Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 shock syndrome or allo-sensitisation due to blood transfusions, and for  
 treatment of allergy, asthma and hypersensitivity reactions, and for  
 nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 lymphoproliferative disorders such as multiple myeloma. The present  
 sequence represents the amino acid sequence of mouse B7-L<sub>m3</sub>.

XX SQ Sequence 223 AA:  
 Query Match 24.0%; Score 494; DB 23; Length 223;  
 Best Local Similarity 31.9%; Pred. No. 7.7e-33;  
 Matches 123; Conservative 37; Mismatches 47; Indels 178; Gaps 7;  
 QY 3 LVTF--LHSGSGNEVIEGPONATVYKSGOARFNCTVSGGKLLMALSDMVYLSVRME 60  
 DB 12 LVTLAQLTASSGSSVYIIEGPONATVYKSGOARFNCTVSGGKLLMALSDMVYLSVRME 60  
 QY 61 PIIITDRFTSQNYDGGNFTSEMIINHNVEPSDGNIRCSLRHGSAYLTVOVGELF 120  
 DB 72 PIIITNREFTVASNSTDSFISELIIHDVQPSDSSGVCCLQNSHGFSATLSVQ----- 125  
 QY 121 IPSVNLVVAENPCEVTCPLPSHWTRLPDISMELGLVSHSSYTFVPEPSDQSAVSITLAL 180  
 DB 126 -----ESTY-----QNEI----- 133  
 QY 181 TPQSNGLTVCAVWTKSLKARKSATVNLTVIRCPQDTGGINIPGLVSLPSLGFSLPWTG 240  
 DB 134 -----RKSANN----- 139  
 QY 241 KVGGLAGTMLTPTCTLTTRCCCRCCGCCGCCCRCCCRKRRKRPRIQFKSEKER 300  
 DB 140 -----R 140  
 QY 301 TNK---ETETESGNGNSGNSDEQKTTDTASLPKSCSSDPORNSGCPPHORADQR 357  
 DB 141 TNKADPETKTKLSKENYSGSSDEKAAQTASLPKSAEYSLPERKSSSL--PYQELNRHQ 198  
 QY 358 PRPASHPOASFNLASPEKVSNTTVV 382  
 DB 199 PGPAIHPRVSEFDIASPQKVRNVTLV 223  
 RESULT 10  
 AAB81925  
 ID AAB81925 standard; protein; 404 AA.  
 XX  
 AC AAB81925;  
 XX  
 DT 15-JUN-2001 (first entry)  
 XX  
 DE Extracorporeal circulation material receptor protein.  
 XX  
 KW Extracorporeal circulation; carbonyl stress product; receptor;  
 KW diabetes; vascular lesion; excretory dysfunction.  
 XX  
 OS Unidentified.  
 XX  
 PN WO200118060-A1.  
 PD 15-MAR-2001.  
 PF 08-SEP-2000; 2000WO-JP06172.  
 PR 08-SEP-1999; 99JP-0254463.  
 PA (TORA) TORAY IND INC.  
 PI Shimizu S, Kubota M, Akiyama H, Usui M;  
 DR WPI: 2001-290314/30.  
 PT Material for extracorporeal circulation, applicable in selective  
 PT elimination of diabetic complication factors such as carbonyl stress  
 PT products caused by abnormally promoted carbonyl stress from excretory  
 PT dysfunction in vascular lesions  
 XX  
 PS Claim 1; Page 31-32; 36pp: Japanese.  
 CC The present invention describes a material for extracorporeal circulation

which is made from a water-insoluble carrier immobilized with a protein having the sequence shown here. The materials of the invention, including adsorbents, are for extracorporeal circulation, which are applicable in the selective elimination of diabetic complication factors from a body fluid, and are therefore useful in treating vascular lesions like arteriosclerosis due to carbonyl stress products caused by abnormally promoted carbonyl stress from excretory dysfunction.

Sequence 404 AA:

Query Match 7.2%; Score 147.5; DB 22; Length 404;  
Best Local Similarity 22.6%; Pred. No. 0.00076;  
Matches 85; Conservative 40; Mismatches 114; Indels 137; Gaps 18;

15 EYIEGPNATVLKGSQARFNCTYSOG---WKLIIMALSDMYLVSRPEPIITNDRTS- 70  
125 EIVDSASELTA--GVPNKVGTCSGSPAGTLSWHLDG-----KPLVPMKGVSV 173  
71 ----QRYDGGNFT--SEMIINVEPSDSGNIR---CSLQNSRLHGSAYLTQVMGELEF 120  
174 KEQTRRHPEPTGLFTLOSSELM---VTPARGGDRPPTSCSFSGPLPRHRALFTAPIQPRVW 230  
121 IP---SVNLVVAENP-----CEVTCLPBHWTRLPDISWELGLVSHSSY 162  
231 EPPVLEEVQLV---EPREGAVAPGGTVTLTCEVPAQPS---PQIHMKMD----- 274  
163 YFVPEPSDIQSAVSIILATPQNSGTLTCVATWKSILKARKSATVNLTVRCPODTGGGINI 222  
275 -GVPPLPSPSPVILPEIPGODGTYSCVATHSSHGQPSRAVSISILP-PEEBG----- 327  
223 PGVLSLPSLGFSLPTWKGVLGLAGTMTLT-----PTCTLTTRCCCRRCGCCGCCNC 275  
328 -----PTAGSVGGSGGLTALALGILGGLTALLIGVILMQR----- 366  
276 CRCCFCCRRKRRFRIOFQKSEKERT--NKETETESGNENSGVNSDEOKTTPTASLPPKS 333  
367 -----QRGGEERKAPENOEDEERAEIN----- 389  
334 CESSDPEQRNNSCGPP 349  
390 -QSEEPAGESSTGCP 404

RESULT 11

AAE23219 standard; Protein; 404 AA.

AAE23219;

27-NOV-2002 (first entry)

Human receptor for advanced glycosylation end product (RAGE) protein.

Human: Receptor for advanced glycosylation end product; RAGE; cardiact; tissue growth; neointimal formation; blood vessel; restenosis; diabetes; myocardial infarction; angioplasty; peripheral vascular surgery; angina; transgenic animal; acute thrombotic stroke; venous thrombosis.

Homo sapiens.

WO200230889-A2.

18-APR-2002.

12-OCT-2001; 2001WO-US32036.

13-OCT-2000; 2000US-0687528.

(UYCO) UNIV COLUMBIA NEW YORK.

Stern DM, Schmidt A, Marso S, Topol E, Lincoff AM;

WPI; 2002-426260/45.

DR N-PSDB; AAD36952.

XX Inhibiting new tissue growth or neointimal formation in blood vessels  
XX of subject suffering from diabetes, stroke and preventing restenosis,  
XX comprising administering inhibitor of receptor for advance glycation end  
XX product

PS Disclosure; Page 16; 43pp; English.

XX The invention relates to a method for inhibiting new tissue growth or  
XX neointimal formation in blood vessels in a subject that has experienced  
XX blood vessel injury and preventing exaggerated restenosis in a diabetic  
XX subject. The method comprises administering an inhibitor of receptor for  
XX advanced glycation/glycosylation end product (RAGE), so as to inhibit new  
XX tissue growth or neointimal formation in subject's blood vessels and  
XX preventing restenosis in the subject. The method is useful for inhibiting  
XX new tissue growth or neointimal formation in blood vessels in a subject  
XX like non-human animal, a transgenic non-human animal or a human suffering  
XX from diabetes, acute thrombotic stroke, venous thrombosis, unstable  
XX angina, myocardial infarction, abrupt closure following angioplasty or  
XX stent placement, or thrombosis as a result of peripheral vascular surgery  
XX The method is also useful for preventing restenosis and for determining  
XX whether a compound inhibits new tissue growth in a blood vessel in a  
XX subject. The present sequence is human receptor for advanced  
XX glycosylation end product (RAGE) protein.

Sequence 404 AA:

Query Match 7.2%; Score 147.5; DB 23; Length 404;  
Best Local Similarity 22.6%; Pred. No. 0.00076;  
Matches 85; Conservative 40; Mismatches 114; Indels 137; Gaps 18;

15 EYIEGPNATVLKGSQARFNCTYSOG---WKLIIMALSDMYLVSRPEPIITNDRTS- 70  
125 EIVDSASELTA--GVPNKVGTCSGSPAGTLSWHLDG-----KPLVPMKGVSV 173  
71 ----QRYDGGNFT--SEMIINVEPSDSGNIR---CSLQNSRLHGSAYLTQVMGELEF 120  
174 KEQTRRHPEPTGLFTLOSSELM---VTPARGGDRPPTSCSFSGPLPRHRALFTAPIQPRVW 230  
121 IP---SVNLVVAENP-----CEVTCLPBHWTRLPDISWELGLVSHSSY 162  
231 EPPVLEEVQLV---EPREGAVAPGGTVTLTCEVPAQPS---PQIHMKMD----- 274  
163 YFVPEPSDIQSAVSIILATPQNSGTLTCVATWKSILKARKSATVNLTVRCPODTGGGINI 222  
275 -GVPPLPSPSPVILPEIPGODGTYSCVATHSSHGQPSRAVSISILP-PEEBG----- 327  
223 PGVLSLPSLGFSLPTWKGVLGLAGTMTLT-----PTCTLTTRCCCRRCGCCGCCNC 275  
328 -----PTAGSVGGSGGLTALALGILGGLTALLIGVILMQR----- 366  
276 CRCCFCCRRKRRFRIOFQKSEKERT--NKETETESGNENSGVNSDEOKTTPTASLPPKS 333  
367 -----QRGGEERKAPENOEDEERAEIN----- 389  
334 CESSDPEQRNNSCGPP 349  
390 -QSEEPAGESSTGCP 404

RESULT 12

AAU77543 standard; Protein; 404 AA.

AAU77543;

05-JUN-2002 (first entry)

Human receptor for advanced glycosylation end product (RAGE).

Receptor for advanced glycation end product; RAGE; receptor;  
amyloid beta peptide; blood-brain barrier; neurovascular stress;

KW cerebral vasoconstriction suppressor; cerebral blood flow enhancer;  
 KW cerebral amyloid angiopathy; transgenic animal; amyloid beta precursor;  
 KW Alzheimer's disease; Down's syndrome; head trauma; stroke; human.  
 OS Homo sapiens.  
 XX  
 XX  
 XX W0200214519-A1.  
 XX  
 XX  
 XX PD 21-FEB-2002.  
 XX  
 XX PF 14-AUG-2001; 2001WO-US25416.  
 XX  
 XX PR 14-AUG-2000; 2000US-0638648.  
 XX  
 XX (UYCO ) UNIV COLUMBIA NEW YORK.  
 XX  
 XX PI Stern DM, Schmidt AM, Yan SD, Zlokovic B.  
 XX  
 XX DR WPI; 2002-257610/30.  
 XX  
 XX DR N-PSDB; ABK10856.  
 XX  
 XX PT Ameliorating neurovascular stress and decreasing cerebral  
 PT vasoconstriction in subject suffering from chronic/acute cerebral  
 PT amyloid angiopathy, by administering inhibitor of receptor for advanced  
 PT glycation endproduct -  
 XX  
 XX PS Disclosure; Page 16; 68pp; English.  
 XX  
 XX CC The invention describes a method of ameliorating neurovascular stress,  
 CC and decreasing cerebral vasoconstriction in subject suffering from  
 CC chronic or acute cerebral amyloid angiopathy, comprising administering  
 CC an inhibitor (I) of receptor for advanced glycation end product (RAGE).  
 CC (I) inhibits transcytosis of amyloid beta peptides across blood-brain  
 CC barrier, thus decreasing cerebral vasoconstriction and increasing  
 CC cerebral blood flow. (I) is useful for treating amyloid angiopathy in a  
 CC subject, decreasing cerebral vasoconstriction in a transgenic non-human  
 CC animal (preferably, transgenic mouse overexpressing mutant human amyloid  
 CC beta precursor protein) or a human, suffering from chronic or acute  
 CC cerebral amyloid angiopathy, preferably, Alzheimer's disease, and for  
 CC ameliorating neurovascular stress comprising cerebral amyloid angiopathy  
 CC in a subject, where the neurovascular stress is caused by Alzheimer's  
 CC disease, aging, Down's syndrome, head trauma or stroke. This is the  
 CC amino acid sequence of human receptor for advanced glycation end  
 CC product (RAGE) described in the invention.  
 CC  
 XX  
 XX SQ Sequence 404 AA;  
 Query Match 7.2%; Score 147.5; DB 23; Length 404;  
 Best Local Similarity 22.6%; Pred. No. 0.00076;  
 Matches 85; Conservative 40; Mismatches 114; Indels 137; Gaps 18;  
 QY 15 EYIEGPNATVLEKGSQARFNCVTSOG---WKLIMWALSDWVLSVPRMEPIITNDRTS- 70  
 DB 125 EIVDSASELTA--GVPNKVGTCVSEGSYPAGTILSHLDG-----KPLVPEKGVSV 173  
 QY 71 ----ORDGOGNFT--SEMIINHPESDSGNIR---CSLONSRLHGSAYLTVOVMGELF 120  
 DB 174 KEQTRRHPEFTGLTQSELM---VTPARGGDPRTFSCSPGLPRHRLRTAPIQPRVW 230  
 QY 121 IP---SVNLVVAENEP-----CEVTCLPSHMTRLPDISWELGLVSHSSY 162  
 DB 231 EPPVLEVOQLV---EEGGAVALPAGGTVITLCVPAQPS-----PQIHMKD----- 274  
 QY 163 YFVEPBDLOSANVITLALPQSNGLTCAVATWKSILKARKSATVNLTVIRCPDGTGGINI 222  
 DB 275 -GVPLPLPSPVILPEIGPDGTYSVATHSHSGPRAVSISILE-PEEB----- 327  
 QY 223 PGVLSLPSLGFSLPMGKVGGLACTMILT-----PTCTLTTRCCCCRRRCGCCNCC 275  
 DB 328 -----PTAGSYGSGGLTALALGILGGLCTALLIGVILWMOR----- 366  
 QY 276 CRCFCRCRRKRGRIQFKKSEKERT--NKEETESGNENSGYNSDEKTTDTASLPPKS 333

DB 367 -----QRGEERKAPENQEEBERALN----- 389  
 QY 334 CESDPEQRNSGCPP 349  
 DB 390 -QSEEPAGESTGCP 404  
 RESULT 13  
 AAM48745  
 ID AAM48745 standard; protein; 404 AA.  
 XX  
 XX AC AAM48745;  
 XX  
 XX DT 02-APR-2002 (first entry)  
 XX  
 XX DE Human RAGE protein SEQ ID NO 1.  
 XX  
 KW Human; RAGE; receptor for advanced glyated endproduct; receptor;  
 KW antidiabetic; neuroprotective; cyostatic; antiinflammatory; vasotropic;  
 KW nephrotropic; dermatological; antiarteriosclerotic; nootropic; diabetes;  
 KW Alzheimer's disease; cancer; inflammation; kidney failure;  
 KW systemic lupus; nephritis; erectile dysfunction; atherosclerosis.  
 XX  
 XX OS Homo sapiens.  
 XX  
 XX PN W0200192892-A2.  
 XX  
 XX PD 06-DEC-2001.  
 XX  
 XX PF 30-MAY-2001; 2001WO-US17447.  
 XX  
 XX PR 30-MAY-2000; 2000US-207342P.  
 XX PR 05-MAR-2001; 2001US-0799152.  
 XX  
 XX PA (TRAN-) TRANS TECH PHARMA.  
 XX  
 XX PI Shahbaz M;  
 XX  
 XX DR WPI; 2002-114372/15.  
 XX  
 XX CC Detecting a receptor for advanced glyated endproducts (RAGE)  
 CC modulators, for treating e.g., cancer, diabetes or inflammation,  
 CC comprises measuring the amount of bound anti-RAGE antibody -  
 XX  
 XX PS Claim 1; Fig 2; 49pp; English.  
 XX  
 XX CC The invention relates to detecting receptor for advanced glyated  
 CC endproducts (RAGE) modulators comprises determining the amount of RAGE  
 CC protein or its fragment bound to the pre-adsorbed ligand by measuring the  
 CC amount of anti-RAGE antibody bound to the solid surface. The method is  
 CC useful for rapid, high-throughput identification of compounds that  
 CC modulate RAGE. The compounds are useful for treating symptoms of diabetes  
 CC and symptoms of diabetic late complications, amyloidosis, Alzheimer's  
 CC disease, cancer, inflammation, kidney failure, systemic lupus nephritis  
 CC or inflammatory lupus nephritis, erectile dysfunction and  
 CC atherosclerosis.  
 CC  
 XX  
 XX SQ Sequence 404 AA;  
 Query Match 7.2%; Score 147.5; DB 23; Length 404;  
 Best Local Similarity 22.6%; Pred. No. 0.00076;  
 Matches 85; Conservative 40; Mismatches 114; Indels 137; Gaps 18;  
 QY 15 EYIEGPNATVLEKGSQARFNCVTSOG---WKLIMWALSDWVLSVPRMEPIITNDRTS- 70  
 DB 125 EIVDSASELTA--GVPNKVGTCVSEGSYPAGTILSHLDG-----KPLVPEKGVSV 173  
 QY 71 ----ORDGOGNFT--SEMIINHPESDSGNIR---CSLONSRLHGSAYLTVOVMGELF 120  
 DB 174 KEQTRRHPEFTGLTQSELM---VTPARGGDPRTFSCSPGLPRHRLRTAPIQPRVW 230  
 QY 121 IP---SVNLVVAENEP-----CEVTCLPSHMTRLPDISWELGLVSHSSY 162

Db 231 EPPVLEEVLYV---EPEGAVAGGTVLTCEVPAQPS-----POLHMKD----- 274

QY 163 YFVPEPSDLSAVSIITLTPQNSGTLTCVATWMSLKARSAVNTLVICPPDTGGGINI 222

Db 275 -GVLPPLPPSVLLPPEIGPDQGTYSVATSHSGHPOESRAVISIIE-PGEEG----- 327

QY 223 PGVLSLSPLSGSLPTWKGKVLGLAGTMTLT-----PTCTLTIRCCCRRCGCCNC 275

Db 328 -----PTAGSVGGSGSLGTALALGILGSLGTAALLIGVILMQRR----- 366

QY 276 CRCCFCCRRKRGFRIOFKKSEKKT--NKETESGNSGNSGNSDEQKTTDTASLPKPS 333

Db 367 -----GRGEERKAPENDEEEERAEIN----- 389

QY 334 CESSDEPQRNSCCPP 349

Db 390 -OSEPEAGESSTGCP 404

RESULT 14

ABR75751 ID ABR75751 standard; Protein: 592 AA.

AC ABR75751;

XX 24-JUN-2002 (first entry)

DE Human immunoglobulin superfamily member GP354.

XX Human: GP354; immunoglobulin; pancreas; central nervous system;

KW diagnosis; gene therapy; pancreatitis; inflammation; tumour; cancer;

KW autoimmune disease; Alzheimer's disease; Parkinson's disease;

KW senile dementia; migraine; epilepsy; neurasthenia; neuropathy;

KW neural degeneration; antiinflammatory; cytostatic; neurotropic;

KW immunosuppressive; antiparkinsonian; neuroprotective; antimigraine;

KW anticonvulsant.

XX Homo sapiens.

XX Location/Qualifiers

FT Key 1..18

FT Peptide /label= Signal\_peptide

FT Protein 19..592

FT /label= Mature\_protein

FT Domain 19..507

FT /note= "extracellular domain"

FT Domain 35..102

FT /note= "Ig domain"

FT Domain 136..203

FT /note= "Ig domain"

FT Domain 239..290

FT /note= "Ig domain"

FT Domain 323..374

FT /note= "Ig domain"

FT Domain 410..485

FT /note= "Ig domain"

FT Domain 508..530

FT /note= "transmembrane domain"

FT Domain 531..592

FT /note= "intracellular domain"

PN WO200198360-A2.

PD 27-DEC-2001.

XX 22-JUN-2001; 2001WO-US19904.

PF 22-JUN-2000; 2000US-213611P.

PR 22-JUN-2000; 2000US-213611P.

XX (BIOI ) BIOGEN INC.

XX (CARU/) CARULLI J P.

XX (LURA/) LUKASHIN A V.

XX (KILB/) KILBURN D R.

PA (SUNC/) SUN C.

XX Carulli JP, Lukashin AV, Kilburn DR, Sun C;

PI WPI: 2002-329171/36.

XX N-PSDB: ABL53873, ABL53875.

DR Novel nucleic acid sequence encoding a member of immunoglobulin

XX superfamily, designated GP354, useful for the treatment of Alzheimer's

XX disease, Parkinson's disease, senile dementia, migraine and epilepsy

PT Claim 17; Fig 1; 163pp; English.

XX The present sequence is the protein sequence of human GP354, a

XX novel member of the immunoglobulin superfamily. GP354 is a

XX pancreas-enriched integral membrane protein, which is also detected

XX at low levels in central nervous system (CNS) tissue. It shares no

XX more than 30% amino acid identity with any previously described

XX protein. The protein structure and tissue distribution of GP354

XX indicate a role in cell-cell recognition, binding, signalling and

XX adhesion events in the pancreas and CNS. The present invention

XX provides GP354 polypeptides and GP354 polynucleotides, as well as

XX vectors, host cells, antibodies and related diagnostic and

XX therapeutic methods. Claimed compositions comprising a GP354

XX nucleic acid or GP354 polypeptide are used in the treatment of

XX pancreatic injury and abnormal or chronic pancreatitis, pancreatic

XX inflammation, pancreatic necrosis, exocrine insufficiency,

XX pancreatic endocrine and hormonal imbalance, pancreatic tumours and

XX associated cancers, and autoimmune disorders which affect the

XX pancreas. They are also used in the treatment of an injury to the

XX CNS and abnormal or disease conditions that relate to the CNS,

XX including Alzheimer's disease, Parkinson's disease, senile dementia,

XX migraine, epilepsy, neuritis, neurasthenia, neuropathy, neural

XX degeneration and neural tumours (all claimed).

XX Sequence 592 AA:

SQ

Query Match 6.7%; Score 138; DB 23; Length 592;

Best Local Similarity 23.8%; Pred. No. 0.0075;

Matches 55; Conservative 40; Mismatches 106; Indels 30; Gaps 10;

QY 3 LVTFILGSGSGNEVIEGPQNAVTLKSGOARFNCYSGQKRLTMALSDMVLYSVRMEPI 62

Db 10 LFCFRSGAGSPHFLQOPEDVLVLEEARLPCALGATYQWTKSGALAGGQR----- 64

QY 63 ITNDRFTSORYDQGNFTS---EMITHNVEPSDSGNIKCSLONSRLHG-SAYLTV----- 113

Db 65 ---DLPQMSKRWISGNMANGQHDHLIRPELEDEASVECOAQAGRSRPAQLHVLVPE 121

QY 114 --QVMGELFTPSVNLVVAENPECEVCLPSHWTR-LPDISW-ELGLVSHSSVY--FYVE 167

Db 122 APQVILGG---PSVSLVA--GVPAHLTCRSRGDKARPPPELLMFPDGLVDGTFHQTLKE 176

QY 168 --PSDLSAVSIITLTPQNSGTLTCVATWMSLKARSAVNTLVICPPDT 216

Db 177 GTPGSVESTLTLPFSHDDGATFVCARASQALPTGRDTALTSLAQYPEVT 227

RESULT 15

ABR75753 ID ABR75753 standard; Protein: 594 AA.

AC ABR75753;

XX 24-JUN-2002 (first entry)

DE Human pancreas GP354.

XX Human: GP354; immunoglobulin; pancreas; central nervous system;

KW diagnosis; gene therapy; pancreatitis; inflammation; tumour; cancer;

KW autoimmune disease; Alzheimer's disease; Parkinson's disease;

KW senile dementia; migraine; epilepsy; neurasthenia; neuropathy;

KW neural degeneration; antiinflammatory; cytostatic; nootropic;  
 KW immunosuppressive; antiparkinsonian; neuroprotective; antimigraine;  
 KW anticonvulsant.  
 OS Homo sapiens.  
 XX  
 XX  
 FT Key Location/Qualifiers  
 FT Peptide 1..18  
 FT Protein /label= Signal\_peptide  
 FT 19..594  
 XX /label= Mature\_protein  
 PN MO200198360-A2.  
 XX  
 PD 27-DEC-2001.  
 XX  
 XX 22-JUN-2001; 2001WO-US19904.  
 XX  
 XX 22-JUN-2000; 2000US-213611P.  
 XX  
 XX (BIOJ ) BIOGEN INC.  
 PA (CARU/) CARULI J P.  
 PA (LUKA/) LUKASHIN A V.  
 PA (KILB/) KILBURN D R.  
 PA (SUNC/) SUN C.  
 XX  
 PI Carulli JP, Lukashin AV, Kilburn DR, Sun C;  
 XX  
 DR WPI: 2002-329171/36.  
 DR N-PSDB; ABL3877.  
 XX  
 PT Novel nucleic acid sequence encoding a member of immunoglobulin  
 PT superfamily, designated GP354, useful for the treatment of Alzheimer's  
 PT disease, Parkinson's disease, senile dementia, migraine and epilepsy -  
 XX  
 PS Claim 17; Fig 8; 163pp; English.  
 XX  
 CC The present sequence is the protein sequence of human pancreatic  
 CC GP354, a novel member of the immunoglobulin superfamily. GP354 is  
 CC a pancreas-enriched integral membrane protein, which is also  
 CC detected at low levels in central nervous system (CNS) tissue. The  
 CC protein structure and tissue distribution indicate a role for GP354  
 CC in cell-cell recognition, binding, signalling and adhesion events  
 CC in the pancreas and CNS. The invention provides GP354 polypeptides  
 CC and gp354 polynucleotides, as well as vectors, host cells,  
 CC compositions comprising a gp354 nucleic acid or GP354 polypeptide  
 CC are used in the treatment of pancreatic injury and abnormal or  
 CC disease conditions that relate to the pancreas, such as acute or  
 CC chronic pancreatitis, pancreatic inflammation, pancreatic necrosis,  
 CC exocrine insufficiency, pancreatic endocrine and hormonal imbalance,  
 CC pancreatic tumours and associated cancers, and autoimmune disorders,  
 CC which affect the pancreas. They are also used in the treatment of  
 CC an injury to the CNS and abnormal or disease conditions that relate  
 CC to the CNS, including Alzheimer's disease, Parkinson's disease,  
 CC senile dementia, migraine, epilepsy, neuritis, neurasthenia,  
 CC neuropathy, neural degeneration and neural tumours (all claimed).  
 XX  
 SQ Sequence 594 AA;  
 QY  
 Query Match 6.6%; Score 136; DB 23; Length 594;  
 Best Local Similarity 23.8%; Pred. NO. 0.011;  
 Matches 55; Conservative 40; Mismatches 106; Indels 30; Gaps 10;  
 QY 3 LVYFLHSGSGGMEVIEGPONATVILKSGQARFNCVSGKLIIMWALSDMVVLSVPRMEPI 62  
 DB 10 LFCFGRGAPSPHFLQOEPEDVILLGEPEARLPCALGAYWGLVQWTKSGIALGQR----- 64  
 QY 63 ITNDRFTSQRYDGGNFTS---EMIIHNVPSDSGNIRCSLQNSRLHG-SAYLTIV----- 113  
 DB 65 ---DLPGMSRYWISGNANAGOHDLHTRPELEDEASYECCQATGAGLRSPAPOLHVLVPPPE 121  
 QY 114 --QVNGELFIPBSVNLVAENBPCEVTCLPSHWR-LPDISW-ELGLLVSHSY--FVPE 167

DB 122 APQVLGG---PSYSIVA--GVFANLTCNRSGDARPTPELWFRDGVLLDGATFHQTLIKE 176  
 QY 168 --PSDLOSAVSIILATPQSNSTLTCVATWKSILKARKSATVNLTVIRCPQDT 216  
 DB 177 GTPGSVESTLTLTPESHDDGATFVCARNSQALPTGRDITATLSIQYPPVE 227

Search completed: April 28, 2003, 18:14:28  
 Job time : 43.0676 secs



Query Match 81.0%; Score 1692; DB 4; Length 315.  
 Best Local Similarity 99.7%; Pred. No. 3.6e-148;  
 Matches 314; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

14 SSGNVEIVGPNARVYKLSQARFNCYVSGQKLMALSDMVYLSVRPMEPIITNDRT 73  
 1 SSGNVEIVGPNARVYKLSQARFNCYVSGQKLMALSDMVYLSVRPMEPIITNDRT 60  
 74 SQRDQGNFTSEMIHNPSPDSGNINCSLONSRLHGSATLVYQWGLFIPSVNLVA 133  
 61 SQRDQGNFTSEMIHNPSPDSGNINCSLONSRLHGSATLVYQWGLFIPSVNLVA 120  
 134 ENPECEVTCVLPBHWMTLPDISWELGLVSHSSYFVPEPDLQSAVSLALTPQSNCTLT 193  
 121 ENPECEVTCVLPBHWMTLPDISWELGLVSHSSYFVPEPDLQSAVSLALTPQSNCTLT 180  
 194 CVATWKSILKARKSATVNLTVIRCPDPTGGGINTIPGVLSLPSLGSFSLPTWKGVLGLAGT 253  
 181 CVATWKSILKARKSATVNLTVIRCPDPTGGGINTIPGVLSLPSLGSFSLPTWKGVLGLAGT 240  
 254 MLTPPTCTLTTRCCCRRCGCCGCCRCRRCRRKGRFIOFQKSEKTKETKETEES 313  
 241 MLTPPTCTLTTRCCCRRCGCCGCCRCRRCRRKGRFIOFQKSEKTKETKETEES 300  
 314 GNENSGYNSDEQKTT 328  
 301 GNENSGYNSDEQKTT 315

## RESULT 2

09D8G2 PRELIMINARY; PRT: 270 AA.

01-JUN-2001 (TREMBLrel. 17, Created)  
 01-JUN-2001 (TREMBLrel. 17, Last sequence update)  
 01-JUN-2001 (TREMBLrel. 17, Last annotation update)  
 2010003D20R1K protein (RIKEN cDNA 2010003D20 gene).  
 2010003D20R1K.  
 Mus musculus (Mouse).  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 NCBI\_TaxID=10090;  
 [1]  
 SEQUENCE FROM N.A.

STRATIN-C57BL/6J; TISSUE=SMALL INTESTINE;  
 MEDLINE=21085660; PubMed=11217851;  
 Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
 Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,  
 Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamana K. I.,  
 Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,  
 Kadota K., Matsuda H. A., Ashburner M., Batalov S., Casavant T.,  
 Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,  
 Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,  
 Schriml L. M., Staudt F., Suzuki R., Tomita M., Wagner L., Washio T.,  
 Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,  
 Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M. F.,  
 Brownstein M. J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
 Gustincich S., Hill D., Hofmann M., Hume D. A., Kamiya M., Lee N. H.,  
 Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
 Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
 Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,  
 Suzuki H., Toyooka K., Wang K. H., Weitz C., Whitaker C., Wilmink L.,  
 Wyshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohsaki S.,  
 Hayashizaki Y.,  
 "Functional annotation of a full-length mouse cDNA collection.";  
 Nature 409:685-690(2001).

SEQUENCE FROM N.A.

Strausberg R.;

Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.

EMBL: AK008060; BAB25436.1;  
 EMBL: BC004806; AA04806.1;  
 MGP: MGI:1919308; 2010003D20R1K.

InterPro: IPR003599; Ig.  
 InterPro: IPR003006; Ig\_MHC.  
 SMART: SM00409; IG: 1.  
 PROSITE: PS00290; IG\_MHC; UNKNOWN\_1.  
 SO SEQUENCE 270 AA; 29604 MW; A39C273DA950DPE CRC64;

Query Match 27.1%; Score 566.5; DB 11; Length 270.  
 Best Local Similarity 34.6%; Pred. No. 3.3e-44;  
 Matches 131; Conservative 42; Mismatches 71; Indels 135; Gaps 5;

14 SSGNVEIVGPNARVYKLSQARFNCYVSGQKLMALSDMVYLSVRPMEPIITNDRT 73  
 21 SSSYVLIIEGPNQVTVLKDSEAHFNCTVTHGKRLMTLQNVVSLITGGPITNNRT 80  
 74 SQRDQGNFTSEMIHNPSPDSGNINCSLONSRLHGSATLVYQWGLFIPSVNLVA 133  
 81 YASVSTDSFISELHIDVQPSDSGVQCSLONSHGSAFLSVQ----- 125  
 134 ENPECEVTCVLPBHWMTLPDISWELGLVSHSSYFVPEPDLQSAVSLALTPQSNCTLT 193  
 126 ----- 125  
 194 CVATWKSILKARKSATVNLTVIRCPDPTGGGINTIPGVLSLPSLGSFSLPTWKGVLGLAGT 253  
 126 ----- 148  
 254 MLTPPTCTLTTRCCCRRCGCCGCCRCRRCRRKGRFIOFQKSEKTKETKETEES 307  
 149 LLLTLITLVLIIFCC-----CASRREKESTYQNEIRKSAMKRNKADP 193  
 308 ETETESGENSGYNSDEQKTTDASLPPKSCSESPDEQNSCGPPHQRADQPPRASH 367  
 194 ETKIKSKSEKVEYIGSSDEAKAQTALPPKSAEVSLEPKRSSL--PYDELNKHQGPAT 251  
 368 PQAESFNIASPEKVSNTTV 386  
 252 PVSFPIASPOKRVNTLV 270

## RESULT 3

09D9I2 PRELIMINARY; PRT: 168 AA.

01-JUN-2001 (TREMBLrel. 17, Created)  
 01-JUN-2001 (TREMBLrel. 17, Last sequence update)  
 01-JUN-2001 (TREMBLrel. 17, Last annotation update)  
 4931420D14R1K protein.  
 4931420D14R1K.  
 Mus musculus (Mouse).  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 NCBI\_TaxID=10090;  
 [1]  
 SEQUENCE FROM N.A.

STRATIN-C57BL/6J; TISSUE=TESTIS;  
 MEDLINE=21085660; PubMed=11217851;

Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
 Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,  
 Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamana K. I.,  
 Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,  
 Kadota K., Matsuda H. A., Ashburner M., Batalov S., Casavant T.,  
 Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,  
 Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,  
 Schriml L. M., Staudt F., Suzuki R., Tomita M., Wagner L., Washio T.,  
 Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,  
 Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M. F.,  
 Brownstein M. J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
 Gustincich S., Hill D., Hofmann M., Hume D. A., Kamiya M., Lee N. H.,  
 Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
 Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
 Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,  
 Suzuki H., Toyooka K., Wang K. H., Weitz C., Whitaker C., Wilmink L.,  
 Wyshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohsaki S.,



RA Hayashizaki Y.;  
 RT "Functional annotation of a full-length mouse cDNA collection."  
 Nature 409:685-690(2001).  
 DR EMBL; AK006892; BAB24782.1;  
 DR MGD; MG1:1913992; 4931420D14RLK.  
 SQ SEQUENCE 168 AA; 18931 MW; 7A2BD279612A5E94 CRC64;

Query Match 6.8%; Score 141; DB 11; Length 168;  
 Best Local Similarity 32.0%; Pred. No. 3.8e-05;  
 Matches 39; Conservative 20; Mismatches 49; Indels 14; Gaps 6;

QY 260 CTTTTCRCRRCCGCGCNC-CORCCGCCRRKRGFR---TQPKSKSEKTKNETETESG 314  
 DB 55 CTSISRSCCCCRRCRC-CCHCCRCNC-CCSRSRFRSRRTLTKFQTEKGEGLRRIRRO 111  
 QY 315 NENGVNSDEQKTTDTASLPKSCSESSDPEQRNSSCGPPHQAADQPPRPASHQASPNL 374  
 DB 112 LTRQLELIERP-PTMALEPSEITVAFFSKHNAVSDP---EEVPPCLSDPPPPNDL 165  
 QY 375 AS 376  
 DB 166 AS 167

RESULT 4  
 ID 092626 PRELIMINARY; PRT; 1496 AA.

AC 092626;  
 DT 01-FEB-1997 (TReMBLrel. 02, Created)  
 DT 01-FEB-1997 (TReMBLrel. 02, Last sequence update)  
 DT 01-JUN-2002 (TReMBLrel. 21, Last annotation update)  
 DE MYELOBLAST KIAA0230 (Fragment).  
 GN KIAA0230.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=bone marrow;  
 RX MEDLINE=97191544; PubMed=9039502;  
 RA Nagase T., Seki N., Ishikawa K., Ohira M., Kawabayashi Y., Ohara O.,  
 Tanaka A., Kotani H., Miyajima N., Nomura N.;  
 RT "Prediction of the coding sequences of unidentified human genes. VI.  
 The coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by  
 RT analysis of cDNA clones from cell line KG-1 and brain."  
 RT DNA Res. 3:321-329(1996).  
 RL [2]  
 RN SEQUENCE FROM N.A.  
 RP TISSUE=MELANOMA;  
 RX MEDLINE=95048383; PubMed=7959781;  
 RA Weller S.R., Taylor S.M., Deans R.J., Kan-Mitchell J., Mitchell M.S.,  
 Trent J.M.;  
 RT "Assignment of a human melanoma associated gene MG50 (D25448) to  
 RT chromosome 2p25.3 by fluorescence in situ hybridization."  
 RL Genomics 22:243-244(1994).  
 RN [3]  
 RN SEQUENCE FROM N.A.  
 RP TISSUE=MELANOMA;  
 RA Mitchell M.S., Kan-Mitchell J., Miney B., Edman C., Deans R.J.;  
 RT "Identification of a novel melanoma gene (MG50) - likely the gene for  
 RT IL-1 receptor antagonist - which encodes epitopes recognized by human  
 RT cytolytic T lymphocytes."  
 RT Submitted (Oct-1999) to the EMBL/GenBank/DBJ databases.  
 RL EMBL; D86983; BA113219.1;  
 DR EMBL; AF200346; AAF06354.1;  
 DR HSSP; P05164; ICXP.  
 DR InterPro: IPR002007; Antim\_peroxidase.  
 DR InterPro: IPR003598; Iq\_c2.  
 DR InterPro: IPR003006; Iq\_MHC.  
 DR InterPro: IPR001611; LRR.  
 DR InterPro: IPR000483; LRR\_Cterm.  
 DR InterPro: IPR000372; LRR\_Nterm.

DR InterPro: IPR003591; LRR\_Typ.  
 DR InterPro: IPR001007; VWF\_C.  
 DR Pfam: PF003098; An\_peroxidase; 1.  
 DR Pfam: PF00047; Iq; 4.  
 DR Pfam: PF00560; LRR; 5.  
 DR Pfam: PF01463; LRRCT; 1.  
 DR Pfam: PF00093; VWC; 1.  
 DR PRINTS; PR00457; ANPEROXIDASE.  
 DR SMART; SM00408; IGC2; 4.  
 DR SMART; SM00082; LRRCT; 1.  
 DR SMART; SM00013; LRRNT; 1.  
 DR SMART; SM00369; LRR\_Typ; 4.  
 DR SMART; SM00214; VWC; 1.  
 DR PROSITE; PS01208; VWF; 1.  
 DR Immunoglobulin domain.  
 KW NON\_TER  
 FT SEQUENCE 1496 AA; 167209 MW; E9B9A7069B1ABFF CRC64;  
 SQ  
 Query Match 6.6%; Score 138; DB 4; Length 1496;  
 Best Local Similarity 25.1%; Pred. No. 0.0013;  
 Matches 78; Conservative 38; Mismatches 127; Indels 68; Gaps 17;

QY 2 VAGAMENRDP---GSGSGNEVTEGPQNAFVKGSGQARENCTVS-QGKLIWALSDMV 56  
 DB 339 VAGEKTOEVTLRFFGSPARPTVQPQNTVEVLVGESVTECSATGHPPRISMTRGDT 398  
 QY 57 VLSVAPMEPIITNDRTSQRDQCGNFTSEKIHNPSPDSNGRSLONS--RLHGSAY 114  
 DB 399 PLPVPBRVNITPS-----GG-----LYIQNVQSGSGEYACSAIINNDSVATAF 443  
 QY 115 LTVQVMEGLFIPSNLYVAENE---PCEVYCLPSHTWLPDISW-ELGLVSHSSYTY 169  
 DB 444 IIVQALPQFTYPPQRRVIEGQYDFQCEAKGNP-----PVLAMTGGQSLSVDRRHV 498  
 QY 170 PEPDLSQASVIALTPQSNGLTFCVATWKSARKKATVNLV-----LRCPDRT- 220  
 DB 499 LSSGLTR--ISGVALHDC--QGYECOAV--NIISQKVAVLTQPPRYTPVFPASIPBDT 552  
 QY 221 ---GGGGINPGLVSLSPISGSLP--TWGKVLGI--AGTMLLPPTCTLT----- 264  
 DB 553 VEVGANVQLP-----CSSGGEPEPATYNNKQGVQTEGKRHISPEGLTINDVPADAG 607  
 QY 265 RCCCCRRRCRC 275  
 DB 608 RYCVARNITG 618

RESULT 5  
 ID 09DAK2 PRELIMINARY; PRT; 173 AA.

AC 09DAK2;  
 DT 01-JUN-2001 (TReMBLrel. 17, Created)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)  
 DE 4931420D14RLK protein.  
 GN 4931420D14RLK.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RN SEQUENCE FROM N.A.  
 RP STRAIN=C57BL/6J; TISSUE=TESTIS;  
 RC MEDLINE=21085660; PubMed=11217851;  
 RX Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
 Arikawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,  
 Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,  
 Saito T., Okazaki Y., Gojobori T., Bono H., Kasuawa T., Saito R.,  
 Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
 Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,  
 Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,  
 Schiml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,  
 Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barash G.,

	Query Match	6.5%;	Score 136.5;	DB 11;	Length 173;
	Best Local Similarity	31.5%;	Pred. No. 0.0001;	Mismatches 40;	Conservative 16;
OY	260 CTTLRCCCCRRRCGCNC-CCRCGFCORRKRGRIOFOKSKSEKYNETESGENNS	318	:	: :	:
Dd	55 CSLSRSOCCCRKC-CICRCRC--CCSRFRFRRTLLRVADPKFG-IITEGEGL	105	:	:	:
OY	319 GYNSEDQKT-----TASLPKSCSSDEQNSSCGEPHNRADQRPREASPQ	365	:	:	:
Dd	110 QRRIRQLRSOLELIEPEPMALPSETIYAFFSHKNANSDP---EEVPCLDSDF	165	:	:	:
OY	370 ASPNLAS	376	:	:	:
Dd	166 PNDGLAS	172	:	:	:

RESULT 6	
ID	063155
AC	063155; PRELIMINARY; PRT; 1445 AA.
DT	01-NOV-1996 (TEMBLrel. 01, Created)
DT	01-JAN-1998 (TEMBLrel. 05, Last sequence update)
DT	01-DEC-2001 (TEMBLrel. 19, Last annotation update)
DE	Colorectal tumor suppressor.
GN	DC.
OS	Rattus norvegicus (Rat).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Rattus.
OX	NCBI_TaxID=10116;
RN	[1]
RP	SEQUENCE FROM N.A.
RX	MEDLINE=97015074; PubMed=8861902;
RA	Keino-Masu K., Masu M., Hinck L., Leonardo E.D., Chan S.S.Y.,
RA	Culotti J.G., Tessier-Lavigne M.;
RT	"Deleted in Colorectal Cancer (DCC) encodes a netrin receptor.";
RL	Cell 87:175-185(1996).
RP	[2]
RX	SEQUENCE OF 387-420 FROM N.A.
RA	MEDLINE=90100559; PubMed=2294591;
RA	Featon E.R., Cho K.R., Nigro J.M., Kern S.E., Simons J.W.,
RA	Ruppert J.M., Hamilton S.R., Preisinger A.C., Thomas G., Kinzler K.W.,
RT	Vogelstein B.;
RT	"Identification of a chromosome 18q gene that is altered in colorectal
RL	cancers.";
RL	Science 247:49-56(1990).
DR	EMBL; U68725; AAB41099.1; -
DR	EMBL; M32291; AAA41086.1; -
DR	HSSP; P56276; ITK
DR	InterPro; IPR003962; FNII_repeat.
DR	InterPro; IPR003961; FN_III.
DR	InterPro; IPR003598; IG_c2.
DR	InterPro; IPR003600; IG_1like.
DR	InterPro; IPR003006; IG_MHC.
DR	Pfam; PF00041; fn3; 6.
DR	Pfam; PF00047; Ig_4.
DR	PRINTS; PR00014; ENTPEPIL1.
DR	SMART; SM00060; FN3; 6.

```

QY 9 RDPGSGSGNEV-----TEGPQNAVRLKSGARFNCVTSQGM--KLIMW 50
Db 215 RNPASTGTGAEAVRLLSPDGLHRLVFLQRPNSVIAIEGKDAVLECCVS--GYPPRSTW 273
QY 51 ALSDMVLLSVRMEPIITTRDFTSQRYPQGGNFTSEAILHNVPSSGIRNG--SLQNSR 108
Db 274 LRGEVY-----QLRSKKKSLGG--SNLLISNATDDSGTYTCVATYRKKN 318
QY 109 LHGSAYLTQYVWGELFIYSVALVVAENDEPCEVTCPLPSHTWTLPPDISW--ELGLSHSSXY 167
Db 319 IASASAEITLVYPPMFLNHPNSMLVYAESMDIEFCASVSGRP--VPVYMMKKNDVITPDIY 377
QY 168 FYVPEPSDLSAVSILALPQSGNGTFLVATWAKLTKARKA 207
Db 378 QIVGSGNLR---ILGVYKSDCEGYQGVAAENEGNAQSSRA 413

```

DT DT-NOV-1996 (TReMBLrel. 01, Created)  
 DT 01-NOV-1996 (TReMBLrel. 01, Last sequence update)  
 DT 01-DEC-2001 (TReMBLrel. 19, Last annotation update)  
 DE tumor suppressor.  
 GN XDCCA.  
 OS *Xenopus laevis* (African clawed frog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;  
 OC *Xenopus*; *Xenopus*.  
 OX NCBI\_TaxID=8353;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE-95113183; PubMed-7813784;  
 RA Plicecell W.E., Reale M.A., Candia A.F., Wright C.V., Cho K.R.,  
 RA Fearon E.R.,  
 RT "Expression of a homologue of the deleted in colorectal cancer (DCC)  
 RT gene in the nervous system of developing *Xenopus* embryos.",  
 RL Dev. Biol. 166:654-665(1994).  
 DR EMBL; U10986; AAA70168.1; -  
 DR HSSP; P40189; 1BQ0.  
 DR InterPro: IPR003962; FN1I\_repeat.  
 DR InterPro: IPR003961; FN\_III.  
 DR InterPro: IPR003598; IG\_C2.  
 DR InterPro: IPR003600; IG\_1like.  
 DR InterPro: IPR003006; IG\_MHC.  
 DR Pfam: PF00041; fn3; 6.  
 DR Pfam: PF00047; 197\_4.  
 DR PRINTS; PRO0014; ENTPPELII.  
 DR SMART; SM00060; FN3; 6.  
 DR SMART; SM00408; IGC2; 3.  
 DR SMART; SM00410; IG\_1like; 2.  
 DR Immunoglobulin domain; repeat.  
 QJ SEQUENCE 1427 AA; 156537 Mw. 51991320;c74000 5555.

Query Match	6.48;	Score 134.5;	DB 13;	Length 1427;
Best Local Similarity	25.48;	Pred. No. 0.0025;		
Matches	65;	Conservative	33;	Mismatches 93; Indels 65; Gaps 15;
QY	12	PGSGS-GNEY-----	IGSPONARYLKGSAQFNCVYSGGW-KITMAL	52
			:::   :	:   :
Db	217	PGSARNGNEMLRIISGSLHQVFLQRPNNVAIEGDAVLECAVS-GYPTPIYVNMQ		275
QY	53	SDMAVLSVPRMEPIITNDRFTSQRFQDGCNFTSMIIHNVEPDSQNNIC--SLQNSRLH		110

Db 276 GD-----EPYPIRTR-----KYSVLGG--SNLLISNTDDDACATYCKNKNENTS 320  
 QY 111 GSAVLTVQVGMGLPFPSPNVLVAANEPCVETCL-----PSHWTLPLDISW-ELGLVSHSS 165  
 Db 321 FSADLTWVPPQPLNHPNANLVAAYESMDIEFECVAGSKPS-----PYYKWKNEEVVIPS 375  
 QY 166 YFVEPEBDLOSANVSLTALTPQSNGLTLCVA-----TWKSLKARKSATVNLTVI-RC 216  
 Db 376 YFOIYDGSNLR-----ILGLVKSDEGRYQCLNENAGNIQYAOQLLIPDPAPVSSSLIPSA 431  
 QY 217 PODTGGGINIPGVLS 232  
 Db 432 PRDV-----VPIVLS 442

## RESULT 8

061987 PRELIMINARY; PRT; 871 AA.  
 AC 061987:  
 DT 01-NOV-1996 (TREMBlrel. 01, Created)  
 DT 01-NOV-1996 (TREMBlrel. 01, last sequence update)  
 DT 01-MAR-2002 (TREMBlrel. 20, last annotation update)  
 DE Nsk2 protein precursor.  
 GN MUSK OR NSK2.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
 OX NCBI\_TaxId=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.

RT TISSUE-MYOBLAST;  
 RX MEDLINE-9534951; PubMed-7624144;  
 RA Ganju P., Wallis E., Brennan J., Relth A.D.;  
 RT "Cloning and developmental expression of Nsk2, a novel receptor  
 tyrosine kinase implicated in skeletal myogenesis..";  
 RL Oncogene 11:281-290(1995).  
 CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.

DR EMBL: X86444; CAA60165.1; -  
 DR HSSP: P11362; IFGK.  
 DR MGD: MGI:103581; Mus.  
 DR InterPro: IPR002453; Beta.tubulin.  
 DR InterPro: IPR000719; Euk.pkinase.  
 DR InterPro: IPR000024; Fz\_domain.  
 DR InterPro: IPR003596; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR002290; Ser\_thr.pkinase.  
 DR InterPro: IPR001245; Tyr\_pkinase.

DR Pfam: PF01392; Fz\_1.  
 DR Pfam: PF00047; Ig\_3.  
 DR Pfam: PF00069; Pkinase\_1.  
 DR PRINTS: PR00109; TYRKINASE.  
 DR PRODOM: PD000001; Euk.pkinase; 1.  
 DR SMART: SM00408; IGC2; 2.  
 DR SMART: SM00410; IG\_Like; 1.  
 DR SMART: SM00219; TyKc; 1.  
 DR PROSITE: PS50038; Fz\_1.  
 DR PROSITE: PS00107; PROTEIN\_KINASE\_ATP; 1.  
 DR PROSITE: PS50011; PROTEIN\_KINASE\_DOM; 1.  
 DR PROSITE: PS00108; PROTEIN\_KINASE\_ST; 1.  
 DR PROSITE: PS00109; PROTEIN\_KINASE\_TYR; 1.  
 DR PROSITE: PS00228; TUBULIN\_B\_AUTOREG; 1.  
 DR ATP-binding; Immunoglobulin domain; Serine/threonine-protein kinase;  
 KW Signal; Transferase.

FT SIGNAL 1  
 SQ SEQUENCE 871 AA: 97047 MW; F3C53DC6AF702AB CRC64;

Query Match 6.4%; Score 133.5; DB 11; Length 871;  
 Best Local Similarity 21.6%; Pred. No. 0.0016;  
 Matches 73; Conservative 45; Mismatches 127; Indels 93; Gaps 17;

QY 4 GAMENRDPGSGSGNEVIEGPQNAVNLKGSQARFNCYSGQWK-LIMALLSDMVVLVSRP 62

Db 113 GALDYKMKP-----KTRRPINVKITEGLKAVLPCTMGNPKPSVSWIKGD----- 158.  
 QY 63 MEPIITNDRTSORYDGGNGFTSEMIHNHVPDSGNCISLONSRLHGSAY-----LTV 117  
 Db 159 -NALRENSRIAALE-----SGSLRIHNQKEDACQYRCVAANSL--GTANISKLKLEY 208  
 QY 118 QVMEGLFIPSNVLVAANEPCVETC-----PSHWTLPLDISW-ELGLVSHSSYFVPEP 172  
 Db 209 EVLGLRLAPESHNTVTSFVTLCTEIGLP-----VPTISWLENGNNAVSSGSIQESVD 263  
 QY 173 SDLOSANVSLTALTPQSNGLTLCVAT-----WKSLSKARKSATVNLTVIR-----CPD 219  
 Db 264 RVIDSRLLDFTIKP-----GLYTCIATNKHGEKFTYAKAAATVSAEWSKSQDSQGYCAQY 320  
 QY 220 TGGGINITG-----VLSSPLSGSLP-----TWCKVGLAGLMTLTPCTLT 264  
 Db 321 REGVLMQGPGEKMLVFLPTTSHRDPEDAOELLIRHANML-----KAVSPLCRPPA 373  
 QY 265 RCCCCRRCCGCGN-----CCCRCC-----FCGR 287  
 Db 374 EALLCYHLFLECSPGVPTPMPICREYCLAVKELFCAK 411

## RESULT 9

061988 PRELIMINARY; PRT; 881 AA.  
 AC 061988:  
 DT 01-NOV-1996 (TREMBlrel. 01, Created)  
 DT 01-NOV-1996 (TREMBlrel. 01, last sequence update)  
 DT 01-MAR-2002 (TREMBlrel. 20, last annotation update)  
 DE Nsk2 protein precursor.  
 GN MUSK OR NSK2.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
 OX NCBI\_TaxId=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.

RT TISSUE-MYOBLAST;  
 RX MEDLINE-9534951; PubMed-7624144;  
 RA Ganju P., Wallis E., Brennan J., Relth A.D.;  
 RT "Cloning and developmental expression of Nsk2, a novel receptor  
 tyrosine kinase implicated in skeletal myogenesis..";  
 RL Oncogene 11:281-290(1995).  
 CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.

DR EMBL: X86445; CAA60166.1; -  
 DR HSSP: P11362; IFGK.  
 DR MGD: MGI:103581; Mus.  
 DR InterPro: IPR002453; Beta.tubulin.  
 DR InterPro: IPR000719; Euk.pkinase.  
 DR InterPro: IPR000024; Fz\_domain.  
 DR InterPro: IPR003596; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR002290; Ser\_thr.pkinase.  
 DR InterPro: IPR001245; Tyr\_pkinase.

DR Pfam: PF01392; Fz\_1.  
 DR Pfam: PF00047; Ig\_3.  
 DR Pfam: PF00069; Pkinase\_1.  
 DR PRINTS: PR00109; TYRKINASE.  
 DR PRODOM: PD000001; Euk.pkinase; 1.  
 DR SMART: SM00408; IGC2; 2.  
 DR SMART: SM00410; IG\_Like; 1.  
 DR SMART: SM00219; TyKc; 1.  
 DR PROSITE: PS50038; Fz\_1.  
 DR PROSITE: PS00107; PROTEIN\_KINASE\_ATP; 1.  
 DR PROSITE: PS50011; PROTEIN\_KINASE\_DOM; 1.  
 DR PROSITE: PS00108; PROTEIN\_KINASE\_ST; 1.  
 DR PROSITE: PS00109; PROTEIN\_KINASE\_TYR; 1.  
 DR PROSITE: PS00228; TUBULIN\_B\_AUTOREG; 1.  
 DR ATP-binding; Immunoglobulin domain; Serine/threonine-protein kinase;  
 KW Signal; Transferase.

FT SIGNAL 1 21 POTENTIAL.  
SQ SEQUENCE 881 AA; 98435 MW; EA0D0282EB28ED7 CRC64;

Query Match 6.4%; Score 133.5; DB 11; Length 881;  
Best Local Similarity 21.6%; Pred. No. 0.0016;

Matches 73; Conservative 45; Mismatches 127; Indels 93; Gaps 17;

QY 4 GAMEDNDPPGSGSGNEVEIGEPONARVYKGSQARFNCQYSGWK-LIMMALSDMVYLSVRP 62  
DB 113 GALQVKKMP-----KITRPINVKILLEGKAVLPCTTMGNPKPSVSWIKGD----- 158  
QY 63 MEPIITNDPFTSQRVDGNGFTSEMIINHVPEPSDGNIRCSLQNSRLHGSAY-----LTV 117  
DB 159 -NALRENSRIALP-----SGSLRIHNVOKEDAGQYRCVAKNSL--GTAYSKLVKLEY 208  
QY 118 QVNGELFIPSVNLVVAENPECEVTC-----LPSHWTMLPDISM-ELGLVSHSSYFVPEP 172  
DB 209 EYLGRIILRAPESHNVTFGSEFVTLCTEIGIP-----VPTISWINGNAVSSGSIQESVKD 263  
QY 173 SDLOSANSIALTPQSNGLTCAVAT-----WKSIAKRSATVNLTVIR-----CPQD 219  
DB 264 RVIDSRQLQLEFTRP---GLYTICIAATNKHGEKFTAKAAATVSIAMSKSQKDSQGYCAQY 320  
QY 220 TGGGINIPG-----VLSSILPSLGSFLP-----TWGVGLGLAGTMLTPCTLTIT 264  
DB 321 RGEVCMNAVLAADALVFLNTSYADPEEAQELVHTANNEC-----KVSPVCRPAABAL 373  
QY 265 RCCCCRRRCGCCN-----CCCRCC-----FCCR 287  
DB 374 EALLCYHLFLRCSPGVVPFMPICREYCLAVKELFCAR 411

## RESULT 10

ID 015146 PRELIMINARY; PRT; 869 AA.  
AC 015146;  
DT 01-JAN-1998 (TREMBLrel. 05, Created)  
DT 01-JAN-1998 (TREMBLrel. 05, Last sequence update)  
DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)  
DE Muscle specific tyrosine kinase receptor.  
GN MUSK.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_Taxid=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=96009854; PubMed=7546737;  
RA Valenzuela D.M., Stitt T.N., Distefano P.S., Rojas E., Mattsson K.,  
RA Compton D.L., Nunez L., Park J.S., Stark J.L., Giles D.R., Thomas S.,  
RA Lebeau M.M., Fernald A.A., Copeland N.G., Jenkins N.A., Burden S.J.,  
RA Glass D.J., Yancopoulos G.D.;  
RT "Receptor tyrosine kinase specific for the skeletal muscle lineage:  
RT expression in embryonic muscle, at the neuromuscular junction, and  
RT after injury.";  
RT Neuron 15:573-584(1995);  
RN [2]  
RP SEQUENCE FROM N.A.  
RA Valenzuela D.M., Rojas E., Yancopoulos G.D.;  
RL Submitted (MAY-1997) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AF006464; AAB63044.1; -  
DR HSP; P11362; IFGK.  
DR InterPro: IPR002453; Beta\_tubulin.  
DR InterPro: IPR000719; Euk\_pkinase.  
DR InterPro: IPR000024; F2\_domain.  
DR InterPro: IPR003598; Ig\_c2.  
DR InterPro: IPR003006; Ig\_MHC.  
DR InterPro: IPR001245; Tyr\_pkinase.  
DR Pfam: PF00392; Fz; 1.  
DR Pfam: PF00047; Ig; 3.  
DR Pfam: PF00069; Pkinase; 1.  
DR PRINTS; PR00109; TYRKINASE.  
DR ProDom; PD000001; Euk\_pkinase; 1.

DR SMART; SM00408; IGC2; 3.  
DR SMART; SM00219; TYRK; 1.  
DR PROSITE; PS00038; Fz; 1.  
DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
DR PROSITE; PS00111; PROTEIN\_KINASE\_DOM; 1.  
DR PROSITE; PS00109; PROTEIN\_KINASE\_TYR; 1.  
DR PROSITE; PS00228; TUBULIN\_B\_AUTOREG; 1.  
KW ATP-binding; Immunoglobulin domain; kinase; Receptor; Transferase;  
KW Tyrosine-protein kinase.  
SQ SEQUENCE 869 AA; 97056 MW; 3DDC20E179FA010C CRC64;

Query Match 6.3%; Score 132.5; DB 4; Length 869;  
Best Local Similarity 20.8%; Pred. No. 0.002;  
Matches 89; Conservative 55; Mismatches 178; Indels 105; Gaps 20;

QY 4 GAMEDNDPPGSGSGNEVEIGEPONARVYKGSQARFNCQYSGWK-LIMMALSDMVYLSVRP 62  
DB 113 GALQVKKMP-----KITRPINVKILLEGKAVLPCTTMGNPKPSVSWIKGD----- 158  
QY 63 MEPIITNDPFTSQRVDGNGFTSEMIINHVPEPSDGNIRCSLQNSRLHGSAY-----LTV 121  
DB 159 -SPLRENSRIALP-----SGSLRIHNVOKEDAGQYRCVAKNSL--GTAYSKLVKLEY 208  
QY 122 ELFIPSVNLVVAENP-----CEVTCPLPSHWTMLPDISM-ELGLVSHSSYFVPEP 172  
DB 209 EYFARILRAPESHNVTFGSEFVTLCTATGIP-----VPTTWINGNAVSSGSIQESVKD 263  
QY 173 SDLOSANSIALTPQSNGLTCAVAT-----WKSIAKRSATVNLTVIRCPDQGGG----- 223  
DB 264 RVIDSRQLQLEFTRP---GLYTICIAATNKHGEKFTAKAAATVSIAMSKSQKDNKGYCAQY 320  
QY 224 ---INIPGVLSLPSLGSFL-----PTGKVGGLAGTMLTPCTLTITRCC 267  
DB 321 RGEVCMNAVLAADALVFLNTSYADPEEAQELVHTANNEC-----KVSPVCRPAABAL 373  
QY 268 CCRRCRCCGN-----CCCRCC-----FCCRKRGRFRIQFQKSKKETNKETETE 312  
DB 374 LCNHIFQECSPGVPPPIPICREYCLAVKELFCAR-----WLYMEKTHRGLYRSEHMLL 429  
QY 313 SGNENSGYNDDEKTDITDASLPPKSCSSDPEQRNNSGCPHORADQP---PRPASHP 368  
DB 430 SVPECKSLKSMHWDPTACARLP---HLDYKNKMLKTFPP--MTSKPSVDIPPLPSSS 482  
QY 369 QASFNLA 375  
DB 483 SSSFSVS 489

## RESULT 11

ID 022048 PRELIMINARY; PRT; 164 AA.  
AC 022048;  
DT 01-NOV-1996 (TREMBLrel. 01, Created)  
DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)  
DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)  
DE T0187.8 protein.  
GN T0187.8.  
OS Caenorhabditis elegans.  
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidae;  
OC Rhabditidae; Peloderinae; Caenorhabditis.  
OX NCBI\_Taxid=6239;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Sins M.A.;  
RL Submitted (OCT-1995) to the EMBL/GenBank/DBJ databases.  
DR MEDLINE=99069613; PubMed=9851916;  
RA none;  
RT "Genome sequence of the nematode C.elegans: A platform for  
RT investigating biology.";  
RL Science 282:2012-2018(1998).  
DR EMBL; Z66499; CAA91301.1; -



DE OBCAM alpha 1 isoform.  
 GN OBCAM.  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 NC NCBI\_TaxID=9031;  
 RN (1)  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=BRAIN;  
 RA MEDLINE=2049204; PubMed=11042360;  
 RX Lodge A.P., Howard M.R., McNamee C.J., Moss D.J.;  
 RT "Co-localisation, heterophilic interactions and regulated expression  
 of IgLON family proteins in the chick nervous system.";  
 RL Brain Res. Mol. Brain Res. 82:84-94(2000).  
 DR EMBL: AF292934; AAG01871.1; -  
 DR InterPro: IPR003598; Ig.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR InterPro: IPR003600; Ig\_MHC.  
 DR Pfam: PF00047; Ig\_3.  
 DR SMART: SM00409; IG; 3.  
 DR SMART: SM00408; IGC2; 3.  
 DR SMART: SM00410; IGLike; 2.  
 KW Immunoglobulin domain.  
 SQ SEQUENCE 344 AA; 37531 MW; 37FE6051CBF0E7B4 CRC64;  
 Query Match 6.0%; Score 125; DB 13; Length 344;  
 Best Local Similarity 25.4%; Pred. No. 0.0029;  
 Matches 64; Conservative 33; Mismatches 97; Indels 58; Gaps 14;  
 QY 26 NARYKSGQARPCNTVSGGKLMALSDMYL-----SVRNEPIITNDRTSQRD 78  
 DB 44 NTVKGGSATLRCTVDVRVAV--LNRSTLYAGNDKMSIDNRVILSN---TKQY- 98  
 QY 79 QGNTSEMIIHNPVSDSGNIRCSLQ-----NSRLHGSYLTVQWGEFLFISVNLV 132  
 DB 99 -----SIKIHNDVYDEGPTCSVQTDNHPKTSRVA---LTVQVPPQIVNISSDITV 147  
 QY 133 AENECEYTC-----PSHTWLPDISWELGLVSHSYFVPEPSDQSAVSIATLPQS 188  
 DB 148 NEGSSVTLMCLAFGRPE-----PVTWR---HLGKGGGFSEDEYLE---LIGITRQ 195  
 QY 189 NGTLVCVATWKSLSKARKATVNLV-----TRCQDPTGGGNTINGVL-----SSLPSLGF 239  
 DB 196 SGVEYCSAV--NDVAVPDVRAKYVTVNPPYISNAKNTGASVGGKILQCEASAVPAVEFQ 254  
 QY 240 LPTWGXVGLGIA 251  
 DB 255 --WFKEDTRLA 263  
 RESULT 15  
 Q9DBP0 PRELIMINARY; PRT; 697 AA.  
 AC Q9DBP0;  
 DT 01-JUN-2001 (TREMBlrel. 17, Created)  
 DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)  
 DT 01-JUN-2002 (TREMBlrel. 21, Last annotation update)  
 DE Solute carrier family 34 (sodium phosphate), member 2.  
 GN SLC34A2.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 NC NCBI\_TaxID=10090;  
 RN (1)  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=LUNG;  
 RX MEDLINE=21085660; PubMed=11217851;  
 RA Kawai J., Shingawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
 RA Arakawa T., Hara A., Fukunishi Y., Kono H., Adachi J., Fukuda S.,  
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaoka I.,  
 RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,

RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
 RA Pletschmann W., Gaasterland T., Gissi C., King B., Kochwa H.,  
 RA Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,  
 RA Schriml L.M., Staabli F., Suzuki R., Tomita M., Wagner L., Washio T.,  
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,  
 RA Blake J., Boffelli D., Bojunga N., Carrinci P., de Bonaldo M.F.,  
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
 RA Gustincich S., Hill D., Hoffmann M., Hume D.A., Kamiya M., Lee N.H.,  
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
 RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,  
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whitaker C., Wilming L.,  
 RA Wyshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohsaki S.,  
 RA Hayaishiaki Y.,  
 RT "Functional annotation of a full-length mouse cDNA collection.";  
 RL Nature 409:685-690(2001).  
 DR EMBL: AK004832; BAB23600.1; -  
 DR MGI: 1342284; SLC34a2.  
 DR InterPro: IPR003841; Na\_P1\_cotrans.  
 DR Pfam: PF02690; Na\_P1\_cotrans; 1.  
 DR TIGRfams: TIGR01013; 2a38; 1.  
 SQ SEQUENCE 697 AA; 76244 MW; 2A7B9384857EF16F CRC64;  
 Query Match 6.0%; Score 125; DB 11; Length 697;  
 Best Local Similarity 25.8%; Pred. No. 0.0074;  
 Matches 41; Conservative 12; Mismatches 45; Indels 61; Gaps 8;  
 QY 233 LPSLGFSLPTWGXVGLGAGTMLTPTCTLTIRCCRRRCG-----CNC-CCRCFCG 286  
 DB 593 LPLMWSLKPMDV-----ISLATTC--FQRRCCCCRCVCCVCGKCCRCRSCG 644  
 QY 287 RRRKGFRIQKKSEKTEKTEKTESGNGNSYNDQKTDPTASLPKSCSSDPEOR 346  
 DB 645 R-----DQGE-----EERKED--IPVKAAGADNMA 671  
 QY 347 NSSCGPHORADPPRPAHPQASFNLASPEKVSNTV 385  
 DB 672 SKEC-----DQEGKQVEVLSMAKLSNTTV 696

Search completed: April 28, 2003, 21:07:38  
 Job time : 41.1283 secs

GenCore version 5.1.4.p5.4578  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 28, 2003, 16:24:30 ; Search time 10.3692 Seconds  
(Without alignments)  
1543.990 Million cell updates/sec

Title: US-09-729-264-4

Perfect score: 2088  
Sequence: 1 MVAGAMENRDPGSGSGNEV.....HPQAFNLASPEKVSMTTVV 386

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 112892 seqs, 41476328 residues  
Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 08  
Maximum Match 100%  
Listing first 45 summaries

Database: SwissProt\_40.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	145.5	7.0	404	1 RAGE_HUMAN	Q15109 homo sapien
2	136	6.5	1447	1 DCC_HUMAN	P43146 homo sapien
3	132	6.3	1447	1 DCC_MOUSE	P70211 mus musculu
4	126	6.0	1914	1 KMLS_HUMAN	Q15746 homo sapien
5	125	6.0	337	1 G55A_CHICK	Q98892 gallus gall
6	122	5.8	353	1 CEPD_CHICK	Q90773 gallus gall
7	121	5.8	344	1 NTR1_RAT	Q62718 rattus norv
8	119	5.7	1070	1 PTK7_HUMAN	Q13308 homo sapien
9	114.5	5.5	862	1 CD22_MOUSE	P35329 mus musculu
10	113	5.4	1461	1 NEOL_HUMAN	Q92859 homo sapien
11	112.5	5.4	345	1 OPCM_HUMAN	Q14982 homo sapien
12	112.5	5.4	416	1 RAGE_BOVIN	Q28173 bos taurus
13	111.5	5.3	345	1 OPCM_BOVIN	P11834 bos taurus
14	111.5	5.3	1443	1 NEOL_CHICK	Q90610 gallus gall
15	111	5.3	620	1 SMP_COTJA	Q92154 coturnix co
16	111	5.3	1377	1 NEOL_RAT	P97603 rattus norv
17	110.5	5.3	345	1 OPCM_RAT	P32736 rattus norv
18	110.5	5.2	4393	1 PGBM_HUMAN	P98160 homo sapien
19	109.5	5.2	249	1 CSP_DROME	Q03751 drosophila
20	109.5	5.2	364	1 DMS2_HUMAN	P20138 homo sapien
21	109	5.1	2481	1 DMS2_MOUSE	Q06561 caenorhabdi
22	106.5	5.1	524	1 BUTY_MOUSE	Q62556 mus musculu
23	106	5.0	1092	1 NCAL_XENLA	P36335 xenopus lae
24	104	5.0	319	1 A33_HUMAN	Q99785 homo sapien
25	104	5.0	764	1 ICCR_DROME	Q08180 drosophila
26	103.5	5.0	365	1 CXAR_MOUSE	P97792 mus musculu
27	103.5	5.0	3707	1 PGBM_MOUSE	Q05793 mus musculu
28	102.5	4.9	333	1 AMAL_DROME	P15364 drosophila
29	102.5	4.9	879	1 PRP3_RAT	Q62786 rattus norv
30	102.5	4.9	890	1 TYO3_HUMAN	Q06448 homo sapien
31	102	4.8	365	1 CXAR_HUMAN	P78310 homo sapien
32	100.5	4.7	348	1 KITO_RAT	Q92038 rattus norv
33	99	4.7	359	1 LACH_DROME	Q24372 drosophila

34	99	4.7	830	1 SREC_HUMAN	Q14162 homo sapien
35	98	4.7	261	1 KLB_RAT	P36374 rattus norv
36	98	4.7	873	1 FAS2_DROME	P34082 drosophila
37	98	4.7	1010	1 CONT_CHICK	P14781 gallus gall
38	97.5	4.7	1449	1 VGL2_CYPMT	P33470 porcine tra
39	97.5	4.7	1906	1 KMLS_CHICK	P11799 gallus gall
40	97	4.6	198	1 DUCS_MOUSE	P54101 mus musculu
41	97	4.6	439	1 SYG2_DISOM	P24506 discopyge o
42	96.5	4.6	338	1 LAMP_CHICK	Q98919 gallus gall
43	96.5	4.6	880	1 TYO3_MOUSE	P55144 mus musculu
44	96.5	4.6	880	1 TYO3_RAT	P55146 rattus norv
45	96.5	4.6	1147	1 KMLS_RABIT	P29294 oryctolagus

## ALIGNMENTS

RESULT 1	RAGE_HUMAN	STANDARD:	PTT:	404 AA.
ID	RAGE_HUMAN	Q15279: Q9Y3R3: Q9H2X7:		
AC	01-NOV-1997 (Rel. 35, Created)			
DT	01-NOV-1997 (Rel. 35, Last sequence update)			
DT	15-JUN-2002 (Rel. 41, Last annotation update)			
DE	Advanced glycosylation end product-specific receptor precursor (Receptor for advanced glycosylation end products).			
GN	AGER OR RAGE.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]	SEQUENCE FROM N.A. (ISOFORM 1).		
RP	TISSUE=Lung;			
RC	MEDLINE=92340547; PubMed=1378843;			
RX	Nepper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A.;			
RA	"Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins."			
RT	J. Biol. Chem. 267:14998-15004(1992).			
RL	[2]	SEQUENCE FROM N.A. (ISOFORM 1).		
RN	MEDLINE=95137587; PubMed=7835890;			
RP	Sugaya K., Fukagawa T., Matsumoto K., Mita K., Takahashi E., Ando A., Inoko H., Ikemura T.;			
RA	"Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homology, human counterpart of mouse mammary tumor gene int-3."			
RT	Genomics 23:408-419(1994).			
RL	[3]	SEQUENCE FROM N.A. (ISOFORM 1).		
RN	Rowen L., Dankers C., Baskin D., Faust J., Loretz C., Ahearn M.E., Banta A., Spies T., Hood L.;			
RA	Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.			
RL	[4]	SEQUENCE FROM N.A. (ISOFORM 1), AND VARIANT ARG-100.		
RN	Abelton M.J., Yonekura H., Migita H., Karasawa J., Yamamoto Y., Yamamoto H.;			
RA	"Molecular heterogeneity of the receptor for advanced glycation endproducts."			
RT	Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.			
RL	[5]	SEQUENCE FROM N.A. (ISOFORM 2).		
RN	Malherbe P., Richards J., Galliard H., Thompson A., Diener C., Schuler A., Huber G.;			
RA	"cDNA cloning of a novel secreted isoform of the human Receptor for Advanced Glycation End products (RAGE) and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein."			
RT	Submitted (MAY-1999) to the EMBL/GenBank/DBJ databases.			
RL	[6]	SEQUENCE FROM N.A. (ISOFORM 1).		

CC TISSUE-Lung;  
 RA Strausberg R.;  
 RL Submitted (JAN-2002) to the EMBL/Genbank/DBJ databases.  
 RN [7]  
 RP SEQUENCE OF 1-12 FROM N.A.  
 RA Hudson B.I., Puters T.S.;  
 RT "Novel polymorphisms in the receptor for advanced glycation  
 end products (RAGE) gene";  
 RL Submitted (NOV-1999) to the EMBL/Genbank/DBJ databases.  
 CC -1 FUNCTION: MEDIATES INTERACTIONS OF ADVANCED GLYCOSYLATION END  
 PRODUCTS (AGE). THESE ARE NONENZYMATICALLY GLYCOSYLATED PROTEINS  
 WHICH ACCUMULATE IN VASCULAR TISSUE IN AGING AND AT AN ACCELERATED  
 RATE IN DIABETES.  
 CC -1 SUBCELLULAR LOCATION: Type I membrane protein (isoform 1).  
 CC -1 Secreted (isoform 2).  
 CC -1 ALTERNATIVE PRODUCTS: 2 ISOFORMS; 1 (SHOWN HERE) AND 2/RAGESEC;  
 CC ARE PRODUCED BY ALTERNATIVE SPLICING.  
 CC -1 TISSUE SPECIFICITY: ENDOTHELIAL CELLS.  
 CC -1 SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.  
 CC -1 SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.  
 CC -1 SIMILARITY: CONTAINS 2 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation  
 the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; M91211; AAA03574.1; -;  
 DR EMBL; D28769; BAA05958.1; -;  
 DR EMBL; U89336; AAB47491.1; -;  
 DR EMBL; AB036432; BAA89369.1; -;  
 DR EMBL; AJ133822; CAB43108.1; -;  
 DR EMBL; BC020669; AAR20669.1; -;  
 DR EMBL; AF208289; AAG35728.1; -;  
 DR Genbank; HGNC:320; AGER.  
 DR MIM; 600214; -;  
 DR InterPro; IPR003006; Ig\_MHC.  
 DR InterPro; IPR003598; Ig\_C2.  
 DR InterPro; IPR003600; Ig\_Like.  
 DR Pfam; PF00047; Ig\_2.  
 DR SMART; SM00410; Ig\_Like; 1.  
 DR SMART; SM00408; IgC2; 1.  
 DR PROSITE; PS00290; Ig\_MHC; 1.  
 KW Immunoglobulin domain; Glycoprotein; Transmembrane; Repeat; Signal;  
 KW Alternative splicing; Polymorphism.  
 FT SIGNAL 1 22  
 FT CHAIN 23 404  
 FT DOMAIN 23 342  
 FT TRANSMEM 343 363  
 FT DOMAIN 364 404  
 FT DOMAIN 31 106  
 FT DOMAIN 137 215  
 FT DOMAIN 252 308  
 FT DISULFID 38 99  
 FT DISULFID 144 208  
 FT DISULFID 259 301  
 FT CARBOHYD 25 25  
 FT CARBOHYD 81 81  
 FT DOMAIN 380 384  
 FT VARSPLIC 54 67  
 FT VARSPLIC 275 404  
 FT VARIANT 100 100  
 FT CONFLICT 1 1  
 M -> G (IN REF. 1).  
 M -> G (IN REF. 1).

SO SEQUENCE 404 AA: 42802 MW: 0D584C436C30CCE7 CRC64;  
 Query Match 7.0%; Score 145.5; DB 1; Length 404;  
 Best Local Similarity 23.5%; Pred. No. 0.00018;  
 Matches 77; Conservative 34; Mismatches 94; Indels 123; Gaps 15;  
 QY 64 EPIITNDRETS-----ORYDQGNFT--SEMIINHVPSDSGNIR-----CSLONSRLHGS 112  
 DB 162 KPLVPEKESVYKEQTRRHPRPETGLTLOSLM---VTPARQGDPRPFCSPGCLPRHR 218  
 QY 113 ALTYQVMELFIP-----SVNLVAENEP-----CEVTCLPSPHTWLPDIS 154  
 DB 219 ALRTAPIQPRWEVPLPELVOLV---EPGCAVAPGVTILCEVPAQS-----PQH 270  
 QY 155 WELGLVSHSSYFVPEPSDQSAVSIATLPQSNGLTCVATMKSLAKKATVNLTY 214  
 DB 271 WKMD-----GVPLPLPSPVLLPEIQPODQGYSCVAHSHSGPESRAVVISII 321  
 QY 215 RCPDPTGGGINIPGVLSPLGFSLPYWGKVGIGLAGTMLT-----PCTLTIRCC 267  
 DB 322 E-PGEEG-----PTAGSVGGSGGLTALALGILGGLGTAALLIGYI 361  
 QY 268 CCRRCGCCNCRCRCRCRRKRGFRIOPKKSEKKT--NKETPESGNSGYNSEDO 325  
 DB 362 LMQRR-----ORGERKAPENDEEBERAEIN----- 389  
 QY 326 KTTDTASLPKSCSSDPDEQRNSCGPP 353  
 DB 390 -----QSEPEAGESESTGTP 404  
 RESULT 2  
 DCC\_HUMAN STANDARD; PRT; 1447 AA.  
 ID DCC\_HUMAN  
 AC P43146;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Tumor suppressor protein DCC precursor (Colorectal cancer suppressor).  
 GN DCC.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=95011532; PubMed=7926722;  
 RA Hedrick L., Cho K.R., Fearon E.R., Wu T.-C., Kinzler K.W.,  
 RT Vogelstein B.;  
 RT "The DCC gene product in cellular differentiation and colorectal  
 tumorigenesis.";  
 RL Genes Dev. 8:1174-1183(1994).  
 RN [2]  
 RP SEQUENCE OF 1-750 FROM N.A.  
 RX MEDLINE=90100559; PubMed=2294591;  
 RA Fearon E.R., Cho K.R., Nigro J.M., Kern S.E., Ruppert J.M.,  
 RA Ruppert J.M., Hamilton S.R., Preisinger A.C., Thomas G., Kinzler K.W.,  
 RT Vogelstein B.;  
 RT "Identification of a chromosome 18q gene that is altered in  
 colorectal cancers.";  
 RL Science 247:49-56(1990).  
 RN [3]  
 RP SEQUENCE OF 107-472 FROM N.A. (SCRAMBELD EXONS).  
 RX MEDLINE=91121517; PubMed=1991322;  
 RA Nigro J.M., Cho K.R., Fearon E.R., Kern S.E., Ruppert J.M.,  
 RA Oliner J.D., Kinzler K.W., Vogelstein B.;  
 RT "Scrambled exons.";  
 RL Cell 64:607-613(1991).  
 RN [4]  
 RP GENE STRUCTURE, AND VARIANTS CARCINOMA HIS-1375.  
 RX MEDLINE=94245241; PubMed=8188295;  
 RA Cho K.R., Oliner J.D., Simons J.W., Hedrick L., Fearon E.R.,  
 RA Preisinger A.C., Hedge P., Silverman G.A., Vogelstein B.;





RC SPRIN-BALB/c; TISSUE-Brain;  
 RL Cooper H.M.;  
 CC Submitted (Jun-1996) to the EMBL/GenBank/DBJ databases.  
 CC -1- FUNCTION: IMPLICATED AS A TUMOR SUPPRESSOR GENE.  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.  
 CC -1- ALTERNATIVE PRODUCTS: 2 isoforms; A (shown here) and B; are  
 CC produced by alternative splicing.  
 CC -1- TISSUE SPECIFICITY: IN THE EMBRYO, EXPRESSED AT HIGH LEVELS IN THE  
 CC DEVELOPING BRAIN AND NEURAL TUBE. IN ADULT, HIGHLY EXPRESSED IN  
 CC BRAIN WITH VERY LOW LEVELS FOUND IN TESTIS, HEART AND THYMUS.  
 CC ISOFORM C IS EXPRESSED ONLY IN THE EMBRYO.  
 CC -1- DEVELOPMENTAL STAGE: LOW LEVELS IN EARLY GESTATION. HIGHEST LEVELS  
 CC EXPRESSED DURING MID GESTATION. LEVELS DECREASE IN LATE GESTATION  
 CC AND REMAIN AT THIS LEVEL IN THE ADULT.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. DCC  
 CC SUPERFAMILY.  
 CC -1- SIMILARITY: CONTAINS 4 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -1- SIMILARITY: CONTAINS 6 FIBRONECTIN TYPE III-LIKE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC DR EMBL; X85788; CA59786.1; -  
 DR HSSP; P56276; 1TLK.  
 DR MGD; MGI:94869; DCC.  
 DR Interpro: IPR003961; FN\_III.  
 DR Interpro: IPR003962; FNIII\_repeat.  
 DR Interpro: IPR003006; Ig\_MHC.  
 DR Interpro: IPR003598; Ig\_C2.  
 DR Interpro: IPR003600; Ig\_IIk.  
 DR Pfam: PF00041; fn3; 6.  
 DR Pfam: PF00047; Ig; 4.  
 DR PRINTS: PRO0014; PNTYPEIII.  
 DR SMART; SM00060; FN3; 6.  
 DR SMART; SM00410; Ig\_IIk; 2.  
 DR SMART; SM00408; IgC2; 3.  
 KW Glycoprotein; Immunoglobulin domain; Transmembrane; Signal;  
 KW Repeat; Anti-oncogene; Alternative initiation; Alternative splicing.  
 FT SIGNAL 1 25  
 FT CHAIN 26 1447  
 FT INIT\_MET 85 1447  
 FT DOMAIN 85 85  
 FT TRANSMEM 26 1097  
 FT DOMAIN 1098 1122  
 FT DOMAIN 1123 1447  
 FT DOMAIN 54 124  
 FT DOMAIN 154 219  
 FT DOMAIN 254 317  
 FT DOMAIN 345 407  
 FT DOMAIN 426 522  
 FT DOMAIN 525 618  
 FT DOMAIN 619 716  
 FT DOMAIN 722 816  
 FT DOMAIN 840 940  
 FT DOMAIN 941 1042  
 FT DISULFID 61 117  
 FT DISULFID 161 117  
 FT DISULFID 261 310  
 FT DISULFID 352 400  
 FT CARBOHYD 60 94  
 FT CARBOHYD 94 94  
 FT CARBOHYD 299 299  
 FT CARBOHYD 318 318  
 FT CARBOHYD 478 478  
 FT CARBOHYD 628 628  
 FT CARBOHYD 702 702  
 FT VARSPLIC 819 838

SQL SEQUENCE 1447 AA; 158298 MW; 0D1F1097C22D5B9F CRC64;  
 Query Match 6.3%; Score 132; DB 1; Length 1447;  
 Best Local Similarity 25.3%; Pred. No. 0.011;  
 Matches 56; Conservative 31; Mismatches 91; Indels 42; Gaps 9;  
 QY 9 RPPPSGSGNEV-----IEGPOAARVLSQSAFNCFTVQGM--KLIMW 50  
 DB 215 RNPASIRIGNEAEVALLDPSGLHQVLFQRPNSVIAIEGKDAVECCS-GTPPSFTW 273  
 QY 51 ALSDWVTVSRMEIITNDFTSQRDQSGNFTSEMIINVEPSDSGNIRC--SLQNSR 108  
 DB 274 LRGEVIT-----QLRSKYSLLGG--SNLLISNVTDSDSGTYTCVYTKNEN 318  
 QY 109 LHGSAYLTVOYMGELFIPSVNLVVAENPECEVCLPSHWLWLPDISM-ELGLVHSSTY 167  
 DB 319 ISASAEFLVLPWPEFLNHPNSLVAYEEMDEFECAVNSGR-VFTVMKNGDVVIPSDFE 377  
 QY 168 FVPEPSDQSAVSTLALTPOSGTGLTCVATWKSLSKARKSA 207  
 DB 378 QIVGGSNDR---TLGVYKSDGEFYQCVAEENAGNAOSSA 413  
 RESULT 4  
 KMLS\_HUMAN STANDARD; PRT: 1914 AA.  
 AC 015746; Q14844; Q16794; Q95796; Q95797; Q95798; Q95799; Q9UBG5;  
 AC Q9UT99;  
 DT 15-JUL-1998 (Rel. 36, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Myosin light chain kinase, smooth muscle and non-muscle isozymes  
 DE (EC 2.7.1.117) (MCK) [contains: Telokin (kinase related protein)  
 DE (KRP)].  
 GN MYLK OR MLCK.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
 OX NCBI\_TaxId=9606;  
 RN 1  
 RP SEQUENCE FROM N.A. (ISOFORM 1).  
 RC TISSUE=umbilical vein endothelial cells;  
 RX MEDLINE=97304466; PubMed=9160829;  
 RA Garcia J.G.N., Lazar V.L., Gilbert-McClain L.I., Gallagher P.J.,  
 RA Verin A.D.;  
 RA "Myosin light chain kinase in endothelium: molecular cloning and  
 RA regulation.";  
 RA Am. J. Respir. Cell Mol. Biol. 16:489-494(1997).  
 RN 12  
 RP REVISIONS.  
 RA Birukov K.G., Garcia J.G.N.;  
 RA Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.  
 RN 13  
 RP SEQUENCE FROM N.A. (ISOFORMS 2; 3A; 3B AND 4).  
 RC TISSUE=umbilical vein;  
 RX MEDLINE=99216419; PubMed=10198165;  
 RA Lazar V.L., Garcia J.G.N.;  
 RA "A single human myosin light chain kinase gene (MLCK; MYLK).";  
 RA Genomics 57:256-267(1999).  
 RN 14  
 RP REVISIONS (ISOFORM 2).  
 RA Birukov K.G., Garcia J.G.N.;  
 RA Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.  
 RN 15  
 RP SEQUENCE OF 923-1914 FROM N.A.  
 RC TISSUE=Hippocampus;  
 RX MEDLINE=96121365; PubMed=8575746;  
 RA Potier M.-C., Chelot E., Pekarsky Y., Gardiner K., Rossier J.,  
 RA Turnell W.G.;  
 RA "The human myosin light chain kinase (MLCK) from hippocampus:  
 RA cloning, sequencing, expression, and localization to 3gen-921.";  
 RA Genomics 29:362-570(1995).  
 RN 16



RESULT 5			
555A_CHICK			
ID	555A_CHICK	STANDARD:	PRT; 337 AA.
AC	096892;		
DT	01-NOV-1997 (Rel. 35, Created)		
DT	30-MAY-2000 (Rel. 39, Last sequence update)		
DT	15-JUN-2002 (Rel. 41, Last annotation update)		
DE	Neurite inhibitor GP55-A precursor (OBSCAM protein gamma isoform).		
OS	Gallus gallus (chicken).		
CC	Eukaryota; Metacoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
CC	Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;		
CC	Gallus.		
OX	NCBI_TaxID=9031;		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RC	TISSUE=Brain;		
RA	Lodge A.P., Kim D.-S., Howard M.R., McNamee C.J., Smith N., Moss D.J.;		
RT	"Cloning of CEPU-s, a secreted isoform of CEPU-1, and OBSCAM cDNAs from		
RT	chick: structural diversity of Igron family proteins."		
RL	Submitted (APR-1999) to the EMBL/genbank/DDJ databases.		
RL	[2]		
RP	SEQUENCE OF 64-337 FROM N.A., AND PARTIAL SEQUENCE.		
RC	TISSUE=Brain;		
RX	MEDLINE=97157768; PubMed=9004047;		
RA	Wilson D.J.A., Kim D.-S., Clarke G.A., Marshall-Clarke S., Moss D.J.;		
RT	A family of glycoproteins (GP55), which inhibit neurite outgrowth,		
RT	are members of the Ig superfamily and are related to OBSCAM,		
RT	neurotrophin, LAMP and CEPU-1."		
RL	J. Cell Sci. 109:3129-3138(1996)		

OY	26	NARVLKSOARENCYTYSOGCKHKLMAALSDMYL-----SVREMEBITNDRTFSQRYD	78
Dd	37	NVTROESATELRCITDYDDRVRVAV--LNKSTILYAANDKMSIDNRVILSN---TKTY-	91
OY	79	QGWFTESEMIITHWPEPSDSGNIRCSIQ-----NSRLGSAIYLTVOMBELTIPSVNLV	137
Dd	92	-----SIIHWDVDYDGPTCTSGVQINDNHPKTSRYH----LTIVOPQIVNISSDITV	144
OY	133	AENPCEVTOL-----PSHTWLDPDISWELGLVSHSYFVPPEPSDLOSASVIALLTPQS	186
Dd	141	NESSVTLMLCLANGRE-----PYTWK--HLGKGQGGVSDEYLE---ITGITREQ	186
OY	189	NGILTCAVMTKSILAKRSATVNLV-----LRCPQDTGGGINIPGV-----SLPLSGS	239
Dd	189	SGETECSAV-NDVAVPDYRKVAVTVNNPPYISNAKNKGASVGKGTLOCEASAVFAVEEQ	247
OY	240	LPTMGKYGIGLA	251
Dd	248	--WFKEDTRLA	256

RESULT 6  
CPU\_CHICK  
AC Q90773; STANDARD; PRT; 353 AA.

DT 01-NOV-1997 (rel. 35, Created)  
DT 01-NOV-1997 (rel. 35, Last sequence update)  
DT 15-JUN-2002 (rel. 41, Last annotation update)











Best Local Similarity 23.1%; Pred. No. 0.37; Indels 72; Gaps 12;  
Matches 65; Conservative 34; Mismatches 110;

18 NEVEEGPQNAVL-----KGSARPCNVSGMKLIMALSDMVLVSREPEITN----- 69  
Db 196 DRVILKPSGLMVISNATEGGDGLYRCVESGGP---KYDEVELKVLPPPEVISLVL 252  
QY 70 -----DRETSORYD--OGNFTSEMILH 90  
Db 253 KQSPPLVAVIGQDVLPCVAGSLPTPIKMKKNEALDTSESLVLLAGS-----LEIS 308  
QY 91 NVEPSDGNIRCSLQNSR--LHGSAYLVQVMGLFIPSNVLAENE-----PCEVTCPL 144  
Db 309 DVEEDDAGTYFCIDNGENETIEAQAELTVQAQPEFLKQPTNIYAHESMDIVFECEVTKRP 368  
QY 145 SHWTLPLDISW-ELGLLVSHSSYFVPEPSDQSAVSLIATLPQSNGLTLCVATWKSILKA 203  
Db 369 T-----PTVKKVKNQMDMVPISDYFKIVEHNLQ-----VLGLVKSDDEGFYCCIAENDVGNA 419  
QY 204 RKSATVNLTVIRCPODTGGGINIP-GVLSLPSLGSFLPW 243  
Db 420 QAGAQI-ILLEHAPATGTPLPSAPRDVVASLSTREIKLTW 459  
RESULT 11  
OPCM HUMAN STANDARD: PRT: 345 AA.  
AC 01A982;  
DT 01-NOV-1997 (Rel. 35, Created)  
DT 01-NOV-1997 (Rel. 35, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Opioid binding protein/cell adhesion molecule precursor (OBPCAM)  
GN OBPCAM OR OBSCAM.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RF SEQUENCE FROM N.A.  
RC TISSUE=Occipital cortex;  
RX MEDLINE=95237612; PubMed=7721093;  
RA Sharr K.B., Lee N.M.;  
RT "Cloning, sequencing and localization to chromosome 11 of a cDNA  
RT encoding a human opioid-binding cell adhesion molecule (OBPCAM).";  
RL Gene 155:213-217(1995).  
CC -1- FUNCTION: BINDS OPIOIDS IN THE PRESENCE OF ACIDIC LIPIDS. PROBABLY  
CC INVOLVED IN CELL CONTACT.  
CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By  
CC similarity).  
CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGION  
CC SUBFAMILY.  
CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
CC at the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC EMBL: L34774; AAA36387.1; .  
CC Genew: HGNC:8143; OPCML.  
CC MIM: 600632; .  
DR InterPro: IPR003006; IG\_MHC.  
DR InterPro: IPR003598; IG\_C2.  
DR InterPro: IPR003600; IG\_Like.  
DR Pfam: PF00047; Ig\_3.  
DR SMART: SM00410; IG\_Like; 1.  
DR SMART: SM00408; IGC2; 2.  
DR Immunoglobulin domain; Cell adhesion; Glycoprotein; GPI-anchor;  
KW Repeat; Signal.

FT SIGNAL 1 27  
FT CHAIN 28 322  
FT PROPEP 323 345  
FT DOMAIN 50 122  
FT DOMAIN 150 209  
FT DOMAIN 237 303  
FT DISULFD 57 115  
FT DISULFD 157 202  
FT DISULFD 244 296  
FT CARBOHYD 44 44  
FT CARBOHYD 70 70  
FT CARBOHYD 140 140  
FT CARBOHYD 285 285  
FT CARBOHYD 293 293  
FT CARBOHYD 306 306  
FT CARBOHYD 322 322  
SQ SEQUENCE 345 AA; 38007 MM; E7AD17BEA1AA3FE4 CRC64;  
Query Match 5.4%; Score 112.5; DB 1; Length 345;  
Best Local Similarity 24.9%; Pred. No. 0.07; Indels 69; Gaps 16;  
Matches 65; Conservative 32; Mismatches 95;

QY 26 NARVYKGSQARPCNVSGMKLIMALSDMVL-----SVRMEPIITNDRETSORYD 78  
Db 44 NTVYRQGESATLRCTIDRVTRVAM-LNKSITLVAGNDKMSIDRVILVN---TPQY- 98  
QY 79 OGNFTSEMILHNEVEPSDGNIRCSLQ-----NSRLHGSAYLVQVMGLFIPSNVLA 132  
Db 99 -----SIMIONVDYDGGPYTGVQDNHPTKSRVH---LIVQVPOQIMNISDITV 147  
QY 133 AENEPEVTCVCL-----PSHWTLPLDISWELGLLVSHSSYF-----FVEPSDQSAVSLIAT 184  
Db 148 NESSSVTLICLAIGRPE-----PTVTKW-----HLVSKEGGQFVSEBYLE-----ISDI 192  
QY 185 TPQSNGLTLCVATWKSILKARKSATVNLVY-----IRCPQDTGGGINIPGVL-----SSLPS 235  
Db 193 KPDQSGYECSAL-NDVAPDVAKKVIITVNPYISKAKNTGSVQGGIISCENSAVPM 251  
QY 236 LGFSLPTWCK-----VGLGLAG 252  
Db 252 AEFQ---WFKETRIATGIDG 269

RESULT 12  
RAGE BOVIN STANDARD: PRT: 416 AA.  
ID RAGE BOVIN  
AC 028173;  
DT 01-NOV-1997 (Rel. 35, Created)  
DT 01-NOV-1997 (Rel. 35, Last sequence update)  
DT 15-JUN-2002 (Rel. 41, Last annotation update)  
DE Advanced glycosylation end product-specific receptor precursor  
DE (Receptor for advanced glycosylation end products).  
GN AGER OR RAGE.  
OS Bos taurus (Bovine).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
OC Bovidae; Bovinae; Bos.  
OX NCBI\_TaxID=9913;  
RN [1]  
RF SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.  
RP TISSUE=Lung;  
RC MEDLINE=92340547; PubMed=1378843;  
RX Neepser M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C.,  
RA Elliston K., Stern D., Shaw A.;  
RT "Cloning and expression of a cell surface receptor for advanced  
RT glycosylation end products of proteins.";  
RL J. Biol. Chem. 267:14998-15004(1992).  
CC -1- FUNCTION: MEDIATES INTERACTIONS OF ADVANCED GLYCOSYLATION END  
CC PRODUCTS (AGE). THESE ARE NONENZYMATICALLY GLYCOSYLATED PROTEINS  
CC WHICH ACCUMULATE IN VASCULAR TISSUE IN AGING AND AT AN ACCELERATED  
CC RATE IN DIABETES.  
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.





Search completed: April 28, 2003, 18:09:41  
Job time : 14.3692 secs

```
CC NONMYELINATING SCHWANN CELLS AND OLIGODENDROCYTES.
CC -1- DEVELOPMENTAL STAGE: FIRST SYNTHESIZED AT EMBRYONIC DAY 5, IT
CC REMAINS EXPRESSED BY CULTURED SCHWANN CELLS.
CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.
CC -1- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.
CC -1- SIMILARITY: CONTAINS 4 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: S83711; AAB21466.1; -.
CC DR HSSP: P56276; ITLK.
CC DR InterPro: IPR003006; Ig_MHC.
CC DR InterPro: IPR003598; Ig_C2.
CC DR InterPro: IPR003600; Ig_Like.
CC DR Pfam: PF00047; Ig_2.
CC DR SMART: SM00410; IG_Like; 1.
CC DR SMART: SM00408; IGC2; 2.
CC KW Myelin; Glycoprotein; Cell adhesion; Transmembrane; Signal; Repeat;
CC KW Immunoglobulin domain.
CC FT SIGNAL 1 17
CC FT CHAIN 1 620
CC FT DOMAIN 18 620 SCHWANN CELL MYELIN PROTEIN.
CC FT TRANSMEM 517 536 EXTRACELLULAR (POTENTIAL).
CC FT DOMAIN 537 620 POTENTIAL.
CC FT DOMAIN 537 620 CYTOPLASMIC (POTENTIAL).
CC FT DOMAIN 28 106 IG-Like V-TYPE DOMAIN.
CC FT DOMAIN 151 223 IG-Like C2-TYPE DOMAIN.
CC FT DOMAIN 253 311 IG-Like C2-TYPE DOMAIN 1.
CC FT DOMAIN 339 398 IG-Like C2-TYPE DOMAIN 2.
CC FT DOMAIN 424 495 IG-Like C2-TYPE DOMAIN 3.
CC FT DISULFD 35 164 IG-Like C2-TYPE DOMAIN 4.
CC FT DISULFD 40 99 BY SIMILARITY.
CC FT DISULFD 158 216 BY SIMILARITY.
CC FT DISULFD 260 304 BY SIMILARITY.
CC FT DISULFD 346 391 BY SIMILARITY.
CC FT DISULFD 420 429 BY SIMILARITY.
CC FT DISULFD 431 488 BY SIMILARITY.
CC FT CARBOHYD 222 222 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CARBOHYD 314 314 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CARBOHYD 331 331 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CARBOHYD 405 405 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CARBOHYD 449 449 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC SQ SEQUENCE 620 AA; 66943 MW; 004B3EC7EDC18FDA CRC64;

Query Match 5.38; Score 111; DB 1; Length 620;
Best Local Similarity 21.58; Pred. No. 0.19;
Matches 54; Conservative 33; Mismatches 84; Indels 80; Gaps 12;

QY 23 GPQNAVYKLSQARFNCTV-SQGWKLIMWALSDWVLSVPRMPEIITNDRFTSQRYDGG 81
DB 246 GP--TEVVEGSDVDELGEAEGRAPALISWFRGSEVL-----REPPGR 285
QY 82 NPTSEMIITHNPEPSDSGNIRCSLONSRLHGSAYITVOVMGELFIPSYN--LVVAENPECE 139
DB 286 NL--RLLSNVGPDGGSFSCVAVENRHRNRSIQLRLVAYAPRAPYVINGSLWVSGDPVS 343
QY 140 VTCLPSHWTMLPDISWELGLVSHSSYYFPEPSDLOSAY---SIALT----- 185
DB 344 VTCRAE-----SEPAAILITVLRGKVMAMAAIYEDHVTMEMR 379
QY 186 ---PQNGTLTCAVATWMSLARKSATVNLTV-----IRCPDPTGGGINIPGVLSL 233
DB 380 PAREPDGTYSCVA--ENQHGASTSFNISEYEPPLVLPASRCTAG-GDSVRCVCMVNSI 436
QY 234 P--SLGFSLEPT 242
DB 437 PDSSLVLELPT 447
```

GenCore version 5.1.4-P5.4578  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 28, 2003, 18:09:54 ; Search time 19.0659 Seconds  
(without alignments)  
1946.300 Million cell updates/sec

Title: US-09-729-264-4

Perfect score: 2088  
Sequence: 1 MVAGMERNRDPGSGSGNEV.....HPQASFNLASPEKYSNTTV 386

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

1: PIR-73:\*  
2: PIR1:\*  
3: PIR2:\*  
4: PIR4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	145.5	7.0	404	1	161596 advanced glycosyla
2	136	6.5	1447	2	AS4100 tumor suppressor p
3	134.5	6.4	1427	2	151659 tumor suppressor -
4	133.5	6.4	871	1	148696 protein-tyrosine k
5	129.5	6.4	881	1	148697 protein-tyrosine k
6	129.5	5.9	164	2	T24272 hypothetical prote
7	123.5	5.9	188	2	T15651 hypothetical prote
8	121	5.8	344	2	156551 neurotrophin - rat
9	119.5	5.7	6642	2	T29757 protein UNC-89 - C
10	119	5.7	1070	2	UC4553 protein-tyrosine k
11	115.5	5.5	946	1	A47299 for-related recept
12	114.5	5.5	152	2	T18975 hypothetical prote
13	114.5	5.5	531	2	S20900 titin - mouse (fira
14	114.5	5.5	862	2	T14583 differentiation an
15	114.5	5.5	26926	1	138344 titin, cardiac mus
16	112.5	5.4	345	2	UC4075 oploid-binding cel
17	112.5	5.4	416	1	A42879 advanced glycosyla
18	112	5.4	868	2	A46512 CD22 homolog/B lym
19	111.5	5.3	345	2	S03159 oploid-binding pro
20	111.5	5.3	1443	2	S03159 oploid-binding pro
21	111.5	5.3	6805	2	S20901 neogennin - chicken
22	111	5.3	620	2	UH0593 titin - rabbit (fir
23	111	5.3	693	2	UH0593 Schwann cell myel
24	110.5	5.3	338	2	UC1238 sodium-dependent p
25	110.5	5.3	345	2	UC1238 oploid-binding pro
26	110.5	5.3	4391	2	A38096 oploid-binding pro
27	109.5	5.2	364	2	A30521 perlecan precursor
28	109	5.1	3375	2	T19821 myeloid cell surfa
29	107	5.1	391	2	T09058 hypothetical prote
					butyrophilin homol

30	106.5	5.1	487	2	S65133 butyrophilin - mou
31	106.5	5.1	802	2	T13149 mitogen and stress
32	106.5	5.1	841	2	JC5894 killer cell inhibi
33	106.5	5.1	1272	2	S26180 neurofascin - chic
34	106	5.1	1092	1	JN0635 neural cell adhesi
35	105.5	5.1	662	2	T16525 hypothetical prote
36	104.5	5.0	1177	2	T16594 hypothetical prote
37	104	5.0	764	2	A49448 irregular chlam C
38	104	5.0	2295	2	C88369 protein unc-52 (lm
39	104	5.0	5825	2	T12117 insulin-like growt
40	103.5	5.0	2491	1	A28372 heparan sulfate pr
41	103.5	5.0	3707	2	S18252 protein-tyrosine k
42	102.5	4.9	890	1	A53743 hypothetical prote
43	102	4.9	721	2	T41530 hypothetical prote
44	101.5	4.9	215	2	T16542 E2 glycoprotein pr
45	101.5	4.9	1449	2	S47423

#### ALIGNMENTS

##### RESULT 1

161596  
Advanced glycosylation end-products receptor precursor - human  
N:Alternate names: advanced glycosylation end product-binding protein, 35K, glycoprot  
C:Species: Homo sapiens (man)  
C:Date: 24-May-1996 #sequence\_revision 07-Feb-1997 #text\_change 16-Jul-1999  
C:Accession: 161596; B42879; S27968  
R:Sugawara, K.; Fukagawa, T.; Matsumoto, K.; Mita, K.; Takahashi, E.; Ando, A.; Inoko, G.  
Genomics 23, 408-419, 1994  
A:Title: Three genes in the human MHC class III region near the junction with the cla  
A:Interpart of mouse mammary tumor gene Int-3  
A:Reference number: A55562; M01D:95137387; PMID:7835890  
A:Accession: 161596  
A:Status: nucleic acid sequence not shown; translation not shown; translated from GB/  
A:Molecule type: DNA  
A:Residues: 1-404 <RES>  
A:Cross-references: GB:D28769; NID:9561657; PIDN:BA05958.1; PID:9561659  
R:Neepfer, M.; Schmidt, A.M.; Brett, J.; Yan, S.D.; Wang, F.; Pan, Y.C.; Elliston, K.;  
J. Biol. Chem. 267, 14998-15004, 1992  
A:Title: Cloning and expression of a cell surface receptor for advanced glycosylation  
A:Reference number: A42879; M01D:92340547; PMID:1378843  
A:Accession: B42879  
A:Molecule type: mRNA  
A:Residues: 'G', '2-99', 'R', '101-404' <NEE>  
A:Cross-references: EMBL:M91211; NID:9190845; PIDN:AAA03574.1; PID:9190846  
A:Experimental source: lung  
A:Note: sequence extracted from NCBI backbone (NCBIP:109438)  
C:Comment: Advanced glycosylation end products are heterogeneous nonenzymatically gly  
cellular function, thus contributing to tissue lesions in diabetes.  
C:Comment: This receptor appears also to mediate the effects of amyloid beta peptide  
ates in the neurotoxic pathway that produces dementia in Alzheimer's disease.  
C:Genetics:  
A:Gene: GDB:AGER  
A:Cross-references: GDB:306354; OMIM:600214  
A:Map position: 6p21.3-6p21.3  
A:Intons: 18/1; 53/3; 119/1; 140/3; 170/1; 231/1; 274/3; 322/1; 331/1; 373/2  
C:Function:  
A:Description: neuronal receptor for amphoterin, a DNA-binding protein involved in ne  
C:Superfamily: advanced glycosylation end products receptor; immunoglobulin homology  
C:Keywords: Alzheimer's disease; glycoprotein; receptor; transmembrane protein  
F:1-22/Domain: signal sequence #status predicted <SIG>  
F:23-404/Product: advanced glycosylation end products receptor #status predicted <MAT  
F:23-344/Domain: extracellular #status predicted <EXT>  
F:31-101/Domain: immunoglobulin homology <IM1>  
F:137-210/Domain: immunoglobulin homology <IM2>  
F:252-303/Domain: immunoglobulin homology <IM3>  
F:345-362/Domain: transmembrane #status predicted <TM>  
F:363-404/Domain: intracellular #status predicted <INT>  
F:35/81/Binding site: carbohydrate (Asn) (covalent) #status predicted  
F:38-99/144-208,259-301/Disulfide bonds: #status predicted

Query Match

7.0%; Score 145.5; DB 1; Length 404;



A: Molecule type: DNA  
 A: Residues: 1-456, 'A', 466-871 <GAN2>  
 A: Cross-references: EMBL:X86445; NID:9929723  
 A: Experimental source: splice form 4  
 C: Comment: For alternate splice forms see PIR:I48697.  
 C: Genetics:  
 A: Gene: nsk2  
 A: Superfamily: mouse for-related receptor; immunoglobulin homology; protein kinase homology  
 C: Keywords: ATP; glycoprotein; phosphotransferase; receptor; transmembrane protein; tyrosine  
 F: 1-21/Domain: signal sequence #status predicted <SIG>  
 F: 22-871/Product: protein-tyrosine kinase nsk2, splice form 2 #status predicted <MAT2>  
 F: 22-456, 'A', 466-871/Product: protein-tyrosine kinase nsk2, splice form 4 #status predicted  
 F: 42-101/Domain: immunoglobulin homology <IMM1>  
 F: 135-192/Domain: immunoglobulin homology <IMM2>  
 F: 226-284/Domain: immunoglobulin homology <IMM3>  
 F: 498-518/Domain: transmembrane #status predicted <TRM>  
 F: 575-865/Domain: protein kinase homology <KIN>  
 F: 583-591/Region: protein kinase ATP-binding motif  
 F: 222,462/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 6.4%; Score 133.5; DB 1; Length 871;  
 Best Local Similarity 21.6%; Pred. No. 0.045;  
 Matches 73; Conservative 45; Mismatches 127; Indels 93; Gaps 17;

4 G A M E N R D P P G S G N E V I E G P O N A R V L K S Q A R F N C T V S Q G W K - L I M A L S D M V L S V R P 62  
 113 G A L O V K M K P - - - - - K I T R P P I N V K I I E G L K A V L P C T T M G N P K P S V S W I K G D - - - - - 158  
 63 M E P I T N D R F T S Q R Y D O G N F T S E M I I H N V E P S D S G I N R S L O N S R L H G S A Y - - - - - L T V 117  
 159 - N A L R E N S R I A L E - - - - - S G S L R I H N V O K E D A G Y C A K N S L - - - G T A V S K L V K L E V 208  
 118 Q V M G E L F I P S V N I L V A N E P E V T C - - - - - L P S H W T M L P D I S W - E L G L V S H S Y F V P E P 172  
 209 E V L G R I L R A P E S H N V T F G S F V T L R C T E I G P - - - - - V P T I S M I E N G A V S S G I O E S V K D 263  
 173 S D L O S A V S I L A L P O S N G T L T C V A T - - - - - W K S L K A R K S A T V N L T V I R - - - - - C P O D 219  
 264 R V I D S R L O L F I T K P - - - - - G L Y T C I A T N K H G E K F S T A K A A T V S I A E W S K O S K O D S G Y C A O Y 320  
 220 T G G I N I T G - - - - - V L S S L P S I G F S L P - - - - - T W G V G L G I A G T M L T P T C T I I 264  
 321 R G E G V L M O G P G E K M L V L P T T S H R D P E D A O E L I H T A M N E L - - - - - K A V S P L C R P A A 373  
 265 R C C C C R R C C G C N - - - - - C C C R C C - - - - - F C C R 287  
 374 E A L L C Y H L F L E C S P G V V P T P M P I C R E Y C L A V K E L F C A K 411

## RESULT 5

I48697  
 protein-tyrosine kinase (EC 2.7.1.112) nsk2 precursor, splice form 1 - mouse  
 N: Alternate names: receptor-type tyrosine kinase  
 C: Species: Mus musculus (house mouse)  
 C: Date: 19-May-2000 #sequence\_revision 19-May-2000 #text\_change 19-May-2000  
 C: Accession: I48697; S60740  
 R: Ganju, P.; Wallis, E.; Brennan, J.; Reith, A. D.  
 Oncogene 11, 281-290, 1995  
 A: Title: Cloning and developmental expression of Nsk2, a novel receptor tyrosine kinase  
 A: Reference number: I48696; MUID:95349951; PMID:762414  
 A: Accession: I48697  
 A: Status: nucleic acid sequence not shown; translated from GB/EMBL/DBJ  
 A: Molecule type: DNA  
 A: Residues: 1-881 <GAN1>  
 A: Cross-references: EMBL:X86445; NID:9929725; PTDN:CA60166.1; PTD:9929726  
 A: Experimental source: splice form 1  
 A: Accession: S60740  
 A: Molecule type: DNA  
 A: Residues: 1-456, 'A', 466-881 <GAN2>  
 A: Cross-references: EMBL:X86445; NID:9929725  
 A: Experimental source: splice form 3

C: Comment: For alternate splice forms see PIR:I48696.

C: Genetics:  
 A: Gene: nsk2  
 A: Superfamily: mouse for-related receptor; immunoglobulin homology; protein kinase homology  
 C: Keywords: ATP; glycoprotein; phosphotransferase; receptor; transmembrane protein; tyrosine  
 F: 1-21/Domain: signal sequence #status predicted <SIG>  
 F: 22-881/Product: protein-tyrosine kinase nsk2, splice form 1 #status predicted <MAT1>  
 F: 22-456, 'A', 466-881/Product: protein-tyrosine kinase nsk2, splice form 3 #status predicted  
 F: 42-101/Domain: immunoglobulin homology <IMM1>  
 F: 135-192/Domain: immunoglobulin homology <IMM2>  
 F: 226-284/Domain: immunoglobulin homology <IMM3>  
 F: 498-518/Domain: transmembrane #status predicted <TRM>  
 F: 575-865/Domain: protein kinase homology <KIN>  
 F: 583-591/Region: protein kinase ATP-binding motif  
 F: 222,462/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 6.4%; Score 133.5; DB 1; Length 881;  
 Best Local Similarity 21.6%; Pred. No. 0.046;  
 Matches 73; Conservative 45; Mismatches 127; Indels 93; Gaps 17;

4 G A M E N R D P P G S G N E V I E G P O N A R V L K S Q A R F N C T V S Q G W K - L I M A L S D M V L S V R P 62  
 113 G A L O V K M K P - - - - - K I T R P P I N V K I I E G L K A V L P C T T M G N P K P S V S W I K G D - - - - - 158  
 63 M E P I T N D R F T S Q R Y D O G N F T S E M I I H N V E P S D S G I N R S L O N S R L H G S A Y - - - - - L T V 117  
 159 - N A L R E N S R I A L E - - - - - S G S L R I H N V O K E D A G Y C A K N S L - - - G T A V S K L V K L E V 208  
 118 Q V M G E L F I P S V N I L V A N E P E V T C - - - - - L P S H W T M L P D I S W - E L G L V S H S Y F V P E P 172  
 209 E V L G R I L R A P E S H N V T F G S F V T L R C T E I G P - - - - - V P T I S M I E N G A V S S G I O E S V K D 263  
 173 S D L O S A V S I L A L P O S N G T L T C V A T - - - - - W K S L K A R K S A T V N L T V I R - - - - - C P O D 219  
 264 R V I D S R L O L F I T K P - - - - - G L Y T C I A T N K H G E K F S T A K A A T V S I A E W S K O S K O D S G Y C A O Y 320  
 220 T G G I N I T G - - - - - V L S S L P S I G F S L P - - - - - T W G V G L G I A G T M L T P T C T I I 264  
 321 R G E G V L M O G P G E K M L V L P T T S H R D P E D A O E L I H T A M N E L - - - - - K A V S P L C R P A A 373  
 265 R C C C C R R C C G C N - - - - - C C C R C C - - - - - F C C R 287  
 374 E A L L C Y H L F L E C S P G V V P T P M P I C R E Y C L A V K E L F C A K 411

## RESULT 6

T24272  
 hypothetical protein T01B7.8 - Caenorhabditis elegans  
 C: Species: Caenorhabditis elegans  
 C: Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 15-Oct-1999  
 C: Accession: T24272  
 R: Sims, M.  
 submitted to the EMBL Data Library, October 1995  
 A: Reference number: T24272  
 A: Accession: T24272  
 A: Status: preliminary; translated from GB/EMBL/DBJ  
 A: Molecule type: DNA  
 A: Residues: 1-164 <MIL>  
 A: Cross-references: EMBL:T66499; PTDN:CA91301.1; GSPDB:GN00020; CESP:T01B7.8  
 A: Experimental source: clone T01B7  
 C: Genetics:  
 A: Gene: CESP:T01B7.8  
 A: Map position: 20/3; 90/2  
 A: Introns: 20/3; 90/2

Query Match 6.2%; Score 129.5; DB 2; Length 164;  
 Best Local Similarity 32.1%; Pred. No. 0.015;  
 Matches 43; Conservative 11; Mismatches 53; Indels 27; Gaps 6;

157 L G L L V S S Y F P E P S D L O S A V S I L A L P O S N G T L T C V A T W K S L K A R K S A T V N L T V I R C 216  
 6 L A I L A I G T P I A V - - - - - S O V O S A V - - - - - L P V S T E L A T G T D V S T A S T A I D L I G N S S R V 57

QY 217 P0TGGGINIPVLSLPSLGFSLPTWKGVLGLACTMILTPCTLTTRCCRRRCCG 276  
 Db 58 KR0GGCGCCGCGC-----GCCGGGGGGG--CGCCCRPRCCCRCCCTC 101  
 QY 277 --NCCC-RCGFCR 287  
 Db 102 CRTCCCTCCTCCR 115

## RESULT 7

T15651

hypothetical protein C27A2.5 - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C&gt;Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 20-Sep-1999

C:Accession: T15651

R:Nhan, M.

submitted to the EMBL Data Library, May 1996

A:Description: The sequence of C. elegans cosmid C27A2.

A:Reference number: 218382

A:Accession: T15651

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-188 &lt;NHA&gt;

A:Cross-references: EMBL:U58760; NID:G1330384; PID:G1330389; PIDN:AAB00710.1; GSPDB:GNOC

A:Experimental source: strain Bristol N2; clone C27A2

C:Genetics:

A:Gene: CESP:C27A2.5

A:Map position: 2

A:Introns: 19/3; 91/2

## Query Match

Best Local Similarity 5.9%; Score 122.5; DB 2; Length 188;  
 Matches 19; Conservative 1; Mismatches 8; Indels 3; Gaps 2;

QY 260 CULTRCCCRRCGCG--NCCC-RCGFCR 287  
 Db 86 CCCRPCCCCCRCCCTCCTCCTCCTCCR 116

## RESULT 8

156551

neurotrophin - rat

C:Species: Rattus norvegicus (Norway rat)

C&gt;Date: 26-Jul-1996 #sequence\_revision 26-Jul-1996 #text\_change 19-May-2000

C:Accession: 156551

R:Struyk, A.F.; Canoll, P.D.; Wolfgang, M.J.; Rosen, C.L.; D'Eustachio, P.; Salzer, J.L.

J. Neurosci. 15, 2141-2156, 1995

A:Title: Cloning of neurotrophin defines a new subfamily of differentially expressed neur

A:Reference number: 156551; MUID:95198094; PMID:7891157

A:Accession: 156551

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 1-344 &lt;RES&gt;

A:Cross-references: EMBL:U06845; NID:9755184; PIDN:AAA67445.1; PID:9755185

C:Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-terminal

## Query Match

Best Local Similarity 5.8%; Score 121; DB 2; Length 344;  
 Matches 59; Conservative 37; Mismatches 93; Indels 56; Gaps 13;

QY 26 NARLKSQARFNCYSQGKLMALSDMVLS-----VRPMEPIITNDRFTSQRDQ 79  
 Db 44 NTVYRQESATLCTIDNRTVAVMNRSTIIYAGNDKWCIDPRVLLSN--TQTY-- 98  
 QY 80 GGNFTSEMIHNVEPSDSGNIRCSLO-----NSRLHGAIVTYOVMEGLFIPSNLYVA 133  
 Db 99 -----SIEQWVDVDEGPTSCVTDNHPKTSRYH-----LIVVSPKIVEISSDISIN 148  
 QY 134 ENPECEVTCL---PSHWTLPDISWELGLLVSHSSYYFVPPSDLOSASVIALTPQSN 189  
 Db 149 EGNNSITFCIATGRPE---PLVTWR---HISPAVGVSDYLE-----IQGITRQS 196

QY 190 GTLTCVATKSLKARSAFVNLTVINCP-----QDTGGGINIPVL-----SLSPLGFSL 240  
 Db 197 GEYECSSAS--NDVAPVRRVNVTVNPPYISAKGFGVPVGGKGLQCEASAVPSAERQ- 254  
 QY 241 PTWKG 245  
 Db 255 --WFK 257

## RESULT 9

T29757

protein UNC-89 - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C&gt;Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 03-Dec-1999

C:Accession: T29757

R:Du, Z.; Lee, T.T.; Wilson, R.

submitted to the EMBL Data Library, May 1997

A:Description: The sequence of C. elegans cosmid C09D1.

A:Reference number: 220679

A:Accession: T29757

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-6642 &lt;DUZ&gt;

A:Cross-references: EMBL:AF003131; PIDN:AAB54132.1; GSPDB:GN00019; CESP:unc-89

A:Experimental source: strain Bristol N2; clone C09D1

C:Genetics:

A:Gene: CESP:unc-89

A:Map position: 1

A:Introns: 17/2; 108/3; 154/2; 211/2; 265/3; 356/3; 352/3; 426/2; 454/1; 500/1; 537/1

/3; 5917/1; 6027/1; 6061/3; 6153/2; 6515/1; 6552/3; 6609/1

## Query Match

Best Local Similarity 5.7%; Score 119.5; DB 2; Length 6642;  
 Matches 51; Conservative 39; Mismatches 93; Indels 35; Gaps 8;

QY 20 VIEGQNAKRVKGSQARFNCYSQGM--KLIMALSDMVLSVRPMEPIITNDRFTSQR 77  
 Db 2077 VVDGKSVYTKETETAEFKATIS--GFPAPVTKWTINKETIYESRTYITTKTEDVYT----- 2131

## RESULT 10

J04593

protein-tyrosine kinase-related receptor PTK7 precursor - human

N:Alternate names: Receptor protein tyrosine kinase-like protein (RPTK)

C:Species: Homo sapiens (man)

C&gt;Date: 16-Apr-1996 #sequence\_revision 24-May-1996 #text\_change 24-Sep-1999

C:Accession: J04593

R:Park, S.K.; Lee, H.S.; Lee, S.T.

J. Biochem. 119, 235-239, 1996

A:Title: Characterization of the human full-length PTK7 cDNA encoding a receptor prot

A:Reference number: J04593; MUID:97037064; PMID:8882711

A:Accession: J04593

A:Molecule type: mRNA

A:Residues: 1-1070 &lt;PAR&gt;

A:Cross-references: GB:U040271; NID:91322231; PIDN:AAC50484.1; PID:91322232

C:Comment: This protein is a member of receptor protein tyrosine kinase family, but p

C:Genetics:

A:Gene: GDB:PTK7

A:Cross-references: GDB:134760; OMIM:601890

A:Map position: 6p21.1-6p12.2

C:Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase hom



Db 264 RVIDSRLOFLITKP---GLYTICIAINNKGEKSTAKAAATISIAEWSKPOKDNKGCAOY 320  
 QY 224 ----INIGVLSLPSLGSFSL-----PTWGVGLAGLGMILLPTCTLLTIRCC 267  
 Db 321 RGEVCNAVLAADALVFLMTSYADPEAOELLVHTAMNEL-----KVSPVCPRAAEAL 373  
 QY 268 CCRRCRCGCGN-----CCCRCC-----FCCRRKGRFRIOPQKSEKTKETETE 312  
 Db 374 LCNHIFQECSPGVPLPIPICREYCLAVKEIFCAKE-----WLWMEKTHRGLYRSEMHLL 429  
 QY 313 SGNENSGVNSDEQKTTDTASLPKSCSESDPEQRNNSCGPHORADRP-----PRPASHP 368  
 Db 430 SYEPCSKLPMSMHMDPTACARLP-----HLDYKNENLKTFFP--MTSSKPSVDIENLPSSS 482  
 QY 369 QASEFNLA 375  
 Db 483 SSSFSVS 489

## RESULT 4

US-08-644-271-29  
 ; Sequence 29, Application US/08644271  
 ; Patent No. 5814478

GENERAL INFORMATION:

APPLICANT: Valenzuela, et al.

TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTORS

TITLE OF INVENTION: AND LIGANDS

NUMBER OF SEQUENCES: 32

CORRESPONDENCE ADDRESS:

ADDRESSEE: Regeneron Pharmaceuticals, Inc.

STREET: 777 Old Saw Mill Road

CITY: Tarrytown

STATE: NY

COUNTRY: USA

ZIP: 10591

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FASTSEQ Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/644,271

FILING DATE: 10-MAY-1996

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: USSN 60/008,657

FILING DATE: 15-DEC-1995

ATTORNEY/AGENT INFORMATION:

NAME: Covert, Robert J

REGISTRATION NUMBER: 36,108

REFERENCE/DOCKET NUMBER: REG 195A

TELECOMMUNICATION INFORMATION:

TELEPHONE: 914-345-7400

TELEFAX: 914-345-7721

TELEX:

INFORMATION FOR SEQ ID NO: 29:

SEQUENCE CHARACTERISTICS:

LENGTH: 869 amino acids

TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: unknown

MOLECULE TYPE: protein

US-08-644-271-29

Query Match 6.3%; Score 132.5; DB 2; Length 869;  
 Best Local Similarity 20.8%; Pred. No. 0.0018;  
 Matches 89; Conservative 55; Mismatches 178; Indels 105; Gaps 20;

QY 4 GANENRDPGSGSGNEVEIGPONARVLKGSQARENCTVSQGWK-LIMMALSDMVYLSVRP 62  
 Db 113 GALQVAKMP-----KITRPPIVKKIIEGLKAVLPCPTMGNPKPSVSIKGD----- 158  
 QY 63 MEPIITNDRTSQRVDGNGFTSEMIINHVEPSDSGNTRCSLQNSRLGSAV-LTVQVWG 121

Db 159 -SPLENSRIAVLE-----SGSLRIHNVQKEDAGQRCVANKSL--GTAYSKVYKLEY 208  
 QY 122 ELFIPTSVNLVAENEP-----CEVTCLPSSHMTMLPDISM-ELGLVSHSSYFVPEP 172  
 Db 209 EVFARILRAPESHNTVFGSFVTLHCTAGIP-----VPTIWIENGNAVSSGSIQESVKD 263  
 QY 173 SDQSAVSLIALTPQNSGTLTCVAT---WKSLSKARSATVNLTVIRCPDGTGGG----- 223  
 Db 264 RVIDSRLOFLITKP---GLYTICIAINNKGEKSTAKAAATISIAEWSKPOKDNKGCAOY 320  
 QY 224 ----INIGVLSLPSLGSFSL-----PTWGVGLAGLGMILLPTCTLLTIRCC 267  
 Db 321 RGEVCNAVLAADALVFLMTSYADPEAOELLVHTAMNEL-----KVSPVCPRAAEAL 373  
 QY 268 CCRRCRCGCGN-----CCCRCC-----FCCRRKGRFRIOPQKSEKTKETETE 312  
 Db 374 LCNHIFQECSPGVPLPIPICREYCLAVKEIFCAKE-----WLWMEKTHRGLYRSEMHLL 429  
 QY 313 SGNENSGVNSDEQKTTDTASLPKSCSESDPEQRNNSCGPHORADRP-----PRPASHP 368  
 Db 430 SYEPCSKLPMSMHMDPTACARLP-----HLDYKNENLKTFFP--MTSSKPSVDIENLPSSS 482  
 QY 369 QASEFNLA 375  
 Db 483 SSSFSVS 489

## RESULT 5

US-09-077-955-33  
 ; Sequence 33, Application US/09077955A  
 ; Patent No. 6413740

GENERAL INFORMATION:

APPLICANT: Valenzuela et al., David M.

TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTORS AND LIGANDS

FILE REFERENCE: REG195-B-PCT-US

CURRENT APPLICATION NUMBER: US/09/077,955A

CURRENT FILING DATE: 1998-09-10

EARLIER APPLICATION NUMBER: PCT/US96/20696

EARLIER FILING DATE: 1996-12-13

EARLIER APPLICATION NUMBER: 08/644,271

EARLIER FILING DATE: 1996-05-10

EARLIER APPLICATION NUMBER: 60/008,657

EARLIER FILING DATE: 1995-12-15

NUMBER OF SEQ ID NOS: 36

SOFTWARE: Patentln Ver. 2.0

SEQ ID NO 33

LENGTH: 869

TYPE: PRT

ORGANISM: Homo sapiens

US-09-077-955-33

Query Match 6.3%; Score 132.5; DB 4; Length 869;  
 Best Local Similarity 20.8%; Pred. No. 0.0018;  
 Matches 89; Conservative 55; Mismatches 178; Indels 105; Gaps 20;

QY 4 GANENRDPGSGSGNEVEIGPONARVLKGSQARENCTVSQGWK-LIMMALSDMVYLSVRP 62  
 Db 113 GALQVAKMP-----KITRPPIVKKIIEGLKAVLPCPTMGNPKPSVSIKGD----- 158  
 QY 63 MEPIITNDRTSQRVDGNGFTSEMIINHVEPSDSGNTRCSLQNSRLGSAV-LTVQVWG 121  
 Db 159 -SPLENSRIAVLE-----SGSLRIHNVQKEDAGQRCVANKSL--GTAYSKVYKLEY 208  
 QY 122 ELFIPTSVNLVAENEP-----CEVTCLPSSHMTMLPDISM-ELGLVSHSSYFVPEP 172  
 Db 209 EVFARILRAPESHNTVFGSFVTLHCTAGIP-----VPTIWIENGNAVSSGSIQESVKD 263  
 QY 173 SDQSAVSLIALTPQNSGTLTCVAT---WKSLSKARSATVNLTVIRCPDGTGGG----- 223  
 Db 264 RVIDSRLOFLITKP---GLYTICIAINNKGEKSTAKAAATISIAEWSKPOKDNKGCAOY 320  
 QY 224 ----INIGVLSLPSLGSFSL-----PTWGVGLAGLGMILLPTCTLLTIRCC 267

Db 321 RGEVCNAVLAQDALVFNLTSTADPEEAQELLVHTANNEI-----KVSPICORAAEAL 373  
 QY 268 CRRRCGCG-----CCRCRC-----FCRRKRGRIOPKSKSEKTNKETE 312  
 Db 374 LCNHIFQECSPGVPTPIPIPCREYCLAVKELFCAKE-----WLMERKTRGLYRSEMILL 429  
 QY 313 SGNNSGYNSDEQKTTDTASLPPKSCSSDPEQRNNSCGPIQADQRP-----PRPASHP 368  
 Db 430 SVPECSXLPMSHMDPTACARLP-----HLDYKNENLKTFRP--MSSKRSVIDPMLPSSS 482  
 QY 369 QASFNLA 375  
 Db 483 SSSRSVS 489

RESULT 6  
 US-08-977-767-3  
 ; Sequence 3, Application US/08977767  
 ; Patent No. 5972684

GENERAL INFORMATION:  
 APPLICANT: Bandman, Olga  
 APPLICANT: Yue, Henry  
 APPLICANT: Greenwald, Sara  
 APPLICANT: Corley, Neil C.  
 TITLE OF INVENTION: CARBONIC ANHYDRASE VIII  
 NUMBER OF SEQUENCES: 3  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Incyte Pharmaceuticals, Inc.  
 STREET: 3174 Porter Drive  
 CITY: Palo Alto  
 STATE: CA

COUNTRY: USA  
 ZIP: 94304  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: DOS  
 SOFTWARE: FastSeq for Windows Version 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/977,767  
 FILING DATE: Herewith  
 CLASSIFICATION: 424  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER:  
 FILING DATE:  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Billings, Lucy J.  
 REGISTRATION NUMBER: 36,749  
 REFERENCE/DOCKET NUMBER: PF-0423 US  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 650-855-0555  
 TELEFAX: 650-845-4166  
 TELEX:

INFORMATION FOR SRO ID NO: 3:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 1345 amino acids  
 TYPE: amino acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 IMMEDIATE SOURCE:  
 LIBRARY: GenBank  
 CLONE: 1532042  
 US-08-977-767-3

Query Match 6.2%; Score 128.5; DB 2; Length 1345;  
 Best Local Similarity 33.0%; Pred. No. 0.0077;  
 Matches 37; Conservative 1; Mismatches 41; Indels 33; Gaps 5;

QY 190 GTTCAATKSLAKRSATVNLTVIRCPDGTGGI-----NIPGVLSLPSLGFSLPTWKG 245  
 Db 414 GTCTGTG-----GC-CGTGGAAGCGTGAAGACCCCGCGATGTGGA 455

QY 246 VGLAGTMLLT-PTCTLTIRCCCRRCGCCNCCRC-----CFCC 286  
 Db 456 CGTGAAGAGGCTCTATGACCCCTTCGCGGCCCTCTGAGACTGACGACC 507

RESULT 7  
 US-09-651-200-2

; Sequence 2, Application US/09651200  
 ; Patent No. 6429303

GENERAL INFORMATION:  
 APPLICANT: Green et al.

TITLE OF INVENTION: Polynucleotides Encoding Members of the Human B  
 Lymphocyte Activation Antigen B-7 Family and  
 TITLE OF INVENTION: Polypeptides Encoded Thereby

FILE REFERENCE: 15966-562 (CURA-62)  
 CURRENT APPLICATION NUMBER: US/09/651,200

PRIOR FILING DATE: 2000-08-30  
 PRIOR APPLICATION NUMBER: 60/152383

PRIOR FILING DATE: 1999-09-03  
 PRIOR APPLICATION NUMBER: 60/172909

PRIOR FILING DATE: 1999-12-21  
 PRIOR APPLICATION NUMBER: 60/183578

NUMBER OF SEQ ID NOS: 25  
 SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 2  
 LENGTH: 340

TYPE: PRT  
 ORGANISM: Homo sapiens

US-09-651-200-2

Query Match 5.9%; Score 123.5; DB 4; Length 340;  
 Best Local Similarity 21.3%; Pred. No. 0.0033;  
 Matches 78; Conservative 50; Mismatches 130; Indels 109; Gaps 17;

QY 11 PPGSSGNEVIEGPONARV-LKGSQARFNCTVS--QGKLT-----IMWALSDWVLSVRPM 63  
 Db 45 PORSPTGAVEVQVEDPVVALVGTDAHLHCSFSPSPGFSLTQNLIMQTLDTQVLY----- 100

QY 64 EPIINDRETSQRYDCCGN-----TSMITHNVEPSDSGNIRCSLONSRL 109  
 Db 101 -----HSFTEGR-DQGSAYANRTALFPDLLAOGNMSLRQRYRVADSESTCFV-SIRD 152

QY 110 HGSAYLVQVYVGELEFIPSVNLV-----VAENPEVCVCLPSHWMLP--DISMELG---L 160  
 Db 153 FGSAAVSLQVAAVPSKSMLEPKDLRPGDVTIIC--SYNGIPEAEVEMQDQGVPL 210

QY 161 VSHSSYFVEPEPDLQSAVSILALTPQSNGLTQVATWKSLSAKRSATVNLTVIRCP--- 217  
 Db 211 TGNVTTQMANEGLFVHSHVVLGVANCTYSC-----LVANPVLYQ 252

QY 218 QDTGGGININGVLSLPSLGFSLPTWKGVLGLAGTMLTPTCTLTIRCCCRRCGCCN 277  
 Db 253 QDAHGSVTITGQMTPTPEAL-----WYVGLSVCLIALLV----- 288

QY 278 CCRRCRCCRRKRGFRIOFKSKSEKTNKETETESGNSGNSYNSDEQKTTDTASLPSKS 337  
 Db 289 ---ALAEVFCWRK-----IKOSCEEENAGAEDDQ-----EEGSKTLQPLKH 328

QY 338 CESSDPE 344  
 Db 329 SDSKEDD 335

RESULT 8  
 US-09-651-200-4

; Sequence 4, Application US/09651200  
 ; Patent No. 6429303

GENERAL INFORMATION:  
 APPLICANT: Green et al

TITLE OF INVENTION: Polynucleotides Encoding Members of the Human B  
 Lymphocyte Activation Antigen B-7 Family and  
 TITLE OF INVENTION: Polypeptides Encoded Thereby

FILE REFERENCE: 15966-562 (CURA-62)  
CURRENT APPLICATION NUMBER: US/09/651,200  
CURRENT FILING DATE: 2000-08-30  
PRIOR APPLICATION NUMBER: 60/152383  
PRIOR FILING DATE: 1999-09-03  
PRIOR APPLICATION NUMBER: 60/172909  
PRIOR FILING DATE: 1999-12-21  
PRIOR APPLICATION NUMBER: 60/183578  
PRIOR FILING DATE: 2000-02-18  
NUMBER OF SEQ ID NOS: 25  
SOFTWARE: Patentln Ver. 2.0  
SEQ ID NO 4  
LENGTH: 441  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-651-200-4

Query Match  
Best Local Similarity 21.3%; Pred. No. 0.0047;  
Matches 78; Conservative 50; Mismatches 130; Indels 109; Gaps 17;

5.9%; Score 123.5; DB 4; Length 441;  
11 PPGSGNEVEIEGPONARY-LKSGQARFNCVTS--OGMKL---IMMALSDMVLVSVRPM 63  
146 PQRSPTGAVEVQVEDPVVALVGTDTALHCSFSPGFSIQLNLIMQLTDTRKQVY---- 201  
64 EPIITNDRTSQRDOGNF-----TSEMIIHVEPDSGNIRCSLONSRL 109  
202 -----HSTFTEGR-DQGSAYANRTALFPDLLAOGNLSRLQRYRVAVDESGFTCFV-SIRD 253  
110 HGSAYTLVQVMGELFIPSVNLV---VAENPECVTLCPSHMTWLP--DISMELGL---L 160  
254 FGSAAVSLQVAAPYSKPSMTLEPNKDLRPDGYTITC--SSYRGYPBAEVFWMDGGQVPL 311  
161 VSHSSYFVEPEPDSLOSASILALTPQSNGLTCVATWKSLSKRSATVNLVIRCP--- 217  
312 TGNVTTISQMANEQGLFVHSLRVLVGANGTYSCL---LVKRPVQLQ 353  
218 QDTGGGINIPGVLSLSLPSLGFSLPTWKGVLGLAGTMLLPCTLTIRCCCCRRCCGCGN 277  
354 QDAHGSVTTIGQPMTFPEAL---WVTGLSVCLLALLV-----BGEKSTALQPLKH 389  
278 CCCRCFCRRKRGFRIOFKKSEKTKETETESGNGNSGNSDEOKTTDTASLPKS 337  
390 ---ALAFVCWRK-----IKSCCEENAGAEQDQ-----EGESKTALQPLKH 429  
338 CESSDPE 344  
430 SDSKEDD 436

RESULT 9  
US-09-651-200-6  
Sequence 6, Application US/09651200  
Patent No. 6429303  
GENERAL INFORMATION:  
APPLICANT: Green et al  
TITLE OF INVENTION: Polynucleotides Encoding Members of the Human B  
TITLE OF INVENTION: Lymphocyte Activation Antigen B-7 Family and  
TITLE OF INVENTION: Polypeptides Encoded Thereby  
FILE REFERENCE: 15966-562 (CURA-62)  
CURRENT APPLICATION NUMBER: US/09/651,200  
CURRENT FILING DATE: 2000-08-30  
PRIOR APPLICATION NUMBER: 60/152383  
PRIOR FILING DATE: 1999-09-03  
PRIOR APPLICATION NUMBER: 60/172909  
PRIOR FILING DATE: 1999-12-21  
PRIOR APPLICATION NUMBER: 60/183578  
PRIOR FILING DATE: 2000-02-18  
NUMBER OF SEQ ID NOS: 25  
SOFTWARE: Patentln Ver. 2.0  
SEQ ID NO 6  
LENGTH: 534  
TYPE: PRT

ORGANISM: Homo sapiens  
US-09-651-200-6

Query Match  
Best Local Similarity 21.3%; Pred. No. 0.0075;  
Matches 78; Conservative 49; Mismatches 131; Indels 109; Gaps 17;

5.9%; Score 122.5; DB 4; Length 534;  
11 PPGSGNEVEIEGPONARY-LKSGQARFNCVTS--OGMKL---IMMALSDMVLVSVRPM 63  
239 PQRSPTGAVEVQVEDPVVALVGTDTALHCSFSPGFSIQLNLIMQLTDTRKQVY---- 294  
64 EPIITNDRTSQRDOGNF-----TSEMIIHVEPDSGNIRCSLONSRL 109  
295 -----HSTFTEGR-DQGSAYANRTALFPDLLAOGNLSRLQRYRVAVDESGFTCFV-SIRD 346  
110 HGSAYTLVQVMGELFIPSVNLV---VAENPECVTLCPSHMTWLP--DISMELGL---L 160  
347 FGSAAVSLQVAAPYSKPSMTLEPNKDLRPDGYTITC--SSYRGYPBAEVFWMDGGQVPL 404  
161 VSHSSYFVEPEPDSLOSASILALTPQSNGLTCVATWKSLSKRSATVNLVIRCP--- 217  
405 TGNVTTISQMANEQGLFVHSLRVLVGANGTYSCL---LVKRPVQLQ 446  
218 QDTGGGINIPGVLSLSLPSLGFSLPTWKGVLGLAGTMLLPCTLTIRCCCCRRCCGCGN 277  
447 QDAHGSVTTIGQPMTFPEAL---WVTGLSVCLLALLV-----LVKRPVQLQ 482  
278 CCCRCFCRRKRGFRIOFKKSEKTKETETESGNGNSGNSDEOKTTDTASLPKS 337  
483 ---ALAFVCWRK-----IKSCCEENAGAEQDQ-----BGEKSTALQPLKH 522  
338 CESSDPE 344  
523 SDSKEDD 529

RESULT 10  
US-09-651-200-24  
Sequence 24, Application US/09651200  
Patent No. 6429303  
GENERAL INFORMATION:  
APPLICANT: Green et al  
TITLE OF INVENTION: Polynucleotides Encoding Members of the Human B  
TITLE OF INVENTION: Lymphocyte Activation Antigen B-7 Family and  
TITLE OF INVENTION: Polypeptides Encoded Thereby  
FILE REFERENCE: 15966-562 (CURA-62)  
CURRENT APPLICATION NUMBER: US/09/651,200  
CURRENT FILING DATE: 2000-08-30  
PRIOR APPLICATION NUMBER: 60/152383  
PRIOR FILING DATE: 1999-09-03  
PRIOR APPLICATION NUMBER: 60/172909  
PRIOR FILING DATE: 1999-12-21  
PRIOR APPLICATION NUMBER: 60/183578  
PRIOR FILING DATE: 2000-02-18  
NUMBER OF SEQ ID NOS: 25  
SOFTWARE: Patentln Ver. 2.0  
SEQ ID NO 24  
LENGTH: 534  
TYPE: PRT  
ORGANISM: Unknown  
FEATURE:  
OTHER INFORMATION: Description of Unknown Organism: Sequence  
US-09-651-200-24

Query Match  
Best Local Similarity 21.3%; Pred. No. 0.0075;  
Matches 78; Conservative 49; Mismatches 131; Indels 109; Gaps 17;

5.9%; Score 122.5; DB 4; Length 534;  
11 PPGSGNEVEIEGPONARY-LKSGQARFNCVTS--OGMKL---IMMALSDMVLVSVRPM 63  
239 PQRSPTGAVEVQVEDPVVALVGTDTALHCSFSPGFSIQLNLIMQLTDTRKQVY---- 294

```

QY 64 EPIITNDRTSQRDOGNF-----TSEMIHNVEPSDSGNIRCSLQNSRL 109
Db 295 -----HSFTEGR-DOGSVAANRTALPDLAQNANSLQVRAVADSESTCFV-STRD 346
QY 110 HGSAYLVVOYMGELFIPSNLV-----VAINECEVTCLPSHWTLP--DISNEGL--L 160
Db 347 FGSANVSLOVAAAPSKPSMTLEPNKDLRPGDVITTC--SSRYGPEAEVEMODQGVPL 404
QY 161 VSHSSYFVEPEPSDLOSASVIALTPQSNGLTCVATWKSLSKARKSATVNLVIRCP--- 217
Db 405 TGVVTSQMANEGGLFVHVSILRVYLGANGTYSCTSC-----LVNNPVLQ 446
QY 218 QDTGGGINIPVLLSPSLGSLPTWKGVLGLAGTMTLLPTCTLLTRCCRRRCGCGN 277
Db 447 QDHGSGVTTTGQPMTEPPPAL-----WVTYGLSVCLIALLV----- 482
QY 278 CCCRCFCRRKRRFRIOKSEKTEKTEKTESGNNNGNSNDEKTTDTASLPKPS 337
Db 483 ---ALAFVCMRK-----IKOSCEENAGAEODG-----EGEGSKTALQPLKH 522
QY 338 CESSDPE 344
Db 523 SDSKEDD 529

```

## RESULT 11

```

US-09-062-365-1
; Sequence 1, Application US/09062365
; Patent No. 6465422
; GENERAL INFORMATION:
; APPLICANT: Schmidt, Ann Marie
; APPLICANT: Stern, David
; TITLE OF INVENTION: METHOD FOR INHIBITING TUMOR INVASION OR SPREADING IN A
; FILE REFERENCE: 55424
; CURRENT APPLICATION NUMBER: US/09/062,365
; CURRENT FILING DATE: 1998-04-17
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 332
; TYPE: PRT
; ORGANISM: Human
US-09-062-365-1

```

```

Query Match 5.88; Score 121.5; DB 4; Length 332;
Best Local Similarity 25.78; Pred. No. 0.0048;
Matches 57; Conservative 27; Mismatches 69; Indels 69; Gaps 11;

```

```

QY 64 EPIITNDRTS-----ORYDOGNFT--SEMIHNVEPSDSGNIR-----CSLQNSRLHGS 112
Db 140 KPLVPNEKGVSVKQTRRHPTGLFTLQSLM---VTPARGDPRPTFSCSFSPGLPRHR 196
QY 113 AYLVOYMGELFIP-----SVNLVAENEP-----CEVTCLPSHWTLPDIS 154
Db 197 ALRTAPLQPRVMEVPLEEVLV---EPEGAVAPGVTTLCEVPAPPS-----PQIH 248
QY 155 WELGLVSHSSYFVEPEPSDLOSASVIALTPQSNGLTCVATWKSLSKARKSATVNLVIR 214
Db 249 WMKD-----CVPLPLPSPVLLPLPELPGDDQCTSCVATHSHGPESSRAVSISII 299
QY 215 RCPDGTGGGINIPVLLSPSLGSLPTWKGVLGLAGTMTLL 256
Db 300 E-PGEEG-----PTAGSVGSGSLGLTAL 321

```

## RESULT 12

```

US-09-540-245A-15
; Sequence 15, Application US/09540245A
; Patent No. 6270984
; GENERAL INFORMATION:
; APPLICANT: Goodman, Corey
; APPLICANT: Kild, Thomas

```

```

; APPLICANT: Brose, Katja
; APPLICANT: Tessier-Lavigne, Marc
; TITLE OF INVENTION: Modulating Robo: Ligand Interactions
; FILE REFERENCE: B98-031-3
; CURRENT APPLICATION NUMBER: US/09/540,245A
; CURRENT FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 60/065,544
; PRIOR FILING DATE: 1997-11-14
; PRIOR APPLICATION NUMBER: 60/081,057
; PRIOR FILING DATE: 1998-04-07
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 15
; LENGTH: 1395
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-540-245A-15

```

```

Query Match 5.78; Score 120; DB 4; Length 1395;
Best Local Similarity 26.28; Pred. No. 0.047;
Matches 66; Conservative 29; Mismatches 101; Indels 56; Gaps 15;

```

```

QY 24 PQNARVLKGSQARENCTVSQG--WKLIMW-----ALSDMVLSVRPEPIITNDRTSOR 76
Db 161 PKDTRVAKGETALLCEGPPKIPETLWIKDGVPLDDLAMSGASSRV-----R 211
QY 77 YDQGNFTSEMIHNVEPSDSGNIRCSLQ--SRLHGSAYLVVOYMGELFIPSNLVYA 133
Db 212 IVDGN-----LLISNVEPIDEGNFKCIAONLVGRSSYAKLIVQKPFMKPKQVWL 267
QY 134 ENEP-----CEVTCLPSHWTLPDISW---ELGLVSHSSYFVEPEPSDLOSANSILALP 186
Db 268 YGQATFHCISGDDP-----PKVLMKEGNGNIPVSARILHD-----EKSLTISNTP 316
QY 187 QSNGLTCVA--TWKLSKARKSATV---NLTVIRCPDGTGGGINIPVLLSPSLGSL 240
Db 317 TDEGTYVCEAHNNVNGQISARASILVHAPNFT--KRPNNKKVGLN--GVV-QLPCNASN 371
QY 241 PT-----NGKXGL 248
Db 372 PPSVFWTKGCV 383

```

## RESULT 13

```

US-08-374-834-1
; Sequence 1, Application US/08374834
; Patent No. 5656473
; GENERAL INFORMATION:
; APPLICANT: Valenzuela, et al.
; TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTOR
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Regeneron Pharmaceuticals, Inc.
; STREET: 777 Old Saw Mill River Road
; CITY: Tarrytown
; STATE: New York
; COUNTRY: USA
; ZIP: 10591
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/374,834
; FILING DATE: 19-JAN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/095,658
; FILING DATE: 21-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Covert, Robert J.
; REGISTRATION NUMBER: 36,108

```

REFERENCE/DOCKET NUMBER: REG 190A  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (914) 345-7400  
 TELEFAX: (914) 345-7721  
 INFORMATION FOR SEQ ID NO: 1:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 868 amino acids  
 TYPE: amino acid  
 STRANDEDNESS:  
 TOPOLOGY: unknown  
 MOLECULE TYPE: protein  
 US-08-374-834-1

Query Match 5.7%; Score 118; DB 1; Length 868;  
 Best Local Similarity 21.0%; Pred. No. 0.037;  
 Matches 83; Conservative 42; Mismatches 151; Indels 120; Gaps 19;

QY 4 GAEHRDPPGSGSNEVIEGPNARVLKGSQARFCTVSGWK-LIMWALSDMYLVSRP 62  
 DB 113 GALQVKKMP-----KITRPINVKIIEGLKAVLPCTTMGNPKPSVSIKGDALRE--- 163  
 QY 63 MEPIITNDPFTSQRYDOGNFTSEMIINHPSPDSGNIRCSLONSRLHGSAY-LTVQVMG 121  
 DB 164 -----NSRIAVLE-----SGSLRIHNVQKEDAGYRCVAKNSL--GTAVSKLVKLEV 208  
 QY 122 ELFIPTVNLVVAENP-----CEVTCPLPSHMTWLPDISW-ELGLVSHSSYFVPEP 172  
 DB 209 EVFARILRAPESHNVTFEGSFVTLRCAIGMP-----VPTISWINGNAVSSGIQENVKD 263  
 QY 173 SDIOSAVSIIALTPQSNGLTFCVAT---WKSILKARKSATVNLTVIR-----CPQD 219  
 DB 264 RVIDSRLOFLITKP---GLYTCLATNKHGKFKSTAKAAATVSIAMWSKQSKESKGYCAQY 320  
 QY 220 TGGGINIPGVLSLPISLPSLSP-----TWKVGGLAGLMTLPTCTLLITRC 267  
 DB 321 RGEVCAVLYKDSLVFNTSYDPDEAOELLIHAWNEL-----KAVSPLCRPAEAL 373  
 QY 268 CCRRCGCCN-----CCORCC-----FCCRRKRGFRIOFKSKSEKTKETETE 312  
 DB 374 LCNHLFQECSPGVLPMPICREYCLAVKELFCA-----KEMWAMEGKTH 418  
 QY 313 SGENSGYNSDEQKTTDTASLPPKSCS-----SDP 343  
 DB 419 RGLYRSGMH-----FLPVPECSKLPSMHQDP 444

RESULT 14  
 US-08-644-271-1  
 ; Sequence 1, Application US/08644271  
 ; Patent No. 5814478  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Valenzuela, et al.  
 ; TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTORS  
 ; TITLE OF INVENTION: AND LIGANDS  
 ; NUMBER OF SEQUENCES: 32  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Regeneron Pharmaceuticals, Inc.  
 ; STREET: 777 Old Saw Mill Road  
 ; CITY: Tarrytown  
 ; STATE: NY  
 ; COUNTRY: USA  
 ; ZIP: 10591  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Diskette  
 ; COMPUTER: IBM Compatible  
 ; OPERATING SYSTEM: DOS  
 ; SOFTWARE: FastSeq Version 2.0  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/644,271  
 ; FILING DATE: 10-MAY-1996  
 ; CLASSIFICATION: 435  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: USSN 60/008,657

FILING DATE: 15-DEC-1995  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Cobert, Robert J  
 REGISTRATION NUMBER: 36,108  
 REFERENCE/DOCKET NUMBER: REG 195A  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 914-345-7400  
 TELEFAX: 914-345-7721  
 TELETYPE:  
 INFORMATION FOR SEQ ID NO: 1:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 868 amino acids  
 TYPE: amino acid  
 STRANDEDNESS:  
 TOPOLOGY: unknown  
 MOLECULE TYPE: protein  
 US-08-644-271-1

Query Match 5.7%; Score 118; DB 2; Length 868;  
 Best Local Similarity 21.0%; Pred. No. 0.037;  
 Matches 83; Conservative 42; Mismatches 151; Indels 120; Gaps 19;

QY 4 GAEHRDPPGSGSNEVIEGPNARVLKGSQARFCTVSGWK-LIMWALSDMYLVSRP 62  
 DB 113 GALQVKKMP-----KITRPINVKIIEGLKAVLPCTTMGNPKPSVSIKGDALRE--- 163  
 QY 63 MEPIITNDPFTSQRYDOGNFTSEMIINHPSPDSGNIRCSLONSRLHGSAY-LTVQVMG 121  
 DB 164 -----NSRIAVLE-----SGSLRIHNVQKEDAGYRCVAKNSL--GTAVSKLVKLEV 208  
 QY 122 ELFIPTVNLVVAENP-----CEVTCPLPSHMTWLPDISW-ELGLVSHSSYFVPEP 172  
 DB 209 EVFARILRAPESHNVTFEGSFVTLRCAIGMP-----VPTISWINGNAVSSGIQENVKD 263  
 QY 173 SDIOSAVSIIALTPQSNGLTFCVAT---WKSILKARKSATVNLTVIR-----CPQD 219  
 DB 264 RVIDSRLOFLITKP---GLYTCLATNKHGKFKSTAKAAATVSIAMWSKQSKESKGYCAQY 320  
 QY 220 TGGGINIPGVLSLPISLPSLSP-----TWKVGGLAGLMTLPTCTLLITRC 267  
 DB 321 RGEVCAVLYKDSLVFNTSYDPDEAOELLIHAWNEL-----KAVSPLCRPAEAL 373  
 QY 268 CCRRCGCCN-----CCORCC-----FCCRRKRGFRIOFKSKSEKTKETETE 312  
 DB 374 LCNHLFQECSPGVLPMPICREYCLAVKELFCA-----KEMWAMEGKTH 418  
 QY 313 SGENSGYNSDEQKTTDTASLPPKSCS-----SDP 343  
 DB 419 RGLYRSGMH-----FLPVPECSKLPSMHQDP 444

RESULT 15  
 US-09-077-955-1  
 ; Sequence 1, Application US/09077955A  
 ; Patent No. 6413740  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Valenzuela et al., David M.  
 ; TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTORS AND LIGANDS  
 ; FILE REFERENCE: REG195-B-PCT-US  
 ; CURRENT APPLICATION NUMBER: US/09/077,955A  
 ; CURRENT FILING DATE: 1998-09-10  
 ; EARLIER APPLICATION NUMBER: PCT/US96/20696  
 ; EARLIER FILING DATE: 1996-12-13  
 ; EARLIER APPLICATION NUMBER: 08/644,271  
 ; EARLIER FILING DATE: 1996-05-10  
 ; EARLIER APPLICATION NUMBER: 60/008,657  
 ; EARLIER FILING DATE: 1995-12-15  
 ; NUMBER OF SEQ ID NOS: 36  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO 1  
 ; LENGTH: 868  
 ; TYPE: PRT  
 ; ORGANISM: Rattus sp.

US-09-077-955-1

Query Match 5.7%; Score 118; DB 4; Length 868;  
 Best Local Similarity 21.0%; Pred. No. 0.037;  
 Matches 83; Conservative 42; Mismatches 151; Indels 120; Gaps 19;

```

QY 4 GAMENDPPGSGGNEVIGPONARVYKGSQARFNCTVSQGWK-LIMWALSDMVVLSYRP 62
Db 113 GALQVKKRP-----KITRPPIINVKIEELKAVLPCTTMGNPKPSVSMIKGDSALRE--- 163
QY 63 MEPIITNDPFTSQRYDQGNFTSEMIINHVEPSDSGNIRCSLQNSRLHGSAY-LTVQYMG 121
Db 164 -----NSRIAYLE-----SGSLRIHNVQKEDAGQYRCVAKNSL--GTAYSKLVKLEV 208
QY 122 ELFIPIVNLVVAENP-----CEVTCLPESHMTWLPDISW-ELGLVSHSSYYFVPEP 172
Db 209 EYFARILRAPESHNVTFGSEFTVLRCTAIGMP-----VPTISMIENGNAVSSGSIQENVKD 263
QY 173 SDIOSAVSILALPQSNCTLCVAT---WKSIRAKSAIVNLVIR-----CPQD 219
Db 264 RYIDSRLQLFITRP--GLYTCTIATNKHGKEFTAKAAATVSIAMWSKQESKGYCAQY 320
QY 220 TGGGINIPGVLSLPSLGSFLP-----TWGKVGGLAGTMLLPPTCTLTIRCC 267
Db 321 RGEVCDAYLVKDSLVFENFTSYDPDEEAQELIHITAMNEL-----KAVSPLCRPAEAL 373
QY 268 CCRRCRCGCGN-----CCCRCC-----FCCRKRGRFRIOPQKSEKERTNKETE 312
Db 374 LCNHLFQECSPGVLPPTPMPICREYCLAVKLELCA-----KMWLAMEGKTH 418
QY 313 SGNENSGYNSDEOKTTDTASLPPKSCES-----SDP 343
Db 419 RGLYRSGMH-----FLPVPECSKLPMSHODP 444

```

Search completed: April 28, 2003, 21:12:19  
 Job time : 19.0485 secs

GenCore version 5.1.4.p5-4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 28, 2003, 16:24:31 ; Search time 38.4662 Seconds  
(without alignments)  
1337.141 Million cell updates/sec

Title: US-09-729-264-4

Perfect score: 2088  
Sequence: 1 MAGAMENDDPPGSGSGNEV.....HPOASFNLAPEKVSNTTVV 386

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database:

1: /SID2/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:\*  
2: /SID2/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:\*  
3: /SID2/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:\*  
4: /SID2/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:\*  
5: /SID2/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:\*  
6: /SID2/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:\*  
7: /SID2/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:\*  
8: /SID2/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:\*  
9: /SID2/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:\*  
10: /SID2/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:\*  
11: /SID2/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:\*  
12: /SID2/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:\*  
13: /SID2/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:\*  
14: /SID2/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:\*  
15: /SID2/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:\*  
16: /SID2/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:\*  
17: /SID2/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:\*  
18: /SID2/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:\*  
19: /SID2/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:\*  
20: /SID2/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:\*  
21: /SID2/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:\*  
22: /SID2/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:\*  
23: /SID2/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2088	100.0	386	23	AAU75541 Human B7-1-like prot
2	2004	96.0	382	23	AAU75540 Human B7-1-like prot
3	2000	95.8	386	23	AAU75542 Human B7-1-like prot
4	1576	75.5	377	23	AAU75543 Human B7-1-like prot
5	1318	63.1	463	22	ABG28169 Novel human diapo
6	913.5	43.8	370	23	AAU75544 Mouse B7-1-like prot
7	572.5	27.4	631	23	AAU75547 Rat B7-1-like prot
8	566.5	27.1	270	23	AAU75545 Mouse B7-1-like prot
9	485	23.2	223	23	AAU75546 Mouse B7-1-like prot
10	145.5	7.0	404	22	AA81925 Extracorporeal cir

11	145.5	7.0	404	23	AAE23219 Human receptor for
12	145.5	7.0	404	23	AAU77543 Human receptor for
13	145.5	7.0	404	23	AAU8745 Human PAGE protein
14	138	6.6	1496	20	AAU81030 Melanoma associate
15	138	6.6	1496	21	AAU70468 Human p53 target m
16	138	6.6	1496	22	AAU70468 Human peroxidase
17	136	6.5	1447	16	AAU86553 Deleted in colorec
18	136	6.5	1447	16	AAU86553 Deleted in colorec
19	136	6.5	1447	16	AAU86553 Deleted in colorec
20	136	6.5	1447	16	AAU86553 Deleted in colorec
21	133.5	6.4	475	19	AAU62575 Alternately splic
22	133.5	6.4	475	19	AAU62575 Alternately splic
23	133.5	6.4	475	19	AAU62575 Alternately splic
24	133.5	6.4	475	19	AAU62575 Alternately splic
25	133.5	6.4	475	19	AAU62575 Alternately splic
26	133.5	6.4	475	19	AAU62575 Alternately splic
27	133.5	6.4	475	19	AAU62575 Alternately splic
28	133.5	6.4	475	19	AAU62575 Alternately splic
29	133.5	6.4	475	19	AAU62575 Alternately splic
30	133.5	6.4	475	19	AAU62575 Alternately splic
31	132.5	6.3	869	18	AAU26506 Human muscle-speci
32	132.5	6.3	869	18	AAU26506 Human muscle-speci
33	131.5	6.3	537	22	AAU77857 Human Dmk receptor
34	131.5	6.3	537	22	AAU77857 Human Dmk receptor
35	131.5	6.3	537	22	AAU77857 Human Dmk receptor
36	131.5	6.3	537	22	AAU77857 Human Dmk receptor
37	130.5	6.2	1483	22	ABG16336 Human immunoglobul
38	128	6.1	592	23	ABU75751 Human pancreas GP3
39	128	6.1	592	23	ABU75751 Human pancreas GP3
40	128	6.1	708	23	AAU29315 Human PRO polypept
41	128	6.1	708	23	AAU29315 Human PRO polypept
42	126	6.0	1953	23	AAU84094 Human gp354 (putat
43	125.5	6.0	467	17	AAU84094 Protein MYLX dilite
44	123.5	5.9	340	22	AAU00904 Human B lymphocyte
45	123.5	5.9	441	22	AAU00905 Human B lymphocyte

#### ALIGNMENTS

RESULT 1	AAU75541	standard; Protein; 386 AA.
ID	AAU75541	
AC	AAU75541	
XX		
DT	23-APR-2002	(first entry)
XX		
DE	Human B7-1-like protein, B7-1.h2.	
XX		
KW	Human: B7-1-like protein; B7-1; antiinfectivity; gynaecological;	
KW	antitumour; cytostatic; immunosuppressive; antiarthritic; antineumatic;	
KW	antiinflammatory; dermatologic; antiproliferative; neuroprotective;	
KW	antidiabetic; haemostatic; antithyroid; anticancer; antiallergic;	
KW	antiproliferative; antineoplastic; antitumour; antitoxic; cancer;	
KW	reproductive disorder; graft versus host disease; autoimmune disease;	
KW	toxic shock syndrome; allergy; nephropathy; skin disorder;	
KW	endocrinopathy; lymphoproliferative disorder.	
OS	Homo sapiens.	
XX		
PN	WO20020710-A2.	
XX		
PD	03-JAN-2002.	
XX		
PF	28-JUN-2001; 2001WO-US20719.	
XX		
XX	28-JUN-2000; 2000US-214512P.	
PR	28-NOV-2000; 2000US-0729264.	
XX		
XX	(AMGE-) AMGEN INC.	
PA		
XX		
PI	Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;	

XX WPI: 2002-130881/17.  
 DR N-PSDB; ABK13029.  
 XX  
 PT New B7-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis -  
 XX  
 PS Claim 13; Fig 2; 135pp; English.  
 XX  
 CC The invention relates to an isolated B7-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or all sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of human B7-L-h2.  
 CC  
 XX  
 SQ Sequence 386 AA;

Query Match 100.0%; Score 2088; DB 23; Length 386;  
 Best Local Similarity 100.0%; Pred. No. 8.8e-165;  
 Matches 386; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MVAGAMENRPPSGSGNEVIEGPNARVLRKSGQAFNCTVSGKLMIMWALSDMVLVLSV 60  
 DB 1 MVAGAMENRPPSGSGNEVIEGPNARVLRKSGQAFNCTVSGKLMIMWALSDMVLVLSV 60  
 QY 61 RPEPIITNDRTSQRYYDGGNFTSEMIITHNPEPSDSGINSRSLNSRHSAVITLVYVM 120  
 DB 61 RPEPIITNDRTSQRYYDGGNFTSEMIITHNPEPSDSGINSRSLNSRHSAVITLVYVM 120  
 QY 121 GELFISVNLVVAENPCVETCLPSHWMLPDISWELGLVSHSSYFVPSPDLSQAVS 180  
 DB 121 GELFISVNLVVAENPCVETCLPSHWMLPDISWELGLVSHSSYFVPSPDLSQAVS 180  
 QY 181 IIALPQSGNLTCAVATKMSLKARSAVNLTIVIRCPDPTGGGINTFGVSSLPSTLSFSL 240  
 DB 181 IIALPQSGNLTCAVATKMSLKARSAVNLTIVIRCPDPTGGGINTFGVSSLPSTLSFSL 240  
 QY 241 PFMGKVGGLAGTMTLTPCTLTTRCCCRRCGCCGCCRCPCRCRRKGRFIOFGKS 300  
 DB 241 PFMGKVGGLAGTMTLTPCTLTTRCCCRRCGCCGCCRCPCRCRRKGRFIOFGKS 300

QY 301 EKEKTKETETESGNSGNSDEKTPDASLPKSCSSSPDEQRNCCGPPHROADQR 360  
 DB 301 EKEKTKETETESGNSGNSDEKTPDASLPKSCSSSPDEQRNCCGPPHROADQR 360  
 QY 361 PPRPASHPOASHFNLASPEKVSNTTVV 386  
 DB 361 PPRPASHPOASHFNLASPEKVSNTTVV 386  
 RESULT 2  
 AAU75540  
 ID AAU75540 standard; Protein; 382 AA.  
 XX  
 AC AAU75540;  
 XX  
 DT 23-APR-2002 (first entry)  
 XX  
 DE Human B7-like protein, B7-L-h1.  
 XX  
 KW Human; B7-like protein; B7-L; antifertility; gynaecological;  
 KW antitumour; cytostatic; immunosuppressive; antiarthritic; antirheumatic;  
 KW antiinflammatory; dermatological; antipsoriatic; neuroprotective;  
 KW antidiabetic; haemostatic; antithyroid; antituber; antiallergic;  
 KW antiasthmatic; nephrotropic; antibacterial; virucide; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200200710-A2.  
 XX  
 PD 03-JAN-2002.  
 XX  
 PF 28-JUN-2001; 2001WO-US20719.  
 XX  
 PR 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX  
 PA (AMGE-) AMGEN INC.  
 XX  
 PI Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 XX  
 DR N-PSDB; ABK13028.  
 XX  
 PT New B7-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis -  
 PS  
 PS Claim 13; Fig 1; 135pp; English.  
 XX  
 CC The invention relates to an isolated B7-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as



CC Inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of human B7-L<sub>h1</sub>.

Query Match 96.0%; Score 2004; DB 23; Length 382;  
 Best Local Similarity 99.5%; Pred. No. 8e-158;  
 Matches 372; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 13 GSGSGNEVIEGPNARVYKGSQARFNCVSGWKLIMWALSDWVLSVRPMEPIITNDRF 72  
 DB 9 GSGSGNEVIEGPNARVYKGSQARFNCVSGWKLIMWALSDWVLSVRPMEPIITNDRF 68  
 QY 73 TSQRYDQGNFTSEMIHNVPEPSDSGNIRCSLQNSRLHGSAYLTVOYMGELFIPSNLVY 132  
 DB 69 TSQRYDQGNFTSEMIHNVPEPSDSGNIRCSLQNSRLHGSAYLTVOYMGELFIPSNLVY 128  
 QY 133 AENEPECVTCLPSHTWTLPDISWELGLVSHSYFVEPEPSDLSAVSIILALTPQSNGLT 192  
 DB 129 AENEPECVTCLPSHTWTLPDISWELGLVSHSYFVEPEPSDLSAVSIILALTPQSNGLT 188  
 QY 193 TCYATKSKARKSATVNTLVIRCPDPTGGGINTGVLSPISLGFSPYMGKVLGAG 252  
 DB 189 TCYATKSKARKSATVNTLVIRCPDPTGGGINTGVLSPISLGFSPYMGKVLGAG 248  
 QY 253 TMLTPTCTLTIRCCCRRCGCCGCCGCCRCRRKRGFRLOPKSKSEKTKNETETE 312  
 DB 249 TMLTPTCTLTIRCCCRRCGCCGCCGCCRCRRKRGFRLOPKSKSEKTKNETETE 308  
 QY 313 SGNENSGYNSDEQKTDTSALPKSCSSDPEQRNNSCGPQRADQRPAPSHPOASF 372  
 DB 309 SGNENSGYNSDEQKTDTSALPKSCSSDPEQRNNSCGPQRADQRPAPSHPOASF 368  
 QY 373 NLASPEKVSNTTVY 386  
 DB 369 NLASPEKVSNTTVY 382

RESULT 3  
 AAU75542  
 ID AAU75542 standard; protein: 386 AA.

XX AC AAU75542;

XX DT 23-APR-2002 (first entry)

XX DE Human B7-L-like protein, B7-L<sub>h3</sub>.

XX Human; B7-L-like protein; B7-L; anti-infectivity; gynaecological;  
 XX antitumour; cytostatic; immunosuppressive; anti-arthritic; anti-rheumatic;  
 XX anti-inflammatory; dermatological; antiproliferative; neuroprotective;  
 XX anti-diabetic; haemostatic; antithyroid; antitumor; antiallergic;  
 XX antidiabetic; nephrotropic; antibacterial; virucide; tumour; cancer;  
 XX reproductive disorder; graft versus host disease; autoimmune disease;  
 XX toxic shock syndrome; allergy; nephropathy; skin disorder;  
 XX endocrinopathy; lymphoproliferative disorder.

OS Homo sapiens.  
 XX  
 PN WO200200710-A2.

XX 03-JAN-2002.  
 PD  
 XX 28-JUN-2001; 2001WO-US20719.  
 XX  
 XX 28-JUN-2000; 2000US-214512P.  
 XX 28-JUN-2000; 2000US-214512P.  
 XX 28-NOV-2000; 2000US-0729264.  
 PR  
 XX (AMGE-) AMGEN INC.  
 PA  
 XX Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 PI  
 XX WPI: 2002-130881/17.  
 XX N-PSDB: ABK13030.  
 DR  
 XX New B7-L-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 PS  
 XX Claim 13; Fig 3; 135pp; English.

CC The invention relates to an isolated B7-L-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-L-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility),  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis). They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of human B7-L<sub>h3</sub>.

XX Sequence 386 AA;

Query Match 95.8%; Score 2000; DB 23; Length 386;  
 Best Local Similarity 99.2%; Pred. No. 1.7e-157;  
 Matches 371; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 13 GSGSGNEVIEGPNARVYKGSQARFNCVSGWKLIMWALSDWVLSVRPMEPIITNDRF 72  
 DB 13 GSGSGNEVIEGPNARVYKGSQARFNCVSGWKLIMWALSDWVLSVRPMEPIITNDRF 72  
 QY 73 TSQRYDQGNFTSEMIHNVPEPSDSGNIRCSLQNSRLHGSAYLTVOYMGELFIPSNLVY 132  
 DB 73 TSQRYDQGNFTSEMIHNVPEPSDSGNIRCSLQNSRLHGSAYLTVOYMGELFIPSNLVY 132  
 QY 133 AENEPECVTCLPSHTWTLPDISWELGLVSHSYFVEPEPSDLSAVSIILALTPQSNGLT 192

```

Db 133 AENPECVETCLPSHWTRLDPDISWELGLVSHSSYFVPEPSDQASVSLATLPQSNGLT 192
OY 193 TCVAWTWKSARKSATVNLVYIRCPDPTGGGINIPGVLSLEPSLGFSTPTWKGVLGLAG 252
Db 193 TCVAWTWKSARKSATVNLVYIRCPDPTGGGINIPGVLSLEPSLGFSTPTWKGVLGLAG 252
OY 253 TMLTPTCTLTIRCCGRRRCGCCGCCRRCKRREFRLOPKSKKTKNETETE 312
Db 253 TMLTPTCTLTIRCCGRRRCGCCGCCRRCKRREFRLOPKSKKTKNETETE 312
OY 313 SGNENSGYNSDEKTTDTASLPKSCSESSDPQRNSSCGPPHQRADQPPPPASHQAS 372
Db 313 SGNENSGYNSDEKTTDTASLPKSCSESSDPQRNSSCGPPHQRADQPPPPASHQAS 372
OY 373 NLASPEKVSNTTYV 386
Db 373 NLASPEKVSNTTYV 386

```

## RESULT 4

AAU75543

ID AAU75543 standard; Protein: 377 AA.

AAU75543;

23-APR-2002 (first entry)

Human B7-1-like protein, B7-L<sub>H4</sub>.

Human: B7-1-like protein; B7-L; antiinfectivity; gynaecological;  
 antitumour; cytostatic; immunosuppressive; antithyroid; antirheumatic;  
 antiinflammatory; dermatological; antipsoriatic; neuroprotective;  
 antidiabetic; haemostatic; antithyroid; antitumor; antiallergic;  
 antiaesthetic; nephrotoxic; antibacterial; virucide; tumour; cancer;  
 reproductive disorder; graft versus host disease; autoimmune disease;  
 toxic shock syndrome; allergy; nephropathy; skin disorder;  
 endocrinopathy; lymphoproliferative disorder.

Homo sapiens.

WO200200710-A2.

03-JAN-2002.

28-JUN-2001; 2001MO-US20719.

28-JUN-2000; 2000US-214512P.

28-NOV-2000; 2000US-0729264.

(AMGE-) AMGEN INC.

Welcher AA, Sarmiento UM, Schultz HU, Chute HT;

WPI; 2002-130881/17.

N-PSDB; ABK13031.

New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 for diagnosing, preventing and treating reproductive, immune and  
 proliferative disorders, e.g. cancer and arteriosclerosis -  
 Claim 13; Fig 4; 135pp; English.

The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).  
 The polypeptide, polynucleotide encoding it and antibody against (I) are  
 useful for treating B7-1-like polypeptide-related disease, disorders or  
 conditions including reproductive disorders (e.g. infertility,  
 miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L

polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions, and for  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of human B7-L<sub>H4</sub>.

Sequence 377 AA;

Query Match 75.5%; Score 1576; DB 23; Length 377;  
 Best Local Similarity 88.6%; Pred. No. 2.4e-122;  
 Matches 296; Conservative 12; Mismatches 20; Indels 6; Gaps 2;

```

OY 1 MVAAMENRDPGGSGSNEVIEGPQNAVLKSGQARFNTVSGWKLIMALSDMWVLSV 60
Db 1 MVAAMENRDPGGSGSNEVIEGPQNAVLKSGQARFNTVSGWKLIMALSDMWVLSV 60
OY 61 RMEPIITNDRETSQRYDOGNFTSEMIHNVPSSGNIRCSLQNSRLHGSAYLTVOVM 120
Db 61 RMEPIITNDRETSQRYDOGNFTSEMIHNVPSSGNIRCSLQNSRLHGSAYLTVOVM 120
OY 121 GELFIPSVNLVVAENPECVETCLPSHWTRLDPDISWELGLVSHSSYFVPEPSDQASV 180
Db 121 GELFIPSVNLVVAENPECVETCLPSHWTRLDPDISWELGLVSHSSYFVPEPSDQASV 180
OY 181 ILALTPOSNGLTCVATWKSARKSATVNLVYIRCPDPTGGGINIPGVLSLEPSLGFSL 240
Db 181 ILALTPOSNGLTCVATWKSARKSATVNLVYIRCPDPTGGGINIPGVLSLEPSLGFSL 240
OY 241 PTWKGVLGLAGTMLTPTCTLTIRCCGRRRCGCCGCCRRCKRREFRLOPKSKKTKNETETE 300
Db 241 PTWKGVLGLAGTMLTPTCTLTIRCCGRRRCGCCGCCRRCKRREFRLOPKSKKTKNETETE 300
OY 301 EKETNKETETESGNSGYNSDEKTTDTASLP 334
Db 301 EKETNKETETESGNSGYNSDEKTTDTASLP 334
OY 298 QTKKLKQVEMKT---PATIQMKRRPOTPLASLP 328
Db 298 QTKKLKQVEMKT---PATIQMKRRPOTPLASLP 328

```

## RESULT 5

ABG28169

ID ABG28169 standard; Protein: 463 AA.

ABG28169;

18-FEB-2002 (first entry)

Novel human diagnostic protein #28160.

Human: chromosome mapping; gene mapping; gene therapy; forensic;  
 CC food supplement; medical imaging; diagnostic; genetic disorder.  
 CC Homo sapiens.

PN WO200175067-A2.  
 XX 11-OCT-2001.  
 PD 30-MAR-2001; 2001WO-US08631.  
 PF 31-MAR-2000; 2000US-0540217.  
 PR 23-AUG-2000; 2000US-0649167.  
 XX (HYSE-) HYSEQ INC.  
 PA Drmanac RT, Liu C, Tang YT;  
 PI WPI, 2001-639362/73.  
 DR N-PSDB; AAS92356.  
 XX  
 PT New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity -  
 PS  
 XX Claim 20; SEQ ID NO 58528; 103pp; English.

XX The invention relates to isolated polynucleotide (I) and  
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,  
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
 CC and gene mapping, and in recombinant production of (II). The  
 CC polynucleotides are also used in diagnostics as expressed sequence tags  
 CC for identifying expressed genes. (I) is useful in gene therapy techniques  
 CC to restore normal activity of (II) or to treat disease states involving  
 CC (II). (II) is useful for generating antibodies against it, detecting or  
 CC quantitating a polypeptide in tissue, as molecular weight markers and as  
 CC a food supplement (II) and its binding partners are useful in medical  
 CC imaging of sites expressing (II). (I) and (II) are useful for treating  
 CC disorders involving aberrant protein expression or biological activity.  
 CC The polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. ABG00010-ABG30377 represent novel human  
 CC diagnostic amino acid sequences of the invention.  
 CC Note: The sequence data for this patent did not appear in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequences.  
 CC  
 XX  
 XX Sequence 463 AA;

Query Match 63.1%; Score 1318; DB 22; Length 463;  
 Best Local Similarity 99.6%; Pred. No. 7.6e-101;  
 Matches 242; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX 49 MMALSDMVLVSVRPEPIITNDRTSORYDGGNTSMITHNPPSSGIRCSLNSR 108  
 PD 1 MMALSDMVLVSVRPEPIITNDRTSORYDGGNTSMITHNPPSSGIRCSLNSR 60  
 DB 109 LHGSATLVQWVGELTIPSVNLVVAENECVETCLPSHMTMLPDISWELGLVSHSYTF 168  
 XX 61 LHGSATLVQWVGELTIPSVNLVVAENECVETCLPSHMTMLPDISWELGLVSHSYTF 120  
 DB 169 VPPSPDQASVITLTPQSNGLTCAVATWKSLSKAKRSATVMTYIRCPDPTGGGGINPG 228  
 XX 121 VPPSPDQASVITLTPQSNGLTCAVATWKSLSKAKRSATVMTYIRCPDPTGGGGINPG 180  
 DB 229 VLSLPLGRLSPWKGKVGGLAGTMLLPTGCLTFRCCCRRCRCCGCCRCFCRR 288  
 XX 181 VLSLPLGRLSPWKGKVGGLAGTMLLPTGCLTFRCCCRRCRCCGCCRCFCRR 240  
 DB 289 KRG 291  
 XX 241 KRG 243

RESULT 6

AAU75544  
 ID AAU75544 standard; Protein; 370 AA.  
 XX  
 AC AAU75544;  
 XX  
 DT 23-APR-2002 (first entry)  
 DE  
 XX Mouse B7-1-like protein, B7-L<sub>ML</sub>.  
 XX  
 XX Mouse; B7-1-like protein; B7-L; antiferility; gynaecological;  
 KW antitumor; cytostatic; immunosuppressive; antiarthritic; anti-neumatic;  
 KW antiinflammatory; dermatological; antipsoriatic; neuroprotective;  
 KW antidiabetic; haemostatic; antithyroid; antitumor; anticancer;  
 KW antidiabetic; nephrotoxic; antibacterial; virucide; tumour disease;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder.  
 OS  
 XX Mus musculus.  
 PN WO200200710-A2.  
 PD 03-JAN-2002.  
 XX  
 XX 28-JUN-2001; 2001WO-US20719.  
 PF 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX (AMGE-) AMGEN INC.  
 PA Welcher AA, Sarmiento UM, Schultz HU, Chute HT;  
 PI WPI; 2002-130881/17.  
 DR N-PSDB; ABR13032.  
 XX  
 XX New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis -  
 PT  
 XX  
 PS Claim 13; Fig 5; 135pp; English.

XX The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-1-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility),  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, chronic inflammatory disease such as  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allensensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and

PI Welcher AA, Sarmiento UM, Schultz HD, Chute HT;  
XX  
DR  
XX WPI; 2002-130881/17.  
PT New B7-like polypeptides, polynucleotides and their modulators, useful  
for diagnosing, preventing and treating

PT      of, affecting and leading reproductive, immune and  
XX      proliferative disorders, e.g. cancer and arteriosclerosis  
PS  
XX      Disclosure; Fig 8; 135pp; English.

The invention relates to an isolated B7-like (B7-L) polypeptide (I), useful for treating B7-like polypeptide-related disease, against (I) are conditions including reproductive disorders (e.g., infertility, miscarriage, preterm labour and delivery and endometriosis) and extracellular disorders. Antibodies, soluble proteins comprising useful for enhancing the immune response of B7-L polypeptides are growth and maintenance of cancer cells based on the observation of seminal vesicle hyperplasia in transgenic mice overexpressing B7-L polypeptide. Hence modulators of (I) are useful for the treatment of cancer including seminal vesicle cancer, lung, brain, breast, ovarian, testicular cancer and cancers of haematopoietic system. B7-L polypeptide pathway can be manipulated to regulate cytotoxic T-lymphocyte response in allograft transplantation, graft versus host disease, T-cell dependent B-cell mediated diseases and autoimmune diseases. T-cell molecules are useful for alleviating the symptoms associated with autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, diabetes, immune thrombocytopenic purpura and psoriasis, chronic inflammatory disease such as inflammatory bowel disease (Crohn's disease and ulcerative colitis), Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They are also useful as immunosuppressive agents for bone marrow and organ transplantation or to prolong graft survival. B7-L molecules are also useful for diagnosis and treatment of diseases involving abnormal cell proliferation, including arteriosclerosis and vascular restenosis. Antibodies of B7-L polypeptides are also useful for the treatment of

CC treatment of allergy, asthma and hypersensitivity reactions, and for  
CC neuropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
CC thrombocytopaenias, Guillain-Barre syndrome and myasthenia gravis, and  
CC lymphoproliferative disorders such as multiple myeloma. The present  
CC sequence represents the amino acid sequence of rat B7-1.  
xx  
SQ Sequence 631 AA;

[illegible]

Db 129 KALLSDYIFCCSEDSIHRIYQKHDKKVLASYISGVEPMFKYKNRTTASYNSTDSFIS 188  
 QY 86 EMTHNVEPDSGANTRCSLQNSRLHGSAYL----- 115  
 Db 189 ELIHIVQPSDGSVQCSLQNSHGSGFSLVQYDIANNYSFLLGLILSDRGTYTCVV 248  
 QY 116 -----TVQVMGELFIPSVNLVVAENEPCEVYCLPSHMTWLPDIDISWELGLV 161  
 Db 249 QREGGSYVYKHLTFVEVMGTLPINNNLIYITEGEPONTCAVGMTSLPDISWELNVP 308

SYFVPEPS 173

RESULT 8  
AAU75545  
ID AAU75545 standard; Protein: 270 AA

Mouse B7-1-like protein, B7-L<sub>m2</sub>

KW Mouse; B7-like protein; B7-L; antiinferility; gynaecological;  
 KW antitumour; cytostatic; immunosuppressive; antiarthritic; antiheumatic  
 KW antinflammatory; dermatological; antiporiatic; neuroprotective;  
 KW antidiabetic; haemostatic; antithyroid; antifucic; anti allergic;  
 KW antasthmatic; nephrotoxic; antibacterial; vitucide; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder.

**Mus musculus.**

PN WO200200710-A2

PD 03-JAN-2002.

PF 28-JUN-2001; 2001WO-US20719.

PR 28-JUN-2000; 2000US-214512P

XX

[illegible]

XX 2003 130891 /17

DR N-PSDB; ABK13033

New B7-like polypeptides, polynucleotides and their modulators, used for preventing and treating reproductive, immune and

proliferative disorders, e.g. cancer and leukaemias

Claim 13; Fig 6; 135bp; English

The polypeptide encoding it and antibody against (I)

conditions including reproductive disorders (e.g. infertility,

proliferative disorders. Antibodies, soluble proteins comprising

useful for enhancing the immune response to tumours. (I) plays a role in

[illegible]

CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
CC polypeptide. Hence modulators of (I) are useful for the treatment of  
CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
CC in allograft transplantation, graft versus host disease, T-cell  
CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
CC molecules are useful for alleviating the symptoms associated with  
CC diseases involving chronic immune cell dysfunction or to treat  
CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
CC purpura and psoriasis, chronic inflammatory disease such as  
CC inflammatory bowel disease (Crohn's disease and diabetes mellitus). They  
CC are also useful as immunosuppressive agents for bone marrow and organ  
CC transplantation or to prolong graft survival. B7-L molecules are also  
CC useful for diagnosis and treatment of diseases involving abnormal cell  
CC proliferation, including arteriosclerosis and vascular restenosis.  
CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
CC shock syndrome or alloensensitisation due to blood transfusions, and for  
CC treatment of allergy, asthma and hypersensitivity reactions,  
CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
CC (extrinsic alveolitis), vasculopathies, colicac disease, anaemia, and  
CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
CC lymphoproliferative disorders such as multiple myeloma. The present  
CC sequence represents the amino acid sequence of mouse B7-L-m2.

Query Match	37.18;	Score	566.5;	DB	23;	Length	270;
Best Similarity	34.68;	Pred. No	7.7e-39;				
Best Local	42;	Mismatches	71;	Indels	135;	Gaps	5

14 SCSGNEVIEGPQNAVLKGSQARENCJVSQGWKLIMWALSDMVAUSVNFMEFLLINDN

Db 21 SSSYQIEGPQNTVLKDSFAHNCIVIHGWLLEMIENQIVESLIGQIAA..... - 33

74 SÖRDBÖGNETSEM LHNVEPSDSGNKCSLQNSKNHSHLVV

Db 81 YASYNISIDSE ISELL IHDVQPSDBGSVQCSLQNSHET OCHH BC V X

134 ENPCEVJCLP SHIMWLFDISNEBGLVCHUCALVLECEK...  
QY

126 T

QY 194 CYAIIWNSLEAKNNSAI VNDI V INCI QZDIOOONNRV OYBBOO

| : | : ||| | : | : :

LB 120

[illegible]

DU 147 UNCLASSIFIED

[illegible]

58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
8

[illegible]

## RESULT 9

ID AAU75546 standard; Protein; 223 AA.

AC AAU75546;

DT 23-APR-2002 (first entry)

DE Mouse B7-1-like protein, B7-L<sub>m3</sub>.

KM Mouse; B7-like protein; B7-L; antiinfectivity; gynaecological;  
 KM antitumor; cytostatic; immunosuppressive; antiarthritic; antineumatic;  
 KM antiinflammatory; dermatological; antipsoriatic; neuroprotective;  
 KM antidiabetic; haemostatic; antithyroid; antileuc; antiallergic;  
 KM antistaphylococcal; antibacterial; virucide; tumour; cancer;  
 KM reproductive disorder; graft versus host disease; autoimmune disease;  
 KM toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KM endocrinopathy; lymphoproliferative disorder.  
 OS Mus musculus.  
 PN WO200200710-A2.  
 XX 03-JAN-2002.  
 PD 28-JUN-2001; 2001WO-US20719.  
 PE 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX (AMGE-) AMGEN INC.  
 PA Welcher AA, Sarmiento UM, Schultz HU, Chute HT;  
 PI MPI; 2002-130881/17.  
 DR N-PSDB; ABR13034.  
 XX New B7-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis -  
 PS Claim 13; Fig 7; 135pp; English.  
 CC The invention relates to an isolated B7-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L.  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions.  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Graves' disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of mouse B7-L<sub>m3</sub>.  
 XX  
 SX Sequence 223 AA:  
 Query Match 23.2%; Score 485; DB 23; Length 223;

Best Local Similarity 31.4%; Pred. No. 3,4e-32;  
 Matches 118; Conservative 37; Mismatches 45; Indels 176; Gaps 6;  
 QY 14 SSGNEVEIEGPONARVNLGSGOAREFCVTGSGMKLIMALSMYVLSVREPEPITINDRET 73  
 DB 21 SSSVQIIEGQONVYVLDSEAHFNCVTYHGMKLLMNLNMYVLSLTGQPIITNRRFT 80  
 QY 74 SORTDGGNFTSEMIINHVEPSDGNIRCSLQNSRLHGSAYLVQVWGELEFIPSVNLVVA 133  
 DB 81 YASYNSTDSFISELIHDVQPSDSGSVQCSLQNSHGFSGAFLSVQ----- 125  
 QY 134 ENPECEVTCPLPSHMTNLPDISMELGLVSHSSYFVEPEPSDGSAYIALTPQSNCTLT 193  
 DB 126 -----ESTY-----ONEI----- 133  
 QY 194 CVATWKSILKARKSATVNLTVIRCPQDTGGGINIPGLVSLPSLGFSLPTGKVGGLAGT 253  
 DB 134 -----RKSANM----- 139  
 QY 254 MLNPTCTLTIRCCGCCRRCCGCCGCCRCCKRKRGRFRIQFKSEKKTNK---ETE 310  
 DB 140 -----RTMKADPEYK 149  
 QY 311 TSGNENSGYNSDEOKTTDTASLPKSCSESSDPEORNSCGPPHORADOPPPAPASHQA 370  
 DB 150 LKSGKENYGYSSDEAKAQTASLPKSAEYSLPERKSSSL--FYQELNKHQEPQATHPRV 207  
 QY 371 SFNIASEKYSNTTVV 386  
 DB 208 SFDIASPKVKNVTLV 223  
 RESULT 10  
 AAB81925  
 ID AAB81925 standard; protein; 404 AA.  
 AC AAB81925;  
 XX 15-JUN-2001 (first entry)  
 DT Extracorporeal circulation material receptor protein.  
 XX Extracorporeal circulation; carbonyl stress product; receptor;  
 KW diabetes; vascular lesion; excretory dysfunction.  
 OS Unidentified.  
 OS WO200118060-A1.  
 PN 15-MAR-2001.  
 PD 08-SEP-2000; 2000WO-JP06172.  
 PE 08-SEP-1999; 99JP-0254463.  
 PR (TORA) TORAY IND INC.  
 PA Shimizu S, Kubota M, Akiyama H, Usui M;  
 PI MPI; 2001-290314/30.  
 DR Material for extracorporeal circulation, applicable in selective  
 XX elimination of diabetic complication factors such as carbonyl stress  
 XX products caused by abnormally promoted carbonyl stress from excretory  
 XX dysfunction in vascular lesions -  
 PS Claim 1; Page 31-32; 36pp; Japanese.  
 CC The present invention describes a material for extracorporeal circulation  
 CC which is made from a water-insoluble carrier immobilized with a protein  
 CC having the sequence shown here. The materials of the invention, including  
 CC adsorbents, are for extracorporeal circulation, which are applicable in  
 CC the selective elimination of diabetic complication factors from a body

XX  
PS Disclosure; Page 16; 43pp; English.

PR 14-AUG-2000; 2000US-0638648.  
 XX (UYCO ) UNIV COLUMBIA NEW YORK.  
 XX  
 XX Stern DM, Schmidt AM, Yan SD, Zlokovic B;  
 PI  
 DR WPI: 2002-257610/30.  
 DR N-PSDB; ABK10856.

PT Ameliorating neurovascular stress and decreasing cerebral  
 PT vasoconstriction in subject suffering from chronic/acute cerebral  
 PT amyloid angiopathy, by administering inhibitor of receptor for advanced  
 PT glycation endproduct  
 XX  
 PS Disclosure; Page 16; 68pp; English.

CC The invention describes a method of ameliorating neurovascular stress,  
 CC and decreasing cerebral vasoconstriction in subject suffering from  
 CC chronic or acute cerebral amyloid angiopathy, comprising administering  
 CC an inhibitor (I) of receptor for advanced glycation end product (RAGE).  
 CC (I) inhibits transcytosis of amyloid beta peptides across blood-brain  
 CC barrier, thus decreasing cerebral vasoconstriction and increasing  
 CC cerebral blood flow. (I) is useful for treating amyloid angiopathy in a  
 CC subject, decreasing cerebral vasoconstriction in a transgenic non-human  
 CC animal (preferably, transgenic mouse overexpressing mutant human amyloid  
 CC beta precursor protein) or a human, suffering from chronic or acute  
 CC cerebral amyloid angiopathy, preferably, Alzheimer's disease, and for  
 CC ameliorating neurovascular stress comprising cerebral amyloid angiopathy  
 CC in a subject, where the neurovascular stress is caused by Alzheimer's  
 CC disease, aging, Down's syndrome, head trauma or stroke. This is the  
 CC amino acid sequence of human receptor for advanced glycation end  
 CC product (RAGE) described in the invention.

XX Sequence 404 AA;

Query Match 7.0%; Score 145.5; DB 23; Length 404;  
 Best Local Similarity 23.5%; Pred. No. 0.001;  
 Matches 77; Conservative 34; Mismatches 94; Indels 123; Gaps 15;

OY 64 EPIITNDRTS-----QRYDGGNFT--SEMIHNVEPSDGNIR-----CSLQNSRLHGS 112  
 DB 162 KPLVFNKGVSVKEQTRRHPTGTLTQSELM---VTPARGDPRPTSCSFSPGLPRHR 218  
 OY 113 AVLTVOVMGELFIP-----SVNLVVAENEP-----CEVTCLPSHMTWLPDIS 154  
 DB 219 ALRTAPIQPRVWEPPVLEEVQLVY---EPEGGAVAPGTVLTCEVPAQPS-----PQIH 270  
 OY 155 WELGLLVSHSYFYFPEPSDLOSASVIALTPQSNGLTCVATWMSLKARSAVNLTVI 214  
 DB 271 WMKD-----GVPLPLPPSPVILPEIGPDQGTSCVATHSSHGQESRAVSISII 321  
 OY 215 RCPDITGGGINIPGVLSLPSLGFSLPTWKGVLGLAGTMLLT-----PTCTLTTRCC 267  
 DB 322 E-PGEGS-----PTAGSVGSGGLTALALGILGIGTALLIGVI 361  
 OY 268 CRRRCGCCGCCRCRCCRRKRGFRIOFKKSEKERT--NKETETESGNGNSGYNSDEQ 325  
 DB 362 LMQR-----GVPLPLPPSPVILPEIGPDQGTSCVATHSSHGQESRAVSISII 389  
 OY 326 KTTDTASLPPKSCSSDPEQRNSSCGPP 353  
 DB 390 -----QSEEPAGESSTGPP 404

RESULT 13  
 AAM48745  
 ID AAM48745 standard; protein; 404 AA.  
 XX  
 AC AAM48745;  
 XX  
 DT 02-APR-2002 (first entry)  
 XX Human RAGE protein SEQ ID NO 1.

XX Human: RAGE; receptor for advanced glyated endproduct; receptor;  
 KW antidiabetic; neuroprotective; cytostatic; antiinflammatory; vasotropic;  
 KW nephrotropic; dermatological; antiarteriosclerotic; nootropic; diabetes;  
 KW Alzheimer's disease; cancer; inflammation; kidney failure;  
 KW systemic lupus; nephritis; erectile dysfunction; atherosclerosis.  
 XX Homo sapiens.  
 OS  
 PN WO200192892-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 30-MAY-2001; 2001WO-US17447.  
 XX  
 PR 30-MAY-2000; 2000US-207342P.  
 PR 05-MAR-2001; 2001US-0799152.  
 XX  
 PA (TRAN-) TRANS TECH PHARMA.  
 XX  
 PI Shabbaz M;  
 DR WPI: 2002-114372/15.

PT Detecting a receptor for advanced glyated endproducts (RAGE)  
 PT modulators, for treating e.g., cancer, diabetes or inflammation,  
 PT comprises measuring the amount of bound anti-RAGE antibody  
 XX  
 PS Claim 1; Fig 2; 49pp; English.

CC The invention relates to detecting receptor for advanced glyated  
 CC endproducts (RAGE) modulators comprises determining the amount of RAGE  
 CC protein or its fragment bound to the pre-adsorbed ligand by measuring the  
 CC amount of anti-RAGE antibody bound to the solid surface. The method is  
 CC useful for rapid, high-throughput identification of compounds that  
 CC modulate RAGE. The compounds are useful for treating symptoms of diabetes  
 CC and symptoms of diabetic late complications, amyloidosis, Alzheimer's  
 CC disease, cancer, inflammation, kidney failure, systemic lupus nephritis  
 CC or inflammatory lupus nephritis, erectile dysfunction and  
 CC atherosclerosis.

XX Sequence 404 AA;

Query Match 7.0%; Score 145.5; DB 23; Length 404;  
 Best Local Similarity 23.5%; Pred. No. 0.001;  
 Matches 77; Conservative 34; Mismatches 94; Indels 123; Gaps 15;

OY 64 EPIITNDRTS-----QRYDGGNFT--SEMIHNVEPSDGNIR-----CSLQNSRLHGS 112  
 DB 162 KPLVFNKGVSVKEQTRRHPTGTLTQSELM---VTPARGDPRPTSCSFSPGLPRHR 218  
 OY 113 AVLTVOVMGELFIP-----SVNLVVAENEP-----CEVTCLPSHMTWLPDIS 154  
 DB 219 ALRTAPIQPRVWEPPVLEEVQLVY---EPEGGAVAPGTVLTCEVPAQPS-----PQIH 270  
 OY 155 WELGLLVSHSYFYFPEPSDLOSASVIALTPQSNGLTCVATWMSLKARSAVNLTVI 214  
 DB 271 WMKD-----GVPLPLPPSPVILPEIGPDQGTSCVATHSSHGQESRAVSISII 321  
 OY 215 RCPDITGGGINIPGVLSLPSLGFSLPTWKGVLGLAGTMLLT-----PTCTLTTRCC 267  
 DB 322 E-PGEGS-----PTAGSVGSGGLTALALGILGIGTALLIGVI 361  
 OY 268 CRRRCGCCGCCRCRCCRRKRGFRIOFKKSEKERT--NKETETESGNGNSGYNSDEQ 325  
 DB 362 LMQR-----GVPLPLPPSPVILPEIGPDQGTSCVATHSSHGQESRAVSISII 389  
 OY 326 KTTDTASLPPKSCSSDPEQRNSSCGPP 353  
 DB 390 -----QSEEPAGESSTGPP 404

RESULT 14









Query Match 81.6%; Score 1694; DB 4; Length 315;  
 Best Local Similarity 99.7%; Pred. No. 7.3e-144;  
 Matches 314; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

14 SSGSENEVEEPONATVYKSGQARFNCCTVSGGKLMALSDMYVLSVRPEPIITNDREFT 73  
 1 SSGSENEVEEPONATVYKSGQARFNCCTVSGGKLMALSDMYVLSVRPEPIITNDREFT 60  
 61 SQRYDQGNFTSEMIITHNVEPSDGNIRCSLQNSRLHGSAYLTVQVMEGLFIPSNLVYA 133  
 74 SQRYDQGNFTSEMIITHNVEPSDGNIRCSLQNSRLHGSAYLTVQVMEGLFIPSNLVYA 120  
 134 ENPECEVTCPSHMTLPDIWSLGLVSHSSYFVEPEPSDQSAVSITLTPQSNGLTL 193  
 121 ENPECEVTCPSHMTLPDIWSLGLVSHSSYFVEPEPSDQSAVSITLTPQSNGLTL 180  
 194 CVATWMSLKARKSATVNLVIRCPDPTGGGINIPGLSLPSLGFSLPTWGVGLAGT 253  
 181 CVATWMSLKARKSATVNLVIRCPDPTGGGINIPGLSLPSLGFSLPTWGVGLAGT 240  
 254 MULTPTCTLTIRCCCRRCGCCGCCGCCFCRCRRKGRFIOFKKSEKTEKTEETES 313  
 241 MULTPTCTLTIRCCCRRCGCCGCCGCCFCRCRRKGRFIOFKKSEKTEKTEETES 300  
 314 GNENSGYNSDEQKTT 328  
 301 GNENSGYNSDEQKTT 315

RESULT 2  
 09D8G2 PRELIMINARY; PRT; 270 AA.  
 AC 09D8G2;  
 DT 01-JUN-2001 (TREMblrel. 17, Created)  
 DT 01-JUN-2001 (TREMblrel. 17, Last sequence update)  
 DE 2010003D20R1K protein (RIKEN CDNA 2010003D20 gene).  
 GN 2010003D20R1K.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=SMALL INTESTINE;  
 RX MEDLINE=21085660; Pubmed=11217851;  
 RA Kawai J., Shnagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,  
 RA Sato T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,  
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
 RA Fieischmann W., Gaasterland T., Gissi C., King B., Kochiya H.,  
 RA Knehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,  
 RA Schirml L.M., Staudil F., Suzuki R., Tomita M., Wagner L., Mashio T.,  
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,  
 RA Blake J., Botfield D., Bojunga N., Carninci P., de Bonaldo M.F.,  
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
 RA Guncionich S., Hill D., Hofmann M., Hume D.A., Kamaya M., Lee N.H.,  
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Komaba N.,  
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
 RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,  
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whitaker C., Wilming L.,  
 RA Wyszynski B., Yoshida K., Hasegawa Y., Kawaji H., Kohsaki S.,  
 RA Hayashizaki Y.;  
 RT "Functional annotation of a full-length mouse cDNA collection."  
 RL Nature 409:685-690(2001).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC Strausberg R.;  
 RL Submitted (MAR-2001) to the EMBL/Genbank/DBJ databases.  
 DR EMBL; AK008060; BAB25436.1;  
 DR EMBL; BC004806; AAH04806.1;  
 DR MGI; 1919308; 2010003D20R1K.

DR InterPro; IPR003599; IG\_MHC.  
 DR InterPro; IPR003006; IG\_MHC.  
 DR SMART; SM00409; IG; 1.  
 DR PROSITE; PS00290; IG\_MHC; UNKNOWN 1.  
 SQ SEQUENCE 270 AA; 29604 MM; A39C273DA950DPE CRC64;

Query Match 27.9%; Score 579.5; DB 11; Length 270;  
 Best Local Similarity 34.3%; Pred. No. 6.3e-44;  
 Matches 133; Conservative 46; Mismatches 74; Indels 135; Gaps 5;

5 LITVEAVGSGSENEVEEPONATVYKSGQARFNCCTVSGGKLMALSDMYVLSVRPE 64  
 12 LVLLAQGLASSSSYQIIBGPONATVYKLDSEAHFNCCTVHGKLMALSDMYVLSVRPE 71  
 65 PIITNDRETSQRYDQGNFTSEMIITHNVEPSDGNIRCSLQNSRLHGSAYLTVQVMEGLF 124  
 72 PIITNDRETSQRYDQGNFTSEMIITHNVEPSDGNIRCSLQNSRLHGSAYLTVQVMEGLF 125  
 125 IPSVNLVVAENPECEVTCPSHMTLPDIWSLGLVSHSSYFVEPEPSDQSAVSITLAL 184  
 126 -----  
 185 TPQSNGLTVCAVWMSLKARKSATVNLVIRCPDPTGGGINIPGLSLPSLGFSLPTWG 244  
 126 -----  
 126 -----  
 245 KYVGLAGTMTLPPTCTLTIRCCCRRCGCCGCCGCCFCRCRRKGRFIOFKKSE 301  
 140 IILAVAFSLILLIILIIILIIIFCC-----CASRRKEESTYQNEIRKSA 184  
 302 KEKTK-----ETESGSENGSYNSDEQKTTETASLPPKSCSSDPQRNSGCPHQRAD 358  
 185 NMRTNKADPETKLSKGENGYSSDEAKAQTSLPDKSAEVSLEPKRSSSL--PYQELN 242  
 359 QREPRASHQASFNALPEKVSNTTVV 386  
 243 KHQPPATHPRVSFDIASPKVKNVTIV 270

RESULT 3  
 09DF61 PRELIMINARY; PRT; 344 AA.  
 AC 09DF61;  
 DT 01-MAR-2001 (TREMblrel. 16, Created)  
 DT 01-MAR-2001 (TREMblrel. 16, Last sequence update)  
 DE 01-DEC-2001 (TREMblrel. 19, Last annotation update)  
 DE OBCAM alpha 1 isoform.  
 GN OBCAM.  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 OX NCBI\_TaxID=9031;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=BRAIN;  
 RX MEDLINE=20499204; Pubmed=11042360;  
 RA Lodge A.P., Howard M.R., McNamee C.J., Moss D.J.;  
 RT "Co-localisation, heterophilic interactions and regulated expression  
 of IgG1 family proteins in the chick nervous system."  
 RL Brain Res. Mol. Brain Res. 82:84-94(2000).  
 DR EMBL; AF292934; AAG01877.1;  
 DR InterPro; IPR003599; IG.  
 DR InterPro; IPR003598; IG\_C2.  
 DR InterPro; IPR003600; IG\_Like.  
 DR InterPro; IPR003006; IG\_MHC.  
 DR Pfam; PF00047; IG\_3.  
 DR SMART; SM00409; IG; 3.  
 DR SMART; SM00408; IG\_C2; 3.  
 DR SMART; SM00410; IG\_Like; 2.  
 KW Immunoglobulin domain.  
 SQ SEQUENCE 344 AA; 37531 MM; 37FE6051CBFE0E7B4 CRC64;

```

Query Match 6.8% Score 141 DB 11 Length 168;
Best Local Similarity 32.0% Pred. No. 7-7e-05;
Matches 39; Conservative 20; Mismatches 49; Indels 14; Gaps 6

260 CTTTIRCCCRRCGCCNC-CCRCCECRRKGR-----IOFKKSEKRNKETETESG 314
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
55 CTSIRSCCCRCCKKC-CHCRCKC-CCSRKRRFSKTTLLFPQTEGEGSLORRRRQ 111

```

```

Query Match      6.6%; Score 137.5; DB 13; Length 519;
Best Local Similarity 26.0%; Pred. No. 0.00033;
Matches 70; Conservative 38; Mismatches 104; Indels 57; Gaps

QY      3 RHLLTPEANGSSSGNEVI--EGGONATYVKKSGQAFNCTVSGO-----GW---KLIMMALS 53
Dh      20 RLLEFLVPAQVPRVSGGATTPPKANDNTVYQGSALRLRCSVDNRVTYRAMLMRRSSLLYAGN 79
QY      54 DMWVLVSRPEMEPIITNDRTFSQRDGGNFTESEMIHNVPEPDSNSNRCSIQ-----NS 107
Dh      80 DKMCLDPRVYLLANTFTKQYSIQ-----IHDDVDYDESPYTCVSQTDNHPKTS 126
QY      108 RLHCSALTPOVWNGELTIPSVLNVVAENEPCEVTLCPHSMTFLPD--ISWELGLLVSHSS 165
Dh      127 RVH-----LIIVQSPKITEIISDSISINEGNAVSLTCA--TERPDPPTIWR--HISPKA 176
QY      166 YFVPEPSDLSQAVSILALTPQSGNGLTVCAVATWKSLSKAKRSATVNLTV-----TRCPDPT 222
Dh      177 VGFISEDEYLE---ITGLIRREGSGGECCAS--NDVAAPVAVORAVRYVNTYNPPIISDAKST 233
QY      221 GGGGINIFGVL-----SSLPSIGFSLTPFWGK 245
Dh      232 GVPVGQKGIIMCEASAVPSPDFQ---WYK 257

```

RESULT 6	
099PJ0	PRELIMINARY;
ID 099PJ0	PRT; 344 AA
AC 099PJ0	
DT 01-JUN-2001	(Tremblrel, 17, Created)

DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)  
 DT 01-DEC-2001 (Tremblrel. 19, Last annotation update)  
 DE Neutrotrilin.  
 OC Mus musculus (Mouse).  
 OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
 NCBI\_Taxid=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=ICR; TISSUE=BRAIN;  
 RA Kim T.H., Choi S.C., Kim J., Jeon J.W., Kim K.D., Lee S.H.;  
 RT "Cloning and expression of mouse neutrotrilin gene in the developing  
 RT nervous system".  
 RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AF282980; AAK0276.1;  
 DR InterPro: IPR003599; Ig.  
 DR InterPro: IPR003598; Ig\_c2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR Pfam: PF00047; Ig\_3.  
 DR SMART: SM00409; Ig; 3.  
 DR SMART: SM00408; IGC2; 3.  
 DR SMART: SM00410; Ig\_Like; 2.  
 KW Immunoglobulin domain.  
 SQ SEQUENCE 344 AA; 37924 MW; 3EC6D5EE6C5C17D CRC64;  
 Query Match 6.6%; Score 137.5; DB 11; Length 344;  
 Best Local Similarity 26.0%; Pred. No. 0.0004;  
 Matches 68; Conservative 36; Mismatches 115; Indels 43; Gaps 13;  
 QY 3 RHLLTPEAVGSSGSGNEVI-EGPQNAITVLSQARFNCYTSQGMKLIMALSMTVLSVR 61  
 DB 20 RLFLVPAAGVPRVSGDTPFRKAMDNTVROGESATLRCSVDNRVTRVAVLNRSSITLYACN 79  
 QY 62 PMEPIITNDRF-TSQRYDQGNFTSE--MIHNVEPSDSGNINCSLQ-----NSRLHGS 112  
 DB 75 ---PYAGNDKWCIDPRVLLIGNTOTQYSIEIQNVVDYDESPYCSQVIDNHPTSVH-- 129  
 QY 113 AYLTVQWGLFIPSVLVVAENPECEVTCLPSSHTRLPD-ISMELGLVSHSSYFVPEP 172  
 DB 130 --LIVQVSPKITEISSISNEGNSISLTCIATGRPE-PLVTRW--HISPAVGFVSD 183  
 QY 173 SDIQSAVSLATLPQSNGLTLCVATWKSILKARKSATVNLTV-IRCPD-----ODTGGGINP 227  
 DB 184 EYLD-----TQGTREQSGEYECAS-NDVAAPVQVRKVTVPNPPFSAKGTGVPVGOK 238  
 QY 228 GVL-----SLPSLGFSLPTWCK 245  
 DB 239 GTLQCEASAVPSAEFO---WFK 257  
 RESULT 7  
 ID 093242 PRELIMINARY; PRT; 344 AA.  
 AC 093242;  
 DT 01-NOV-1998 (Tremblrel. 08, Created)  
 DT 01-NOV-1998 (Tremblrel. 08, Last sequence update)  
 DT 01-DEC-2001 (Tremblrel. 19, Last annotation update)  
 DE CEP-1.  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianidae;  
 OC Gallus.  
 NCBI\_Taxid=9031;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Kimura Y., Shirabe K., Fukushima M., Takeshita M., Tanaka H.;  
 RT "CEP-1: an immunoglobulin superfamily molecule, has cell adhesion  
 RT activity and shows dynamic expression patterns in Chick Embryonic  
 RT Spinal Cord".  
 RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AB011810; BAA31514.1;  
 DR InterPro: IPR003598; Ig\_c2.

DR InterPro: IPR003600; Ig\_Like.  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR Pfam: PF00047; Ig\_3.  
 DR SMART: SM00408; IGC2; 2.  
 DR SMART: SM00410; Ig\_Like; 1.  
 KW Immunoglobulin domain.  
 SQ SEQUENCE 344 AA; 37613 MW; 22CAABF526A6B57E CRC64;  
 Query Match 6.6%; Score 137.5; DB 13; Length 344;  
 Best Local Similarity 26.0%; Pred. No. 0.0004;  
 Matches 70; Conservative 38; Mismatches 104; Indels 57; Gaps 14;  
 QY 3 RHLLTPEAVGSSGSGNEVI-EGPQNAITVLSQARFNCYTSQGMKLIMALSMTVLSVR 53  
 DB 20 RLFLVPAAGVPRVSGDTPFRKAMDNTVROGESATLRCSVDNRVTRVAVLNRSSITLYACN 79  
 QY 54 DMVLSVRPEPIITNDRFTSQRYDQGNFTSEMIHNVEPSDSGNINCSLQ-----NS 107  
 DB 80 DKWCIDPRVLLANTKTQYSIQ-----IHVDVYDESPYCSQVIDNHPTSVH-- 126  
 QY 108 RLHGSAYLVQWGLFIPSVLVVAENPECEVTCLPSSHTRLPD-ISMELGLVSHSS 165  
 DB 127 RVH-----LIVQVSPKITEISSISNEGNSISLTCIATGRPE-PLVTRW--HISPA 176  
 QY 166 YFVPEPSDQSAVSLATLPQSNGLTLCVATWKSILKARKSATVNLTV-IRCPDPT 220  
 DB 177 VGFISDEYLE-----TGTREQSGEYECAS-NDVAAPVQVRKVTVPNPPFSAKGTGVP 231  
 QY 221 GGINIPGVL-----SLPSLGFSLPTWCK 245  
 DB 232 GVPVGOKGILMCEASAVPSAEFO---WFK 257  
 RESULT 8  
 ID 09DAK2 PRELIMINARY; PRT; 173 AA.  
 AC 09DAK2;  
 DT 01-JUN-2001 (Tremblrel. 17, Created)  
 DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)  
 DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)  
 DE 4931420D14RIK protein.  
 CN 4931420D14RIK.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 NCBI\_Taxid=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=TESTIS;  
 RA MEDLINE=21085660; PubMed=11217851;  
 RA Kawai J., Shingawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
 RA Arikawa T., Hara A., Fukunishi Y., Kono H., Adachi J., Fukuda S.,  
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamana K.,  
 RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,  
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
 RA Fleischmann W., Gaasterland T., Glessi C., King B., Kochiwa H.,  
 RA Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,  
 RA Schriml L.M., Staudli F., Suzuki R., Tomita M., Wagner L., Washio T.,  
 RA Sakai K., Okido T., Furuno M., Aono H., Balderelli R., Barsh G.,  
 RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,  
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
 RA Guinchard S., Hill D., Holtzman M., Hume D.A., Kamiya M., Lee N.H.,  
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
 RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,  
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whitaker C., Wilming L.,  
 RA Wysshaw-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohlsuki S.,  
 RA Hayashizaki Y.,  
 RT "Functional annotation of a full-length mouse cDNA collection".  
 RL Nature 409:685-690(2001).  
 DR EMBL; AK016467; BAB30253.1;  
 DR MGI; MGI:1913992; 4931420D14RIK.  
 SQ SEQUENCE 173 AA; 19581 MW; 147B6F155AC29FDF CRC64;



QY 60 -----VAPMEPIITNDRETSORDGNGFTSEMIINHVESDGNRCISQ-----NSRL 109  
 DB 80 DKWCLDPRVVLN-----TQYQY-----SIEIQNVVLYDDEGPYCSVQTDNHPKTSYV 128  
 QY 110 HGSAYLVTVQVWGLFIPSNVLYVAENEPCEVTCPLSHMTLRDIPISMLLVLVSHSYFV 169  
 DB 129 H-----LIVQVSPKIVATISSDINSGNNISLTCIATGRPE-PLVYWR--HISPRAGVY 180  
 QY 170 PEPSDQSAVSIATLPQSNGLTLCVATWKSILKARKSATVNLTKPC-----ODTGGGI 224  
 DB 181 SEDEYLE-----IGITRREGSGVECSAS-NDVAAPVYRVKVTYVNPYISAKGTGPV 235  
 QY 225 NIPGVY-----SSLPISGLSELPWVGK 245  
 DB 236 GQKGTLCCEASAVPSAEQ---WYK 257  
 RESULT 11  
 Q91562  
 ID 091562 PRELIMINARY; PRT; 1427 AA.  
 AC 091562;  
 DT 01-NOV-1996 (TREMBlrel. 01, Created)  
 DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)  
 DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)  
 DE Tumor suppressor.  
 GN XDCCA.  
 OS Xenopus laevis (African clawed frog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pidae;  
 OC Xenopodinae; Xenopus.  
 OX NCBI\_TaxID=8335;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=95113183; PubMed=7813784;  
 RA Piecetti M.E., Keale M.A., Candia A.F., Wright C.V., Cho K.R.,  
 RA Fearon E.R.;  
 RT "Expression of a homologue of the deleted in colorectal cancer (DCC)  
 RT gene in the nervous system of developing Xenopus embryos."  
 RL Dev. Biol. 166:654-665(1994).  
 DR EMBL: U10986; AAA70168.1; -  
 DR HSSP; P40189; 180U.  
 DR InterPro: IPR003962; FNIII\_repeat.  
 DR InterPro: IPR003961; FN\_III.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR Pfam; PF00047; fn3; 6.  
 DR Pfam; PF00047; Ig; 4.  
 DR PRINTS; PR00014; FNTPRIII.  
 DR SMART; SM00060; FN3; 6.  
 DR SMART; SM00408; IGC3; 3.  
 DR SMART; SM00410; IG\_Like; 2.  
 KW Immunoglobulin domain; Repeat.  
 SQ SEQUENCE 1427 AA; 156533 MW; 61FEA12C8A674972 CRC64;

Query Match 6.4%; Score 133; DB 13; Length 1427;  
 Best Local Similarity 25.7%; Pred. No. 0.0065;  
 Matches 59; Conservative 33; Mismatches 90; Indels 48; Gaps 13;

QY 21 IEQONATVVLKGSARFCTYSQGM--KLIMWLSMDVYLSVRMEPIITNDRETSORDY 78  
 DB 243 LQPSNVVAIEGDVAIECAVS-GYPTPTVMQGD-----EPVPIRTR---KYS 288  
 QY 79 QGNFTSEMIINHVESDGNIRC--SLQNSRLHGSAYLVTVQVWGLFIPSNVLYVAENE 136  
 DB 289 VLGG--SNLISNVTDDAGATVATYKNDNSESADLVVMPPOPLNHPANLYAESM 346  
 QY 137 PCEVTCI---PSHMTLRPLISW-ELGLVSHSYFVPEPSDQSAVSIATLPQSNGT 191  
 DB 347 DIEFECAVSGKPS-----PLVYKTKNGEVYIPSDYFQIVGSMNR-----ILGLVKSDEG 397  
 QY 192 LTCVA-----TWKSLARKSATVNLTVI-KCPQDTGGGINIPGVLS 232

DB 398 YQCIANEAGNIQYVAQLIIPDPAVPSLSIPASRPDY-----VPVLYSS 442  
 RESULT 12  
 Q9DBP0  
 ID Q9DBP0 PRELIMINARY; PRT; 697 AA.  
 AC Q9DBP0;  
 DT 01-JUN-2001 (TREMBlrel. 17, Created)  
 DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)  
 DT 01-JUN-2002 (TREMBlrel. 21, Last annotation update)  
 DE Solute carrier family 34 (sodium phosphate), member 2.  
 GN SLC34A2.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=LUNG;  
 RX MEDLINE=21085660; PubMed=11217851;  
 RA Kawai J., Shingawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
 RA Arikawa T., Hara A., Fukunishi Y., Konno H., Adachi T., Fukuda S.,  
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaoka I.,  
 RA Saito T., Okazaki Y., Gojohori T., Bono H., Kasukawa T., Saito R.,  
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
 RA Fleischmann W., Gaasterland T., Giusti C., King B., Koehli H.,  
 RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,  
 RA Schirml L.M., Staudt F., Suzuki R., Tomita M., Wagner L., Washio T.,  
 RA Sakai K., Okido T., Furuno M., Aono H., Balderelli R., Barsh G.,  
 RA Blake J., Bonfield D., Bojunga N., Carninci P., de Bonaldo M.F.,  
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
 RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamuya M., Lee N.H.,  
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
 RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,  
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whitlaker C., Wilming L.,  
 RA Wyshak-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohlsuki S.,  
 RA Hayashizaki Y.;  
 RT "Functional annotation of a full-length mouse cDNA collection";  
 RL Nature 409:685-690(2001).  
 DR EMBL; AK004832; BAB23600.1; -  
 DR MGD; MGI:1342284; Slc34a2.  
 DR InterPro: IPR003841; Na\_Pi\_cotrans.  
 DR Pfam; PF02690; Na\_Pi\_cotrans; 1.  
 DR TIGRfams; TIGR01013; 2a58; 1.  
 SQ SEQUENCE 697 AA; 76244 MW; 2A7B9384857EF16F CRC64;

Query Match 6.3%; Score 131; DB 11; Length 697;  
 Best Local Similarity 20.3%; Pred. No. 0.0039;  
 Matches 88; Conservative 53; Mismatches 124; Indels 168; Gaps 22;

QY 5 LITVPEAVSGSGNEVIEGPONATVTK-----GSOARFCTYS 42  
 DB 380 LITVTKLDS-----VLRG-QVATVTKTLNDFPPFAMLTGYLALVAGAMTIVQSS 433  
 QY 43 QGKWLIMWLSMDVYLSVRMEPIITNDRETSORDGNGFTSEMIINHVESDGNIRC 102  
 DB 434 SVFTSAMTPILIGIVISIRAVPLTGSNI-----GTTTALIALASGNT--LRS 483  
 QY 103 SLQNSRLHGSAYLVTVQVWGLFIPSNVLYVAENEPCEVTCPLSHMTLRP-----DIS 154  
 DB 484 SIQIALCH-----FFNINSGI-----LAMPPIPTLRPLRLAKGLGNIS 522  
 QY 155 -----WELGLVSHSYFVPEPSDQSAVSIATLPQSNGLTLCVATWKSILKARKSATVN 210  
 DB 523 AKYRW---FAVYLLIEFFVTP-----LTVFGLS-----LAGRPVLYGVGPITL 564  
 QY 211 LVVI-----KCPQDTGGGINIPGVY---SSLPISGLSELPWVGKGLAGMLTLP 258  
 DB 565 LILVLCRLMLOFCRPR-----ILPLKLRDMNPLPLMHSILKAPWDVN-----ISLAT 611  
 QY 259 TCTLTITRCCCRRRRCG-----CNC-CCRCFCRCRRKGRFLQROKSEKKTNETE 312



Db 612 TC-FORCCCCCVCRCVCCWCGCKCCRCSCCRD-----GGEEREEQ----- 656  
 QY 313 SCNENSGYNSDQKTTERTASLPPKSCSSDPEQRNSCGPPHORADQPPRASHPOASF 372  
 Db 657 -----DIPVKAAGAFDNAMSKRC-----QDEGKGQV 683  
 QY 373 NLASPEKVSNTTV 385  
 Db 684 EYLSMKALSNNTTV 696

## RESULT 13

Q92290 PRELIMINARY: PRT: 697 AA.  
 AC 092290:  
 DT 01-MAY-1999 (TREMBLrel. 10, Created)  
 DT 01-MAY-1999 (TREMBLrel. 10, Last sequence update)  
 DT 01-JUN-2002 (TREMBLrel. 21, Last annotation update)  
 DE Type IIb Na/phosphate-cotransporter.  
 GN SLC34A2 OR NP12B.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OC NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=NRI; TISSUE=SMALL INTESTINE;  
 RX MEDLINE=99045724; PubMed=9826740;  
 RA Hillebrand H., Hattenhauer O., Traebert M., Forster I., Murer H.,  
 RA Biber J., Characterization of a murine type II sodium-phosphate cotransporter  
 RT expressed in mammalian small intestine.  
 RL Proc. Natl. Acad. Sci. U.S.A. 95:14564-14569(1998).  
 DR EMBL: AF081499; AAC80007.1;  
 DR MGD: MGI:134284; SLC34a2.  
 DR InterPro: IPR003841; Na.Pi.cotrans.  
 DR Pfam: PF00590; Na.Pi.cotrans. 1.  
 DR TrEMBL: TIGR01013; 2858.1.  
 DR TrEMBL: TIGR01013; 2858.1.  
 SQ SEQUENCE 697 AA; 76286 MW; 83955CCE0F565265 CRC64;

Query Match 6.3%; Score 131; DB 11; Length 697;  
 Best Local Similarity 20.3%; Pred. No. 0.0039;  
 Matches 88; Conservative 53; Mismatches 124; Indels 168; Gaps 22;

QY 5 LITVEAVGSGNVEITGPNATYK-----GSOARFNCTVS 42  
 Db 380 LITVIVKLLGS-----VLRG-OVATVTKTLNTDPPPPAMLTGLVLAIVGAGMTFVQSS 433  
 QY 43 OGKMLIMALSDMYLVSRPMETITNDRTSORYDOGNFTSEMIHNVSPDSGNIRC 102  
 Db 434 SVFTSAMPTLIGIVISIERAVPLTGSNI-----GTTTALIALAASPGNT--LRS 483  
 QY 103 SLONSRLHGSAYLVQVGMGEFIPSVNLVVAENECVETCLPSHMTPLP-----DIS 154  
 Db 484 SLQIALCH-----FFENISGI-----LLWYPIPTPLPLAAGLGNIS 522  
 QY 155 ----WELGLVHSSYFVEPESDLSAVSIALTPQSNGLTCAVATWSLKARKSATVN 210  
 Db 523 AKTRW---FAVYLIFFFTVP-----LTVRGLS-----LAGPVLVGVGPITL 564  
 QY 211 LTVI-----RCQDPTGGGINIPGV---SLPSLGSFSLPTWKGVLGAGMLLTP 258  
 Db 565 LLLVLCILMLDRCRPR-----ILPLKLRDWNFLPLMWSHLKPDVN-----ISLAT 611  
 QY 259 TCTLTIRCCCRRCRCG-----CNC-CGRCCFCRRKRGFRIFQPKSEKTKETETETE 312  
 Db 612 TC-FORCCCCCVCRCVCCWCGCKCCRCSCCRD-----QDEGKGQV 683  
 QY 313 SCNENSGYNSDQKTTERTASLPPKSCSSDPEQRNSCGPPHORADQPPRASHPOASF 372  
 Db 657 -----DIPVKAAGAFDNAMSKRC-----QDEGKGQV 683  
 QY 373 NLASPEKVSNTTV 385

Db 684 EYLSMKALSNNTTV 696

## RESULT 14

Q22048 PRELIMINARY: PRT: 164 AA.  
 AC 022048:  
 DT 01-NOV-1996 (TREMBLrel. 01, Created)  
 DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)  
 DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)  
 DE T01B7.8 protein.  
 GN T01B7.8.  
 OS Caenorhabditis elegans.  
 OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditioidea;  
 OC Rhabditidae; Peloderinae; Caenorhabditis.  
 OC NCBI\_TaxID=6239;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Submitted (Oct-1995) to the EMBL/Genbank/DBJ databases.  
 RL [2]  
 RC SEQUENCE FROM N.A.  
 RX MEDLINE=99069613; PubMed=9851916;  
 RA none;  
 RT "Genome sequence of the nematode C.elegans: A platform for  
 investigating biology."  
 RL Science 282:2012-2018(1998).  
 DR EMBL: Z66499; CA91301.1;  
 DR InterPro: IPR001450; 4Fe4S\_ferredoxin.  
 DR InterPro: IPR001271; Defensin\_mammal.  
 DR InterPro: IPR000561; EGF-like.  
 DR InterPro: IPR001007; WVF-C.  
 DR PROSITE: PS00198; 4Fe4S\_FERREDOXIN; UNKNOWN.1.  
 DR PROSITE: PS00269; DEFENSIN; UNKNOWN.1.  
 DR PROSITE: PS00022; EGF\_1; UNKNOWN.1.  
 DR PROSITE: PS01208; WVF; UNKNOWN.1.  
 SQ SEQUENCE 164 AA; 16499 MW; C002D4BD36C9FECED CRC64;

Query Match 6.2%; Score 129.5; DB 5; Length 164;  
 Best Local Similarity 32.1%; Pred. No. 0.00081;  
 Matches 43; Conservative 11; Mismatches 53; Indels 27; Gaps 6;

QY 157 LGLVHSSYFVEPESDLSAVSIALTPQSNGLTCAVATWSLKARKSATVNLTVIRC 216  
 Db 6 LAILAIGTFIAV---SOVSAV-----LPVSTELATVGTDTSTASTAIDTLGNSSRY 57  
 QY 217 PDGTGGGINIPGVLSLPSLGSFSLPTWKGVLGAGMLLPTTCLTIRCCCRRCRCG 276  
 Db 58 KRGGCGCGCGCGC-----GCCGCGGCGGG--CGCCCRPRCCCGCCRCRCYC 101  
 QY 277 --NCCC-RCCFCR 287  
 Db 102 CRTCCCTCCTCCR 115  
 RESULT 15  
 ID 001761 PRELIMINARY: PRT: 6632 AA.  
 AC 001761:  
 DT 01-JUL-1997 (TREMBLrel. 04, Created)  
 DT 01-JUN-2002 (TREMBLrel. 21, Last sequence update)  
 DT 01-JUN-2002 (TREMBLrel. 21, Last annotation update)  
 DE C. elegans UNC-89 protein (corresponding sequence C09D1.1).  
 GN UNC-89.  
 OS Caenorhabditis elegans.  
 OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditioidea;  
 OC Rhabditidae; Peloderinae; Caenorhabditis.  
 OC NCBI\_TaxID=6239;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=BRISTOL N2;  
 RX MEDLINE=99069613; PubMed=9851916;

RA Waterston R.;  
 RT "Genome sequence of the nematode C. elegans: a platform for  
 RT investigating biology. The C. elegans Sequencing Consortium.";  
 RL Science 282:2012-2018(1998).  
 RN [2]

RP SEQUENCE FROM N.A.  
 RC STRAIN-BRISTOL N2;

RA Du Z., Le T.T., Wilson R.;

RT "The sequence of C. elegans cosmid C09D1.";  
 RL Submitted (May-1997) to the EMBL/GenBank/DBJ databases.

RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-BRISTOL N2;

RA Waterston R.;

RL Submitted (Apr-2002) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AF003131; AAB54132.2; -

SO SEQUENCE 6632 AA; 731665 MW; 262D3EDD62960E89 CRC64;

# Query Match

Best Local Similarity 23.0%; Score 129; DB 5; Length 6632;  
 Matches 59; Conservative 41; Mismatches 97; Indels 60; Caps 10;

QY 6 LTVPEAVGSG-----SGNE-----VIEGPQNAVYLKGSQARFNCT 40  
 Db 2038 LIPMAQDSCKITVEASNEVGSSSSNQLTVNPPSTTPIVVDGPKSVTIKETETAEFKAT 2097  
 QY 41 VSQGM--KLIMWALSDWVLSVRPMPEITINDRFTSORXDGGNFTSEMIHNVPEPSDSG 98  
 Db 2098 IS-GPPAPTYVMTINEKIVEESRTITIKTEDVYT-----LKISMAKIEQNG 2143  
 QY 99 NIRCSONSRILHGSAYLTVQVMGELFIPS-----VNIYVAENRCEVTCI--PSHWRL 150  
 Db 2144 TVKVTAGNSAGQDSKQADLVEPVRKAFKFSQLTIDKVADEGEPLRWNLLELDGPPSPGT-- 2201  
 QY 151 PDISMEL-GLIVSHSSTYFVPEPSDLOSASVILALTPQSNGLTLCVATWKSILKARKSATV 209  
 Db 2202 -EWSWMLNGQPLKSDTVQVVDHGDGYHTVIAEAKPEMSGTLLAKAKNAAGECETSAKV 2260  
 QY 210 NLT-----VIRCPD 219  
 Db 2261 TVNGNKKPFEVQAPON 2277

Search completed: April 28, 2003, 21:07:42  
 Job time : 41.1283 secs

GenCore version 5.1.4-p5.4578  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using SW model

Run on: April 28, 2003, 16:24:30 ; Search time 10.3692 Seconds

(without alignments)  
1543,990 Million cell updates/sec

Title: US-09-729-264-6

Perfect score: 2077  
Sequence: 1 MEHLLTVPKAVSGSGSNGEV.....HPQASFNLASPEKSVNTTVV 386

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database : SwissProt\_40:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	151	7.3	404	1 RAGE_HUMAN	015109 homo sapien
2	139.5	6.7	344	1 NTRI_RAT	062718 rattus norv
3	133	6.4	337	1 G55A_CHICK	098892 gallus gall
4	131	6.3	1447	1 DCC_MOUSE	P70211 mus musculu
5	130	6.3	345	1 OPCM_HUMAN	014982 homo sapien
6	129	6.2	345	1 OPCM_BOVIN	P18343 bos taurus
7	129	6.2	353	1 CEPV_CHICK	090773 gallus gall
8	128	6.2	345	1 OPCM_RAT	P32736 rattus norv
9	128	6.2	1447	1 DCC_HUMAN	P43146 homo sapien
10	128	6.2	1914	1 KML5_HUMAN	013746 homo sapien
11	125	6.0	1070	1 PTK7_HUMAN	013508 homo sapien
12	122.5	5.9	4393	1 PGBM_HUMAN	P98160 homo sapien
13	118.5	5.7	620	1 SMP_COTUJA	092154 coturnix co
14	117.5	5.7	1443	1 NEOL_CHICK	090610 gallus gall
15	114.5	5.5	1461	1 NEOL_HUMAN	092859 homo sapien
16	113.5	5.5	416	1 RAGE_BOVIN	Q28173 bos taurus
17	113.5	5.5	1377	1 NEOL_RAT	P97603 rattus norv
18	111	5.3	365	1 CXAR_HUMAN	P78310 homo sapien
19	110.5	5.3	524	1 BUTY_MOUSE	062556 mus musculu
20	110.5	5.3	764	1 ICCR_DROME	008180 drosophila
21	109.5	5.3	249	1 CSP_DROME	003751 drosophila
22	109.5	5.3	880	1 TYO3_HUMAN	006418 homo sapien
23	106	5.1	1092	1 NCAL_XENLA	P36335 xenopus lae
24	105.5	5.1	862	1 CD22_MOUSE	P05793 mus musculu
25	105.5	5.1	3707	1 PGBM_MOUSE	005793 mus musculu
26	105	5.1	319	1 A33_HUMAN	099795 homo sapien
27	104.5	5.0	333	1 AMAL_DROME	P15664 drosophila
28	104.5	5.0	879	1 FPRP_RAT	062786 rattus norv
29	103.5	4.9	338	1 LAMP_CHICK	098919 gallus gall
30	102.5	4.9	344	1 CD2_RAT	P08921 rattus norv
31	102.5	4.9	348	1 KILO_RAT	092018 rattus norv
32	102.5	4.9	365	1 CXAR_MOUSE	P97992 mus musculu
33	100.5	4.8	830	1 SRBC_HUMAN	Q14162 homo sapien

34	100.5	4.8	1906	1 KML5_CHICK	P11799 gallus gall
35	100.5	4.8	2481	1 UN52_GAEEL	006561 caenorhabdi
36	100	4.8	873	1 PAS2_DROME	P34082 drosophila
37	100	4.8	1010	1 CONT_CHICK	P14781 gallus gall
38	100	4.8	1241	1 NPHN_HUMAN	060500 homo sapien
39	99.5	4.8	880	1 TYO3_RAT	P55146 rattus norv
40	99.5	4.8	1260	1 CAML_MOUSE	P11627 mus musculu
41	99	4.8	338	1 LAMP_HUMAN	013449 homo sapien
42	99	4.8	338	1 LAMP_RAT	062813 rattus norv
43	99	4.8	359	1 LACH_DROME	Q24372 drosophila
44	99	4.8	2499	1 MPRI_BOVIN	P08169 bos taurus
45	98.5	4.7	858	1 NCAL_RAT	P13596 rattus norv

## ALIGNMENTS

RESULT 1  
RAGE\_HUMAN  
ID RAGE\_HUMAN STANDARD; PRT; 404 AA.  
AC 015109; 015279; 09Y3R3; 09H2X7;  
DT 01-NOV-1997 (Rel. 35, Created)  
DT 01-NOV-1997 (Rel. 35, Last sequence update)  
DT 15-JUN-2002 (Rel. 41, Last annotation update)  
DE Advanced glycosylation end product-specific receptor precursor  
DE (Receptor for advanced glycosylation end products).  
GN RAGE OR RAGE.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
OX NCBI\_Taxid=9606;  
RN [1]  
RP SEQUENCE FROM N.A. (ISOFORM 1).  
RC TISSUE=Lung;  
RX MEDLINE=92340547; PubMed=1378843;  
RA Neepser M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C.,  
RA Elliston K., Stern D., Shaw A.;  
RT "Cloning and expression of a cell surface receptor for advanced  
RT glycosylation end products of proteins.";  
RT J. Biol. Chem. 267:14998-15004(1992).  
RL [1]  
RN [2]  
RP SEQUENCE FROM N.A. (ISOFORM 1).  
RX MEDLINE=95137587; PubMed=7835890;  
RA Sugaya K., Fukagawa T., Matsumoto K., Mila K., Takahashi E., Ando A.,  
RA Inoko H., Ikemura T.;  
RT "Three genes in the human MHC class III region near the junction with  
RT the class II: gene for receptor of advanced glycosylation end  
RT products, PBX2 homeobox gene and a notch homolog, human counterpart  
RT of mouse mammary tumor gene int-3.";  
RT Genomics 23:408-419(1994).  
RL [3]  
RN [4]  
RP SEQUENCE FROM N.A. (ISOFORM 1).  
RX Banta A., Dinkers C., Baskin D., Faust J., Loretz C., Ahearn M.E.,  
RA Banta A., Spies T., Hood L.;  
RT Submitted (FEB-1997) to the EMBL/Genbank/DBJ databases.  
RL [5]  
RN [6]  
RP SEQUENCE FROM N.A. (ISOFORM 1).  
RX Malherbe P., Richards J., Gailiard H., Thompson A., Diener C.,  
RA Schlier A., Huber G.;  
RT "cDNA cloning of a novel secreted isoform of the human Receptor for  
RT Advanced Glycation End products (RAGE) and characterization of cells  
RT co-expressing cell-surface scavenger receptors and Swedish mutant  
RT amyloid precursor protein.";  
RT Submitted (MAY-1999) to the EMBL/Genbank/DBJ databases.  
RL [6]  
RN [6]  
RP SEQUENCE FROM N.A. (ISOFORM 1).

RC TISSUE-Lung;  
 RA Strausberg R.;  
 RN Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.  
 RP SEQUENCE OF 1-12 FROM N.A.  
 RA Hudson B.I., Futers T.S.;  
 RT "Novel polymorphisms in the receptor for advanced glycation  
 end-products (RAGE) gene";  
 RL Submitted (NOV-1999) to the EMBL/GenBank/DBJ databases.  
 CC -1- FUNCTION: MEDIATES INTERACTIONS OF ADVANCED GLYCOSYLATION END  
 PRODUCTS (AGE). THESE ARE NONENZYMATICALLY GLYCOSYLATED PROTEINS  
 WHICH ACCUMULATE IN VASCULAR TISSUE IN AGING AND AT AN ACCELERATED  
 RATE IN DIABETES.  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein (isoform 1).  
 CC Secreted (isoform 2).  
 CC -1- ALTERNATIVE PRODUCTS: 2 ISOFORMS: 1 (SHOWN HERE) AND 2/RAESEC;  
 ARE PRODUCED BY ALTERNATIVE SPLICING.  
 CC -1- TISSUE SPECIFICITY: ENDOTHELIAL CELLS.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.  
 CC -1- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.  
 CC -1- SIMILARITY: CONTAINS 2 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation  
 at the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL; M91211; AAA03574.1; -;  
 DR EMBL; D28769; BAA05958.1; -;  
 DR EMBL; U89336; AAB47491.1; -;  
 DR EMBL; AB036432; BAA89369.1; -;  
 DR EMBL; AJ133822; CAB43108.1; -;  
 DR EMBL; BC020669; AAB20669.1; -;  
 DR EMBL; AF208289; AAG55728.1; -;  
 DR Genew; HGNC:320; AGER.  
 DR MIM; 600214; -;  
 DR InterPro; IPR003006; IG\_MHC.  
 DR InterPro; IPR003598; IG\_C2.  
 DR InterPro; IPR003600; IG\_Like.  
 DR Pfam; PF00047; Ig\_2.  
 DR SMART; SM00410; Ig\_Like; 1.  
 DR SMART; SM00408; IGC2; 1.  
 DR PROSITE; PS00290; IG\_MHC; 1.  
 KW Immunoglobulin domain; Glycoprotein; Transmembrane; Repeat; Signal;  
 KW Alternative splicing; Polymorphism.  
 FT SIGNAL 1 22  
 FT CHAIN 23 404  
 FT DOMAIN 23 342  
 FT TRAMEM 343 363  
 FT DOMAIN 364 404  
 FT DOMAIN 31 106  
 FT DOMAIN 137 215  
 FT DOMAIN 252 308  
 FT DISULFID 38 99  
 FT DISULFID 144 208  
 FT DISULFID 259 301  
 FT CAROHRD 25 25  
 FT CAROHRD 81 81  
 FT CAROHRD 380 384  
 FT DOMAIN 54 67  
 FT VARSPIC 275 404  
 FT VARSPIC 275 404  
 FT VARIANT 100 100  
 FT CONFLICT 1 1  
 M-> G (IN REF. 1).  
 P/TID-VAR\_011338.  
 M-> G (IN REF. 1).

SEQ SEQUENCE 404 AA; 42802 MW; 0D584C436C30CE7 CRC64;  
 Query Match 7.3%; Score 151; DB 1; Length 404;  
 Best Local Similarity 23.3%; Pred. NO. 7e-05;  
 Matches 90; Conservative 38; Mismatches 112; Indels 146; Gaps 19;  
 QY 9 PEAVSGSGNEVIEGPONATVILKSGQARFNCVSG--WKILMALSDMYLVSRPEEP 65  
 DB 124 PEIVDSAS--ELTAGVPN-----KVTGVSSEGSYPAGTLVSHLDG-----KP 163  
 QY 66 IITNDFTS-----QHYDGGNFT--SEMIINHVPSGSGNIR-----CSLQSRHLGSAY 114  
 DB 164 LVPEKGVSVKEQTRRHPTGLFTLQSELM--VTPARAGDPRPFPSGFSGLPRHRL 220  
 QY 115 LTVQVAGELFIP--SVNLVVAENP-----CEVTCLPDSHWRPLDISWE 156  
 DB 221 RTAPIDPRWEPEVPEEVQLVY--EPEGAVAPGGVTLTCEVPAQS-----PQIHMM 272  
 QY 157 LGLVSHSSYFVPEPSDQASVILALTPQSNGLTCAVTKSLKARSATVNLTVIRC 216  
 DB 273 KD-----GVPLPSPVPLIPEIGPODGYSCVATHSHGQPSRAVSISILE- 322  
 QY 217 PODTGGGINIPVLSLPSLGFSLPTWGRVGLIAGTMLLT-----PTCTLTIRCCC 269  
 DB 323 PGEEG-----PTAGSVGSGGLTALALGILGCTALLIGVILM 363  
 QY 270 RRRCCGCCNCCRCFCRCRRKGRFIOFQKSEKKT--NKEPTESGNENSGYNSDQKT 327  
 DB 364 QRR-----QRRGERKAPENQEEERALELN----- 389  
 QY 328 TETASLPKSCSSDPENRSSGCP 353  
 DB 390 -----QSEEPAGESSITGP 404  
 RESULT 2  
 NTRL\_RAT  
 ID NTRL\_RAT STANDARD; PRI: 344 AA.  
 AC Q62718;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 30-MAY-2000 (Rel. 39, Last annotation update)  
 DE Neurotrophin precursor (GP65).  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_TaxID=10116;  
 RN [1]  
 RP SEQUENCE FROM N.A., AND SEQUENCE OF 217-229.  
 RC STRAIN=Sprague-Dawley;  
 RX MEDLINE=95198094; PubMed=7891157;  
 RA Struyk A.F., Canoll P.D., Wolfigang M.J., Rosen C.L., D'Eustachio P.,  
 RT Salzer J.L.;  
 RT "Cloning of neurotrophin defines a new subfamily of differentially  
 expressed neural cell adhesion molecules.";  
 RL J. Neurosci. 15:2141-2156(1995).  
 CC -1- FUNCTION: NEURAL CELL ADHESION MOLECULE.  
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.  
 CC -1- TISSUE SPECIFICITY: CENTRAL NERVOUS SYSTEM.  
 CC -1- DEVELOPMENTAL STAGE: EXPRESSED AT HIGH LEVELS IN SEVERAL  
 DEVELOPING PROJECTION SYSTEMS: IN NEURONS OF THE THALAMUS,  
 SUBPATE, AND LOWER CORTICAL LAMINAE IN THE FOREBRAIN AND IN THE  
 PONTINE NUCLEUS, CEREBELLAR GRANULE CELLS, AND PURKINE CELLS IN  
 THE HINDBRAIN.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGLON  
 SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation  
 at the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL: U16845; AAA67445.1; -  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR Pfam: PF00047; Ig; 3.  
 DR SMART: SM00410; Ig\_Like; 1.  
 DR SMART: SM00408; IgC2; 2.  
 KW Immunoglobulin domain; Cell adhesion; Glycoprotein; GPI-anchor;  
 KW Repeat: Signal.  
 FT SIGNAL 1 31  
 FT CHAIN 32 321  
 FT PROPEP 322 344  
 FT DOMAIN 50 122  
 FT DOMAIN 150 208  
 FT DOMAIN 236 302  
 FT DISULFID 57 115  
 FT DISULFID 157 201  
 FT DISULFID 243 295  
 FT CARBOHYD 44 44  
 FT CARBOHYD 70 70  
 FT CARBOHYD 152 152  
 FT CARBOHYD 216 216  
 FT CARBOHYD 284 284  
 FT CARBOHYD 292 292  
 FT CARBOHYD 305 305  
 FT CARBOHYD 321 321  
 FT LIPID 321 321  
 SQ SEQUENCE 344 AA; 37998 MW; CBB39BE53B3B224 CRC64;

Query Match  
 Best Local Similarity 24.9%; Score 139.5; DB 1; Length 344;  
 Matches 66; Conservative 40; Mismatches 110; Indels 49; Gaps 13;

QY 3 RHLLTVEAVSGSGNEVT-EGPQNAVYLGSGARFCTVSGGKGLMMLSDMNVLS-- 59  
 Db 20 RLFLVLPVGVVRRSGDATFPFAMDNVTVRGESATLRCITDNRYAVAMNRSITLACN 79

QY 60 ---VRPEPIITNDRTSORYDOGNFTSEMIHNVEPDSGNGIRCSLQ-----NSRL 109  
 Db 80 DKWCLDRVYVLSN---TQYQ-----SIEIQNDVYDEGPHYTSVOTDNHPTSKRV 128

QY 110 HGSAYLVQVNGELFIPSVNLVAENPECEVYCLPSHMTLRPLDISMELGLVSHSYFEV 169  
 Db 129 H----LIVQVSPKIVEISDISINEGNNISILCTATGRPE-PTVYWR---HISPKAVGFV 180

QY 170 PEPDLSQAVSIALTPQSNGLTLCVATWKSLSKARKSATVNLVYIRCP-----QDTGGGT 224  
 Db 181 SEDEYLE---TQGITREQSGEYECSSA-NDVAPVVRVNVVNPPIYSEAKGTGVPV 235

QY 225 NIPGVL---SSLPGLGFSLPYTWK 245  
 Db 236 GQKGTLCCEASAVPSAEFG---WFK 257

RESULT 3  
 G55A\_CHICK STANDARD; PRT; 337 AA.  
 AC 098892;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Neurite inhibitor GP55-A precursor (OBSCAM protein gamma isoform).  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 OX NCBI\_TaxID=9031;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;

RA Lodge A.P., Kim D.-S., Howard M.R., McNamee C.J., Smith N., Moss D.J.;  
 RT "Cloning of CEPU-5, a secreted isoform of CEPU-1, and OBSCAM CDNA's from  
 RT chick: structural diversity of Iglon family proteins."  
 RL Submitted (Apr-1999) to the EMBL/Genbank/DBD databases.  
 RN [2]  
 RP SEQUENCE OF 64-337 FROM N.A., AND PARTIAL SEQUENCE.  
 RC TISSUE=Brain;  
 RX MEDLINE-97157768; PubMed-9004047;  
 RA Wilson D.J.A., Kim D.-S., Clarke G.A., Marshall-Clarke S., Moss D.J.;  
 RT "A family of glycoproteins (GP55), which inhibit neurite outgrowth,  
 RT are members of the Ig superfamily and are related to OBSCAM,  
 RT neurotrophin, IAMP and CEPU-1."  
 RL J. Cell Sci. 109:3129-3138(1996).  
 CC -1- FUNCTION: INHIBITS NEURITE OUTGROWTH.  
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.  
 CC -1- TISSUE SPECIFICITY: RESTRICTED TO THE NERVOUS SYSTEM.  
 CC -1- DEVELOPMENTAL STAGE: INCREASES DURING DEVELOPMENT FROM VERY LOW  
 CC LEVELS AT EMBRYONIC DAY 10 AND IS MOST ABUNDANT AFTER HATCHING.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGLON  
 CC SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL: Y08170; CAB41420.1; -  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR Pfam: PF00047; Ig; 3.  
 DR SMART: SM00410; Ig\_Like; 1.  
 DR SMART: SM00408; IgC2; 2.  
 KW Immunoglobulin domain; Cell adhesion; Glycoprotein; GPI-anchor;  
 KW Repeat: Signal.  
 FT SIGNAL 1 20  
 FT CHAIN 21 317  
 FT PROPEP 318 337  
 FT DOMAIN 43 115  
 FT DOMAIN 143 201  
 FT DOMAIN 229 295  
 FT DISULFID 50 108  
 FT DISULFID 150 194  
 FT DISULFID 236 288  
 FT CARBOHYD 133 133  
 FT CARBOHYD 277 277  
 FT CARBOHYD 285 285  
 FT CARBOHYD 298 298  
 SQ SEQUENCE 337 AA; 36887 MW; BAET17551856551E CRC64;

Query Match  
 Best Local Similarity 6.4%; Score 133; DB 1; Length 337;  
 Matches 71; Conservative 36; Mismatches 107; Indels 60; Gaps 16;

QY 5 LITVPEAVSGSGNEVT-EGPQNAVYLGSGARFCTVSGGKGLMMLSDMNVLS----- 58  
 Db 16 LFLIP-GVFPVRRSGDATFPFAMDNVTVRGESATLRCITDQDVRVRAV-LNRSTIYLACND 73

QY 59 ---SVRPEPIITNDRTSORYDOGNFTSEMIHNVEPDSGNGIRCSLQ-----NSRLH 110  
 Db 74 KMSIDRRVYVLSN---TKYQ-----SIEIHNVDYDEGPHYTSVOTDNHPTSKRVH 122

QY 111 GSAVYLVQVNGELFIPSVNLVAENPECEVYCL---PSHMTLRPLDISMELGLVSHSY 166  
 Db 123 ---LIVQVPPQIVNISDITVNEGSSVYLMCLAGRBE-----PTVYWR---HLSGKGQ 170

QY 167 YFVPEPDLQAVSIALTPQSNGLTLCVATWKSLSKARKSATVNLVYIRCP-----IRCPDGT 221  
 Db 171 GFVSEDEYLE---ITGITREQSGEYECSSA-NDVAPVVRVNVVNPPIYSEAKGTGVPV 225

Oy 222 GGINIPGVL---SSLPISGSLPTWCKVGLA 251  
 Db 226 ASVGKGILQCEASAVPAEFO---WEKEDIRLA 256

RESULT 4  
 DCC\_MOUSE STANDARD: PRT: 1447 AA.  
 ID DCC\_MOUSE P70211:  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Tumor suppressor protein DCC precursor.  
 GN DCC.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 ON NCBI\_Taxid=10090;  
 RX SEQUENCE FROM N.A. (ISOFORMS A; B AND C).  
 RC STRAIN-BALB/c; TISSUE-Brain;  
 RA MEDLINE=96112625; PubMed=8570174;  
 RA Cooper H.M., Armes P., Brito J., Gad J., Wilks A.F.;  
 RT "Cloning of the mouse homologue of the deleted in colorectal cancer  
 gene (mdcc) and its expression in the developing mouse embryo.";  
 RL Oncogene 11:2243-2254(1995).  
 RN [2]  
 RP REVISIONS.  
 RC STRAIN-BALB/c; TISSUE-Brain;  
 RA Cooper H.M.;  
 RL Submitted (JUN-1996) to the EMBL/GenBank/DBJ databases.  
 CC -1- FUNCTION: IMPLICATED AS A TUMOR SUPPRESSOR GENE.  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.  
 CC -1- ALTERNATIVE PRODUCTS: 2 isoforms: A (shown here) and B; are  
 CC produced by alternative splicing.  
 CC -1- TISSUE SPECIFICITY: IN THE EMBRYO, EXPRESSED AT HIGH LEVELS IN THE  
 CC DEVELOPING BRAIN AND NEURAL TUBE. IN ADULT, HIGHLY EXPRESSED IN  
 CC BRAIN WITH VERY LOW LEVELS FOUND IN TESTIS, HEART AND THYMUS.  
 CC ISOFORM C IS EXPRESSED ONLY IN THE EMBRYO.  
 CC -1- DEVELOPMENTAL STAGE: LOW LEVELS IN EARLY GESTATION. HIGHEST LEVELS  
 CC EXPRESSED DURING MID GESTATION. LEVELS DECREASE IN LATE GESTATION  
 CC AND REMAIN AT THIS LEVEL IN THE ADULT.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. DCC  
 CC SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 6 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -1- SIMILARITY: CONTAINS 6 FIBRONECTIN TYPE III-LIKE DOMAINS.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
 CC -----  
 CC EMBL: X85788; CAA59786.1; -  
 DR HSSP: P56276; 1TLK.  
 DR MGD: MGI:94869; DCC.  
 DR InterPro: IPR003961; FN.III.  
 DR InterPro: IPR003006; FN.III\_repeat.  
 DR InterPro: IPR003598; 19-MHC.  
 DR InterPro: IPR003600; 19-Like.  
 DR Pfam: PF00041; fn3; 6.  
 DR Pfam: PF00047; 19; 4.  
 DR PRINTS: PR00014; ENTPEPITI.  
 DR SMART: SM00060; FN3; 6.  
 DR SMART: SM00410; IG\_Like; 2.  
 DR SMART: SM00408; IGc2; 3.  
 KW Glycoprotein; Immunoglobulin domain; Transmembrane; Signal;  
 KW Repeat; Anti-oncogene; Alternative Initiation; Alternative splicing.

FT SIGNAL 1 25  
 FT CHAIN 26 1447  
 FT CHAIN 85 1447  
 FT INIT MET 85 85  
 FT DOMAIN 26 1097  
 FT TRANSMEM 1098 1122  
 FT DOMAIN 1123 1447  
 FT DOMAIN 54 124  
 FT DOMAIN 154 219  
 FT DOMAIN 254 317  
 FT DOMAIN 345 407  
 FT DOMAIN 426 522  
 FT DOMAIN 525 618  
 FT DOMAIN 619 716  
 FT DOMAIN 722 816  
 FT DOMAIN 840 940  
 FT DOMAIN 941 1042  
 FT DISULFID 61 117  
 FT DISULFID 161 212  
 FT DISULFID 261 310  
 FT DISULFID 352 400  
 FT CARBOHYD 60 60  
 FT CARBOHYD 94 94  
 FT CARBOHYD 299 299  
 FT CARBOHYD 318 318  
 FT CARBOHYD 478 478  
 FT CARBOHYD 628 628  
 FT CARBOHYD 702 702  
 FT VARSPLIC 819 838  
 SQ SEQUENCE 1447 AA; 158298 MW; 0D1F1097C22D5B9F CRC64;

POTENTIAL.  
 TUMOR SUPPRESSOR PROTEIN DCC, ISOFORM A.  
 TUMOR SUPPRESSOR PROTEIN DCC, ISOFORM B.  
 FOR ISOFORM B.  
 EXTRACELLULAR (POTENTIAL).  
 POTENTIAL.  
 CYTOPLASMIC (POTENTIAL).  
 IG-LIKE C2-TYPE DOMAIN 1.  
 IG-LIKE C2-TYPE DOMAIN 2.  
 IG-LIKE C2-TYPE DOMAIN 3.  
 IG-LIKE C2-TYPE DOMAIN 4.  
 FIBRONECTIN TYPE-III 1.  
 FIBRONECTIN TYPE-III 2.  
 FIBRONECTIN TYPE-III 3.  
 FIBRONECTIN TYPE-III 4.  
 FIBRONECTIN TYPE-III 5.  
 FIBRONECTIN TYPE-III 6.  
 BY SIMILARITY.  
 BY SIMILARITY.  
 BY SIMILARITY.  
 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 MISSING (IN ISOFORM C).  
 Query Match 6.3%; Score 131; DB 1; Length 1447;  
 Best Local Similarity 25.2%; Pred. No. 0.014;  
 Matches 55; Conservative 33; Mismatches 90; Indels 40; Gaps 9;

Oy 9 PEAVSGSGNEV-----IEGQNFVTKGSGARNCVSGGW-KLIMNAL 52  
 Db 217 PASRTTENEAEVRILSPGHLRQLYFLQRPSTVIAIEGDAVIECCVS-GYPPSTWLR 275  
 Oy 53 SDVVVLSVRMEPIITNDRTSQRYDGGNFTSEMIHNVPSDSGNIRC-SLQNSRLH 110  
 Db 276 GEEVI-----QLRSKYSLLGG-SNLLISNVTDDSDGTYCVVYKNENIS 320  
 Oy 111 GSAYLTQVWGEFLFIPVNLVAENECVETCLPMSHTRLPDLSW-ELGLIVSHSSYIV 169  
 Db 321 ASAEITLVLPVPEWFLMHPNSNYAYESMDIEFECAVS-GKPPVTVMKNGDVVIPSDFEI 379  
 Oy 170 PEPDLSAVSILALFPQNSGTLTCVATWKSLSARKSA 207  
 Db 380 VGSNLR-----ILGVVSDGCFYQCAVNAENAGNQSQA 413

RESULT 5  
 OPMC\_HUMAN STANDARD: PRT: 345 AA.  
 ID OPMC\_HUMAN Q14982;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Opioid binding protein/cell adhesion molecule precursor (OBCCAM)  
 DE Opioid-binding cell adhesion molecule (OPCML).  
 GN OPCML OR OBCCAM.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
 ON NCBI\_Taxid=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE-Occipital cortex;  
 RX MEDLINE=95237612; PubMed=7721093;  
 RA Shark K.B., Lee N.M.;  
 RT "Cloning, sequencing and localization to chromosome 11 of a cDNA  
 encoding a human opioid-binding cell adhesion molecule (OBCCAM).";

RL Gene 155:213-217(1995).  
 CC -1- FUNCTION: BINDS OPIOIDS IN THE PRESENCE OF ACIDIC LIPIDS; PROBABLY INVOLVED IN CELL CONTACT.  
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By similarity).  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGLON SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
 CC -----  
 DR EMBL: U34774; AAA36387.1; -  
 DR Genbank: HGNC:8143; OPMCL.  
 DR MIM: 600632; -  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR Pfam: PF00047; Ig\_3.  
 DR SMART: SM00410; Ig\_Like; 1.  
 DR SMART: SM00408; Igc2; 2.  
 KW Immunoglobulin domain; Cell adhesion; Glycoprotein; GPI-anchor;  
 KW Repeat; Signal.  
 FT SIGNAL 1 27  
 FT CHAIN 28 322  
 FT PROPEP 323 345  
 FT DOMAIN 50 122  
 FT DOMAIN 150 209  
 FT DOMAIN 237 303  
 FT DISULEFID 57 115  
 FT DISULEFID 157 202  
 FT DISULEFID 244 296  
 FT CARBOHYD 44 44  
 FT CARBOHYD 70 70  
 FT CARBOHYD 140 140  
 FT CARBOHYD 285 285  
 FT CARBOHYD 293 293  
 FT CARBOHYD 306 306  
 FT LIPID 322 322  
 SQ SEQUENCE 345 AA; 38007 MW; E7AD17BEA1AA3FF4 CRC64;  
 Query Match 6.3%; Score 130; DB 1; Length 345;  
 Best Local Similarity 25.6%; Pred. No. 0.0028;  
 Matches 73; Conservative 34; Mismatches 108; Indels 70; Gaps 17;  
 OY 3 RHLLTPEAVSGSGNEVI-EGPQNAIVLKSGQARFNCTVSGWKLIMALSDNVVL---58  
 DB 20 RLLEFVPEGVPRVSGDAIFPKAMDNVTVROGSAFLRCTIDDRVRYAW-LNRSTILLAG 78  
 OY 59 ----SVRPEPIITNDRTSQRYDOGNGFTSMITHNPEPSDNGIRSLQ-----NSR 108  
 DB 79 NDKWSIDPRVITLVN---TPROY-----SIMQNDVYDEGPTYTSVQTDNHPKTSR 127  
 OY 109 LAGSAIVTVQVWGLFIPSVNLVVAENEPCEVTCU---PSHWRLPDISMELGLVSHS 164  
 DB 128 VH---LTVQVPPQIMNISTSDITVNEGSSVLLCLALRPE-----PVTYMR-----HL 172  
 OY 165 SYV---FVPEPSDQSAVSIALLTPQSGNGLTVCAVTKSLKARKSATVNLTV-----IR 215  
 DB 173 SVKEGQGVSEDEYLE---ISDIKRDQSGEYECAL-NDVAADPRVKKTVVNPVYS 227  
 OY 216 CPQDTGGGINIPGVL-----ISLPSLGFSLPTMGK-----VGLGLAG 252  
 DB 228 KAKNIGVGVGQKGIILSCASAVPAEFO---WFKETRLATGLDG 269

OPCM\_BOVIN  
 ID OPCM\_BOVIN STANDARD: PRT: 345 AA.  
 AC P11834;  
 DT 01-OCT-1989 (Rel. 12, Created)  
 DT 01-OCT-1989 (Rel. 12, Last annotation update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Opioid binding protein/cell adhesion molecule precursor (OBAM)  
 DE (Opioid-binding cell adhesion molecule) (OPCML).  
 GN OPCML OR OBAM OR OCAM.  
 OS Bos taurus (Bovine).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
 OC Bovidae; Bovinae; Bos.  
 NX NCBI\_TaxID=9913;  
 RN [1]  
 RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.  
 RC TISSUE=Brain;  
 RX MEDLINE=69251576; PubMed=2721489;  
 RA Schofield P.R., McFarland K.C., Hayflick J.S., Wilcox J.N.,  
 RA Cho T.M., Roy S., Lee N.M., Loh H.H., Seeburg P.H.;  
 RT "Molecular characterization of a new immunoglobulin superfamily protein with potential roles in opioid binding and cell contact";  
 RL EMBO J. 8:489-495(1989).  
 CC -1- FUNCTION: BINDS OPIOIDS IN THE PRESENCE OF ACIDIC LIPIDS; PROBABLY INVOLVED IN CELL CONTACT.  
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By similarity).  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGLON SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
 CC -----  
 DR EMBL: X12672; CAA31192.1; -  
 DR PIR: S03199; S03199.  
 DR InterPro: IPR003006; Ig\_MHC.  
 DR InterPro: IPR003598; Ig\_C2.  
 DR InterPro: IPR003600; Ig\_Like.  
 DR Pfam: PF00047; Ig\_3.  
 DR SMART: SM00410; Ig\_Like; 1.  
 DR SMART: SM00408; Igc2; 2.  
 KW Immunoglobulin domain; Cell adhesion; Glycoprotein; GPI-anchor;  
 KW Repeat; Signal.  
 FT SIGNAL 1 27  
 FT CHAIN 28 322  
 FT PROPEP 323 345  
 FT DOMAIN 50 122  
 FT DOMAIN 150 209  
 FT DOMAIN 237 303  
 FT DISULEFID 57 115  
 FT DISULEFID 157 202  
 FT DISULEFID 244 296  
 FT CARBOHYD 44 44  
 FT CARBOHYD 70 70  
 FT CARBOHYD 140 140  
 FT CARBOHYD 285 285  
 FT CARBOHYD 293 293  
 FT CARBOHYD 306 306  
 FT LIPID 322 322  
 SQ SEQUENCE 345 AA; 37914 MW; D1ECB09E7D8CB19 CRC64;  
 Query Match 6.2%; Score 129; DB 1; Length 345;  
 Best Local Similarity 25.7%; Pred. No. 0.0034;  
 Matches 72; Conservative 33; Mismatches 109; Indels 66; Gaps 16;  
 OY 3 RHLLTPEAVSGSGNEVI-EGPQNAIVLKSGQARFNCTVSGWKLIMALSDNVVL---58

Db 20 RLFLVPGVYKSGDPTFKAMDNTVYRQESATLCTIDDRTRAM-LNRSITIIYAG 78  
 QY 59 -----SVRPMETITNDRTSQRDQGNFTSEMIIHVEPSDSGNIRCSIQ-----NSR 108  
 Db 79 NDKMSIDPRVILIVN---TPTQY-----SIMQNVVDYDEGPYCSVQTDNHPKTR 127  
 QY 109 LHGSAIYLVQVWGEFLIPSVLVVAENEPCEVYCL-----PSHWRLDISELGLVSHS 164  
 Db 128 VH---LIVQVPPQIMNITSDVTNEGSSVTLCLAIGRPE-----PVTWIR-----HL 172  
 QY 165 SYV---FVPEPSDQSAVSTIALTPQSNGLTCVATWKSILKARKSATVNLTV-----IR 215  
 Db 173 SYKEQGVSEDEYLE-----ISDLKROSGGEYCSAL-NDVAADPVKRVKITVYPPYIS 227  
 QY 216 CPDGTGGGINIPGVL---SSLPSLGFSLPTWKGVLGLA 251  
 Db 228 KAKNTGVSVGQKGLSCASAVPMAEFQ---WFKEDTRLA 264

RESULT 7  
 CEPU\_CHICK STANDARD; PRT; 353 AA.  
 AC Q90773;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE CEPU-1 protein precursor.  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 NX NCBI\_TaxID=9031;  
 RX [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RX MEDLINE=96370549; PubMed=8774445;  
 RA Spaltmann F., Brumentdorf T.;  
 RT "CEPU-1, a novel immunoglobulin superfamily molecule, is expressed by  
 developing cerebellar Purkinje cells.";  
 RL J. Neurosci. 16:11770-11779(1996).  
 CC -1- FUNCTION: IT MAY BE A CELLULAR ADDRESS MOLECULE SPECIFIC TO  
 PURKINJE CELLS. IT MAY REPRESENT A RECEPTOR OR A SUBUNIT OF A  
 RECEPTOR COMPLEX.  
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.  
 CC -1- ALTERNATIVE PRODUCTS: 2 ISOFORMS; A MAJOR FORM AND A MINOR FORM.  
 CC (SHOWN HERE) ARE PRODUCED BY ALTERNATIVE SPLICING.  
 CC -1- TISSUE SPECIFICITY: FOUND ON THE DENDRITES, SOMATA AND AXONS OF  
 DEVELOPING PURKINJE CELLS. UNDETECTABLE ON OTHER NEURONS LIKE  
 GOLGI OR GRANULE CELLS.  
 CC -1- DEVELOPMENTAL STAGE: EXPRESSED BY DEVELOPING CEREBELLAR PURKINJE  
 CELLS. EXPRESSION COINCIDES WITH THE GROWTH OF THE DENDRITIC TREE,  
 AFTER PURKINJE CELLS HAVE FINISHED THEIR MIGRATION FROM THE  
 VENTRICULAR ZONE (FROM E15 UNTIL E21). EXPRESSED IN THE ADULT.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGLON  
 SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation  
 at the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 DR EMBL: Z72497; CA96578.1; -  
 DR InterPro: IPR003006; IG\_LMC.  
 DR InterPro: IPR003598; IG\_C2.  
 DR InterPro: IPR003600; IG\_Like.  
 DR Pfam: PF00047; Ig\_3.  
 DR SMART: SM00410; Ig\_Like; 1.  
 DR SMART: SM00408; IGC2; 2.

KW Immunoglobulin domain; Cell adhesion; glycoprotein; GPI-anchor;  
 KW Repeat; Signal; Alternative splicing.  
 FT CHAIN 1 28  
 FT SIGNAL 29 330  
 FT PROPEP 331 353  
 FT DOMAIN 48 120  
 FT DOMAIN 148 206  
 FT DOMAIN 234 300  
 FT DISULFID 55 113  
 FT DISULFID 155 199  
 FT DISULFID 241 293  
 FT CARBOHYD 42 42  
 FT CARBOHYD 68 68  
 FT CARBOHYD 150 150  
 FT CARBOHYD 282 282  
 FT CARBOHYD 290 290  
 FT CARBOHYD 303 303  
 FT CARBOHYD 330 330  
 FT LIPID 320 320  
 FT VARSPLIC 310 320  
 SQ SEQUENCE 353 AA; 38736 MW; 2550C48591EBBBA6 CRC64;  
 Query Match 6.2%; Score 129; DB 1; Length 353;  
 Best Local Similarity 25.0%; Pred No. 0.0035;  
 Matches 66; Conservative 38; Mismatches 92; Indels 68; Gaps 14;

QY 7 TYPEAVGSGSGNEVIBGPONATVLYKSGARFNCTVSQ-----GW---KLIMALSDMVL 58  
 Db 35 TFPKAM-----DNVTVRQGESATLRCSVDNRTVRAMLRRSSILYAGNKKMCL 82  
 QY 59 SVRPMETITNDRTSQRDQGNFTSEMIIHVEPSDSGNIRCSIQ-----NSRLHGS 112  
 Db 83 DPRVLIANTKRTQYSIQ-----IHVDYIDSGPTICSVQTDNHPKTRSVH-- 127  
 QY 113 AYLVQVWGEFLIPSVLVVAENEPCEVYCLPSHWRLPD--ISWELGLVSHSYEVP 170  
 Db 128 --LIVQVSPKITESSDISINEGNVSLCIA--TGRDPPTITWR--HISPKAVGFIS 179  
 QY 171 EPSDQSAVSTIALTPQSNGLTCVATWKSILKARKSATVNLTV-----TRCPDGTGGGIN 225  
 Db 180 EDEYLE---ITGITRQSGEYCSAS-NDVAAPVQVRKAVTVNPPYISDAKSTGVPGV 234  
 QY 226 IPGVL---SSLPSLGFSLPTWKG 245  
 Db 235 QKGLMCEASAVPSADPQ---WYK 255  
 RESULT 8  
 OPCM\_RAT STANDARD; PRT; 345 AA.  
 ID OPCM\_RAT P32736; 001654; P32735; 001653;  
 AC P32736; 001654; P32735; 001653;  
 DT 01-JUL-1993 (Rel. 26, Created)  
 DT 01-FEB-1996 (Rel. 33, Last sequence update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Opioid binding protein/cell adhesion molecule precursor (OBPAM)  
 DE (Opioid-binding cell adhesion molecule) (OPCML).  
 OS OPCML OR OBPAM.  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 NX NCBI\_TaxID=10116;  
 RX [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RX MEDLINE=92347701; PubMed=1339369;  
 RA Lippman D.A., Lee N.W., Loh H.H.;  
 RT "Opioid-binding cell adhesion molecule (OBPAM)-related clones from a  
 rat brain cDNA library."  
 RL Gene 117:249-254(1992).  
 RN [2]  
 RP SEQUENCE OF 195-214, AND GPI-ANCHOR.  
 RX MEDLINE=9518094; PubMed=7891157;  
 RA Struys A.F., Canoll P.D., Wolfigang M.J., Rosen C.L., D'Eustachio P.,  
 Salzer J.L.;



RT Cloning of neurotrophin defines a new subfamily of differentially  
 RT expressed neural cell adhesion molecules.\*;  
 RL J. Neurosci. 15:2141-2156(1995).  
 CC -1- FUNCTION: BINDS OPIOIDS IN THE PRESENCE OF ACIDIC LIPIDS; PROBABLY  
 CC INVOLVED IN CELL CONTACT.  
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.  
 CC -1- ALTERNATIVE PRODUCTS: AT LEAST 2 ISOFORMS; 1 (SHOWN HERE) AND 2;  
 CC MAY BE PRODUCED BY ALTERNATIVE SPLICING.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. IGLON  
 CC SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; M88710; AAA40859.1; -;  
 DR EMBL; M88711; AAA40860.1; -;  
 DR EMBL; M88709; AAA40858.1; -;  
 DR PIR; JCI239; JCI239;  
 DR InterPro; IPR003006; Ig\_MHC.  
 DR InterPro; IPR003598; Ig\_C2.  
 DR InterPro; IPR003600; Ig\_Like.  
 DR Pfam; PF00047; Ig; 3.  
 DR SMART; SM00410; Ig\_Like; 1.  
 DR SMART; SM00408; IGC2; 2.  
 DR Immunoglobulin domain; Cell adhesion; glycoprotein; GPI-anchor;  
 KW Repeat; Signal; Alternative splicing.  
 FT SIGNAL 1 27  
 FT CHAIN 1 322  
 FT PROPER 323 345  
 FT DOMAIN 50 122  
 FT DOMAIN 150 209  
 FT DOMAIN 237 303  
 FT DISULFID 57 115  
 FT DISULFID 157 202  
 FT DISULFID 244 296  
 FT CARBOHYD 44 44  
 FT CARBOHYD 70 70  
 FT CARBOHYD 140 140  
 FT CARBOHYD 285 285  
 FT CARBOHYD 293 293  
 FT CARBOHYD 306 306  
 FT LIPID 322 322  
 FT VARSPLIC 1 27  
 SQ SEQUENCE 345 AA; 38067 MW; A3181B0753F9658E CRC64;  
 Query Match 6.28; Score 128; DB 1; Length 345;  
 Best local Similarity 25.3%; Pred. No. 0.0041;  
 Matches 73; Conservative 35; Mismatches 110; Indels 70; Gaps 17;  
 QY 3 RHLLVPEAVSGSGGNEVI-EGPQNAVTLKSGQAFNCTVSGMKLIMWALSDMWVL- 58  
 DB 20 RLLELVPGVVRSGDAFPKAMNVTVRQGESATLRCTIDRVTKRAM-INKRTIILYAG 78  
 QY 59 -SVRMEPLITNDRTSQRYDQGNFTSEMIITHNVEPSDSGNIRCSLO-NSR 108  
 DB 79 NDKWSIDRVIILVN--TPQY-----SIMQNVDDYDEGPTGSCVQTDNPKRSR 127  
 QY 109 LHGSALYVQVWGLFISVNLVVAENPECVTCL-PSHWRLPLPISSELGLVSHS 164  
 DB 128 VH-----LIVQVPPQIMNISDITVNEISVLLCLAIARPE-----PVTWR- 172  
 QY 165 SVY-----FVPEPSDLSQASVSLALPQSGNLTCAVATKSKARKSATVNLVW-IR 215  
 DB 173 SVKEGGFVSEDEYLE-----ISDIKRDQSGEYESCAL-NDVAADPVKRVKIVNTPIYS 227

QY 216 CPDITGGGINIPGVL-----SSLPISLGFSLPTWCK-----VGLCLAGTML 255  
 DB 228 KAKNTGSVQKGIILSCFASAVPMAEFQ--WFKEDTRLATGLDGVRI 272  
 RESULT 9  
 ID DCC\_HUMAN STANDARD; PRT; 1447 AA.  
 AC P43146;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Tumor suppressor protein DCC precursor (colorectal cancer suppressor).  
 GN DCC.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN (1)  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE-95011532; PubMed-7926722;  
 RA Hedrick L., Cho K.R., Fearon E.R., Wu T.-C., Kinzler K.W.,  
 RA Vogelstein B.;  
 RT "The DCC gene product in cellular differentiation and colorectal  
 RT tumorigenesis.";  
 RL Genes Dev. 8:1174-1183(1994).  
 RN (2)  
 RP SEQUENCE OF 1-750 FROM N.A.  
 RX MEDLINE-90100559; PubMed-2294591;  
 RA Fearon E.R., Cho K.R., Nigro J.M., Kern S.E., Simons J.W.,  
 RA Ruppert J.M., Hamilton S.R., Preisinger A.C., Thomas G., Kinzler K.W.,  
 RA Vogelstein B.;  
 RT "Identification of a chromosome 18q gene that is altered in  
 RT colorectal cancers.";  
 RL Science 247:49-56(1990).  
 RN (3)  
 RP SEQUENCE OF 107-472 FROM N.A. (SCRAMBLED EXONS).  
 RX MEDLINE-91121517; PubMed-191322;  
 RA Nigro J.M., Cho K.R., Fearon E.R., Kern S.E., Ruppert J.M.,  
 RA Oliner J.D., Kinzler K.W., Vogelstein B.;  
 RT "Scrambled exons.";  
 RL Cell 64:607-613(1991).  
 RN (4)  
 RP GENE STRUCTURE AND VARIANTS CARCINOMA HIS-1375.  
 RX MEDLINE-94245241; PubMed-8188295;  
 RA Cho K.R., Oliner J.D., Simons J.W., Hedrick L., Fearon E.R.,  
 RA Preisinger A.C., Hedge P., Silverman G.A., Vogelstein B.;  
 RT "The DCC gene: structural analysis and mutations in colorectal  
 RT carcinomas.";  
 RL Genomics 19:525-531(1994).  
 RN (5)  
 RP VARIANT CARCINOMA THR-168, AND VARIANT GHY-201.  
 RX MEDLINE-94243823; PubMed-8187090;  
 RA Miyake S., Nagai K., Yoshino K., Ota M., Endo M., Yuasa Y.;  
 RT "Point mutations and allelic deletion of tumor suppressor gene DCC in  
 RT human esophageal squamous cell carcinomas and their relation to  
 RT metastasis.";  
 RL Cancer Res. 54:3007-3010(1994).  
 CC -1- FUNCTION: IMPLICATED AS A TUMOR SUPPRESSOR GENE.  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.  
 CC -1- TISSUE SPECIFICITY: FOUND IN AXONS OF THE CENTRAL AND PERIPHERAL  
 CC NERVOUS SYSTEM AND IN DIFFERENTIATED CELL TYPES OF THE INTESTINE.  
 CC -1- DISEASE: COLORECTAL TUMORS THAT LOST THEIR CAPACITY TO  
 CC DIFFERENTIATE INTO MUCUS PRODUCING CELLS UNIFORMLY LACK DCC  
 CC EXPRESSION. INACTIVATION OF DCC DUE TO ALLELIC DELETION AND/OR  
 CC POINT MUTATIONS MAY CAUSE BOTH LYMPHATIC AND HEMATOGENOUS  
 CC METASTASIS OF OESOPHAGEAL SQUAMOUS CELL CARCINOMAS.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. DCC  
 CC SUBFAMILY.  
 CC -1- SIMILARITY: CONTAINS 4 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -1- SIMILARITY: CONTAINS 6 FIBRONECTIN TYPE III-LIKE DOMAINS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC -----  
 DR EMBL; X76132; CAA53735.1; -  
 DR EMBL; M32292; AAA5751.1; -  
 DR EMBL; M32286; AAA52174.1; -  
 DR EMBL; M32288; AAA52175.1; ALT\_SEQ.  
 DR EMBL; M32280; AAA52176.1; -  
 DR EMBL; M63696; AAA52177.1; -  
 DR EMBL; M63700; AAA52178.1; -  
 DR EMBL; M63702; AAA52179.1; -  
 DR EMBL; M63718; AAA52180.1; -  
 DR EMBL; M63698; AAA52181.1; -  
 DR PIR; A54100; A54100.  
 DR PIR; A40098; A40098.  
 DR PIR; A38442; A38442.  
 DR HSP; P56276; 1TLK.  
 DR Genew; HGNC:2701; DCC.  
 DR MIM; 120470; -  
 DR InterPro; IPR003961; FN\_III.  
 DR InterPro; IPR003962; FNIII\_repeat.  
 DR InterPro; IPR003006; 19\_MHC.  
 DR InterPro; IPR003598; 19\_C2.  
 DR InterPro; IPR003600; 19\_1like.  
 DR Pfam; PF00041; fn3; 6.  
 DR Pfam; PF00047; 1g; 4.  
 DR PRINTS; PR00014; FNTYPEIII.  
 DR SMART; SM00060; FN3; 6.  
 DR SMART; SM00410; IG\_1like; 2.  
 DR SMART; SM00408; IGC2; 3.  
 KW Glycoprotein; Immunoglobulin domain; Transmembrane; Signal;  
 KW Repeat; Anti-oncogene; Disease mutation; Polymorphism.  
 FT SIGNAL 1 25  
 FT CHAIN 26 1447  
 FT DOMAIN 26 1097 TUMOR SUPPRESSOR PROTEIN DCC.  
 FT TRANSMEM 1098 1122 EXTRACELLULAR (POTENTIAL).  
 FT DOMAIN 1123 1447 POTENTIAL.  
 FT DOMAIN 1123 1447 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 154 124 IG-LIKE C2-TYPE DOMAIN 1.  
 FT DOMAIN 154 219 IG-LIKE C2-TYPE DOMAIN 2.  
 FT DOMAIN 354 317 IG-LIKE C2-TYPE DOMAIN 3.  
 FT DOMAIN 345 407 IG-LIKE C2-TYPE DOMAIN 4.  
 FT DOMAIN 426 522 FIBRONECTIN TYPE-III 1.  
 FT DOMAIN 525 618 FIBRONECTIN TYPE-III 2.  
 FT DOMAIN 619 716 FIBRONECTIN TYPE-III 3.  
 FT DOMAIN 722 816 FIBRONECTIN TYPE-III 4.  
 FT DOMAIN 840 940 FIBRONECTIN TYPE-III 5.  
 FT DOMAIN 941 1042 FIBRONECTIN TYPE-III 6.  
 FT DISULFID 61 117 BY SIMILARITY.  
 FT DISULFID 161 212 BY SIMILARITY.  
 FT DISULFID 261 310 BY SIMILARITY.  
 FT DISULFID 352 400 BY SIMILARITY.  
 FT CARBOHYD 94 94 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 299 299 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 318 318 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 478 478 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 628 628 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 702 702 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT VARIANT 168 168 M -> T (IN OESOPHAGEAL CARCINOMA).  
 FT VARIANT 201 201 /FTID-VAR\_003909.  
 FT VARIANT 201 201 R -> G.  
 FT VARIANT 1375 1375 /FTID-VAR\_003910.  
 FT VARIANT 1375 1375 P -> H (IN A COLORECTAL CARCINOMA).  
 FT CONFLICT 138 138 /FTID-VAR\_003911.  
 FT CONFLICT 233 329 MISSING (IN REF. 3).  
 FT CONFLICT 421 421 MISSING (IN REF. 3).  
 SQ SEQUENCE 1447 AA; 158456 MW; 4A8612766BD0471F CRC64;  
 Query Match 6.2%; Score 128; DB 1; Length 1447;

Best Local Similarity 24.8%; Pred. No. 0 024;  
 Matches 60; Conservative 33; Mismatches 99; Indels 50; Gaps 10;  
 QY 14 SGSGNEV-----IEGPQATVTKGSGARNCYSGGW--KLIMNALSDM 55  
 Db 220 SRTGNEAEVRILSDPGLRHOLYFLQRPNSVVAIEGKDAVLECCVS--GYPPSFYTLRGE 278  
 QY 56 VVLSVRMEPIITNDRTSGRYDGGNFTEMIHNEPDSGNINC--SLQSRLLGSA 113  
 Db 279 VI-----QURSKKYSLLGG--SNLLISNTDDSCMYTCVVYKKNENISASA 323  
 QY 114 YLTQVNGELFIPSVNVVAENEPCEVTCPSWTRLPDISW--ELGLVSHSSYFVPEP 172  
 Db 324 ELFTLVPEPWFILNPSNLYAESMDIEFCVVS--GKPYPTVNMKNKGDPVIPSDFQIVG 382  
 QY 173 SDLOSANVSIILATPQSGNLTCAVTKMSLAKRSATVNLTVICPDGTGGGINIPGVLS 232  
 Db 383 SNLR---ILGVKSDGDFYQVAENAGNAQTSQALIVKPAIPSSS-----VLPS 430  
 QY 233 LP 234  
 Db 431 AP 432  
 RESULT 10  
 KMLS\_HUMAN STANDARD: PRT: 1914 AA.  
 ID KMLS\_HUMAN  
 AC 015746; Q14844; Q16794; Q95796; Q95797; Q95798; Q95799; Q9UBG5;  
 AC Q9UT19;  
 DT 15-JUN-1998 (Rel. 36, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Myosin light chain kinase, smooth muscle and non-muscle isozymes  
 DE (BC 2.7.1.117) (MCK) [contains: telokin (kinase related protein)]  
 DE (RRP).  
 GN MYLK OR MLCK.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
 OX NCBI\_TaxId=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A. (ISOFORM 1).  
 RC TISSUE-Umbilical vein endothelial cells;  
 RX MEDLINE=97304466; Pubmed=9160829;  
 RA Garcia J.G.N., Lazar V.L., Gilbert-McClain L.I., Gallagher P.J.,  
 RA Verin A.D.;  
 RT "Myosin light chain kinase in endothelium: molecular cloning and  
 RT regulation.";  
 RL Am. J. Respir. Cell Mol. Biol. 16:489-494(1997).  
 RN [2]  
 RP REVISIONS.  
 RA Birukov K.G., Garcia J.G.N.;  
 RA Submitted (MAR-2000) to the EMBL/Genbank/DBJ databases.  
 RN [3]  
 RP SEQUENCE FROM N.A. (ISOFORMS 2; 3a; 3B AND 4).  
 RC TISSUE-Umbilical vein;  
 RX MEDLINE=99216419; Pubmed=10198165;  
 RA Lazar V.L., Garcia J.G.N.;  
 RT "A single human myosin light chain kinase gene (MLCK; MYLK).";  
 RL Genomics 57:256-267(1999).  
 RN [4]  
 RP REVISIONS (ISOFORM 2).  
 RA Birukov K.G., Garcia J.G.N.;  
 RA Submitted (MAR-2000) to the EMBL/Genbank/DBJ databases.  
 RN [5]  
 RP SEQUENCE OF 923-1914 FROM N.A.  
 RC TISSUE-Hippocampus;  
 RX MEDLINE=96121365; Pubmed=8575746;  
 RA Potter M.-C., Chelot E., Pekarsky Y., Gardiner K., Rossier J.,  
 RA Turnell W.G.;  
 RT "The human myosin light chain kinase (MCK) from hippocampus:  
 RT cloning, sequencing, expression, and localization to 3qcen-q21.";  
 RL Genomics 29:562-570(1995).





FT DOMAIN 606 671 IG-LIKE C2-TYPE DOMAIN 7.  
 FT DISULFID 796 1066 PROTEIN KINASE; INACTIVE.  
 FT DISULFID 53 101 BY SIMILARITY.  
 FT DISULFID 150 200 BY SIMILARITY.  
 FT DISULFID 246 301 BY SIMILARITY.  
 FT DISULFID 343 391 BY SIMILARITY.  
 FT DISULFID 433 481 BY SIMILARITY.  
 FT DISULFID 524 570 BY SIMILARITY.  
 FT CARBOHYD 613 664 BY SIMILARITY.  
 FT CARBOHYD 116 116 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 175 175 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 184 184 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 214 214 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 268 268 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 283 283 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 405 405 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 463 463 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 567 567 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 646 646 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CONFLICT 92 92 P -> R (IN REF. 2 AND 3).  
 FT CONFLICT 147 147 K -> T (IN REF. 2 AND 3).  
 FT CONFLICT 207 207 S -> G (IN REF. 2 AND 3).  
 FT CONFLICT 495 495 VL -> RV (IN REF. 2 AND 3).  
 FT CONFLICT 515 515 E -> E (IN REF. 2 AND 3).  
 FT CONFLICT 881 881 G -> G (IN REF. 2 AND 3).  
 FT CONFLICT 969 969 A -> P (IN REF. 2 AND 3).  
 FT CONFLICT 992 992 S -> F (IN REF. 2 AND 3).  
 SQ SEQUENCE 1070 AA; 118260 MW; 47CDE25B8E3698A5 CRC64;

Query Match 6.0%; Score 125; DB 1; Length 1070;  
 Best Local Similarity 24.8%; Pred. No. 0.029;  
 Matches 59; Conservative 34; Mismatches 109; Indels 36; Gaps 10;

QY 11 AVSSGSGNEVEEPONATVLSQARFNCVTS-OGMKLIMWALSDWVLSVPRMEIITN 69  
 Db 218 SIADSEARVAVLPQDVVARYEAMFHCFSQAPPSPLOMFEDETPIITNSRPHLR 277  
 QY 70 DRTSQRIDGNGFTSEMIHNEPSSDGNISLNSR---LHGSATLVYQVNGELF 124  
 Db 278 ATVFA-----NSGLLTQVRPNRAGIYRCIGOGORPPIILBATLAEIEDMPLE 328  
 QY 125 IPSVNLVVAENECVTCPSHWTRLPDISME-LGL-LVSHSYTVVPPESDQSAVSL 182  
 Db 329 EPRVFTAGSE---RYTCPLPKLPSPVSWHEHAGVRLPHGRVY-----QKGHELV 378  
 QY 183 ALTPQSN-GLTLCVATWKSILKARKSATVNLTV-----IRCPDGTGGGINIPGLSSL 233  
 Db 379 ANTAESDAGVYTCMA--NLAGORODVNTVATVPSWMLKKPDQSLDEGKREYLDCL 434

RESULT 12  
 PGBM\_HUMAN STANDARD; PRT; 4393 AA.  
 AC P98160; 016287;  
 DT 01-OCT-1996 (Rel. 34, Last sequence update)  
 DT 01-OCT-1996 (Rel. 34, Last sequence update)  
 DT 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Basement membrane-specific heparan sulfate proteoglycan core  
 DE protein precursor (HSPG) (Perlecan) (PLC).  
 GN HSPG2.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN 1;  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=92112994; PubMed=1730768;  
 RA Kallunki P., Tryggvason K.;  
 RT "Human basement membrane heparan sulfate proteoglycan core protein: a  
 RT 467-kD protein containing multiple domains resembling elements of the  
 RT low density lipoprotein receptor, laminin, neural cell adhesion  
 RT molecules, and epidermal growth factor.";  
 RL J. Cell Biol. 116:559-571(1992).

RN [2]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Skin, and Colon;  
 RX MEDLINE=92235084; PubMed=1569102;  
 RA Murdoch A.D., Dodge G.R., Cohen I., Tuan R.S., Iozzo R.V.;  
 RT "Primary structure of the human heparan sulfate proteoglycan from  
 RT basement membrane (HSPG2/perlecan). A chimeric molecule with multiple  
 RT domain homologues to the low density lipoprotein receptor, laminin,  
 RT neural cell adhesion molecules, and epidermal growth factor.";  
 RL J. Biol. Chem. 267:8544-8557(1992).  
 RN [3]  
 RP SEQUENCE OF 1018-1472 FROM N.A.  
 RC TISSUE=Colon;  
 RX MEDLINE=91365373; PubMed=1679749;  
 RA Dodge G.R., Kovacszy I., Chu M.L., Hassell J.R., McBride O.W.,  
 RA Yi H.F., Iozzo R.V.;  
 RT "Heparan sulfate proteoglycan of human colon: partial molecular  
 RT cloning, cellular expression, and mapping of the gene (HSPG2) to the  
 RT short arm of human chromosome 1.";  
 RL Genomics 10:673-680(1991).  
 RN [4]  
 RP SEQUENCE OF 892-1398 FROM N.A.  
 RC TISSUE=Fibroblasts;  
 RX MEDLINE=92120660; PubMed=1685141;  
 RA Kallunki P., Eddy R.L., Byers M.G., Kestila M., Shows T.B.,  
 RA Tryggvason K.;  
 RT "Cloning of human heparan sulfate proteoglycan core protein,  
 RT assignment of the gene (HSPG2) to 1p36.1--p35 and identification of  
 RT a BamHI restriction fragment length polymorphism.";  
 RL Genomics 11:389-396(1991).  
 RN [5]  
 RP SEQUENCE OF 1-21 FROM N.A.  
 RX MEDLINE=94052171; PubMed=8234307;  
 RA Cohen I.R., Graessle S., Murdoch A.D., Iozzo R.V.;  
 RT "Structural characterization of the complete human perlecan gene and  
 RT its promoter.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 90:10404-10408(1993).  
 CC -I- FUNCTION: This protein is an integral component of basement  
 CC membranes. It is responsible for the fixed negative electrostatic  
 CC charge and is involved in the charge-selective ultrafiltration  
 CC properties. It serves as an attachment substrate for cells.  
 CC -I- SUBUNIT: Purified perlecan has a strong tendency to aggregate in  
 CC dimers or stellate structures. It interacts with other basement  
 CC membrane components such as laminin, prolargin and collagen type  
 CC IV.  
 CC -I- SUBCELLULAR LOCATION: Extracellular.  
 CC -I- TISSUE SPECIFICITY: FOUND IN THE BASEMENT MEMBRANES.  
 CC -I- PTM: CONTAINS THREE HEPARAN SULFATE CHAINS AS WELL AS N-LINKED  
 CC AND O-LINKED OLIGOSACCHARIDES.  
 CC -I- SIMILARITY: CONTAINS 4 LDL-RECEPTOR CLASS A DOMAINS.  
 CC -I- SIMILARITY: CONTAINS 10.5 LAMININ EGF-LIKE DOMAINS.  
 CC -I- SIMILARITY: CONTAINS 3 LAMININ DOMAINS IV.  
 CC -I- SIMILARITY: CONTAINS 22 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -I- SIMILARITY: CONTAINS 3 LAMININ G-LIKE DOMAINS.  
 CC -I- SIMILARITY: CONTAINS 4 EGF-LIKE DOMAINS.  
 CC -I- SIMILARITY: CONTAINS 1 SEA DOMAIN.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; X62515; CAA44373.1; -;  
 DR EMBL; M85289; AAA52700.1; -;  
 DR EMBL; M64283; AAA52699.1; -;  
 DR EMBL; S76436; AAB21121.2; -;  
 DR EMBL; L22078; -; NOT\_ANNOTATED\_CDS.  
 DR HSSP; P00740; IEDM.  
 DR Siona-ZDPAGE; P98160; -;  
 DR Genew; HGNC:5273; HSPG2.



[1]  
 RN SEQUENCE FROM N.A., AND SEQUENCE OF 18-28; 120-132; 135-157 AND  
 RP 563-571.  
 RX MEDLINE=92153423; PubMed=1739462;  
 RA Dulac C., Tropak W.B., Cameron-Curry P., Rossier J., Marshak D.R.,  
 Roder J., le Douarin N.M.;  
 RT "Molecular characterization of the Schwann cell myelin protein, SMP:  
 RT structural similarities within the immunoglobulin superfamily.";   
 RL Neuron 8:323-334(1992).  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.  
 CC -1- TISSUE SPECIFICITY: EXCLUSIVELY EXPRESSED BY MYELINATING AND  
 CC NONMYELINATING SCHWANN CELLS AND OLIGODENDROCYTES.  
 CC -1- DEVELOPMENTAL STAGE: FIRST SYNTHESIZED AT EMBRYONIC DAY 5, IT  
 CC REMAINS EXPRESSED BY CULTURED SCHWANN CELLS.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.  
 CC -1- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.  
 CC -1- SIMILARITY: CONTAINS 4 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 DR EMBL; S83711; AAB21466.1; -.  
 DR HSSP; P56276; 1TLK.  
 DR InterPro; IPR003006; Ig\_MHC.  
 DR InterPro; IPR003598; Ig\_C2.  
 DR InterPro; IPR003600; Ig\_Like.  
 DR Pfam; PF00047; Ig; 2.  
 DR SMART; SM00410; Ig\_Like; 1.  
 DR SMART; SM00408; IgC2; 2.  
 KM Myelin; Glycoprotein; Cell adhesion; Transmembrane; Signal; Repeat;  
 KW Immunoglobulin domain.  
 FT SIGNAL 1 17  
 FT CHAIN 18 620  
 FT DOMAIN 18 516  
 FT TRANSMEM 517 536  
 FT DOMAIN 537 620  
 FT DOMAIN 28 106  
 FT DOMAIN 151 223  
 FT DOMAIN 253 311  
 FT DOMAIN 339 398  
 FT DOMAIN 424 495  
 FT DISULFID 35 164  
 FT DISULFID 40 99  
 FT DISULFID 158 216  
 FT DISULFID 260 304  
 FT DISULFID 346 391  
 FT DISULFID 420 429  
 FT DISULFID 431 488  
 FT CARBOHYD 222 222  
 FT CARBOHYD 314 314  
 FT CARBOHYD 331 331  
 FT CARBOHYD 405 405  
 FT CARBOHYD 449 449  
 SO SEQUENCE 620 AA; 66943 MW; 004B3ECEDC18FBA CRC64;  
 Query Match 5.78; Score 118.5; DB 1; Length 620;  
 Best Local Similarity 21.5%; Pred. No. 0.049;  
 Matches 57; Conservative 33; Mismatches 88; Indels 87; Gaps 12;

DB 330 INSLMWVSGDVSVCRAE-----SEPAILFLVNGKVM 365  
 QY 183 ALT-----POSNGLCVATWLSLRKRNATVLY-----TRCQD 219  
 DB 366 AAAYEDHYTMEMRPAREPDGGTSCVA--ENMGASSTSFNIVPEPLVLPASRCTAG 423  
 QY 220 TGGGINIFGVLSLP--SIGFSLP 242  
 DB 424 -GDVAVCVANVSIFDSSLVFELPT 447  
 RESULT 14  
 ID NEOL CHICK STANDARD; PRT; 1443 AA.  
 AC 090610;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DE 15-JUN-2002 (Rel. 41, Last annotation update)  
 DE Neogenin (Fragment).  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 OX NCBI\_TaxID=9031;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=White leghorn; TISSUE=Embryonic brain;  
 RX MEDLINE=95105243; PubMed=7806578;  
 RA Vielmetter J., Roman J.M., Dreyer W.J.;  
 RT "Neogenin, an avian cell surface protein expressed during terminal  
 RT neuronal differentiation, is closely related to the human tumor  
 RT suppressor molecule deleted in colorectal cancer";   
 RL J. Cell Biol. 127:2009-2020(1994).  
 CC -1- FUNCTION: MAY BE INVOLVED AS A REGULATORY PROTEIN IN THE  
 CC TRANSITION OF UNDIFFERENTIATED PROLIFERATING CELLS TO THEIR  
 CC DIFFERENTIATED STATE. MAY ALSO FUNCTION AS A CELL ADHESION  
 CC MOLECULE IN A BROAD SPECTRUM OF EMBRYONIC AND ADULT TISSUES.  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.  
 CC -1- DEVELOPMENTAL STAGE: IN RETINA, EXPRESSED ON GANGLION CELL FIBERS  
 CC AS SOON AS THEY BEGIN TO EXTEND THEIR AXONS.  
 CC -1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY. DCC  
 CC SUPERFAMILY.  
 CC -1- SIMILARITY: CONTAINS 4 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.  
 CC -1- SIMILARITY: CONTAINS 6 FIBRONECTIN TYPE III-LIKE DOMAINS.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 DR EMBL; U07644; AAC59662.1; -.  
 DR HSSP; P11276; 2MEN.  
 DR InterPro; IPR003961; FN\_III.  
 DR InterPro; IPR003962; FNIII\_repeat.  
 DR InterPro; IPR003006; Ig\_MHC.  
 DR InterPro; IPR003598; Ig\_C2.  
 DR InterPro; IPR003600; Ig\_Like.  
 DR Pfam; PF00041; In3; 6.  
 DR Pfam; PF00047; In3; 6.  
 DR PRINTS; PRO0014; FNTYPEIII.  
 DR SMART; SM00060; FN3; 6.  
 DR SMART; SM00410; Ig\_Like; 2.  
 DR SMART; SM00408; IgC2; 2.  
 KW Transmembrane; Immunoglobulin domain; Glycoprotein; Repeat.  
 FT NON\_TER 1 1  
 FT DOMAIN 1 1090  
 FT TRANSMEM 1091 1111  
 FT DOMAIN 1112 1443  
 FT DOMAIN 33 102  
 EXTRACELLULAR (POTENTIAL).  
 POTENTIAL.  
 CYTOPLASMIC (POTENTIAL).  
 IG-LIKE C2-TYPE DOMAIN 1.

```

FT  DOMAIN  132  194  IG-LIKE C2-TYPE DOMAIN 2.
FT  DOMAIN  229  293  IG-LIKE C2-TYPE DOMAIN 3.
FT  DOMAIN  321  383  IG-LIKE C2-TYPE DOMAIN 4.
FT  DOMAIN  422  519  FIBRONECTIN TYPE-III 1.
FT  DOMAIN  522  615  FIBRONECTIN TYPE-III 2.
FT  DOMAIN  616  714  FIBRONECTIN TYPE-III 3.
FT  DOMAIN  720  814  FIBRONECTIN TYPE-III 4.
FT  DOMAIN  835  915  FIBRONECTIN TYPE-III 5.
FT  DOMAIN  936  1037  FIBRONECTIN TYPE-III 6.
FT  DISULFID  139  187  BY SIMILARITY.
FT  DISULFID  236  286  BY SIMILARITY.
FT  DISULFID  328  376  BY SIMILARITY.
FT  CARBOHYD  39  39  N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD  176  176  N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD  292  292  N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD  456  456  N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD  475  475  N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD  625  625  N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD  700  700  N-LINKED (GLCNAC. . .) (POTENTIAL).
FT  CARBOHYD  894  894  N-LINKED (GLCNAC. . .) (POTENTIAL).
SO  SEQUENCE  1443 AA; 158050 MW; 558C6795579C0E26 CRC64;

Query Match      5.7%; Score 117.5; DB 1; Length 1443;
Best Local Similarity 26.2%; Pred. No. 0.17;
Matches 49; Conservative 28; Mismatches 73; Indels 37; Gaps 11;

OY  21  IEGPQNAVYKGSQAFNCTVSGW--KLIMVALSDMVLYSRPMPEITNDRTFSORY- 77
DB  218  VQPSSTLTAVTQGNVFP-C-VAGGFPTPVYKTKN-----ELITED---SERFA 264
OY  78  -DQGNFTSEMIITHNVPDSGNIRC--SLQNSRLGSAVLTQVYGELEFIPSNLVYAE 134
DB  265  LRAGGS-----LLISDVEDVGTCTCIADNENETIEAQLAVQVPEFLKRPANIYAE 320
OY  135  NE-----PCEVTCLPSPHWTLPDISW-ELGLYSHSYVPPPSDQSVSLATLPQSN 189
DB  321  SMDIYECFETGKPT-----PTVKWKNQDVVIPSDFYKIVEHNLQ---VLGLVKSDE 371
OY  190  GTLTGVA 196
DB  372  GFYQCTA 378

RESULT 15
NEO1_HUMAN
AC  092859; 000340; STANDARD; PRT; 1461 AA.
ID  NEO1_HUMAN
DT  16-OCT-2001 (Rel. 40, Created)
DT  16-OCT-2001 (Rel. 40, Last sequence update)
DT  15-JUN-2002 (Rel. 41, Last annotation update)
DE  Neogenin precursor.
GN  NEO1 OR NGN.
OS  Homo sapiens (Human).
OC  Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC  Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX  NCBI_TaxID=9606;
RN  [1]
RP  SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
RC  TISSUE=Fetal brain;
RA  MEDLINE=97236653; PubMed=9121761;
RT  Meyerhardt J.A., Look A.T., Bigner S.H., Fearon E.R.;
RT  "Identification and characterization of neogenin, a DCC-related
RT  gene.";
RL  Oncogene 14:1129-1136(1997).
RN  [2]
RP  SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
RC  TISSUE=Fetal brain;
RA  MEDLINE=97312693; PubMed=9169140;
RA  Vielmetter J., Chen X.-N., Miskewich F., Lane R.P., Yamakawa K.,
RA  Korenberg J.R., Dreyer W.J.;
RT  "Molecular characterization of human neogenin, a DCC-related protein,
RT  and the mapping of its gene (NEO1) to chromosomal position 15q22.3-

```

```

RT  923.";
RL  Genomics 41:414-421(1997).
CC  -1- FUNCTION: MAY BE INVOLVED AS A REGULATORY PROTEIN IN THE
CC  TRANSITION OF UNDIFFERENTIATED PROLIFERATING CELLS TO THEIR
CC  DIFFERENTIATED STATE. MAY ALSO FUNCTION AS A CELL ADHESION
CC  MOLECULE IN A BROAD SPECTRUM OF EMBRYONIC AND ADULT TISSUES.
CC  -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC  -1- ALTERNATIVE PRODUCTS: AT LEAST 2 ISOFORMS, 1 (SHOWN HERE) AND 2;
CC  ARE PRODUCED BY ALTERNATIVE SPLICING.
CC  -1- TISSUE SPECIFICITY: WIDELY EXPRESSED AND ALSO IN CANCER CELL
CC  LINES.
CC  -1- SIMILARITY: BELONGS TO THE IMUNOGLOBULIN SUPERFAMILY. DCC
CC  SUBFAMILY.
CC  -1- SIMILARITY: CONTAINS 4 IMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
CC  -1- SIMILARITY: CONTAINS 6 FIBRONECTIN TYPE III-LIKE DOMAINS.
CC  -----
CC  THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC  between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC  the European Bioinformatics Institute. There are no restrictions on its
CC  use by non-profit institutions as long as its content is in no way
CC  modified and this statement is not removed. Usage by and for commercial
CC  entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC  or send an email to license@isb-sib.ch).
CC  -----
DR  EMBL; U61262; AB017263.1; -.
DR  EMBL; U72391; AAC51287.1; -.
DR  HSSP; P02751; ITTF.
DR  GeneW; HGNC:754; NEO1.
DR  MIM; 601907; -.
DR  InterPro; IPR003961; FN_III.
DR  InterPro; IPR003962; FNIII_repeat.
DR  InterPro; IPR003006; Ig_MHC.
DR  InterPro; IPR003598; Ig_c2.
DR  InterPro; IPR003600; Ig_1like.
DR  Pfam; PF00041; fn3; 6.
DR  Pfam; PF00047; Ig; 4.
DR  PRINTS; PR00014; FNYPEIII.
DR  SMART; SM00060; FN3; 6.
DR  SMART; SM00410; IG_1like; 1.
DR  SMART; SM00408; IGC2; 3.
DR  Transmembrane; Immunoglobulin domain; Glycoprotein; Signal; Repeat;
KW  Alternative splicing.
FT  SIGNAL  1 33
FT  CHAIN  34 1461
FT  DOMAIN  34 1105
FT  TRANSMEM 1106 1126
FT  DOMAIN  1127 1461
FT  DOMAIN  67 136
FT  DOMAIN  166 228
FT  DOMAIN  263 327
FT  DOMAIN  355 417
FT  DOMAIN  436 533
FT  DOMAIN  536 629
FT  DOMAIN  630 729
FT  DOMAIN  735 829
FT  DOMAIN  850 950
FT  DOMAIN  951 1052
FT  DOMAIN  1118 1121
FT  DISULFID  74 129
FT  DISULFID  173 221
FT  DISULFID  270 320
FT  DISULFID  362 410
FT  CARBOHYD  73 73
FT  CARBOHYD  210 210
FT  CARBOHYD  326 326
FT  CARBOHYD  470 470
FT  CARBOHYD  489 489
FT  CARBOHYD  639 639
FT  CARBOHYD  715 715
FT  CARBOHYD  909 909
FT  CARBOHYD  1248 1300
FT  CONFLICT 168 168
FT  CONFLICT 1461 AA; 159958 MW; 7AAEB97EB965A21 CRC64;
SO  SEQUENCE

```







GenCore version 5.1.4\_p5.4578  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 28, 2003, 18:09:54 ; Search time 19.0659 Seconds  
(without alignments)  
1946.300 Million cell updates/sec

Title: US-09-729-264-6

Perfect score: 2077  
Sequence: 1 MRRHLLTPEAVGSSGSGNEV.....HPQASFNLASPEKVSNTTV 386

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database : PIR\_73:\*  
1: PIR1:\*  
2: PIR2:\*  
3: PIR3:\*  
4: PIR4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	151	7.3	404	1	I61596 advanced glycosyla
2	139.5	6.7	344	1	I56551 neurotlimin - rat
3	133	6.4	1427	2	I51659 tumor suppressor
4	130	6.3	345	2	JC4025 oploid-binding cel
5	129.5	6.2	164	2	T24272 hypothetical prote
6	129	6.2	345	2	S03199 oploid-binding pro
7	129	6.2	6642	2	T29757 protein UNC-89 - C
8	128	6.2	345	2	JC1239 oploid-binding pro
9	128	6.2	1447	2	AS4100 tumor suppressor p
10	127.5	6.1	871	1	I48696 protein-tyrosine k
11	127.5	6.1	881	1	I48697 protein-tyrosine k
12	125	6.0	1070	2	JC4593 hypothetical prote
13	122.5	5.9	188	2	T15651 perlecan precursor
14	122.5	5.9	4391	2	A38096 oploid-binding pro
15	118.5	5.7	338	2	JH0593 neogenin cell myeli
16	118.5	5.7	620	2	JH0593 neogenin cell myeli
17	117.5	5.7	1443	2	I50600 hypothetical prote
18	114.5	5.5	152	2	T18975 advanced glycosyla
19	113.5	5.5	416	1	A42879 sodium-dependen
20	111	5.3	693	2	S49228 sodium-dependen
21	110.5	5.3	764	2	A49448 irregular chiasm C
22	110.5	5.3	1177	2	T16594 hypothetical prote
23	109.5	5.3	880	1	AS3743 protein-tyrosine k
24	109	5.2	391	2	T09058 butyrophilin homol
25	108.5	5.2	487	2	S65133 butyrophilin - mou
26	106.5	5.1	802	2	T13149 mitogen-and stress
27	106.5	5.1	946	1	A47299 ror-related recept
28	106.5	5.1	2491	1	A28372 insulin-like growt
29	106	5.1	1092	1	JN0635 neural cell adhesi

30	105.5	5.1	862	2	I49583 differentiation an
31	105.5	5.1	882	2	I38912 receptor tyrosine
32	105.5	5.1	3707	2	S18252 heparan sulfate pr
33	105	5.1	662	2	T16525 hypothetical prote
34	105	5.1	5825	2	T12117 polyprotein - fava
35	104	5.0	2222	2	T13924 ssk protein - frui
36	103.5	5.0	423	2	T29549 hypothetical prote
37	103.5	5.0	1323	2	PN0568 connectin 3B - chi
38	103	5.0	365	2	JC7780 coxsackie- and ade
39	103	5.0	1273	2	T42405 sax-3 protein - Ca
40	102	4.9	721	2	T41530 hypothetical prote
41	102	4.9	868	2	A46512 CD22 homolog/B lym
42	101.5	4.9	344	1	RWRT2 T-cell surface gly
43	101.5	4.9	421	2	T46266 hypothetical prote
44	101.5	4.9	841	2	JC5894 killer cell inhibi
45	101	4.9	338	2	JC5519 50K glycoprotein p

## ALIGNMENTS

## RESULT 1

I61596 advanced glycosylation end-products receptor precursor - human

N:Alternate names: advanced glycosylation end product-binding protein, 35K, glycoprot  
C:Species: Homo sapiens (man)

C>Date: 24-May-1996 #sequence revision 07-Feb-1997 #text change 16-Jul-1999

C:Accession: I61596; B42879; S27968

R: Sugaya, K.; Fukagawa, T.; Matsumoto, K.; Mita, K.; Takahashi, E.; Ando, A.; Inoko, G.  
Genomics 23, 408-419, 1994

A:Title: Three genes in the human MHC class III region near the junction with the c1a  
interpart of mouse mammary tumor gene int-3.

A:Reference number: A55562; MUID:95137587; PMID:7835890

A:Accession: I61596

A>Status: nucleic acid sequence not shown; translation not shown; translated from GB/  
A:Molecule type: DNA

A:Residues: 1-404 <RES>

A:Cross-references: GB:D28769; NID:9561657; PIDN:BA05958.1; PID:9561659

R: Neepser, M.; Schmidt, A.M.; Brett, J.; Yan, S.D.; Wang, F.; Pan, Y.C.; Elliston, K.;  
J. Biol. Chem. 267, 14998-15004, 1992

A:Title: Cloning and expression of a cell surface receptor for advanced glycosylation  
A:Reference number: A42879; MUID:92340547; PMID:1378843

A:Accession: B42879

A:Molecule type: mRNA

A:Residues: 'G', '2-99', 'R', '101-404 <NDE>

A:Cross-references: EMBL:M91211; NID:9190845; PIDN:AAA03574.1; PID:9190846

A:Experimental source: lung

A:Note: sequence extracted from NCBI backbone (NCBI:109438)

C:Comment: Advanced glycosylation end products are heterogeneous nonenzymatically gly  
cellular function, thus contributing to tissue lesions in diabetes.

C:Comment: This receptor appears also to mediate the effects of amyloid beta peptide  
ates in the neurotoxic pathway that produces dementia in Alzheimer's disease.

C:Genetics:

A:Gene: GDB:AGER

A:Cross-references: GDB:306354; OMIM:600214

A:Map position: 6p21.3-6p21.3

A:Introns: 18/1; 53/3; 119/1; 140/3; 170/1; 231/1; 274/3; 322/1; 331/1; 373/2

C:Function:

A:Description: neuronal receptor for amphoterin, a DNA-binding protein involved in ne  
C:Superfamily: advanced glycosylation end products receptor; immunoglobulin homology

C:Keywords: Alzheimer's disease; glycoprotein; receptor; transmembrane protein  
F:1-22/Domains: signal sequence #status predicted <SIG>

F:23-404/Product: advanced glycosylation end products receptor #status predicted <MAT  
F:23-444/Domains: extracellular #status predicted <EXT>

F:31-101/Domains: immunoglobulin homology <IM1>

F:137-210/Domains: immunoglobulin homology <IM2>

F:252-303/Domains: immunoglobulin homology <IM3>

F:345-362/Domains: transmembrane #status predicted <TM>

F:363-404/Domains: intracellular #status predicted <INT>

F:25, 81/Binding site: carbohydrate (Asn) (covalent) #status predicted

F:38-99, 144-208, 259-301/Disulfide bonds: #status predicted

Query Match 7.3%, Score 151; DB 1; Length 404;

Best Local Similarity 23.3%; Pred. No. 0.001;  
Matches 90; Conservative 38; Mismatches 112; Indels 146; Gaps 19;

QY 9 PEAVSGSGNEVEIEGPQNAIVLKSGQARFNCVSGW---WKIMALSDMWLVSRPMEP 65  
Db 124 PEIVDSAS--ELTAGVPN-----KVTGCVSGSGYPAGTLVHLDG-----KP 163  
QY 66 IITNDRFTS-----ORYDGGNFT--SEMIINHPDSGNIR---CSLONSRLHGSAY 114  
Db 164 LVPNEGVSVKQTRRHPTGTGLTQSLM---VPPARGDPRPFSCSFGSLPRHRL 220  
QY 115 LVQVWGLFIP---SVNLVAENEP-----CEVCLPSHMTLPDISWE 156  
Db 221 RTAPLOPRWVEPPLVEEVLVY---EPREGAVAPGVTLLCEVPAOPS---FOIHMM 272  
QY 157 LGLVSHSSYFVPPPSDQASVSLIALTPQSGNLTLCVATWKLAKKASATVNTVTRC 216  
Db 273 KD-----GVPLPLPPSVLLIPEIGPODQGYSCVAHSHSGPESRAVSISILE- 322  
QY 217 PODTGGGINIPGVLSLPSLGFSLPTWGVGLAGTMTLT-----PTCLTTRCCCC 269  
Db 323 PEEEG-----PTAGSVGSGSLGTLALAGILGIGTALLIGVILM 363  
QY 270 RRRCCGCCNCCGCCRCRKRKGRFIOFOKSKSEKT--NKLETETSGNDSGYSDEKT 327  
Db 364 QRR-----ORGERAKAPENOEBEERAEIN----- 389  
QY 328 TETASLPKSCSSDPEQNSSCGPP 353  
Db 390 -----QSEPEAGESSSTGCP 404

## RESULT 2

156551  
neurofilamin - rat

C:Species: Rattus norvegicus (Norway rat)  
C>Date: 26-Jul-1996 #sequence\_revision 26-Jul-1996 #text\_change 19-May-2000  
C:Accession: J156551  
R:Struyk, A.F.; Canoll, P.D.; Molifang, M.J.; Rosen, C.L.; D'Eustachio, P.; Salzer, J.L.  
J. Neurosci. 15, 2141-2156, 1995  
A:Title: Cloning of neurofilamin defines a new subfamily of differentially expressed neur  
A:Reference number: 156551; MUID:95198094; PMID:7891157  
A:Accession: J156551  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-344 <RES>  
A:Cross-references: EMBL:U16845; NID:9755184; PIDN:AAA67445.1; PID:9755185  
C:Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-termin

## Query Match

Best Local Similarity 6.7%; Score 139.5; DB 2; Length 344;  
Matches 66; Conservative 40; Mismatches 110; Indels 49; Gaps 13;

QY 3 RHLLTPEAVSGSGNEVI-EGPQNAIVLKSGQARFNCVSGWKLIMALSDMWLVLS-- 59  
Db 20 RLFLVPTGVVPSRGDAITFPKAMDVTVRQGESATLRCTIDRVTAVMLNKRSTILVGN 79  
QY 60 -----VRPMEPIITNDRFTSQRYDGGNFTSEMIINHPDSGNIRCSLQ-----NSRL 109  
Db 80 DKWCIDPRVYLISN---TGTQY-----STEQNVADYDEGPTGCVQTDNHPKTSRV 128  
QY 110 HGSAYLVQVWGLFIPSVNLVAENEPCEVCLPSHMTLPDISWGLGLVSHSSYFV 169  
Db 129 H-----LIQVSPKIVIEISDISINSGNNISLCTATGRPE-PLYTW---HISPRVAHFV 180  
QY 170 PEPSSDQASVSLIALTPQSGNLTLCVATWKLAKKASATVNTVTRC-----QDTGGGI 224  
Db 181 SDEYLE-----IQGITREGSGEYESAS--NDVAAPVRRVNVTVVPPYISAKGTGVPV 235  
QY 225 NIPGVL-----SSLPSLIGFSLPTWGR 245  
Db 236 GQKGTLOCBAASAVPSAEFO---WFK 257

## RESULT 3

151669  
tumor suppressor - African clawed frog

C:Species: Xenopus laevis (African clawed frog)  
C>Date: 13-Sep-1996 #sequence\_revision 13-Sep-1996 #text\_change 21-Jul-2000  
C:Accession: J151669  
R:Pearceall, W.E.; Reale, M.A.; Candia, A.F.; Wright, C.V.; Cho, K.R.; Fearon, E.R.  
Dev. Biol. 166, 654-665, 1994  
A:Title: Expression of a homologue of the deleted in colorectal cancer (DCC) gene in  
A:Reference number: 151668; MUID:95113183; PMID:7813784  
A:Accession: J151669  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-1427 <PIE>  
A:Cross-references: EMBL:U10986; NID:9606873; PIDN:AAA70168.1; PID:9606874  
C:Gene: XDCCA

## Query Match

Best Local Similarity 6.4%; Score 133; DB 2; Length 1427;  
Matches 59; Conservative 33; Mismatches 90; Indels 48; Gaps 13;

QY 21 IEGPQNAIVLKSGQARFNCVSGW--KLIMALSDMWLVSRPMEPIITNDRFTSQRYD 78  
Db 243 LQPSNVVAIEGDAVLECAVS--GYPPRTIVMAGD-----BPVPIRTR---KYS 288  
QY 79 QGGNFTSEMIINHPDSGNIR---SLONSRLHGSAYLVQVWGLFIPSVNLVAENEP 136  
Db 289 VLGG--SNLISNVTDDAAGATYCAATYKKNENTSPSADLTVMVPPQFLNHPANLVYESM 346  
QY 137 PCEVTCI---PSHMTLPDISW-ELGLVSHSSYFVPPPSDQASVSLIALTPQSGNCT 191  
Db 347 DIEFECAVSGKPS-----PIVTKTKNGEVVIPSDYQIVDGSMLR---ILGLVSKDEG 397  
QY 192 LTCVA-----TWKSLAKKASATVNTVTRC-RCPQDTGGGINIPGVLS 222  
Db 398 YQCIANEAGNIQYQTLIIPDPAPVSSSILPSAPRQV---VPLVSS 442

## RESULT 4

JC4025  
opioid-binding cell adhesion protein - human

C:Species: Homo sapiens (man)  
C>Date: 13-Jun-1995 #sequence\_revision 14-Jul-1995 #text\_change 17-Mar-2000  
C:Accession: JC4025  
R:Shark, K.B.; Lee, N.M.  
Gene 155, 213-317, 1995  
A:Title: Cloning, sequencing and localization to chromosome 11 of a cDNA encoding a h  
A:Reference number: JC4025; MUID:95237612; PMID:7721093  
A:Accession: JC4025  
A:Molecule type: mRNA  
A:Residues: 1-345 <SHA>

A:Cross-references: GB:J34774; NID:9514373; PIDN:AAA36387.1; PID:9514374  
A:Experimental source: brain  
C:Comment: This protein binds opioid alkaloids in the presence of acidic lipids, exhi  
A:Gene: GDB:OPCML; OBCAM; OPCM  
A:Cross-references: GDB:251677; OMIM:600632  
A:Map position: 11pter-11qter  
C:Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-ter

## Query Match

Best Local Similarity 6.3%; Score 130; DB 2; Length 345;  
Matches 73; Conservative 34; Mismatches 108; Indels 70; Gaps 17;

QY 3 RHLLTPEAVSGSGNEVI-EGPQNAIVLKSGQARFNCVSGWKLIMALSDMWLVLS-- 58  
Db 20 RLFLVPTGVVPSRGDAITFPKAMDVTVRQGESATLRCTIDRVTAVMLNKRSTILVAG 78  
QY 59 -----SVRPMPIITNDRFTSQRYDGGNFTSEMIINHPDSGNIRCSLQ-----NSR 108  
Db 79 NDKWSIDPRVILIVN---TPTQY-----SIMQNVADYDEGPTGCVQTDNHPKTSR 127

```

RESULT 6
S03199
    oploid-binding protein OPCAM precursor - bovine
C:Species: Bos primigenius taurus (cattle)
C:Date: 04-Dec-1992 #sequence_revision 04-Dec-1992 #text_change 17-Mar-2000
C:Accession: S03199
R:Schneid, P.R.; McFarland, K.C.; Hayflick, J.S.; Wilcox, J.N.; Cho, T.M.; Roy, S.; Le
EMO J. 8, 489-495, 1989
A:Title: Molecular characterization of a new immunoglobulin superfamily protein with pot
A:Reference number: S03199; MUID:89251576; PMID:2721489
A:Accession: S03199
A:Molecule type: mRNA
A:Residues: 1-345 <SCD>
A:Cross-references: EMBL:X12672; NID:9585; PIDD:CA31192.1; PIDD:9586
C:Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-termi
C:Keywords: transmembrane protein
F:1-27/Domain: signal sequence #status predicted <SIG>
F:28-345/Product: oploid-binding protein OPCAM #status predicted <MAP>

Query Match          6.2%;   Score 129;  DB 2;   Length 345;
Best Local Similarity 25.7%;   Pred. NO. 0.037;
Matches 72;  Conservative 33;  Mismatches 109;  Indels 66;  Gaps 16;

```

RESULT 8  
JC1239  
opioid-binding protein (clones S68 and S613) - rat  
C;Species: Rattus norvegicus (Norway rat)

C>Date: 03-May-1994 #sequence\_revision 03-May-1994 #text\_change 19-May-2000  
 C/Accession: JCI1239  
 R:Alipman, D.A.; Lee, N.M.; Loh, H.H.  
 Gene 117, 249-254, 1992  
 A>Title: Opioid-binding cell adhesion molecule (ORCAM)-related clones from a rat brain  
 A/Reference number: JCI1238; MUID:92347701; PMID:1339369  
 A/Accession: JCI1239  
 A/Molecule type: mRNA  
 A/Residues: 1-345 <LIP>  
 A/Cross-references: GB:M88710; NID:9203247; PIDN:AAA0859.1; PID:9203246; GB:M88711; NID:9203248  
 C/Suprafamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-terminal  
 C/Keywords: transmembrane protein

Query Match 6.2%; Score 128; DB 2; Length 345;  
 Best Local Similarity 25.3%; Pred. No. 0.044;  
 Matches 73; Conservative 35; Mismatches 110; Indels 70; Gaps 17;

QY 3 RHLTVPEAVGSGSGNEVI-EGPQNAVTLKSGQARENCVTSGKMLIMMALSMDVYL-- 58  
 Db 20 RLFLVLPVPGVVRSGDATFPKAMDNTVROGESATIRCTIDRVTRVAM-LNRSTILVAG 78  
 QY 59 ----SVRPMPEITINDFTSQRYDQGNFTSEMIHNVPSDSGNIRCSLQ-----NSR 108  
 Db 79 NDKMSIDPRVILVNV--PTQY-----SIMIQNDVYDEGTYCTSGTQDNHPRKTSR 127  
 QY 109 LHGSAYLVTVQVMEFLFIPSVNLVAENEPCEVTC-----PSHWTLPLDISLGLVSHS 164  
 Db 128 VH-----LIVQVPPQIMNISSDITVNEISSVTLICAIARPE-----PLVTWR-----HL 172  
 QY 165 SYT-----FVPEPSDLOSANSIALPPQSNGLTCVATWKSLSKARSAVTNLTV-----IR 215  
 Db 173 SVKEGGGFVSEDEYLE---ISDIKRDQSGEYECAL-NDVAAPADVKKVITVNPYIIS 227  
 QY 216 CPDQTGGGGINIPGVL-----SLPSLGFSLPMGK-----VGLGLAGTMYL 255  
 Db 228 KAKNTGVSVGQKGLISCEASAVPAEFO---WEKEDTSLATGLDGVRI 272

## RESULT 9

A54100  
 Tumor suppressor protein DCC precursor - human  
 N/Alternate names: colorectal cancer suppressor DCC  
 C/Species: Homo sapiens (man)  
 C/Date: 02-Aug-1994 #sequence\_revision 02-Aug-1994 #text\_change 05-Nov-1999  
 C/Accession: A54100; A40098  
 R:Hedrick, L.; Cho, K.R.; Fearon, E.R.; Wu, T.C.; Kinzler, K.W.; Vogelstein, B.  
 Genes Dev. 8, 1174-1183, 1994  
 A>Title: The DCC gene product in cellular differentiation and colorectal tumorigenesis.  
 A/Reference number: A54100; MUID:95011532; PMID:7926722  
 A/Accession: A54100  
 A/Molecule type: mRNA  
 A/Residues: 1-1447 <HED>  
 A/Cross-references: EMBL:X76132; NID:9453209; PIDN:CAA53735.1; PID:9453210  
 R:Fearon, E.R.; Cho, K.R.; Nigro, J.M.; Kern, S.E.; Simons, J.W.; Ruppert, J.M.; Hamllt  
 Science 247, 49-56, 1990  
 A>Title: Identification of a chromosome 18q gene that is altered in colorectal cancers.  
 A/Reference number: A40098; MUID:90100559; PMID:2294591  
 A/Accession: A40098  
 A/Molecule type: mRNA  
 A/Residues: 1-750 <FEA>  
 A/Cross-references: GB:M32292; NID:9181492; PIDN:AAA35751.1; PID:9181493  
 C/Genetics:  
 A:Gene: GDB:DCC  
 A/Cross-references: GDB:119838; OMIM:120470  
 A/Map position: 18q21.1-18q21.1  
 C/Keywords: transmembrane protein; tumor suppressor  
 F:1-25/Domain: signal sequence #status predicted <SIG>  
 F:26-1447/Product: tumor suppressor protein DCC #status predicted <MAT>

Query Match 6.2%; Score 128; DB 2; Length 1447;  
 Best Local Similarity 24.8%; Pred. No. 0.21;  
 Matches 60; Conservative 33; Mismatches 99; Indels 50; Gaps 10;

QY 14 SSGSNEY-----IEGPNAVTLKSGQARENCVTSGQM--KLIMMALSMD 55  
 Db 220 SRQNEAEVAILSDPOLHQLFLPQPSNVVAIECKDVLVLECCVS--GYPPSPFTWLNGEE 278  
 QY 56 VLVSVRPMPEITINDFTSQRYDQGNFTSEMIHNVPSDSGNIRCSLQ-----NSR 108  
 Db 279 VI-----QLRSKRYSLIG--SNLLISNTVDDDSGMYTCVTVYKNNENISASA 323  
 QY 114 YLVQVMEFLFIPSVNLVAENEPCEVTCPLPSHWTLPLDISW-ELGLVSHSSYFVPEP 172  
 Db 324 ELTVLVPPEFLNHPSSLVAIESMDIEFECTVS--GKPPVPTVMNMKNGDVVIPSDFQIVG 382  
 QY 173 SDIQSAVSTIALTPQSNGLTCVATWKSLSKARSAVTNLTVPCPDQTGGGGINIPGVLS 232  
 Db 383 SNLR-----ILGVKKSDSEGYCQVAENEGNAGNQTSAQLIVKPAIPSSS-----VLPS 430  
 QY 233 LP 234  
 Db 431 AP 432

## RESULT 10

148696  
 Protein-tyrosine kinase (EC 2.7.1.112) nsk2 precursor, splice form 2 - mouse  
 N/Alternate names: receptor-type tyrosine kinase  
 N/Contents: protein-tyrosine kinase nsk2 precursor, splice form 4  
 C/Species: Mus musculus (house mouse)  
 C/Date: 19-May-2000 #sequence\_revision 19-May-2000 #text\_change 19-May-2000  
 C/Accession: I48696; S60738  
 R:Ganju, P.; Walls, E.; Brennan, J.; Reith, A.D.  
 Oncogene 11, 281-290, 1995  
 A>Title: Cloning and developmental expression of Nsk2, a novel receptor tyrosine kinase  
 A/Reference number: I48696; MUID:95349951; PMID:7624144  
 A/Accession: I48696  
 A/Status: nucleic acid sequence not shown; translated from GB/EMBL/DBJ  
 A/Molecule type: mRNA  
 A/Residues: 1-871 <GANI>  
 A/Cross-references: EMBL:X86444; NID:9292723; PIDN:CAA60165.1; PID:9292724  
 A/Experimental source: splice form 2  
 A/Accession: S60738  
 A/Molecule type: DNA  
 A/Residues: 1-456, A', 466-871 <GAN2>  
 A/Cross-references: EMBL:X86444; NID:9292723  
 A/Experimental source: splice form 4  
 C/Comment: For alternate splice forms see PIR:I48697.  
 C/Genetics:  
 A:Gene: nsk2  
 A/Cross-references: MGI:103308  
 C/Suprafamily: mouse for-related receptor; immunoglobulin homology; protein kinase ho  
 F:1-21/Domain: signal sequence #status predicted <SIG>  
 F:22-871/Product: protein-tyrosine kinase nsk2, splice form 2 #status predicted <MAT2  
 F:22-456, A', 466-871/Product: protein-tyrosine kinase nsk2, splice form 4 #status pre  
 F:135-199/Domain: immunoglobulin homology <IMM1>  
 F:135-199/Domain: immunoglobulin homology <IMM2>  
 F:226-284/Domain: immunoglobulin homology <IMM3>  
 F:498-518/Domain: transmembrane #status predicted <TRM>  
 F:575-865/Domain: transmembrane #status predicted <TRM>  
 F:583-591/Region: protein kinase ATP-binding motif  
 F:222,462/Binding site: carbohydrate (asn) (covalent) #status predicted

Query Match 6.1%; Score 127.5; DB 1; Length 871;  
 Best Local Similarity 21.7%; Pred. No. 0.13;  
 Matches 70; Conservative 41; Mismatches 125; Indels 87; Gaps 16;

QY 19 EVIEGPNAVTLKSGQARENCVTSGQM-LIMMALSMDVLSVRPMPEITINDFTSQRY 77  
 Db 122 KITRPPINVKIIGLKAVALPCTTMGNPKRSVYKIGD-----NALRENSRIALE- 171  
 QY 78 DQGNFTSEMIHNVPSDSGNIRCSLQNSRLRGSAY-----LTVQVMEFLFIPSVNLVY 132  
 Db 172 -----SGSLRIHNVQEKEDAGQRCVAKNSL--GVAASKVLKLEVEVLGLILAPESHNV 223

Qy 133 AENECEVTC-----LPSHMTLPDISW-ELGLVSHSSYFVPEPSDLOSASVILALTPQ 187  
 Db 224 TFGSVTLKRCHEIGIP-----VPTISWENGNNAVSSGSIQSVNDRVIDSLQLEFITRP- 277  
 Qy 188 SNGILTCVAT-----WKSIAKRSATVNLTVIR-----CPDDTGGGINIPG-----V 229  
 Db 278 --GLTYCIATNKGKGFSTAKAAATVSIAMWSKQSDQCYCAQYRGEGVLMQGPGEKML 335  
 Qy 230 LSLSPSLGFSLP-----TWKVGGLAGTMTLPTCTLTIRCCCCRRCCGCN-- 277  
 Db 336 LVFLPTTSHRDPDAQELLHTAMNEL-----KAVSPLCRPAABALLCYHLFLCSPG 388  
 Qy 278 -----CCCRCC-----FCCR 287  
 Db 389 VVPTPMPICREYCLAVKEIFCAK 411

## RESULT 11

148697  
 protein-tyrosine kinase (EC 2.7.1.112) nsK2 precursor, splice form 1 - mouse  
 N:Alternate names: receptor-tyrosine kinase  
 N:Contains: protein-tyrosine kinase nsK2 precursor, splice form 3  
 C:Species: Mus musculus (house mouse)  
 C:Date: 19-May-2000 #sequence\_revision 19-May-2000 #text\_change 19-May-2000  
 C:Accession: 148697; S60740  
 R:Ganju, P.; Wallis, E.; Brennan, J.; Reith, A.D.  
 O:Oncogene 11, 281-290, 1995  
 A:Title: Cloning and developmental expression of nsK2, a novel receptor tyrosine kinase  
 A:Reference number: 148696; MUID:95349551; PMID:7624114  
 A:Accession: 148697  
 A:Status: nucleic acid sequence not shown; translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-881 <GAN1>  
 A:Cross-references: EMBL:X86445; NID:9929725; PIDN:CA60166.1; PID:9929726  
 A:Experimental source: splice form 1  
 A:Accession: S60740  
 A:Molecule type: DNA  
 A:Residues: 1-456, 'A', 466-881 <GAN2>  
 A:Cross-references: EMBL:X86445; NID:9929725  
 A:Experimental source: splice form 3  
 A:Comment: For alternate splice forms see PIR:148696.  
 C:Genetics:  
 A:Gene: nsK2  
 A:Cross-references: MGI:103308  
 C:Superfamily: mouse ror-related receptor; immunoglobulin homology; protein kinase homol  
 C:Keywords: ATP; glycoprotein; phosphotransferase; receptor; transmembrane protein; tyro  
 F:1-21/Domain: signal sequence #status predicted <SIG>  
 F:22-881/Product: protein-tyrosine kinase nsK2, splice form 1 #status predicted <MAT1>  
 F:22-456, 'A', 466-881/Product: protein-tyrosine kinase nsK2, splice form 3 #status predi  
 F:42-101/Domain: immunoglobulin homology <IMM1>  
 F:135-192/Domain: immunoglobulin homology <IMM2>  
 F:226-284/Domain: immunoglobulin homology <IMM3>  
 F:498-518/Domain: transmembrane #status predicted <TRM>  
 F:575-865/Domain: protein kinase homology <KIN>  
 F:583-591/Region: protein kinase ATP-binding motif  
 F:222,462/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 6.1%; Score 127.5; DB 1; Length 881;  
 Best Local Similarity 21.7%; Pred. No. 0.13;  
 Matches 70; Conservative 41; Mismatches 125; Indels 87; Gaps 16;

Qy 19 EYIESPQATVYKGSQARNCTVSQGW-LIMMALSDMVLVSRPMEITITNDRFTSORY 77  
 Db 122 KITRPINWKIEGLKAVLPCTTGMNPKPSYWIKGD-----NALRENSRIAALE- 171  
 Qy 78 DQGNFTSEMIIHNEPDSGNINCSLQNSRLHGSAY-----LTVQWGEFLTISVNLV 132  
 Db 172 -----SSSLRIHYNQKDAQYRCVANKSL--STAYSKLWLEVEYIGRLRAPESHNV 223  
 Qy 133 AENECEVTC-----LPSHMTLPDISW-ELGLVSHSSYFVPEPSDLOSASVILALTPQ 187  
 Db 224 TFGSVTLKRCHEIGIP-----VPTISWENGNNAVSSGSIQSVNDRVIDSLQLEFITRP- 277

Qy 188 SNGILTCVAT-----WKSIAKRSATVNLTVIR-----CPDDTGGGINIPG-----V 229  
 Db 278 --GLTYCIATNKGKGFSTAKAAATVSIAMWSKQSDQCYCAQYRGEGVLMQGPGEKML 335  
 Qy 230 LSLSPSLGFSLP-----TWKVGGLAGTMTLPTCTLTIRCCCCRRCCGCN-- 277  
 Db 336 LVFLPTTSHRDPDAQELLHTAMNEL-----KAVSPLCRPAABALLCYHLFLCSPG 388  
 Qy 278 -----CCCRCC-----FCCR 287  
 Db 389 VVPTPMPICREYCLAVKEIFCAK 411

## RESULT 12

JC4593  
 protein-tyrosine kinase-related receptor PK7 precursor - human  
 N:Alternate names: receptor protein tyrosine kinase-like protein (RPTK)  
 C:Species: Homo sapiens (man)  
 C:Date: 16-Apr-1996 #sequence\_revision 24-May-1996 #text\_change 24-Sep-1999  
 C:Accession: JC4593  
 R:Park, S.K.; Lee, H.S.; Lee, S.T.  
 J. Biochem. 119, 235-239, 1996  
 A:Title: Characterization of the human full-length PK7 cDNA encoding a receptor prot  
 A:Reference number: JC4593; MUID:97037064; PMID:8882711  
 A:Accession: JC4593  
 A:Molecule type: mRNA  
 A:Residues: 1-1070 <PAR>  
 A:Cross-references: GB:U040271; NID:91322231; PIDN:MAC50484.1; PID:91322232  
 C:Comment: This protein is a member of receptor protein tyrosine kinase family, but p  
 C:Genetics:  
 A:Gene: GDB:PK7  
 A:Cross-references: GDB:134760; OMIM:601890  
 A:Map position: 6p21.1-6p12.2  
 C:Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase hom  
 C:Keywords: cell adhesion; extracellular protein; glycoprotein; phosphotransferase; t  
 F:1-30/Domain: signal sequence #status predicted <SIG>  
 F:31-1070/Product: protein-tyrosine kinase 7 #status predicted <MAT>  
 F:31-703/Domain: extracellular #status predicted <EXC>  
 F:704-725/Domain: transmembrane #status predicted <TRM>  
 F:726-1070/Domain: intracellular #status predicted <KIN>  
 F:794-1065/Domain: protein kinase homology <KIN>  
 F:116,175,184,214,268,283,405,463,567,646/Binding site: carbohydrate (Asn) (covalent)

Query Match 6.0%; Score 125; DB 2; Length 1070;  
 Best Local Similarity 24.8%; Pred. No. 0.25;  
 Matches 59; Conservative 34; Mismatches 109; Indels 36; Gaps 10;

Qy 11 AVSGSGNEVIEGPQATVYKGSQARNCTVS-QGKMLIMMALSDMVLVSRPMEITITN 69  
 Db 218 SIADSEFARVVLAPQDVVARVEAMFHQFSAPPPSLQWLFEDETPTITNSRPHLRR 277  
 Qy 70 DRTSQYDDGNGFTSEMIHNEPDSGNIRCSLQNSR-----LHGSAYLTVQWGEFL 124  
 Db 278 ATYFA-----NSSLITVYRPRNAGTYRIGGQRPPIITLALHLEIEDMPLE 328  
 Qy 125 IPSVNLVAENECVETCLPSHMTLPDISWE-LGL-LVSHSSYFVPEPSDLOSASVIL 182  
 Db 329 EPRVFTAGSE--RVTCLEPPKGLPEPSWWEHAGVRLPHGVY-----QKGEHLV 378  
 Qy 183 ALTPQSN-GILTVATWKSIAKRSATVNLTV-----TRCPDDTGGGINITGVSSL 233  
 Db 379 ANIAESDAGVYTHAA--NLAGORQDVNTVATVPSWLKRPQDSOLEBGRKGVLDCL 434

## RESULT 13

T15651  
 hypothetical protein C27A2.5 - Caenorhabditis elegans  
 C:Species: Caenorhabditis elegans  
 C:Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 20-Sep-1999  
 C:Accession: T15651  
 R:Nhan, M.  
 Submitted to the EMBL Data Library, May 1996  
 A:Description: The sequence of C. elegans cosmid C27A2.





Gene 117, 249-254, 1992  
A:Title: Optoid-binding cell adhesion molecule (OBCAM)-related clones from a rat brain c  
A:Reference number: JCI238; MUID:92347701; PMID:1339369  
A:Accession: JCI238  
A:Molecule type: mRNA  
A:Residues: 1-338 <LTP>  
A:Cross-references: GB:M88709; NID:g203245; PIDN:AAA40858.1; PID:g203246  
A:Experimental source: brain  
C:Genetics:  
A:Gene: OBCAM  
C:Superfamily: carcinoembryonic antigen; carcinoembryonic antigen precursor amino-termin

Query Match 5.7%; Score 118.5; DB 2; Length 338;  
Best Local Similarity 25.2%; Pred. No. 0.22;  
Matches 72; Conservative 36; Mismatches 107; Indels 71; Gaps 18;

OY 5 LITVEAVGSSGSGNEVI-EGPQNAIVLKSGQARFNCIVSGMKLIMVALSDMYL----- 58  
DB 16 LLEFIP-GVPRVSGDNTFPKAMDNTVVRQGESATLRCTIIDDRTVRVAM-LNRSTILVAGND 73  
OY 59 --SVRPMETITNDRTSQRYDQGNFTSEMIHNVSPDSGNIRCSLQ-----NSRLH 110  
DB 74 KMSIDPRVILIVN---FPTQY-----SIMQNVVDYDEGPYTCGVQTDNHPKTSRVH 122  
OY 111 GSAYLTVQVMEGLFTPSNVLVAENEPCEVTCL-----PSHWTRLPDISWEIGLLVSHSSY 166  
DB 123 ---LIVQVPPQIMNISDIIVNEISSVTLICLAIGRPE-----PTVWTR-----HLSV 167  
OY 167 Y----FVPEPSDLSAVSILALTPQSGNGLTFCVATWKSILKARKSATVNLTV-----IRCP 217  
DB 168 KEGGCFVSEDEYLE-----ISDIKRDQSGEYECNAL-NDVAAAPDVAKVKITVNPYPYISKA 222  
OY 218 QDTGGGINIPGVL---SSLPISLGFSLPTWCK---VGLGLAGTML 255  
DB 223 KNTGVSVGQKGLSCASAVPMAEFQ---WPKEDTRLATGLDGVRI 265

Search completed: April 28, 2003, 21:09:17  
Job time : 27.0659 secs





```
Db      324 -PGEFG-----PRAGS+GSGGSLTGLALAGIIGLGTALLIGVL 363
QY      269 CRRRCGCCNCCRCFCFCGRKRGFRIDFOKKSEKRT--NKETTESGNNSGYNDSEOK 326
        :|||
Db      364 WQRR-----QRGRGERKAPEQDEEEENAEIN----- 390
QY      327 TTTETASLPKCSSESDPEQRNSSCGPP 333
        :||| |||
Db      391 -----QSEEPAGESSSTGGP 405
```

RESULT 2  
US-10-184-644-559

```

Sequence 559, Application US/10184644
Publication No. US20030044930A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Chen, Jian
APPLICANT: Desnoyers, Luc
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Pan, James
APPLICANT: Smith, Victoria
APPLICANT: Watanabe, Colin K.
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3430R1C227
CURRENT APPLICATION NUMBER: US/10/184,644
CURRENT FILING DATE: 2002-06-28
Prior Application removed - See file wrapper of Palm
NUMBER OF SEQ ID NOS: 612
SEQ ID NO 559
LENGTH: 2473
TYPE: DNA
ORGANISM: Homo Sapien
US-10-184-644-559

```

Query Match	6-7%	Score 138.5;	DB 9,	Length 2473;
Best Local Similarity	29.5%;	Pred.	No. 0.088;	
Matches	31;	Conservative	3;	Mismatches 36; Indels 35; Gaps 2.

  

Qy	183	ATPQSNGLTTCVATWTSKLARKSATVNLFIYRQDPIGGGINIPVLSSPLGSLPT	242
Db	2274	AATTGAAGTTTCAATTAAATTTATAATGTTCC-----	2307
Qy	243	WGVGLGLAGTMLTPCTLTITRCRCC-RRCGCNCCRRCCFC	286
Db	2308	-----ATTCCCATCGCCACCCCACCACCCCCGCCGCCCACACC	2344

RESULT 3  
US-10-184-634-559

Sequence 559, Application US/10184634  
Publication No. US2003008684A1  
GENERAL INFORMATION:  
APPLICANT: Baker, Kevin P.  
APPLICANT: Chen, Jian  
APPLICANT: Desnoyers, Luc  
APPLICANT: Goddard, Audrey  
APPLICANT: Godowski, Paul J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Pan, James  
APPLICANT: Smith, Victoria  
APPLICANT: Watanabe, Colin K.  
APPLICANT: Wood, William I.  
APPLICANT: Zhang, Zemin  
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS  
TITLE OF INVENTION: ACIDS ENCODING THE SAME  
FILE REFERENCE: P3430R1C217  
CURRENT APPLICATION NUMBER: US/10/184,634

```

CURRENT FILING DATE: 2002-06-28
Prior Application removed - See File Wrapper or Patent
NUMBER OF SEQ ID NOS: 612
SEQ ID NO 559
LENGTH: 2473
TYPE: DNA
ORGANISM: Homo Sapien
OS-10-184-634-559

```

Query Match	6.7%;	Score 138.5;	DB 9;	Length 2473;
Best Local Similarity	29.5%;	Pred. No. 0.088;		
Matches 31; Conservative	3;	Mismatches 36;	Indels 35;	Gaps 2

OY	183	ALTPQSGNTLTCAVMTSLKARSFAVNLTVEICPDQTGGGINIPGVLSLPSLSLPST	242
Dd	2274	AATFGAGTTTCATTAAATTAATAINTGTTTTCC-----	2307
OY	243	WGRKGTLAAGTMLTPTCTLTITGCCCR-RRCGCMCCRCRCPCC	286
Dd	2308	-----AFTTCGTCAATCGCCACGCCACCCCCCGCCCCCACCACCC	2344

## RESULT 4

```

Sequence 584, Application US/10174590
Publication No. US2003008352A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Chen, Jian
APPLICANT: Desnoyers, Luc
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Pan, James
APPLICANT: Smith, Victoria
APPLICANT: Watanabe, Colin K.
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3430R1C42
CURRENT APPLICATION NUMBER: US/10/174,590
CURRENT FILING DATE: 2002-06-18
Prior application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 612
SEQ ID NO 584
LENGTH: 708
TYPE: prt
ORGANISM: Homo Sapien
US-10-174-590-584

```

Query Match	6.5%	Score 134;	DB 9;	Length 708;
Best Local Similarity	23.7%;	Pred. No. 0.045;		
Matches	53;	Conservative	40;	Mismatches 101;
			Indels	30;
			Gaps	10;

QY	14	SSQSGNEVIEGPNQNAVTLKGSQAFRENCVISOQWKLIMWALSDMWVLYLSVRPMEIITNDRET	73
Db	20	AGPSPHETLQEPDLVYELGEBEARLPCLGAYWYLVMTSGIALGQR-----DLPG	71
QY	74	SQRYDQGNFTS---EMLIHNVESDSGNIRCSLQNSRLHG--SAYLVY-----QWNGE	122
Db	72	WSRYWISGMAANGQDHLIRVELLEDGASVIECGATAGLRSRPADLHVLPPEARQVYLCG	133
QY	123	LTIPTSVNLVYVAENEPCEVYTCCLPSHWTR-LPDLSW-ELGLLVSHSY--FVPE--PSDQ	176
Db	132	---PVSYLVA--GVYANLTCSRGDAPRPPELLMFEDQGVYLLDGAFTQTLKEGPSVE	186
QY	177	SAVSILALTPQSNGLTLCVATWWSLKARKSATVNLVIVICPDY	220
Db	187	STVLTLPSPSHDGAIVQCRASQALTPGRDTALTITSLQPPVYT	230

## RESULT 5

```

US-10-176-758-584
; Sequence 584, Application US/10176758
; Publication No. US2003008353A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C104
; CURRENT APPLICATION NUMBER: US/10/176,758
; CURRENT FILING DATE: 2002-06-21
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; LENGTH: 708
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-176-758-584

```

```

Query Match 6.5%; Score 134; DB 9; Length 708;
Best Local Similarity 23.7%; Pred. No. 0.045;
Matches 53; Conservative 40; Mismatches 101; Indels 30; Gaps 10;

```

```

QY 14 SSGSNEVIEGPONATVYKSGQARFNCYSGQKLMWALSDMVVLSVRPMEPIITNDRT 73
DB 20 AGSPHFLOQPEDLVLLGEARLPCALGAYWGLVQWTKSGLAGQR-----DLPG 71
QY 74 SORYDOGNFTS---EMIIHNVPSDSGNIRCSLONSRLHG-SAYLVY-----QVNGE 122
DB 72 WSRWISGNANANGOHDLHIREVELEDEASYEQATQAGLRSPAPOLHVLVPEAPQVLGG 131
QY 123 LFIPSVNLVVAENPECEVTCIPSHWTR-LPDISW-ELGLVSHSSY--FYVE--PSDLQ 176
DB 132 ---PSVSLVA--GVPAWLTCSRSGDARPTPELLMFRDGVLLDGATFHQTLLKEGTPGSVE 186
QY 177 SAVSILALTPQSNGLTCAVATWKSILKARKSATVNLTVIRCPDPT 220
DB 187 STLTLPFSHDDGATFVCRARSQALPTGRDRAITLSIQYPEVT 230

```

## RESULT 6

```

US-10-175-737-584
; Sequence 584, Application US/10175737
; Publication No. US2003003153A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C105
; CURRENT APPLICATION NUMBER: US/10/175,737
; CURRENT FILING DATE: 2002-06-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 584

```

```

LENGTH: 708
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-175-737-584

```

```

Query Match 6.5%; Score 134; DB 9; Length 708;
Best Local Similarity 23.7%; Pred. No. 0.045;
Matches 53; Conservative 40; Mismatches 101; Indels 30; Gaps 10;

```

```

QY 14 SSGSNEVIEGPONATVYKSGQARFNCYSGQKLMWALSDMVVLSVRPMEPIITNDRT 73
DB 20 AGSPHFLOQPEDLVLLGEARLPCALGAYWGLVQWTKSGLAGQR-----DLPG 71
QY 74 SORYDOGNFTS---EMIIHNVPSDSGNIRCSLONSRLHG-SAYLVY-----QVNGE 122
DB 72 WSRWISGNANANGOHDLHIREVELEDEASYEQATQAGLRSPAPOLHVLVPEAPQVLGG 131
QY 123 LFIPSVNLVVAENPECEVTCIPSHWTR-LPDISW-ELGLVSHSSY--FYVE--PSDLQ 176
DB 132 ---PSVSLVA--GVPAWLTCSRSGDARPTPELLMFRDGVLLDGATFHQTLLKEGTPGSVE 186
QY 177 SAVSILALTPQSNGLTCAVATWKSILKARKSATVNLTVIRCPDPT 220
DB 187 STLTLPFSHDDGATFVCRARSQALPTGRDRAITLSIQYPEVT 230

```

## RESULT 7

```

US-10-173-706-584
; Sequence 584, Application US/10173706
; Publication No. US2003002293A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C107
; CURRENT APPLICATION NUMBER: US/10/173,706
; CURRENT FILING DATE: 2002-06-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 584
; LENGTH: 708
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-173-706-584

```

```

Query Match 6.5%; Score 134; DB 9; Length 708;
Best Local Similarity 23.7%; Pred. No. 0.045;
Matches 53; Conservative 40; Mismatches 101; Indels 30; Gaps 10;

```

```

QY 14 SSGSNEVIEGPONATVYKSGQARFNCYSGQKLMWALSDMVVLSVRPMEPIITNDRT 73
DB 20 AGSPHFLOQPEDLVLLGEARLPCALGAYWGLVQWTKSGLAGQR-----DLPG 71
QY 74 SORYDOGNFTS---EMIIHNVPSDSGNIRCSLONSRLHG-SAYLVY-----QVNGE 122
DB 72 WSRWISGNANANGOHDLHIREVELEDEASYEQATQAGLRSPAPOLHVLVPEAPQVLGG 131
QY 123 LFIPSVNLVVAENPECEVTCIPSHWTR-LPDISW-ELGLVSHSSY--FYVE--PSDLQ 176
DB 132 ---PSVSLVA--GVPAWLTCSRSGDARPTPELLMFRDGVLLDGATFHQTLLKEGTPGSVE 186
QY 177 SAVSILALTPQSNGLTCAVATWKSILKARKSATVNLTVIRCPDPT 220

```

Db 187 STLTTPFSHDDGATFVCRARSQALPTGRDITLTLQYPPVET 230

## RESULT 8

US-10-175-738-584  
Sequence 584, Application US/10175738  
Publication No. US20030022294A1

## GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
APPLICANT: Chen, Jian  
APPLICANT: Desnoyers, Luc  
APPLICANT: Goddard, Audrey  
APPLICANT: Godowski, Paul J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Pan, James  
APPLICANT: Smith, Victoria  
APPLICANT: Watanabe, Colin K.  
APPLICANT: Wood, William I.

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P3430R1C45

CURRENT FILING DATE: 2002-06-19

Prior application removed - See file wrapper or Palm

NUMBER OF SEQ ID NOS: 612

SEQ ID NO 584

LENGTH: 708

TYPE: PRT

ORGANISM: Homo Sapien

US-10-175-738-584

Query Match 6.5%; Score 134; DB 9; Length 708;  
Best Local Similarity 23.7%; Pred. No. 0.045;

Matches 53; Conservative 40; Mismatches 101; Indels 30; Gaps 10;

QY 14 SSGSNEVIEGPONATVYKSGARFNCVTSQGWKLIMALSDMVYLSVRPMEPIITNDRET 73

Db 20 AGPSPHFLOQPEDIVVLGGEARLPCALGAYWGLVQWTKSGLAGGQ-----DLPG 71

QY 74 SQRDQGNFTS---EMITHNVEPSDSGNIRCSLONSRLHG-SAYLVV-----QVNGE 122

Db 72 WSRWISGNANAGOHDLHIRPELEDEASVYECQATQAGLRSPRQQLHVLVPEAPQVLOG 131

QY 123 LFIPSVNLVVAENPECEVTCPLPSHWTR-LPDISW-ELGLVSHSSY--FVPE--PSDLQ 176

Db 132 ---BSVSLVA--GVPAWLTCRSRGDARPTPELIMFRDGVLLDGAFTFHTLKEGTGGSVE 186

QY 177 SAVSILALTPQSNGLTLCVATWKSILKARKSATVNLTVIRCPDPT 220

Db 187 STLTTPFSHDDGATFVCRARSQALPTGRDITLTLQYPPVET 230

## RESULT 9

US-10-175-752-584  
Sequence 584, Application US/10175752  
Publication No. US20030022295A1

## GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
APPLICANT: Chen, Jian  
APPLICANT: Desnoyers, Luc  
APPLICANT: Goddard, Audrey  
APPLICANT: Godowski, Paul J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Pan, James  
APPLICANT: Smith, Victoria  
APPLICANT: Watanabe, Colin K.  
APPLICANT: Wood, William I.

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P3430R1C60

CURRENT APPLICATION NUMBER: US/10/175,752

CURRENT FILING DATE: 2002-06-19

Prior Application removed - See file wrapper or Palm

NUMBER OF SEQ ID NOS: 612

SEQ ID NO 584

LENGTH: 708

TYPE: PRT

ORGANISM: Homo Sapien

US-10-175-752-584

Query Match 6.5%; Score 134; DB 9; Length 708;  
Best Local Similarity 23.7%; Pred. No. 0.045;

Matches 53; Conservative 40; Mismatches 101; Indels 30; Gaps 10;

QY 14 SSGSNEVIEGPONATVYKSGARFNCVTSQGWKLIMALSDMVYLSVRPMEPIITNDRET 73

Db 20 AGPSPHFLOQPEDIVVLGGEARLPCALGAYWGLVQWTKSGLAGGQ-----DLPG 71

QY 74 SQRDQGNFTS---EMITHNVEPSDSGNIRCSLONSRLHG-SAYLVV-----QVNGE 122

Db 72 WSRWISGNANAGOHDLHIRPELEDEASVYECQATQAGLRSPRQQLHVLVPEAPQVLOG 131

QY 123 LFIPSVNLVVAENPECEVTCPLPSHWTR-LPDISW-ELGLVSHSSY--FVPE--PSDLQ 176

Db 132 ---BSVSLVA--GVPAWLTCRSRGDARPTPELIMFRDGVLLDGAFTFHTLKEGTGGSVE 186

QY 177 SAVSILALTPQSNGLTLCVATWKSILKARKSATVNLTVIRCPDPT 220

Db 187 STLTTPFSHDDGATFVCRARSQALPTGRDITLTLQYPPVET 230

## RESULT 10

US-10-176-482-584  
Sequence 584, Application US/10176482  
Publication No. US20030022296A1

## GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
APPLICANT: Chen, Jian  
APPLICANT: Desnoyers, Luc  
APPLICANT: Goddard, Audrey  
APPLICANT: Godowski, Paul J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Pan, James  
APPLICANT: Smith, Victoria  
APPLICANT: Watanabe, Colin K.  
APPLICANT: Wood, William I.

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P3430R1C70

CURRENT FILING DATE: 2002-06-20

Prior Application removed - See file wrapper or Palm

NUMBER OF SEQ ID NOS: 612

SEQ ID NO 584

LENGTH: 708

TYPE: PRT

ORGANISM: Homo Sapien

US-10-176-482-584

Query Match 6.5%; Score 134; DB 9; Length 708;  
Best Local Similarity 23.7%; Pred. No. 0.045;

Matches 53; Conservative 40; Mismatches 101; Indels 30; Gaps 10;

QY 14 SSGSNEVIEGPONATVYKSGARFNCVTSQGWKLIMALSDMVYLSVRPMEPIITNDRET 73

Db 20 AGPSPHFLOQPEDIVVLGGEARLPCALGAYWGLVQWTKSGLAGGQ-----DLPG 71

QY 74 SQRDQGNFTS---EMITHNVEPSDSGNIRCSLONSRLHG-SAYLVV-----QVNGE 122

Db 72 WSRWISGNANAGOHDLHIRPELEDEASVYECQATQAGLRSPRQQLHVLVPEAPQVLOG 131

QY 123 LFIPSVNLVVAENPECEVTCPLPSHWTR-LPDISW-ELGLVSHSSY--FVPE--PSDLQ 176

Db 132 ---PSVSIVA--GVPANLTCRSRGDARFPPELLMFEDVLLDGAFTHQTLKECTPGSVE 186  
 QY 177 SAVSIIALTPOSGNGLTCVATWKSILKARSAVNLVTRPCDDT 220  
 Db 187 STLTLPFSHDDGATFVCRASQALPTGRDTAITSLOYPEEVT 230

# RESULT 11

US-10-176-757-584  
 ; Sequence 584, Application US/10176757  
 ; Publication No. US20030022296A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 FILE OF INVENTION: ACIDS ENCODING THE SAME

FILE REFERENCE: P3430R1C86  
 CURRENT APPLICATION NUMBER: US/10/176,757

PRIOR FILING DATE: 2002-06-20  
 PRIOR APPLICATION REMOVED - See file wrapper or Palm

NUMBER OF SEQ ID NOS: 612  
 SEQ ID NO 584

LENGTH: 708  
 TYPE: PRT

ORGANISM: Homo Sapien  
 US-10-176-757-584

Query Match 6.5%; Score 134; DB 9; Length 708;  
 Best Local Similarity 23.7%; Pred. No. 0.045;

Matches 53; Conservative 40; Mismatches 101; Indels 30; Gaps 10;

QY 14 SSGSNEVEIEGPONATVTKSGQARFNCVTSQGWKLIMWALSDMVLSVRPMEPIITNDRET 73  
 Db 20 AGSPHFLQOPEDVLLGEARLPALGAYWGLVQWTKSGLAIGQR-----DLPG 71  
 QY 74 SQRVDGNGFTS---EMIHNVPSDSGNIRCSLQNSRLHG-SAYLTV-----QVNGE 122  
 Db 72 WSRWISGNANQHDHLPVELEDEASTYECATQAGLRSPRAQLHVLVPEAPQVLLG 131  
 QY 123 LFIISVNLVAENEPCEVTCIPSHWTR-LPDISW-ELGLVSHSSY--FVPE--PSDLQ 176  
 Db 132 ---PSVSIVA--GVPANLTCRSRGDARFPPELLMFEDVLLDGAFTHQTLKECTPGSVE 186  
 QY 177 SAVSIIALTPOSGNGLTCVATWKSILKARSAVNLVTRPCDDT 220  
 Db 187 STLTLPFSHDDGATFVCRASQALPTGRDTAITSLOYPEEVT 230

# RESULT 12

US-10-176-913-584  
 ; Sequence 584, Application US/10176913  
 ; Publication No. US20030022296A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 ; FILE OF INVENTION: ACIDS ENCODING THE SAME  
 ; FILE REFERENCE: P3430R1C66  
 ; CURRENT APPLICATION NUMBER: US/10/176,913  
 ; CURRENT FILING DATE: 2002-06-20  
 ; PRIOR APPLICATION REMOVED - See file wrapper or Palm

NUMBER OF SEQ ID NOS: 612  
 SEQ ID NO 584

LENGTH: 708  
 TYPE: PRT

ORGANISM: Homo Sapien  
 US-10-176-913-584

Query Match 6.5%; Score 134; DB 9; Length 708;  
 Best Local Similarity 23.7%; Pred. No. 0.045;

Matches 53; Conservative 40; Mismatches 101; Indels 30; Gaps 10;

QY 14 SSGSNEVEIEGPONATVTKSGQARFNCVTSQGWKLIMWALSDMVLSVRPMEPIITNDRET 73  
 Db 20 AGSPHFLQOPEDVLLGEARLPALGAYWGLVQWTKSGLAIGQR-----DLPG 71  
 QY 74 SQRVDGNGFTS---EMIHNVPSDSGNIRCSLQNSRLHG-SAYLTV-----QVNGE 122  
 Db 72 WSRWISGNANQHDHLPVELEDEASTYECATQAGLRSPRAQLHVLVPEAPQVLLG 131  
 QY 123 LFIISVNLVAENEPCEVTCIPSHWTR-LPDISW-ELGLVSHSSY--FVPE--PSDLQ 176  
 Db 132 ---PSVSIVA--GVPANLTCRSRGDARFPPELLMFEDVLLDGAFTHQTLKECTPGSVE 186  
 QY 177 SAVSIIALTPOSGNGLTCVATWKSILKARSAVNLVTRPCDDT 220  
 Db 187 STLTLPFSHDDGATFVCRASQALPTGRDTAITSLOYPEEVT 230

# RESULT 13

US-10-180-552-584

; Sequence 584, Application US/10180552

; Publication No. US20030022300A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 FILE OF INVENTION: ACIDS ENCODING THE SAME

FILE REFERENCE: P3430R1C153  
 CURRENT APPLICATION NUMBER: US/10/180,552

PRIOR FILING DATE: 2002-06-25  
 PRIOR APPLICATION REMOVED - See file wrapper or Palm

NUMBER OF SEQ ID NOS: 612  
 SEQ ID NO 584

LENGTH: 708  
 TYPE: PRT

ORGANISM: Homo Sapien  
 US-10-180-552-584

Query Match 6.5%; Score 134; DB 9; Length 708;  
 Best Local Similarity 23.7%; Pred. No. 0.045;

Matches 53; Conservative 40; Mismatches 101; Indels 30; Gaps 10;

QY 14 SSGSNEVEIEGPONATVTKSGQARFNCVTSQGWKLIMWALSDMVLSVRPMEPIITNDRET 73  
 Db 20 AGSPHFLQOPEDVLLGEARLPALGAYWGLVQWTKSGLAIGQR-----DLPG 71  
 QY 74 SQRVDGNGFTS---EMIHNVPSDSGNIRCSLQNSRLHG-SAYLTV-----QVNGE 122  
 Db 72 WSRWISGNANQHDHLPVELEDEASTYECATQAGLRSPRAQLHVLVPEAPQVLLG 131  
 QY 123 LFIISVNLVAENEPCEVTCIPSHWTR-LPDISW-ELGLVSHSSY--FVPE--PSDLQ 176  
 Db 132 ---PSVSIVA--GVPANLTCRSRGDARFPPELLMFEDVLLDGAFTHQTLKECTPGSVE 186  
 QY 177 SAVSIIALTPOSGNGLTCVATWKSILKARSAVNLVTRPCDDT 220  
 Db 187 STLTLPFSHDDGATFVCRASQALPTGRDTAITSLOYPEEVT 230

Db 72 WSRWISGNANGQHDHTRPVELEDEASYEQATQAGLRSPADLHVLPPEAPQVLGG 131  
 QY 123 LFIPIVNLVAENEPCEVTCLEPSHWTR-LPDISW-ELGLVSHSSY--FVPE--PSDLQ 176  
 Db 132 ---PSVSLVA--GVANLTCRSRGDARPTPELLMFRDGLLDGATFHQTLKEGTGSVE 186  
 QY 177 SAVSIALTPQSNGLTCVATWKSILKARKSATVNLTVIRCPDPT 220  
 Db 187 STLTLPFSHDDGATFVFCARASQALPTGRDTATLTSLQYPPVPT 230

## RESULT 14

US-10-180-557-584  
 ; Sequence 584, Application US/10180557  
 ; Publication No. US2003002201A1  
 ; GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin  
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 FILE REFERENCE: P3430R1C14  
 CURRENT APPLICATION NUMBER: US/10/180,557  
 CURRENT FILING DATE: 2002-06-25  
 NUMBER OF APPLICATION removed - See file wrapper or Palm  
 NUMBER OF SEQ ID NOS: 612  
 SEQ ID NO 584  
 LENGTH: 708  
 TYPE: PRT  
 ORGANISM: Homo Sapien  
 US-10-180-557-584

Query Match 6.5%; Score 134; DB 9; Length 708;  
 Best Local Similarity 23.7%; Pred. No. 0.045;  
 Matches 53; Conservative 40; Mismatches 101; Indels 30; Gaps 10;

QY 14 SSGNEVIEGPNATVILKSGQAFNCTVSQMKLIMWALSDMVLSVRPEPIITNDRET 73  
 Db 20 AGSPHFLOQPEDLVLLGEBARLPALGAYWGIWQTKSGIALGGR-----DLPG 71  
 QY 74 SQRDGGNFTS---EMIHNVPSDSGNIRCSLQNSRLHG-SAYLTV-----QVNGE 122  
 Db 72 WSRWISGNANGQHDHTRPVELEDEASYEQATQAGLRSPADLHVLPPEAPQVLGG 131  
 QY 123 LFIPIVNLVAENEPCEVTCLEPSHWTR-LPDISW-ELGLVSHSSY--FVPE--PSDLQ 176  
 Db 132 ---PSVSLVA--GVANLTCRSRGDARPTPELLMFRDGLLDGATFHQTLKEGTGSVE 186  
 QY 177 SAVSIALTPQSNGLTCVATWKSILKARKSATVNLTVIRCPDPT 220  
 Db 187 STLTLPFSHDDGATFVFCARASQALPTGRDTATLTSLQYPPVPT 230

## RESULT 15

US-10-173-700-584  
 ; Sequence 584, Application US/10173700  
 ; Publication No. US20030027262A1  
 ; GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James

APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin  
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 FILE REFERENCE: P3430R1C14  
 CURRENT APPLICATION NUMBER: US/10/173,700  
 CURRENT FILING DATE: 2002-06-17  
 NUMBER OF APPLICATION removed - See file wrapper or Palm  
 NUMBER OF SEQ ID NOS: 612  
 SEQ ID NO 584  
 LENGTH: 708  
 TYPE: PRT  
 ORGANISM: Homo Sapien  
 US-10-173-700-584

Query Match 6.5%; Score 134; DB 9; Length 708;  
 Best Local Similarity 23.7%; Pred. No. 0.045;  
 Matches 53; Conservative 40; Mismatches 101; Indels 30; Gaps 10;

QY 14 SSGNEVIEGPNATVILKSGQAFNCTVSQMKLIMWALSDMVLSVRPEPIITNDRET 73  
 Db 20 AGSPHFLOQPEDLVLLGEBARLPALGAYWGIWQTKSGIALGGR-----DLPG 71  
 QY 74 SQRDGGNFTS---EMIHNVPSDSGNIRCSLQNSRLHG-SAYLTV-----QVNGE 122  
 Db 72 WSRWISGNANGQHDHTRPVELEDEASYEQATQAGLRSPADLHVLPPEAPQVLGG 131  
 QY 123 LFIPIVNLVAENEPCEVTCLEPSHWTR-LPDISW-ELGLVSHSSY--FVPE--PSDLQ 176  
 Db 132 ---PSVSLVA--GVANLTCRSRGDARPTPELLMFRDGLLDGATFHQTLKEGTGSVE 186  
 QY 177 SAVSIALTPQSNGLTCVATWKSILKARKSATVNLTVIRCPDPT 220  
 Db 187 STLTLPFSHDDGATFVFCARASQALPTGRDTATLTSLQYPPVPT 230

Search completed: April 29, 2003, 20:17:34  
 Job time : 27.0659 secs



GenCore version 5.1.4\_p5.4578  
Copyright (c) 1993 - 2003 Comphen Ltd.

## OM protein - protein search, using sw model

Run on: April 28, 2003, 18:14:43 ; Search time 14.0485 seconds

(without alignments)  
808.430 Million cell updates/sec

Title: US-09-729-264-6

Perfect score: 2077  
Sequence: 1 MERHLTVEAVGSGSGNEV.....HPQASPNLASPEKVSNTTVV 386Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database : Issued\_Patents\_AA:\*  
1: /cgn2\_6/ptodata/1/1aa/5A.COMB.pep:\*  
2: /cgn2\_6/ptodata/1/1aa/5B.COMB.pep:\*  
3: /cgn2\_6/ptodata/1/1aa/6A.COMB.pep:\*  
4: /cgn2\_6/ptodata/1/1aa/6B.COMB.pep:\*  
5: /cgn2\_6/ptodata/1/1aa/PCTUS.COMB.pep:\*  
6: /cgn2\_6/ptodata/1/1aa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	128.5	6.2	1345	2	US-08-977-767-3
2	128	6.2	1447	4	US-09-041-886-25
3	128	6.2	1447	5	PCT-US94-05277-2
4	127.5	6.1	869	1	US-08-374-834-16
5	127.5	6.1	869	2	US-08-644-271-29
6	127.5	6.1	869	4	US-09-077-955-33
7	127	6.1	332	4	US-09-062-365-1
8	124.5	6.0	340	4	US-09-651-200-2
9	124.5	6.0	441	4	US-09-651-200-4
10	123.5	5.9	534	4	US-09-651-200-6
11	123.5	5.9	534	4	US-09-651-200-24
12	122	5.9	318	2	US-08-633-148-4
13	122	5.9	340	2	US-08-633-148-2
14	114	5.5	868	1	US-08-374-834-1
15	114	5.5	868	2	US-08-644-271-1
16	114	5.5	868	4	US-09-077-955-1
17	114	5.5	1395	4	US-09-540-245A-15
18	113	5.4	689	4	US-09-499-964-1
19	113	5.4	689	2	US-08-979-424-3
20	111	5.3	365	4	US-09-272-496-2
21	109.5	5.3	325	4	US-09-651-200-20
22	109.5	5.3	478	5	PCT-US95-08493-15
23	109.5	5.3	860	5	PCT-US95-08493-19
24	109.5	5.3	868	5	PCT-US95-08493-21
25	109.5	5.3	890	1	US-08-445-640-2
26	109.5	5.3	890	3	US-08-170-558-2
27	109.5	5.3	890	3	US-08-447-314-2

28	109.5	5.3	890	3	US-08-445-641-2	Sequence 2, Appli
29	109.5	5.3	911	1	US-08-286-305A-1	Sequence 1, Appli
30	109.5	5.3	911	2	US-08-441-104A-1	Sequence 1, Appli
31	109.5	5.3	911	2	US-08-440-816A-1	Sequence 1, Appli
32	109.5	5.3	911	4	US-09-417-381A-1	Sequence 1, Appli
33	107.5	5.2	362	1	US-08-415-751-6	Sequence 6, Appli
34	106.5	5.1	946	5	PCT-US95-08493-13	Sequence 1, Appli
35	106	5.1	801	1	US-07-906-349A-6	Sequence 6, Appli
36	105	5.1	319	4	US-08-597-495B-22	Sequence 22, Appli
37	105	5.1	319	4	US-09-068-051A-72	Sequence 2, Appli
38	105	5.1	319	4	US-09-336-536-67	Sequence 67, Appli
39	105	5.1	319	4	US-09-254-465A-6	Sequence 6, Appli
40	105	5.1	365	4	US-08-928-383B-2	Sequence 2, Appli
41	105	5.1	690	4	US-08-935-433-2	Sequence 2, Appli
42	105	5.1	690	4	US-09-553-132-2	Sequence 2, Appli
43	105	5.1	1297	4	US-09-540-245A-17	Sequence 17, Appli
44	105	5.1	1381	4	US-09-540-245A-16	Sequence 16, Appli
45	104.5	5.0	879	1	US-08-554-612C-1	Sequence 1, Appli

## ALIGNMENTS

RESULT 1  
US-08-977-767-3  
Sequence 3, Application US/08977767

Patent No. 5972684

GENERAL INFORMATION:

Query Match

6.2%; Score 128.5; DB 2; Length 1345;

Best Local Similarity 33.0%; Pred. No. 0.0098;  
Matches 37; Conservative 1; Mismatches 41; Indels 33; Gaps 5;

QY 190 GTLVCAATWMSLKARKSATVNLVIRCPDGTGGI-----NIPGVLSLPSLFTPMCK 245  
Db 414 GTCTCTGT-----GC-CGTGGAAAGCTCAGAGCCCGGTGATGTGA 455

QY 246 VGLGLAGTMLLT-PICLTIRCCCRRCGCCRC-----CFCC 286  
Db 456 CGTGAGAGAGGTCCTCTATGACCCCTTCTGCCCTGTGAGACACAGACAC 507

## RESULT 2

US-09-041-886-25  
Sequence 25, Application US/09041886  
Patent No. 6235872

GENERAL INFORMATION:  
APPLICANT: Bredesen, Dale E.  
APPLICANT: Rabizadeh, Sharoz  
TITLE OF INVENTION: Proapoptotic Peptides, Dependence  
TITLE OF INVENTION: Polypeptides and Methods of Use  
NUMBER OF SEQUENCES: 72  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Campbell & Flores LLP  
STREET: 4370 La Jolla Village Drive, Suite 700  
CITY: San Diego  
STATE: California  
COUNTRY: United States  
ZIP: 92122

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/041.886  
FILING DATE:  
CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:  
NAME: Campbell, Cathryn A.  
REGISTRATION NUMBER: 31,815  
REFERENCE/DOCKET NUMBER: P-LJ 2626  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (619) 535-9001  
TELEFAX: (619) 535-8949  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1447 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-09-041-886-25

Query Match 6.2%; Score 128; DB 4; Length 1447;  
Best Local Similarity 24.8%; Pred. No. 0.012;  
Matches 60; Conservative 33; Mismatches 99; Indels 50; Gaps 10;

QY 14 SSGSNEV-----IEGPONATVYKSGQARFNCYVSGW--KLIMWALSDM 55  
Db 220 SRTGNEAEVRLISDPGLRHOLYFLQRPNSVVAIEGKDAVLECCVS-GYPPSPFTWLGE 278  
QY 56 VLVSVRMEPIITNDRFTSORYDOGNFTSEMIITHNVEPSDSGNIRC--SLONSRLHGS 113  
Db 279 VI-----QLRSKYSILGG--SNLLISNVTDDSGMTCCVYTKNENISASA 323  
QY 114 YLVVQVMEGLFIPSVNLVAENEPCEVTCPLPSHWRPLDISW-ELGLVSHSSYFVEPEP 172  
Db 324 ELTVLVPWFLNHPNSLVAYESMDIEFECTVS-GKVPVTVMMKNGDVVIPSDFQIVGG 382  
QY 173 SDLOSASVIALTPQSGNLTLCVATWMSLKARKSATVNLVIRCPDGTGGGINIGVLS 232  
Db 383 SNLR-----ILGVKSDGEFYQCAVNEAGNAOTSQOLIVKPAIPSSS-----VLPS 430

QY 233 LP 234  
Db 431 AP 432

## RESULT 3

PCT-US94-05277-2  
Sequence 2, Application PC/TUS9405277

GENERAL INFORMATION:  
APPLICANT: Bruskin, Arthur  
APPLICANT: Jarosz, David E.  
APPLICANT: Johnson, Karen  
APPLICANT: Kinzler, Kenneth W.  
APPLICANT: Vogelstein, Bert  
APPLICANT: Zaretsky, James R.  
TITLE OF INVENTION: Antibodies Specific for DCC Gene Product  
NUMBER OF SEQUENCES: 2  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Banner, Birch, McKie & Beckett  
STREET: 1001 G Street, N.W.  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20001

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US94/05277  
FILING DATE:  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Kagan, Sarah A.  
REGISTRATION NUMBER: 32,141  
REFERENCE/DOCKET NUMBER: 01107.42709  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202.508.9100  
TELEFAX: 202.508.9299  
TELEX: 197430 BMB UT  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1447 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
PCT-US94-05277-2

Query Match 6.2%; Score 128; DB 5; Length 1447;  
Best Local Similarity 24.8%; Pred. No. 0.012;  
Matches 60; Conservative 33; Mismatches 99; Indels 50; Gaps 10;

QY 14 SSGSNEV-----IEGPONATVYKSGQARFNCYVSGW--KLIMWALSDM 55  
Db 220 SRTGNEAEVRLISDPGLRHOLYFLQRPNSVVAIEGKDAVLECCVS-GYPPSPFTWLGE 278  
QY 56 VLVSVRMEPIITNDRFTSORYDOGNFTSEMIITHNVEPSDSGNIRC--SLONSRLHGS 113  
Db 279 VI-----QLRSKYSILGG--SNLLISNVTDDSGMTCCVYTKNENISASA 323  
QY 114 YLVVQVMEGLFIPSVNLVAENEPCEVTCPLPSHWRPLDISW-ELGLVSHSSYFVEPEP 172  
Db 324 ELTVLVPWFLNHPNSLVAYESMDIEFECTVS-GKVPVTVMMKNGDVVIPSDFQIVGG 382  
QY 173 SDLOSASVIALTPQSGNLTLCVATWMSLKARKSATVNLVIRCPDGTGGGINIGVLS 232  
Db 383 SNLR-----ILGVKSDGEFYQCAVNEAGNAOTSQOLIVKPAIPSSS-----VLPS 430  
QY 233 LP 234  
Db 431 AP 432

```

RESULT 4
US-08-374-834-16
; Sequence 16, Application US/08374834
; Patent No. 5636473
; GENERAL INFORMATION:
; APPLICANT: Valenzuela, et al.
; TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTOR
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Regeneron Pharmaceuticals, Inc.
; STREET: 777 Old Saw Mill River Road
; CITY: Tarrytown
; STATE: New York
; COUNTRY: USA
; ZIP: 10591
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/374,834
; FILING DATE: 19-JAN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/095,658
; FILING DATE: 21-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Cobert, Robert J.
; REGISTRATION NUMBER: 36,108
; REFERENCE/DOCKET NUMBER: REG 190A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (914) 345-7400
; TELEFAX: (914) 345-7721
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 869 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
; US-08-374-834-16

Query Match 6.1%; Score 127.5; DB 1; Length 869;
Best Local Similarity 20.9%; Pred. No. 0.0065;
Matches 86; Conservative 51; Mismatches 176; Indels 99; Gaps 19

QY 19 EYIESPQNAATYKSGOARNCTVSOGWK-LIMMALSDMVNLVSRPMEPIITTDRTFSQRI 77
Db 122 KTRRPINWKILIEGKAVLPCTTGMNPKPSVSMIKD-----SPLRENSRIAVLE- 171
QY 78 DGGNFTSMITHNVEPSPSGNIRCSLONRSLHGSAY-LTYVOMGEFLFIPSVNLVAENE 136
Db 172 -----SGSLRIHNQKEDAGQRCYAKNSL--GTIYSKYVAKIEVYEFARILRAPESHV 223
QY 137 P-----CEYTLCPSHWTRLPDISW-ELGLVHSHSYTFVPEPSDLSAVALTPO 187
Db 224 TFGSFVTLHCTATGTP-----VPTIWMINGNAVSGSIOESVKDRVIDSRQLFTKRP- 277
QY 188 SNGTLTCVAT---WKSLSARKSATIVNLTVICRPDQTGG-----INIPGVLSLP 234
Db 278 ---GLYTCLATNKHGEKFTSTAKAAATISIAEWSKPKQDNKGCAQYRGEVCNAVLAARDALV 335
QY 235 SLGFSL-----PTWGKVVGLAGLTMLPPTCTLTTRCCCRRCRCGCN----- 277
Db 336 FLNTSTADPEBAOELLVHTAMNEL-----KYVSVCRAAFALLCNHIFQCSFGVVP 388
QY 278 -----CCCRCC-----FCCRRKRGFRIOFOKSKSEKETNKETETESGENSGYNSDEOKT 327
Db 389 TPPICREYCLAIVKELFCAKE---WLVMEEKTHRGILYSEMHLLSVPECSKLPMSHWDP 444
QY 328 TETASLTPPKSCSSDPEQANSSCGPRPHQADQRP-----FRAPSHPADSFILA 375

```

```

Db      445  TACARLP-----HLDYKNENKLTPEP--MTSSKPEVDIPLNLPSSSSSSFSVS 489

RESULT 5
US-08-644-271-29
; Sequence 29, Application US/08644271
; Patent No. 5814478
;
; GENERAL INFORMATION:
; APPLICANT: Valenzuela, et al.
; TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTORS
; TITLE OF INVENTION: AND LIGANDS
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Regeneron Pharmaceuticals, Inc.
; STREET: 777 Old Saw Mill Road
; CITY: Tarrytown
; STATE: NY
; COUNTRY: USA
; ZIP: 10591
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/644,271
; FILING DATE: 10-MAY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 60/008,657
; FILING DATE: 15-DEC-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Cobert, Robert J
; REGISTRATION NUMBER: 36,108
; REFERENCE/DOCKET NUMBER: REG 195A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 914-345-7400
; TELEFAX: 914-345-7721
;
; TELEX:
;
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 869 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
;
; US-08-644-271-29
;
; Query Match      6.1%; Score 127.5; DB 2; Length 869;
; Best Local Similarity 20.9%; Pred. No. 0.0065;
; Matches 86; Conservative 51; Mismatches 176; Indels 99; Gaps 19;
;
; QY      19  EYIEGQNAATVLKGSQARNCYVSQWK-LIMALSDMYVLSRPMELITNDRFTSQRY 77
;          :::::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
; DB      122 KITRPINIKIIIEGLAAVLCCTMGNPKRSVSWIKD-----SPLRNSRLAVLE- 171
;
; QY      78  DQGNFTSEMIINVPSPSGNIRCSLQNSRLGSAV-LTVQVMGELFIPSVNLVAENE 136
; DB      172  -----SGSLRIHNQKEDAGQYRCYAKNSL--GTAYSKYVKLEVEFARILRAPESHV 223
;
; QY      137 P-----CEVTCLPDSHMTRLPIDISW-ELGLLVSHSSYYFVPEPSDLOSANVIALTPQ 187
; DB      224 TFGSEFTLHCTANGIP-----VPTIIMIENGNAVSSGIODESVKDEVIDSRLOLFTTKP- 277
;
; QY      188 SNGTLICVAT-----WMSLARKSATYNNLYIRPQDTGG-----INIPGVLSLP 234
; DB      278  --GLYCIATINKHGEKFSATAKAATISIAEWSKPKQDNNGYCAQYGEVCNAVLAADALV 335
; QY      235 SLGFSL-----PTWGVKVGGLAGTMLLTPTCTLTIRCCCCRRCGCGN----- 277
; DB      336 FLWTSTADPEADEOLLVHTRANML-----KVSVYVCRAAALALCNHIFQCSGSPGVVP 388

```

QY 278 -----CCCRCC-----FCCRRKRGFRIDPOKSEKETEETESGNGNSGYNDEOQT 327  
 Db 389 TPIPIREYCLAVKEFLCAKE-----WLVMEKTHRGILYSEMHLLSYEPCSLPBMHMDP 444  
 QY 328 TETASIPRPSCESSDEQONSSCGPPHQAADRP-----PRPASHQASFNLA 375  
 Db 445 TACARLP-----HLDYKKNELKTFPP--MTSSKPSVDIPNLPSSSSSSSFSVS 489

## RESULT 6

US-09-077-955-33  
 ; Sequence 33, Application US/09077955A  
 ; Patent No. 6413740

GENERAL INFORMATION:  
 ; APPLICANT: Valenzuela et al., David M.  
 ; TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTORS AND LIGANDS  
 ; FILE REFERENCE: REG195-B-PCT-US  
 ; CURRENT APPLICATION NUMBER: US/09/077,955A  
 ; EARLIER FILING DATE: 1998-09-10  
 ; EARLIER APPLICATION NUMBER: PCT/US96/20696  
 ; EARLIER FILING DATE: 1996-12-13  
 ; EARLIER APPLICATION NUMBER: 08/644,271  
 ; EARLIER FILING DATE: 1996-05-10  
 ; EARLIER APPLICATION NUMBER: 60/008,657  
 ; EARLIER FILING DATE: 1995-12-15  
 ; NUMBER OF SEQ ID NOS: 36  
 ; SOFTWARE: Patent In Ver. 2.0  
 ; SEQ ID NO 33  
 ; LENGTH: 869  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 ; US-09-077-955-33

Query Match 6.1%; Score 127.5; DB 4; Length 869;  
 Best Local Similarity 20.9%; Pred. No. 0.0065;  
 Matches 86; Conservative 51; Mismatches 176; Indels 99; Gaps 19;

QY 19 EYIEGPONATYVKGSOARPNCTVSGWK-LIMMALSDMVLSVPRMEPIITNDRFTSQRY 77  
 Db 122 KITRPPINVKIIEGLKAVLPCTMGNPKPSVMIKD-----SPLRNSRIAYLE- 171  
 QY 78 DQGNMTSEMITIHVPEPSDSGNIRCSLNSRLHGSAY-LTYVGMGEFLTPSVNLVAENE 136  
 Db 172 -----SSLRHNOKEDAGQRCVAKNSL--GTAISKVVKLEVEFARILRAPESHNV 223  
 QY 137 P-----CEVTLPSHMTLRPLDISW-ELGLVSHSSYFVPPPSDLSASVILATLPQ 187  
 Db 224 TFGSFVTLHCTATGIP-----VPTITWIEGNNAVSSGSIQESVMDRVIDSLQLEFTRK- 277  
 QY 188 SNGTLTCVAT-----WKSIAKRSATVNLTVTRCPQDIDGG-----INIPGVLSLP 234  
 Db 278 --GLYTCAIATNKHGEKSTAAATISIAEWSKPKQKDKNGYCAQYRGEVCNAVLAADALV 335  
 QY 235 SLGFSJL-----PTWKGVLGLAGTMLLTPCTLTIRCCCRRCRCCGCGN----- 277  
 Db 336 FLNVSYPADPEEAQELLVHTANL-----KVSVPQCPAAEALLCNHIFQESCPGV 388  
 QY 278 -----CCCCCC-----FCRRKRKGRFIOFOKSEKETEETESGNGNSGYNDEOQT 327  
 Db 389 TPIPIREYCLAVKEFLCAKE-----WLVMEKTHRGILYSEMHLLSYEPCSLPBMHMDP 444  
 QY 328 TETASIPRPSCESSDEQONSSCGPPHQAADRP-----PRPASHQASFNLA 375  
 Db 445 TACARLP-----HLDYKKNELKTFPP--MTSSKPSVDIPNLPSSSSSSSFSVS 489

## RESULT 7

US-09-062-365-1  
 ; Sequence 1, Application US/09062365  
 ; Patent No. 6463422  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Schmidt, Ann Marie  
 ; APPLICANT: Stern, David

;; TITLE OF INVENTION: METHOD FOR INHIBITING TUMOR INVASION OR SPREADING IN A  
 ;; FILE REFERENCE: 55424  
 ;; CURRENT APPLICATION NUMBER: US/09/062,365  
 ;; CURRENT FILING DATE: 1998-04-17  
 ;; NUMBER OF SEQ ID NOS: 6  
 ;; SOFTWARE: Patent In Ver. 2.1  
 ;; SEQ ID NO 1  
 ;; LENGTH: 332  
 ;; TYPE: PRT  
 ;; ORGANISM: Human  
 ; US-09-062-365-1

Query Match 6.1%; Score 127; DB 4; Length 332;  
 Best Local Similarity 25.0%; Pred. No. 0.0019;  
 Matches 70; Conservative 31; Mismatches 87; Indels 92; Gaps 15;

QY 9 PEAVSGSGNEVIEGPONATVKGSOARFNCVSGW-KLIMMALSDMVLSVPRMEPI 65  
 Db 102 PEYDSAS--ELTAGVFN-----KVGTCSGSGYPAGTISWHLDG-----KP 141  
 QY 66 IITNDRFTS-----QRIDCGNFT--SEMITIHVPEPSDSGNIR-----CSLQNSRLHGSAY 114  
 Db 142 LVPRKGVSVKEQTRRHPEGTGLTQSELM--VTPARGGDPRPTSCSFSPCLPRHRL 198  
 QY 115 LTYVGMGEFLP-----SVNLVAENEP-----CEVTLPSHMTLRPLDISW 156  
 Db 199 RTAPIQPRVMEPPVLEVOLV--EPEGAVAPGGTWTITCEVPAPPS-----PQIHMM 250  
 QY 157 LGLVSHSSYFVPPPSDLSASVILATLPQNSGTLTCVATWKSIAKRSATVNLTVIRC 216  
 Db 251 KD-----GVPLPLPSPVLILPEIGPDQGTYSVATHSHQPSRAVSIIIE- 300  
 QY 217 PDIDGGGINIPGVLSLPSLGFSLPTWKGVLGLAGTMLL 256  
 Db 301 PGEKG-----PTAGSVGSGGLGTAL 321

## RESULT 8

US-09-651-200-2  
 ; Sequence 2, Application US/09651200  
 ; Patent No. 6429303  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Green et al

;; TITLE OF INVENTION: Polynucleotides Encoding Members of the Human B  
 ;; TITLE OF INVENTION: Lymphocyte Activation Antigen B-7 Family and  
 ;; FILE REFERENCE: 15966-562 (CURA-62)  
 ;; CURRENT APPLICATION NUMBER: US/09/651,200  
 ;; CURRENT FILING DATE: 2000-08-30  
 ;; PRIOR APPLICATION NUMBER: 60/152383  
 ;; PRIOR FILING DATE: 1999-09-03  
 ;; PRIOR APPLICATION NUMBER: 60/172909  
 ;; PRIOR FILING DATE: 1999-12-21  
 ;; PRIOR APPLICATION NUMBER: 60/183578  
 ;; PRIOR FILING DATE: 2000-02-18  
 ;; NUMBER OF SEQ ID NOS: 25  
 ;; SOFTWARE: Patent In Ver. 2.0  
 ;; SEQ ID NO 2  
 ;; LENGTH: 340  
 ;; TYPE: PRT  
 ;; ORGANISM: Homo sapiens  
 ; US-09-651-200-2

Query Match 6.0%; Score 124.5; DB 4; Length 340;  
 Best Local Similarity 21.2%; Pred. No. 0.0033;  
 Matches 77; Conservative 51; Mismatches 127; Indels 109; Gaps 17;

QY 14 SSGSNEVIEGPONATV-LKSGARFNCVTS--QGWKL-----IMMALSDMVLSVPRMEPI 66  
 Db 48 SPTGAVEGVQVEDPVVALVGTADTLHCSFSPRGSLSVLQNLINWGLDTPTKQLV----- 100  
 QY 67 IITNDRFTSQRYDGGNF-----TSEMITIHVPEPSDSGNIRCSLQNSRLHGS 112



```

: GENERAL INFORMATION:
: APPLICANT: Green et al
: TITLE OF INVENTION: Polynucleotides Encoding Members of the Human B
: TITLE OF INVENTION: Lymphocyte Activation Antigen B-7 Family and
: FILE REFERENCE: 15966-562 (CURA-62)
: CURRENT APPLICATION NUMBER: US/09/651,200
: PRIOR FILING DATE: 2000-08-30
: PRIOR APPLICATION NUMBER: 60/152383
: PRIOR FILING DATE: 1999-09-03
: PRIOR APPLICATION NUMBER: 60/172909
: PRIOR FILING DATE: 1999-12-21
: PRIOR APPLICATION NUMBER: 60/183578
: PRIOR FILING DATE: 2000-02-18
: NUMBER OF SEQ ID NOS: 25
: SOFTWARE: PatentIn Ver. 2.0
: SEQ ID NO 24
: LENGTH: 534
: TYPE: PRT
: ORGANISM: Unknown
: FEATURE:
: OTHER INFORMATION: Description of Unknown Organism: Sequence
: OTHER INFORMATION: m25020.protein from Figure 4.
: US-09-651 200-24

```

```

Query Match          5.9%; Score 123.5; DB 4; Length 534;
Best Local Similarity 21.2%; Pred. No. 0.0076;
Matches 77; Conservative 50; Mismatches 128; Indels 109; Gaps 17;

```

```

QY 14 SGGSGNEVIEGPNATV-LKGSQARFNCTVSG--QGMKL---IMMALSDMNVLSVRMEPI 66
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 242 SPGAVEVGVPPEDPVVALVGTATLRCSPSPGFSGLAOLNIMWLTDTKOLV----- 294
QY 67 ITNDRFSQRYDQGNF-----TSEMIIHVPEPSDGNINCSLQNSRLHGS 112
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 295 ---HSTTEGR-DGGSAYANKRTALFPDLAQGNASRLQVRRVADSGFTCFV-STRDGSS 349
QY 113 AYLTVQMGELFIPSVNLV---VAENEPCEVTCLPSHWTRLP--DISNELGL---LVSH 163
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 350 AAVSLQVAPYSKPSMTLPENKDLRPGDVTITTC--SSYRGYPEAEVFMQDQGVPLNGN 407
QY 164 SSYTFPEPSDDQANSILALTPQSNGLTCVATKWSLKARSAIVNLVIRCP--QDT 220
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 408 VITSQANQOGLFVDHVSIVRVLVGANGTSC-----LVNRPVLQODA 449
QY 221 GGGINIPGVLSLPSLGSFLPTMGKVGGLAGTMLTPTCTLTIRCCCRRCGCCNCCC 280
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 450 HGSVITITGQPMTPPEAL---WTVYGLSVCLLALLV----- 482
QY 281 RCFCCRRRRGRFRIQFKKSEKKTINKETETESGNENSGYNSDEOKTETASLPKSCSS 340
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 483 ALAFVCMRK-----IKQSCFEENAGAEQDQD-----EGGSKTALQPLKHSDS 525
QY 341 SDPE 344
DB 526 KEDD 529

```

```

RESULT 12
US-08-633-148-4
: Sequence 4, Application US/08633148
: Patent No. 5864018
: GENERAL INFORMATION:
: APPLICANT: MORSEY, MICHAEL J.
: APPLICANT: NAGASHIMA, MARIKO
: APPLICANT: HOLLANDER, DORIS A.
: TITLE OF INVENTION: ANTIBODIES TO ADVANCED GLYCOSYLATION
: TITLE OF INVENTION: END-PRODUCT RECEPTOR POLYPEPTIDES AND USES THEREFOR
: NUMBER OF SEQUENCES: 23
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: TOWNSEND & TOWNSEND & CREW LLP
: STREET: TWO EMBARCADERO CENTER, 8TH FLOOR
: CITY: SAN FRANCISCO

```

```

: STATE: CALIFORNIA
: COUNTRY: U.S.A.
: ZIP: 94111
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/633,148
: FILING DATE: 16-APR-1996
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: MURPHY ESO., MATTHEW B.
: REGISTRATION NUMBER: 39,787
: REFERENCE/DOCKET NUMBER: 014618-005600US
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (415) 326-2400
: TELEFAX: (415) 326-2422
: INFORMATION FOR SEQ ID NO: 4:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 318 amino acids
: TYPE: amino acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: peptide
: US-08-633-148-4

```

```

Query Match          5.9%; Score 122; DB 2; Length 318;
Best Local Similarity 24.9%; Pred. No. 0.005;
Matches 69; Conservative 30; Mismatches 86; Indels 92; Gaps 15;

```

```

QY 9 PEAVSGSGNEVIEGPNATV-LKGSQARFNCTVSG--WKLIMMALSDMNVLSVRMEPI 65
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 102 PEYDSAS--ELTAGVFN-----KVGTCVSEGSYPAGTILSMHLDG-----KP 141
QY 66 ITNDRFTS-----QRDQGNFT--SEMIIHVPEPSDGNIR---CSLQNSRLHGSAY 114
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 142 LVNPEKGVSVKEQRRHETGLFTLOSELN---VTPARGDPRPTFSQSPGIPRRHRL 198
QY 115 LTVQMGELFIP---SVNLVAENEP-----CEVTCLPSHWTRLPDISWE 156
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 199 RTAPLPQPMWEPVPLEEVQVYV---EPGGAIVAPGTVTLTCEVPAOP---PQIHM 250
QY 157 LGLVSHSSSYTFPEPSDDQANSILALTPQSNGLTCVATKWSLKARSAIVNLVIRCP 216
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 251 KD-----GVPLPLPSPVLLPRLGPDQGTYSQVATSHSHGQESRAVSISIE- 300
QY 217 PDGTGGGINIPGVLSLPSLGSFLPTMGKVGGLAGT 253
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 301 PGEER-----PTAGSVGGSGIGT 318

```

```

RESULT 13
US-08-633-148-2
: Sequence 2, Application US/08633148
: Patent No. 5864018
: GENERAL INFORMATION:
: APPLICANT: MORSEY, MICHAEL J.
: APPLICANT: NAGASHIMA, MARIKO
: APPLICANT: HOLLANDER, DORIS A.
: TITLE OF INVENTION: ANTIBODIES TO ADVANCED GLYCOSYLATION
: TITLE OF INVENTION: END-PRODUCT RECEPTOR POLYPEPTIDES AND USES THEREFOR
: NUMBER OF SEQUENCES: 23
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: TOWNSEND & TOWNSEND & CREW LLP
: STREET: TWO EMBARCADERO CENTER, 8TH FLOOR
: CITY: SAN FRANCISCO
: STATE: CALIFORNIA
: COUNTRY: U.S.A.
: ZIP: 94111
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk

```

COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/633,148  
FILING DATE: 16-APR-1996  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: MURPHY ESO., MATTHEW B.  
REGISTRATION NUMBER: 39,787  
REFERENCE/DOCKET NUMBER: 014618-005600US.  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 326-2400  
TELEFAX: (415) 326-2422  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 340 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-08-633-148-2

Query Match 5.9%; Score 122; DB 2; Length 340;  
Best Local Similarity 24.9%; Pred. No. 0.0055;  
Matches 69; Conservative 30; Mismatches 86; Indels 92; Gaps 15;

QY 9 PEAVSGSSGNEVIEGPONATVLKGSQARFNCYSOG---WKLIMALSDMVLSVRMEP 65  
DB 124 PELVSDAS--ELTAGVFN-----KVGTSSEGSYPACTLSMHDG-----RP 163  
QY 66 IITNDRETS-----QRYDQGNFT--SEMIHNVEPSDSGNIR-----CSLONSRLHGSAY 114  
DB 164 LVNNEKGVSVKEQTRRPETGLFTLQSELM---VTPARGDPRPTSCSPSLPRHRL 220  
QY 115 LVVQNGELFIP-----SVNLVAENED-----CEVTLPSHMTLPDISME 156  
DB 221 RTAPIDPRWEPVPLEVQLV---EPEGAVAPGCTVLTLCVPAQPS-----POIHMM 272  
QY 157 LGLVSSSYVPEPSDLSAVSIALTPQSNCTLCVATWKSLSKARSATVNLVINC 216  
DB 273 KD-----GVPLPPSPVILPEIGPDGTVSCVATHSSHPQESRAVSIITE- 322  
QY 217 PDGTGGGINIPGVLSLPSLSGLFTPTWKGVLGAGT 253  
DB 323 PGEEG-----PTAGSYGSGSLGT 340

RESULT 14  
US-08-374-834-1  
Sequence 1, Application US/08374834  
Patent No. 5656473  
GENERAL INFORMATION:  
APPLICANT: Valenzuela, et al.  
TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTOR  
NUMBER OF SEQUENCES: 17  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Regeneron Pharmaceuticals, Inc.  
STREET: 777 Old Saw Mill River Road  
CITY: Tarrytown  
STATE: New York  
COUNTRY: USA  
ZIP: 10591  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/374,834  
FILING DATE: 19-JAN-1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/095,658  
FILING DATE: 21-JUL-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: Covert, Robert J.  
REGISTRATION NUMBER: 36,108  
REFERENCE/DOCKET NUMBER: REG 190A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (914) 345-7400  
TELEFAX: (914) 345-7721  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 868 amino acids  
TYPE: amino acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: protein  
US-08-374-834-1

Query Match 5.5%; Score 114; DB 1; Length 868;  
Best Local Similarity 21.3%; Pred. No. 0.1;  
Matches 80; Conservative 40; Mismatches 150; Indels 106; Gaps 18;

QY 19 EVIEGPONATVLKGSQARFNCYSQGMK-LIMALSDMVLSVRMEPITNDRETSQR 77  
DB 122 KITRPPINVKILIEGLKAVLPCTTMGNPKPSVWIKGDSALRE-----NSRIAYLE- 171  
QY 78 DCGMFTSEMIHNVEPSDSGNIRCSLONSRLHGSAY-LTVQNGELFIPSVNLVAENE 136  
DB 172 -----SGSLRIHNQKEDAGRCYAKNSL--GTAISKYKLEVEYARILRAPESINV 223  
QY 137 P-----CEVTLPSHMTLPDISW-ELGLVSSSYVPEPSDLSQSAVSIALTPO 187  
DB 224 TFGSEVTLRCTAIGMP-----VPTISWLENGNAVSSGSIQENVKORVIDSLQFLTRP- 277  
QY 188 SNGTLCAVAT-----WKSLSKARSATVNLTVIR-----CPQDTGGGINIPVLSLP 234  
DB 278 --GLYTCLATNKHGKFSYAKAAATVSAIEMSKSQESKGYCAQYRGVCAVLYKOSL 335  
QY 235 SLGFSLP-----TWGKVLGAGTMLTPTCTLTIRCCGCRRCGCGN----- 277  
DB 336 FNTSTYPPDEEAOELLITAMNEL-----KAVSPLCRPAEALCLNHLQESPGVLP 388  
QY 278 -----CCCRCC-----FCCRRKRGFRIOFKKSEKENTKETESGENSGYNSDEQKT 327  
DB 389 TEMPLCREYCLAVKELFCA-----KEMLAMGKTRHGLYRSGMHE--LPV 431  
QY 328 TETASLP-----PKSC 338  
DB 432 PECSKLPSMHDPTAC 447

RESULT 15  
US-08-644-271-1  
Sequence 1, Application US/08644271  
Patent No. 5814478  
GENERAL INFORMATION:  
APPLICANT: Valenzuela, et al.  
TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTORS  
NUMBER OF SEQUENCES: 32  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Regeneron Pharmaceuticals, Inc.  
STREET: 777 Old Saw Mill Road  
CITY: Tarrytown  
STATE: NY  
COUNTRY: USA  
ZIP: 10591  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 2.0  
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/644,271  
FILING DATE: 10-MAY-1996  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 60/008,657  
FILING DATE: 15-DEC-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Cobert, Robert J  
REGISTRATION NUMBER: 36,108  
REFERENCE/DOCKET NUMBER: REG 195A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 914-345-7400  
TELEFAX: 914-345-7721  
TELEX:  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 868 amino acids  
TYPE: amino acid  
STRANDEDNESS:  
TOPOLOGY: unknown  
MOLECULE TYPE: protein  
US-08-644-271-1

Query Match 5.5%; Score 114; DB 2; Length 868;  
Best Local Similarity 21.3%; Pred. No. 0.1; Mismatches 18;  
Matches 80; Conservative 40; Indels 106; Gaps 18;  
QY 19 EVIEGPONATVVKGSQARFNCVTSQGWK-LIMMALSDMVVLSVRPMEPITNDRTSORY 77  
DB 122 KITRPPIINKITEGLKAVLPCTMGNPKPSVMIKGDSALRE-----NSRIAYLE- 171  
QY 78 DOGGNFTSMITHNVEPSDSGNIRCSLONSRLHGSAY-LTYOVMGELFIPSYNLVVAENE 136  
DB 172 -----SGSLRIHNVOKEDAGQRCVAKNSL--GTAYSRLVLEVEFARILRAPESHNV 223  
QY 137 P-----CEVTCLEPSHMTRLPDISM-ELGLVSHSYFVPEPSDLOSAVSIATLPQ 187  
DB 224 TPGSEVTLTACTAIGMP-----VPTISWLENGNAVSSGSIQENVKDRAVIDSRQLFTTP- 277  
QY 188 SNGTLTCVAT---WKSLEAKRSATVNLTVIR-----CPDPTGGGINIPGYLSSLP 234  
DB 278 --GLYTCIATNKHGEKFTSAKAAATVSLAEWSKSQKESKGYCAQYRGVECDVILKDSLV 335  
QY 235 SLGFSLP-----TWGKVGIGLAGTMLLPTCTLTIRCCCCRRRCGCGN----- 277  
DB 336 FNTSTYPPDEAEQELLHTAMNEL-----KAVSPLCRPAEALLCNHLFQECSPGYLP 388  
QY 278 -----CCCRCC-----FCCRRKRGRFRIQPKKSEKTKNETETESGNGNSGYNDEQKT 327  
DB 389 TTPMPTCREKCYLAVKELFCA-----KEMLAMEGKTHRGILYRSGMNF--LPV 431  
QY 328 TETASLP---PKSC 338  
DB 432 PECSKLPMSMHODPTAC 447

Search completed: April 28, 2003, 21:12:23  
Job time: 18.0485 secs



GenCore version 5.1.4.P5-4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 28, 2003, 16:24:31 ; Search time 38.4662 Seconds  
(without alignments)  
1337.141 Million cell updates/sec

Title: US-09-729-264-6  
Perfect score: 2077  
Sequence: 1 MERLLTVPAVAGSGSGNEV.....HPQAFNLASPEKVSNTTV 386

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues  
Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

A\_Geneseq\_101002.\*  
1: /SID52/gcgdata/geneseq/geneseq-emb1/AA1980.DAT.\*  
2: /SID52/gcgdata/geneseq/geneseq-emb1/AA1981.DAT.\*  
3: /SID52/gcgdata/geneseq/geneseq-emb1/AA1982.DAT.\*  
4: /SID52/gcgdata/geneseq/geneseq-emb1/AA1983.DAT.\*  
5: /SID52/gcgdata/geneseq/geneseq-emb1/AA1984.DAT.\*  
6: /SID52/gcgdata/geneseq/geneseq-emb1/AA1985.DAT.\*  
7: /SID52/gcgdata/geneseq/geneseq-emb1/AA1986.DAT.\*  
8: /SID52/gcgdata/geneseq/geneseq-emb1/AA1987.DAT.\*  
9: /SID52/gcgdata/geneseq/geneseq-emb1/AA1988.DAT.\*  
10: /SID52/gcgdata/geneseq/geneseq-emb1/AA1989.DAT.\*  
11: /SID52/gcgdata/geneseq/geneseq-emb1/AA1990.DAT.\*  
12: /SID52/gcgdata/geneseq/geneseq-emb1/AA1991.DAT.\*  
13: /SID52/gcgdata/geneseq/geneseq-emb1/AA1992.DAT.\*  
14: /SID52/gcgdata/geneseq/geneseq-emb1/AA1993.DAT.\*  
15: /SID52/gcgdata/geneseq/geneseq-emb1/AA1994.DAT.\*  
16: /SID52/gcgdata/geneseq/geneseq-emb1/AA1995.DAT.\*  
17: /SID52/gcgdata/geneseq/geneseq-emb1/AA1996.DAT.\*  
18: /SID52/gcgdata/geneseq/geneseq-emb1/AA1997.DAT.\*  
19: /SID52/gcgdata/geneseq/geneseq-emb1/AA1998.DAT.\*  
20: /SID52/gcgdata/geneseq/geneseq-emb1/AA1999.DAT.\*  
21: /SID52/gcgdata/geneseq/geneseq-emb1/AA2000.DAT.\*  
22: /SID52/gcgdata/geneseq/geneseq-emb1/AA2001.DAT.\*  
23: /SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2077	100.0	386	23	AAU75542 Human B7-1-like prot
2	2014	97.0	382	23	AAU75540 Human B7-1-like prot
3	2000	96.3	386	23	AAU75541 Human B7-1-like prot
4	1514	72.9	377	23	AAU75543 Human B7-1-like prot
5	1326	63.8	463	22	ABG28169 Novel human diagno
6	928.5	44.7	370	23	AAU75544 Mouse B7-1-like prot
7	587.5	28.3	631	23	AAU75547 Rat B7-1-like prot
8	579.5	27.9	270	23	AAU75545 Mouse B7-1-like prot
9	498	24.0	223	23	AAU75546 Mouse B7-1-like prot
10	151	7.3	404	22	AA81925 Extracellular cit

11	151	7.3	404	23	AAE23219 Human receptor for
12	151	7.3	404	23	AAU77543 Human RAGE protein
13	151	7.3	404	23	AAW48745 Human RAGE protein
14	135	6.5	1496	21	AAW81030 Melanoma associate
15	135	6.5	1496	21	AAU70469 Human p53 target m
16	135	6.5	1498	22	ABH11587 Human peroxidase
17	134	6.5	592	23	ABH75751 Human immunoglobul
18	134	6.5	594	23	ABH75753 Human immunoglobul
19	134	6.5	708	22	AAU29315 Human pancreas GP3
20	134	6.5	708	22	AAU29315 Human gp354 (putat
21	133.5	6.4	344	22	AAW38713 Human polypeptide
22	128	6.2	1447	16	AAW68553 Deleted in colorec
23	128	6.2	1447	20	AAW33498 Human DCC protein.
24	128	6.2	1447	22	AAW50693 Human UNC-40 prote
25	128	6.2	1728	12	AAW13144 Deleted in colorec
26	128	6.2	1953	23	AAW84351 Protein MYK diffe
27	127.5	6.1	467	19	AAW62575 Alternatively spli
28	127.5	6.1	475	17	AAW94982 Nsk2 extracellular
29	127.5	6.1	863	19	AAW62569 Alternatively spli
30	127.5	6.1	867	19	AAW62583 Alternatively spli
31	127.5	6.1	869	18	AAW26611 Human muscle-speci
32	127.5	6.1	869	18	AAW26506 Human Dmk receptor
33	127.5	6.1	871	17	AAW84087 Nsk2 receptor. Mu
34	127.5	6.1	871	19	AAW62568 Nsk2 receptor tyr
35	127.5	6.1	873	17	AAW84092 Alternatively spli
36	127.5	6.1	873	19	AAW62573 Nsk2 receptor with
37	127.5	6.1	881	17	AAW84091 Nsk2 receptor with
38	127.5	6.1	881	19	AAW62572 Nsk2 receptor to
39	126	6.1	332	21	AAV52130 Human Receptor mu
40	125.5	6.0	537	22	AAW77857 Mutant protein mu
41	125.5	6.0	576	22	AAW77856 Protein of muscle
42	125.5	6.0	869	22	AAW68421 Amino acid sequenc
43	125.5	6.0	869	22	AAW68421 Human colon carcin
44	125	6.0	1070	18	AAW08747 Prostate cancer-as
45	125	6.0	1070	23	ABG61942

#### ALIGNMENTS

RESULT 1	AAU75542 standard; Protein; 386 AA.
ID	AAU75542:
XX	AAU75542:
AC	23-APR-2002 (first entry)
XX	
DT	Human B7-1-like protein, B7-L <sub>h3</sub> .
XX	
DE	Human: B7-1-like protein; B7-L; antiinfectility; gynaecological;
XX	antitumor; cytostatic; immunosuppressive; antiarthritic; antineumatic;
KW	antiinflammatory; dermatological; antipruritic; neuroprotective;
KW	antidiabetic; haemostatic; antithyroid; antileuc; antiallergic;
KW	antistimatic; nephrotoxic; antibacterial; vitruide; tumor; cancer;
KW	reproductive disorder; graft versus host disease; autoimmune disease;
KW	toxic shock syndrome; allergy; nephropathy; skin disorder;
KW	endocrinopathy; lymphoproliferative disorder.
XX	
OS	Homo sapiens.
XX	
PN	WO200200710-A2.
XX	
PD	03-JAN-2002.
XX	
PF	28-JUN-2001; 2001WO-US20719.
XX	
PR	28-JUN-2000; 2000US-214512P.
XX	
PR	28-NOV-2000; 2000US-0729264.
XX	
PA	(AMGE-) AMGEN INC.
XX	
PI	Welcher AA, Sarmiento UM, Schultiz HJ, Chute HT;

XX WPI: 2002-130881/17.  
 DR N-PSDB: ABK13030.  
 XX  
 PT New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 XX  
 PS Claim 13; Fig 3; 135pp; English.

XX The invention relates to an isolated B7-1-like (B7-L) polypeptide (1).  
 CC The polypeptide, polynucleotide encoding it and antibody against (1) are  
 CC useful for treating B7-1-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility, and  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (1) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (1) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or all sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions.  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of human B7-L<sub>h3</sub>.

XX Sequence 386 AA:

Query Match 100.0%; Score 2077; DB 23; Length 386;  
 Best Local Similarity 100.0%; Pred. No. 1,9e-164;  
 Matches 386; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MEHHLTVEAVSGSGNVEIEGPNATVYKGSQARFNTVSGMKLIMALSDMWVLSV 60  
 DB 1 MEHHLTVEAVSGSGNVEIEGPNATVYKGSQARFNTVSGMKLIMALSDMWVLSV 60  
 QY 61 RPEPITITNDRTSQRYDGGNFTSMITHNVEPSDSGNIRSLONSRLHGSAYLTVOYM 120  
 DB 61 RPEPITITNDRTSQRYDGGNFTSMITHNVEPSDSGNIRSLONSRLHGSAYLTVOYM 120  
 QY 121 GELFITSVNVVAVNEPCVTCPSHWTPLDPSWELGLVSHSSYFPEPSDQSAAS 180  
 DB 121 GELFITSVNVVAVNEPCVTCPSHWTPLDPSWELGLVSHSSYFPEPSDQSAAS 180  
 QY 181 ILALFQSNQTLTCVATWKSILKRSATVNLATYIRCPDPTGGGINIPGLVSLPSIGFSL 240  
 DB 181 ILALFQSNQTLTCVATWKSILKRSATVNLATYIRCPDPTGGGINIPGLVSLPSIGFSL 240  
 QY 241 PTMGKVGGLAGTMTLPTCTLTIRCCCRRCRCGCCGCCFCFCRRRRGRIFQKKS 300  
 DB 241 PTMGKVGGLAGTMTLPTCTLTIRCCCRRCRCGCCGCCFCFCRRRRGRIFQKKS 300

QY 301 EKEKTKETETESGNGNSGNSDEQKTTETASLPKSCSSDPEQNNSCGPHQADQR 360  
 DB 301 EKEKTKETETESGNGNSGNSDEQKTTETASLPKSCSSDPEQNNSCGPHQADQR 360  
 QY 361 PPRPASHPOASFNINASPEKVSNTTV 386  
 DB 361 PPRPASHPOASFNINASPEKVSNTTV 386

# RESULT 2

AAU75540  
 ID AAU75540 standard; Protein; 382 AA.  
 AC AAU75540;  
 XX  
 DT 23-APR-2002 (first entry)  
 XX  
 DE Human B7-1-like protein, B7-L<sub>h1</sub>.  
 XX  
 KW Human: B7-1-like protein; B7-L; anti-infectivity; gynaecological;  
 KW antitumour; cytostatic; immunosuppressive; antiarthritis; anti-rheumatic;  
 KW anti-inflammatory; dermatological; antipsoriasis; neuroprotective;  
 KW antidiabetic; haemostatic; antithyroid; anticancer; antifungal;  
 KW antitubercular; nephroprotective; antibacterial; virucide; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W0200200710-A2.  
 XX  
 PD 03-JAN-2002.  
 XX  
 PE 28-JUN-2001; 2001WO-US20719.  
 XX  
 PR 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX  
 PA (AMGE-) AMGEN INC.  
 XX  
 PI Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 XX  
 DR WPI: 2002-130881/17.  
 DR N-PSDB: ABK13028.  
 XX  
 PT New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 XX  
 PS Claim 13; Fig 1; 135pp; English.

The invention relates to an isolated B7-1-like (B7-L) polypeptide (1).  
 CC The polypeptide, polynucleotide encoding it and antibody against (1) are  
 CC useful for treating B7-1-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility, and  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (1) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (1) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, Rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as

CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions, and for  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of human B7-L<sub>h1</sub>.

XX Sequence 386 AA;

Query Match 97.0%; Score 2014; DB 23; Length 382;  
 Best Local Similarity 99.7%; Pred. No. 3,36-159;  
 Matches 373; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 13 GSGSGNEVEEGPQNAIVLKGSQARFNCTVSGQKLMALSDMYVLSVRPEPIITNDRF 72  
 DB 9 GSGSGNEVEEGPQNAIVLKGSQARFNCTVSGQKLMALSDMYVLSVRPEPIITNDRF 68  
 QY 73 TSQRYDQGNFTSEMIHNVEPSDSGNIRCSLQNSRLHSAVLYVQVNGELFIPSVNLV 132  
 DB 69 TSQRYDQGNFTSEMIHNVEPSDSGNIRCSLQNSRLHSAVLYVQVNGELFIPSVNLV 128  
 QY 133 AENECVETCLPSHWTRLPDISWELGLVSHSSYFVPEPSDQASVITALTPQSNCTL 192  
 DB 129 AENECVETCLPSHWTRLPDISWELGLVSHSSYFVPEPSDQASVITALTPQSNCTL 188  
 QY 193 TCVAWTKSKARKSATVNLTYRCPDQDGGGINTPGVLSLPSIGFSLPTGKVLGLAG 252  
 DB 189 TCVAWTKSKARKSATVNLTYRCPDQDGGGINTPGVLSLPSIGFSLPTGKVLGLAG 248  
 QY 253 TMLLPTGCTLTIRCCCRRCGCCGCCRCFCRCRRKGFIOFOKSEKETKETETE 312  
 DB 249 TMLLPTGCTLTIRCCCRRCGCCGCCRCFCRCRRKGFIOFOKSEKETKETETE 308  
 QY 313 SGENSGNSDOKTTERASLPKSCSSDDEQRNNSCGPRHQRADQRPAPASHPOASF 372  
 DB 309 SGENSGNSDOKTTERASLPKSCSSDDEQRNNSCGPRHQRADQRPAPASHPOASF 368  
 QY 373 NLASPEKYSNTTV 386  
 DB 369 NLASPEKYSNTTV 382

RESULT 3  
 AAU75541  
 ID AAU75541 standard; Protein: 386 AA.  
 AC AAU75541;  
 DT 23-APR-2002 (first entry)  
 XX  
 DE Human B7-L-like protein, B7-L<sub>h2</sub>.  
 XX  
 KW Human; B7-L-like protein; B7-L; anti-infectivity; gynaecological;  
 KW antitumour; cytostatic; immunosuppressive; antiarthritic; antirheumatic;  
 KW antidiabetic; haemostatic; antihypertensive; antiproliferative;  
 KW antiallergic; nephrotropic; antitubercular; virucide; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200200710-A2.

XX 03-JAN-2002.  
 PD  
 XX  
 PF 28-JUN-2001; 2001MO-US20719.  
 XX  
 PR 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX  
 PA (AMGE-) AMGEN INC.  
 XX  
 PI Welcher AA, Sarmiento DM, Schultz HJ, Chute HT;  
 XX WPI: 2002-130881/17.  
 DR N-PSDB; ABK13029.  
 XX  
 PT New B7-L-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis.  
 XX  
 Claim 13; Fig 2; 135pp; English.

CC The invention relates to an isolated B7-L-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-L-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of human B7-L<sub>h2</sub>.

XX  
 SQ Sequence 386 AA;

Query Match 96.3%; Score 2000; DB 23; Length 386;  
 Best Local Similarity 99.2%; Pred. No. 4,8e-158;  
 Matches 371; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 13 GSGSGNEVEEGPQNAIVLKGSQARFNCTVSGQKLMALSDMYVLSVRPEPIITNDRF 72  
 DB 13 GSGSGNEVEEGPQNAIVLKGSQARFNCTVSGQKLMALSDMYVLSVRPEPIITNDRF 72  
 QY 73 TSQRYDQGNFTSEMIHNVEPSDSGNIRCSLQNSRLHSAVLYVQVNGELFIPSVNLV 132  
 DB 73 TSQRYDQGNFTSEMIHNVEPSDSGNIRCSLQNSRLHSAVLYVQVNGELFIPSVNLV 132  
 QY 133 AENECVETCLPSHWTRLPDISWELGLVSHSSYFVPEPSDQASVITALTPQSNCTL 192

DB 133 ANEECEVTCLPSSHMTWLPDISMELGLVSHSSYFVEPEPSDIQSAVSIILALTPQSNGL 192  
 QY 193 TCVAATWKSILKARKSATVNLVTIRCPQDTGGGINIPGVLSLPSLGFSLPTWKGVLGLAG 252  
 DB 193 TCVAATWKSILKARKSATVNLVTIRCPQDTGGGINIPGVLSLPSLGFSLPTWKGVLGLAG 252  
 QY 253 TMLLPTCTLTIRCCCRRCGCCGCCRCRRKGRFRIOFQKSEKTEKTE 312  
 DB 253 TMLLPTCTLTIRCCCRRCGCCGCCRCRRKGRFRIOFQKSEKTEKTE 312  
 QY 313 SGNENSGYNSDEQKTTETASLPKSCSSDEPQRNSCGPPHQADQRPAPSHPOASF 372  
 DB 313 SGNENSGYNSDEQKTTETASLPKSCSSDEPQRNSCGPPHQADQRPAPSHPOASF 372  
 QY 373 NLASPEKVSNTTVV 386  
 DB 373 NLASPEKVSNTTVV 386

## RESULT 4

AAU75543  
 ID AAU75543 standard; Protein; 377 AA.

AC AAU75543;

DT 23-APR-2002 (first entry)

DE Human B7-like protein, B7-L<sub>h4</sub>.

XX Human; B7-like protein; B7-L; anti-infectivity; gynaecological;  
 KW antitumor; cytostatic; immunosuppressive; antitubercular; antineoplastic;  
 KW anti-inflammatory; dermatological; antiparasitic; neuroprotective;  
 KW antidiabetic; haemostatic; antithyroid; antileuk; antiallergic;  
 KW antilastmatic; nephrotoxic; antibacterial; vitruoid; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder.

XX Homo sapiens.

PN WO200200710-A2.

PD 03-JAN-2002.

PF 28-JUN-2001; 2001WO-US20719.

PR 28-JUN-2000; 2000US-214512P.

PR 28-NOV-2000; 2000US-0729264.

PA (AMGE-) AMGEN INC.

PI Welher AA, Sarmiento UM, Schultz HJ, Chute HT;

PI WPI: 2002-130881/17.

DR N-PSDB; ABK1331.

PT New B7-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis -

PS Claim 13; Fig 4; 135pp; English.

XX The invention relates to an isolated B7-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-like polypeptide-related disease disorders or  
 CC conditions including reproductive disorders (e.g. infertility, and  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L

CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allensensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia, and  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of human B7-L<sub>h4</sub>.

SQ Sequence 377 AA:

Query Match 72.9%; Score 1514; DB 23; Length 377;

Best Local Similarity 86.2%; Pred. No. 1,3e-117; Mismatches 284; Conservative 12; Mismatches 20; Indels 6; Gaps 2;

QY 13 GSGGNEVIEBQPNATVVKSGQARFNCTVSGKLMALSDWVLSVRPEEITLNDRE 72  
 DB 13 GSGGNEVIEBQPNATVVKSGQARFNCTVSGKLMALSDWVLSVRPEEITLNDRE 72  
 QY 73 TSQRYDQGNFTSMITHNVEPSDSGNIRCSLNSRLHGSAYLTVQYMGELTIPSNLVY 132  
 DB 73 TSQRYDQGNFTSMITHNVEPSDSGNIRCSLNSRLHGSAYLTVQYMGELTIPSNLVY 132  
 QY 133 AENEPECVTCLPSSHMTWLPDISMELGLVSHSSYFVEPEPSDIQSAVSIILALTPQSNGL 192  
 DB 133 AENEPECVTCLPSSHMTWLPDISMELGLVSHSSYFVEPEPSDIQSAVSIILALTPQSNGL 192  
 QY 193 TCVAATWKSILKARKSATVNLVTIRCPQDTGGGINIPGVLSLPSLGFSLPTWKGVLGLAG 252  
 DB 193 TCVAATWKSILKARKSATVNLVTIRCPQDTGGGINIPGVLSLPSLGFSLPTWKGVLGLAG 252  
 QY 253 TMLLPTCTLTIRCCCRRCGCCGCCRCRRKGRFRIOFQKSEKTEKTE 312  
 DB 253 TMLLPTCTLTIRCCCRRCGCCGCCRCRRKGRFRIOFQKSEKTEKTE 312  
 QY 313 SGNENSGYNSDEQKTTETASLP 334  
 DB 313 T---PATIQMKRPQTLPISLP 328

## RESULT 5

ABG28169  
 ID ABG28169 standard; Protein; 463 AA.

AC ABG28169;

DT 18-FEB-2002 (first entry)

DE Novel human diagnostic protein #28160.

XX Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder.  
 XX Homo sapiens.  
 XX

PN W0200175067-A2.  
 XX 11-OCT-2001.  
 PD 30-MAR-2001; 2001WO-US08631.  
 XX 31-MAR-2000; 2000US-0540217.  
 PR 23-AUG-2000; 2000US-0649167.  
 XX (HYSE-) HYSEQ INC.  
 PA Dmanac RT, Liu C, Tang YT;  
 PI WPI: 2001-639362/73.  
 DR N-PSDB; AAS92356.  
 XX  
 PT New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity  
 PS Claim 20; SEQ ID NO 58528; 103pp; English.  
 XX  
 CC The invention relates to isolated polynucleotide (I) and  
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,  
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
 CC and gene mapping, and in recombinant production of (II). The  
 CC polynucleotides are also used in diagnostics as expressed sequence tags  
 CC for identifying expressed genes. (I) is useful in gene therapy techniques  
 CC to restore normal activity of (II) or to treat disease states involving  
 CC (II). (II) is useful for generating antibodies against it, detecting or  
 CC quantitating a polypeptide in tissue, as molecular weight markers and as  
 CC a food supplement. (II) and its binding partners are useful in medical  
 CC imaging of sites expressing (II). (I) and (II) are useful for treating  
 CC disorders involving aberrant protein expression or biological activity.  
 CC The polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. AbG00010-ABG30377 represent novel human  
 CC diagnostic amino acid sequences of the invention.  
 CC Note: The sequence data for this patent did not appear in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at [ftp.wipo.int/pub/published\\_pct\\_sequences](http://ftp.wipo.int/pub/published_pct_sequences).  
 CC  
 XX  
 SO Sequence 463 AA;  
 Query Match 63.8%; Score 1326; DB 22; Length 463;  
 Best Local Similarity 100.0%; Pred. No. 7.3e-102;  
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 49 MMALSDMVLVSVRMEPIITNDRTSGRYDGGNFTSEMIHANEPSDSGNIRCSIONSR 108  
 Db 1 MMALSDMVLVSVRMEPIITNDRTSGRYDGGNFTSEMIHANEPSDSGNIRCSIONSR 60  
 QY 109 LHGSAYLVQVQMGELTIPSVNLVVAENPECVTLPSHWRPLDISWELGLVSHSSYF 168  
 Db 61 LHGSAYLVQVQMGELTIPSVNLVVAENPECVTLPSHWRPLDISWELGLVSHSSYF 120  
 QY 169 VPESDLOASVSIILTPQSNGLTCAVATWSLKARSAVNTLVTRCPDGTGGGINIPG 228  
 Db 121 VPESDLOASVSIILTPQSNGLTCAVATWSLKARSAVNTLVTRCPDGTGGGINIPG 180  
 QY 229 VLSSLPISGFLPTMGVKGJLACTMTLLTPCTLTIRCCCRRCGCCNCCRCFCRR 288  
 Db 181 VLSSLPISGFLPTMGVKGJLACTMTLLTPCTLTIRCCCRRCGCCNCCRCFCRR 240  
 QY 289 KRG 291  
 Db 241 KRG 243  
 RESULT 6

AAU75544  
 ID AAU75544 standard; Protein; 370 AA.  
 XX  
 AC AAU75544;  
 XX  
 DT 23-APR-2002 (first entry)  
 DE Mouse B7-like protein, B7-L<sub>m1</sub>.  
 XX  
 KW Mouse; B7-like protein; B7-L; antifertility; gynaecological;  
 KW antitumour; cytostatic; immunosuppressive; antiarthritic; antineumatic;  
 KW antiinflammatory; dermatological; antiporiatic; neuroprotective;  
 KW antidiabetic; haemostatic; antihypertoid; antileuc; antiallergic;  
 KW antisthmatic; nephrotropic; antibacterial; virucide; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder.  
 XX  
 OS Mus musculus.  
 PN W0200200710-A2.  
 XX  
 PD 03-JAN-2002.  
 XX  
 PF 28-JUN-2001; 2001WO-US20719.  
 XX  
 PR 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX  
 PA (AMGE-) AMGEN INC.  
 PI Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 XX  
 DR WPI: 2002-130861/17.  
 DR N-PSDB; ABX13032.  
 XX  
 PT New B7-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 PS Claim 13; Fig 5; 135pp; English.  
 XX  
 CC The invention relates to an isolated B7-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage), preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and

CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of mouse B7-L<sub>m1</sub>.

XX Sequence 370 AA;

Query Match 44.7%; Score 928.5; DB 23; Length 370;  
 Best Local Similarity 50.0%; Pred. No. 6.4e-69;  
 Matches 194; Conservative 54; Mismatches 105; Indels 35; Gaps 5;

QY 5 LLTPVAVSGSGNEVEYEQNAVTVKGSQARNCVSGSKMLIMLSDMYLVSRPME 64  
 DB 12 LVLLAQLTASSSYQIIEBPQNTVLKDEAHNCVTGTGKMLMTLQNMVSLTTOG 71  
 QY 65 PITNDRFTSQRDQGNFTSEMIHNVPSDSGNIRCSLONSRLHGSAYLVYVWGELE 124  
 DB 72 PITNDRFTSQRDQGNFTSEMIHNVPSDSGNIRCSLONSRLHGSAYLVYVWGELE 131  
 QY 125 IPSVNLVAENEPCEVTCPLSHWTRLPDISMELGLVSHSSYYFVPEPSDLQSAVSIATL 184  
 DB 132 IPSVNLVAENEPCEVTCPLSHWTRLPDISMELGLVSHSSYYFVPEPSDLQSAVSIATL 191  
 QY 185 TPQSNGLTCAVATKMKARKSATVNLVYIRCPDQGGGINIPVLSLPSGFSPTWG 244  
 DB 192 TPQSNGLTCAVATKMKARKSATVNLVYIRCPDQGGGINIPVLSLPSGFSPTWG 239  
 QY 245 KVGIGLAGMGLLPPTCTLTIRCCCRRCGCCGCCRCRRKGRFIOQ---KKSE 301  
 DB 240 ILLAAVAFBLLLVLLVLIIFCC-----CASRRKESTYQNELRKSA 284  
 QY 302 KEKTNK---ETETSGENSGVNSDEQKTTETASLPKSCSSDPEORNSGCPPHQAD 358  
 DB 285 NMRTNKADETKLKSKEVGYSSDEAKAQAATASLPKSAVELEPKRSSSL--PYQELN 342  
 QY 359 QRPRAHPQASFNLASPEXSNNTTV 386  
 DB 343 KHOPGPAHPRVSEDIASPOKRVNTLV 370

RESULT 7  
 ID AAU75547 standard; Protein; 631 AA.

XX AAU75547;

DT 23-APR-2002 (first entry)

XX Rat B7-like protein, B7-1.

XX Rat; B7-like protein; B7-L; antiinferility; gynaecological;  
 KW antitumour; cytostatic; immunosuppressive; antiallergic; antineumatic;  
 KW antiinflammatory; dermatological; antipsoriatic; neuroprotective;  
 KW antidiabetic; haemostatic; antithyroid; antituber; antiallergic;  
 KW antiaesthetic; nephrotoxic; antibacterial; vitruode; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder.

XX Ratus rattus.

PN WO200200710-A2.

PD 03-JAN-2002.

PF 28-JUN-2001; 2001WO-US20719.

XX 28-JUN-2000; 2000US-214512P.

PR 28-NOV-2000; 2000US-0729264.

XX (AMGE-) AMGEN INC.

PI Weicher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 XX WPI; 2002-130881/17.  
 DR  
 XX  
 XX New B7-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis

XX Disclosure; Fig 8; 135pp; English.

CC The invention relates to an isolated B7-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis) vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of rat B7-L.

XX Sequence 631 AA;

Query Match 28.3%; Score 587.5; DB 23; Length 631;  
 Best Local Similarity 26.4%; Pred. No. 3e-40;  
 Matches 170; Conservative 47; Mismatches 112; Indels 315; Gaps 10;

QY 5 LLTPVAVSGSGNEVEYEQNAVTVKGSQARNCVSGSKMLIMLSDMYLVSRPME 25  
 DB 12 LVLLAQLTASSSYQIIEBPQNTVLKDEAHNCVTGTGKMLMTLQNMVSLTTOG 71  
 QY 26 -----NATVKGSAQARENCTVSGKMLIMLSDMYLVSRPMEPTITNDRF---- 72  
 DB 72 VGVYKSKVRNTVTLKDEAHNCVTGTGKMLMTLQNMVSLTTOGPTITNDRKAL 131  
 QY 73 -----TSQRDQGNFTSEMI 88  
 DB 132 LSCDYKFCSEFOSIHRITVQKHKDKMVLVSGVEVPKRYKNTVYASVNSTDSFISELI 191  
 QY 89 IHANPEPSDSGNIRCSLONSRLHGSAYL----- 115  
 DB 192 IHVQPSDSGSGVQCSLONSHGFGSAFLSVQYDIANNYSFLLGLLSDRGTYTCVQVR 251  
 QY 116 -----TVQVWGELEFIPSVNLVAENEPCEVTCPLSHWTRLPDISMELGLVSHS 164  
 DB 252 EGGSYVVKHLTTVVWGLTNLIPSNMLIVTGEBCNVTCAVWGTSPLDISMELEVSVSHS 311

QY 165 -----SYFVPEPSDQ 176  
 Db 312 LSVADPEPTNTEYGNPSADIKRTCFASGGPKPRLMLNGRELNSYNLFEPGNEM 371  
 QY 177 SAVSIALTPQSNGLTLCVATWKLKARKSATVNL-----211  
 Db 372 RVLSTVLDLTPGLNGTLCVAVELKDLQASKSLVTNLGINTTISDPESELTYTSSOLDPNA 431  
 QY 212 -----TVIRCPDQDGGGINIPGVSLSPLSGFSPTMGKVGIGL 250  
 Db 432 TYDHFIDCFIEYGAHVSQNTVYQPPD-----STGECPALPTVAIILLAY 479  
 QY 251 AGTML-----TPP 259  
 Db 480 AFSILLITVLLITFWKPPEDPDEKQTVFPAWAGPAVAKAIIFFAITVAVIAIA 539  
 QY 260 CTLVIRCCRRRCGCCGCCRCFCRRRRGRFIOQ-KKSEKTKN---ETETESGN 315  
 Db 540 IATIIFFCCCSR-----REKEESTYONEIRKSANMRTNKADPETKLSGK 585  
 QY 316 ENSGYNSEDQKTEETASLPKSCSESDPEQRNNSCGPPHORADQ 359  
 Db 586 ENYSSDDECTVFRRCFRRRNASRETNKNLIGPVEAARD 629  
 RESULT 8  
 AAU75545  
 ID AAU75545 standard; Protein; 270 AA.  
 AC AAU75545;  
 DT 23-APR-2002 (first entry)  
 DE Mouse B7-1-like protein, B7-L<sub>m2</sub>.  
 XX  
 XX Mouse; B7-1-like protein; B7-L; antiinfertility; gynaecological;  
 KM antitumor; cytostatic; immunosuppressive; antirheumatic;  
 KM antiinflammation; dermatological; antiproliferative;  
 KM antidiabetic; haemostatic; antihypertensive; antiallergic;  
 KM antistimulant; nephrotoxic; antibacterial; virucide; tumour; cancer;  
 KM reproductive disorder; graft versus host disease; autoimmune disease;  
 KM toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KM endocrinopathy; lymphoproliferative disorder.  
 OS  
 XX Mus musculus.  
 PN MO200200710-A2.  
 PD 03-JAN-2002.  
 PE 28-JUN-2001; 2001MO-0520719.  
 PR 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 PA (AMGE-) AMGEN INC.  
 PI Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 DR WPI: 2002-130881/17.  
 DR N-PSDB; ABR13033.  
 XX  
 PT New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 XX  
 PS Claim 13: Fig 6; 135pp; English.  
 CC The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-1-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and

CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular stenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allodermatitis due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of mouse B7-L<sub>m2</sub>.  
 XX  
 SQ Sequence 270 AA:

Query Match 27.9%; Score 579.5; DB 23; Length 270;  
 Best Local Similarity 34.3%; Pred. No. 4.7e-40;  
 Matches 133; Conservative 46; Mismatches 74; Indels 135; Gaps 5;

QY 5 LITVPAVSSGSGNEVEEPONAVILKSGQARFNTVSGKMLIMWALSDMVLVSVRME 64  
 Db 12 LVILAQLTSSGSSYQITIEPQVNTYVLDKSEAHFNCTVTHGKMLMTNLQKMYLSLTQOG 71  
 QY 65 PTTNDRTSQRDQGNFTSEMIHNVPPSDSGNIRCSLQNSRLHGSAYLVTVYMGELF 124  
 Db 72 PTTNRTFTYASVNSDPSISLIIHDVQPSDGSVQCSLQNSHGFSAFLSVQ-----125  
 QY 125 IPSVNLVAENPECVTCLPSHWTPLPDISMELGLVSHSSYFFPEPSDQASVITLAL 184  
 Db 126 -----125  
 QY 185 TPQSNGLTLCVATWKLKARKSATVNLVIRCPDQDGGGINIPGVSLSPLSGFSLPTWG 244  
 Db 126 -----DSTGECPALPTVA 139  
 QY 245 KVLGLAGTMLTPCTLTIRCCCRRCGCCGCCRCFCRRRRGRFIOQ---KKSE 301  
 Db 140 IILLAVAFSLILLIIVLIIFCCC-----CASRREKEESTYQNEIRKSA 184  
 QY 302 KEKTKN---ETETESGNENSGYNSEDQKTEETASLPKSCSESDPEQRNNSCGPPHORAD 358  
 Db 185 NMTNKADPETKLSGKENVGYSSDEAKNAQFASLPPKSAEVSILPEKRSPL--PYQELN 242  
 QY 359 GRPPASHPOASFNLASPEKSVNTTV 386  
 Db 243 KHQPGATHPRVSPDIASQKRVNTLV 270

RESULT 9  
 AAU75546  
 ID AAU75546 standard; Protein; 223 AA.  
 AC AAU75546;  
 XX

DT 23-APR-2002 (first entry)  
 XX  
 DE Mouse B7-1-like protein, B7-L<sub>m3</sub>.  
 XX  
 KW Mouse; B7-1-like protein; B7-L; antifertility; gynaecological;  
 KW antitumour; cytostatic; immunosuppressive; antiarthritic; antileukemic;  
 KW antinflammatory; dermatological; antiposrotic; neuroprotective;  
 KW antidiabetic; haemostatic; antihypertensive; antileukemic; antiallergic;  
 KW antischistosomal; antiparasitic; antibacterial; virucide; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder.  
 XX  
 OS Mus musculus.  
 XX  
 PN MO200200710-A2.  
 XX  
 PD 03-JAN-2002.  
 XX  
 PF 28-JUN-2001; 2001MO-US20719.  
 XX  
 PR 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX  
 PA (AMGE-) AMGEN INC.  
 XX  
 PI Welcher AA, Samlento UM, Schultz HJ, Chute HT;  
 XX WPI: 2002-130881/17.  
 DR N-PSDB; ABK13034.  
 XX  
 PT New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis -  
 XX  
 PS Claim 13; Fig 7; 135pp; English.  
 XX  
 CC The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-1-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility, and  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allosensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions.  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the amino acid sequence of mouse B7-L<sub>m3</sub>.

XX  
 SQ Sequence 223 AA;  
 Query Match 24.0%; Score 498; DB 23; Length 223;  
 Best Local Similarity 31.2%; Pred. No. 2.2e-33;  
 Matches 120; Conservative 41; Mismatches 48; Indels 176; Gaps 6;  
 QY 5 LITVPEAVGSGSGNEVIEGPQNAITVLSQARFRCVYSGKLIIMALSDMYLVSVRPM 64  
 DB 12 LVIAQLFLASSSSQIEGFPQNTVLKDSFAHNCVTHGKMLMTNQMVLNQLTGG 71  
 QY 65 PIITNDRFTSORDYDGNFTSEMIINAVPSDSGNIRCSIQNSRLGSAITVQVNGELF 124  
 DB 72 PIITNDRFTYASVNSTSFISELIHDVQPSDSGVCSLQNSHGFSAFLSVQ----- 125  
 QY 125 IPSVNLVAENEPCEVYCLPSHMTRLPDISMELGLVSHSSYFVEPESDQSAVSLAL 184  
 DB 126 -----ESTY-----ONEI----- 133  
 QY 185 TPQSGTGLTCVATWKSLSKRSATVNLTVRCPDQDGGINIPGLVSLPSLGFSLPTWG 244  
 DB 134 -----RKSANM----- 139  
 QY 245 KVLGLAGTMLLPCTGLTTRCCCRRCGCCMCRCRCRKRGRFRIQFKSKSEK 304  
 DB 140 -----R 140  
 QY 305 TNK---ETTESGNGENSGYNSDEKTTETASLPKSCSSDPQRNSSCGPPHORADPR 361  
 DB 141 TNKADPETKLKSGKENYSGSDKAQAOTASLPKSAEVSLEPKRSSL--PIQELNKHQ 198  
 QY 362 PRPASHPOASEFNLASPEKVSNTTVV 386  
 DB 199 PGATPHRVSFDIASPQKVRNVTLV 223  
 RESULT 10  
 ID AAB81925 standard; protein; 404 AA.  
 XX  
 AC AAB81925;  
 XX  
 DT 15-JUN-2001 (first entry)  
 XX  
 DE Extracorporeal circulation material receptor protein.  
 XX  
 KW Extracorporeal circulation; carbonyl stress product; receptor;  
 KW diabetes; vascular lesion; excretory dysfunction.  
 XX  
 OS Unidentified.  
 XX  
 PN WO200118060-A1.  
 XX  
 PD 15-MAR-2001.  
 XX  
 PF 08-SEP-2000; 2000WO-JP06172.  
 XX  
 PR 08-SEP-1999; 99JP-0254463.  
 XX  
 PA (TORA) TORAY IND INC.  
 XX  
 PI Shimitzu S, Kubota M, Akiyama H, Usui M;  
 XX WPI: 2001-290314/30.  
 DR  
 XX  
 PT Material for extracorporeal circulation, applicable in selective  
 PT elimination of diabetic complication factors such as carbonyl stress  
 PT products caused by abnormally promoted carbonyl stress from excretory  
 PT dysfunction in vascular lesions -  
 XX  
 PS Claim 1; Page 31-32; 36pp; Japanese.  
 XX  
 CC The present invention describes a material for extracorporeal circulation



CC which is made from a water-insoluble carrier immobilized with a protein  
 CC having the sequence shown here. The materials of the invention, including  
 CC adsorbents, are for extracorporeal circulation, which are applicable in  
 CC the selective elimination of diabetic complication factors from a body  
 CC fluid, and are therefore useful in treating vascular lesions like  
 CC arteriosclerosis due to carbonyl stress products caused by abnormally  
 CC promoted carbonyl stress from excretory dysfunction.

XX Sequence 404 AA:

Query Match 7.3%; Score 151; DB 22; Length 404;  
 Best Local Similarity 23.3%; Pred. No. 0.00035;

Matches 90; Conservative 38; Mismatches 112; Indels 146; Gaps 19;

QY 9 PEAVSGSGNEVIEGPONATVILKSGQARFNCVTSQG--WKLIMMALSDMVVLSVRMPMP 65  
 DB 124 PEIVDSAS--ELTAGVFN-----KVGTCVSEGSYPAGTISWHLDG-----KP 163  
 QY 66 IITNDRFTS-----QRYDGGNFT--SEMITHNVEPSDSGNIR-----CSLQNSRLHGSAY 114  
 DB 164 LVPNEGVSVKQGTNRHPTGLFTLOSELN--VTPARGDPRPTSCSFSPGLPRHRAL 220  
 QY 115 LTVQVNGELFIP---SVNLVVAENEP-----CEVTCLPISHWTLPDISWE 156  
 DB 221 RTAPIQPRVMEPVPLEVQLVY---EPEGGAVALPGTWTITCEVPAQPS-----PQIHWM 272  
 QY 157 LGLVSHSSYFYPEPSDLQSAVSIILATPQNSGTLTCVAIWKSLKARKSATVNLTVIRC 216  
 DB 273 KD-----GVPLPLPPSPVLIILPEIQPDQGTYSVATFHSHPGSRANVSISIE- 322  
 QY 217 PDGTGGGINIPGVLSLPLGFSLPTWGVGGLAGTMLT-----PTCLITTRCCCC 269  
 DB 323 PGEEG-----PTAGSVGGSGGLGTALALGILGLGTALLIGVILM 363  
 QY 270 RRRCCGCCNCCRCFCRCRRKRGFRIOFKKSEKKT--NKETETESGNGNSGNSDEQKT 327  
 DB 364 QRR-----QRRGERKAPENQEEEBERALELN----- 389  
 QY 328 TETASLPKSCSSDPEQRNSCGPP 353  
 DB 390 -----QSEPEPAGESSTGCP 404

RESULT 11

ID AAE3219 standard; Protein: 404 AA.

AC AAE3219;

XX 27-AUG-2002 (first entry)

DE Human receptor for advanced glycosylation end product (RAGE) protein.

KW Human; Receptor for advanced glycosylation end product; RAGE; cardiact;  
 KW tissue growth; neointimal formation; blood vessel; restenosis; diabetes;  
 KW myocardial infarction; angioplasty; peripheral vascular surgery; angina;  
 KW transgenic animal; acute thrombotic stroke; venous thrombosis.

OS Homo sapiens.

XX WO200230889-A2.

XX 18-APR-2002.

XX 12-OCT-2001; 2001WO-US32036.

XX 13-OCT-2000; 2000US-0687528.

XX (UYCO ) UNIV COLUMBIA NEW YORK.

XX Stern DM, Schmidt A, Marso S, Topol E, Lincoff AM;

XX WPI; 2002-426260/45.

DR N-PSDB; AAD36952.

XX Inhibiting new tissue growth or neointimal formation in blood vessels  
 PT of subject suffering from diabetes, stroke and preventing restenosis,  
 PT comprising administering inhibitor of receptor for advance glycation end  
 PT product

PS Disclosure; Page 16; 43pp; English.

CC The invention relates to a method for inhibiting new tissue growth or  
 CC neointimal formation in blood vessels in a subject that has experienced  
 CC blood vessel injury and preventing exaggerated restenosis in a diabetic  
 CC subject. The method comprises administering an inhibitor of receptor for  
 CC advanced glycation/lycosylation end product (RAGE), so as to inhibit new  
 CC tissue growth or neointimal formation in subject's blood vessels and  
 CC preventing restenosis in the subject. The method is useful for inhibiting  
 CC new tissue growth or neointimal formation in blood vessels in a subject  
 CC like non-human animal, a transgenic non-human animal or a human suffering  
 CC from diabetes, acute thrombotic stroke, venous thrombosis, unstable  
 CC angina, myocardial infarction, abrupt closure following angioplasty or  
 CC stent placement, or thrombosis as a result of peripheral vascular surgery  
 CC whether a compound inhibits for preventing restenosis and for determining  
 CC subject. The present sequence is human receptor for advanced  
 CC glycosylation end product (RAGE) protein.

XX Sequence 404 AA:

Query Match 7.3%; Score 151; DB 23; Length 404;  
 Best Local Similarity 23.3%; Pred. No. 0.00035;

Matches 90; Conservative 38; Mismatches 112; Indels 146; Gaps 19;

QY 9 PEAVSGSGNEVIEGPONATVILKSGQARFNCVTSQG--WKLIMMALSDMVVLSVRMPMP 65  
 DB 124 PEIVDSAS--ELTAGVFN-----KVGTCVSEGSYPAGTISWHLDG-----KP 163  
 QY 66 IITNDRFTS-----QRYDGGNFT--SEMITHNVEPSDSGNIR-----CSLQNSRLHGSAY 114  
 DB 164 LVPNEGVSVKQGTNRHPTGLFTLOSELN--VTPARGDPRPTSCSFSPGLPRHRAL 220  
 QY 115 LTVQVNGELFIP---SVNLVVAENEP-----CEVTCLPISHWTLPDISWE 156  
 DB 221 RTAPIQPRVMEPVPLEVQLVY---EPEGGAVALPGTWTITCEVPAQPS-----PQIHWM 272  
 QY 157 LGLVSHSSYFYPEPSDLQSAVSIILATPQNSGTLTCVAIWKSLKARKSATVNLTVIRC 216  
 DB 273 KD-----GVPLPLPPSPVLIILPEIQPDQGTYSVATFHSHPGSRANVSISIE- 322  
 QY 217 PDGTGGGINIPGVLSLPLGFSLPTWGVGGLAGTMLT-----PTCLITTRCCCC 269  
 DB 323 PGEEG-----PTAGSVGGSGGLGTALALGILGLGTALLIGVILM 363  
 QY 270 RRRCCGCCNCCRCFCRCRRKRGFRIOFKKSEKKT--NKETETESGNGNSGNSDEQKT 327  
 DB 364 QRR-----QRRGERKAPENQEEEBERALELN----- 389  
 QY 328 TETASLPKSCSSDPEQRNSCGPP 353  
 DB 390 -----QSEPEPAGESSTGCP 404

RESULT 12

ID AAU77543 standard; Protein: 404 AA.

AC AAU77543;

XX 05-JUN-2002 (first entry)

DE Human receptor for advanced glycosylation end product (RAGE).

KW Receptor for advanced glycation end product; RAGE; receptor;  
 KW amyloid beta peptide; blood brain barrier; neurovascular stress;

KW cerebral vasoconstriction suppressor; cerebral blood flow enhancer;  
 KW cerebral amyloid angiopathy; transgenic animal; amyloid beta precursor;  
 KW Alzheimer's disease; Down's syndrome; head trauma; stroke; human.  
 XX  
 OS Homo sapiens.  
 FN WO200214519-A1.  
 XX  
 XX 21-FEB-2002.  
 PD  
 XX 14-AUG-2001; 2001WO-US25416.  
 PF  
 XX 14-AUG-2000; 2000US-0638648.  
 PR  
 XX (UYCO ) UNIV COLUMBIA NEW YORK.  
 PA  
 PI Stern DM, Schmidt AM, Van SD, Zlokovic B;  
 XX  
 XX WPI; 2002-257610/30.  
 DR N-PSDB; ABK10836.  
 XX  
 XX Ameliorating neurovascular stress and decreasing cerebral  
 PT vasoconstriction in subject suffering from chronic/acute cerebral  
 PT amyloid angiopathy, by administering inhibitor of receptor for advanced  
 PT glycation endproduct -  
 XX  
 XX Disclosure: Page 16; 68pp; English.  
 PS  
 XX The invention describes a method of ameliorating neurovascular stress,  
 CC and decreasing cerebral vasoconstriction in subject suffering from  
 CC chronic or acute cerebral amyloid angiopathy, comprising administering  
 CC an inhibitor (I) of receptor for advanced glycation end product (RAGE).  
 CC (I) inhibits transcytosis of amyloid beta peptides across blood-brain  
 CC barrier, thus decreasing cerebral vasoconstriction and increasing  
 CC cerebral blood flow. (I) is useful for treating amyloid angiopathy in a  
 CC subject, decreasing cerebral vasoconstriction in a transgenic non-human  
 CC animal (preferably, transgenic mouse overexpressing mutant human amyloid  
 CC beta precursor protein) or a human, suffering from chronic or acute  
 CC cerebral amyloid angiopathy, preferably, Alzheimer's disease, and for  
 CC ameliorating neurovascular stress comprising cerebral amyloid angiopathy  
 CC in a subject, where the neurovascular stress is caused by Alzheimer's  
 CC disease, aging, Down's syndrome, head trauma or stroke. This is the  
 CC amino acid sequence of human receptor for advanced glycation end  
 CC product (RAGE) described in the invention.  
 CC  
 XX  
 XX Sequence 404 AA:  
 SQ  
 Query Match 7.3%; Score 151; DB 23; Length 404;  
 Best Local Similarity 23.3%; Pred. No. 0.00035;  
 Matches 90; Conservative 38; Mismatches 112; Indels 146; Gaps 19;  
 QY 9 PEAVGSGNEVEIGPONATVYKSGQARFNCVSG---WKLIMALSDMVLYSVRPMR 65  
 DB 124 PEIVDSAS--ELTAGVFN-----KVGTCVSEGSYPAGTISWHLDG-----KP 163  
 QY 66 IITNDRFTS---ORYDGGNFT--SEMIHNPESDSGNIR---CSLQNSRLHGSAY 114  
 DB 164 LVPNKGVSVKEQTRRHPTGLFTLQSELM---VTPARGDPRPTEFCSPGLPRHRAL 220  
 QY 115 LVYVWVGELFIP---SVNLVVAENR-----CEVTCPSHWTRLPDISWE 156  
 DB 221 RRAPIPRWEPVPLEEVLVY--EPGGAVALPGGTVTLTCEVPAQPS-----PQIHMM 272  
 QY 157 LGLLVSHSYEYVPEPSDQASVITALTPOSGNTLTCVATKSKARKSATVNLTVIRC 216  
 DB 273 KD-----GYPLPLPSPVILLPEIGPOGQITSCAHTSHSGPQSRVASTISIE 322  
 QY 217 PODTGGGINTPGVLSPLSGSLPTWAGVYGLACTMLT-----PTCLTTLRCCCC 269  
 DB 323 PREG-----PTAGSVGSGGLGTLTALALGILGLCTALLIGVILM 363  
 QY 270 RRCGCCGNCRCRCRCRRRGRIFORFKSEKMT--NKETETESGNSGVNSDEQKT 327

DB 364 QRR-----QRGERKAPENQEEBEEBALN----- 389  
 QY 328 TETASLPKSCSSDPEQNSSCGPP 353  
 DB 390 -----QSEPEAGESSSTGPP 404  
 RESULT 13  
 ID AAM48745  
 ID AAM48745 standard; protein; 404 AA.  
 AC AAM48745;  
 XX  
 XX 02-APR-2002 (first entry)  
 DT  
 XX Human RAGE protein SEQ ID NO 1.  
 DE  
 XX  
 KW Human; RAGE; receptor for advanced glycated endproduct; receptor;  
 KW antidiabetic; neuroprotective; cytosolic; antiinflammatory; vasotropic;  
 KW nephrotropic; dermatological; arteriosclerotic; nontropic; diabetes;  
 KW Alzheimer's disease; cancer; inflammation; kidney failure;  
 KW systemic lupus; nephritis; erectile dysfunction; atherosclerosis.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200192892-A2.  
 XX  
 XX 06-DEC-2001.  
 XX  
 XX 30-MAY-2001; 2001WO-US17447.  
 XX  
 XX 30-MAY-2000; 2000US-207342P.  
 XX 05-MAR-2001; 2001US-0799152.  
 XX  
 XX (TRAN-) TRANS TECH PHARMA.  
 XX  
 XX Shabazz M;  
 XX  
 XX WPI; 2002-114372/15.  
 PT Detecting a receptor for advanced glycated endproducts (RAGE)  
 PT modulators, for treating e.g., cancer, diabetes or inflammation,  
 PT comprises measuring the amount of bound anti-RAGE antibody -  
 XX  
 XX Claim 1; Fig 2; 49pp; English.  
 PS  
 XX The invention relates to detecting receptor for advanced glycated  
 CC endproducts (RAGE) modulators comprises determining the amount of RAGE  
 CC protein or its fragment bound to the pre-adsorbed ligand by measuring the  
 CC amount of anti-RAGE antibody bound to the solid surface. The method is  
 CC useful for rapid, high-throughput identification of compounds that  
 CC modulate RAGE. The compounds are useful for treating symptoms of diabetes  
 CC and symptoms of diabetic late complications, amyloidosis, Alzheimer's  
 CC disease, cancer, inflammation, kidney failure, systemic lupus nephritis  
 CC or inflammatory lupus nephritis, erectile dysfunction and  
 CC atherosclerosis.  
 CC  
 XX  
 XX Sequence 404 AA:  
 SQ  
 Query Match 7.3%; Score 151; DB 23; Length 404;  
 Best Local Similarity 23.3%; Pred. No. 0.00035;  
 Matches 90; Conservative 38; Mismatches 112; Indels 146; Gaps 19;  
 QY 9 PEAVGSGNEVEIGPONATVYKSGQARFNCVSG---WKLIMALSDMVLYSVRPMR 65  
 DB 124 PEIVDSAS--ELTAGVFN-----KVGTCVSEGSYPAGTISWHLDG-----KP 163  
 QY 66 IITNDRFTS---ORYDGGNFT--SEMIHNPESDSGNIR---CSLQNSRLHGSAY 114  
 DB 164 LVPNKGVSVKEQTRRHPTGLFTLQSELM---VTPARGDPRPTEFCSPGLPRHRAL 220  
 QY 115 LVYVWVGELFIP---SVNLVVAENR-----CEVTCPSHWTRLPDISWE 156

DB 221 RAFLPIOPRWEVPEEVLQVY--EPEGAVAPGSGTVLTCVEVPAQS-----PQIHWM 272  
 QY 157 LGLVSHSSSYVPEPSDLSQASVITLTPQNSGTLVCAVTKSLKARSAVNLTVIRC 216  
 DB 273 KD-----GVPLPLPSPVLLIPEIFPDQGTYSVATHSHGPOSRAVVISITIE- 322  
 QY 217 PODTGGGINIPGVLSLPSLGFSLPTWKGVLGTLGTLMTLT-----PTCTLTTRCCC 269  
 DB 323 PSEEG-----PTAGSVGGSGGLTALALGILGGLTALLGVILM 363  
 QY 270 RRRCCGNCNCCHCCFCRCRRKGRFRIOFQKSEKKT--NKELETSGNENSGYNDEOKT 327  
 DB 364 QRR-----ORGEERRAPNOEEERAEIN----- 389  
 QY 328 TETASLPPKSCSSDPEORNSCGPP 353  
 DB 390 -----QSEPEAGESSTGCP 404

RESULT 14  
 AAM81030  
 ID AAM81030 standard; Protein: 1496 AA.  
 AC AAM81030;  
 XX  
 DT 10-MAY-1999 (first entry)  
 XX  
 DE Melanoma associated antigen MG50.  
 KW MG50; melanoma gene-50; melanoma associated antigen; human;  
 KW T cell epitope; cancer; lung cancer; rhabdomyosarcoma; diagnosis;  
 KW therapy; vaccine.  
 OS Homo sapiens.  
 XX  
 PN W0985513-A1.  
 XX  
 PD 10-DEC-1998.  
 XX  
 PF 04-JUN-1998; 98WO-US11533.  
 XX  
 PR 06-JUN-1997; 97US-0870941.  
 XX  
 PA (REGC ) UNIV CALIFORNIA.  
 PA (URS-) UNIV SOUTHERN CALIFORNIA.  
 PL Deans RJ, Kap-Mitchell J, Minev BR, Mitchell MS;  
 DR WPI: 1999-080820/07.  
 DR N-PSDB; AAV99922.  
 XX  
 PS Claim 1; Page 45-49; 79pp; English.  
 XX  
 CC This polypeptide comprises a portion of a new human melanoma  
 CC associated antigen, designated MG50. The amino acid sequence was  
 CC deduced from a cDNA clone (see AAV99922) isolated from melanoma  
 CC cell line MSW M-1 cDNA by subtractive hybridisation. The 5' region  
 CC of MG50 cDNA was not obtained. MG50 mRNA has been detected in  
 CC melanoma, lung carcinoma and rhabdomyosarcoma cells, foetal brain,  
 CC foetal heart and human placenta. The invention also provides T  
 CC cell epitopes (see AAM81031-54) from MG50, including cytotoxic and  
 CC helper T cell epitopes, antibodies that specifically bind to MG50  
 CC or an MG50 T cell epitope, recombinant vectors, and antigen  
 CC presenting cells. Methods are provided for identifying an MG50  
 CC melanoma associated antigen in an individual and for identifying an  
 CC immune response against an MG50 melanoma associated antigen, as  
 CC well as methods of stimulating T lymphocytes that are reactive  
 CC against cancer cells expressing MG50 and for treating an individual

CC having cancer cells that express MG50. The products and methods  
 CC can be used for the detection, treatment and prevention of  
 CC MG50-expressing cancers, e.g. melanomas, lung cancer or  
 CC rhabdomyosarcoma.  
 XX  
 SQ Sequence 1496 AA;  
 Query Match 6.5%; Score 135; DB 20; Length 1496;  
 Best Local Similarity 25.0%; Pred. No. 0.041;  
 Matches 73; Conservative 36; Mismatches 127; Indels 56; Gaps 15;

QY 13 GSGSGNEVIEGPONATVLKGSQARFNCTVS-QGKLIIMALSDMVVSVPMPEITNDR 71  
 DB 354 GSPARPFVIVIQPQNTVELVGSVTLKESATGHPPRRISWTRGRTRLPVPRNNIPS-- 411  
 QY 72 FTSRTOGCFNFTSEMIIHNVEPSDSGNIRCSLONS--RLHGSAYLVTVQMGELFIPSVN 129  
 DB 412 -----GG-----LYIONVVGDSGSEVACASATNNIDSVHATAFTIVQALPQFTVPD 458  
 QY 130 LVVAENPECEVTCLEPSHMTRLPDISW-ELGLVSHSSSYVPEPSDLSQASVITLALTPQS 188  
 DB 459 RVVIEGQTVDFQC-EAKGNPPEVYIATMTKGSQSLSVDRRHVLSSGTLR--ISGVALHDQ- 514  
 QY 189 NGTLVCAVATWKSILKARSAVNLTV-----IRCPQDT-----GGGINIPGVLSLPSL 236  
 DB 515 -GQYECQAV--NIIGSKVVAHLTVQPRVPPVFPASIPSDITVEGVANVQLP-----CSSQ 566  
 QY 237 GFSLP--TWGKVGIGL--AGTMLTPTCTLT-----RCCCRRCRG 275  
 DB 567 GEPPALTMNKDGQVYESGRFHSPEGFLLINDVGPADAGRECVARNRTIG 618

RESULT 15  
 AAY70469  
 ID AAY70469 standard; Protein: 1496 AA.  
 AC AAY70469;  
 XX  
 DT 21-JUN-2000 (first entry)  
 XX  
 DE Human p53 target molecule, PRG2 protein.  
 XX  
 KW PRG2; p53 target; human; modulate; cell proliferation; immunomodulatory;  
 KW chromosome 2p24.3; cytostatic; gene therapy; tumour cell; inducer;  
 KW diagnosis; therapeutic; proliferative disease; cell cycle arrest; cancer;  
 KW treatment; apoptosis; knockout animal; cancer susceptibility; dxn; hpxn;  
 KW peroxidasin; redox-regulation; reactive oxygen species; ROS.  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FH Peptide 1..29  
 FT /label= Signal-peptide  
 FT Protein 30..1496  
 FT /note= "Mature\_human\_PRG2\_protein  
 FT /note= "Homologue of Drosophila peroxidasin, dxpn"  
 PN W0200012526-A1.  
 XX  
 PD 09-MAR-2000.  
 XX  
 PF 27-AUG-1999; 99WO-US19551.  
 XX  
 PR 28-AUG-1998; 98US-0098251.  
 XX  
 PA (UYPR-) UNIV PRINCETON.  
 PI Horikoshi N, Shenk T;  
 XX  
 DR WPI: 2000-246724/21.  
 DR N-PSDB; AA251671.  
 XX  
 PT New p53-inducible isolated nucleic acid molecule including open reading

PT frame encoding human homolog of Drosophila melanogaster peroxidase,  
 PT useful e.g. in detection and treatment of cancer -

PS Disclosure; Page 71-74; 83pp; English.

XX  
 CC The present sequence is the protein encoded by PRG2 gene, that is  
 CC upregulated in response to induction of p53 activity in human colon  
 CC cancer EBI cells. This sequence is the human homologue (hpxn) of  
 CC Drosophila peroxidase gene dpxn, that is expressed in heart, placenta,  
 CC spleen, ovary and intestines. PRG2 is involved in p53-mediated growth  
 CC suppression pathways and plays a role in redox regulation. It is a  
 CC haem-peroxidase that increases the intracellular content of reactive  
 CC oxygen species (ROS). They are potential targets of p53 regulatory  
 CC activity and are useful for modulation of cellular proliferation. PRG2  
 CC gene is localised to human chromosome 2p24.3. The PRG target molecules  
 CC have cytostatic and immunomodulatory activity. PRG polynucleotides,  
 CC proteins and antibodies are useful as diagnostic and therapeutic agents  
 CC for detection and treatment of cancer and other proliferative diseases.  
 CC The gene/cDNA may be used for gene therapy, to restore a gene function  
 CC downstream of p53, that cannot be activated in the p53-deficient tumour  
 CC cell. Antibodies can be used as inducers of cell cycle arrest and/or  
 CC apoptosis. The DNA sequences can be used to generate 'knockout' animals  
 CC as a model of cancer susceptibility.

SQ Sequence 1496 AA;

Query Match

6.5%; Score 135; DB 21; Length 1496;

Best Local Similarity 25.0%; Pred. No. 0.041;

Matches 73; Conservative 36; Mismatches 127; Indels 56; Gaps 15;

QY 13 GSGSGNEVIEGPNATVILKGSQARFNCTVS--QGMKLIMMALSDMVILSVRPMPEITNDR 71  
 DB 354 GSPARPTFVIOQNTVEVLVGSVLTLECSATGHPPRISMTRGDRPLVDPRVNITPS-- 411  
 QY 72 FTSQRYDGGNTSMITHNRPDSGNIRCSLONS--RLGSAVITVQVMGELIPSVN 129  
 DB 412 -----GG-----LYIQNVVQSGSGEYACSAIINNDSVHATAFITVQALPQFTVTPOD 458  
 QY 130 LVVAENEPCEVTCPLPSHWTRLPDISM-ELGLIVSHSYFVPEPSDLOSASVILATPQS 188  
 DB 459 RVIEGQVVDPOC-EAKGNPPVIAWTKGSGLSVDRRHVLSSGTLR--ISGVALHDQ- 514  
 QY 189 NGLTCVATWKSILKARKSATVNLIV-----IRCPQDT-----GGINIPGVLSLPSL 236  
 DB 515 -GQYECQAV--NIISQKVAHLFVQPRVTFVFASIPSDTVEVGANYQLP-----CSSQ 566  
 QY 237 GFSLP--TWGKVGGLT--AGTMLLPPTCTLPT-----RCCCCRRCOG 275  
 DB 567 GEPEPATVWKNKDGVOVTEGKHFHISPEGLIINDVGPADAGRICEVARNITIG 618

Search completed: April 28, 2003, 18:14:34  
 Job time : 41.4662 secs

GenCore version 5.1.4 p5.4578  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 28, 2003, 23:25:02 ; Search time 1905.64 Seconds  
(without alignments)  
9985.963 Million cell updates/sec

Title: US-09-729-264-1

Perfect score: 1175

Sequence: 1 ctgtctgccatctgaataa.....gtaatacaactgtatag 1175

Scoring table:

IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

EST:\*  
1: em\_estbta:\*  
2: em\_estbta:\*  
3: em\_estbta:\*  
4: em\_estbta:\*  
5: em\_estbta:\*  
6: em\_estbta:\*  
7: em\_estbta:\*  
8: em\_estbta:\*  
9: em\_estbta:\*  
10: em\_estbta:\*  
11: em\_estbta:\*  
12: em\_estbta:\*  
13: em\_estbta:\*  
14: em\_estbta:\*  
15: em\_estbta:\*  
16: em\_estbta:\*  
17: em\_estbta:\*  
18: em\_estbta:\*  
19: em\_estbta:\*  
20: em\_estbta:\*  
21: em\_estbta:\*  
22: em\_estbta:\*  
23: em\_estbta:\*  
24: em\_estbta:\*  
25: em\_estbta:\*  
26: em\_estbta:\*  
27: em\_estbta:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result NO.	Score	Match Length	ID	Description
1	308.6	26.3	784 12	BG863468 602796941
2	279	23.7	794 12	BF784177 602108039
3	267.4	22.8	725 12	BG740428 602633817
4	259.4	22.1	631 10	BB663870 BB663870
5	247.8	21.1	527 10	BE032610 132035 MA
6	199	16.9	517 10	BE476432 159670 BA

7	191.6	16.3	524	10	AV601192
8	190.8	16.2	622	17	AG069679
9	190.8	16.2	677	17	AG107877
10	186	15.8	471	9	AA265274
11	186	15.8	611	10	AW990468
12	186	15.8	931	12	BG173684
13	186	15.8	1552	11	AK008060
14	185	15.7	466	9	AI425363
15	184.4	15.7	663	10	BE376580
16	182.8	15.6	650	10	BB625217
17	168.2	14.3	600	17	AZ379623
18	153.2	13.0	216	12	BG206666
19	153.2	13.0	556	9	AI788300
20	151.6	12.9	530	9	AI790785
21	145.8	12.4	423	10	BB846577
22	143.8	12.2	291	17	AZ411779
23	128.8	11.0	471	12	BF040046
24	127.4	10.8	394	10	BB846133
25	124	10.6	685	17	AG142221
26	110	9.4	785	13	BI452873
27	102.8	8.7	889	13	BI454276
28	100	8.5	185	14	M47851
29	100	8.5	224	14	N93995
30	98.4	8.4	525	17	AQ403719
31	78.6	6.7	350	9	AI647601
32	78.6	6.7	374	9	AI648720
33	78.6	6.7	406	9	AI788973
34	77.7	6.6	644	10	BB531388
35	67.8	5.8	397	10	AW112084
36	63.6	5.4	282	10	BB564363
37	56	4.8	818	12	BG445021
38	52.6	4.5	422	9	AI756062
39	51	4.3	457	9	AJ003343
40	50.8	4.3	458	9	AL514929
41	50	4.3	447	10	AV431233
42	49.8	4.2	428	9	AA635064
43	49.6	4.2	925	17	CNS0381E
44	49.6	4.2	942	17	CNS00601
45	49.4	4.2	481	10	BE017134

## ALIGNMENTS

RESULT 1  
BG863468 784 bp mRNA linear EST 29-MAY-2001  
DEFINITION 602796941F1 NCI\_CGAP\_Mam4 Mus musculus cDNA clone IMAGE:4917803 5',  
LOCUS BG863468  
ACCESSION BG863468  
VERSION BG863468.1 GI:14214006  
KEYWORDS EST.  
SOURCE house mouse.  
ORGANISM Mus musculus  
REFERENCE NIH-MGC http://mgc.nci.nih.gov/  
AUTHORS National Institutes of Health, Mammalian Gene Collection (MGC)  
TITLE Unpublished (1999)  
JOURNAL Contact: Robert Strausberg, Ph.D.  
COMMENT Email: cgaaps-r@mail.nih.gov  
Tissue Procurement: Lothar Hennighausen Ph.D., Priscilla Furth Ph.D.

CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:  
http://image.llnl.gov  
Plate: LLAM10830 row: b column: 12  
High quality sequence stop: 768.  
Location/Qualifiers

## FEATURES

source

1. 784  
/organism="Mus musculus"  
/strain="NMRI"  
/db\_xref="taxon:10090"  
/clone="IMAGE:4917803"  
/clone\_lib="NCI\_CGAP\_Man4"  
/tissue\_type="tumor, gross tissue"  
/dev\_stage="5 months"  
/lab\_host="DH10B"  
/note="Organ: mammary; Vector: pCMV-SPORT6; Site:1: SalI; Site:2: NotI; Cloned unidirectionally. Primer: Oligo dt. library constructed by Life Technologies. Investigators providing samples: Lotmar Hennighausen/Priscilla Furth, NIH Reference for transgenic model: Li et al., Cell Growth and Differentiation 7, 3-11 (1996)."

BASE COUNT 188 a 202 c 208 g 186 t

Query Match 26.3%; Score 308.6; DB 12; Length 784;  
Best Local Similarity 69.5%; Pred. No. 2.3e-61;  
Matches 447; Conservative 0; Mismatches 194; Indels 2; Gaps 2;

24 GAGATGGGGCTTGTGATTTCTCCACGGTCTGGCTGTGAATGAACTAGAAGGC 83  
123 GTGCTGTGATCTCGCTCAGCTGACAGCTTCGGATCCAGTTATCAGATAGAAGT 182  
84 CCCCAGATTCAGACATCTCTGAAGGCTCCAGGCTCGCTTCACTGACCCCTCCAG 143  
183 CCTCAGAAATGTAACATCTCTAAAGGACTAGAGGCTCACTTAACCTGACCGTGA 242  
144 GCGTGAAGCTCATCTGTGGGCTCAGTGAATGGTGTCTAAGCTCAGGCCCATG 203  
243 GCGTGAAGCTTCTCATGTGGAGTCTTAACCAATGTGTGTCTGCTGCTACCA 302  
204 GAGCCATCATCACAATGACGCTTCACTCAGAGGTACGACGAGGCGGAGACTTC 263  
303 GGACCCATCATCACAACACCGCTTCACTTACGACGATTAACAGCAGCTACAG 362  
264 ACCTGGAGATGATCATCAATGAGAGGAGGAGGAGTTCGGGGAACATCAGAT 323  
363 ATCTCGAGTGTATCATCTCATGATGTGACAGCCAGTGAATCCGTGCAATGAC 422  
324 CTCAGAACAGTCCCTGATGATGATCTTACCTTACCTTACCTTACCTTACCT 383  
423 CTCAGAACAGGATGATGATGATGATGATGATGATGATGATGATGATGATG 482  
384 TTCTATTCACGATTTATCTTGTAGTCCGTGAGATGAACTTTGTAACTTCT 443  
483 AACATTCCTAGCAACACCTTATATGACGAGGTAACCCCTGATATGTGACT 542  
444 CCGTCACAGTGAACGCGGCTCCGGATATTTCTGGAGCTGGGTCTCTGGTCA 503  
543 GCGGTGGGCTGACCTCACTCCCGGATATTTCTGGAGCTTGAAGTTCCCTGA 602  
504 TCAAGTATTTATTTGTTCGAGAGCCAGGACCTTCAAGTGAAGTCAAGTCT 563  
603 TCGAGTAACTATTCCTTGTGAGAGCCGGAATTTATGAGGCTTGTAGTGT 662  
564 CTGACCCACAGAGCAATGGGACTTTGACTTGGTGTGCTTCACTGGAAGG 623  
623 CTGACCAACA-TGGGCAACGAGGACCTTGAATGTGTGGAGAGTCAAGTCT 721  
624 CGAAGCTGCAACTGTAATCTCAGTGTGATCGGTGATCC 666  
722 AGCAAGTCTTAACCTGCA-CTGACTGTGTGCTTCACTTCCAC 763

RESULT 2  
BF784177 794 bp mRNA linear EST 12-JAN-2001  
LOCUS BF784177  
DEFINITION 602108039P1 NCI\_CGAP\_Kid14 Mus musculus cDNA clone IMAGE:4236489  
5', mRNA sequence.  
ACCESSION BF784177

VERSION BF784177.1 GI:12089213  
KEYWORDS EST.  
SOURCE house mouse.  
ORGANISM Mus musculus  
REFERENCE Eukaryote; Metazoa; Chordata; Crustacea; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
AUTHORS 1 (bases 1 to 794)  
TITLE NIH-MGC http://mgi.nci.nih.gov/  
JOURNAL National Institutes of Health, Mammalian Gene Collection (MGC)  
COMMENT Unpublished (1999)  
Contact: Robert Strausberg, Ph.D.  
Email: c9abs-r@mail.nih.gov  
Tissue Procurement: Jeffrey E. Green, M.D.  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:  
http://image.llnl.gov  
Plate: L1AM9844 row: n column: 10  
High quality sequence stop: 694.

FEATURES  
Location/Qualifiers

source

1. 794  
/organism="Mus musculus"  
/strain="FVB/N"  
/db\_xref="taxon:10090"  
/clone="IMAGE:4236489"  
/clone\_lib="NCI\_CGAP\_Kid14"  
/lab\_host="DH10B (T1 phage-resistant)"  
/note="Organ: kidney; Vector: pCMV-SPORT6; Site:1: NotI; Site:2: SalI; Cloned unidirectionally. Primer: Oligo dt. Average insert size 1.75 kb. Constructed by Life Technologies. Note: this is a NCI\_CGAP Library. "

BASE COUNT 186 a 214 c 215 g 179 t

Query Match 23.7%; Score 279; DB 12; Length 794;  
Best Local Similarity 68.3%; Pred. No. 1.8e-54;  
Matches 416; Conservative 0; Mismatches 190; Indels 3; Gaps 2;

24 GAGATGGGGCTTGTGATTTCTCCACGGTCTGGCTGTGAATGAACTAGAAGGC 83  
123 GTGCTGTGATCTCGCTCAGCTGACAGCTTCGGATCCAGTTATCAGATAGAAGT 182  
84 CCCCAGATTCAGACATCTCTGAAGGCTCCAGGCTCGCTTCACTGACCCCTCCAG 143  
183 CCTCAGAAATGTAACATCTCTAAAGGACTAGAGGCTCACTTAACCTGACCGTGA 242  
144 GCGTGAAGCTCATCTGTGGGCTCAGTGAATGGTGTGTGCTAAGCGTACGCCCATG 203  
243 GCGTGAAGCTTCTCATGTGGAGTCTTAACCAATGTGTGTGCTGACTCACCA 302  
204 GAGCCATCATCACAATGACGCTTCACTCAGAGGTACGACGAGGCGGAGACTTC 263  
303 GGACCCATCATCACAACACCGCTTCACTTACGACGATTAACAGCAGCTACAG 362  
363 ATCTCGAGTGTATCATCTCATGATGTGACAGCCAGTGAATCCGTGCAATGAC 422  
423 CTCAGAACAGGATGATGATGATGATGATGATGATGATGATGATGATGATG 482  
384 TTCTATTCACGATTTATCTTGTAGTCCGTGAGATGAACTTTGTAACTTCT 443  
483 AACATTCCTAGCAACACCTTATATGACGAGGTAACCCCTGATATGTGACT 542  
542 CCGTCACAGTGAACGCGGCTCCGGATATTTCTGGAGCTGGGTCTCTGGTCA 503  
503 GCGGTGGGCTGACCTCACTCCCGGATATTTCTGGAGCTTGAAGTTCCCTGA 602  
543 GCGGTGGGCTGACCTCACTCCCGGATATTTCTGGAGCTTGAAGTTCCCGTGA 602  
504 TCAAGTATTTATTTGTTCGAGAGCCAGGACCTTCAAGTGAAGTCAAGTCT 563

Db 603 TCGAGTACATTCCTTCTGAGACC--GGGACCTTATGAGGTCTGAGTGTCTGGAA 660  
 Oy 564 CTTGCCCCAGAGGAGCATTTGAGCTTGTGCTGCTTACCTTGAAGACCTTGAAGGCC 623  
 Db 661 CTCA-CACACTGGGACAGGAGGACCTTGTGTGCAAGAGCTGAAGACTTGCAGGC 719  
 Oy 624 CGCAAGTCT 632  
 Db 720 CAGCAGTCT 728

# RESULT 3 BG740428

LOCUS 725 bp mRNA linear EST 15-MAY-2001  
 DEFINITION 60263817F1 NCI\_CGAP\_Skn3 Homo sapiens cDNA clone IMAGE:4778789 5',  
 mRNA sequence.  
 ACCESSION BG740428  
 VERSION BG740428.1 GI:14051081  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
 1 (bases 1 to 725)  
 NIH-MGC http://mgi.nci.nih.gov/  
 TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
 JOURNAL Unpublished (1999)  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Email: cgaabs-remail.nih.gov  
 Tissue Procurement: James Cleaver, M.D.  
 cDNA Library Preparation: Life Technologies, Inc.  
 cDNA library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA  
 Sequencing by: Incyte Genomics, Inc.  
 Clone distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
 http://image.llnl.gov  
 Plate: LLNL0635 row: b column: 06  
 High quality sequence stop: 725.  
 Location/Qualifiers  
 1..725

# FEATURES

source  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone\_image="4778789"  
 /clone\_lib="NCI\_CGAP\_Skn3"  
 /lab\_host="DH10B (T1 phage-resistant)"  
 /note="Organ: skin; Vector: pCMV-SPORT6; Site\_1: NotI;  
 Site\_2: SalI; Cloned unidirectionally. Primer: Oligo dT.  
 Average insert size 1.5kb. Library constructed by Life  
 Technologies. Note: this is a NCI\_CGAP library."  
 BASE COUNT 227 a 163 c 159 g 176 t  
 ORIGIN

Query Match 22.8%; Score 267.4; DB 12; Length 725;  
 Best Local Similarity 99.6%; Pred. No. 8.9e-52;  
 Matches 268; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 906 AAGAAATCTGAAAAAGAGAAACAAGAACTGAGACAGAAGTGAATGAATAAC 965  
 Db 377 AGGAAATCTGAAAAAGAGAAACAAGAACTGAGACAGAAGTGAATGAATAAC 436  
 Oy 966 TCCGGCTACATTTCAATGATGACAAAAGACACAGACCCGCTTCTCTCCCAATCC 1025  
 Db 437 TCCGGCTACATTTCAATGATGACAAAAGACACAGACCCGCTTCTCTCCCAATCC 496  
 Oy 1026 TGTGATCAGTGTGATGACAAAGAAAGTACTGTGGCCCTCCACACAGGGCT 1085  
 Db 497 TGTGATCAGTGTGATGACAAAGAAAGTACTGTGGCCCTCCACACAGGGCT 556  
 Oy 1086 GATCAAGTTCACACGAGCCAGCAAGTATCCACAGGCTTCTTTAATCTGGCAGTCT 1145  
 Db 557 GATCAAGTTCACACGAGCCAGCAAGTATCCACAGGCTTCTTTAATCTGGCAGTCT 616

Oy 1146 GAGAGCTGATATACACTGATATTA 1174  
 Db 617 GAGAGCTGATATACACTGATATTA 645

RESULT 4  
 LOCUS BB663870  
 DEFINITION BB663870 RIKEN full-length enriched, 0 day neonate lung Mus  
 musculus cDNA clone E030016M12 5', mRNA sequence.  
 ACCESSION BB663870  
 VERSION BB663870.1 GI:16497624  
 KEYWORDS EST.  
 SOURCE house mouse.  
 ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
 1 (bases 1 to 631)  
 Arakawa, T., Carninci, P., Fukuda, S., Furuno, M., Hanagaki, T., Hara, A.,  
 Hiramoto, K., Horii, F., Ishii, Y., Ito, M., Kawai, J., Kono, H., Kouda,  
 M., Koye, S., Matsuyama, T., Miyazaki, A., Nomura, K., Ohno, M.,  
 Okazaki, Y., Okido, T., Saito, R., Sakai, C., Sakai, K., Sano, H., Sasaki,  
 D., Shibata, K., Shinagawa, A., Shiraki, T., Sogabe, Y., Suzuki, H.,  
 Tagami, M., Tagawa, A., Takahashi, F., Takeda, Y., Tanaka, T., Toyota, T.,  
 Muramatsu, M., and Hayashizaki, Y.  
 RIKEN Mouse ESTs (Arakawa, T., et al. 2001)  
 JOURNAL Unpublished (2001)  
 COMMENT Contact: Yoshihide Hayashizaki  
 Laboratory for Genome Exploration Research Group, RIKEN Genomic  
 Sciences Center (GSC), Yokohama Institute  
 The Institute of Physical and Chemical Research (RIKEN)  
 1-7-22 Saitama-cho, Tsukuba-Ku, Yokohama, Kanagawa 230-0045, Japan  
 Tel: 81-45-503-9222  
 Fax: 81-45-503-9216

Email: genome-res@sc.riken.go.jp,  
 URL: http://genome.gsc.riken.go.jp/  
 Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K., Itoh,  
 M., Kono, H., Okazaki, Y., Muramatsu, M., and Hayashizaki, Y.  
 Normalization and subtraction of cap-trapper-selected cDNAs to  
 prepare full-length cDNA libraries for rapid discovery of new  
 genes. Genome Res. 10 (10), 1617-1630 (2000)  
 wagi, K., Fujiwara, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E.,  
 Watabiki, M., Yoneda, Y., Ishikawa, T., Ozawa, K., Tanaka, T., Matsura,  
 S., Kawai, J., Okazaki, Y., Muramatsu, M., Inoue, Y., Kira, A., and  
 Hayashizaki, Y.  
 RIKEN integrated sequence analysis (RISA) system--384-format  
 sequencing pipeline with 384 multipillar sequencer. Genome Res.  
 10 (11), 1757-1771 (2000)  
 Kono, H., Fukunishi, Y., Shibata, K., Itoh, M., Carninci, P., Sugahara,  
 Y., and Hayashizaki, Y.  
 Computer-based methods for the mouse full-length cDNA  
 encyclopedia: real-time sequence clustering for construction of a  
 nonredundant cDNA library. Genome Res. 11 (2), 281-289 (2001)  
 Kondo, S., Shinagawa, A., Saito, T., Kiyosawa, H., Yamana, I., Aizawa,  
 K., Fukuda, S., Hara, A., Itoh, M., Kawai, J., Shibata, K., and  
 Hayashizaki, Y.  
 Computational Analysis of Full-length Mouse cDNAs Compared with  
 Human Genome Sequences. Mamm. Genome. 12, 673-677 (2001)  
 Please visit our web site (http://genome.gsc.riken.go.jp) for  
 further details.  
 e mouse tissues.

# FEATURES

source  
 location/Qualifiers  
 1..631  
 /organism="Mus musculus"  
 /db\_xref="taxon:10090"  
 /clone\_image="E030016M12"  
 /clone\_lib="RIKEN full-length enriched, 0 day neonate  
 lung"  
 /tissue\_type="lung"  
 /dev\_stage="0 day neonate"  
 /lab\_host="DH10B"  
 /note="Site\_1: SalI; Site\_2: BamHI; cDNA library was  
 prepared and sequenced in Mouse Genome Encyclopedia





REFERENCE 1 (bases 1 to 517)  
 Sonstegard, T.S., Capuco, A.V., Van Tassel, C.P., Ashwell, M.S. and Wells, K.D.  
 Mapping of Expressed Sequence Tags from a normalized bovine mammary gland cDNA library  
 Unpublished (2000)  
 JOURNAL Contact: Sonstegard TS  
 USDA, ARS, Beltsville Agricultural Research Center  
 Bldg. 200 Rm 2A, Beltsville, MD 20705, USA  
 Tel: 301 504 8416  
 Fax: 301 504 8414  
 Email: tads@amri.barc.usda.gov  
 Single pass sequencing. Bases called and alt trimmed with phred v0.980904.e. Vector identified by cross\_match with the -mismatch 18 and -mismatch 12 options.  
 PCR primers  
 FORWARD: AGGAACAGCTATGACCAT  
 BACKWARD: GTTTCCTCAGCAGCAG  
 Plate: 27 row: H column: 19  
 Seq primer: ATTGAGTGACACTATAG.  
 FEATURES  
 source Location/Qualifiers  
 1..517  
 /organism="Bos taurus"  
 /db\_xref="taxon:9913"  
 /clone\_lib="BARC 5BOV"  
 /tissue\_type="pooled"  
 /lab\_host="DH10B"  
 /note="Vector: pCMV SPORT6; Site\_1: NotI; Site\_2: SalI; library made from pooled mRNA isolated from mammary tissues at eight physiological, developmental, and disease states."  
 BASE COUNT 117 a 133 c 165 g 102 t  
 ORIGIN  
 Query Match 16.9%; Score 199; DB 10; Length 517;  
 Best Local Similarity 73.8%; Pred. No. 7.1e-36;  
 Matches 253; Conservative 0; Mismatches 90; Indels 0; Gaps 0;  
 QY 24 GAGATGGGCTTGATTTCTCCACGGTCTGTAATGAATGATAGAGGC 83  
 Db 175 GTGCTGGTGGTCTGGCCCTGCTGCGAGCCTGTGATCCAGAGTAATGATAGAGGT 234  
 QY 84 CCCAGATGCAACAGCTCTGAAGGGCTCCAGGCTCGCTTCACTGACCTCTCCAG 143  
 Db 235 CCCAAGATGTCACAGCCCTGAAGGGCTCGAGGCTCGCTTCACTGACCTCTCCAG 294  
 QY 144 GGCTGGAAGCTCATATGAGGCTCTCACTGATGCTGCTAAGCTCAGGCCATG 203  
 Db 295 GGCTGGAAGCTCATATGAGGCTCTCACTGATGCTGCTAAGCTCAGGCCATG 354  
 QY 204 GAGCCCATCATCAACATGACCGCTTCACTGATGATGAGGAGGAGGAGGAGCTT 263  
 Db 355 GAGACCATCATCAACATGACCGCTTCACTGATGATGAGGAGGAGGAGGAGCTT 414  
 QY 264 ACCTGGAGATATATCCACATATGAGCCCACTGATGGGGAGACATGATGACG 323  
 Db 415 ATCTGTGATATATATATGATGAGCAATGAGCGATGCGGGCAATGATGAGCAGC 474  
 QY 324 CTCGAGAACAGTGCCTGATGATGCTGATACCTTACCGCTCC 366  
 Db 475 CTTGAGAACGCAATCGGATGAGCGCCCTTCTTCTGTTT 517

ORGANISM Bos taurus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae; Bovidae; Bovinae; Bos.  
 REFERENCE 1 (bases 1 to 524)  
 Takasuga, A., Hirotsune, S., Itoh, R., Jitohzono, A., Suzuki, H., Aso, H. and Sugimoto, Y.  
 Establishment of a high throughput EST sequencing system using poly(A) tail-removed cDNA libraries and determination of 36,000 bovine ESTs  
 Nucleic Acids Res. 29 (22), E108 (2001)  
 JOURNAL MEDLINE  
 COMMENT Contact: Yoshikazu Sugimoto  
 Animal Genetics Division  
 Shriakawa Institute of Animal Genetics  
 Odakura, Nishigo, Nishi-shirakawa, Fukushima 961-8061, Japan  
 Tel: 81-248-25-5641  
 Fax: 81-248-25-5725  
 Email: kazusugie@ocn.ne.jp  
 Single pass sequencing.  
 This clone was obtained from a polyA-deleted cDNA library.  
 FEATURES  
 source Location/Qualifiers  
 1..524  
 /organism="Bos taurus"  
 /db\_xref="taxon:9913"  
 /clone="EIKI002H04"  
 /clone\_lib="Bos taurus kidney fetus"  
 /tissue\_type="kidney"  
 /dev\_stage="fetus"  
 /lab\_host="DH10B"  
 /note="Vector: pRL1; Site\_1: SalI; Site\_2: NotI; Poly A was deleted from a NotI site"  
 BASE COUNT 120 a 135 c 168 g 96 t 5 others  
 ORIGIN  
 Query Match 16.3%; Score 191.6; DB 10; Length 524;  
 Best Local Similarity 73.6%; Pred. No. 3.7e-34;  
 Matches 242; Conservative 0; Mismatches 87; Indels 0; Gaps 0;  
 QY 24 GAGATGGGCTTGATTTCTCCACGGTCTGCTGCTGTAATGAATGATAGAGGC 83  
 Db 196 GTGCTGGTGGTCTGGCCCTGCTGCGAGCCTGTGATCCAGATGTAATCATGAGGT 255  
 QY 84 CCCAGATGCAACAGTCTGAAGGGCTCCAGGCTCGCTTCACTGACCTCTCCAG 143  
 Db 256 CCCAAGATGTCACAGCCCTGAAGGGCTCGAGGCTGCTTCACTGACCTCTCCAG 315  
 QY 144 GGCTGGAAGCTCATATGAGGCTCTCACTGATGCTGCTAAGCTCAGGCCATG 203  
 Db 316 GGCTGGAAGCTCATATGAGGCTCTCACTGATGCTGCTAAGCTCAGGCCATG 375  
 QY 204 GAGCCCATCATCAACATGACCGCTTCACTGATGATGAGGAGGAGGAGGAGCTT 263  
 Db 376 GAGACCATCATCAACATGACCGCTTCACTGATGATGAGGAGGAGGAGGAGCTT 435  
 QY 264 ACCTGGAGATATATCCACATATGAGCCCACTGATGGGGAGACATGATGACG 323  
 Db 436 ATCTGTGATATATATGATGAGCAATGAGCGATGCGGGCAATGATGAGCAGC 495  
 QY 324 CTCGAGAACAGTGCCTGATGATGCTGATACCTTACCGCTCC 352  
 Db 496 CTTGAGAACGCAATCGGATGAGCGCCCTTCTTCTGTTT 524

RESULT 7  
 AV601192 524 bp mRNA linear EST 27-NOV-2001  
 LOCUS AV601192 Bos taurus kidney fetus Bos taurus cDNA clone EIKI002H04  
 DEFINITION 5' mRNA sequence.  
 ACCESSION AV601192  
 VERSION AV601192.1 GI:9723510  
 KEYWORDS EST.  
 SOURCE cclw.

RESULT 8  
 AG069679 622 bp DNA linear GSS 03-NOV-2001  
 LOCUS AG069679 Pan troglodytes DNA, clone: PTB-060F12.F, genomic survey sequence.  
 DEFINITION AG069679  
 ACCESSION AG069679  
 VERSION AG069679.1 GI:16621481  
 KEYWORDS GSS.  
 SOURCE Pan troglodytes male lymphoblast DNA, clone\_lib: PTB Chimpanzee Male  
 BAC Library clone: PTB-060F12.F.

ORGANISM	Pan troglodytes			
REFERENCE	Eukaryotes; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.			
AUTHORS	Fujiyama, A., Hattori, M., Toyoda, A., Taylor, T. D., Yada, T., Totoki, Y., Watanabe, H. and Sakaki, Y.			
TITLE	BAC end sequences of library PTB			
JOURNAL	Unpublished			
REFERENCE	2 (bases 1 to 622)			
AUTHORS	Fujiyama, A., Hattori, M., Toyoda, A., Taylor, T. D., Yada, T., Totoki, Y., Watanabe, H. and Sakaki, Y.			
COMMENT	Direct Submission Submitted (02-AUG-2001) Asao Fujiyama, The Institute of Physical and Chemical Research (RIKEN), Genomic Sciences Center (GSC); 1-7-22 Suehiro-chou, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan (E-mail:shimboe@gscc.riken.go.jp, YUKU:http://hpg.gsc.riken.go.jp/, Tel:81-45-503-9111, Fax:81-45-503-9170) Clones are derived from the chimpanzee BAC library PTB This BAC end was generated during the R&D process and may have higher chance of clone tracking errors.			
PRIMERS	Sequencing: -21M13			
LIBRARY	Vector : pKS145			
R.Site 1 :	SacI			
R.Site 2 :	SacI.			
Location/Qualifiers	1..622			
/organism="Pan troglodytes"	/db_xref="taxon:9598"			
/clone="PTB-060F12.F"	/sex="male"			
/cell-type="lymphoblast"	/clone_lib="PTB Chimpanzee Male BAC Library"			
BASE COUNT	165 a	153 c	128 g	176 t
ORIGIN				
Query Match	16.2%	Score 190.8	DB 17	Length 622;
Best Local Similarity	94.3%	Pred. No. 5.8e-34		
Matches 198;	Conservative	0;	Mismatches 12;	Indels 0;
Gaps	0;			
Oy	474	TCCGTGGAGCTCGCGTCTCTCTGTGTCAGCCATTCACGCTATTATTGTTCCGGAGCCACG	533	
Db	72	TCCGGGAGAGCTCGGTCCTCTCTGTGTCAGCCATTCACGCTATTATTGTTCCGGAGCCACG	131	
Oy	534	GACCTTCAAAGTGCAGTGCATCTCTGGCTGCACCCACAGAGCAATGGACCTTGGACT	593	
Db	132	GACCTTCAAAGTGCAGTGCATCTCTGGCTGCACCCACAGAGCAATGGACCTTGGACT	191	
Oy	594	TCCGGGCTACTCGGAAGGCGCTGAAGGCGCCGCAAGTGCACATGTAATCTCACTGTG	653	
Db	192	TCCGGGCTACTCGGAAGGCGCTGAAGGCGCCGCAAGTGCACATGTAATCTCACTGTG	251	
Oy	654	ATTCCGTGTCCCAAGACACTGGAGGTGT	683	
Db	252	ATTCCGTGTCCCAAGACACTGGAGGTGT	281	
RESULT 9				
AG107877	677 bp DNA linear GSS 03-NOV-2001			
LOCUS	Pan troglodytes DNA, clone: PTB-112N07.F, genomic survey sequence.			
DEFINITION	AG107877			
ACCESSION	AG107877.1 GI:16728395			
VERSION	GSS.			
KEYWORDS	Pan troglodytes male lymphoblast DNA, clone_lib:PTB Chimpanzee Male			
SOURCE	BAC library clone:PTB-112N07.F.			
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.			
REFERENCE	1			
AUTHORS	Fujiyama, A., Hattori, M., Toyoda, A., Taylor, T. D., Yada, T., Totoki, Y., Watanabe, H. and Sakaki, Y.			

TITLE	BAC end sequences of Library PTB
JOURNAL	Unpublished
REFERENCE	2 (bases 1 to 677)
AUTHORS	Fujiyama,A., Hattori,M., Toyoda,A., Taylor,T.D., Yada,T., TotoKI,Y., Matanabe,H. and Sakaki,Y.
TITLE	Direct Submission
JOURNAL	Submitted (02-ANG-2001) Asao Fujiyama, The Institute of Physical and Chemical Research (RIKEN), Genomic Sciences Center (GSC); 1-7-22 Suehiro-chou,Tsurumi-Ku, Yokohama, Kanagawa 230-0045, Japan (E-mail:tchimbbs@sc.friken.go.jp, URL:http://hgpc.friken.go.jp/, Tel:81-45-503-9111). Fax:81-45-503-9170)
COMMENT	Clones are derived from the chimpanzee BAC library PTB This BAC end was generated during the R&D process and may have higher chance of clone tracking errors. PRIMERS Sequencing: -21M13
FEATURES	LIBRARY Vector : pKS145 R.Site 1 : SacI R.Site 2 : SacI. Location/Qualifiers 1..677 /organism="Pan troglodytes" /db_xref="taxon:9598" /clone="PMB-112N07.F" /sex="male" /cell_type="lymphoblast" /clone_1lb="PTB Chimpanzee Male BAC Library"
BASE COUNT	168 a 159 c 143 g 207 t
ORIGIN	
Query Match	16.2% Score 190.8; DB 17; Length 677;
Best Local Similarity	94.3%; Pred.No.5.9e-34;
Matches 198; Conservative	0; Mismatches 12; Indels 0; Gaps 0;
OY	474 TCCTGGAGAGTCGGTCTCCTCGTGCAGCCATTAATTATTTGTCCGGAGCCACC 533       Db 72 TCCGCAGAGCTGGTCTCTCGTGCAGCCATTAATTATTTGTCCGGAGCCACC 131 
OY	534 GACCTTCAAAGTCAGCATGAGCATCTCTGGCTCTGACCCACAGAGCAATGGACTTTGACT 593 
Db	132 GACCTTCAAAGTCAGCATGAGCATCTCTGGCTCTGACCCACAGAGCAATGGACTTTGACT 191 
OY	594 TGGGTGGTCACTCGAAGAAGCCTGAAGGCCCGCAAGTCTGCACACTGTAAATCTCACTGTG 653 
Db	192 TGGGTGGTCACTCGAAGAAGCCTGAAGGCCCGCAAGTCTGCACACTGTAAATCTCACTGTG 251 
OY	654 ATTGGGTGTCCTCCAGACACTGGAGGTGCT 683 
Db	252 ATTCGGCGTCCCAGTAGTGAAGATGT 281 
RESULT 10	
AA265274	AA265274 471 bp MRNA linear EST 20-MAR-1997
DEFINITION	mx91d09.r1 Soares mouse NMU Mus musculus CDNA clone IMAGE:693713
ACCESSION	AA265274
VERSION	AA265274.1 GI:1901370
KEYWORDS	EST.
SOURCE	house mouse.
ORGANISM	Mus musculus
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (Bases 1 to 471) Matte,K., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T., Geisler,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M., Schellenberg,R., Steptoe,M., Tan,F., Underwood,K., Moore,B., Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and Waterston,R.
TITLE	The WashU-HMI Mouse EST Project
JOURNAL	Unpublished (1996)
COMMENT	Contact: Maria W/Mouse EST project

WashU-HHMI Mouse EST Project  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: mouseest@wustl.wustl.edu  
This clone is available royalty-free through LNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:427273  
Seq primer: -28ml3 rev2 ET from Amersham  
High quality sequence stop: 454.

## FEATURES

Location/Qualifiers

1..471

/organism="Mus musculus"

/db\_xref="taxon:10090"

/clone="IMAGE:693713"

/clone\_1lb="Soares mouse NML"

/tissue\_type="Liver"

/lab\_host="DH10B"

/note="Vector: pT73D-Pac (Pharmacia) with a modified

polylinker; Site 1: Not I; Site 2: Eco RI; 1st strand cDNA

was primed with a Not I - oligo(dT) primer [5];

double-stranded cDNA was ligated to Eco RI adaptors

(Pharmacia), digested with Not I and Eco RI sites of the

modified pT73 vector. Library

constructed and normalized by Bento Soares and M. Fatima

Bonaldo."

BASE COUNT 118 a 126 c 122 g 105 t

## ORIGIN

## Query Match

Best Local Similarity 15.8%; Score 186; DB 9; Length 471;  
Matches 246; Conservative 0; Mismatches 100; Indels 0; Gaps 0;

QY 24 GAGATGGGCTGTGATTTCTCCACGGTCTGGTGGTAATGAGTATGAAAGGC 83  
DB 90 GTGCTGTGATCTGCTGAGTGTGACAGCTTCGATCCAGTATCATATGAAAGT 149  
QY 84 CCCAGATGCAACAGTCTGGAAGGCTCCAGGCTCCATCACTGACCGTCTCCAG 143  
DB 150 CCTCAGAAATGTAAAGTCTTAAGAGCTCAGAGGCTCACTCACTGACCGTAC 209  
QY 144 GGCTGGAAGCTCATATGAGGCTCTGAGTATGATGAGTGTGCTTAAAGCTGAG 203  
DB 210 GGCTGGAAGCTCTCATATGAGGCTCTGAGTATGATGAGTGTGCTTAAAGCT 269  
QY 204 GAGCCCATCATCACCAGTCCCTTCACTCTCAGAGTATGAGTATGAGTATGAG 263  
DB 270 GAGCCCATCATCACCAGTCCCTTCACTCTCAGAGTATGAGTATGAGTATGAG 329  
QY 264 ACCCTGGAGATGATCATCACAATGTGAGAGCCAGATGATGAGTATGAGTATGAG 323  
DB 330 ATCTGGAGATGATCATCACAATGTGAGAGCCAGTATGAGTATGAGTATGAGTATGAG 389  
QY 324 CTCGAGAACAGTGTGCTGATGATGATGATGATGATGATGATGATGATGATGATG 369  
DB 390 CTCGAGAACAGTGTGCTGATGATGATGATGATGATGATGATGATGATGATGATG 435

## RESULT 11

AW990468

LOCUS

DEFINITION

AW990468 611 bp mRNA linear EST 02-JUN-2000  
u3705.y1 Soares mammary\_gland\_NMLMG Mus musculus cDNA clone  
IMAGE:1513545 5' similar to TR:060962 060962 L549.1.; mRNA

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

AW990468.1 GI:8186027  
EST.  
house mouse.  
Mus musculus  
Eukaryota; Metazoa; Chordata; Cranialata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 611)  
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.  
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
Tumor Gene Index  
JOURNAL Unpublished (1997)  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: cgap@r-email.nih.gov  
This clone is available royalty-free through LNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:940397  
Seq primer: -40RP from Gibco  
High quality sequence stop: 474.

## FEATURES

Location/Qualifiers

1..611

/organism="Mus musculus"

/db\_xref="taxon:10090"

/clone="IMAGE:1513545"

/clone\_1lb="Soares mammary\_gland\_NMLMG"

/sex="Female (lactating)"

/tissue\_type="mammary gland"

/lab\_host="DH10B"

/note="Vector: pT73D-Pac (Pharmacia) with a modified

polylinker; 1st strand cDNA was prepared from mammary

gland tissue from a lactating female, and was then primed

with a Not I - oligo(dT) primer. Double-stranded cDNA was

ligated to Eco RI adaptors (Pharmacia), digested with Not

I and Eco RI sites of the

modified pT73 vector. Library

was constructed by Bento Soares and M. Fatima

Bonaldo."

BASE COUNT 152 a 155 c 156 g 148 t

## ORIGIN

Query Match 15.8%; Score 186; DB 10; Length 611;  
Best Local Similarity 71.1%; Pred. No. 7.6e-33;

Matches 246; Conservative 0; Mismatches 100; Indels 0; Gaps 0;

QY 24 GAGATGGGCTGTGATTTCTCCACGGTCTGGTGGTAATGAGTATGAAAGGC 83  
DB 99 GTGCTGTGATCTGCTGAGTGTGACAGCTTCGATCCAGTATCATATGAAAGT 158  
QY 84 CCCAGATGCAACAGTCTGGAAGGCTCCAGGCTCCATCACTGACCGTCTCCAG 143  
DB 159 CCTCAGAAATGTAAAGTCTTAAGAGCTCAGAGGCTCACTCACTGACCGTAC 218  
QY 144 GGCTGGAAGCTCATATGAGGCTCTGAGTATGATGAGTGTGCTTAAAGCTGAG 203  
DB 219 GGCTGGAAGCTCTCATATGAGGCTCTGAGTATGATGAGTGTGCTTAAAGCT 278  
QY 204 GAGCCCATCATCACCAGTCCCTTCACTCTCAGAGTATGAGTATGAGTATGAG 263  
DB 279 GAGCCCATCATCACCAGTCCCTTCACTCTCAGAGTATGAGTATGAGTATGAG 338  
QY 264 ACCCTGGAGATGATCATCACAATGTGAGAGCCAGTATGAGTATGAGTATGAG 323  
DB 339 ATCTGGAGATGATCATCACAATGTGAGAGCCAGTATGAGTATGAGTATGAGTATGAG 398  
QY 324 CTCGAGAACAGTGTGCTGATGATGATGATGATGATGATGATGATGATGATGATG 369  
DB 399 CTCGAGAACAGTGTGCTGATGATGATGATGATGATGATGATGATGATGATGATG 444

## RESULT 12

BG173684

LOCUS

DEFINITION

BG173684 931 bp mRNA linear EST 06-FEB-2001  
602336823F1 NCI-CGAP\_Mam1 Mus musculus cDNA clone IMAGE:4459973 5',  
mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

BG173684.1 GI:12680387  
EST.  
house mouse.  
Mus musculus  
Eukaryota; Metazoa; Chordata; Cranialata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.





Db 150 CCTGAGATGTAACAGTCTTAAGAGCTCAGAGGCTCATTCAACTGCACCGTACTCAG 209  
 Oy 144 GGCTGGAAGCTCATCATGTTGGGCTCTCAGTGCATGTTGGTGTCTTAAGCGTCAAGCCCATG 203  
 Db 210 GGCTGGAAGCTCTCATGTTGGGCTCTTAAGCAATGTTGGTGTCTTAAGCGTCAAGCCCA 269  
 Oy 204 GAGCCCATCATCAGCAATGAGCCGCTTCACTCTCAGAGGTAACGACCGAGGCGGGAATTC 263  
 Db 270 GAGCCCATCATCAGCAATGAGCCGCTTCACTCTCAGAGGTAACGACCGAGGCGGGAATTC 329  
 Oy 264 ACCTGGAAGTATCATCATGTTGGGCTCTCAGTGCATGTTGGTGTCTTAAGCGTCAAGCCCATG 323  
 Db 330 ATCTCGAGTGTATCATCATGTTGGGCTCTCAGTGCATGTTGGTGTCTTAAGCGTCAAGCCCA 389  
 Oy 324 CTCGAGAACAGTGCCTCATGATGATCTGCTTACCTTACCGTCCAG 369  
 Db 390 CTCGAGAACAGGCGGTTGGATCTGCTTCCCTCCTCAGTGCAG 435

## RESULT 15

BE376590

LOCUS

DEFINITION

BE376590 663 bp mRNA linear EST 21-JUL-2000  
 601226419P1 NCI\_CGAP\_Mam1 Mus musculus cDNA clone IMAGE:3584645 5',  
 mRNA sequence.

ACCESSION

BE376590

VERSION

BE376590.1 GI:9321955

KEYWORDS

EST.

SOURCE

house mouse.

ORGANISM

Mus musculus

REFERENCE

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

AUTHORS

NIH-MGC http://mgi.nci.nih.gov/  
 1 (bases 1 to 663)

TITLE

National Institutes of Health, Mammalian Gene Collection (MGC)  
 Unpublished (1999)

JOURNAL

Contact: Robert Strausberg, Ph.D.  
 Email: cga@bbs-r@mail.nih.gov

COMMENT

Tissue Procurement: Gilbert Smith, Ph.D.  
 cDNA Library Preparation: Life Technologies, Inc.  
 DNA Sequencing by: Incyte Genomics, Inc.  
 Clone distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LNL at:  
 http://image.llnl.gov  
 Plate: LLM8743 row: f column: 06  
 High quality sequence stop: 498.

## FEATURES

source

Location/Qualifiers  
 1..663

/organism="Mus musculus"

/strain="FVB/N"  
 /db\_xref="taxon:10090"  
 /clone="IMAGE:3584645"  
 /clone\_1ib="NCI\_CGAP\_Mam1"  
 /tissue\_type="tumor, biopsy sample"  
 /dev\_stage="10 months, virgin"  
 /lab\_host="DH10B"  
 /note="Organ: mammary; Vector: PCMV-SPORT6; Site: 1; Salt;  
 Site: 2; Not: Cloned unidirectionally. Primer: Oligo dT.  
 Library constructed by Life Technologies. Investigator  
 providing samples: Gilbert Smith, NIH"

BASE COUNT  
 ORIGIN

143 a 193 c 170 g 157 t

Query Match

15.7%; Score 184.4; DB 10; Length 663;

Best Local Similarity

70.8%; Pred. No. 1.8e-32;

Matches 245; Conservative

0; Mismatches 101; Indels 0; Gaps 0;

Oy 24 GAGATGGGCTGTGATTTCTCCACGCTTGGGCTGTGATGAAGTATAGAAAGC 83  
 Db 65 GTGCTGTCATCTGCTCAGCTGACGCTTCCGATCCAGTATCAGATCATAGAAAGT 124  
 Oy 84 CCCAGATGATGACAGTCTGAGAGGCTCCAGGCTTCAACTGCACCGTCCAG 143

Db 125 CCTGAGATGTAACAGTCTTAAGAGCTCAGAGGCTCATTCAACTGCACCGTACTCAG 184  
 Oy 144 GGCTGGAAGCTCATCATGTTGGGCTCTCAGTGCATGTTGGTGTCTTAAGCGTCAAGCCCATG 203  
 Db 185 GGCTGGAAGCTCTCATGTTGGGCTCTTAAGCAATGTTGGTGTCTTAAGCGTCAAGCCCA 244  
 Oy 204 GAGCCCATCATCAGCAATGAGCCGCTTCACTCTCAGAGGTAACGACCGAGGCGGGAATTC 263  
 Db 245 GAGCCCATCATCAGCAATGAGCCGCTTCACTCTCAGAGGTAACGACCGAGGCGGGAATTC 304  
 Oy 264 ACCTGGAAGTATCATCATGTTGGGCTCTCAGTGCATGTTGGTGTCTTAAGCGTCAAGCCCATG 323  
 Db 305 ATCTCGAGTGTATCATCATGTTGGGCTCTCAGTGCATGTTGGTGTCTTAAGCGTCAAGCCCA 364  
 Oy 324 CTCGAGAACAGTGCCTCATGATGATCTGCTTACCTTACCGTCCAG 369  
 Db 365 CTCGAGAACAGGCGGTTGGATCTGCTTCCCTCCTCAGTGCAG 410

Search completed: April 29, 2003, 09:24:07

Job time: 1924.64 secs

GenCore version 5.1.4.p5.4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 28, 2003, 16:24:32 ; Search time 139.373 Seconds  
(Without alignments)  
9173.565 Million cell updates/sec

Title: US-09-729-264-1

Perfect score: 1175

Sequence: 1 ctgctgcccactcgtgaataa.....gtaataactgtagatag 1175

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 709820 seqs, 544064369 residues

Total number of hits satisfying chosen parameters: 1419640

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published\_Applications\_NA:\*

- 1: /cgn2\_6/ptodata/1/pubpna/US07\_PUBCOMB.seq:\*
- 2: /cgn2\_6/ptodata/1/pubpna/PCR\_NEM\_PUB.seq:\*
- 3: /cgn2\_6/ptodata/1/pubpna/US06\_NEM\_PUB.seq:\*
- 4: /cgn2\_6/ptodata/1/pubpna/US06\_PUBCOMB.seq:\*
- 5: /cgn2\_6/ptodata/1/pubpna/US07\_NEM\_PUB.seq:\*
- 6: /cgn2\_6/ptodata/1/pubpna/PCRUS\_PUBCOMB.seq:\*
- 7: /cgn2\_6/ptodata/1/pubpna/US08\_NEM\_PUB.seq:\*
- 8: /cgn2\_6/ptodata/1/pubpna/US08\_PUBCOMB.seq:\*
- 9: /cgn2\_6/ptodata/1/pubpna/US09\_NEM\_PUB.seq:\*
- 10: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq:\*
- 11: /cgn2\_6/ptodata/1/pubpna/US10\_NEM\_PUB.seq:\*
- 12: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 13: /cgn2\_6/ptodata/1/pubpna/US60\_NEM\_PUB.seq:\*
- 14: /cgn2\_6/ptodata/1/pubpna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Match	Query Length	ID	Description
1	269	22.9	474	US-09-918-995-3342	Sequence 3342, Ap
2	190.4	16.2	401	US-09-864-761-16305	Sequence 16305, A
3	142	12.1	398	US-09-983-965-4945	Sequence 4945, Ap
4	46	3.9	3577	US-10-008-739A-1	Sequence 1, Appl
5	44.8	3.8	1310	US-09-849-243-13	Sequence 13, Appl
6	44.8	3.8	2614	US-08-822-846-491	Sequence 491, Appl
7	44.8	3.8	3263	US-09-849-243-15	Sequence 15, Appl
8	44.8	3.8	4286	US-09-849-243-14	Sequence 14, Appl
9	44.8	3.8	6604	US-09-880-107-1748	Sequence 1748, Ap
10	44	3.7	455	US-09-728-444-151	Sequence 151, App
11	43.4	3.7	384	US-09-738-626-544	Sequence 544, App
12	43.4	3.7	3309400	US-09-738-626-1	Sequence 1, Appl
13	43.2	3.7	293	US-09-864-761-18923	Sequence 18923, A
14	43.2	3.7	459	US-09-864-761-2182	Sequence 2182, Ap
15	43.2	3.7	1791	US-09-416-384A-6	Sequence 6, Appl
16	42.6	3.6	2424	US-10-029-217A-25	Sequence 25, Appl
17	42.6	3.6	4959	US-10-029-217A-1	Sequence 1, Appl
18	42.6	3.6	4960	US-10-029-217A-30	Sequence 30, Appl
19	42.2	3.6	5959	US-09-954-456-1996	Sequence 1996, Ap

20	41.6	3.5	238	US-09-864-761-24079	Sequence 24079, A
21	41.6	3.5	554	US-09-864-761-7357	Sequence 7357, Ap
22	41.6	3.5	3899	US-09-735-367B-5	Sequence 5, Appl
23	41.6	3.5	6504	US-09-969-347-171	Sequence 171, App
24	41.6	3.5	6504	US-09-735-367B-9	Sequence 9, Appl
25	41.6	3.5	6878	US-09-735-367B-1	Sequence 1, Appl
26	41.4	3.5	2572	US-09-925-300-486	Sequence 486, App
27	41.2	3.5	424	US-09-918-995-10212	Sequence 10212, A
28	41.2	3.5	725	US-09-919-580-878	Sequence 878, App
29	41	3.5	2517	US-09-476-242-16	Sequence 16, Appl
30	40.8	3.5	2352	US-09-476-242-26	Sequence 26, Appl
31	40.8	3.5	2536	US-09-822-846-129	Sequence 129, App
32	40.8	3.5	6177	US-09-916-145-1	Sequence 1, Appl
33	40.8	3.5	6332	US-09-917-800A-1546	Sequence 1546, Ap
34	40.6	3.5	547	US-09-918-995-11012	Sequence 11012, A
35	40.4	3.4	954	US-10-078-090-83	Sequence 83, Appl
36	40.4	3.4	2674	US-10-003-295-1	Sequence 1, Appl
37	40.2	3.4	216	US-09-728-444-25	Sequence 25, Appl
38	40.2	3.4	545	US-09-919-580-371	Sequence 371, App
39	40.2	3.4	557	US-09-919-580-475	Sequence 475, App
40	40.2	3.4	572	US-09-919-580-570	Sequence 570, App
41	40.2	3.4	1143	US-09-938-842A-1399	Sequence 1399, App
42	40.2	3.4	2523	US-09-476-242-15	Sequence 15, Appl
43	40.2	3.4	83450	US-09-811-469-3	Sequence 3, Appl
44	40	3.4	270	US-10-007-557-8	Sequence 8, Appl
45	40	3.4	488	US-09-918-995-19918	Sequence 19918, A

## ALIGNMENTS

RESULT 1  
US-09-918-995-3342  
; Sequence 3342, Application US/09918995  
; Publication No. US20030073623A1  
; GENERAL INFORMATION:  
; APPLICANT: Hyseq, Inc.  
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED  
; FILE REFERENCE: 20411-756  
; CURRENT APPLICATION NUMBER: US/09/918,995  
; CURRENT FILING DATE: 2001-07-30  
; PRIOR APPLICATION NUMBER: US/09/235,076  
; PRIOR FILING DATE: 1999-01-20  
; NUMBER OF SEQ ID NOS: 38054  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 3342  
; LENGTH: 474  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: misc-feature  
; LOCATION: (1)..(474)  
; OTHER INFORMATION: n = A,T,C or G  
US-09-918-995-3342

Query Match 22.9%; Score 269; DB 9; Length 474;  
Best local Similarity 98.2%; Pred. No. 1.9e-72;  
Matches 272; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY	899	ATTTCAAAGAAATCTGAAAAGAGACAAACAAAGAACTGACAGCAAGATGGGAAA	958
DB	54	ACCTTTAAGGAATCTGAAAAGAGACAAACAAAGAACTGACAGCAAGATGGGAAA	113
QY	959	TGAAAATCTGGCTACAAATTCAGATTAACAAAGACACACCGCTTCTCTCCCTCC	1018
DB	114	TGAAAATCTGGCTACAAATTCAGATTAACAAAGACACACCGCTTCTCTCCCTCC	173
QY	1019	CAATCTCTGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTC	1078
DB	174	CAATCTCTGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTC	233
QY	1079	GCGGGCTGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTC	1138

Db 234 GCGGGGATGATCAAGTCCAGCCAGCAGCACTCATCCAGCTCTTATCTGCG 293  
 QY 1139 CAGTCTGAGAGGCTAGTATACACTGAGTATAG 1175  
 Db 294 CAGTCTGAGAGGCTAGTATACACTGAGTATAG 330

## RESULT 2

US-09-864-761-16305  
 ; Sequence 16305, Application US/09864761  
 ; Patent No. US20020048763A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Penn, Sharon G.  
 ; APPLICANT: Rank, David R.  
 ; APPLICANT: Hanzel, David K.  
 ; APPLICANT: Chen, Wensheng  
 ; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR  
 ; FILE REFERENCE: Aecomica-X-1  
 ; CURRENT FILING DATE: 2001-05-23  
 ; PRIOR APPLICATION NUMBER: US/09/864,761  
 ; PRIOR FILING DATE: 2000-02-04  
 ; PRIOR APPLICATION NUMBER: US 60/180,312  
 ; PRIOR FILING DATE: 2000-02-04  
 ; PRIOR APPLICATION NUMBER: US 60/207,456  
 ; PRIOR FILING DATE: 2000-05-26  
 ; PRIOR APPLICATION NUMBER: US 09/632,366  
 ; PRIOR FILING DATE: 2000-08-03  
 ; PRIOR APPLICATION NUMBER: GB 24263,6  
 ; PRIOR FILING DATE: 2000-10-04  
 ; PRIOR APPLICATION NUMBER: US 60/236,359  
 ; PRIOR FILING DATE: 2000-09-27  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: US 60/234,687  
 ; PRIOR FILING DATE: 2000-09-21  
 ; PRIOR APPLICATION NUMBER: US 09/608,408  
 ; PRIOR FILING DATE: 2000-06-30  
 ; PRIOR APPLICATION NUMBER: US 09/774,203  
 ; PRIOR FILING DATE: 2001-01-29  
 ; NUMBER OF SEQ ID NOS: 49117  
 ; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1  
 ; SEQ ID NO 16305  
 ; LENGTH: 401  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 ; FEATURE:  
 ; OTHER INFORMATION: MAP TO AF121782.1  
 ; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.9  
 ; US-09-864-761-16305

Query Match 16.2%; Score 190.4; DB 10; Length 401;  
 Best Local Similarity 97.0%; Pred. No. 2,7e-48;  
 Matches 194; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 42 TTCTCCACGGTTCTGGCTGTGTATGATAGTATAGAGGCCCCCAAGATGCAACAGTC 101  
 Db 202 TACCTTCAGGTTCTGGCTGTGTATGATAGTATAGAGGCCCCCAAGATGCAACAGTC 261  
 QY 102 CTGAAGGGCTCCCGAGGCTTCGCTTCACTGCAACCGTCTCCAGGGCTGGAAGCTATCATG 161  
 Db 262 CTGAAGGGCTCCCGAGGCTTCGCTTCACTGCAACCGTCTCCAGGGCTGGAAGCTATCATG 321  
 QY 162 TGGGCTCAGTATGATGTGTGTGTATGAGGCTGCAAGGCCCATGAGCCCATCATCACCAT 221  
 Db 322 TGGGCTCAGTATGATGTGTGTGTATGAGGCTGCAAGGCCCATGAGCCCATCATCACCAT 381  
 QY 222 GACCGCTTCACCTTCAGAG 241  
 Db 382 GACCGCTTCACCTTCAGAG 401

## RESULT 3

US-09-983-965-4945  
 ; Sequence 4945, Application US/09983965  
 ; Patent No. US20020137160A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Warren, Wesley C.  
 ; APPLICANT: Tao, Nengping  
 ; APPLICANT: Byatt, John C.  
 ; TITLE OF INVENTION: NUCLEIC ACID AND OTHER MOLECULES ASSOCIATED WITH LACTATION AND  
 ; FILE REFERENCE: 37-21(10297)C  
 ; CURRENT APPLICATION NUMBER: US/09/983,965  
 ; CURRENT FILING DATE: 2001-10-26  
 ; PRIOR APPLICATION NUMBER: US 09/465,231  
 ; PRIOR FILING DATE: 1999-12-15  
 ; PRIOR APPLICATION NUMBER: US 60/113,678  
 ; PRIOR FILING DATE: 1998-12-17  
 ; NUMBER OF SEQ ID NOS: 5912  
 ; SEQ ID NO 4945  
 ; LENGTH: 398  
 ; TYPE: DNA  
 ; ORGANISM: Bos taurus  
 ; FEATURE:  
 ; OTHER INFORMATION: Clone ID: 26-LIB34-017-Q1-EL-69  
 ; US-09-983-965-4945

Query Match 12.1%; Score 142; DB 10; Length 398;  
 Best Local Similarity 74.8%; Pred. No. 2.2e-33;  
 Matches 178; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

QY 24 GAGATGGGCTGTGATTTTCTCCACGCTTCGCTGTGTATGAGTATAGAGGC 83  
 Db 161 GTGCTGGTGTCTCTGCGCTGTGACAGCTGTGATCAGAGTATAGAGGT 220  
 QY 84 CCCCAAGTGAACAGTCTGTAAGGGCTCCAGGCTTCCTCAACTGCACCGTCTCCAG 143  
 Db 221 CCCAAGTGAACAGTCTGTAAGGGCTCCAGGCTTCCTCAACTGCACCGTCTCCAG 280  
 QY 144 GGCTGAGAGCTCATGTGTGGCTCTCAGTACATGTGTGTCTAAGCGTACGCCCATG 203  
 Db 281 GGCTGAGAGCTCATGTGTGGCTCTCAGTACATGTGTGTCTAAGCGTACGCCCATG 340  
 QY 204 GAGCCATCATGCAATGAGCCGCTTCACCTCTCAGTACATGTGTGTCTAAGCGTACGCCCATG 261  
 Db 341 GAGCCATCATGCAATGAGCCGCTTCACCTCTCAGTACATGTGTGTCTAAGCGTACGCCCATG 398

## RESULT 4

US-10-008-739A-1/C  
 ; Sequence 1, Application US/10008739A  
 ; Patent No. US20020161194A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Pfizer Inc.  
 ; APPLICANT: Castleberry, Tessa A.  
 ; APPLICANT: Lu, Binhong







Qy 172 PSDLSAVSIALTPQSNCTLTVCATWKSILKARKSATVNLTVIRCPQDT 220  
 Db 182 PGSESTLTLPFSHDDGATFVCRARSQALPTGRDPAITLSIQYPPREV 230

## RESULT 14

US-10-176-913-584  
 ; Sequence 584, Application US/10176913  
 ; Publication No. US2003002298A1  
 ; GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin  
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 TITLE OF INVENTION: ACIDS ENCODING THE SAME  
 FILE REFERENCE: P3430R1C66  
 CURRENT FILING DATE: 2002-06-20  
 Prior Application removed - See file wrapper or Palm  
 NUMBER OF SEQ ID NOS: 612  
 SEQ ID NO 584  
 LENGTH: 708  
 TYPE: PRT  
 ORGANISM: Homo Sapien  
 US-10-176-913-584

Query Match 6.1%; Score 128; DB 9; Length 708;

Best Local Similarity 23.1%; Pred. No. 0.095;  
 Matches 53; Conservative 41; Mismatches 95; Indels 40; Gaps 11;

Qy 14 SSGSNEVIEGPNARVYLKSGARFNCYVSGWKLMALSDMYLSVRPMEPIITNDREFT 73  
 Db 20 AGSPHFLOQPEDLVLLGEARLPCALGAYWGLVMTKSGLAGGOR-----DLPG 71  
 Qy 74 SQRYDGGNFTS---EMIIHNEPDSGNIRCSLONSRLHG-SAYITV-----QVNGE 122  
 Db 72 WSRWTWISGNANQGHDLHIRPELEDEASYEQATQAGLSRPAQLHVLVPEAPQVILGG 131  
 Qy 123 LFPSTNVLVAENEPCEVTC-----LPSHWTWLPDISW-ELGLVSHSSY--FYPE-- 171  
 Db 132 ---PSVSLVA--GVPA NLTCRSRGDARPT-----PELLMFRDGVLDGATFHQTLLKEGT 181  
 Qy 172 PSDLSAVSIALTPQSNCTLTVCATWKSILKARKSATVNLTVIRCPQDT 220  
 Db 182 PGSESTLTLPFSHDDGATFVCRARSQALPTGRDPAITLSIQYPPREV 230

## RESULT 15

US-10-180-552-584  
 ; Sequence 584, Application US/10180552  
 ; Publication No. US20030022300A1  
 ; GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
 APPLICANT: Chen, Jian  
 APPLICANT: Desnoyers, Luc  
 APPLICANT: Goddard, Audrey  
 APPLICANT: Godowski, Paul J.  
 APPLICANT: Gurney, Austin L.  
 APPLICANT: Pan, James  
 APPLICANT: Smith, Victoria  
 APPLICANT: Watanabe, Colin K.  
 APPLICANT: Wood, William I.  
 APPLICANT: Zhang, Zemin  
 TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
 TITLE OF INVENTION: ACIDS ENCODING THE SAME

FILE REFERENCE: P3430R1C153  
 CURRENT APPLICATION NUMBER: US/10/180,552  
 CURRENT FILING DATE: 2002-06-25  
 Prior Application removed - See file wrapper or Palm  
 NUMBER OF SEQ ID NOS: 612  
 SEQ ID NO 584  
 LENGTH: 708  
 TYPE: PRT  
 ORGANISM: Homo Sapien  
 US-10-180-552-584

Query Match 6.1%; Score 128; DB 9; Length 708;

Best Local Similarity 23.1%; Pred. No. 0.095;  
 Matches 53; Conservative 41; Mismatches 95; Indels 40; Gaps 11;

Qy 14 SSGSNEVIEGPNARVYLKSGARFNCYVSGWKLMALSDMYLSVRPMEPIITNDREFT 73  
 Db 20 AGSPHFLOQPEDLVLLGEARLPCALGAYWGLVMTKSGLAGGOR-----DLPG 71  
 Qy 74 SQRYDGGNFTS---EMIIHNEPDSGNIRCSLONSRLHG-SAYITV-----QVNGE 122  
 Db 72 WSRWTWISGNANQGHDLHIRPELEDEASYEQATQAGLSRPAQLHVLVPEAPQVILGG 131  
 Qy 123 LFPSTNVLVAENEPCEVTC-----LPSHWTWLPDISW-ELGLVSHSSY--FYPE-- 171  
 Db 132 ---PSVSLVA--GVPA NLTCRSRGDARPT-----PELLMFRDGVLDGATFHQTLLKEGT 181  
 Qy 172 PSDLSAVSIALTPQSNCTLTVCATWKSILKARKSATVNLTVIRCPQDT 220  
 Db 182 PGSESTLTLPFSHDDGATFVCRARSQALPTGRDPAITLSIQYPPREV 230

Search completed: April 29, 2003, 20:17:26  
 Job time : 47.0659 secs

```

RESULT 11
US-10-175-752-584
; Sequence 584, Application US/10175752
; Publication No. US20030022295A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C60
; CURRENT FILING DATE: 2002-06-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 584
; LENGTH: 708
; TYPE: PRT
; ORGANISM: Homo Saplen
US-10-175-752-584

Query Match
Best Local Similarity 23.1%; Score 128; DB 9; Length 708;
Pred. No. 0.095;
Matches 53; Conservative 41; Mismatches 95; Indels 40; Gaps 11;

QY 14 SSGSNEVIEGPONARVYKGSQARFNCVSGQKLMALSDMYVLSVRPMEPIITNDRT 73
DB 20 AGSPHFHQPDVLLGGEARLPCALGAYGVLQWTKSGIALGGQR-----DLPG 71
QY 74 SORYDQGNFTS---EMIHNVPSDSGNIRCSLONSRLHG-SAYLVY-----QVMGE 122
DB 72 WSRWISGNANAGOHDLIRPVELEDEASYEQATQAGLRPAQLHVLVPPAPQVYLG 131
QY 123 LFIPSVNLVVAENPECEVTC-----LPSHWTWLPDISW-ELGLVSHSSY--FVPE-- 171
DB 132 ---PSVSLVA--GVFANLTCRSRGDARPT-----PELIMFRDGVLLDGAIFHOTLLKEGT 181
QY 172 PSDLOSASVIALTPQSGNGLTCVATWKSLSKARKSATVNLVYIRCPQDT 220
DB 182 PGVESTLTLPFSSHDDGATFVCARASQALPTGRDITATLSIQYPEEVT 230

RESULT 12
US-10-176-482-584
; Sequence 584, Application US/10176482
; Publication No. US20030022296A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C70
; CURRENT FILING DATE: 2002-06-20
; Prior Application removed - See File Wrapper or Palm

```

```

; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 584
; LENGTH: 708
; TYPE: PRT
; ORGANISM: Homo Saplen
US-10-176-482-584

Query Match
Best Local Similarity 23.1%; Score 128; DB 9; Length 708;
Pred. No. 0.095;
Matches 53; Conservative 41; Mismatches 95; Indels 40; Gaps 11;

QY 14 SSGSNEVIEGPONARVYKGSQARFNCVSGQKLMALSDMYVLSVRPMEPIITNDRT 73
DB 20 AGSPHFHQPDVLLGGEARLPCALGAYGVLQWTKSGIALGGQR-----DLPG 71
QY 74 SORYDQGNFTS---EMIHNVPSDSGNIRCSLONSRLHG-SAYLVY-----QVMGE 122
DB 72 WSRWISGNANAGOHDLIRPVELEDEASYEQATQAGLRPAQLHVLVPPAPQVYLG 131
QY 123 LFIPSVNLVVAENPECEVTC-----LPSHWTWLPDISW-ELGLVSHSSY--FVPE-- 171
DB 132 ---PSVSLVA--GVFANLTCRSRGDARPT-----PELIMFRDGVLLDGAIFHOTLLKEGT 181
QY 172 PSDLOSASVIALTPQSGNGLTCVATWKSLSKARKSATVNLVYIRCPQDT 220
DB 182 PGVESTLTLPFSSHDDGATFVCARASQALPTGRDITATLSIQYPEEVT 230

RESULT 13
US-10-176-757-584
; Sequence 584, Application US/10176757
; Publication No. US20030022297A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C66
; CURRENT FILING DATE: 2002-06-20
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 584
; LENGTH: 708
; TYPE: PRT
; ORGANISM: Homo Saplen
US-10-176-757-584

Query Match
Best Local Similarity 23.1%; Score 128; DB 9; Length 708;
Pred. No. 0.095;
Matches 53; Conservative 41; Mismatches 95; Indels 40; Gaps 11;

QY 14 SSGSNEVIEGPONARVYKGSQARFNCVSGQKLMALSDMYVLSVRPMEPIITNDRT 73
DB 20 AGSPHFHQPDVLLGGEARLPCALGAYGVLQWTKSGIALGGQR-----DLPG 71
QY 74 SORYDQGNFTS---EMIHNVPSDSGNIRCSLONSRLHG-SAYLVY-----QVMGE 122
DB 72 WSRWISGNANAGOHDLIRPVELEDEASYEQATQAGLRPAQLHVLVPPAPQVYLG 131
QY 123 LFIPSVNLVVAENPECEVTC-----LPSHWTWLPDISW-ELGLVSHSSY--FVPE-- 171
DB 132 ---PSVSLVA--GVFANLTCRSRGDARPT-----PELIMFRDGVLLDGAIFHOTLLKEGT 181

```

```

; Publication No. US20030013153A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C50
; CURRENT FILING DATE: 2002-06-19
; PRIOR APPLICATION removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 584
; LENGTH: 708
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-173-737-584

```

```

Query Match          6.1%; Score 128; DB 9; Length 708;
Best Local Similarity 23.1%; Pred. No. 0.095; Indels 40; Gaps 11;
Matches 53; Conservative 41; Mismatches 95;

```

```

QY 14 SSGNEVIEGPNARVILKSGQARENCTVSGQWKLIMALSDMVLSVRPEPIITNDRET 73
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 20 AGSPHFILQDPEDLVYLIGEARELPCALGAYWGLVQWTKSGLAGGQR-----DLPG 71

QY 74 SQRDQGNFTS---EMITHNVEPSDSGNIRCSLQNSRLHG-SAVLYV-----QWNGE 122
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 72 WSRWISGNMANGQHDHIREVELEDEASVCOATQAGLSRPAQLHVLVPPAPQVLGG 131

QY 123 LFTPSVNLVVAENPECEVTC-----LPSHWTWLPDISW-ELGLVSHSSY--FVPE-- 171
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 132 ---PSVSLVA--GVPA NLTCRSRGDARPT-----PELLMFROGVLLDGA TFHQLKEGT 181

QY 172 PSDLOSASVILALTPQSNGLTLCVATWKSILKARKSATVNLTVIRCPDPT 220
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 182 PGVSESTLTLTPFSHDDGATFVCARASQALPTGRDTAITLSIQYPPREV 230

```

```

RESULT 9
US-10-173-706-584
; Sequence 584, Application US/10173706
; Publication No. US2003002293A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C7
; CURRENT FILING DATE: 2002-06-17
; PRIOR APPLICATION removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 584
; LENGTH: 708
; TYPE: PRT

```

```

; ORGANISM: Homo Sapien
US-10-173-706-584

```

```

Query Match          6.1%; Score 128; DB 9; Length 708;
Best Local Similarity 23.1%; Pred. No. 0.095; Indels 40; Gaps 11;
Matches 53; Conservative 41; Mismatches 95;

```

```

QY 14 SSGNEVIEGPNARVILKSGQARENCTVSGQWKLIMALSDMVLSVRPEPIITNDRET 73
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 20 AGSPHFILQDPEDLVYLIGEARELPCALGAYWGLVQWTKSGLAGGQR-----DLPG 71

QY 74 SQRDQGNFTS---EMITHNVEPSDSGNIRCSLQNSRLHG-SAVLYV-----QWNGE 122
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 72 WSRWISGNMANGQHDHIREVELEDEASVCOATQAGLSRPAQLHVLVPPAPQVLGG 131

QY 123 LFTPSVNLVVAENPECEVTC-----LPSHWTWLPDISW-ELGLVSHSSY--FVPE-- 171
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 132 ---PSVSLVA--GVPA NLTCRSRGDARPT-----PELLMFROGVLLDGA TFHQLKEGT 181

QY 172 PSDLOSASVILALTPQSNGLTLCVATWKSILKARKSATVNLTVIRCPDPT 220
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 182 PGVSESTLTLTPFSHDDGATFVCARASQALPTGRDTAITLSIQYPPREV 230

```

```

RESULT 10
US-10-175-738-584
; Sequence 584, Application US/10175738
; Publication No. US2003002294A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C45
; CURRENT FILING DATE: 2002-06-19
; PRIOR APPLICATION removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 584
; LENGTH: 708
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-175-738-584

```

```

Query Match          6.1%; Score 128; DB 9; Length 708;
Best Local Similarity 23.1%; Pred. No. 0.095; Indels 40; Gaps 11;
Matches 53; Conservative 41; Mismatches 95;

```

```

QY 14 SSGNEVIEGPNARVILKSGQARENCTVSGQWKLIMALSDMVLSVRPEPIITNDRET 73
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 20 AGSPHFILQDPEDLVYLIGEARELPCALGAYWGLVQWTKSGLAGGQR-----DLPG 71

QY 74 SQRDQGNFTS---EMITHNVEPSDSGNIRCSLQNSRLHG-SAVLYV-----QWNGE 122
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 72 WSRWISGNMANGQHDHIREVELEDEASVCOATQAGLSRPAQLHVLVPPAPQVLGG 131

QY 123 LFTPSVNLVVAENPECEVTC-----LPSHWTWLPDISW-ELGLVSHSSY--FVPE-- 171
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 132 ---PSVSLVA--GVPA NLTCRSRGDARPT-----PELLMFROGVLLDGA TFHQLKEGT 181

QY 172 PSDLOSASVILALTPQSNGLTLCVATWKSILKARKSATVNLTVIRCPDPT 220
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 182 PGVSESTLTLTPFSHDDGATFVCARASQALPTGRDTAITLSIQYPPREV 230

```

6.18; Score 128; DB 9; Length 708;

; Sequence 584, Application US/10175737

Db 362 ILNORR-----ORRGERRKAPENOEERERALEIN----- 390  
Qy 325 OKTTDTASLPKSCSESDPEORNSCGPP 353  
Db 391 -----QSEPEPAGESSTGPF 405

## RESULT 2

US-10-184-644-559  
Sequence 559, Application US/10184644  
Publication No. US20030044930A1  
GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
APPLICANT: Chen, Jian  
APPLICANT: Desnoyers, Luc  
APPLICANT: Goddard, Audrey  
APPLICANT: Goddowskl, Paul J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Pan, James  
APPLICANT: Smith, Victoria  
APPLICANT: Watanabe, Colin K.  
APPLICANT: Wood, William I.  
APPLICANT: Zhang, Zemin  
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P3430RIC227  
CURRENT APPLICATION NUMBER: US/10/184,644  
CURRENT FILING DATE: 2002-06-28  
Prior Application removed - See File Wrapper or Palm  
NUMBER OF SEQ ID NOS: 612  
SEQ ID NO 559  
LENGTH: 2473  
TYPE: DNA  
ORGANISM: Homo Sapien  
US-10-184-644-559

Query Match  
Best Local Similarity 29.5%; Score 138.5; DB 9; Length 2473;  
Matches 31; Conservative 3; Mismatches 36; Indels 35; Gaps 2;

Qy 183 ALTPQSGTLTCVATWKSILKARKSATVNLTVIRCPDGTGGGINIPGVLSLPSLGFSLPT 242  
Db 2274 AATTGAGTTTCAATTAATAATTAATATATGTTCC----- 2307

Qy 243 WGVVGLAGTMTLPTCTLTTRCCCR-RRCCGCNCCRCFCFC 286  
Db 2308 -----ATTCCATCGCCACCCACCCGCCGCCGCCACCCACCC 2344

## RESULT 3

US-10-184-634-559  
Sequence 559, Application US/10184634  
Publication No. US20030068684A1  
GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.  
APPLICANT: Chen, Jian  
APPLICANT: Desnoyers, Luc  
APPLICANT: Goddard, Audrey  
APPLICANT: Goddowskl, Paul J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Pan, James  
APPLICANT: Smith, Victoria  
APPLICANT: Watanabe, Colin K.  
APPLICANT: Wood, William I.  
APPLICANT: Zhang, Zemin  
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
FILE REFERENCE: P3430RIC217  
CURRENT APPLICATION NUMBER: US/10/184,634  
CURRENT FILING DATE: 2002-06-28  
Prior Application removed - See File Wrapper or Palm  
NUMBER OF SEQ ID NOS: 612  
SEQ ID NO 559

LENGTH: 2473  
TYPE: DNA  
ORGANISM: Homo Sapien  
US-10-184-634-559

Query Match  
Best Local Similarity 29.5%; Score 138.5; DB 9; Length 2473;  
Matches 31; Conservative 3; Mismatches 36; Indels 35; Gaps 2;

Qy 183 ALTPQSGTLTCVATWKSILKARKSATVNLTVIRCPDGTGGGINIPGVLSLPSLGFSLPT 242  
Db 2274 AATTGAGTTTCAATTAATAATTAATATATGTTCC----- 2307

Qy 243 WGVVGLAGTMTLPTCTLTTRCCCR-RRCCGCNCCRCFCFC 286  
Db 2308 -----ATTCCATCGCCACCCACCCGCCGCCGCCACCCACCC 2344

## RESULT 4

US-10-016-283-33  
Sequence 33, Application US/10016283  
Patent No. US20020164702A1  
GENERAL INFORMATION:

APPLICANT: Valenzuela et al., David M.  
TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTORS AND LIGANDS  
FILE REFERENCE: REG195-B-PCT-US  
CURRENT APPLICATION NUMBER: US/10/016,283  
CURRENT FILING DATE: 2001-11-30  
Prior Application NUMBER: US/09/077,955A  
Prior Filing DATE: 1998-09-10  
Prior Application NUMBER: PCT/US96/20696  
Prior Filing DATE: 1996-12-13  
NUMBER OF SEQ ID NOS: 36  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 33  
LENGTH: 869  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-016-283-33

Query Match  
Best Local Similarity 20.8%; Score 132.5; DB 9; Length 869;  
Matches 89; Conservative 55; Mismatches 178; Indels 105; Gaps 20;

Qy 4 GARNRDPGGSGGNEVIEGPQNAKRVLKSGQARNCVTSQGW-LIMWALSDMYLSVRP 62  
Db 113 GALQYKMP-----KITRPINVKIIEGLKAVLPCTTMGNPKPSVSMIKGD----- 158

Qy 63 MEPTTNDRTSQRYDQGNFTSEMIITHNVPDSQNRCSLQNSRLHGSAY-LTVQYMG 121  
Db 159 -SPLENSRIAVLE-----SGSLRIHNQKEDAGQRCVAKNSL--GRAYSKVYLEV 208

Qy 122 ELFTPSVNLVVAENEP-----CEVTCPLPSHTWLPDISW-ELGLVSHSYVFPPEP 172  
Db 209 EYFARILLAPSHNVTRESFYLHCTATGTP-----VPTIWIENGNAVSSGSIQESVKD 263

Qy 173 SDLOSAYSILALTPQSGTLTCVATWKSILKARKSATVNLTVIRCPDGTGG----- 223  
Db 264 RVIDSRQLFTKRP--GLYCIATNKHGEKFSYAKAAATSIEMWPKPKDKMNGYCAQY 320

Qy 224 -----INIFGVLSLPSLGFSL-----PTWGVGLAGTMTLPTCTLTTRCC 267  
Db 321 RGEVCNAVLAARDALVFNITSYADPEAEQELLVHTAMNEL-----KVSPVCRPAEAL 373

Qy 268 CRRRCGCCN-----CCCRCC-----FCCRRRGRIOROKKSEKTKETETE 312  
Db 374 LCNHIFQCSGVVPTPTPCREYCLAVKELFCKE---WLVWEKTHGLRSEHHL 429

Qy 313 SGENSGYNSDEQKTTTASLPKSCSESDPEORNSCGPPHQRADRP-----PRPASHP 368  
Db 430 SVPEGSKLPSNHMPPTACARLP-----HLDYNNKKNLMTTPP--MTSSKPSVDLPNLPSSS 482

Qy 369 QASFNLA 375







C:Superfamily: titin; fibronectin type III repeat homology; immunoglobulin homology; pro  
C:Keywords: alternative splicing; calmodulin binding; cardiac muscle; duplication; glyco  
structural protein

F:24752-25008/Domain: protein kinase homology <KIN>  
F:84,177,905,2276,2378,2459,2481,2563,2669,2763,2896,3088,3179,3384,3432,3628,3772,4068,  
98,11066,11488,11515,11635,11949,12170,12478,12526,12645,12875,13001,13036,13295,13540,1  
tatus Predicted  
F:16780,16976,17579,17602,17667,17681,17845,17899,18121,18188,18209,18336,18670,18680,18  
F:21900,21935,22295,22495,22627,22897,23024,23318,23883,24012,24177,24290,24447,24642,248  
F:26171,26178,26184,26190/Binding site: phosphate (Ser) (covalent) #status experimental

Query Match 5.5%; Score 114.5; DB 1; Length 26926;  
Best Local Similarity 22.1%; Pred. No. 45;  
Matches 62; Conservative 31; Mismatches 87; Indels 101; Gaps 12;

QY 3 AGAMENDPPEGSGSGNEVEIEGPQ-----NARV-----LKGQARFNCIVS 42  
DB 16422 AGVEHADVPGPPIVEEKELEAPDIDLDELKTIINIRAGSLRLEVPKGRP-----TPE 16476  
QY 43 QGKRLIMALSDMYVLSVRMEPIITNDRTSQRYDOGSGNFTSEMIHNVPSDSGNIRC 102  
DB 16477 VKMGKVDEIRDAIIDVT-----SSFTS-LVLDNVRNRYDSGKRYTL 16516  
QY 103 SLONSRLHGSAYLTVOYMGELFIPSVNLVVAENEPECEVTCLPSSHWTWLPDI----- 153  
DB 16517 TLENSSGTKSAFYVRYL-DTPSPVNLKYTEITKDSVST-----TWEPPLDGGSKIKN 16570  
QY 154 -----SWEIGLLVSHSSYTF-----VPEPSDLQSAVST 181  
DB 16571 YIVEKREATRKSYAAVVTNCHKNKMKIDQLQEGCSYFRVTAENENYIGILPAQTADPIKY 16630  
QY 182 LALTPQSGTLTCVATWKSILKARKSATVNLTVIRCPODTGG 222  
DB 16631 -AEVDPQPPGKITVDV-----TRNSVSLSWTK---PEHDSG 16662

Search completed: April 28, 2003, 21:09:09  
Job time : 40.0659 secs

Db 145 TPEVKGKVDGDIRDAIIVTSSFTS-LVLDNNVYDSGKYLTLLENSSGTKSAFYVR 203  
 QY 119 VMGELFIPSNLVVAENECVETCLPSHWTWLPDI----- 153  
 Db 204 VL-DTSPPVNKLKVEITIDSVI-----TWEPPLLDGSKIKNTIVKREKTRKSYAAV 257  
 QY 154 -----SMELGLVSHSSYFVPEPSDLSQSAVSIILALT-----POSNGTLTCVAT 197  
 Db 258 VTNCHKNMKIDQLQSGCYVF-RVTAENEYGIAGLAAPADPIKVAEYVQPPGKITVDV 316  
 QY 198 WSKLRKRSATVNLVIRCPDTCG 222  
 Db 317 -----TRNSYSLSWTK---PEHDGG 333

## RESULT 14

differentiation antigen - mouse

C:Species: Mus musculus (house mouse)

C:Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 05-Nov-1999

C:Accession: I49583

R:Law, C.

J. Immunol. 151, 175-187, 1993

A:Title: Organization of the murine Cd22 locus. Mapping to chromosome 7 and characteriza

A:Reference number: I49583; MUID:93315834; PMID:8100843

A:Accession: I49583

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 1-862 &lt;RES&gt;

A:Cross-references: GB:I49583; NID:9348965; PIDN:AAA02562.1; PID:9348966

C:Genetics: CD22

A:Gene: CD22

Query Match 5.5%; Score 114.5; DB 2; Length 862;

Best Local Similarity 19.1%; Pred. No. 1.1; Mismatches 126; Indels 203; Gaps 18;

Matches 86; Conservative 36; Mismatches 126; Indels 203; Gaps 18;

QY 10 DPFGSGGNEVIEGPONARVYKSGQARFN-----CTVSQGKML-----IMMA 51  
 Db 472 NPGSGS-----VLKPGVLRICKVTDMSMPVSCACNHCMSALPILNVAHA 519  
 QY 52 LSDMYLVSRPMEPIITNDRFTSQ-----RIDQGNFTSE---MIINVEPS 95  
 Db 520 PRDVKVLYKSPASEIRAGQFVLLQCDFAESNPAEVRFFPKKNGSLVQEGRYLSEFGSVSE 579  
 QY 96 DSGNIRCSLONSLHGSAYITVQMGELFIPSNLV-----VAENEC 138  
 Db 580 DSGYINCMVNN-----IGETLSQAMNLOVLIAPRLRVISISPDHVMGCKA 627  
 QY 139 EYTCLP-----SHWTWLPDISWELGLVSHSSYFVPEPSDLSQSAVSIILALT---QSN 189  
 Db 628 TLSCESDANPIQIYTW-----FDSSGQDLHSSGOKLRLEPLEVQHT 669  
 QY 190 GTLTCAVTWMSLKARSAIVNLVIRCPDTCGGINIPVGLSLPGLSPLPWGAVG 249  
 Db 670 GSYRCKCT-NGISTGESPPSTLVYSPETIG-----KRAVAG 706  
 QY 250 LAGTMLTPTCTLIRCCCRRCGCCGCCRCFCORRKRGRIO-----FOK 298  
 Db 707 LGFCLTI---CLAI-----WGKTIQKKKKQNSQGLDE 738  
 QY 299 KSE-----KEKTKETETESGNSG-----YNSDEKTTDT 330  
 Db 739 NSSQGSFFVNRKKARPTPLSEGGQSGCYNPAMDPTVSAIILRFPSMDHNMAGDAGTPT 798  
 QY 331 ASLPKSCS-----SPEDQNSC 350  
 Db 799 QAPPPNNSDVYTSVIQKRPMDGYENVPSC 829

## RESULT 15

I38344  
 titin, cardiac muscle [validated] - human

N:Alternate names: connectin  
 N:Contents: serine/threonine-specific protein kinase (EC 2.7.1.-)  
 C:Species: Homo sapiens (man)  
 C:Date: 12-Aug-1996 #sequence\_revision 12-Aug-1996 #text\_change 15-Sep-2000  
 C:Accession: I38344; I38345; S20898; S20897; S20899; S6365; S37393  
 R:Label: S.; Kolmerer, B.  
 Science 270, 293-296, 1995  
 A:Title: Tiltins: giant proteins in charge of muscle ultrastructure and elasticity.  
 A:Reference number: A57430; MUID:96026330; PMID:7569978  
 A:Accession: I38344  
 A:Status: nucleic acid sequence not shown; translation not shown; translated from GB/  
 A:Molecule type: mRNA  
 A:Residues: 1-26926 <LAB1>  
 A:Cross-references: EMBL:X90568; NID:91017424; PID:91017425  
 R:Musco, G.; Tziatzios, C.; Schuck, P.; Pastore, A.  
 Biochemistry 34, 553-561, 1995  
 A:Title: Dissecting titin into its structural motifs: identification of an alpha-hel  
 A:Reference number: I38345; MUID:95119041; PMID:7819249  
 A:Accession: I38345  
 A:Status: nucleic acid sequence not shown  
 A:Molecule type: mRNA  
 A:Residues: 1977-2014 <MUS>  
 A:Cross-references: EMBL:X83270; NID:9602579; PIDN:CAA58243.1; PID:9602580  
 A>Note: conformation and properties are reported for a synthetic peptide correspondin  
 R:Label: S.; Gautel, M.; Lakey, A.; Trinick, J.  
 EMBO J. 11, 1711-1716, 1992  
 A:Title: Towards a molecular understanding of titin.  
 A:Reference number: S20897; MUID:92258380; PMID:1582406  
 A:Accession: S20897  
 A:Status: nucleic acid sequence not shown  
 A:Molecule type: mRNA  
 A:Residues: 13597-14200, 'I', 14202-14696 <LAB2>  
 A:Cross-references: EMBL:X64698; NID:937192; PIDN:CAA45939.1; PID:937193  
 A:Accession: S20897  
 A:Status: nucleic acid sequence not shown; translation not shown  
 A:Molecule type: mRNA  
 A:Residues: 16330-16382, 'S', 16384-16756, 'F', 16758-16860 <LAB3>  
 A:Cross-references: EMBL:X64699; NID:937190; PIDN:CAA45940.1; PID:937191  
 A:Accession: S20899  
 A:Status: nucleic acid sequence not shown; translation not shown  
 A:Molecule type: mRNA  
 A:Residues: 'P', 22278-22431, 'R', 22433-22448, 'G', 22450-22453, 'Q', 22455-22480, 'TR', 2248  
 A:Cross-references: EMBL:X64697; NID:937190; PIDN:CAA45938.1; PID:937195  
 R:Kolmerer, B.; Olivieri, N.; Wilt, C.C.; Herrmann, B.G.; Labelle, S.  
 J. Mol. Biol. 256, 556-563, 1996  
 A:Title: Genomic organization of M line titin and its tissue-specific expression in t  
 A:Reference number: S6365; MUID:96177761; PMID:8604138  
 A:Accession: S6365  
 A:Status: nucleic acid sequence not shown  
 A:Molecule type: DNA  
 A:Residues: 26729-26825 <KOL>  
 A:Cross-references: EMBL:X92412; NID:91236761  
 R:Gautel, M.; Leonard, K.; Labelle, S.  
 EMBO J. 12, 3827-3834, 1993  
 A:Title: Phosphorylation of KSP motifs in the C-terminal region of titin in different  
 A:Reference number: S37393; MUID:94008990; PMID:8404852  
 A:Accession: S37393  
 A:Molecule type: mRNA  
 A:Residues: 26831-26926 <GAU>  
 R:Improta, S.; Politou, A.S.; Pastore, A.  
 Submitted to the Brookhaven Protein Data Bank, February 1996  
 A:Reference number: A6736; PDB:1TIT  
 A:Contents: annotation; conformation by (1)H-NMR, residues 5253-5341  
 R:Fuhr, M.; Pastore, A.  
 Submitted to the Brookhaven Protein Data Bank, August 1996  
 A:Reference number: A66201; PDB:1NCT  
 A:Contents: annotation; conformation by (1)H-NMR, residues 'S', 26059-26155  
 C:Genetics: CD22  
 A:Gene: GDB:JTIN  
 A:Cross-references: GDB:127867; OMIM:188840  
 A:Map position: 2q31-2q32  
 A:Description: structural protein forming filaments in striated muscle

```

0Y      63 MEPI-----ITNDRTSQRYYDQGNFSEMIHNHVEPDSGJIRCSLONSRLHSGAYLTQO 118
      :      :      :      :      :      :      :      :      :      :      :
      :      :      :      :      :      :      :      :      :      :      :

```

```

Db 274 LRGEVLT-----QLRSKRYSLLG--SNLLISNVTDDSGMTVCVATYKNEN 318
QY 109 LHSAYLTVOVMGELFIPSVNLVVAENPECEVCLPSHWTMLPDISW-ELGLIVSHSSY 167
Db 319 ISASAEITVLPVPMFLNHPNSLIAYESMDIEFECTVSGKP-VPTVNMKNKGDVYIPSDYF 377
QY 168 FVPEPSDLSQASVILALTPQSNGLTCVATWKSILKARKSATVNLVIRCPDPTGGGINIP 227
Db 378 QIVGGSNLR-----ILGVKSDGEFYQCVAENENAGNQTSAQLVPRPAIPSSS----- 426
QY 228 GVLSLIP 234
Db 427 -VLPSAP 432

RESULT 2
PCT-US94-05277-2
; Sequence 2, Application PC/TUS9405277
; GENERAL INFORMATION:
; APPLICANT: Bruskin, Arthur
; APPLICANT: Jarosz, David E.
; APPLICANT: Johnson, Karen
; APPLICANT: Kinzler, Kenneth W.
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zadbrecty, James R.
; TITLE OF INVENTION: Antibodies Specific for DCC Gene Product
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner, Birch, McKie & Beckett
; STREET: 1001 G Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20001
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05277
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A.
; REGISTRATION NUMBER: 32,141
; REFERENCE/DOCKET NUMBER: 01107.42709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202.508.9100
; TELEFAX: 202.508.9299
; TELEX: 197430 BBMB UT
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1447 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
PCT-US94-05277-2

Query Match 6.5%; Score 136; DB 5; Length 1447;
Best Local Similarity 25.1%; Pred. No. 0.0018;
Matches 62; Conservative 34; Mismatches 101; Indels 50; Gaps 10;
QY 9 RDPGSGSGNEV-----IGPONARVLKGSQARFNCTVSQGW-KLIW 50
Db 215 RNPASSRKGNAEYRIISDEGLHROLFLQRPNSVVAIEGKDAVLECCVS-GTPPSEFTW 273
QY 51 ALSDMVVLVSRMPEITITNDRFTSQRYDOGNGFTSEMIINHPSPSDSGNTRC-SLQNSR 108
Db 274 LRGEVLT-----QLRSKRYSLLG--SNLLISNVTDDSGMTVCVATYKNEN 318
QY 109 LHSAYLTVOVMGELFIPSVNLVVAENPECEVCLPSHWTMLPDISW-ELGLIVSHSSY 167

```

```

Db 319 ISASAEITVLPVPMFLNHPNSLIAYESMDIEFECTVSGKP-VPTVNMKNKGDVYIPSDYF 377
QY 168 FVPEPSDLSQASVILALTPQSNGLTCVATWKSILKARKSATVNLVIRCPDPTGGGINIP 227
Db 378 QIVGGSNLR-----ILGVKSDGEFYQCVAENENAGNQTSAQLVPRPAIPSSS----- 426
QY 228 GVLSLIP 234
Db 427 -VLPSAP 432

RESULT 3
US-08-374-834-16
; Sequence 16, Application US/08374834
; Patent No. 5656473
; GENERAL INFORMATION:
; APPLICANT: Valenzuela, et al
; TITLE OF INVENTION: NOVEL TYROSINE KINASE RECEPTOR
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Regeneron Pharmaceuticals, Inc.
; STREET: 777 Old Saw Mill River Road
; CITY: Tarrytown
; STATE: New York
; COUNTRY: USA
; ZIP: 10591
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/374,834
; FILING DATE: 19-JAN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/095,658
; FILING DATE: 21-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Coibert, Robert J.
; REGISTRATION NUMBER: 36,108
; REFERENCE/DOCKET NUMBER: REG 190A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (914) 345-7400
; TELEFAX: (914) 345-7721
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 869 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
US-08-374-834-16

Query Match 6.3%; Score 132.5; DB 1; Length 869;
Best Local Similarity 20.8%; Pred. No. 0.0018;
Matches 89; Conservative 55; Mismatches 178; Indels 105; Gaps 20;
QY 4 GAMEDNDPPGSGSGNEVIEGPNARVLKGSQARFNCTVSQGW-KLIWALSDMVVLVSRP 62
Db 113 GAQVWAKP-----KTRPPINVKITIEGLKAVLPCTTMGNKPSVSIKGD----- 158
QY 63 MEPIITNDRFTSQRYDOGNGFTSEMIINHPSPSDSGNTRC-SLQNSR 121
Db 159 -SPLRENSKRIAYLE-----SGSLRIHNVQKEDAGQRCVAKKNL-GTAYSKVVKLEV 208
QY 122 ELFIPSVNLVVAENEP-----CEVTCPSHWTMLPDISW-ELGLIVSHSSYTFVEP 172
Db 209 EVFARILRAPESHNVTFGFSVTILHCTANGIP-----VPTIWIENGNAVSSGSIQESYKD 263
QY 173 SLDQASVSLALTPQSNGLTCVAT-----WKSILKARKSATVNLVIRCPDPTGGG----- 223

```

GenCore version 5.1.4-p5.4578  
Copyright (c) 1993 - 2003 Comugen Ltd.

OM protein - protein search, using sw model

Run on: April 28, 2003, 18:14:43 ; Search time 14.0485 Seconds  
(Without alignments)  
808.430 Million cell updates/sec

Title: US-09-729-264-4  
Perfect score: 2088  
Sequence: 1 MVAGAMENRDPGSGSNEY.....HPQASFNLASPEKVSNTTVV 386

Scoring table:  
BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

Issued\_Patents\_AA:\*  
1: /cgn2\_6/ptodata/1/1aa/5A.COMB.pep:\*  
2: /cgn2\_6/ptodata/1/1aa/5B.COMB.pep:\*  
3: /cgn2\_6/ptodata/1/1aa/6A.COMB.pep:\*  
4: /cgn2\_6/ptodata/1/1aa/6B.COMB.pep:\*  
5: /cgn2\_6/ptodata/1/1aa/PCTUS.COMB.pep:\*  
6: /cgn2\_6/ptodata/1/1aa/backfile1.pep:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	136	6.5	1447	4	US-09-041-886-25
2	136	6.5	1447	5	PCT-US94-05277-2
3	132.5	6.3	869	1	US-08-374-834-16
4	132.5	6.3	869	2	US-08-644-271-29
5	132.5	6.3	869	4	US-09-077-955-33
6	128.5	6.2	1345	2	US-08-977-767-3
7	123.5	5.9	340	4	US-09-651-200-2
8	123.5	5.9	441	4	US-09-651-200-4
9	122.5	5.9	534	4	US-09-651-200-6
10	122.5	5.9	534	4	US-09-651-200-24
11	121.5	5.8	332	4	US-09-062-365-1
12	120	5.7	1395	4	US-09-540-245A-15
13	118	5.7	868	1	US-08-374-834-1
14	118	5.7	868	2	US-08-644-271-1
15	118	5.7	868	4	US-09-077-955-1
16	116.5	5.6	318	2	US-08-633-148-4
17	116.5	5.6	340	2	US-08-633-148-2
18	115.5	5.5	478	5	PCT-US95-08493-15
19	115.5	5.5	860	5	PCT-US95-08493-19
20	115.5	5.5	868	5	PCT-US95-08493-21
21	115.5	5.5	946	5	PCT-US95-08493-13
22	113	5.4	325	4	US-09-651-200-20
23	112	5.4	689	4	US-09-499-964-1
24	109	5.2	421	4	US-08-659-984A-1
25	109	5.2	421	4	US-08-660-531-1
26	109	5.2	444	4	US-08-659-984A-5
27	109	5.2	444	4	US-08-660-531-5

28	107.5	5.1	362	1	US-08-415-751-6	Sequence 6, Appl
29	107	5.1	1297	4	US-09-540-245A-17	Sequence 17, Appl
30	106	5.1	801	1	US-07-906-349A-6	Sequence 6, Appl
31	105	5.0	285	3	US-08-482-085B-20	Sequence 20, Appl
32	104	5.0	319	1	US-08-597-495B-22	Sequence 22, Appl
33	104	5.0	319	4	US-09-068-051A-22	Sequence 22, Appl
34	104	5.0	319	4	US-09-336-536-67	Sequence 67, Appl
35	104	5.0	319	4	US-09-254-465A-6	Sequence 6, Appl
36	104	5.0	690	4	US-08-935-433-2	Sequence 2, Appl
37	104	5.0	690	4	US-09-553-132-2	Sequence 2, Appl
38	103.5	5.0	365	4	US-08-928-382B-26	Sequence 26, Appl
39	102.5	4.9	879	1	US-08-554-612C-1	Sequence 1, Appl
40	102.5	4.9	890	1	US-08-445-640-2	Sequence 2, Appl
41	102.5	4.9	890	3	US-08-170-558-2	Sequence 2, Appl
42	102.5	4.9	890	3	US-08-447-314-2	Sequence 2, Appl
43	102.5	4.9	890	3	US-08-445-461-2	Sequence 2, Appl
44	102.5	4.9	911	1	US-08-286-305A-1	Sequence 1, Appl
45	102.5	4.9	911	2	US-08-441-104A-1	Sequence 1, Appl

#### ALIGNMENTS

```
RESULT 1
US-09-041-886-25
; Sequence 25, Application US/09041886
; Patent No. 6235872
; GENERAL INFORMATION:
; APPLICANT: Bredesen, Dale E.
; TITLE OF INVENTION: Proapoptotic Peptides, Dependence
; TITLE OF INVENTION: Polypeptides and Methods of Use
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/041,886
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1447 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-041-886-25

Query Match          6.5%; Score 136; DB 4; Length 1447;
Best Local Similarity 25.1%; Pred. No. 0.0018;
Matches 62; Conservative 34; Mismatches 101; Indels 50; Gaps 10;

QY 9 RDPGSGSNEY-----IEGPNRVLKSGARNCVSGW--KLIMW 50
    ||| |||||
Db 215 RNASSRTNEAEVRLSPGJLHRLYFLQRPSSNVVALEGKDAVECCVS-GYPPPSFTW 273
QY 51 ALSDMVLSVRMEPIITNDRTSQRXDGCGNFTSEMIHNVEPSDGNIRC--SLQNSR 108
```







MOLECULE TYPE: DNA (genomic)  
ORIGINAL SOURCE:  
ORGANISM: Saccharomyces cerevisiae  
IMMEDIATE SOURCE:  
CLONE: lambda yPt  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 1..1626  
US-08-258-442-12

Query Match 3.4%; Score 42.6; DB 1; Length 3292;  
Best Local Similarity 64.9%; Pred. No. 0.033;  
Matches 63; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

OY 869 ATACGCTGCTGCTGCGCCGCTGTTGGCTGCAACGCTGCGCTGTGTGT 928  
DB 818 AGATGATGATGTTGTGTGTAAGTTGTGTGTGTCGAACGCTGCTGTGAC 759

OY 929 TTCTGCTGTAAGAAAAGAGATTTCGTAATTCAT 965  
DB 758 TCCTGCTGTGCTGCAACTGCTGTGTGTGTAATT 722

RESULT 7  
US-08-328-809-7/C  
Sequence 7, Application US/08328809  
Patent No. 5705334

GENERAL INFORMATION:

APPLICANT: Lippard, Stephen J.  
APPLICANT: Essigmann, John M.  
APPLICANT: Donahue, Brian A.  
APPLICANT: Toney, Jeffrey H.  
APPLICANT: Bruhn, Suzanne L.  
APPLICANT: Pili, Pieter M.  
APPLICANT: Brown, Steven  
APPLICANT: Kellett, Patti  
TITLE OF INVENTION: Uses for DNA Structure-Specific  
TITLE OF INVENTION: Recognition Proteins  
NUMBER OF SEQUENCES: 8  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Patent Administrator, Testa, Hurwitz & Thibault  
STREET: 53 State Street  
CITY: Boston  
STATE: MA  
COUNTRY: USA  
ZIP: 02109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/328,809  
FILING DATE:

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Fenton, Gillian M.

REGISTRATION NUMBER: 36,508

REFERENCE/DOCKET NUMBER: MIT-023 (5473/24)

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617-248-7000

TELEFAX: 617-248-7100

INFORMATION FOR SEQ ID NO: 7:

SEQUENCE CHARACTERISTICS:

LENGTH: 3292 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

ORIGINAL SOURCE:

ORGANISM: Saccharomyces cerevisiae

IMMEDIATE SOURCE:

CLONE: lambda yPt

FEATURE:  
NAME/KEY: CDS  
LOCATION: 1..1626  
US-08-328-809-7

Query Match 3.4%; Score 42.6; DB 1; Length 3292;  
Best Local Similarity 64.9%; Pred. No. 0.033;  
Matches 63; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

OY 869 ATACGCTGCTGCTGCGCCGCTGTTGGCTGCAACGCTGCGCTGTGTGT 928  
DB 818 AGATGATGATGTTGTGTGTAAGTTGTGTGTGTCGAACGCTGCTGTGAC 759

OY 929 TTCTGCTGTAAGAAAAGAGATTTCGTAATTCAT 965  
DB 758 TCCTGCTGTGCTGCAACTGCTGTGTGTGTAATT 722

RESULT 8  
PCT-US92-11107-12/C

Sequence 12, Application PC/TUS9211107

GENERAL INFORMATION:

APPLICANT: Donahue, Brian A.  
APPLICANT: Toney, Jeffrey H.  
APPLICANT: Bruhn, Suzanne L.  
APPLICANT: Pili, Pieter M.  
APPLICANT: Brown, Steven  
APPLICANT: Kellett, Patti  
APPLICANT: Essigmann, John M.  
APPLICANT: Lippard, Stephen J.  
TITLE OF INVENTION: DNA Structure Specific Recognition  
TITLE OF INVENTION: Protein and Uses Therefor  
NUMBER OF SEQUENCES: 13  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
STREET: 2 Millilla Drive  
CITY: Lexington  
STATE: MA  
COUNTRY: USA  
ZIP: 02173

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US92/11107  
FILING DATE: 19921218  
CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/539,906

FILING DATE: 18-JUN-1990

ATTORNEY/AGENT INFORMATION:

NAME: Granahan, Patricia

REGISTRATION NUMBER: 32,227

REFERENCE/DOCKET NUMBER: MIT-4787AAA

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617-861-6240

TELEFAX: 617-861-9540

INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:

LENGTH: 3292 base pairs

TYPE: NUCLEIC ACID

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

ORIGINAL SOURCE:

ORGANISM: Saccharomyces cerevisiae

IMMEDIATE SOURCE:

CLONE: lambda yPt

NAME/KEY: CDS

LOCATION: 1..1626

TELEPHONE: (619) 535-9001  
TELEFAX: (619) 535-8949  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1776 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 36..1116  
US-09-041-886-12

Query Match 3.5%; Score 42.8; DB 4; Length 1776;  
Best Local Similarity 61.8%; Pred. No. 0.021;  
Matches 68; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

QY 873 GCTGCTGCTGCTGCGCGCGCTGTTGTTGCTGCACTGCTGCGCTGTTGTTCT 932  
DB 975 GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 916  
QY 933 GCTGTAGAGAAAGAGAGATTGCTATTCATTCAATTCAAGAAATCTGAA 982  
DB 915 GCTGCTGTTTTCAGAGTAGGCTTCGCTCTTCGACAGCTCTTGAA 866

## RESULT 5

US-07-814-964-12/C  
Sequence 12, Application US/07814964  
Patent No. 5359047

## GENERAL INFORMATION:

APPLICANT: Donahue, Brian A.  
APPLICANT: Toney, Jeffrey H.  
APPLICANT: Bruhn, Suzanne L.  
APPLICANT: Pil, Pieter M.  
APPLICANT: Brown, Steven  
APPLICANT: Kellelt, Patli  
APPLICANT: Essigmann, John M.  
APPLICANT: Lippard, Stephen J.  
TITLE OF INVENTION: DNA Structure Specific Recognition  
NUMBER OF SEQUENCES: 13  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
STREET: 2 Militia Drive  
CITY: Lexington  
STATE: MA  
COUNTRY: USA  
ZIP: 02173

## COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/814,964  
CLASSIFICATION: 435  
FILING DATE: 19911226  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US 07/539,906  
FILING DATE: 18-JUN-1990

## ATTORNEY/AGENT INFORMATION:

NAME: Granahan, Patricia  
REGISTRATION NUMBER: 32,227  
REFERENCE/DOCKET NUMBER: MIT-4787AAA  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-861-6240  
TELEFAX: 617-861-9540

## INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:  
LENGTH: 3292 base pairs  
TYPE: NUCLEIC ACID

STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
ORIGINAL SOURCE:  
ORGANISM: Saccharomyces cerevisiae  
IMMEDIATE SOURCE:  
CLONE: lambda ypt  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 1..1626  
US-07-814-964-12

Query Match 3.4%; Score 42.6; DB 1; Length 3292;  
Best Local Similarity 64.9%; Pred. No. 0.033;  
Matches 63; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 869 ATACGCTGCTGCTGCGCGCGCTGTTGTTGCTGCACTGCTGCGTTGTTGT 928  
DB 818 AGATGATGATGATGTTGTTGAGATTGTTGTTGTTGCACTGCTGTTGTAAC 759  
QY 929 TTCTGCTAGAGAAAGAGATTGCTATTCAT 965  
DB 758 TGCTGCTGTTGCTGCACTGCTGTTGTTGTAAT 722

## RESULT 6

US-08-258-442-12/C  
Sequence 12, Application US/08258442  
Patent No. 5670621

## GENERAL INFORMATION:

APPLICANT: Donahue, Brian A.  
APPLICANT: Toney, Jeffrey H.  
APPLICANT: Bruhn, Suzanne L.  
APPLICANT: Pil, Pieter M.  
APPLICANT: Brown, Steven  
APPLICANT: Kellelt, Patli  
APPLICANT: Essigmann, John M.  
APPLICANT: Lippard, Stephen J.  
TITLE OF INVENTION: DNA Structure Specific Recognition  
NUMBER OF SEQUENCES: 13  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
STREET: 2 Militia Drive  
CITY: Lexington  
STATE: MA  
COUNTRY: USA  
ZIP: 02173

## COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/258,442  
CLASSIFICATION: 530  
FILING DATE:  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US 07/539,906  
FILING DATE: 18-JUN-1990

## ATTORNEY/AGENT INFORMATION:

NAME: Granahan, Patricia  
REGISTRATION NUMBER: 32,227  
REFERENCE/DOCKET NUMBER: MIT-4787AAA  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-861-6240  
TELEFAX: 617-861-9540

## INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:  
LENGTH: 3292 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear

```

MEDUT TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/531,927B
FILING DATE: 21-SEP-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP H6-251600
FILING DATE: 21-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia
REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: ATH95-01A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 1776 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: CDS
LOCATION: 36..1115
US-08-531-927B-1

Query Match          3.5%; Score 42.8; DB 2; Length 1776;
Best Local Similarity 61.8%; Pred. No. 0.021; Gaps 0;
Matches 68; Conservative 0; Mismatches 42; Indels 0;

OY      873 GCCTGACGTCTCCGCCCGTCCTGTTGGTGCAGCAGTGCTGCGCGCTTTGTTCT 932
Db       975 GCTGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 916
        |||||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||
OY      933 GCTGTGAAGAAAGAAGAGATTTGTAATCAATTTCAAAAGAAATTCGAA 962
Db       915 GCTGCTGTTTTTCAAAGTAGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCGAA 866
        |||||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||  ||

RESULT 4
US-09-041-886-12/c
Sequence 12, Application US/09041886
Patent No. 6235872
GENERAL INFORMATION:
APPLICANT: Bredesen, Dale E.
APPLICANT: Rabizadeh, Sharroz
TITLE OF INVENTION: Proapoptotic Peptides, Dependence
TITLE OF INVENTION: Polypeptides and Methods of Use
NUMBER OF SEQUENCES: 72
CORRESPONDENCE ADDRESS:
ADDRESSEE: Campbell & Flores LLP
STREET: 4370 La Jolla Village Drive, Suite 700
CITY: San Diego
STATE: California
COUNTRY: United States
Zip: 92122
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/041,886
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Campbell, Cathryn A.
REGISTRATION NUMBER: 31,815
REFERENCE/DOCKET NUMBER: P-LJ 2626
TELECOMMUNICATION INFORMATION:
```

GenCore version 5.1.4\_p5\_4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 28, 2003 ; Search time 51.9118 Seconds

7325.486 Million cell updates/sec

Title: US-09-729-264-5  
Perfect score: 1340

Sequence: 1 agtgtgtgagtcagccaaca.....gtatacaactgtagtatag 1240

Scoring table: IDENTITY\_NUC

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 882724

```
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
```

Post-Proc: Match 09

Maximum Match 1008

Listing first 45 summaries

Database : Issued\_Patents\_NA:\*

```

1: /cgn2_6/ptodata1/1/ina/5A.COMB.seq:*
2: /cgn2_6/ptodata1/1/ina/5B.COMB.seq:*
3: /cgn2_6/ptodata1/1/ina/6A.COMB.seq:*
4: /cgn2_6/ptodata1/1/ina/6B.COMB.seq:*
5: /cgn2_6/ptodata1/1/ina/PCRTUS.COMB.seq:*
6: /cgn2_6/ptodata1/1/ina/backfiles1.seq:*

```

**Pred.** No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
C 1	51.8	4.2	397	3	US-09-253-691-3..	Sequence 3, Appl1
C 2	48.2	3.9	325	2	US-08-531-927B-3..	Sequence 3, Appl1
C 3	42.8	3.5	1776	2	US-08-531-927B-1..	Sequence 1, Appl1
C 4	42.8	3.5	1776	4	US-09-041-886-12	Sequence 12, Appl1
C 5	42.6	3.4	3292	1	US-07-814-964-12	Sequence 12, Appl1
C 6	42.6	3.4	3292	1	US-08-258-442-12	Sequence 12, Appl1
C 7	42.6	3.4	3292	1	US-08-328-809-7..	Sequence 7, Appl1
C 8	42.6	3.4	3292	5	PCT-US92-11107-18	Sequence 12, Appl1
C 9	42.6	3.4	40000	4	US-09-780-049-12	Sequence 12, Appl1
C 10	42.2	3.4	2674	4	US-09-817-180-1..	Sequence 1, Appl1
C 11	41.6	3.4	78	4	US-09-043-303-12	Sequence 12, Appl1
C 12	41.6	3.4	203	4	US-09-043-303-7..	Sequence 7, Appl1
C 13	41.2	3.3	379	1	US-08-145-617-5..	Sequence 5, Appl1
C 14	41.1	3.3	3771	1	US-08-185-432-3..	Sequence 3, Appl1
C 15	41.1	3.3	3771	1	US-08-185-432-23	Sequence 23, Appl1
C 16	41.1	3.3	5063	1	US-08-185-432-1..	Sequence 1, Appl1
C 17	40.8	3.3	6177	4	US-08-479-913E-1	Sequence 1, Appl1
C 18	40.8	3.3	7257	4	US-09-091-042A-1	Sequence 1, Appl1
C 19	40.4	3.3	4854	6	5496550-5	Patent No. 5496555
C 20	40.4	3.3	10348	2	US-08-557-273B-41	Sequence 41, Appl1
C 21	40.4	3.3	10348	3	US-08-556-419-13	Sequence 13, Appl1
C 22	40.4	3.3	10348	4	US-09-041-886-14	Sequence 14, Appl1
C 23	40.4	3.3	10366	1	US-08-246-982A-5	Sequence 5, Appl1
C 24	40.4	3.3	10366	1	US-08-453-265-5	Sequence 5, Appl1
C 25	40	3.2	75	4	US-09-043-303-10	Sequence 10, Appl1
C 26	40	3.2	78	4	US-09-043-303-11	Sequence 11, Appl1
C 27	40	3.2	124	1	US-08-469-302B-6	Sequence 6, Appl1

C	28	40	3.2	154	2	US-08-267-803B-6	Sequence 6, Appl 1
C	29	40	3.2	165	4	US-09-043-303-17	Sequence 17, Appl 1
C	30	40	3.2	168	1	US-08-469-802B-4	Sequence 4, Appl 1
C	31	40	3.2	168	2	US-08-267-803B-4	Sequence 4, Appl 1
C	32	40	3.2	171	1	US-08-469-802B-5	Sequence 5, Appl 1
C	33	40	3.2	171	1	US-08-267-803B-5	Sequence 5, Appl 1
C	34	40	3.2	195	1	US-08-469-802B-2	Sequence 2, Appl 1
C	35	40	3.2	195	2	US-08-267-803B-3	Sequence 2, Appl 1
C	36	40	3.2	234	1	US-08-469-802B-3	Sequence 3, Appl 1
C	37	40	3.2	234	2	US-08-267-803B-3	Sequence 3, Appl 1
C	38	40	3.2	270	4	US-09-146-054-8	Sequence 8, Appl 1
C	39	40	3.2	270	4	US-09-664-977A-8	Sequence 8, Appl 1
C	40	40	3.2	477	4	US-09-135-994-1	Sequence 1, Appl 1
C	41	40	3.2	506	1	US-08-469-802B-7	Sequence 7, Appl 1
C	42	40	3.2	506	2	US-08-267-803B-7	Sequence 7, Appl 1
C	43	40	3.2	623	4	US-09-043-303-5	Sequence 5, Appl 1
C	44	40	3.2	3366	1	US-08-469-802B-1	Sequence 1, Appl 1
C	45	40	3.2	3366	2	US-08-267-803B-1	Sequence 1, Appl 1

## ALIGNMENTS

```

RESULT 1
US-09-253-691-3/C
Sequence 3, Application US/09253691
Patent No. 6124100
GENERAL INFORMATION:
APPLICANT: Dong Kyu JIN
TITLE OF INVENTION: Diagnostic Method and Kit for Neuropsychiatric Diseases
FILE REFERENCE: 1942/36
CURRENT APPLICATION NUMBER: US/09/253,691
CURRENT FILING DATE: 1999-02-22
EARLIER APPLICATION NUMBER: KR 98-6,278
EARLIER FILING DATE: 1996-02-26
NUMBER OF SEQ ID NOS: 3
SOFTWARE: WordPerfect 6.1/Windows
SEQ ID NO 3
LENGTH: 397
TYPE: DNA
ORGANISM: human
US-09-253-691-3

Query Match          4.2%; Score 51.8; DB 3: Length 397;
Best Local Similarity 58.9%; Pred. No. 2.5e-05;
Matches 89; Conservative 0; Mismatches 62; Indels 0; Gaps 0

Qy 873 GCTGCTGCTGCTGCGCCGCGTGGTGGTGCGTGAACGCTGCGCGTGTGTTCT 932
      |||||
Db 200 GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 141

Qy 933 GCTGTGACAGAAAAAGAGATTTCTGATTCAATTTCAAAAGAAATCTGAAAAAGAGA 992
      |||||
Db 140 GCTGTGCTGCTTTTCTGCTGCTGCTGAACATTTCAAAAGATGAAGATATTTAAAAACAA 81

Qy 993 CAACCAAGAACTGACAGACAGAAAGTGCAA 1023
      |||||
Db 80 AACTTAAAGATTAATACACCATGAGAAA 50

RESULT 2
US-08-531-927B-3/C
Sequence 3, Application US/08531927B
Patent No. 5840491
GENERAL INFORMATION:
APPLICANT: Kakizuka, Akira
TITLE OF INVENTION: DNA Sequence Encoding the Machado-Joseph
Patent No. 5840491
TITLE OF INVENTION: Disease Gene and Uses Thereof
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESS: Hamilton, Brook, Smith & Reynolds, P.C.

```

Db 296 CACCTATGCGAGTTACACAGCAGTACAGTTCATCTCGAGTTGATCATCATGATGT 355  
 QY 355 GGAGCCCATGATTCGGGGAACATCATGATGAGCTCCAGAACAGTCCGCTCATGATC 414  
 Db 356 GCAGCCCATGATTCGGGGAACATCATGATGAGCTCCAGAACAGTCCGCTCATGATC 415  
 QY 415 TGCTTACCTTACGCTCCAG 434  
 Db 416 TGCTTACCTTACGCTCCAG 435

## RESULT 15

BE376590

LOCUS BE376590 663 bp mRNA linear EST 21-JUL-2000  
 DEFINITION 601226419P1 NCI\_CGAP\_Mam1 Mus musculus cDNA clone IMAGE:3584645 5',  
 mRNA sequence.

ACCESSION

BE376590

VERSION

BE376590.1

KEYWORDS

EST.

SOURCE

house mouse.

ORGANISM

Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

REFERENCE

1 (bases 1 to 663)

AUTHORS

NIH-MGC

TITLE

http://mgs.nci.nih.gov/

JOURNAL

National Institutes of Health, Mammalian Gene Collection (MGC)

COMMENT

Unpublished (1999)

Contact: Robert Strausberg, Ph.D.

Email: cgabbs-remail.nih.gov

Tissue Procurement: Gilbert Smith, Ph.D.

CDNA Library Preparation: Life Technologies, Inc.

DNA Sequencing by: Incyte Genomics, Inc.

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LLNL at:

http://image.llnl.gov

plate: L1A68743 row: f column: 06

High quality sequence stop: 498.

Location/Qualifiers

1. 663

/organism="Mus musculus"

/strain="FVB/N"

/db\_xref="taxon:10090"

/clone="IMAGE:3584645"

/clone\_lib="NCI\_CGAP\_Mam1"

/tissue\_type="tumor, biopsy sample"

/dev\_stage="10 months, virgin"

/lab\_host="DH10B"

/note="Organ: mammary; Vector: pCMV-Sport6; Site\_1: SalI;

Site\_2: NotI; Cloned unidirectionally. Primer: Oligo dT.

Library constructed by Life Technologies. Investigator

providing samples: Gilbert Smith, NIH"

BASE COUNT

143 a 193 c 170 g 157 t

ORIGIN

Query Match 14.8%; Score 184; DB 10; Length 663;  
 Best Local Similarity 73.4%; Pred. No. 3.4e-32;  
 Matches 235; Conservative 0; Mismatches 85; Indels 0; Gaps 0;

Db 271 CACCTATGCGAGTTACACAGCAGTACAGTTCATCTCGAGTTGATCATCATGATGT 330  
 QY 355 GGAGCCCATGATTCGGGGAACATCATGATGAGCTCCAGAACAGTCCGCTCATGATC 414  
 Db 331 GCAGCCCATGATTCGGGGAACATCATGATGAGCTCCAGAACAGTCCGCTCATGATC 390  
 QY 415 TGCTTACCTTACGCTCCAG 434  
 Db 391 TGCTTACCTTACGCTCCAG 410

Search completed: April 29, 2003, 09:24:22  
 Job time: 2018.06 secs

FEATURES	Location/Qualifiers
source	1. .1552

```

/note="data source:SPR, source key:09NS15, evidence:ISS
homolog to IGFS PROTEIN (FRAGMENT)
putative"
/codon_start=1
/protein_id="BAB25436.1"
/db_xref="GI:12842010"
/db_xref="MGI:MGI:1919308"
/translation="MEGSRPVIIVITIAQTASGSSVQIIEGPNVYVLDKSAH
NCVYTGMIILMMTINOMVYLSITGGIITNNRFTYASINSTDISTSLIHDQPS
DSCVTSIQNSHGSGSALSYQSDSIGEEGPALPTMILILAAFAEISLILVITII
PCCCAKREKEESTYQNDIRKSAMRRNRKADPETKLSKEKVEYGSDEAAVQTA
LPKSAEVALPERKSSSLPYQLNKHQGPATHPRVSFDIASFQKRVNTLY
1354 . 1539
polya_signal

```

QY	115	AGCTTGTGGGTGTGGTAATGAAGATATTAAGAGCCCCCGAAGTGGCAAGAGTCTGTGAAGG	174
Db	129	ACCTTCGGGATCCAGTTATACAGATCATGAAGAGTCTCTGCAATGTACAGTCTCTTAAGGA	188
QY	175	CTCCCAAGGTCGCTTTCACCTGCACCGCTCTCCAGGGCTGGAAGCTCATGATGGGCTCT	234
Db	189	CTCAGAAGGCTCCTTTCACCTGACCGGTGACTACGCGCTGGGAAGCTTCTCATGTGCACTCT	248
QY	235	CAGTGACATGTGTGTGTCTAAGCGTAGGCGCCATGGAGCCCATCATCACCAATGACCGCTT	294
Db	249	TAAACCAATGGTGGTGTGTGTGTCTACCCACCCCAAGAGACCCATCATCCACAACCGCTT	308
QY	295	CACCTCTCAGAGGTACGACACAGGGCGGGAACTTCACTTCGGAGATGATCATCCACAATGT	354
Db	309	CACCTATCCCGATTACAACAGCAGCATGACAGCTTCACTTCGGAGTGTGATCATCATGATGT	368
QY	355	GGAGCCCAAGTATTTGGGGGAACATCAGATGGCAGCCTCCGAACAGTGGCGCTCATGGATTC	414
Db	369	GCAGCCCAAGTACTTGGGATCCGTCATATGCAGCCTCGAGAACACCATGGGTTTGATTC	428
QY	415	TGCTTACCTTACCGTCCAAAG	434
Db	429	TGCCTTCCTTCAGTGCAAG	448

## REFERENCE

## AUTHORS

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: mouse@stetson.wustl.edu  
This clone is available royalty-free through LNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
This read is a RESEQUENCE of a previously sequenced mouse clone  
This read has been verified (found to hit its original self in the  
correct orientation)  
MGI:427273  
Seq primer: -40RP from Gibco  
High quality sequence stop: 459  
POLYA=No.

```

/organism="Mus musculus"
/db_xref="taxon:10090"
/clone="IMAGE:693713"
/clone_1lb="Soares mouse NML"
/tissue_type="Liver"
/lab_host="DH10B"
/note="Vector: pT73D-Pac (Pharmacia) with a modified
polylinker; site.1: Not I; site.2: Eco RI; 1st strand cDNA
was primed with a Not I - oligo(dT) primer [5',
TCCTACCACTCTGAACTGGAGCGCCGCGAATCTTTTTTTTTTT 3'];
double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Not I and cloned into the Not I
and Eco RI sites of the modified pT73 vector. Library
constructed and normalized by Bento Soares and M.Fatima
Bonaldo."

```

QY	115	AGGTTGGGGTCTGGTATGATGAATGCATAGAAGGCCCCCAAAATGACAAACTCCTGAAGG	174
Db	116	AGCTTCGGATCCAGTATTATGATCATAGAAAGTCTCTCAAAATGTACAATCTCTTAAGA	175
QY	175	CTCCCAAGGCTCGTTCAACTGCACCGCTTCCAGGGCTGGAACTCATCTATGTGGGCTCT	234
Db	176	CTGAGAGGCTCACTTCAACTGCACCGTGACTGCACGGCTGGAACTTCTCTGTGGACTCT	235
QY	235	CAGTGCATGTGTGTCTTAGCGTCAAGGCCAATGAGAGCCCATATACCAATATACCCTT	294
Db	236	TAAACCAATGTGTGTCTGAGTCTCACCAACCAAGAACCATATATACCAACACCGCTT	295
QY	295	CACCTTCAAGAGTACGACCAAGGCGGGAATTACCTGGAGATGATCATCCACAAATGT	354

FEATURES	Location/Qualifiers
source	1. .931

Query Match	15.0%;	Score 185.6;	DB 12;	Length 931;
Best Local Similarity	73.8%;	Pred. No. 1.5e-32;		
Matches 236;	Conservative	0;	Mismatches 84;	Indels 0;
				Gaps 0;

QY	115	AGGTTGGGCTCGGTAATGAGTAGTATGAAAGGCCCGCCAGAAATGCACACAGTCCCTGAAAGG	174
Db	157	AGGTTGGGCTCGGTAATGAGTAGTATGAAAGGCCCGCCAGAAATGCACACAGTCCCTGAAAGG	216
QY	175	CTCCAGAGGCTCGTTCATGTCACCGCTTCCGAGGGCTGGAAGTCAATGTTGGGCTCT	234
Db	217	CTGAGAGGCTCACTTCATCACTGCACCGTATGACAGGGCTGGAAGTCAATGTTGGGCTCT	276
QY	235	CAGTGCATGATGTTGCTAAGCGTACAGGCCCATGGAGCCCATCATCAACATACAGGCTT	294
Db	277	TAAACAAATGGTTGGTCTGAGTCTCACCAACCCAAAGAACCCATCATCAACAAACCGCTT	336
QY	295	CACCTTCAGAGGTGACACAGGGGGGAACTTCACCTCGSAGATGATCATCCACAATGT	354
Db	337	CACCTTCAGAGGTGACACAGGGGGGAACTTCACCTCGSAGATGATCATCCACAATGT	396
QY	355	GGAAGCCAGTGTTCGGGGAAATCAGATCAGATGAGGCTCCAGAAACAGTGGCTGCATGATTC	414
Db	397	GCAGCCAGTGTTCGGGGAAATCAGATCAGATGAGGCTCCAGAAACAGTGGCTGCATGATTC	456
QY	415	TGCTTACCTTACCCTCCAG	434
Db	457	TGCTTACCTTACCCTCCAG	476

LOCUS	AK008060	1552 bp	mRNA	linear	HFC 19-JAN-2002			
DEFINITION	Mus musculus adult male small intestine cDNA, RIKEN full-length enriched library clone:2010003b20:homolog to ISFS protein (FRAGMENT), full insert sequence.							
ACCESSION	AK008060							
VERSION	AK008060.1	gi:12842009						
KEYWORDS	HTC; CAP Trapper.							
SOURCE	Mus musculus (strain:G78r/67) adult male small intestine cDNA to mRNA, clone_11b:RIKEN full-length enriched mouse cDNA library clone:2010003b20.							

ORGANISM	REFERENCE
<i>Mus musculus</i>	Carninci, P. and Hayashizaki, Y. High-efficiency full-length cDNA cloning Meth. Enzymol. 303, 19-44 (1999)
<i>Eukaryota</i> ; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sclerogomathi; Muridae; Murinae; Mus	99279253

TITLE	JOURNAL	DATE
RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer	Genome Res.	10 (11), 1757-1771 (2000)
		20520013

**AUTHORS**  
 Kawai, J., Shitagawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y.,  
 Aikawa, T., Hara, A., Fukunishi, Y., Konno, H., Adachi, T., Fukuda, S.,  
 Aizawa, K., Izawa, M., Nishi, K., Kiyosawa, H., Ando, S., Yamanaoka, I.,  
 Saito, T., Okazaki, Y., Gohjori, T., Bono, H., Kasukawa, T., Saito, R.,  
 Kadota, K., Matsuda, H., Ashburner, M., Batalov, S., Casavant, T.,  
 Fleischmann, W., Gaasterland, T., Gissi, C., Kling, B., Kochiya, H.,  
 Kuehl, P., Lewis, S., Matsuno, Y., Nikaido, I., Pesole, G.,  
 Quackenbush, J., Schriml, L. M., Stambli, F., Suzuki, R., Tomita, M.,  
 Wagner, L., Washio, T., Sakai, K., Okido, T., Furuno, M., Aono, H.,  
 Baldarelli, R., Barsh, G., Blake, J., Boffelli, D., Bojunga, N.,  
 Carninci, P., de Bonaldo, M. F., Brownstein, M. J., Bulc, C., Hill, D.,  
 Fletcher, C., Fujita, M., Garlbold, M., Gustincich, S., Hill, D.,  
 Hofmann, M., Hume, D. A., Kamitani, M., Lee, N. H., Lyons, P.,  
 Marchionni, L., Mashima, J., Mazzarelli, J., Mombetta, S., Nordone, P.,  
 Ring, B., Ringwald, M., Rodriguez, I., Sakamoto, N., Sasaki, H.,  
 Sato, K., Schonbach, C., Seya, T., Shibata, Y., Storch, K. F., Suzuki, H.,  
 Toyooka, K., Wang, K. H., Weitz, C., Whitaker, C., Wilming, L.,  
 Wyszynski-Boris, A., Yoshida, K., Hasegawa, Y., Kawai, H., Kohlschki, S.,  
 and Hayashizaki, Y.

**TITLE**  
 Functional annotation of a full-length mouse cDNA collection  
 Nature 409 (6821), 685-690 (2001)

REFERENCE	AUTHORS
5 (bases 1 to 1552)	
	Adachi, J., Aikawa, K., Akahira, S., Akimura, T., Aono, H., Arai, A., Arakawa, T., Baldarelli, R., Bonu, H., Brownstein, M., Bull, C., Carninci, P., Fukuda, S., Fukunishi, Y., Furuno, M., Hanagaki, T., Hara, A., Hayasu, N., Hill, D., Hiramoto, K., Hiraoka, T., Hori, F., Hume, D., Imotani, K., Ishii, Y., Itoh, M., Izawa, M., Katsukawa, T., Kato, H., Kawai, J., Kojima, Y., Konno, H., Kouda, M., Koya, S., Kurihara, C., Matsuyama, T., Miyazaki, A., Nishi, K., Nomura, K., Numazaki, R., Ohno, M., Okazaki, Y., Okido, T., Owa, C., Queckenbush, J., Saito, H., Saito, R., Sakai, C., Sakai, K., Sano, H., Sasaki, D., Schiml, L., Shibata, K., Shibata, Y., Shinagawa, A., Shiraki, T., Sogabe, Y., Suzuki, H., Tagami, M., Tagawa, A., Takahashi, F., Tanaka, T., Tejima, Y., Toya, T., Yamamura, T., Yamazaki, I., Yasunishi, A., Yoshida, K., Yoshino, M., Muramatsu, M., and Hayashizaki, Y.
TITLE	Direct Submission
JOURNAL	Submitted (10-JUL-2000) Yoshihide Hayashizaki, The Institute of Physical and Chemical Research (RIKEN), Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama Kanagawa 230-0045, Japan (E-mail: genome-res@gsc.riken.go.jp, URL: <a href="http://genome.gsc.riken.go.jp/">http://genome.gsc.riken.go.jp/</a> , Fax: 81-45-503-9216)
COMMENT	Please visit our web site ( <a href="http://genome.gsc.riken.go.jp/">http://genome.gsc.riken.go.jp/</a> ) for further details.
	CDNA Library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken





S-7-22 Suehiro-chou, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan  
 E-mail: chimpbbs@cc.riken.go.jp, URL: <http://bjp.gsc.riken.go.jp/>,  
 Tel: 81-45-503-9111, Fax: 81-45-503-9170  
 Genomes are derived from the chimpanzee BAC library PTB This BAC end  
 was generated during the Rsd process and may have higher chance of  
 clone tracking errors.  
 PRIMERS

Sequencing: -21M13  
LIBRARY

```
Vector      : PKS145
R.Site 1   : Saci
R.Site 2   : Saci.
```

FEATURES	Location/Qualifiers
source	1. .677

```

/organism="Pan troglodytes"
/db_xref="taxon:9598"
/clone="PTB-112N07.F"
/sex="male"
/cell_line="lymphoblast"
/clone_id="PTB Chimpanzee Male BAC Library"
BASE COUNT      168 a      159 c      143 g      207 t
ORIGIN

```

Query Match	15.4%	Score 190.8	DB 17	Length 677
Best Local Similarity	94.3%	Pred. No. 9e-34		
Matches 198, Conservative	0	Mismatches 12	Indels 0	Gaps 0

**QY**    539 TCCGCGGAGCTCGGTTCCTTGGTCAGCCATTCAAGCTATTTTGTTCCGGAGGCCAGC 598  
       ||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||  
**Db**     72 TCCGCGGAGCTCGGTTCCTTGGTCAGCCATTCAAGCTATTTTGTTCCGGAGGCCAGC 131

**QY** 599 GACCTTCAAGTCGACGTGAGCATCCTGGCTTGACCCACAGAGCAATGGACTTTGACT 658  
**Ddb** 132 GACCTTCAAAGTCGACGTGAGCATCCTGGCTTGACCCACAGAGCAATGGACTTTGACT 191

**QY** 659 TGCCTGGCTACTGGAAGAGCCTGAAAGCCCGCAAGTCTGCCAAGCTAAATTCACGTG 718  
|||||  
|||  
**Db** 192 TGCCTGGCTACTGGAAGAGCCTGAAAGCCCGCAAGTCTGCCAAGCTAAATTCACGTG 251

Qy	719	ATTCGGTGTCCCAAGACACTGGAGGTGT	748
Db	252	ATTCGGCGTCCCAAGGTAAGTGAAGATGT	281

RESULT 9	1
AV601192	
FLOOR	
AV601193	
FLOOR	
AV601194	
FLOOR	
AV601195	
FLOOR	
AV601196	
FLOOR	
AV601197	
FLOOR	
AV601198	
FLOOR	
AV601199	
FLOOR	
AV601200	
FLOOR	
AV601201	
FLOOR	
AV601202	
FLOOR	
AV601203	
FLOOR	
AV601204	
FLOOR	
AV601205	
FLOOR	
AV601206	
FLOOR	
AV601207	
FLOOR	
AV601208	
FLOOR	
AV601209	
FLOOR	
AV601210	
FLOOR	
AV601211	
FLOOR	
AV601212	
FLOOR	
AV601213	
FLOOR	
AV601214	
FLOOR	
AV601215	
FLOOR	
AV601216	
FLOOR	
AV601217	
FLOOR	
AV601218	
FLOOR	
AV601219	
FLOOR	
AV601220	
FLOOR	
AV601221	
FLOOR	
AV601222	
FLOOR	
AV601223	
FLOOR	
AV601224	
FLOOR	
AV601225	
FLOOR	
AV601226	
FLOOR	
AV601227	
FLOOR	
AV601228	
FLOOR	
AV601229	
FLOOR	
AV601230	
FLOOR	
AV601231	
FLOOR	
AV601232	
FLOOR	
AV601233	
FLOOR	
AV601234	
FLOOR	
AV601235	
FLOOR	
AV601236	
FLOOR	
AV601237	
FLOOR	
AV601238	
FLOOR	
AV601239	
FLOOR	
AV601240	
FLOOR	
AV601241	
FLOOR	
AV601242	
FLOOR	
AV601243	
FLOOR	
AV601244	
FLOOR	
AV601245	
FLOOR	
AV601246	
FLOOR	
AV601247	
FLOOR	
AV601248	
FLOOR	
AV601249	
FLOOR	
AV601250	
FLOOR	
AV601251	
FLOOR	
AV601252	
FLOOR	
AV601253	
FLOOR	
AV601254	
FLOOR	
AV601255	
FLOOR	
AV601256	
FLOOR	
AV601257	
FLOOR	
AV601258	
FLOOR	
AV601259	
FLOOR	
AV601260	
FLOOR	
AV601261	
FLOOR	
AV601262	
FLOOR	
AV601263	
FLOOR	
AV601264	
FLOOR	
AV601265	
FLOOR	
AV601266	
FLOOR	
AV601267	
FLOOR	
AV601268	
FLOOR	
AV601269	
FLOOR	
AV601270	
FLOOR	
AV601271	
FLOOR	
AV601272	
FLOOR	
AV601273	
FLOOR	
AV601274	
FLOOR	
AV601275	
FLOOR	
AV601276	
FLOOR	
AV601277	
FLOOR	
AV601278	
FLOOR	
AV601279	
FLOOR	
AV601280	
FLOOR	
AV601281	
FLOOR	
AV601282	
FLOOR	
AV601283	
FLOOR	
AV601	

LOCUS	AV6031192	524 bp	MRNA	linear	EST 27-NOV-2001
DEFINITION	AV6031192	Bos taurus	kidney	fetus	Bos taurus cDNA clone EIKI002H04
DESCRIPTION	5', mRNA sequence.				

VERSION	AV601192.1	GI:9723510
KEYWORDS	EST.	
SOURCE	COW.	

Eukaryota; Metazoa; Chordata; Cranista; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidea; Bovidae; Bovinae; Bos.

AUTHORS	Takasuga, A., Hirotsune, S., Itoh, R., Itohazono, A., Suzuki, H., Aso, H.
TITLE	Establishment of a high throughput EST sequencing system using

JOURNAL	Nucleic Acids Res. 29 (22), E108 (2001),
MEDLINE	21570554
COMMENT	Contact: Yoshikazu Sugimoto

Animal Genetics Division  
Shirakawa Institute of Animal Genetics  
Okudaira, Nishigo, Nishi-Shirakawa, Fukushima 961-8061, Japan  
Tel: 81-248-25-5941  
Fax: 81-248-25-5725  
Email: kazusugi@cocoa.ocn.ne.jp  
Single pass sequencing.

This clone was obtained from a polyA-deleted cDNA library

FEATURES	Location/Qualifiers
source	1..524
	/organism="Dros. taeniorhynchus"

```

/organism="Bos taurus"
/db_xref="taxon:9913"
/clone="E1K1002H04"
/clone_lib="Bos taurus kidney fetus"

```

```

/ tissue_type="kidney
/dev_stage="fetus"
/lab_host="DH10B"
/notes="Vector: pZLL; Site_1: SalI; Site_2: NotI; Poly A
was deleted from a NotI site"

```

BASE COUNT	120 a	135 c	168 g	96 t	5 others
ORIGIN					

Query Match	15.38;	Score 190;	DB 10;	Length 524;
Best Local Similarity	76.18;	Pred. No. 1.3e-33;		
Matches 232;	Conservative	0;	Mismatches 73;	Indels 0;
				Gaps 0

0y 113 GTAGGTTCTGGGTCTGTGAATGAGTAGAAGGCCCCCGAGAATGCACAGTCTTGAAg 172  
| | | | | | | | | | | | | | | | | | | | |  
Db 220 GCAGCCTGTGGATTCACAGCAGTGAATCATAGAGGGTCCCAGAAGATGTCAcAGCCCTGAAG 279

QY 173 GGCTCCAGGCTCGCTTCAACTGCACCGCTCTCCAGGCGCTGGAAGCTCATATGTGGGCT 232  
|||||  
280 GGCTCGGAGGCTCGCTTCAACTGCACACATCTCCAGGCGCTGGAAGCTCGTCATGTGGGCT 339  
Db

Oy    233 CTGAGTGACATGGTGGTCCTAAAGCGGTGAAGGCCCATGGAGCCCATCATTCAACCAATGACC GC   292

Dd    340 CTGAGAGGCACAGTGGTGGCTGAGCATGACACCATTAATGAGACCATTCACACAGTAGAC CGC   399

QY 293 TTACCTCTCAGAGGATACGACCAGGGGGGAACTTCACCTCGGAGATGATCATCCACAAT 352  
||||| ||||| ||||||||| ||||||| |||||  
Db 400 TTCACTTCGGCAAGCTACCAAGAGGGGGGAATTCATCTNTGAGATGATAATTCAATGAC 459

Qy 353 GTGGAGCCCCAGTATTCCGGGGACATCATGATGCGCCCTCCAGAACAGTCCGCTGCATGGA 4122

Db 460 GTGCAACTCAGCGATGCCGGGCAAGTAAATGACGCCCTCANAAAGCAATCGGGATGGA 519

QY	413	TCTGC	417
Db	520	GCCGC	524

RESULT 10  
AA265274

LOCUS	AA265274	471 bp	mRNA	linear	EST 20-MAR-1997
DEFINITION	mx91d09.r1 Soares mouse NML Mus musculus CDNA clone IMAGE:693713 5', mRNA sequence.				

```

VERSION      AA265274.1  GI:1901370
KEYWORDS
SOURCE       house mouse.

```

REFERENCE  
1 (bases 1 to 471)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, R., Steptoe, M., Tan, F., Underwood, K., Moore, B., Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.

**JOURNAL COMMENT**  
Unpublished (1996)  
Contact: Maira M/Mouse EST Project  
WashU-HHMI Mouse EST Project

Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: [mouesest@wustl.edu](mailto:mouesest@wustl.edu)  
This clone is available royalty-free through LINT; contact the  
IMAB Consortium ([info@imab.llnl.gov](mailto:info@imab.llnl.gov)) for further information.



primed with a primer [5'  
GAGAGAGAGGCGCCGCACTGAGATTTTCTTTTCTTNN 3']. cDNA was  
prepared by using trihaloase thermo-activated reverse  
transcriptase and subsequently enriched for full-length by  
cap-trapper. Second strand cDNA was prepared with the  
primer adapter of sequence [5'  
GAGAGAGATTCGAGTTAAATTAATTCCTCCCTCCCTCC 3']. cDNA  
was cleaved with BamHI and XhoI. Vector: a modified  
pBluescript KS(+) after bulk excision from lambda FHC I."

BASE COUNT 154 a 167 c 161 g 149 t  
ORIGIN

Query Match 20.9%; Score 259; DB 10; Length 631;  
Best Local Similarity 72.2%; Pred. No. 1.4e-49;  
Matches 337; Conservative 0; Mismatches 130; Indels 0; Gaps 0;

QY 115 AGGTTCTGGTCTGTAATGATAGAGAGGCCCCGCAATGCAACAGTCTCTGAAGG 174  
DB 162 AGCTTCGGATCCAGTTATCATAGATGAGAGGCTCTCAATGATACAGTCTTAAGA 221  
QY 175 CTCCAGGCTCGCTTCACTGACACCGCTCTCCAGGGCTGAGAGCTATCTGGGCTCT 234  
DB 222 CTGAGAGGCTCACTTCAATGACACCGGACTCAAGGCTGAGAGCTTCTCATGTGACTCT 281  
QY 235 CAGTGAATGCTGCTTAAGCTGAGGCCATGAGGCCATCATCAACAGCCGCTT 294  
DB 282 TAACCAATAGTGTGCTGAGTCTACACCAAGGACCCATCATCAACCAACCGCTT 341  
QY 295 CACCTTCAGAGGATGAGGAGGCGGAGTCACTGAGATGATGATCACTCAATG 354  
DB 342 CACCTTATGCAATGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 401  
QY 355 GAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 414  
DB 402 GAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 461  
QY 415 TGCTTACTTACGCTCAATGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 474  
DB 462 TGCTTACTTACGCTCAATGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 521  
QY 475 CGCTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 534  
DB 522 CAGTGAATGCTGCTTAAGCTGAGGCCATGAGGCCATCATCAACAGCCGCTT 581  
QY 535 TATTTCCTGGAGCTGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 581  
DB 582 TATTTCCTGGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 628

RESULT 5  
LOCUS BE032610 527 bp mRNA linear EST 09-JUL-2000  
DEFINITION 132035 MARC 1P1G Sus scrofa cDNA 5', mRNA sequence.  
ACCESSION BE032610  
VERSION BE032610.1 GI:8327619  
KEYWORDS EST.  
SOURCE pig.  
ORGANISM Sus scrofa

REFERENCE  
AUTHORS Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.  
Fahrenkrug, S.C., Frelking, B.A., Rohrer, G.A., Smith, T.P.L., Casas, E.,  
Stone, R.T., Heaton, M.P., Grosse, W.M., Bennett, G.A., Laegreid, W.W.,  
and Keeler, J.W.

TITLE Design and use of two pooled tissue normalized cDNA libraries for  
EST discovery in swine

JOURNAL COMMENT  
Contact: Smith TPL  
Contact: Smith TPL  
USDA, ARS, US Meat Animal Research Center  
PO Box 166, Clay Center, NE 68933-0166, USA  
Tel: 402 762 4366  
Fax: 402 762 4390  
Email: smith@mail.marc.usda.gov

Single pass sequencing. Bases called and alt-trimmed with phred  
v0.980904.e. Vector identified by cross-match with the -mismatches 18  
and -mismatch 12 options.  
PCR primers  
FORWARD: AGGAACAGCTATGACCAT  
BACKWARD: GTTTCCAGTCAAGAG  
Plate: 63 row: E column: 13  
Seq primer: ATTTAGTACATATAG.  
Location/Qualifiers  
1..527  
/organism="Sus scrofa"  
/db\_xref="taxon:9823"  
/clone\_lib="MARC 1P1G"  
/tissue\_type="pooled"  
/lab\_host="DH10B"  
/note="Vector: pCMV SPORT6; Site 1: NotI; Site 2: SalI;  
Library made from pooled tissue from day 11, 13, 15, 20,  
and 30 embryos."

FEATURES  
source

BASE COUNT 105 a 147 c 176 g 99 t  
ORIGIN

Query Match 19.9%; Score 246.2; DB 10; Length 527;  
Best Local Similarity 79.0%; Pred. No. 1.2e-46;  
Matches 293; Conservative 0; Mismatches 78; Indels 0; Gaps 0;

QY 113 GTAGTTCTGGTCTGTAATGATGAGGAGGCCCCGCAATGCAACAGTCTCTGAAG 172  
DB 157 GAGGCTTGTGATCCGGCAATGATGATGAGGCTCCAGAGAGGAGGAGGAGGAGGAGG 216  
QY 173 GCTCCAGAGGCTGCTTCACTGACACCGCTCTCCAGGGCTGAGAGCTATCATGTGGCT 232  
DB 217 GCTCCAGAGGCTGCTTCACTGACACCGCTCTCCAGGGCTGAGAGCTATCATGTGGCT 276  
QY 233 CTCAGTGAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 292  
DB 277 CTGAAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 336  
QY 293 TTCACCTTCAGAGGTAGACACCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 352  
DB 337 TTCACCTTCAGAGGTAGACACCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 396  
QY 353 GTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 412  
DB 397 GTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 456  
QY 413 TCTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTT 472  
DB 457 TCCGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 516

RESULT 6  
LOCUS BE476432 517 bp mRNA linear EST 28-AUG-2000  
DEFINITION 159670 BARC 5BOV Bos taurus cDNA 5', mRNA sequence.  
ACCESSION BE476432  
VERSION BE476432.1 GI:9595965  
KEYWORDS EST.  
SOURCE cow.  
ORGANISM Bos taurus

REFERENCE  
AUTHORS Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
Bovidae; Bovinae; Bos.  
Sonstegard, T.S., Capuco, A.V., Van Tassel, C.P., Ashwell, M.S. and  
Wells, K.D.

TITLE Mapping of Expressed Sequence Tags from a normalized bovine mammary  
gland cDNA library

JOURNAL COMMENT  
Contact: Sonstegard TS  
Contact: Sonstegard TS

Db 629 --GGGCACTTATGAGGCTGCTGAGTCTGCTGAGTCTCA-CACACTGGGCAAGGACCTT 685  
 QY 655 GACTTGGCTGGCTACCTGAGAGAGCCGAGAGCCGCAAGCT 697  
 Db 686 GACTTGTGTGGCAGAGCTGAGAGCTGAGAGCCGCAAGCTT 728

RESULT 3  
 BG740428  
 LOCUS BG740428 725 bp mRNA linear EST 15-MAY-2001  
 DEFINITION 6026381/F1 NCI\_CGAP\_Skn3 Homo sapiens cDNA clone IMAGE:4778789 5',  
 mRNA sequence.  
 BG740428  
 VERSION BG740428.1 GI:14051081  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
 1 (bases 1 to 725)  
 NIH-MGC http://mgc.nci.nih.gov/  
 National Institutes of Health, Mammalian Gene Collection (MGC)  
 Unpublished (1999)  
 CONTACT: Robert Strausberg, Ph.D.  
 Email: cgaabs-remail.nih.gov  
 Tissue Procurement: James Cleaver, M.D.  
 CDNA Library Preparation: Life Technologies, Inc.  
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA  
 Sequencing by: Incyte Genomics, Inc.  
 Clone distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
 http://image.llnl.gov  
 Plate: LHAM10635 row: b column: 06  
 High quality sequence stop: 725.

FEATURES  
 Source  
 1..725  
 Location/Qualifiers  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /clone="IMAGE:4778789"  
 /lab\_host="NCI\_CGAP\_Skn3"  
 /map\_host="DH10B (T1 phage-resistant)"  
 /note="Organ: Skin; Vector: pCMV-Sport6; Site\_1: NotI;  
 Site\_2: SalI; Cloned unidirectionally. Primer: Oligo dt.  
 Average insert size 1.5kb. Library constructed by Life  
 Technologies. Note: this is a NCI\_CGAP Library."

BASE COUNT 227 a 163 c 159 g 176 t  
 ORIGIN

Query Match 21.4%; Score 265.8; DB 12; Length 725;  
 Best Local Similarity 99.3%; Pred. No. 3,7e-51;  
 Matches 267; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 971 AAGAAATGTGAAAAAGAGACAAACAAGAACTGAGACAGAAATGGAATGAAC 1030  
 Db 377 AGGAATCTGAAAAAGAGACAAACAAGAACTGAGACAGAAATGGAATGAAC 436  
 QY 1031 TCCGGCTCAATTCAGATGAGACAAAGACACAGAACCGCTTCTCCGCCCAATTC 1090  
 Db 437 TCCGGCTCAATTCAGATGAGACAAAGACACAGAACCGCTTCTCCGCCCAATTC 496  
 QY 1091 TGTGAATCCAGTGTGATGAGACAAAGACAGAGTGTGGCCCTCTCCACAGCGGCT 1150  
 Db 497 TGTGAATCCAGTGTGATGAGACAAAGACAGAGTGTGGCCCTCTCCACAGCGGCT 556  
 QY 1151 GATCAAGTCCACCCAGGCGCAGCAAGTCATCCACAGGCTTCTTTAATCTGGCCAGTCTT 1210  
 Db 557 GATCAAGTCCACCCAGGCGCAGCAAGTCATCCACAGGCTTCTTTAATCTGGCCAGTCTT 616  
 QY 1211 GAGAAAGTCAGTATACACTGTAGTATA 1239  
 Db 617 GAGAAAGTCAGTATACACTGTAGTATA 645

RESULT 4  
 BB663870  
 LOCUS BB663870 631 bp mRNA linear EST 26-OCT-2001  
 DEFINITION BB663870 Riken full-length enriched, 0 day neonate lung Mus  
 musculus cDNA clone E030016M12 5', mRNA sequence.  
 BB663870  
 VERSION BB663870.1 GI:16497624  
 KEYWORDS EST.  
 SOURCE house mouse.  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus

REFERENCE  
 1 (bases 1 to 631)  
 Arkawa,T., Carninci,P., Fukuda,S., Furuno,M., Hanagaki,T., Hara,A.,  
 Hiramoto,K., Hori,F., Ishii,Y., Ito,M., Kawai,J., Konno,H., Kouda  
 M., Koya,S., Matsuyama,T., Miyazaki,A., Nomura,K., Ohno,M.,  
 Okazaki,Y., Okido,T., Saito,R., Sakai,C., Sakai,K., Sano,H., Sasaki  
 D., Shibata,K., Shinagawa,A., Shiraki,T., Sogabe,Y., Suzuki,H.,  
 Tagami,M., Tagawa,A., Takahashi,F., Takeda,Y., Tanaka,T., Toya,T.,  
 Muramatsu,M. and Hayashizaki,Y.  
 RIKEN Mouse ESTs (Arkawa,T., et al. 2001)  
 Unpublished (2001)

JOURNAL  
 CONTACT: Yoshinobu Hayashizaki  
 Laboratory for Genome Exploration Research Group, RIKEN Genomic  
 Sciences Center(GSC), Yokohama Institute  
 The Institute of Physical and Chemical Research (RIKEN)  
 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan  
 Tel: 81-45-503-9222  
 Fax: 81-45-503-9216  
 Email: genome-res@gsr.riken.go.jp,  
 URL: http://genome.gsc.riken.go.jp/  
 Carninci,P., Shibata,Y., Hayashizaki,Y., Sugahara,Y., Shibata,K., Itoh  
 M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.  
 Normalization and subtraction of cap-trapper-selected cDNAs to  
 prepare full-length cDNA libraries for rapid discovery of new  
 genes. Genome Res. 10 (10), 1617-1630 (2000)  
 wagi,K., Fujiwara,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E.,  
 Watahiki,M., Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsura  
 S., Kawai,J., Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and  
 Hayashizaki,Y.  
 RIKEN integrated sequence analysis (RISA) system--384-format  
 sequencing pipeline with 384 multicapillary sequencer. Genome Res.  
 10 (11), 1757-1771 (2000)  
 Konno,H., Fukunishi,Y., Shibata,K., Itoh,M., Carninci,P., Sugahara  
 Y. and Hayashizaki,Y.  
 Computer-based methods for the mouse full-length cDNA  
 encyclopedia: real-time sequence clustering for construction of a  
 nonredundant cDNA library. Genome Res. 11 (2), 281-289 (2001)  
 Kondo,S., Shinagawa,A., Saito,T., Kiyosawa,H., Yamahaka,I., Aizawa  
 K., Fukuda,S., Hara,A., Itoh,M., Kawai,J., Shibata,K. and  
 Hayashizaki,Y.  
 Computational Analysis of Full-length Mouse cDNAs Compared with  
 Human Genome Sequences. Mamm. Genome. 12, 673-677 (2001)  
 Please visit our web site (http://genome.gsc.riken.go.jp) for  
 further details.

FEATURES  
 Source  
 1..631  
 Location/Qualifiers  
 /organism="Mus musculus"  
 /db\_xref="taxon:10090"  
 /clone="E030016M12"  
 /clone\_lib="RIKEN full-length enriched, 0 day neonate  
 lung"  
 /tissue\_type="lung"  
 /dev\_stage="0 day neonate"  
 /lab\_host="DH10B"  
 /note="Site\_1: SalI; Site\_2: BamHI; cDNA library was  
 prepared and sequenced in Mouse Genome Encyclopedia  
 Project of Genome Exploration Research Group in Riken  
 Genomic Sciences Center and Genome Science Laboratory in  
 RIKEN. Division of Experimental Animal Research in Riken  
 contributed to prepare mouse tissues. 1st strand cDNA was



GenCore version 5.1.4.P5\_4578  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 28, 2003, 23:25:02 ; Search time 2011.06 Seconds  
(without alignments)  
9985.963 Million cell updates/sec

Title: US-09-729-264-5

Perfect score: 1240

Sequence: 1 aggtgtgagtcacgaacaa.....gtatacaactgtatag 1240

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 16154066 segs, 8097743376 residues

Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database :

EST:\*  
1: em\_estba:\*  
2: em\_estbm:\*  
3: em\_estin:\*  
4: em\_estnu:\*  
5: em\_estov:\*  
6: em\_estpl:\*  
7: em\_estro:\*  
8: em\_hic:\*  
9: gb\_estl:\*  
10: gb\_est2:\*  
11: gb\_hic:\*  
12: gb\_est3:\*  
13: gb\_est4:\*  
14: gb\_est5:\*  
15: em\_estfun:\*  
16: em\_estom:\*  
17: gb\_gss:\*  
18: em\_gss\_hum:\*  
19: em\_gss\_inv:\*  
20: em\_gss\_pin:\*  
21: em\_gss\_vrt:\*  
22: em\_gss\_fun:\*  
23: em\_gss\_mam:\*  
24: em\_gss\_mus:\*  
25: em\_gss\_other:\*  
26: em\_gss\_pro:\*  
27: em\_gss\_rod:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	308.2	24.9	784	12	BG863468
2	278.6	22.5	794	12	BG863468 602796941
3	265.8	21.4	725	12	BF784177 602108039
4	259	20.9	631	10	BG740428 602633817
5	246.2	19.9	527	10	BB663870 602633870
6	197.4	15.9	517	10	BE032610 132035 MA
					BE476432 159670 BA

7	190.8	15.4	622	17	AG069679
8	190.8	15.4	677	17	AG107877
9	190	15.3	524	10	AV601192
10	185.6	15.0	471	9	AA255274
11	185.6	15.0	611	10	AW990468
12	185.6	15.0	931	12	BG173684
13	185.6	15.0	1552	11	AK008060
14	184.6	14.9	468	9	A1425363
15	184	14.7	663	10	BE376590
16	182.4	14.7	650	10	BE625217
17	168.2	13.6	600	17	A2379623
18	154.8	12.3	216	12	BG206666
19	152.8	12.3	556	9	A1788300
20	151.2	12.2	530	9	A1790785
21	145.4	11.7	423	10	BB846577
22	143.8	11.6	291	17	AZ411779
23	128.8	10.4	471	12	BF040046
24	127	10.2	394	10	BB846133
25	124	10.0	685	17	AG142221
26	110	8.9	785	13	BI452873
27	102.8	8.3	889	13	BI454276
28	100	8.1	185	14	N47851
29	100	8.1	234	14	N93995
30	98.4	7.9	325	17	AQ403719
31	78.6	6.3	360	9	A1647601
32	78.6	6.3	374	9	A1648720
33	78.6	6.3	406	9	A1788973
34	77	6.2	644	10	BB513388
35	67.8	5.5	397	10	AW112084
36	63.2	5.1	282	10	BB564363
37	58.4	4.7	466	17	AQ224346
38	56	4.5	818	12	BG445021
39	52.6	4.2	422	9	A1756062
40	52.4	4.2	458	9	A1514929
41	50.6	4.1	639	17	AG133259
42	50	4.0	427	17	AO595624
43	50	4.0	447	10	AV431233
44	49.8	4.0	428	9	AA695064
45	49.6	4.0	925	17	CNS0381E

#### ALIGNMENTS

RESULT 1  
BG863468 784 bp mRNA linear EST 29-MAY-2001  
LOCUS 602796941P1 NCI\_GAP\_Mam4 Mus musculus cDNA clone IMAGE:4917803 5'  
DEFINITION BG863468.1 GI:14214006  
ACCESSION BG863468  
VERSION BG863468.1  
KEYWORDS  
SOURCE house mouse.  
ORGANISM Mus musculus

REFERENCE  
AUTHORS NIH-MGC  
TITLE NIH-MGC http://mgc.nci.nih.gov/  
JOURNAL National Institutes of Health, Mammalian Gene Collection (MGC)  
COMMENT Unpublished (1999)  
Contact: Robert Strussberg, Ph.D.  
Email: cgepstr@mail.nih.gov  
Tissue Procurement: Lothar Hennighausen Ph.D., Priscilla Furth Ph.D.

CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:  
http://image.llnl.gov  
Plate: LLNL0830 row: b column: 12  
High quality sequence stop: 768.  
Location/Qualifiers



Query Match	3.5%;	Score 40.8;	DB 4;	Length 6177;
Best Local Similarity	75.0%;	Pred. No. 0.097;		
Matches	51;	Conservative	0;	Mismatches 17;
			Indels	0;
			Gaps	0;

Search completed: April 29, 2003, 10:49:49  
Job time : 81.8976 secs



```

US-08-185-432-3/C
: Sequence 3, Application US/08185432
: Patent No. 5750652
:
: GENERAL INFORMATION:
: APPLICANT: Artavanis-Tsakonas, Spyridon
: APPLICANT: Bussau, Isabelle
: APPLICANT: Diederich, Robert J.
: APPLICANT: Xu, Tian
: APPLICANT: Matsuno, Kenji
: TITLE OF INVENTION: DELTEX PROTEINS, NUCLEIC ACIDS, AND
: TITLE OF INVENTION: ANTIBODIES, AND RELATED METHODS AND COMPOSITIONS
: NUMBER OF SEQUENCES: 23
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: PENNIE & EDMONDS
: STREET: 1155 Avenue of the Americas
: CITY: New York
: STATE: New York
: COUNTRY: U.S.A.
: ZIP: 10036-2711
:
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/185,432
: FILING DATE: 21-JAN-1994
: CLASSIFICATION: 530
: ATTORNEY/AGENT INFORMATION:
: NAME: Mistrock, S. Leslie
: REGISTRATION NUMBER: 18,872
: REFERENCE/DOCKET NUMBER: 7326-006
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (212) 790-9090
: TELEFAX: (212) 869-8864/9741
:
: INFORMATION FOR SEQ ID NO: 3:
:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 3771 base pairs
: type: nucleic acid
: STRANDEDNESS: double
: TOPOLOGY: unknown
: MOLECULE TYPE: cDNA
: FEATURE:
: NAME/KEY: CDS
: LOCATION: 345..2558
:
US-08-185-432-3
:
: Query Match 3.5%; Score 41; DB 1; Length 3771;
: Best Local Similarity 66.3%; Pred No. 0.064;
: Matches 55; Conservative 0; Mismatches 30; Indels 0; Gaps 0
:
QY 801 GCTGCTGCTGCTGCCGCCGCTGTTGTTGGCTGCACACTGCTGCGCTGTTGTTCTT 860
      |||||||
Db 1875 GCTCTGCTGCTGCGCTGTGCTGCTGCTGCTGCATGCGAGCTGTTGCTGCTGTTGCTGCT 1816
      |||||||
QY 861 GCTGTACAGAAAAGACGATTCGATT 889
      |||||
Db 1815 GCTGTGCTGCTGCGGATGCGATGCTGTAAT 1787
      |||||
:
: RESULT 13
: US-08-185-432-23
: Sequence 23, Application US/08185432
: Patent No. 5750652
:
: GENERAL INFORMATION:
: APPLICANT: Artavanis-Tsakonas, Spyridon
: APPLICANT: Bussau, Isabelle
: APPLICANT: Diederich, Robert J.
: APPLICANT: Xu, Tian
: APPLICANT: Matsuno, Kenji
: TITLE OF INVENTION: DELTEX PROTEINS, NUCLEIC ACIDS, AND

```

```

TITLE OF INVENTION: ANTIBODIES, AND RELATED METHODS AND COMPOSITIONS
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: PENNIE & EDMONDS
STREET: 1155 Avenue of the Americas
City: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/185,432
FILING DATE: 21-JAN-1994
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7326-006
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-8864/9741
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 3771 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: unknown
MOLECULE TYPE: cDNA
US-08-185-432-23

Query Match          3.5%   Score 41; DB 1; Length 3771;
Best Local Similarity 66.3%; Pred. No. 0.064;
Matches 59; Conservative 0; Mismatches 30; Indels 0; Gaps 0;

QY      801 GCCTGCTGTCCTCCGCCCGTGTGGTGCTGCACACTGCTGCGCTGTGTTCT 860
        ||||||| | | | | | | | | | | | | | | | | | | | | | | |
Db      1897 GCCTGCTGTCCTCCGCCCTTCTGCTGTGCANTCTGCAGCTGTGCTGTTGCTGCT 1956
QY      861 GCCTGCAAGAAGAAAGAGATTCGTAAT 889
        ||||| | | | | | | | | | | | | | | | | | | | | | | |
Db      1957 GCTGTGCTGTCCGGCATGCAGTGTAAT 1985

RESULT 14
US-08-185-432-1/c
Sequence 1, Application US/08185432
Patent No. 5750652
GENERAL INFORMATION:
APPLICANT: Artavanis-Tsakonas, Spyridon
APPLICANT: Bussseau, Isabelle
APPLICANT: Diederich, Robert J.
APPLICANT: Xu, Tian
APPLICANT: Matsuno, Kenji
TITLE OF INVENTION: DELTEX PROTEINS, NUCLEIC ACIDS, AND
TITLE OF INVENTION: ANTIBODIES, AND RELATED METHODS AND COMPOSITIONS
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: PENNIE & EDMONDS
STREET: 1155 Avenue of the Americas
City: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
```

PCT-US92-11107-12

## Query Match

Best Local Similarity 64.9%; Score 42.6; DB 5; Length 3292;  
Matches 63; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 797 ATACGCTGCTGCTGCGCGCGTGTGTGTGCTGCAACTGCTGCGCGTGTGTGTGT 856

DB 818 AGATGATATGTTGTGTGTGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 759

QY 857 TTCTGCTGTAGAGAAAAGAGATTGTGTATCAAT 893

DB 758 TGTCTGCTGT 722

## RESULT 9

US-09-043-303-12/c  
Sequence 12, Application US/09043303

Patent No. 6251589

GENERAL INFORMATION:

APPLICANT: TSUJI, Shoji

TITLE OF INVENTION: Method for Diagnosing Spinocerebellar Ataxia Type 2 and

FILE REFERENCE: 0760-0241P

CURRENT FILING DATE: 1998-05-18

EARLIER APPLICATION NUMBER: PCT/J996/01999

NUMBER OF SEQ ID NOS: 17

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 12

LENGTH: 78

TYPE: DNA

ORGANISM: Homo sapiens

US-09-043-303-12

Query Match

Best Local Similarity 78.1%; Score 41.6; DB 4; Length 78;

Matches 50; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 801 GCTGCTGCTGCTGCGCGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 860

DB 67 GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 8

QY 861 GCTG 864

DB 7 GCTG 4

## RESULT 10

US-09-043-303-7/c

Sequence 7, Application US/09043303

Patent No. 6251589

GENERAL INFORMATION:

APPLICANT: TSUJI, Shoji

TITLE OF INVENTION: Method for Diagnosing Spinocerebellar Ataxia Type 2 and

FILE REFERENCE: 0760-0241P

CURRENT FILING DATE: 1998-05-18

EARLIER APPLICATION NUMBER: PCT/J996/01999

NUMBER OF SEQ ID NOS: 17

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 7

LENGTH: 203

TYPE: DNA

ORGANISM: p-2093 plasmid

US-09-043-303-7

Query Match

Best Local Similarity 78.1%; Score 41.6; DB 4; Length 203;

Best Local Similarity 78.1%; Pred. No. 0.0081;  
Matches 50; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 801 GCTGCTGCTGCTGCGCGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 860

DB 67 GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 8

QY 861 GCTG 864

DB 7 GCTG 4

## RESULT 11

US-08-145-617-5/c  
Sequence 5, Application US/08145617

Patent No. 5766847

GENERAL INFORMATION:

APPLICANT: JACKIE, Herbert

APPLICANT: Tautz, diethard

TITLE OF INVENTION: PROCESS FOR ANALYZING LENGTH

NUMBER OF SEQUENCES: 6

CORRESPONDENCE ADDRESS:

ADDRESSEE: BIRCH, STEWART, KOLASCH & BIRCH

STREET: 301 N. Washington Street, P.O. Box 747

CITY: Falls Church

STATE: Virginia

COUNTRY: United States of America

ZIP: 22046

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/145,617

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/6681,494

FILING DATE: 10-JUN-1991

APPLICATION NUMBER: DE P3834636.2

FILING DATE: 11-OCT-1988

ATTORNEY/AGENT INFORMATION:

NAME: Svensson, Leonard R.

REGISTRATION NUMBER: 30,330

REFERENCE/DOCKET NUMBER: 147-122PCT

TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-241-1300

TELEFAX: 703-241-2848

TELEX: 248345

INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:

LENGTH: 379 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

US-08-145-617-5

Query Match

Best Local Similarity 67.4%; Score 41.2; DB 1; Length 379;

Matches 58; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 779 CGAGCGTACTCTTACAAATACGCTGCTGCGCGCGTGTGTGTGTGTGTGTGT 838

DB 214 CGAAGCTCCAGGCGCTCGAATGCTGTGTGTGTGTGTGTGTGTGTGTGTGT 155

QY 839 TGCTGCTGCGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 864

DB 154 TGCTGCTGTGATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 129

```

FEATURE:
NAME/KEY: CDS
LOCATION: 1..1626
US-08-328-809-7

Query Match 3.6%; Score 42.6; DB 1; Length 3292;
Best Local Similarity 64.9%; Pred. No. 0.02;
Matches 63; Conservative 0; Mismatches 34; Indels 0; Gaps

OY 797 ATACGCTGCTGCTGCTGCCGCCGCGCTGTTGTGTGCTGCACACTGCTGCCGTTGTTGT 856
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 818 AGATGATGATGATGTTGTTGTGAAGTGTGTTGTTGTTGTCACACTGCGTGTGTGAC 755
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

OY 857 TTCTGCTGTAGAAAGAAAAGAGATTGCGATTTCAT 893
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 758 TCTGCTGTTGCTGCACACTGCTGTTGTTGTTGTAATT 722
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 8
PCT-US92-11107-12/c
Sequence 12, Application PC/TUS9211107
GENERAL INFORMATION:
APPLICANT: Donahue, Brian A.
APPLICANT: Toney, Jeffrey H.
APPLICANT: Bruhn, Suzanne L.
APPLICANT: Pill, Pieter M.
APPLICANT: Brown, Steven
APPLICANT: Kellelt, Patti
APPLICANT: Essigmann, John M.
APPLICANT: Lippard, Stephen J.
TITLE OF INVENTION: DNA Structure Specific Recognition
TITLE OF INVENTION: Protein and Uses Therefor
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
STREET: 2 Militia Drive
CITY: Lexington
STATE: MA
COUNTRY: USA
ZIP: 02173
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/11107
FILING DATE: 19921218
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/539,906
FILING DATE: 18-JUN-1990
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia
REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: MIT-4787AAA
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 3292 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE:
ORGANISM: Saccharomyces cerevisiae
IMMEDIATE SOURCE:
CLONE: lambda ypt
FEATURE:
NAME/KEY: CDS
LOCATION: 1..1626

```



```

MEDUIM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/531,927B
FILING DATE: 21-SEP-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP H6-251600
FILING DATE: 21-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia
REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: ATH95-01A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 1776 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: CDS
LOCATION: 36..1115
US-08-531-927B-1

Query Match 3.7%; Score 42.8; DB 2; Length 1776;
Best Local Similarity 61.8%; Pred. No. 0.012; Indels 0; Gaps 0.
Matches 68; Conservative 0; Mismatches 42;

QY 801 GCTGCGTCGTCGCCGCCGCTGTTGTGGCTGCACTGCTGCGCCGTTGTTGTC 860
Db 975 GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 916
QY 861 GCTGTAGAGAAAAGAGAGATTGCTATTCAATTCCAAAAGAAATTCGAA 910
Db 915 GCTGCTGTTTTCAAAGTAGGCTCTCGTCTTCGCCAAGCTCTTCGAA 866

RESULT 4
US-09-041-886-12/c
; Sequence 12, Application US/09041886
; Patent No. 6235872
; GENERAL INFORMATION:
; APPLICANT: Redesen, Dale E.
; TITLE OF INVENTION: Proapoptotic Peptides, Dependence
; TITLE OF INVENTION: Polypeptides and Methods of Use
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDUIM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/041,886
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-17 2626
; TELECOMMUNICATION INFORMATION:

```









XX This invention relates to the use of a plasmid vector array  
 CC containing a neuropsychiatric gene containing trinucleotide repeats.  
 CC Tri-nucleotide repeats and their expansion are known to be involved  
 CC in a number of diseases including fragile X syndrome, spinocerebellar  
 CC ataxia type III, hereditary hypertrrophic, cardiomyopathy, dentatorubral  
 CC and pallidoluysian atrophy (DRPLA), spinocerebellar ataxia, Marfan  
 CC syndrome, X-linked spinobulbar atrophy. The present sequence represents  
 CC a tri-nucleotide repeat related sequence #5 disclosed in the scope  
 CC of the invention.  
 CC Note: Nucleotides which were illegible in the specification have  
 CC been represented by an n to keep nucleotide numbering correct.  
 XX  
 SQ Sequence 389 BP; 107 A; 92 C; 91 G; 93 T; 6 other;

Query Match 4.4%; Score 51.8; DB 21; Length 389;  
 Best Local Similarity 57.4%; Pred. No. 0.00035;  
 Matches 89; Conservative 0; Mismatches 66; Indels 0; Gaps 0;

QY 801 GCTGCTCTGCTGCGCCGCTGTTGTTGGTGCACACTGCTGCGCTGTTGTTGTTCT 860  
 DB 178 GCTGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 119  
 QY 861 GCTGTAGAGAAAAAGAGATTTCATTTCAATTTCAAGAAATCTGAAAAAGAGAGA 920  
 DB 118 GCTGTCTGCTCTTTTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 59  
 QY 921 CAACAAAGAACTGACAGCAAGAAAGTGAATGAA 955  
 DB 58 AANTTAAGAAANACCTACACCATGAGNTANAAAA 24

RESULT 13  
 AAX89891/c  
 ID AAX89891 standard; DNA: 397 BP.

XX AAX89891;

XX AC 05-NOV-1999 (first entry)

XX DE Spinocerebellar ataxia type III (SCAIII) gene fragment.

XX KM Spinocerebellar ataxia type III; SCAIII; reverse dot hybridisation;  
 KM PCR-microplate hybridisation; PCR-MPH; trinucleotide repeat; TNR.  
 XX KM SCAIII syndrome; ss.

XX OS Homo sapiens.

XX Key Location/Qualifiers  
 FH repeat\_region 137..355  
 FT repeat\_unit /tag= a  
 FT repeat\_unit 137..139  
 FT repeat\_unit /tag= b  
 FT repeat\_unit /note= "trinucleotide repeat"

XX MO9943852-A1.

XX PD 02-SEP-1999.

XX PF 18-FEB-1999; 99MO-KR00078.

XX PR 26-FEB-1998; 98KR-0006278.

XX PA (JIND/) JIN D K.  
 PA (SMSU ) SAMSUNG FINE CHEM CO LTD.

XX PI Jin DK;

XX WPI; 1999-527634/44.

XX PT Diagnosis of spinocerebellar ataxia type III (SCA III) syndrome  
 XX using techniques which ensure highly accurate diagnosis  
 XX

PS Claim 1; Page 12-13; 28pp; English.

XX The invention relates to the diagnosis of spinocerebellar ataxia type  
 CC III (SCAIII) syndrome using reverse dot hybridisation or PCR-microplate  
 CC hybridisation (PCR-MPH). The method comprises attaching a portion of the  
 CC SCAIII gene containing 73 copies of the trinucleotide (CAG) repeat unit  
 CC (the present sequence) to a substrate, and hybridising with amplified  
 CC testee genomic DNA containing copies of the trinucleotide units, PCR  
 CC amplified with labeled primers (AAX89899-90). The new method is useful  
 CC for diagnosis of SCAIII syndrome, and for determining the severity of  
 CC the disease. The present sequence represents the SCAIII gene fragment  
 CC containing 73 trinucleotide (TNR) repeats.  
 XX

SQ Sequence 397 BP; 124 A; 104 C; 104 G; 65 T; 0 other;

Query Match 4.4%; Score 51.8; DB 20; Length 397;  
 Best Local Similarity 58.9%; Pred. No. 0.00035;  
 Matches 89; Conservative 0; Mismatches 62; Indels 0; Gaps 0;

QY 801 GCTGCTGCTGCTGCGCCGCTGTTGTTGGTGCACACTGCTGCGCTGTTGTTGTTCT 860  
 DB 200 GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 141  
 QY 861 GCTGTAGAGAAAAAGAGATTTCATTTCAATTTCAAGAAATCTGAAAAAGAGAGA 920  
 DB 140 GCTGTGCTGCTTTTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 81  
 QY 921 CAACAAAGAACTGACAGCAAGAAAGTGAATGAA 951  
 DB 80 AACTTAAGAAATTAATACCATGAGAAAA 50

RESULT 14  
 ABR10240/c  
 ID ABR10240 standard; DNA: 403 BP.

XX ABR10240;

XX AC 20-MAY-2002 (first entry)

XX DE Trinucleotide repeat sequence #3.

XX KM Trinucleotide repeat; fragile X syndrome; ds;  
 KM spinocerebellar ataxia type III; DRPLA; neuropsychiatric;  
 KM hereditary hypertrrophic cardiomyopathy; Marfan syndrome;  
 KM dentatorubral and pallidoluysian atrophy;  
 KM spinocerebellar ataxia; X-linked spinobulbar atrophy.

XX OS Homo sapiens.

XX Key Location/Qualifiers  
 FH repeat\_region 152..347  
 FT repeat\_unit /tag= a  
 FT repeat\_unit /rpt\_type= TANDEM  
 FT repeat\_unit 152..154  
 FT repeat\_unit /tag= b  
 FT repeat\_unit /note= "CAG type repeat"

XX MO9943852-A1.

XX PD 15-JAN-2000.

XX PF KR2000003004-A.

XX PR 25-JUN-1998; 98KR-0024064.

XX PA (JIND/) JIN D G.

XX PI (SMSU ) SAMSUNG MEDICAL CENT.

XX WPI; 1999-527634/44.

XX PT Diagnosis of spinocerebellar ataxia type III (SCA III) syndrome  
 XX using techniques which ensure highly accurate diagnosis  
 XX





RESULT 8	
ID	ABK13034
AC	ABK13034 standard; cDNA; 754 BP.
XX	
XX	ABK13034;
DT	23-APR-2002 (first entry)
XX	
DE	DNA encoding mouse B7-1-like protein, B7-L <sub>m3</sub> .
XX	
KW	Mouse; B7-1-like protein; B7-L; antiinfectility; gynaecological;
KW	antitumour; cytostatic; immunosuppressive; antiarthritic; antirheumatic;
KW	antiinflammatory; dermatological; antiparasitic; neuroprotective;
KW	antidiabetic; haemostatic; antithyroid; antitumor; antiallergic;
KW	antiasmatic; nephrotoxic; antibacterial; virucide; tumour; cancer;
KW	reproductive disorder; graft versus host disease; autoimmune disease;
KW	toxic shock syndrome; allergy; nephropathy; skin disorder;
KW	endocrinopathy; lymphoproliferative disorder; gene; ss.
XX	
OS	Mus musculus.
XX	
PH	Key
FT	Location/Qualifiers
FT	CDS
FT	53..724
FT	/tag= a
FT	/product= "B7-1-like protein, B7-L <sub>m3</sub> "
PN	W0200200710-A2.
XX	
XX	03-JAN-2002.
PF	28-JUN-2001; 2001MO-US20719.
XX	
PR	28-JUN-2000; 2000US-214512P.
XX	
PR	28-NOV-2000; 2000US-0729264.
XX	
PA	(AMGE-) AMGEN INC.
PI	Weicher AA, Sarmiento UM, Schultz HJ, Chute HT;
DR	WPI: 2002-130881/17.
XX	P-PSDB: AAU75546.
PT	New B7-1-like polypeptides, polynucleotides and their modulators, useful
PT	for diagnosing, preventing and treating reproductive, immune and
XX	proliferative disorders, e.g. cancer and arteriosclerosis -
PS	Claim 1; Fig 7; 135pp; English.
XX	
CC	The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).
CC	The polypeptide, polynucleotide encoding it and antibody against (I) are
CC	useful for treating B7-1-like polypeptide-related disease, disorders or
CC	conditions including reproductive disorders (e.g. infertility,
CC	miscarriage, preterm labour and delivery and endometriosis) and
CC	proliferative disorders. Antibodies, soluble proteins comprising are
CC	extracellular domains and other regulators of B7-L polypeptides are
CC	useful for enhancing the immune response to tumours. (i) plays a role in
CC	growth and maintenance of cancer cells based on the observation of
CC	seminal vesicle hyperplasia in transgenic mice overexpressing B7-L
CC	polypeptide. Hence modulators of (I) are useful for the treatment of
CC	cancer including seminal vesicle cancer, lung, brain, breast, ovarian,
CC	testicular cancer and cancers of haematopoietic system. B7-L polypeptide
CC	pathway can be manipulated to regulate cytotoxic T-lymphocyte response
CC	in allograft transplantation, graft versus host disease, T-cell
CC	dependent B-cell mediated diseases and autoimmune diseases. B7-L
CC	molecules are useful for alleviating the symptoms associated with
CC	diseases involving chronic immune cell dysfunction or to treat
CC	autoimmune diseases such as systemic lupus erythematosus, rheumatoid
CC	arthritis, multiple sclerosis, diabetes, immune thrombocytopenic
CC	purpura and psoriasis, chronic inflammatory disease such as
CC	inflammatory bowel disease (Crohn's disease and ulcerative colitis),
CC	grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They
CC	are also useful as immunosuppressive agents for bone marrow and organ

CC	transplantation or to prolong graft survival. B7-L molecules are also
CC	useful for diagnosis and treatment of diseases involving abnormal cell
CC	proliferation, including arteriosclerosis and vascular restenosis.
CC	Antagonists of B7-L polypeptides are useful for alleviation of toxic
CC	shock syndrome or allosensitisation due to blood transfusions, and for
CC	treatment of allergy, asthma and hypersensitivity reactions,
CC	nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and
CC	pemphigoid), endocrinopathies (Graves' disease), various pneumopathies
CC	(extrinsic alveolitis) vasculopathies, coeliac disease, anaemia,
CC	thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and
CC	lymphoproliferative disorders such as multiple myeloma. The present
CC	sequence represents the coding sequence of mouse B7-L <sub>m3</sub> .
SQ	Sequence 754 BP; 220 A; 191 C; 175 G; 168 T; 0 other;
Query Match	15.6% Score 181.8; DB 24; Length 754;
Best Local Similarity	72.9%; Pred.No.3.3e-40;
Matches 234; Conservative	0; Mismatches 87; Indels 0; Gaps 0
OY	42 CCGGTTCTGGGTCTGTGTAATGAAGTCAATGAAGGCCCCCAAATGCAGACGTCTGAAGG 101
Dd	108 CAGCITTCGGATTCACAGTATCATGATCATGAAAGTGCTCAGATGTAACAAGTCTAAGAAG 167
OY	102 GTCTCCAGAGCTCGCTTCAACTGCACCGRTCCTCCAGAGCTGGAAGCTCATCATGTGGGCTC 161
Dd	168 ACTCAGAGGCTACTTCAACTGCACCGRTCACACGGCTGGAAGCTTCTCATGTGGACATC 227
OY	162 TCAGTAGCATGTGTGTGTCATAGCTCAGAGCCCATGGAGCCCATCATCACCAATGACCGCT 221
Dd	228 TTACCAAAATGGTGTGGTGTGCTGAGTCTCACACCCAAAGAACCCATCATCACCACAAACCGCT 287
OY	222 TCACCTCTCAGAGGTACGACCAAGGGGGGAACTTCACTCGSAGATGATCACCACATG 281
Dd	288 TCACCTATGCCCAGTTACCAACACGACTGCAGCTTCACTCTCGGAGTTGATCATCATCAGAG 347
OY	282 TGAGAGCCAGTGATTTCGGGAGACATCAATGAGAGCCTCCAGAAACAGTGCCTGCATGGAT 341
Dd	348 TGCAGCCCCAGTACTTCGGGATCCGTGCATGAGAGCCTGCAAGACACGCCATGGGTTTGGAT 407
OY	342 CTGCTTACCTTACCTGCTCAAG 362
Dd	408 CTGCCTTCTCTCAGTGCMAAG 428
RESULT 9	
ID	ABK13033 standard; cDNA; 895 BP.
XX	ABK13033;
XX	23-APR-2002 (first entry)
DE	DNA encoding mouse B7-like protein, B7-L <sub>m2</sub> .
XX	Mouse; B7-like protein; B7-L; antifertility; gynaecological;
KW	antitumour; cytostatic; immunosuppressive; antithalritic; anti-neumatic;
KW	antiinflammatory; dermatological; antiporiatic; neuroprotective;
KW	antidiabetic; haemostatic; antithyroid; antituber; antiallergic;
KW	antilastrmatic; nephrotropic; antibacterial; virucide; tumour; cancer;
KW	reproductive disorder; graft versus host disease; autoimmune disease;
KW	toxic shock syndrome; allergy; nephropathy; skin disorder;
XX	endocrinopathy; lymphoproliferative disorder; gene; ss.
XX	Mus musculus.
XX	
FH	Key Location/Qualifiers
FT	CDS 53..865
FT	/tag= A
FT	/product= "B7-like protein, B7-L <sub>m2</sub> "
FN	WO200200710-A2.
XX	
DD	03-JAN-2002.

QY 42 CCGTCTCGGCTCTGTAATGAGTCAATAGAGGCCCCCAAAATGCAAGAGCTCTGAAG 101  
 Db 108 CAGCTTCGGGATCCAGTATACATAGAGGTCTCTCAGAAATGTAACGCTTAAGG 167  
 QY 102 GCTCCAGGGCTCGCTCAACGTCCACCGCTCCCGGGCTGGAAGCTCATCATGGGGCTC 161  
 Db 168 ACTGAGAGGCTCACTTCACTGACCGCTGACTCAGCTGAGCTGAGCTTCTCATGTGGACTC 227  
 QY 162 TCAGTGAATAGTGTGCTAAGCTCAGGCCCATGAGCCCATCATGACCAATGACCGCT 221  
 Db 228 TTAACCAATAGTGTGTGAGTGTCTACACCAAGAGAGCCCATCATGACCAACCGCT 267  
 QY 222 TCACCTCTCAGAGGTAGACAGCGGGGGAATTCACCTGAGAGATGATCATCCACATG 261  
 Db 288 TCACCTATGCGAGTTAACAACGACACTGACACTTCATCTCAGAGTTGATCATCATATG 347  
 QY 282 TGGAGCCAGTATGTTGGGGGAACATGACAGCTCCAGCAACAGCGGCTCGATGAT 341  
 Db 348 TGCAGCCAGTACTCGGGATCCGTCAATGACGCTGCAAGAACGCCATGAGGTTGGAT 407  
 QY 342 CTGCTACCTTACCGTCAAGTATAGGAGAGCTGTTCATTCCTCCAGTGAATCTGTAG 401  
 Db 408 CTGCTCTCTCAGTCAAGTCAAGTCAAGGGAACCTGAAACATTCCTAGCAACACCTATAG 467  
 QY 402 TCGCTGAAGTGAACCTTGAAGTACTGTCTACCTCAGACTGAGCTGGCTCCGG 461  
 Db 468 TCACCTGAGGGGGAACCTGTAAATGTGACTGTATGCGGCTGAGCTCCTCCTCCGG 527  
 QY 462 ATATTCTCGGAGCTCGTCTCCTGCTCAGCCATTCAGCTATTAATTTGTTCCGAGC 521  
 Db 528 ATATTCTCGGAGCTGAGGTTCCCTTAAGCCATTCGATTAATTTCTTTCTGAGC 567  
 QY 522 CCAAGCACTTCAAAAGTCAAGTGAAGTCACTGCTGACCCCAAGAGCAATGAGACTT 561  
 Db 588 CGGCAACTTATAGGAGTCTGTAGTCTCTGAGCTCACACCACTGAGGAGCGGAGCT 647  
 QY 582 TGACTTGGGGTACTGCTGAAGAGCTGAAGGCCCAAGTCTGCACTGTAATCTCA 641  
 Db 648 TGACTTGTGGGAGAGCTGAAGAGCTGAGGCGAGCAAGCTTAACTGTAACCTGA 707  
 QY 642 CTGTGATTCGGTCCCAAGACACTGAGGTGTTATTAATTCAGGTATTTATCA 701  
 Db 708 CTGTGATTCAGCTCCACCTGACAGTATGTAAGGA----- 744  
 QY 702 GTTTACGAGTTAGTTTTCATTCCTACTTGGGGCAAGTTGAGTGAAGTGAAG 761  
 Db 745 -----AGGCCAGCACTGCCGACCTGGGCCATTCCTGCTGGAGTGGCCT 791  
 QY 762 GCACCATGCTTTCAGAGCCGACGCTGTAATACATACGCTGCTGCTGCCGCCCTC 821  
 Db 792 TTTCTTGTCTCTGATCTGATCATGTTTGAATTAATATTCCTGTGTG----- 843  
 QY 822 GTTGTGTGCTGCAACTGCTGCGCTGTGTTGTTCTGCTGTAAGAAAGAGAT 881  
 Db 844 -----TTGTGCTTCACAGAGAGAAAGAGATCTACTTATCAAAATGAAATAGAGAA 898  
 QY 882 TTGCTATTCATTTCAAAAGAAATCTGAAAAAGAGAGACAAACAAAGTGAAGACG 941  
 Db 899 TCTGCAAACTGAGAGCA-----ACAAAGAGATCCGAGACAAAGTTAA 944  
 QY 942 AAGTGAATGAAGAACTCGGCTACATTCAGATGAACAAAGAGACAGACAGACCGCTT 1001  
 Db 945 AAGTGAAGAAAGAAATACAGGCTACGATGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1004  
 QY 1002 CTCTCCCTCCCAATCTCTGTAATTCAGATGCTTCAACAAAGAGAGAGTGTGGCC 1061  
 Db 1005 CTCTCCCTCTTAATCTGTAAGTCAAGCTTCAGAAAAAGCAGACAGTA-----GCC 1058  
 QY 1062 CTCTCTACAGCGGGGCTGATCAAGCTCAAGCCAGGCGAGAGTCAATCCACAGCTTCTT 1121  
 Db 1059 TTCTTATTCAGGAATCAATTAATCAATCAGCCGCTCAGCAACTCAACAGGCTTCTT 1118

QY 1122 TTAATCTGGCCAGTCTCTGGAAGGTCTAGTAATACACTGTAGTATA 1167  
 Db 1119 TTGACATCGCCAGTCTCTCAGAGGTCAAGTAATGTACTTATGTA 1164

RESULT 7  
 AA136582  
 ID AA136582 standard; DNA; 401 BP.  
 XX  
 AC AA136582;  
 XX  
 DT 17-OCT-2001 (first entry)  
 XX  
 DE Probe #5266 used to measure gene expression in human placenta sample.  
 XX  
 KW Probe; microarray; human; placenta; antenatal diagnosis;  
 KW genetic disorder; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200157272-A2.  
 XX  
 PD 09-AUG-2001.  
 XX  
 PE 30-JAN-2001; 2001WO-US00663.  
 XX  
 PR 04-FEB-2000; 2000US-0180312.  
 XX  
 PR 26-MAY-2000; 2000US-0207456.  
 XX  
 PR 30-JUN-2000; 2000US-0608408.  
 XX  
 PR 03-AUG-2000; 2000US-0632365.  
 XX  
 PR 21-SEP-2000; 2000US-0233687.  
 XX  
 PR 27-SEP-2000; 2000US-0236359.  
 XX  
 PR 04-OCT-2000; 2000GB-0024263.  
 XX  
 PA (MOLE-) MOLECULAR DYNAMICS INC.  
 XX  
 PI Penn SG, Hanzel DK, Chen W, Rank DR;  
 XX  
 DR WPI; 2001-488897/53.  
 XX  
 PT Human genome-derived single exon nucleic acid probes useful for  
 PT analyzing gene expression in human placenta -  
 XX  
 PS Claim 25; SEQ ID No 5266; 654bp; English.  
 XX  
 CC The present invention relates to single exon nucleic acid probes (SENP).  
 CC The present sequence is one such probe. The probes are useful for  
 CC producing a microarray for predicting, measuring and displaying gene  
 CC expression in samples derived from human placenta. The probes are useful  
 CC for antenatal diagnosis of human genetic disorders.  
 XX  
 SQ Sequence 401 BP; 105 A; 98 C; 111 G; 87 T; 0 other;

Query Match 16.8%; Score 196.8; DB 22; Length 401;  
 Best Local Similarity 96.6%; Pred. No. 1.6e-44;  
 Matches 201; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 27 AATATAGAGACCCAGCCGCTCTGAGTCTGTAATGAGTCAATGAGAGGCCCAAAATG 86  
 Db 194 AATATGAGTCTGAGTCTGAGTCTGAGTCTGTAATGAGTCAATGAGAGGCCCAAAATG 253  
 QY 87 CAAGAGTCTGAGAGGCTCCAGAGCTGCTTCAACTGACAGCGTCTCCAGGGCTGGAAGC 146  
 Db 254 CAAGAGTCTGAGAGGCTCCAGAGCTGCTTCAACTGACAGCGTCTCCAGGGCTGGAAGC 313  
 QY 147 TCATATGAGGCTCTGAGTCAATGAGTGTGCTAAGGCTGAGGCCATGAGGCCATCA 206  
 Db 314 TCATATGAGGCTCTGAGTCAATGAGTGTGCTAAGGCTGAGGCCATGAGGCCATCA 373  
 QY 207 TCACCAATGAGCGCTTCACTCTCAGAG 234  
 Db 374 TCACCAATGAGCGCTTCACTCTCAGAG 401



Db 241 GGAAGCTCAGCTCGAGATGATCATCCACAATGTGGAGCCAGATTCGGGAAACATC 300  
 QY 308 AGATGACAGCTCCAGAACAGTCCCTGATGATTCCTTACCTTACCTGCAAGTATG 367  
 Db 301 AGATGACAGCTCCAGAACAGTCCCTGATGATTCCTTACCTTACCTGCAAGTATG 360  
 QY 368 GAGAGCTGTTCAATCCAGTGTATTCCTGTAGTCGCTGAGAAATGAACCTGTGAAGT 427  
 Db 361 GAGAGCTGTTCAATCCAGTGTATTCCTGTAGTCGCTGAGAAATGAACCTGTGAAGT 420  
 QY 428 ACTGTCTACCTCAGACAGTGGCTGGGATATTCCTGGAGAGCTGGCTCCG 487  
 Db 421 ACTGTCTACCTCAGACAGTGGCTGGGATATTCCTGGAGAGCTGGCTCCG 480  
 QY 488 GTGAGCCATTCAAGCTTATTTTGTCCGAGCCAGCCAGCTTCAAGTGAAGTGAAG 547  
 Db 481 GTGAGCCATTCAAGCTTATTTTGTCCGAGCCAGCCAGCTTCAAGTGAAGTGAAG 540  
 QY 548 ATCTGTGCTGTGACCCAGACAGCAATGGAGCTTGTGCTGGCTGCTGCAAGAGC 607  
 Db 541 ATCTGTGCTGTGACCCAGACAGCAATGGAGCTTGTGCTGGCTGCTGCAAGAGC 600  
 QY 608 CTGAGAGCCCGCAAGTGTGCACTGTGAATCTGATGTGATGGTGGTCCCAAGACAT 667  
 Db 601 CTGAGAGCCCGCAAGTGTGCACTGTGAATCTGATGTGATGGTGGTGGTCCCAAGACAT 660  
 QY 668 GAGAGTGTATATATATTCAGGTGTATATATCAAGTTTACCGATTAGTTTTCATTG 727  
 Db 661 GAGAGTGTATATATATTCAGGTGTATATATCAAGTTTACCGATTAGTTTTCATTG 720  
 QY 728 CCACTGTGGGCAAGTGTGACTGTGACAGGACCAATGCTTGTGACGCGGAGCTGT 787  
 Db 721 CCACTGTGGGCAAGTGTGACTGTGACAGGACCAATGCTTGTGACGCGGAGCTGT 780  
 QY 788 ACTTTCATATACGCTGCTGCTGCGCGCGCTGTGTGTGTGCTGCAACTGCTGCTGC 847  
 Db 781 ACTTTCATATACGCTGCTGCTGCGCGCGCTGTGTGTGTGCTGCAACTGCTGCTGC 840  
 QY 848 CGTTGTGTGTGCTGT 907  
 Db 841 CGTTGTGTGTGCTGT 878  
 QY 908 GAAAAAGAGAGCAAAAGAAAGAACTGAGACAGAAAGTGAAGTGAAGTGAAGTGAAGT 967  
 Db 879 GAAAAAGAGAGCAAAAGAAAGAACTGAGACAGAAAGTGAAGTGAAGTGAAGTGAAGT 938  
 QY 968 AATTGAGATGACAAAGAGACAGACACCGCTTCTCTCCCTCCCAATCTGTGATTC 1027  
 Db 939 AATTGAGATGACAAAGAGACAGACACCGCTTCTCTCCCTCCCAATCTGTGATTC 998  
 QY 1028 AGTGTCTCTACCAAGAAAGAGTGTGTGCGCTCTCTACCAAGCGGGCTGATCAAGT 1087  
 Db 999 AGTGTCTCTACCAAGAAAGAGTGTGTGCGCTCTCTACCAAGCGGGCTGATCAAGT 1058  
 QY 1088 CCAGCCAGGAGAGT 1147  
 Db 1059 CCAGCCAGGAGAGT 1118  
 QY 1148 AGTATATCAACTGTATATA 1167  
 Db 1119 AGTATATCAACTGTATATA 1138  
 RESULT 5  
 AAS92356 ID AAS92356 standard; cDNA; 1392 BP.  
 XX AAS92356;  
 AC  
 XX 13-FEB-2002 (first entry)  
 DT  
 XX  
 DE DNA encoding novel human diagnostic protein #28160.  
 XX

KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder; ss.  
 OS Homo sapiens.  
 PN WO200175067-A2.  
 XX 11-OCT-2001.  
 PD 30-MAR-2001; 2001WO-US08631.  
 PF 31-MAR-2000; 2000US-0540217.  
 PR 23-AUG-2000; 2000US-0649167.  
 XX (HYSE-) HYSEQ INC.  
 PA Drmanac RT, Liu C, Tang YT;  
 PI WPI: 2001-639362/73.  
 DR P-PSDB; ABG28169.  
 DX  
 XX  
 PT New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity  
 PS  
 PS Claim 1; SEQ ID No 28160; 103pp; English.  
 CC The invention relates to isolated polynucleotide (I) and  
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,  
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
 CC and gene mapping, and in recombinant production of (II). The  
 CC polynucleotides are also used in diagnostics as expressed sequence tags  
 CC for identifying expressed genes. (I) is useful in gene therapy techniques  
 CC to restore normal activity of (II) or to treat disease states involving  
 CC (II). (II) is useful for generating antibodies against it, detecting or  
 CC quantitating a polypeptide in tissue, as molecular weight markers and as  
 CC a food supplement. (II) and its binding partners are useful in medical  
 CC imaging of sites expressing (II). (I) and (II) are useful for treating  
 CC disorders involving aberrant protein expression or biological activity.  
 CC The polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. AAS64197-AAS94564 represent novel human  
 CC diagnostic coding sequences of the invention.  
 CC Note: The sequence data for this patent did not appear in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequences.  
 XX  
 SQ Sequence 1392 BP; 338 A; 361 C; 341 G; 352 T; 0 other;  
 Query Match 66.6%; Score 777.6; DB 23; Length 1392;  
 Best Local Similarity 87.2%; Pred. No. 6.8e-206;  
 Matches 912; Conservative 0; Mismatches 24; Indels 110; Gaps 1;  
 QY 152 ATGTGGGCTTCAGTACAGATGT 211  
 Db 1 ATGTGGGCTTCAGTACAGATGT 60  
 QY 212 ATGTGGGCTTCAGTACAGATGT 271  
 Db 61 ATGTGGGCTTCAGTACAGATGT 120  
 QY 272 ATTCACAAATGTGAGCCAGAGTATTCGAGGAAATCAGATCAGCTCCAGAAAGTCCG 331  
 Db 121 ATTCACAAATGTGAGCCAGAGTATTCGAGGAAATCAGATCAGCTCCAGAAAGTCCG 180  
 QY 332 CTGATGATCTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCT 391  
 Db 181 CTGATGATCTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCT 240  
 QY 392 ATCTTTGTAGTCGCTGAGAAATGAACCTTGTGAAGTACTTGTCACTCACTCACTCACTGAGC 451

QY 634 AATCTCAGTGTGATGCTGCTCCCAAGACAGTGGATGATTAATATTCAGGTGT 693  
 DB 706 AAATCTCAGTGTGATGCTGCTCCCAAGACAGTGGATGATTAATATTCAGGTGT 765  
 QY 694 ATATCAAGTTTACCGATTAGGTTTTCATTGCTTCTGCTGGGCAAGTGGACTTGG 753  
 DB 766 ATATCAAGTTTACCGATTAGGTTTTCATTGCTTCTGCTGGGCAAGTGGACTTGG 825  
 QY 754 ACTGACGAGCAGCATGCTTCTGACGCGGAGTGTACTTCAATATAGCTGCTGCTG 813  
 DB 826 ACTGACGAGCAGCATGCTTCTGACGCGGAGTGTACTTCAATATAGCTGCTGCTG 885  
 QY 814 CCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 873  
 DB 886 CCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 945  
 QY 874 AAGAGGATTTGCTGATTCATTTCAAAAGAAATCTGAAAAGAGAGACAAACAAAGAAC 933  
 DB 946 AAGAGGATTTGCTGATTCATTTCAAAAGAAATCTGAAAAGAGAGACAAACAAAGAAC 1005  
 QY 934 TGAGACGAGGATTTGCTGATTCATTTCAAAAGAAATCTGAAAAGAGAGACAAACAAAGAAC 993  
 DB 1006 TGAGACGAGGATTTGCTGATTCATTTCAAAAGAAATCTGAAAAGAGAGACAAACAAAGAAC 1065  
 QY 994 CACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1053  
 DB 1066 AAGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1125  
 QY 1054 CTGTGGCCCTTCTGACGAGGCTGATTCACAGTCCACGAGGCGACAGTCAATCCACA 1113  
 DB 1126 CTGTGGCCCTTCTGACGAGGCTGATTCACAGTCCACGAGGCGACAGTCAATCCACA 1185  
 QY 1114 GCGTTCTTTTATCTGCGCAGTCTCTGAGAGGTGATTAATCAACTGTAGTATAG 1168  
 DB 1186 GCGTTCTTTTATCTGCGCAGTCTCTGAGAGGTGATTAATCAACTGTAGTATAG 1240  
 RESULT 4  
 ABK13031  
 ID ABK13031 standard; cDNA: 1139 BP.  
 AC ABK13031;  
 XX 23-APR-2002 (first entry)  
 DE DNA encoding human B7-1-like protein, B7-L<sub>h4</sub>.  
 XX Human; B7-1-like protein; B7-L; antiinfectivity; gynaecological;  
 KW antitumour; cytostatic; immunosuppressive; antiarthritic; antirheumatic;  
 KW antiinflammatory; dermatological; antipsoriatic; neuroprotective;  
 KW antidiabetic; haemostatic; antithyroid; antitumor; antiallergic;  
 KW antiautismal; nephrotropic; antibacterial; virucide; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder; gene; ss.  
 XX Homo sapiens.  
 OS  
 XX  
 FH Key Location/Qualifiers  
 FT CDS 1..1134  
 FT /\*tag= a  
 FT /product= "B7-1-like protein, B7-L<sub>h4</sub>"  
 XX  
 PN MO200200710-A2.  
 PD 03-JAN-2002.  
 XX 28-JUN-2001; 2001WO-US20719.  
 PE 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX

PA (AMGE-) AMGEN INC.  
 XX Melcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 PI WPI; 2002-130881/17.  
 DR  
 XX  
 XX  
 PT New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 PS Claim 1; Fig 4; 135pp; English.  
 XX  
 XX The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-1-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility),  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular stenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or all sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the coding sequence of human B7-L<sub>h4</sub>.  
 XX  
 SO Sequence 1139 BP; 290 A; 300 C; 283 G; 266 T; 0 other:  
 Query Match 94.4%; Score 1102.8; DB 24; Length 1139;  
 Best Local Similarity 97.9%; Pred. No. 1.9e-296;  
 Matches 1136; Conservative 0; Mismatches 2; Indels 22; Gaps 1;  
 QY 8 ATGTGTGAGGAGCCATGGAATAAGAGACCCAGCGTGTGCGTGTGATTAAGATC 67  
 DB 1 ATGTGTGAGGAGCCATGGAATAAGAGACCCAGCGTGTGCGTGTGATTAAGATC 60  
 QY 68 ATAGAAGGCCCCCAAAATGCAAGAGTCTGAAAGGCTCCAGGCTGCTCACTGACCC 127  
 DB 61 ATAGAAGGCCCCCAAAATGCAAGAGTCTGAAAGGCTCCAGGCTGCTCACTGACCC 120  
 QY 128 GTCTCCAGGCTGGAAGTCAATGATGAGGCTCTGAGTGAATGATGATGATGATG 187  
 DB 121 GTCTCCAGGCTGGAAGTCAATGATGAGGCTCTGAGTGAATGATGATGATGATG 180  
 QY 188 AGGCCATGAGGCCATCATCAATGACCGCTTCACTCTCAGAGTACGACGAGGC 247  
 DB 181 AGGCCATGAGGCCATCATCAATGACCGCTTCACTCTCAGAGTACGACGAGGC 240  
 QY 248 GGGAACTTCACTCGAGATGATCATCAATGATGAGCCAGTATTCGGGGAACATC 307  
 DB 248 GGGAACTTCACTCGAGATGATCATCAATGATGAGCCAGTATTCGGGGAACATC 307





DT 23-APR-2002 (first entry)  
 DE DNA encoding human B7-1-like protein, B7-L\_h1.  
 XX  
 KW Human; B7-1-like protein; B7-L; antiinfectivity; gynaecological;  
 KW antitumour; cytostatic; immunosuppressive; antirheumatic;  
 KW antiinflammatory; dermatological; antiproliferative; neuroprotective;  
 KW antidiabetic; haemostatic; antihypertensive; antiallergic;  
 KW antischistosomal; antiparasitic; antibacterial; virus; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT 27.1175  
 FT CDS /tag="a  
 FT /product="B7-1-like protein, B7-L\_h1"  
 FT  
 PN WO200200710-A2.  
 XX  
 PN 03-JAN-2002.  
 XX  
 PE 28-JUN-2001; 2001WO-US20719.  
 XX  
 PR 28-JUN-2000; 2000US-214512P.  
 XX  
 PR 28-NOV-2000; 2000US-0729264.  
 XX  
 PA (AMGE-) AMGEN INC.  
 PI Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 DR WPI: 2002-130881/17.  
 PT P-PSDB: AA075540.  
 PT New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 XX  
 XX Claim 1; Fig 1; 135pp; English.  
 PS  
 CC The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-1-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility) and  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, Rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or alloimmunisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions, and for  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and

CC pemphigoid), endocrinopathies (Grave's disease), various neuropathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia, and  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the coding sequence of human B7-L\_h1.  
 XX  
 SO Sequence 1175 BP; 295 A; 307 C; 286 G; 287 T; 0 other;  
 Query Match 96.1%; Score 1122.4; DB 24; Length 1175;  
 Best Local Similarity 99.5%; Pred. No. 6.8e-302;  
 Matches 1126; Conservative 0; Mismatches 6; Indels 0; Gaps 0;  
 37 CCCACCCGCTTCTGGGCTGCTGTAATGAAGTCATGAAGGCCCCCAAAATGCAAGAGTCTT 96  
 44 CCTCCACGCGTCTGGGCTGCTGTAATGAAGTCATGAAGGCCCCCAAAATGCAAGAGTCTT 103  
 97 GAAGGGCTCCAGGCTGCTTCAACTGACCGCTCTCCAGGCTGGAAGTCATCATGTG 156  
 104 GAAGGGCTCCAGGCTGCTTCAACTGACCGCTCTCCAGGCTGGAAGTCATCATGTG 163  
 157 GGCCTCAGTGCATGAGTGGTGTCTAAGCTCAGGCGCCATGAGGCCATCATCACAATGA 216  
 164 GACTTCAGTGCATGAGTGGTGTCTAAGCTCAGGCGCCATGAGGCCATCATCACAATGA 223  
 217 CCGCTTCACTCTCAGAGGTACGACGAGCGGGAACTTCACTCTCGAGATGATCATCA 276  
 224 CCGCTTCACTCTCAGAGGTACGACGAGCGGGAACTTCACTCTCGAGATGATCATCA 283  
 277 CAATGTGAGGCCGAGTGTGGGGAACTCATGATGACGCTCCAGAACTGCTGCA 336  
 284 CAATGTGAGGCCGAGTGTGGGGAACTCATGATGACGCTCCAGAACTGCTGCA 343  
 337 TGGATCTGCTTACCTTACCGTCCAAAGTATGAGAGCTGTTCATCCAGTGTAACT 396  
 344 TGGATCTGCTTACCTTACCGTCCAAAGTATGAGAGCTGTTCATCCAGTGTAACT 403  
 397 TGTAGTCTGAGTGAATGAACTGTAAGTAACTTGTACCTCCAGTGTAACT 456  
 404 TGTAGTCTGAGTGAATGAACTGTAAGTAACTTGTACCTCCAGTGTAACT 463  
 457 CCGGATATTTCTGGAGAGCTGCTCTGCTGTCAGCCATTCAGTATTTGTTTC 516  
 464 CCGGATATTTCTGGAGAGCTGCTCTGCTGTCAGCCATTCAGTATTTGTTTC 523  
 517 GGAGCCGACGACCTTCAAAATGACATGACATCTGCTGACCCCAAGACAAATG 576  
 524 GGAGCCGACGACCTTCAAAATGACATGACATCTGCTGACCCCAAGACAAATG 583  
 577 GACTTGAATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 636  
 584 GACTTGAATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 643  
 637 TCTCACTGATTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 696  
 644 TCTCACTGATTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 703  
 697 ATCAAGTTACGAGTTTGGTTTTCATTTGCTTCTGCTGCTGCTGCTGCTGCTGCT 756  
 704 ATCAAGTTACGAGTTTGGTTTTCATTTGCTTCTGCTGCTGCTGCTGCTGCTGCT 763  
 757 AGAGGACACATGCTCTGACGCGGACGCTGCTTACAAATACGCTGCTGCTGCTGCTG 816  
 764 AGAGGACACATGCTCTGACGCGGACGCTGCTTACAAATACGCTGCTGCTGCTGCTG 823  
 817 CCGTCTGTTGTTGGCTGCAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 876  
 824 CCGTCTGTTGTTGGCTGCAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 883  
 877 AGGATTTGATTTCAATTTCAAAAGAAATCTGAAAAGAGAGACAAAGAAAGAACTGA 936  
 884 AGGATTTGATTTCAATTTCAAAAGAAATCTGAAAAGAGAGACAAAGAAAGAACTGA 943  
 937 GACAGAAAGAGAAATGAAAGAACTCCGGCTACAAATTCAGATGAACAAGAACACAGACAC 996

PR 28-JUN-2000; 2000US-214512P.  
PR 28-NOV-2000; 2000US-0729264.

XX (AMGE-) AMGEN INC.

PI Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;

DR WPI; 2002-130881/17.

XX P-PDB; AAU75541.

PT New B7-like polypeptides, polynucleotides and their modulators, useful  
PT for diagnosing, preventing and treating reproductive, immune and  
PT proliferative disorders, e.g. cancer and arteriosclerosis

XX Claim 1; Fig 2; 135pp; English.

CC The invention relates to an isolated B7-like (B7-L) polypeptide (I).  
CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
CC useful for treating B7-like polypeptide-related disease, disorders or  
CC conditions including reproductive disorders (e.g. infertility,  
CC miscarriage, preterm labour and delivery and endometriosis) and  
CC proliferative disorders. Antibodies, soluble proteins comprising  
CC extracellular domains and other regulators of B7-L polypeptides are  
CC useful for enhancing the immune response to tumours. (I) plays a role in  
CC growth and maintenance of cancer cells based on the observation of  
CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
CC polypeptide. Hence modulators of (I) are useful for the treatment of  
CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
CC in allograft transplantation, graft versus host disease, T-cell  
CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
CC molecules are useful for alleviating the symptoms associated with  
CC diseases involving chronic immune cell dysfunction or to treat  
CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
CC purpura and psoriasis, chronic inflammatory disease such as  
CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
CC are also useful as immunosuppressive agents for bone marrow and organ  
CC transplantation or to prolong graft survival. B7-L molecules are also  
CC useful for diagnosis and treatment of diseases involving abnormal cell  
CC proliferation, including arteriosclerosis and vascular restenosis.  
CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
CC shock syndrome or all sensitisation due to blood transfusions, and for  
CC treatment of allergy, asthma and hypersensitivity reactions,  
CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
CC lymphoproliferative disorders such as multiple myeloma. The present  
CC sequence represents the coding sequence of human B7-L<sub>h2</sub>.

XX Sequence 1168 BP; 299 A; 302 C; 288 G; 279 T; 0 other;

Query Match 100.0%; Score 1168; DB 24; Length 1168;

Best Local Similarity 100.0%; Pred. No. 1.1e-314;

Matches 1168; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATCATGTGGTGGAGAGCATGGAATATAGAGCCCGGTTCTGGGCTGGTAA 60  
DB 1 AGTATCATGTGGTGGAGAGCATGGAATATAGAGCCCGGTTCTGGGCTGGTAA 60  
QY 61 TGAAGTCATAGAAAGCCGCCCAAAATGCAAGAGTCTGAAAGGCTCCAGGCTGCTCAA 120  
DB 61 TGAAGTCATAGAAAGCCGCCCAAAATGCAAGAGTCTGAAAGGCTCCAGGCTGCTCAA 120  
QY 121 CTGACACGCTCCCGAGGCTGGAAGCTCATCATGTGGCTCTAGTACATGGTGGTCT 180  
DB 121 CTGACACGCTCCCGAGGCTGGAAGCTCATCATGTGGCTCTAGTACATGGTGGTCT 180  
QY 181 AAGGCTCAGGCCCATGAGGCCATCATCACCATGACCGCTTACCGCTCAGAGGTACGA 240  
DB 181 AAGGCTCAGGCCCATGAGGCCATCATCACCATGACCGCTTACCGCTCAGAGGTACGA 240

DB 181 AAGGCTCAGGCCCATGAGGCCATCATCACCATGACCGCTTACCGCTCAGAGGTACGA 240  
QY 241 CCAGGGCGGSAACCTTCCACCTGGAGATGATCATCCAAATGTGGAGCCAGTATGGG 300  
DB 241 CCAGGGCGGSAACCTTCCACCTGGAGATGATCATCCAAATGTGGAGCCAGTATGGG 300  
QY 301 GAACATCAGATGACAGCTCCAGAACAGTGCCTGCATGATGCTCTTACCTTACCTCA 360  
DB 301 GAACATCAGATGACAGCTCCAGAACAGTGCCTGCATGATGCTCTTACCTTACCTCA 360  
QY 361 AGTTATGGGAGAGCTGTTCAATCCAGTGTAACTTGTATGCTGATGATGATGATG 420  
DB 361 AGTTATGGGAGAGCTGTTCAATCCAGTGTAACTTGTATGCTGATGATGATGATG 420  
QY 421 TGAATCTATTGTCTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTT 480  
DB 421 TGAATCTATTGTCTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTT 480  
QY 481 TCTCTGTGTCAGCCATTCAGCTATTTTGTTCGGAGCCAGCCAGCTTCAAGTGC 540  
DB 481 TCTCTGTGTCAGCCATTCAGCTATTTTGTTCGGAGCCAGCCAGCTTCAAGTGC 540  
QY 541 AGTGAAGCATCTGCTGCTGACCCACAGAGCAATGGAGCTTGAATGCTGCTGCTG 600  
DB 541 AGTGAAGCATCTGCTGCTGACCCACAGAGCAATGGAGCTTGAATGCTGCTGCTG 600  
QY 601 GAAGAGCTGGAAGGCCCGCAAGTGTGCACTGTAATCTCATCTGATTCGGTCCCA 660  
DB 601 GAAGAGCTGGAAGGCCCGCAAGTGTGCACTGTAATCTCATCTGATTCGGTCCCA 660  
QY 661 AGACACTGAGGTGATTTATATATTCAGGTATTTATCAAGTTTACCAGTTTATGTT 720  
DB 661 AGACACTGAGGTGATTTATATATTCAGGTATTTATCAAGTTTACCAGTTTATGTT 720  
QY 721 TTTATTTGCTTATTTGGGCAAGTGTGAGTGTGACTGACAGCAACATGCTTGCAGCC 780  
DB 721 TTTATTTGCTTATTTGGGCAAGTGTGAGTGTGACTGACAGCAACATGCTTGCAGCC 780  
QY 781 GAGGTATCTTTTACAAATACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 840  
DB 781 GAGGTATCTTTTACAAATACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 840  
QY 841 CTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 900  
DB 841 CTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 900  
QY 901 GAAATCTGAAAAGAGAGAGCAAAAGAACTGAGACAGAAAGTGAATGAAAATCTC 960  
DB 901 GAAATCTGAAAAGAGAGAGCAAAAGAACTGAGACAGAAAGTGAATGAAAATCTC 960  
QY 961 CGGCTACATTCAGATGAAACAAAGAGACACACCGCTTCTCTCCCTCCAAATCTG 1020  
DB 961 CGGCTACATTCAGATGAAACAAAGAGACACACCGCTTCTCTCCCTCCAAATCTG 1020  
QY 1021 TGAATTCAGTATTCCTGTAACAAAGAAAGAGTATGCTGCTGCTGCTGCTGCTG 1080  
DB 1021 TGAATTCAGTATTCCTGTAACAAAGAAAGAGTATGCTGCTGCTGCTGCTGCTG 1080  
QY 1081 TCAAGCTCAGCCAGGAGAGCAAGTATCATCAGAGCTTCTTAAATCTGGAGCTCTGA 1140  
DB 1081 TCAAGCTCAGCCAGGAGAGCAAGTATCATCAGAGCTTCTTAAATCTGGAGCTCTGA 1140  
QY 1141 GAAGTCACTAATTAACACTGTATATAG 1168  
DB 1141 GAAGTCACTAATTAACACTGTATATAG 1168

RESULT 2

ABK13028 standard; cDNA; 1175 BP.

XX ABK13028;  
XX  
XX

GenCore version 5.1.4.p5.4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 28, 2003, 23:25:03 ; Search time 282.628 Seconds

(without alignments)  
9306.701 Million cell updates/sec

Title: US-09-729-264-3

Perfect score: 1168  
Sequence: 1 agtgcacgcgtgctgcagag.....gtaatacactgtagatag 1168

Scoring table: IDENTITY\_NUC  
Gapop 10.0, Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database :

Listing first 45 summaries

```

N_Geneseq_101002:*
1: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
8: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
9: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
10: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
11: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
12: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
13: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
14: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
15: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
16: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
17: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
18: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
19: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
20: /SID22/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
21: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
22: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
23: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
24: /SID22/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1168	100.0	1168	24	ABK13029
2	1122.4	96.1	1175	24	ABK13028
3	1119	95.8	1240	24	ABK13030
4	1102.8	94.4	1139	24	ABK13031
5	777.6	66.6	1392	23	AA592356
6	378.4	32.4	1195	24	ABK13032
7	196.8	16.8	401	22	NA136582
8	181.8	15.6	754	24	ABK13034
9	181.8	15.6	895	24	ABK13033

c	10	53.4	4.6	277	21	ABK10239	Trinucleotide rep
c	11	52.8	4.5	7029	23	ABL29756	Drosophila melanog
c	12	51.8	4.4	389	21	ABK10248	Tri-nucleotide rep
c	13	51.8	4.4	397	21	AAK89891	Spinocerebellar at
c	14	51.8	4.4	403	21	ABK10240	Trinucleotide repe
c	15	49.4	4.2	46954	23	ABL16830	Drosophila melanog
c	16	48.4	4.1	3217	10	AAK91578	Rat androgen recep
c	17	48.4	4.1	3217	12	AAQ12002	Full-length rat an
c	18	48.4	4.1	4180	10	AAK91773	Rat androgen recep
c	19	47.8	4.1	381	23	ABV54466	Human prostate exp
c	20	47.6	4.1	2733	20	AAK84442	Mouse brain CNG-1
c	21	47.4	4.1	3894	23	ABL03353	Drosophila melanog
c	22	47.4	4.1	22341	23	ABL03352	Drosophila melanog
c	23	46.6	4.0	2333	22	AAK75339	Human TGF-beta rec
c	24	46.4	4.0	1983	23	ABL24483	Drosophila melanog
c	25	46.4	4.0	4044	23	ABL24482	Drosophila melanog
c	26	45.8	3.9	2682	23	ABL16097	Drosophila melanog
c	27	45.8	3.9	8821	23	ABL16096	Drosophila melanog
c	28	45.6	3.9	1509	23	ABL24571	Drosophila melanog
c	29	45.6	3.9	3884	23	ABL24570	Drosophila melanog
c	30	45.4	3.9	3042	23	ABL28445	Drosophila melanog
c	31	45.4	3.9	3135	23	ABL28445	Drosophila melanog
c	32	45.4	3.9	5115	23	ABL28444	Drosophila melanog
c	33	45.4	3.9	5447	23	ABL25652	Drosophila melanog
c	34	45.2	3.9	5397	23	ABL29757	Drosophila melanog
c	35	45	3.9	462	23	ABL26941	Drosophila melanog
c	36	45	3.9	2115	23	ABL26940	Drosophila melanog
c	37	45	3.9	2260	23	ABL03191	Drosophila melanog
c	38	45	3.9	3210	23	ABL08977	Drosophila melanog
c	39	45	3.9	3624	23	ABL03190	Drosophila melanog
c	40	45	3.9	5975	23	ABL08976	Drosophila melanog
c	41	45	3.9	6541	23	ABL04172	Drosophila melanog
c	42	44.8	3.8	254	21	AAZ45758	Polyomphic region
c	43	44.8	3.8	1310	20	AAV08558	Transgene for epit
c	44	44.8	3.8	2614	24	ABK36100	CDNA sequence #491
c	45	44.8	3.8	3263	20	AAV08560	Transgene for epit

## ALIGNMENTS

RESULT 1	ABK13029	standard; CDNA; 1168 BP.
ID	ABK13029	
AC	ABK13029	
XX	23-APR-2002	(first entry)
DE	DNA encoding human B7-like protein, B7-L <sub>h2</sub> .	
XX		
KW	Human; B7-like protein; B7-L; antiinfectivity; gynaecological;	
KW	antitumour; cytostatic; immunosuppressive; antirheumatic;	
KW	antiinflammatory; dermatological; antiproliferative; neuroprotective;	
KW	antidiabetic; haemostatic; antihypertensive; antitumor; cancer;	
KW	antiallergic; nephrotoxic; antibacterial; vitruicide; tumour; cancer;	
KW	reproductive disorder; graft versus host disease; autoimmune disease;	
KW	toxic shock syndrome; allergy; nephropathy; skin disorder;	
KW	endocrinopathy; lymphoproliferative disorder; gene; ss.	
XX		
OS	Homo sapiens.	
XX		
XX		
FT	Key	Location/Qualifiers
FT	CDS	8..1168
FT		/*tag= a
FT		/product= "B7-like protein, B7-L <sub>h2</sub> "
PN	WO200200710-A2.	
XX		
PD	03-JAN-2002.	
XX		
XX		
PF	28-JUN-2001; 2001WO-US20719.	
XX		











Meisterernst, Michael  
Polites, Greg  
TITLE OF INVENTION: PURIFICATION OF HIGHER ORDER TRANSCRIPTION  
COMPLEXES FROM TRANSGENIC  
NON-HUMAN ANIMALS  
NUMBER OF SEQUENCES: 17  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: HELLER, EHRMAN, WHITE & MCAULIFFE  
STREET: 1666 K Street, N.W., Suite 300  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20006  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/849,243  
FILING DATE: 07-May-2001  
ATTORNEY/AGENT INFORMATION:  
NAME: Granados, Patricia D.  
REGISTRATION NUMBER: 33,683  
REFERENCE/DOCKET NUMBER: 38005-0148  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)912-2000  
TELEFAX: (202)912-2020  
INFORMATION FOR SEQ ID NO: 15:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 3263 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
FEATURE:  
NAME/KEY: exon  
LOCATION: 1..3263  
SEQUENCE DESCRIPTION: SEQ ID NO: 15:  
US-09-849-243-15  
Query Match 3.8%; Score 44.8; DB 9; Length 3263;  
Best Local Similarity 81.2%; Pred. No. 0.0087;  
Matches 52; Conservative 0; Mismatches 12; Indels 0; Gaps 0;  
QY 801 GCTGCTGCTGCTGCCGCGTGTGTTGCGCTGCACTGCTGCGCGTGTGTTCT 860  
|||||  
DB 1430 GCTGCTGCTGCTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1371  
QY 861 GCTG 864  
|||||  
DB 1370 GCTG 1367  
RESULT 8  
US-09-849-243-14/C  
Sequence 14, Application US/09849243  
Patent No. US20020157127A1  
GENERAL INFORMATION:  
APPLICANT: Kirschbaum, Bernd  
Berglund, Erick  
Meisterernst, Michael  
Polites, Greg  
TITLE OF INVENTION: PURIFICATION OF HIGHER ORDER TRANSCRIPTION  
COMPLEXES FROM TRANSGENIC  
NON-HUMAN ANIMALS  
NUMBER OF SEQUENCES: 17  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: HELLER, EHRMAN, WHITE & MCAULIFFE  
STREET: 1666 K Street, N.W., Suite 300  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA

ZIP: 20006  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/849,243  
FILING DATE: 07-May-2001  
ATTORNEY/AGENT INFORMATION:  
NAME: Granados, Patricia D.  
REGISTRATION NUMBER: 33,683  
REFERENCE/DOCKET NUMBER: 38005-0148  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)912-2000  
TELEFAX: (202)912-2020  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 4286 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
FEATURE:  
NAME/KEY: exon  
LOCATION: 1..4286  
SEQUENCE DESCRIPTION: SEQ ID NO: 14:  
US-09-849-243-14  
Query Match 3.8%; Score 44.8; DB 9; Length 4286;  
Best Local Similarity 81.2%; Pred. No. 0.01;  
Matches 52; Conservative 0; Mismatches 12; Indels 0; Gaps 0;  
QY 801 GCTGCTGCTGCTGCCGCGTGTGTTGCGCTGCACTGCTGCGCGTGTGTTCT 860  
|||||  
DB 2767 GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2708  
QY 861 GCTG 864  
|||||  
DB 2707 GCTG 2704  
RESULT 9  
US-09-880-107-1748/C  
Sequence 1748, Application US/09880107  
Patent No. US20020142981A1  
GENERAL INFORMATION:  
APPLICANT: Horne, Darci T.  
Vockley, Joseph G.  
APPLICANT: Scherf, Uwe  
APPLICANT: Gene Logic, Inc.  
TITLE OF INVENTION: Gene Expression Profiles in Liver Cancer  
FILE REFERENCE: 44921-5028-WO  
CURRENT APPLICATION NUMBER: US/09/880,107  
CURRENT FILING DATE: 2001-06-14  
PRIOR APPLICATION NUMBER: US 60/211,379  
PRIOR FILING DATE: 2000-06-14  
PRIOR APPLICATION NUMBER: US 60/237,054  
PRIOR FILING DATE: 2000-10-02  
NUMBER OF SEQ ID NOS: 3950  
SOFTWARE: Patentin Ver. 2.1  
SEQ ID NO 1748  
LENGTH: 6604  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
OTHER INFORMATION: Genbank Accession No. US20020142981A1 DB3783  
US-09-880-107-1748  
Query Match 3.8%; Score 44.8; DB 10; Length 6604;  
Best Local Similarity 76.4%; Pred. No. 0.014;  
Matches 55; Conservative 0; Mismatches 17; Indels 0; Gaps 0;



Db 234 GCGGGCTATCAAGCTCCACCCAGCCGAGCATCATCCAGCGCTCTTTATCTGGC 293  
QY 1132 CAGTCTGAGAAGTCACTAATATACAGCTAGTAG 1168  
Db 294 CAGTCTGAGAAGTCACTAATATACAGCTAGTAG 330

## RESULT 2

US-09-864-761-16305  
; Sequence 16305, Application US/09864761  
; Patent No. US20020048763A1  
; GENERAL INFORMATION:  
; APPLICANT: Penn, Sharon G.  
; APPLICANT: Rank, David R.  
; APPLICANT: Hanzel, David K.  
; APPLICANT: Chen, Wensheng  
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR  
; FILE REFERENCE: Acomica-X-1  
; CURRENT FILING DATE: 2001-05-23  
; PRIOR APPLICATION NUMBER: US 60/180,312  
; PRIOR FILING DATE: 2000-02-04  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: US 09/632,366  
; PRIOR FILING DATE: 2000-08-03  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 09/608,408  
; PRIOR FILING DATE: 2000-06-30  
; PRIOR APPLICATION NUMBER: US 09/774,203  
; PRIOR FILING DATE: 2001-01-29  
; NUMBER OF SEQ ID NOS: 49117  
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1  
; SEQ ID NO 16305  
; LENGTH: 401  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; OTHER INFORMATION: MAP TO AF121782.1  
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.9  
US-09-864-761-16305

Query Match 16.8%; Score 196.8; DB 10; Length 401;  
Best Local Similarity 96.6%; Pred No. 6.5e-50;  
Matches 201; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 27 AATAAGAGACCCAGCCGGTCTGGGTCTGTATAGATCATAGAGCCCAAAATG 86  
Db 194 AAATGGCTACTCTTCAGAGGCTGTGGGTGTATATAGTATAGAGGCCCAAAATG 253  
QY 87 CAAGAGTCTGAGAGGCTCCAGGCTCGCTTCAACTGACACCGCTCCAGGCTGGAAGC 146  
Db 254 CAAGAGTCTGAGAGGCTCCAGGCTCGCTTCAACTGACACCGCTCCAGGCTGGAAGC 313  
QY 147 TCATCATGTGGGTCTTCATGATGATGTGTGTAAAGCTCAGAGCCCATGAGCCCATCA 206  
Db 314 TCATCATGTGGGTCTTCATGATGATGTGTGTAAAGCTCAGAGCCCATGAGCCCATCA 373  
QY 207 TCACCAATGACCGCTTCACCTCTCAGAG 234  
Db 374 TCACCAATGACCGCTTCACCTCTCAGAG 401

## RESULT 3

US-09-983-965-4945  
; Sequence 4945, Application US/09983965  
; Patent No. US20020137160A1  
; GENERAL INFORMATION:  
; APPLICANT: Warren, Wesley C.  
; APPLICANT: Tao, Nengbing  
; APPLICANT: Byatt, John C.  
; APPLICANT: Mathialagan, Nagappan  
; TITLE OF INVENTION: NUCLEIC ACID AND OTHER MOLECULES ASSOCIATED WITH LACTATION AND  
; FILE REFERENCE: 37-21(10257)C  
; CURRENT FILING DATE: US/09/983,965  
; PRIOR APPLICATION NUMBER: US 2001-10-26  
; PRIOR FILING DATE: 1999-12-15  
; PRIOR APPLICATION NUMBER: US 60/113,678  
; PRIOR FILING DATE: 1998-12-17  
; NUMBER OF SEQ ID NOS: 5912  
; SEQ ID NO 4945  
; LENGTH: 398  
; TYPE: DNA  
; ORGANISM: Bos taurus  
; FEATURE:  
; OTHER INFORMATION: Clone ID: 26-LIB34-017-Q1-E1-G9  
US-09-983-965-4945

Query Match 11.7%; Score 136.2; DB 10; Length 398;  
Best Local Similarity 77.5%; Pred. No. 2.3e-31;  
Matches 165; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

QY 42 CCGGTTTCGGGCTGTGTATGATGATAGAGAGGCCCCAAATGCAAGAGTCTGAAG 101  
Db 186 GAGCCTGTGGATCCAGAGTGAATCATAGAGGCTCCCAAGAAATGTCACAGCCTGAAG 245  
QY 102 GGTCCAGGCTCGCTTCAACTGACACCGTCCAGGGCTGGAAGCTCATATGTGGGCTC 161  
Db 246 GGTCCAGGCTCGCTTCAACTGACACCATCTCGAGGGCTGGAAGCTCATATGTGGGCTC 305  
QY 162 TCAGTACATGGGTGTGTAAAGCTCAGGCCCATGAGCCCATCATCATCAACCAATGCGCT 221  
Db 306 TGAGAGGACAGAGTGTGTGTAGCATGACCATTAATGAGACCATCATCATCAACCAATGCGCT 365  
QY 222 TCACCTCTCAGAGGTACACACCAAGGCGGGAAGT 254  
Db 366 TCACCTCTCAGAGGTACACACCAAGGCGGGAAGT 398

## RESULT 4

US-10-008-739A-1/C  
; Sequence 1, Application US/10008739A  
; Patent No. US20020161194A1  
; GENERAL INFORMATION:  
; APPLICANT: Pfizer Inc.  
; APPLICANT: Castleberry, Tessa A.  
; APPLICANT: Lu, Bihong









MGI:427273

Seq primer: -28ml3 rev2 ET from Amersham  
High quality sequence stop: 454.

## FEATURES

source

Location/Qualifiers

1. 471

/organism="Mus musculus"

/db\_xref="taxon:10090"

/clone="IMAGE:693713"

/clone\_lib="Soares mouse NML"

/tissue\_type="Liver"

/lab\_host="Dh10B"

/note="Vector: p773D-Pac (Pharmacia) with a modified polylinker. Site 1: Not I; Site 2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5', TGTTACCAATCTAAGTGGAGGCGGCGGAACTTTTCTTTTCTTTT 3']; double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified p773 vector. Library constructed and normalized by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 118 a 126 c 122 g 105 t  
ORIGIN

Query Match

Best Local Similarity 72.9%; Score 181.8; DB 9; Length 471;

Matches 234; Conservative 0; Mismatches 87; Indels 0; Gaps 0;

42 CCGGTTCTGGTCTGTGTAATGATGATGAGAGGCCCCCAATGCAAGAGCTCTGAGG 101  
115 CAGCTTCCGGATCCAGTTATGATGATGAGAGGCTCTGAGATGATGATGATGATG 174  
102 GCTCCAGGAGGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATG 161  
175 ACTGAGAGGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 234  
162 TCAGTGACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 221  
235 TTAACCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 294  
222 TCACCTCTCAGAGTACGACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 281  
295 TCACCTATGACGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 354  
282 TGGAGCCAGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 341  
335 TGCAGCCAGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 414  
342 CTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTAC 362  
415 CTGCTTCT 435

## RESULT 11

AM990468

LOCUS

DEFINITION

u637d05.y1 Soares mammary gland NMLMG Mus musculus cDNA clone IMAGE:1513545 5' similar to TR:060962 060962 L549.1.; mRNA

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Unpublished (1997)  
Contact: Robert Strausberg, Ph.D.  
Email: cgabds-remail.nih.gov  
This clone is available royalty-free through LNL; contact the

IMAGE Consortium (info@image.lnl.gov) for further information.

MGI:940397

Seq primer: -40RP from Gibco  
High quality sequence stop: 474.

## FEATURES

source

Location/Qualifiers

1. 611

/organism="Mus musculus"

/db\_xref="taxon:10090"

/clone="IMAGE:1513545"

/clone\_lib="Soares mammary gland NMLMG"

/sex="female (lactating)"

/tissue\_type="mammary gland"

/lab\_host="Dh10B"

/note="Vector: p773D-Pac (Pharmacia) with a modified polylinker. 1st strand cDNA was prepared from mammary gland tissue from a lactating female, and was then primed with a Not I - oligo(dT) primer. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified p773 vector. Library is normalized. Library was constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 152 a 155 c 156 g 148 t  
ORIGIN

Query Match

Best Local Similarity 72.9%; Score 181.8; DB 10; Length 611;

Matches 234; Conservative 0; Mismatches 87; Indels 0; Gaps 0;

42 CCGGTTCTGGTCTGTGTAATGATGATGATGATGATGATGATGATGATGATGATG 101  
124 CAGCTTCCGGATCCAGTTATGATGATGATGATGATGATGATGATGATGATGATG 183  
102 GCTCCAGGAGGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATG 161  
184 ACTGAGAGGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 243  
162 TCAGTGACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 221  
244 TTAACCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 303  
222 TCACCTCTCAGAGTACGACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 281  
304 TCACCTATGACGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 363  
282 TGGAGCCAGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 341  
364 TGCAGCCAGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 423  
342 CTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTAC 362  
424 CTGCTTCT 444

## RESULT 12

BG173684

LOCUS

DEFINITION

602336823F1 NCI\_CGAP\_Mam1 Mus musculus cDNA clone IMAGE:445973 5', mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Unpublished (1999)  
Contact: Robert Strausberg, Ph.D.  
Email: cgabds-remail.nih.gov  
Tissue Procurement: Gilbert Smith, Ph.D.  
cDNA Library Preparation: Life Technologies, Inc.



**Fax:** 81-248-25-5725  
**Email:** [kazusugi@cocoa.ocn.ne.jp](mailto:kazusugi@cocoa.ocn.ne.jp)  
**Single pass sequencing.**

Email: [mouseeest@watson.wustl.edu](mailto:mouseeest@watson.wustl.edu)  
This clone is available royalty-free through LNL ; contact the  
IMAGE Consortium ([info@image.lnl.gov](mailto:info@image.lnl.gov)) for further information.



Unpublished (2000)  
Contact: Smith TPJ  
USDA, ARS, US Meat Animal Research Center  
PO Box 166, Clay Center, NE 68933-0166, USA  
Tel: 402 762 4366  
Fax: 402 762 4390  
Email: smitht@mail.marc.usda.gov

QY	42	CCCTTCCTGGGCGTGGTATATGAAGTCATAAGAAGGCCCAAAATGTCAAGAGTGCTCAGG	101
Db	158	CAGCTTTGTGGATTCCGGCAATGAAATCTTAGAAGGGTCCAGGAAAGTCACGCGCGGTGAAG	217
QY	102	GCTCCACGAGCTCGCTTCAACTGCACCAGTCTCCACAGGCGTGGAAAGCTCATATGNGGAGTC	161
Db	218	GCTCGAAGGCTCGCTTCAACTGCACCAGTCTCCAGGCGTGGAAAGCTCATATGNGGAGTC	277
QY	162	TCAATGACATAGTGTGTCAGCGTCAGAGCCCATGAGAGCCCATCATCAACAATGACCGCT	221
Db	278	TGAAGGACAGGAGGTTCGTGAGGGTACAGCCACCGACCCATCATCAACCAAGACCGAT	337
QY	222	TCACTCTCAGAGAGTACGACCCAGGCGGGAGTAACCTCGGAAATATATCACCAATG	281
Db	338	TCACGTCCTCAAAATTTGAAAGAGGCGGAGTAACCTTCATGAAATGATCATCATGACAG	397
QY	282	TGGAGCCCAATGATTGCGGGAAACATACAGTGCAGGCTCCAAAGACAGTGGCTCATGAGAT	341
Db	398	TGCAAGCTCAATGTGCGGGGACAGTCAATATGAGGCTCCAAABAAGTACCGGGATGAGAT	457
QY	342	CTGCTTACCTTACCGTCACAAAGTTATGGAGAGAGCTTTCATCCACAGTGTAAATCTTGATG	401
Db	458	CCGCTTTCCTTCCGTCACAAAGTCATGGGGGCTGCTCATATTCGCCGAGAGCAGCCCTGTAG	517

REFERENCE	1 (Pages 1 to 517)
AUTHORS	Sonstegard, T. S., Capuco, A. V., Van Tassell, C. P., Ashwell, M. S. and Wells, K. D.
TITLE	Mapping of Expressed Sequence Tags from a normalized bovine mammary gland cDNA library
JOURNAL	Unpublished (2000)
COMMENT	Contact: Sonstegard TS

Db 628 C--GGGACCTTATGAGGCTGTGAGTGTCTCCCTGGAATCA--CAACCTGGGCAAGGAGCCT 684

QY 582 TGACTTGGGTCGCTACTCGAAGAGCCTGAAGCCCCGCAAGTCT 625

Db 685 TGACTTGTGTGGCAAGAGCTGAAGAGCTGACGCGCAGCAGTCT 728

RESULT 3  
BG740428 725 bp mRNA linear EST 15-MAY-2001  
LOCUS BG740428  
DEFINITION 602633817F1 NCI\_CGAP\_Skn3 Homo sapiens cDNA clone IMAGE:4778789 5',  
mRNA sequence.  
ACCESSION BG740428  
VERSION BG740428.1 GI:14051081  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
REFERENCE 1 (bases 1 to 725)  
NIH-MGC <http://mgc.nci.nih.gov/>  
AUTHORS National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: [cgaps@mail.nih.gov](mailto:cgaps@mail.nih.gov)  
Tissue Procurement: James Cleaver, M.D.  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL) DNA  
Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LNL at:  
<http://image.llnl.gov>  
Plate: LLAM0635 row: b column: 06  
High quality sequence stop: 725.  
Location/Qualifiers  
1..725  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="IMAGE:4778789"  
/lab\_host="NCI\_CGAP\_Skn3"  
/lab\_host="DH10B (T1 phage-resistant)"  
/note="Organ: Skin; Vector: PCWV-SPORE; Site: 1: NotI;  
Site: 2: SalI; Cloned unidirectionally. Primer: Oligo dT.  
Average insert size 1.5kb. Library constructed by Life  
Technologies. Note: this is a NCI\_CGAP Library."  
BASE COUNT 227 a 163 c 159 g 176 t  
ORIGIN

Query Match 22.9%; Score 267.4; DB 12; Length 725;  
Best Local Similarity 99.6%; Pred. No. 2e-52;  
Matches 268; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 899 AAGAAATCTGAAAAAGAAAGACAAAGAACTGAGACAGAAAGTGAATGAAAC 958

Db 377 AGGAAATCTGAAAAAGAAAGACAAAGAACTGAGACAGAAAGTGAATGAAAC 436

QY 959 TCCGGCTACAAATTCAGTGAACAAAGACACACCGCTCTCCCTCCCAATCC 1018

Db 437 TCCGGCTACAAATTCAGTGAACAAAGACACACCGCTCTCCCTCCCAATCC 496

QY 1019 TGTGAATCCAGTATCTCTGAACAAAGACAGTGTGGCCCTCTCCACGCGGCT 1078

Db 497 TGTGAATCCAGTATCTCTGAACAAAGACAGTGTGGCCCTCTCCACGCGGCT 556

QY 1079 GATCAAGCTCCACCGACGCGACAGCAAGTCAACAGGCTCTTTATCTGGCCAGTCT 1138

Db 557 GATCAAGCTCCACCGACGCGACAGCAAGTCAACAGGCTCTTTATCTGGCCAGTCT 616

QY 1139 GAGAAGTCTAGTATACACTGATGATA 1167

Db 617 GAGAAGTCTAGTATACACTGATGATA 645

RESULT 4  
BB663870 631 bp mRNA linear EST 26-OCT-2001  
LOCUS BB663870  
DEFINITION BB663870 RIKEN full-length enriched, 0 day neonate lung Mus  
musculus cDNA clone E030016M12 5', mRNA sequence.  
ACCESSION BB663870  
VERSION BB663870.1 GI:16497624  
KEYWORDS EST.  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE 1 (bases 1 to 631)  
Arakawa, T., Carinci, P., Fukuda, S., Furuno, M., Hanagaki, T., Hara, A.,  
Hiramoto, K., Horii, F., Ishii, Y., Ito, M., Kawai, J., Komoto, H., Kouda,  
M., Koya, S., Matsuyama, T., Miyazaki, A., Nomura, K., Ohno, M.,  
Okazaki, Y., Okido, T., Saito, R., Sakai, C., Sakai, K., Sano, H., Sasaki,  
D., Shibata, K., Shinagawa, A., Shiraki, T., Sogabe, Y., Suzuki, H.,  
Tagami, M., Tagawa, A., Takahashi, F., Takeda, Y., Tanaka, T., Toya, T.,  
Muramatsu, M. and Hayashizaki, Y.  
RIKEN Mouse ESTs (Arakawa, T., et al. 2001)  
Unpublished (2001)  
Contact: Yoshihide Hayashizaki  
Laboratory for Genome Exploration Research Group, RIKEN Genomic  
Sciences Center (GSC), Yokohama Institute  
The Institute of Physical and Chemical Research (RIKEN)  
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan  
Tel: 81-45-503-9222  
Fax: 81-45-503-9216  
Email: [genome-res@sc.riken.go.jp](mailto:genome-res@sc.riken.go.jp),  
[URL:http://genome-gsc.riken.go.jp/](mailto:URL:http://genome-gsc.riken.go.jp/)  
Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K., Itoh,  
M., Kono, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.  
Normalization and subtraction of csp-trapper-selected cDNAs to  
prepare full-length cDNA libraries for rapid discovery of new  
genes. Genome Res. 10 (10), 1617-1630 (2000)  
Wagii, K., Fujiwara, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E.,  
Watanabe, M., Yoneda, Y., Ishikawa, T., Ozawa, K., Tanaka, T., Matsura,  
S., Kawai, J., Okazaki, Y., Muramatsu, M., Inoue, Y., Kira, A. and  
Hayashizaki, Y.  
RIKEN integrated sequence analysis (RISA) system-384-format  
sequencing pipeline with 384 multipillar sequencer. Genome Res. 10  
(11), 1757-1771 (2000)  
Kono, H., Fukunishi, Y., Shibata, K., Itoh, M., Carninci, P., Sugahara,  
Y. and Hayashizaki, Y.  
Computer-based methods for the mouse full-length cDNA  
encyclopedia: real-time sequence clustering for construction of a  
nonredundant cDNA library. Genome Res. 11 (2), 281-289 (2001)  
Kondo, S., Shinagawa, A., Saito, T., Kiyosawa, H., Yamanaka, I., Aizawa,  
K., Fukuda, S., Hara, A., Itoh, M., Kawai, J., Shibata, K. and  
Hayashizaki, Y.  
Computational Analysis of Full-length Mouse cDNAs Compared with  
Human Genome Sequences. Mamm. Genome. 12, 673-677 (2001)  
Please visit our web site (<http://genome-gsc.riken.go.jp>) for  
further details.  
e mouse tissues.  
Location/Qualifiers  
1..631  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
/clone="E030016M12"  
/clone\_lib="RIKEN full-length enriched, 0 day neonate  
lung"  
/tissue\_type="lung"  
/dev\_stage="0 day neonate"  
/lab\_host="DH10B"  
/note="Site: 1: SalI; Site: 2: BamHI; cDNA library was  
prepared and sequenced in Mouse Genome Encyclopedia  
Project of Genome Exploration Research Group in Riken  
Genomic Sciences Center and Genome Science Laboratory in  
RIKEN. Division of Experimental Animal Research in Riken  
contributed to prepare mouse tissues. 1st strand cDNA was

```

source
1. 784
/organism="Mus musculus"
/strain="NMRI"
/db_xref="taxon:10090"
/clone_lib="IMAGE:4917803"
/clone_id="NCI_CGAP_Mam4"
/tissue_type="tumor, gross tissue"
/dev_stage="5 months"
/lab_host="DH10B"
/Note="Organ: mammary; Vector: pCMV-Sport6; Site:1: SalI; Site:2: NotI; Cloned unidirectionally. Primer: Oligo dT. Library constructed by Life Technologies. Investigators providing samples: Lothar Hennighausen/Priscilla Furch, NIH Reference for transgenic model: Li et al., Cell Growth and Differentiation 7, 3-11 (1996)."
```

BASE COUNT 188 a 202 c 208 g 186 t

ORIGIN

Query Match 26.2%; Score 306; DB 12; Length 784;  
 Best Local Similarity 70.6%; Pred. No. 1.7e-61;  
 Matches 436; Conservative 0; Mismatches 180; Indels 2; Gaps 2;

```

42 CCGGTTCTGGGTCGTGTAATGATAGATAGAGCCGCCCAATGCAAGTCTGAGG 101
148 CAGCTTCGGATCAGTTATCAGATCAGAGGCTCTCAGATGTACAGTCTTAAGG 207
102 GCTCCAGGCTCGCTTCACTGACAGCTCTCCAGGCTGGAAGCTCATCTGAGGCTC 161
208 ACTCAGAGGCTCACTTCACTGACAGCTCTCCAGGCTGGAAGCTCTCATCTGAGCTC 267
162 TCAGTGCATGTGTGTCTCAAGCTCAGGCCATGAGCCCATCATCACCATGACCGCT 221
268 TTAAACCAATGAGTGTGCTGATCTCACACCCAGAGGCCATCATCACCACCAACCGCT 327
222 TCACCTCTCAGAGGTACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 281
328 TCACCTCTCAGAGGTACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 387
282 TGAGAGCCAGTGTATTCGGGAGATCAGATGACAGCTCTCCAGGAGTCTGATGATGAT 341
388 TGAGAGCCAGTGTATTCGGGAGATCAGATGACAGCTCTCCAGGAGTCTGATGATGAT 447
342 CTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTT 401
448 CTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTT 507
402 TCAGTGCATGTGTGTCTCAAGCTCAGGCCATGAGCCCATCATCACCATGACCGCT 461
508 TCACCTCTCAGAGGTACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 567
462 ATATTTCTCGGAGCTCGCTCTCTGCTCAGCATTCAAGCTTATTTTGTCCGGAGC 521
568 ATATTTCTCGGAGCTCGCTCTCTGCTCAGCATTCAAGCTTATTTTGTCCGGAGC 627
522 CCAGGACCTTCAAGAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGT 581
628 CGGACCACTTATGAGGCTTATGAGTCTCTGAGCCTCAACACA-TGGGCAAGGAGCCT 686
582 TGACTTCGTGAGTACCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCT 641
687 TGACTTCGTGAGTACCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCT 745
642 CTGTGATCGGTGCTCCG 659
746 CTGTGATCGGTGCTCCAC 763

```

RESULT 2  
 BF784177 794 bp mRNA linear EST 12-JAN-2001  
 LOCUS 602108039F1 NCI\_CGAP\_Ki14 Mus musculus cDNA clone IMAGE:4236489  
 DEFINITION 5', mRNA sequence.  
 ACCESSION BF784177

```

VERSION BF784177.1 GI:12089213
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 794)
TITLE NIH-MGC http://mgi.nci.nih.gov/
JOURNAL National Institutes of Health, Mammalian Gene Collection (MGC)
COMMENT Unpublished (1999)
CONTACT: Robert Strausberg, Ph.D.
Email: cgapbs@mail.nih.gov
Tissue Procurement: Jeffrey E. Green, M.D.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LNL at:
http://image.lnl.gov
Plate: L1AM9844 row: n column: 10
High quality sequence stop: 694.
```

FEATURES

source

1. 794

/organism="Mus musculus"

/strain="FVB/N"

/db\_xref="taxon:10090"

/clone\_lib="IMAGE:4236489"

/clone\_id="NCI\_CGAP\_Ki14"

/lab\_host="DH10B (TL phage-resistant)"

/Note="Organ: kidney; Vector: pCMV-Sport6; Site:1: NotI; Site:2: SalI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.75 kb. Constructed by Life Technologies. Note: this is a NCI\_CGAP Library."

BASE COUNT 186 a 214 c 215 g 179 t

ORIGIN

Query Match 23.7%; Score 276.4; DB 12; Length 794;  
 Best Local Similarity 69.3%; Pred. No. 1.6e-54;  
 Matches 405; Conservative 0; Mismatches 176; Indels 3; Gaps 2;

```

42 CCGGTTCTGGGTCGTGTAATGATAGATAGAGCCGCCCAATGCAAGTCTGAGG 101
148 CAGCTTCGGATCAGTTATCAGATCAGAGGCTCTCAGATGTACAGTCTTAAGG 207
102 GCTCCAGGCTCGCTTCACTGACAGCTCTCCAGGCTGGAAGCTCATCTGAGGCTC 161
208 ACTCAGAGGCTCACTTCACTGACAGCTCTCCAGGCTGGAAGCTCTCATCTGAGCTC 267
162 TCAGTGCATGTGTGTCTCAAGCTCAGGCCATGAGCCCATCATCACCATGACCGCT 221
268 TTAAACCAATGAGTGTGCTGATCTCACACCCAGAGGCCATCATCACCACCAACCGCT 327
222 TCACCTCTCAGAGGTACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 281
328 TCACCTCTCAGAGGTACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 387
282 TGAGAGCCAGTGTATTCGGGAGATCAGATGACAGCTCTCCAGGAGTCTGATGATGAT 341
388 TGAGAGCCAGTGTATTCGGGAGATCAGATGACAGCTCTCCAGGAGTCTGATGATGAT 447
342 CTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTT 401
448 CTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTT 507
402 TCAGTGCATGTGTGTCTCAAGCTCAGGCCATGAGCCCATCATCACCATGACCGCT 461
508 TCACCTCTCAGAGGTACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 567
462 ATATTTCTCGGAGCTCGCTCTCTGCTCAGCATTCAAGCTTATTTTGTCCGGAGC 521
568 ATATTTCTCGGAGCTCGCTCTCTGCTCAGCATTCAAGCTTATTTTGTCCGGAGC 627
522 CCAGGACCTTCAAGAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGT 581

```





Wed Apr 30 10:00:03 2003

us-09-729-264-1.rge

Page 17

||||| | ||||| |||  
Db 121168 AGAGGCTCACCCTCAACTGCTGACTCATGCGCTGA 121205

Search completed: April 29, 2003, 14:10:30  
Job time : 4555.27 secs



TITLE  
JOURNAL  
COMMENT

Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.  
Submitted (09-MAY-2002) Whitehead Institute/MIT Center for Genome  
Research, 320 Charles Street, Cambridge, MA 02141, USA  
On May 9, 2002 this sequence version replaced gi:20503171.  
All repeats were identified using RepeatMasker:  
Smith, A.F.A. & Green, P. (1996-1997)  
<http://ftp.genome.washington.edu/RM/RepeatMasker.html>

Center: Whitehead Institute/ MIT Center for Genome Research  
Genome Center

Center code: WIBR

Web site: <http://www-seq.wi.mit.edu>

Contact: [sequence\\_submissions@genome.wi.mit.edu](mailto:sequence_submissions@genome.wi.mit.edu)

Project Information

Center Project name: L20921

Center Clone name: 147\_E.11

Summary Statistics

Sequencing vector: Plasmid; n/a; 100% of reads  
Chemistry: Dye-terminator Big Dye; 100% of reads  
Assembly program: Phrap; version 0.960731

Consensus quality: 169879 bases at least Q40

Consensus quality: 172188 bases at least Q30

Consensus quality: 173133 bases at least Q20

Insert size: 176000; agarose-fp

Insert size: 173761; sum-of-coverage

Quality coverage: 8.3 in Q20 bases; sum-of-coverage

Quality coverage: 8.4 in Q20 bases; sum-of-coverage

\* NOTE: This is a 'working draft' sequence. It currently  
\* consists of 22 contigs. Gaps between the contigs  
\* are represented as runs of N. The order of the pieces  
\* is believed to be correct as given, however the sizes  
\* of the gaps between them are based on estimates that have  
\* provided by the submitter.

\* This sequence will be replaced

\* by the finished sequence as soon as it is available and  
\* the accession number will be preserved.

1 28835: contig of 28835 bp in length

28836 28935: gap of 100 bp

28936 29562: contig of 627 bp in length

29562 29662: gap of 100 bp

29662 30328: contig of 666 bp in length

30328 30428: gap of 100 bp

30428 32005: contig of 1577 bp in length

32005 32105: gap of 100 bp

32105 33128: contig of 1023 bp in length

33128 33228: gap of 100 bp

33228 34512: contig of 1284 bp in length

34512 34612: gap of 100 bp

34612 36079: contig of 1467 bp in length

36079 36179: gap of 100 bp

36179 37483: contig of 1304 bp in length

37483 37583: gap of 100 bp

37583 39166: contig of 1583 bp in length

39166 39266: gap of 100 bp

39266 41065: contig of 1799 bp in length

41065 41165: gap of 100 bp

41165 43203: contig of 2038 bp in length

43203 43303: gap of 100 bp

43303 47489: contig of 4186 bp in length

47489 47589: gap of 100 bp

47589 50604: contig of 3015 bp in length

50604 50704: gap of 100 bp

50704 56370: contig of 5666 bp in length

56370 56470: gap of 100 bp

56470 64079: contig of 7609 bp in length

64079 64179: gap of 100 bp

64179 72619: contig of 8440 bp in length

72619 72719: gap of 100 bp

72719 81566: contig of 8847 bp in length

81566 81666: gap of 100 bp

81666 96774: contig of 15108 bp in length

96774 96874: gap of 100 bp

\* 96875 119647: contig of 22773 bp in length  
\* 119648 119747: gap of 100 bp  
\* 119748 147772: contig of 28025 bp in length  
\* 147773 147872: gap of 100 bp  
\* 147873 174557: contig of 26685 bp in length  
\* 174558 174657: gap of 100 bp  
\* 174658 175861: contig of 1204 bp in length.  
Location/Qualifiers  
1. 175861  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
/clone="RP23-147B11"  
/clone\_id="RP23-147B11"  
1. 28835  
/note="assembly-fragment"  
clone\_end:SP6  
vector\_side:left"

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

misc\_feature

BASE COUNT 48903 a 39540 c 39029 g 46286 t 2103 others  
ORIGIN

Query Match 4.9%; Score 58; DB 2; Length 175861;  
Best Local Similarity 74.5%; Pred. No. 0.0043;

Matches 73; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 53 TTCTGGTCTGCTAATGAAGTCAAGAGCCCAAGATCAACAGTCTGAGAGGCTC 112

DB 121108 TTCTGGATCCGCTTATCAGATCAATGAGCCCTAAGAAATATACAGCTACAGGCTC 121167

QY 113 CCAAGCTGCTTCACTGACCGCTCCAGGCTGCA 150

Query Match	8.5%	Score 100;	DB 9;	Length 199665;
Best Local Similarity	100.0%;	Pred. No. 3.3e-13;		
Matches 100;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

**TITLE** Direct Submission  
**JOURNAL** Submitted (06-MAY-2002) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA  
**REFERENCE** 3 (bases 1 to 17561)  
**AUTHORS** Birren, B., Linton, L., Nusbaum, C., Lander, E., All, A., Allen, N.,

Birren, B., Linton, L., Nussbaum, C., Lander, E., Ali, A., Allen, N.,  
 Anderson, S., Barna, N., Bastien, V., Bloom, T., Boguslavsky, L.,  
 Boukhalter, B., Brown, A., Camarata, J., Campopiano, A., Chang, J.,  
 Chazaro, B., Chopelet, Y., Colangelo, M., Collins, S., Collimore, A.,  
 Cook, A., Cooke, P., DeAtrellano, K., Dewar, K., Diaz, J. S., Dodge, S.,  
 Ferro, S., Ferreira, P., Fitzhugh, W., Gage, D., Galagan, J., Gaidyna, S.,  
 McCarthy, M., McEwan, P., McKernan, K., Meldrim, J., Menus, L.,  
 Norbu, C., Norman, C. H., O'Connor, T., O'Donnell, P., O'Neill, D.,  
 Oliver, J., Peterson, K., Pinukhang, P., Pierre, N., Pollara, V.,  
 Raymond, C., Retta, R., Rieback, M., Riley, R., Rise, C., Rogov, P.,  
 Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupbach, R.,  
 Seaman, S., Severy, P., Spencer, B., Strange-Rhomon, N., Stojanovic, N.,  
 Strauss, N., Subramanian, A., Talamas, J., Tesfaye, S., Theodore, J.,  
 Topham, K., Travers, M., Travis, N., Triggilio, J., Vassiliev, H.,  
 Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W. J., Young, G.,  
 Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.  
 Direct Submission  
 Submitted (06-MAY-2002) Whitehead Institute/MIT Center for Genome  
 Research, 320 Charles Street, Cambridge, MA 02141, USA  
 3 (bases 1 to 175861)



[illegible]



REFERENCE	AUTHORS	TITLE	JOURNAL
1	Welcher A.A., Sarmiento U.M., Schultz H.J. and Chute H.T.	B7-like molecules and uses thereof	Patent: WO 0200710-A 11 03-JAN-2002;
2	Amgen, Inc. (US)	Location/Qualifiers	
3	1. .895	/organism="Mus musculus"	
4	53. .865	/db_xref="taxon:10090"	
5		/note="unnamed protein product"	
6		/codon_start=1	
7		/protein_id="CAD8221.1"	
8		/db_xref="GI:19575337"	
9		/translation="MEGSRDYLAVLYILAIQASGSSYOIEIPONTYVLKDSAH	
10		NOTYHGRKILMTLNQMYVLSTTQPIITNNRFTYASINSTDSEISLIIHDQPS	
11		DSGVSQSLNSHGSAFLVSVDISGEESPALPTVAIIILVAVSFLILITLII	
12		IPCCASRREESTYONEIKRSMNTNADEPTLAKSGKENYGSSEAKAAQTAA	
13		LPKFAEYSLPEKSSSLPYOELKHHPPGPAITPRVSPFIASPOKRVNVTIV"	
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			
61			
62			
63			
64			
65			
66			
67			
68			
69			
70			
71			
72			
73			
74			
75			
76			
77			
78			
79			
80			
81			
82			
83			
84			
85			
86			
87			
88			
89			
90			
91			
92			
93			
94			
95			
96			
97			
98			
99			
100			
101			
102			
103			
104			
105			
106			
107			
108			
109			
110			
111			
112			
113			
114			
115			
116			
117			
118			
119			
120			
121			
122			
123			
124			
125			
126			
127			
128			
129			
130			
131			
132			
133			
134			
135			
136			
137			
138			
139			
140			
141			
142			
143			
144			
145			
146			
147			
148			
149			







```

repeat_region /rpt_family="MER34"
                complement(17633..17669)
                /evidence=not_experimental
repeat_region /rpt_family="AluSg1"
                complement(18004..18334)
                /evidence=not_experimental
repeat_region /rpt_family="L1R17"
                complement(18335..18632)
                /evidence=not_experimental
                /rpt_family="HERV17"
                18352..18420
                /note="GRAIL, score = 51.000%, comment = good shadow"
exon /evidence=not_experimental
                complement(18397..18584)
                /note="GRAIL, score = 66.000%, comment = good"
repeat_region /evidence=not_experimental
                complement(18643..24647)
                /evidence=not_experimental
exon /evidence=not_experimental
                /rpt_family="HERV17"
                complement(19228..19361)
                /note="MZF, score = 92.8%"
                /evidence=not_experimental
                20900..21135
                /note="MZF, score = 51.4%"
                /evidence=not_experimental
                21150..21275
                /note="Xpound exon prediction, score = 74% (0%)"
                /evidence=not_experimental

```

```

Query Match 27.3%; Score 320.2; DB 9; Length 142742;
Best Local Similarity 97.6%; Pred. No. 2,8e-66;
Matches 325; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

```

```

QY 42 TTCCTCAGCGTCTGTGGTCTGTAATGAAGTGAAGGCCCCCAGAGTGAACATC 101
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 44265 TACCTTCAGAGTCTGTGGTCTGTAATGAAGTGAAGGCCCCCAGAGTGAACATC 44324
QY 102 CTGAAGGGCTCCAGGCTGCTTCAACCTGACCGTCCAGGCTGGAAGCTCATCATC 161
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 44325 CTGAAGGGCTCCAGGCTGCTTCAACCTGACCGTCCAGGCTGGAAGCTCATCATC 44384
QY 162 TGGGCTCTCGTACATGAGTGGTGTGTAAGCTGAGGCCCATGAGCCCATCATCATC 221
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 44385 TGGGCTCTCGTACATGAGTGGTGTGTAAGCTGAGGCCCATGAGCCCATCATCATC 44444
QY 222 GACCGCTTCACTCTCTAGAGTACGACCAAGGGGGAAGTCACTCTGAGAGTATCATC 281
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 44445 GACCGCTTCACTCTCTAGAGTACGACCAAGGGGGAAGTCACTCTGAGAGTATCATC 44504
QY 282 CACAATGTGAGCCAGTGTATCGGGGAACATCATGACCTCCAGAACATGCGCTG 341
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 44505 CACAATGTGAGCCAGTGTATCGGGGAACATCATGACCTCCAGAACATGCGCTG 44564
QY 342 CATGATCTGCTTACCTTACCGTCAAGTTATG 374
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 44565 CATGATCTGCTTACCTTACCGTCAAGTTATG 44597

```

```

RESULT 8
LOCUS HS21C080 340000 bp DNA linear PRI 24-MAY-2000
DEFINITION Homo sapiens chromosome 21 segment HS21C080.
ACCESSION AL163280 APO01735 BA000005
VERSION AL163280.2 GI:7717369
KEYWORDS
SOURCE
ORGANISM Homo sapiens
human.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 340000)
Hattori,M., Fujiyama,A., Taylor,T.D., Matsumae,H., Yada,T.,
Park,H.S., Toyoda,A., Ishii,K., Totoki,Y., Tanabe,D.K., Soeda,E.,
Ohki,M., Takagi,T., Sakaki,Y., Taudien,S., Blechschmidt,K.,

```

TITLE  
JOURNAL  
Direct Submission  
Submitted (05-MAY-2000) The Chromosome 21 Mapping and Sequencing Consortium: \* RIKEN Genomic Sciences Center, Human Genome Research Group \* Institute of Molecular Biotechnology, Genome Analysis Keio University School of Medicine, Dept. of Molecular Biology \* GBF, Dept. of Genome Analysis \* Max-Planck Institute for Molecular Genetics (addresses see below)  
The Chromosome 21 Mapping and Sequencing Consortium consists of \* RIKEN Genomic Sciences Center, Human Genome Research Group, \* Sagamihara 228-8555, Japan, \* e-mail: sakaki@sc.riken.go.jp  
\* URL: http://hgp.gsc.riken.go.jp/  
and  
\* Institute of Molecular Biotechnology, Genome Analysis, \* Beutenbergstrasse 11, D-07745 Jena, Germany, \* e-mail: gscf-submit@genome.imb-jena.de  
\* URL: http://genome.imb-jena.de/  
and  
\* Keio University School of Medicine, Dept. of Molecular Biology, \* Tokyo 160-8562, Japan, \* e-mail: shimizue@mb-med.keio.ac.jp  
\* URL: http://adenine.dmb.med.keio.ac.jp/  
and  
\* Mascheroder Weg 1, D-38124 Braunschweig, Germany, \* e-mail: info.genome@bf.de  
\* URL: http://genome.bf.de/  
and  
\* Max-Planck Institute for Molecular Genetics, \* Ihnestrasse 73, D-14195 Berlin, Germany, \* e-mail: info-chr21@molgen.mpg.de  
\* URL: http://chr21.mpg.de/  
Location/Qualifiers  
1..340000  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="21"  
/map="21q22.3"  
1..125946  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="21"  
/map="21q22.3"  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="21"  
/map="21q22.3"  
/clone="P160L9, 5' partial"  
/clone\_id="RPC11,3-5 PAC library"  
/note="Accession No. AF121897"  
73410..24353  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="21"  
/map="21q22.3"  
/clone="P206A10, 3' partial"  
/clone\_id="RPC11,3-5 PAC library"  
/note="Accession No. AF064860"  
224137..>340000  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="21"  
/map="21q22.3"  
/clone="P206A10, 3' partial"  
/clone\_id="RPC11,3-5 PAC library"  
/note="Accession No. AF121782"  
286628..>340000

SOURCE

```

repeat_region complement(140. .415)
/evidence-not_experimental
/rpt_family="MLR2P"
repeat_region complement(668. .881)
/evidence-not_experimental
/rpt_family="MER58A"
complement(1078. .1162)
/note="GRAIL, score = 86.000%, comment = excellent shadow"
/evidence-not_experimental
repeat_region 1114. .1403
/evidence-not_experimental
/rpt_family="MLR1J"
repeat_region 1481. .1603
/evidence-not_experimental
/rpt_family="L2"
exon 1576. .1710
/note="MZE, score = 66.1%"
/evidence-not_experimental
1576. .1710
/note="GRAIL, score = 99.000%, comment = excellent"
/evidence-not_experimental
repeat_region complement(1693. .1741)
/evidence-not_experimental
/rpt_family="MIR"
repeat_region complement(1780. .2326)
/evidence-not_experimental
/rpt_family="MLR1P"
exon complement(1834. .1955)
/note="GRAIL, score = 50.000%, comment = good shadow"
/evidence-not_experimental
2629. .2831
/evidence-not_experimental
/rpt_family="AluSx"
repeat_region 3012. .3122
/evidence-not_experimental
/rpt_family="MLR1J"
repeat_region 3123. .3478
/evidence-not_experimental
/rpt_family="THER1B"
repeat_region 3479. .3618
/evidence-not_experimental
/rpt_family="MLR1J"
exon complement(3502. .3540)
/note="GRAIL, score = 65.000%, comment = good shadow"
/evidence-not_experimental
4674. .4781
/note="GRAIL, score = 42.000%, comment = marginal"
/evidence-not_experimental
4712. .4749
/note="Xpound exon prediction, score = 70% (0%)"
/evidence-not_experimental
5385. .6104
/evidence-not_experimental
/rpt_family="HERVL"
exon 6682. .6751
/note="MZE, score = 95.1%"
/evidence-not_experimental
6746. .6751
/note="Genscan, score = 1.83%, comment = Initial_exon 6 bp
frame: 1 phase: 0"
repeat_region 6901. .7339
/evidence-not_experimental
/rpt_family="MLR1C"
repeat_region 7347. .7457
/evidence-not_experimental
/rpt_family="LIR16C"
repeat_region complement(7561. .7696)
/evidence-not_experimental
/rpt_family="MIR"
repeat_region complement(7819. .8220)
/evidence-not_experimental
/rpt_family="MLR1J"
exon 8097. .8119
/note="GRAIL, score = 45.000%, comment = marginal"
/evidence-not_experimental
complement(8738. .9232)
/evidence-not_experimental
/rpt_family="MLR1C"
complement(9273. .9420)
/note="GRAIL, score = 71.000%, comment = good"
/evidence-not_experimental
exon 9290. .9371
/note="GRAIL, score = 81.000%, comment = excellent shadow"
/evidence-not_experimental
9666. .10041
/note="homology = 100.00%, score = 38, counts = 2"
/evidence-not_experimental
repeat_region /rpt_type=" tandem
/rpt_unit="ctcttcgacactctctgttgagagctgttatcgc
10244. .10664
/evidence-not_experimental
/rpt_family="MLR1E"
repeat_region 10665. .11028
/evidence-not_experimental
/rpt_family="MLR1P"
repeat_region 11318. .11417
/evidence-not_experimental
/rpt_family="L1MC/D"
repeat_region 11503. .11818
/evidence-not_experimental
/rpt_family="AluSg"
exon complement(11525. .11777)
/note="MZE, score = 79.4%"
/evidence-not_experimental
complement(12346. .12827)
/evidence-not_experimental
/rpt_family="MLR1C"
repeat_region 12902. .13180
/evidence-not_experimental
/rpt_family="AluSg"
exon complement(13057. .13161)
/note="MZE, score = 76.1%"
/evidence-not_experimental
complement(13226. .13364)
/evidence-not_experimental
/rpt_family="L1MC2"
repeat_region complement(13613. .13908)
/evidence-not_experimental
/rpt_family="AluSx"
repeat_region complement(14317. .14614)
/evidence-not_experimental
/rpt_family="LIR37A"
exon complement(14962. .15036)
/note="MZE, score = 93%"
/evidence-not_experimental
15255. .15299
/evidence-not_experimental
/rpt_family="L1P6"
exon complement(15469. .15497)
/note="Xpound exon prediction, score = 62% (0%)"
/evidence-not_experimental
16045. .16768
/evidence-not_experimental
/rpt_family="MER21A"
exon complement(16555. .16655)
/note="GRAIL, score = 54.000%, comment = good"
/evidence-not_experimental
16823. .16850
/evidence-not_experimental
/rpt_family="MER34"
repeat_region complement(16851. .17208)
/evidence-not_experimental
/rpt_family="THER1A"
repeat_region 17209. .17632
/evidence-not_experimental

```

LOCUS AX380404 1195 bp DNA linear PAT 18-MAR-2002  
 DEFINITION Sequence 9 from Patent WO0200710.  
 ACCESSION AX380404  
 VERSION AX380404.1 GI:19575334  
 KEYWORDS  
 SOURCE house mouse.  
 ORGANISM Mus musculus.  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE  
 1. Welcher A.A., Sarmiento U.M., Schultz H.J. and Chute H.T.  
 B7-like molecules and uses thereof  
 Patent: WO 0200710-A 9 03-JAN-2002;  
 Amgen, Inc. (US)  
 FEATURES  
 source Location/Qualifiers  
 1. 1195  
 /organism="Mus musculus"  
 /db\_xref="taxon:10090"  
 53..1165  
 /note="unnamed protein product"  
 CDS  
 /codon\_start=1  
 /protein\_id="CAD28220.1"  
 /db\_xref="GI:19575335"  
 /translation="MEGSMRDYLAIVLIIAQLTASGSYQIIEGPNVYLIDSEAH  
 NCTVTHGKILMTLNMVYLSITGPIITNNRPTIYASINSDSIFSLIHIDVPS  
 DSGSVCSLONSHGFSFASLSVOVMTLNPISNMLVTGEPCNMTCAVNGTSLPDI  
 SWELEVPVSHSSINSLFEPGNEKRVSLVDLPGLGELTCAVLEKLDQASLSLVN  
 TVVQPPDSITGEERPALPTWAILLAVASFLILIVLIIIFCCCSARREESTY  
 QNEIRKSAMNRTKADPETKLSKENYGSSEDAEQAFTASLPSRAVSLSPEKRS  
 SLPEYELNKHOPATHPRVPSPIASPOQVRNVTLY"

BASE COUNT 313 a 304 c 291 g 287 t  
 ORIGIN

Query Match 32.4%; Score 381; DB 6; Length 1195;  
 Best Local Similarity 61.9%; Pred. No. 4.6e-81;  
 Matches 712; Conservative 0; Mismatches 370; Indels 69; Gaps 4;

24 GAGATGGGGCTTGATTTCTCCACAGCTTGGCTGTGATAGATCAATAGAGGC 83  
 83 GTGCTGTATCTCTGGCTACAGCTGCGGATCCGATCCAGTTATCATAGATAGAGGT 142  
 84 CCCAGAAATCAACAGCTGAGAGGCTCCAGGCTCCGCTCAACTGACCCGCTCCAG 143  
 143 CCTCAGATGTAAACAGCTCTTAAGAGACTCAGAGGCTACTTCAACTGACCCGCTCAC 202  
 144 GGCTGAGAGCTCATCATGTGGCTCTCAGTACATGGTGTCTAAGCGTCAAGCCATG 203  
 203 GGCTGAGAGCTCTCATGTGACTCTTAACCAATAGTGTGTCTGATGCTCACACCCAA 262  
 204 GAGCCCATCATACCAATGACCGCTTCACTCAGAGAGTACAGACAGGCGGGAACCTTC 263  
 263 GGACCCATCATACCAACACCGCTTCACTATGCAAGTACCAACAGCACTGACACCTTC 322  
 264 ACCTGAGATGATCATACCAATGAGAGCCAGTATGCGGGAACATACATGATCAGC 323  
 323 ATCTCGAGATGTAAATCATCATGTGAGAGCCAGTACCTCGGATCCGTGCAATCAGC 382  
 324 CTCAGAGACAGTGGCTGATGATGCTTACCTTACCGTCCAGTAAATGAGAGAGCTG 383  
 383 CTCAGAGACAGTGGTGTGATGCTTCTCTCTCAGTCAAGTCAATGAGGAGACCTG 442  
 384 TTGATTTCCAGTGTATATCTTGTAGTCCGTGAGATGAACCTTGTAAATCTTCTTA 443  
 443 AACATTTCTTGAACAACACTTATAGTACATGAGGAGTAAACCTGTATATGACTGCTAT 502  
 444 CCTCAGACTGAGACCGGCTCCGATATTTCTGAGAGCTGCTCTCTGCTGACAGCAT 503  
 503 GCGTGGGCTGAGACTGACCTCCCGGATATTTCTGAGAGCTTGAAGTCCCGTAAGCAT 562  
 504 TCAGATATATTTTGTGCGGAGCCAGGACCTTCAAAAGTGCAGTGCATCTGGCT 563  
 563 TCAGATTAATTCCTTCTGAGAGCCGCAACTTATAGAGGCTTGTGAGTCTCGTGGAC 622

564 CTGACCCCAAGAGCAATGGACTTGTAGTTCGCTGCTACCTGAGAGAGCCTGAGGCC 623  
 623 CTCACACCACTGGGCGAGAGGACCTTGTGCTGCTGAGAGACTGAGAGACTTGCAGGCC 682  
 624 CGCAAGCTGCAACTGTAAATCTCACTGTGATCGGTGCCCAAGACAGTGAAGTGT 683  
 683 AGCAAGCTCTTCACTGTCAACTGACTGTGTGTCAGCCCTCACAGTCAAGTGTGAGAG 742  
 684 ATTAATATCCAGGTATATTAATCAAGTTTACGAGTTTGAAGTTTCAATGGCTACTGG 743  
 743 GA-----AGGCCAGCACTGCCGACTGG 766  
 744 GGCAGATGGAGCTTGGACTAGACAGCACCACTCTTGTACGCCGAGTACTCTTACA 803  
 767 GCATCATCTCTGCTGAGAGGCTTCTTCTGCTGCTGATCTGATCATTTGTTGAT 826  
 804 ATACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 863  
 827 ATTAATATCTGTTGCTGTTGT-----GCTTCCAGAGAGAAAGAGAAATC 873  
 864 TTCTGCTGAGAGAGAGAGATTTCTGATTTCAATTTCAAAAGAAATCGAAAGAG 923  
 874 TACTTATCAAAATGAAATTAAGAAATCTGCAACATGAGAGCA-----AC 919  
 924 AAGACAAACAAAGAACTGAGACAGAAAGTGAATGAATCTCCGCTACAAATTCAGAT 983  
 920 AAGACGATCCGAGACAAAGTTAAAGTGAAGAAAGAACTACGAGGATCGGAT 979  
 984 GAACAAACACCAAGACAGACCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1043  
 980 GAGGCAAGGCTGACAGACCTCATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1039  
 1044 GAACAAAGAAAGAGTGTGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1103  
 1040 GAAAGAGAGAGAGT-----GCTTCTCTTATCAAGAACTCAAGAACTACAGCCGGT 1093  
 1104 CCAGCAAGTATCAACAGGCTTCTTAAATCTGCGCACTCTGAGAGAGTCAATATACA 1163  
 1094 CCAGCAAGTATCAACAGGCTTCTTAAATCTGCGCACTCTGAGAGAGTCAATATGTG 1153  
 1164 ACTGATGATA 1174  
 1154 ACTTATGATTA 1164

RESULT 7  
 AF121782 142742 bp DNA linear PRI 02-FEB-1999  
 LOCUS AF121782  
 DEFINITION Homo sapiens chromosome 21q22.3 PAC 206A10, complete sequence.  
 ACCESSION AF121782  
 VERSION AF121782.1 GI:4210991  
 KEYWORDS HTG.  
 SOURCE Homo sapiens.  
 ORGANISM Homo sapiens.  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE  
 1 (bases 1 to 142742)  
 Taudien,S., Dagand,E., Hildmann,T., Nordstiek,G., Drescher,B.,  
 Schattevoy,R., Weber,J., Schilling,M., Menzel,U., Yaspo,M.L. and  
 Rosenthal,A.  
 TITLE Direct Submission  
 JOURNAL Submitted (21-JUN-1999) Genome Analysis, Institute for Molecular  
 Biotechnology, Beutenbergstrasse 11, Jena 07745, Germany  
 FEATURES  
 source Location/Qualifiers  
 1. 142742  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="21"  
 /map="21q22.3"  
 /clone="PAC 206A10"  
 3. 118  
 repeat\_region  
 /evidence=not experimental  
 /rpt\_family="MIR"



QY 351 GCTTACCTTACGTCCTCAAGTTATGGAGAGCTGTGTCATTCCACAGTGTATCTTGTAGTC 410  
 |||||  
 Db 416 GCTTACCTTACGTCCTCAAGTTATGGAGAGCTGTGTCATTCCAGTGTATCTTGTAGTC 475  
 |||||  
 QY 411 GCTGAAATGAACCTTGTGAAGTACTTGTCTACCTCTACCTGAGCCGGCTCCCGGAT 470  
 |||||  
 Db 476 GCTGAAATGAACCTTGTGAAGTACTTGTCTACCTCTACCTGAGCCGGCTCCCGGAT 535  
 |||||  
 QY 471 ATTTCCTGGAGCTCGGTCTCTGTCAGCCATTCAAGTATTATTTTGTCCGAGCC 530  
 |||||  
 Db 536 ATTTCCTGGAGCTCGGTCTCTGTCAGCCATTCAAGTATTATTTTGTCCGAGCC 595  
 |||||  
 QY 531 AGGACCTTCAAAAGTCAAGTCAAGTCTGCTCTGAGCCCAAGCAAGCAAGTGGAGCTTTG 590  
 |||||  
 Db 596 AGGACCTTCAAAAGTCAAGTCAAGTCTGCTCTGAGCCCAAGCAAGTGGAGCTTTG 655  
 |||||  
 QY 591 ACTTGGGCTGCTACCTGGAAGAGCTGGAAGGCCCAAGTCTGCAATCTAATCTCACT 650  
 |||||  
 Db 656 ACTTGGGCTGCTACCTGGAAGAGCTGGAAGGCCCAAGTCTGCAATCTAATCTCACT 715  
 |||||  
 QY 651 GTGATTCGCTGCTCCCAAGACACTGGAAGGTGATTAATATTCAGGTATTTATCACT 710  
 |||||  
 Db 716 GTGATTCGCTGCTCCCAAGACACTGGAAGGTGATTAATATTCAGGTATTTATCACT 775  
 |||||  
 QY 711 TTACCGAGTTAGTTTTCATTGCTTACTTGGGCAAAAGTTGAGCTTGGAGTACGAGC 770  
 |||||  
 Db 776 TTACCGAGTTAGTTTTCATTGCTTACTTGGGCAAAAGTTGAGCTTGGAGTACGAGC 835  
 |||||  
 QY 771 ACCATGCTTGTACGCGGAGCTACTCTTACATACGCTGCTGCTGCGCGCTCT 830  
 |||||  
 Db 836 ACCATGCTTGTACGCGGAGCTACTCTTACATACGCTGCTGCTGCGCGCTCT 895  
 |||||  
 QY 831 TGTGTGCTGCTCAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 890  
 |||||  
 Db 896 TGTGTGCTGCTCAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 955  
 |||||  
 QY 891 CGTATTCATTTTCAAAAGAAATCTGAAAAAGAGAGACAACAAGAACTGAGACAGA 950  
 |||||  
 Db 956 CGTATTCATTTTCAAAAGAAATCTGAAAAAGAGAGACAACAAGAACTGAGACAGA 1015  
 |||||  
 QY 951 AGTGAATGAATGAATGCGGCTACATTCAGATGAACAAAGCCACACACCGCTTCT 1010  
 |||||  
 Db 1016 AGTGAATGAATGAATGCGGCTACATTCAGATGAACAAAGCCACACACCGCTTCT 1075  
 |||||  
 QY 1011 CTCCTCTCCCAATCTCTGTGATCTCACTGATCTGACAAAGAAAGTGTGCTGCT 1070  
 |||||  
 Db 1076 CTCCTCTCCCAATCTCTGTGATCTCACTGATCTGACAAAGAAAGTGTGCTGCT 1135  
 |||||  
 QY 1071 CTCCTCTCCCAATCTCTGTGATCTCACTGATCTGACAAAGAAAGTGTGCTGCT 1130  
 |||||  
 Db 1136 CTCCTCTCCCAATCTCTGTGATCTCACTGATCTGACAAAGAAAGTGTGCTGCT 1195  
 |||||  
 QY 1131 AATCTGGCCAGCTCTGAGAAAGTCAATTAACACTGTGTATATG 1175  
 |||||  
 Db 1196 AATCTGGCCAGCTCTGAGAAAGTCAATTAACACTGTGTATATG 1240  
 |||||

RESULT 4  
 AX380398 1168 bp DNA linear PAT 18-MAR-2002  
 LOCUS AX380398  
 DEFINITION Sequence 3 from Patent WO0200710.  
 ACCESSION AX380398  
 VERSION AX380398.1 GI:19575328  
 KEYWORDS  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
 REFERENCE  
 1 Welcher, A.A., Sarmiento, U.M., Schultz, H.J. and Chute, H.T.  
 B7-like molecules and uses thereof  
 JOURNAL Patent: WO 0200710-A 3 03-JAN-2002.

FEATURES Amgen, Inc. (US)  
 Location/Qualifiers  
 source 1..1168  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 8..1168  
 CDS  
 /note="unnamed protein product"  
 /codon\_start=1  
 /protein\_id="CAD28217.1"  
 /translation="MVAGAMENRDPGSGNEVIGPONARYLKSOARENCVYSG  
 WKILMALSPMYLVSVRAMEPILITNDPFSQRPDQGNFTSEKLIHNVPSQNRIC  
 SLONSRHGSAYILFVOMGEFLTPSNLVVAENRPEVTCLEP-WTWLPDISBELIL  
 VSHSXYFVEPESDILQSAVSIILATPQSNLTICVATWMSLA-FKSAIVNLVTRCPQ  
 DTGGGINIPGVLSPLSLPSTWKGVLGAGMLTPCTI-TTRCCCRRCGCG  
 NCCRCFCRRKRGFRIQFQKSEKETWKEFTEGNSGNSINDEQKTDPLSLP  
 PKQSSSDPQRNSGCPPIHQRADQPPRASHPOASFNLASFKSNITTV"  
 BASE COUNT 299 a 302 c 288 g 279 t  
 ORIGIN  
 Query Match 95.5%; Score 1122.4; DB 6; Length 1168;  
 Best Local Similarity 99.5%; Pred. No. 9.7e-260;  
 Matches 1126; Conservative 0; Mismatches 6; Indels 0; Gaps 0;  
 QY 44 COTCCAGGTTCTGGGCTGTGTAATGAAGTCATGAAGGCCCCAGATGCACAGTCTT 103  
 |||||  
 Db 37 CCACACCCCTGCTGTGCTGTCTGTAATGAAGTCATGAAGGCCCCAGATGCACAGTCTT 96  
 |||||  
 QY 104 GAAGGGCTCCAGGCTGCTCAACTGACGCTCCAGGCTGGAAGGCTCATCTGTG 163  
 |||||  
 Db 97 GAAGGGCTCCAGGCTGCTCAACTGACGCTCCAGGCTGGAAGGCTCATCTGTG 156  
 |||||  
 QY 164 GGCCTCAGTACATGAGTGTGCTAAGGCTCAGGCCCATGGAGGCCATATCAACCAATGA 223  
 |||||  
 Db 157 GGCCTCAGTACATGAGTGTGCTAAGGCTCAGGCCCATGGAGGCCATATCAACCAATGA 216  
 |||||  
 QY 224 CCGCTTCACTCTCAGAGTACGACACAGGCGGGAACCTTCACTCTGAGATGATATCA 283  
 |||||  
 Db 217 CCGCTTCACTCTCAGAGTACGACACAGGCGGGAACCTTCACTCTGAGATGATATCA 276  
 |||||  
 QY 284 CAATGTGAGGCCAGTGTGTTGGGGAACATCAGATGACGCTCCAGAAAGTCCCTGCA 343  
 |||||  
 Db 277 CAATGTGAGGCCAGTGTGTTGGGGAACATCAGATGACGCTCCAGAAAGTCCCTGCA 336  
 |||||  
 QY 344 TGGATCTGCTTACCTTACCTGCTCAAGTTATGGAGAGCTGTTCAATCCAGTGTATCT 403  
 |||||  
 Db 337 TGGATCTGCTTACCTTACCTGCTCAAGTTATGGAGAGCTGTTCAATCCAGTGTATCT 396  
 |||||  
 QY 404 TGTACTGCTGAGAAATGAACTTTGTAAGTACTTGTCTACCTCACAACCTGAGCCGCT 463  
 |||||  
 Db 397 TGTACTGCTGAGAAATGAACTTTGTAAGTACTTGTCTACCTCACAACCTGAGCCGCT 456  
 |||||  
 QY 464 CCGGATATTTCTCGGAGCTCGGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 523  
 |||||  
 Db 457 CCGGATATTTCTCGGAGCTCGGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 516  
 |||||  
 QY 524 GGAGCCAGGACCTTCAAAAGTGAAGTGAAGTCACTGCTGCTGCAAGCCACAGCAATGG 583  
 |||||  
 Db 517 GGAGCCAGGACCTTCAAAAGTGAAGTGAAGTCACTGCTGCTGCAAGCCACAGCAATGG 576  
 |||||  
 QY 584 GACTTTGACTTGTGCTGCTTACTGGAAGAGCTTGAAGGCCCGGCAAGTCTGCAACTGATA 643  
 |||||  
 Db 577 GACTTTGACTTGTGCTGCTTACTGGAAGAGCTTGAAGGCCCGGCAAGTCTGCAACTGATA 636  
 |||||  
 QY 644 TCTCAGTGTGATGGGTGCTCCCAAGACACAGAGGTGTATTAATATTCAGGTGAT 703  
 |||||  
 Db 637 TCTCAGTGTGATGGGTGCTCCCAAGACACAGAGGTGTATTAATATTCAGGTGAT 696  
 |||||  
 QY 704 ATCAAGTTTACGAGTTAGTTTTCATTCCTACTTGGGCAAAAGTGTGACTTGGACT 753  
 |||||  
 Db 697 ATCAAGTTTACGAGTTAGTTTTCATTCCTACTTGGGCAAAAGTGTGACTTGGACT 756  
 |||||  
 QY 764 AGCAGGCCACATGCTTCTGACGCCGAGCTGACTTCAATACGCTGCTGCTGCCG 823  
 |||||

```

/clone="PLACE6017788"
/issue_type="placenta"
/clone.lib="PLACE6"
/notes="cloning vector: PME18SFL3"
BASE COUNT      580 a      463 c      474 g      534 t
ORIGIN

```

```

Query Match      95.8%; Score 1125.4; DB 9; Length 2051;
Best Local Similarity 99.9%; Pred. No. 1.9e-260;
Matches 1126; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 49 ACGGTTGGGCTGTGAATGAGTATAGAAAGGCCCCAGAAATGACAAGTCTCTGAAG 108
DB 201 ACGGTTGGGCTGTGAATGAGTATAGAAAGGCCCCAGAAATGACAAGTCTCTGAAG 260
QY 109 GCTCCAGAGCTGCTCAACAGCAACGCTCCCGAGGCTGGAAGCTCATGCTGGGCTC 168
DB 261 GCTCCAGAGCTGCTCAACAGCAACGCTCCCGAGGCTGGAAGCTCATGCTGGGCTC 320
QY 169 TCAGTGAATGATGCTGCTAAGCTCAGAGCCCATGAGCCCATCATCACCAGTACCGCT 228
DB 321 TCAGTGAATGATGCTGCTAAGCTCAGAGCCCATGAGCCCATCATCACCAGTACCGCT 380
QY 229 TCACCTCTCAGAGGTACAGCAAGGCGGGAACCTTACCTCGAGATGATCATCCCAATG 288
DB 381 TCACCTCTCAGAGGTACAGCAAGGCGGGAACCTTACCTCGAGATGATCATCCCAATG 440
QY 289 TGGAGCCCAAGTATCGGGGAAACATCAGATGCAAGCCCTCCAGAACAGTCCGCTCAGAT 348
DB 441 TGGAGCCCAAGTATCGGGGAAACATCAGATGCAAGCCCTCCAGAACAGTCCGCTCAGAT 500
QY 349 CTGCTTACCTTACCGTCAAGTATGAGAGAGCTGTTCATCTCCAGTATATCTTGTAG 408
DB 501 CTGCTTACCTTACCGTCAAGTATGAGAGAGCTGTTCATCTCCAGTATATCTTGTAG 560
QY 409 TCGCTGAAGATGAACCTTGTGAAGTACTTGTCTACCTCAGACTGAGCCGGCTCCGG 468
DB 561 TCGCTGAAGATGAACCTTGTGAAGTACTTGTCTACCTCAGACTGAGCCGGCTCCGG 620
QY 469 ATATTCTCGGAGCTGCTGCTCTCTGTCAGCCATTCACACTATATTTGTTCCGAGC 528
DB 621 ATATTCTCGGAGCTGCTGCTCTCTGTCAGCCATTCACACTATATTTGTTCCGAGC 680
QY 529 CCAGCGACTTCAAGTGAAGTGAAGTCTGCTGCTGAGCCCAAGAGCAATGGGACTT 588
DB 681 CCAGCGACTTCAAGTGAAGTGAAGTCTGCTGCTGAGCCCAAGAGCAATGGGACTT 740
QY 589 TGACTTGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 648
DB 741 TGACTTGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 800
QY 649 CTGCTGATTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 708
DB 801 CTGCTGATTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 860
QY 709 GTTACCGAGTTGAGTTTTCATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 768
DB 861 GTTACCGAGTTGAGTTTTCATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 920
QY 769 GCACCATGCTTCTGACGCGCAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 828
DB 921 GCACCATGCTTCTGACGCGCAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 980
QY 829 GTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 888
DB 981 GTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1040
QY 889 TTGCTATTCATTTCAAAAGAAATCTGAAAAGAGAGCAAAAGAAAGAGAGAGAG 948
DB 1041 TTGCTATTCATTTCAAAAGAAATCTGAAAAGAGAGCAAAAGAAAGAGAGAGAG 1100
QY 949 AAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGA 1008
DB 1008 AAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGA

```

```

DB 1101 AAGGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 1160
QY 1009 CTCTCCCTCCCAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1068
DB 1161 CTCTCCCTCCCAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1220
QY 1069 CTCTCCCTCCCAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1128
DB 1221 CTCTCCCTCCCAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1280
QY 1129 TTAATCTGCGCAGTCTGAGAAAGTCAATGATGATGATGATGATGATGATGATGAT 1175
DB 1281 TTAATCTGCGCAGTCTGAGAAAGTCAATGATGATGATGATGATGATGATGATGAT 1327

RESULT 3
AX380400      1240 bp      DNA      linear      PAT 18-MAR-2002
LOCUS
DEFINITION   Sequence 5 from Patent WO0200710.
ACCESSION   AX380400
VERSION      AX380400.1 GI:19575330
KEYWORDS
SOURCE
ORGANISM     human.
              Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1            Welcher, A.A., Sarmiento, U.M., Schultz, H.J. and Chute, H.T.
              B7-like molecules and uses thereof
              Patent: WO 0200710-A 5 03-JAN-2002;
              Amgen, Inc. (US)
FEATURES
source       Location/Qualifiers
              1..1240
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              80..1240
              /note="unnamed protein product"
              /codon_start=1
              /db_xref="GI:19575331"
              /translation="MERHLTVPEAVSGSGSENYIEBPQNAVLYLKSQARPNCTVSG
              WKLIIMALSDMVLVSVRMEPIITNDRETSORYDGGNFSEMIHNVEDSDGNCIN
              SLONSRHLSAYLIVOVWGELEFISVNLVVAENEPCEVTCIPSHWRLPDISMELGL
              VSHSRXYVPEPSDLOSVALITLPOSNGLTVCVAVMKSLAKASATVNLIVRCQ
              DTGGGINPGLVLSLPSLGFSLPTMGVGLAGTMTLFTPCITLIRCCCRRCGCC
              NCCCRCCCRKRGRFRLOPKSEKEKTKETETBSGNEENSGTNSDQTTETASLP
              PKSCSSDPEORNSCGPPHORADURPRPASHPOASFNLASPEKVSNTTV"
BASE COUNT   318 a      319 c      305 g      298 t
ORIGIN
Query Match      95.6%; Score 1123.4; DB 6; Length 1240;
Best Local Similarity 99.9%; Pred. No. 5.6e-260;
Matches 1124; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 51 GCTTGGGCTGTGAATGAGTATAGAAAGGCCCCAGAAATGACAAGTCTCTGAAGGC 110
DB 116 GCTTGGGCTGTGAATGAGTATAGAAAGGCCCCAGAAATGACAAGTCTCTGAAGGC 175
QY 111 TCCAGAGCTGCTCAACTGACACCGCTTCCAGGCGCTGGAAGCTCATGCTGGCTCTC 170
DB 176 TCCAGAGCTGCTCAACTGACACCGCTTCCAGGCGCTGGAAGCTCATGCTGGCTCTC 235
QY 171 AGTGACATGCTGCTGAAGCTCAGGCGCCATGAGAGCCCATCATACCAATGACCGCTTC 230
DB 236 AGTGACATGCTGCTGAAGCTCAGGCGCCATGAGAGCCCATCATACCAATGACCGCTTC 295
QY 231 ACCCTCAGAGGTAGACAGAGGCGGGAACCTTACCTCGAGATGATGATCATCCAAATGTG 290
DB 296 ACCCTCAGAGGTAGACAGAGGCGGGAACCTTACCTCGAGATGATGATCATCCAAATGTG 355
QY 291 GAGCCAGATGATGAGGGAACATCAGATGCAAGCTTCCAGAACAGTCCGCTCAGATGATCT 350
DB 356 GAGCCAGATGATGAGGGAACATCAGATGCAAGCTTCCAGAACAGTCCGCTCAGATGATCT 415

```



GenCore version 5.1.4.p5.4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 28, 2003, 23:25:03 ; Search time 3244.94 Seconds

(without alignments) 10538.186 Million cell updates/sec

Title: US-09-729-264-1

Perfect score: 1175

Sequence: 1 cctctgcacatcgtgataa.....gtaatacaactgtatgataag 1175

Scoring table:

IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 4109280

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl:\*  
1: gb\_da:\*  
2: gb\_htg:\*  
3: gb\_in:\*  
4: gb\_om:\*  
5: gb\_ov:\*  
6: gb\_pat:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_sts:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vl:\*  
15: em\_ba:\*  
16: em\_fun:\*  
17: em\_hum:\*  
18: em\_in:\*  
19: em\_mu:\*  
20: em\_om:\*  
21: em\_or:\*  
22: em\_ov:\*  
23: em\_pat:\*  
24: em\_ph:\*  
25: em\_pl:\*  
26: em\_ro:\*  
27: em\_sts:\*  
28: em\_un:\*  
29: em\_vl:\*  
30: em\_htg\_hum:\*  
31: em\_htg\_inv:\*  
32: em\_htg\_other:\*  
33: em\_htg\_mus:\*  
34: em\_htg\_pln:\*  
35: em\_htg\_rdt:\*  
36: em\_htg\_mam:\*  
37: em\_htg\_vrt:\*  
38: em\_sy:\*  
39: em\_htgo\_hum:\*  
40: em\_htgo\_mus:\*  
41: em\_htgo\_other:\*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	1175	100.0	1175	6	AX380396	AX380396 Sequence
2	1125.4	95.8	2051	6	AK092516	AK092516 Homo sapi
3	1123.4	95.6	1240	6	AX380400	AX380400 Sequence
4	1122.4	95.5	1168	6	AX380398	AX380398 Sequence
5	1067.4	90.8	1139	6	AX380402	AX380402 Sequence
6	381	32.4	1195	6	AX380404	AX380404 Sequence
7	320.2	27.3	142742	9	AF121782	AF121782 Homo sapi
8	320.2	27.3	340000	9	HS210080	HS210080 Homo sapi
9	188.6	16.1	196900	2	AC020851	AC020851 Mus muscu
10	186	15.8	754	6	AX380408	AX380408 Sequence
11	186	15.8	895	6	AX380406	AX380406 Sequence
12	186	15.8	1556	10	BC004806	BC004806 Mus muscu
13	177.6	15.1	175861	2	AC120346	AC120346 Mus muscu
14	100	8.5	199665	9	AF064857	AF064857 Homo sapi
15	58	4.9	175861	2	AC120346	AC120346 Mus muscu
16	58	4.9	196900	2	AC020851	AC020851 Mus muscu
17	57	4.9	40205	9	AF045450	AF045450 Homo sapi
18	57	4.9	170121	9	AF064860	AF064860 Homo sapi
19	56.6	4.8	427	9	HS063332	HS063332 Human super
20	55.4	4.7	53908	2	AC120145	AC120145 Mus muscu
21	55	4.7	1061	9	HSCAGCTG	AC100501 Homo sapi
22	53	4.5	178052	2	AC118358	AC118358 Rattus no
23	52.8	4.5	138685	2	AC017582	AC017582 Drosophi
24	52.8	4.5	166249	3	AC093502	AC093502 Drosophi
25	52.8	4.5	185404	3	AC104703	AC104703 Drosophi
26	52.8	4.5	341319	3	AE003536	AE003536 Drosophi
27	51.8	4.4	397	6	BD010479	BD010479 Diagnosti
28	51.4	4.4	85584	2	AC099238	AC099238 Rattus no
29	50.8	4.3	162971	2	AC103439	AC103439 Rattus no
30	50.6	4.3	147185	9	AC020589	AC020589 Homo sapi
31	50.6	4.3	165675	2	AC113925	AC113925 Rattus no
32	50.6	4.3	195460	2	AC128068	AC128068 Rattus no
33	50	4.3	94674	2	AC128466	AC128466 Rattus no
34	50	4.3	179494	2	AC113770	AC113770 Rattus no
35	50	4.3	185487	2	AC108346	AC108346 Rattus no
36	49.8	4.2	299	9	HS131896	HS131896 Homo sapi
37	49.8	4.2	161170	2	AC129166	AC129166 Rattus no
38	49.4	4.2	49845	2	AC100974	AC100974 Mus muscu
39	49.4	4.2	160650	3	AC008188	AC008188 Drosophi
40	49.4	4.2	160885	2	AC018184	AC018184 Drosophi
41	49.4	4.2	162384	2	AC007840	AC007840 Drosophi
42	49.4	4.2	172334	2	AC122602	AC122602 Rattus no
43	49.4	4.2	173373	3	AC099016	AC099016 Drosophi
44	49.4	4.2	306854	3	AE003797	AE003797 Drosophi
45	49.4	4.2	312634	2	AC095096	AC095096 Rattus no

# ALIGNMENTS

RESULT 1  
AX380396 LOCUS AX380396 1175 bp DNA linear PART 18-MAR-2002  
DEFINITION Sequence 1 from Patent WO0200710.  
ACCESSION AX380396  
VERSION AX380396.1 GI:19575326  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Welcher/A.A., Sarmiento,U.M., Schultz,H.J. and Chute,H.T.  
TITLE B7-like molecules and uses thereof  
JOURNAL Patent: WO 0200710-A 1 03-JAN-2002;







Query Match	4.48;	Score 51.8;	DB 21;	Length 369;
Best Local Similarity	57.48;	Pred. No. 0.00038;		
Matches 89; Conservative	0;	Mismatches 66;	Indels 0;	Gaps 0

RESULT 13  
AAx89891/c  
ID AAx89891 standard; DNA; 397 BP.

DT 05-NOV-1999 (first entry)  
XX

KM Spinnocerebellar ataxia type IIT; SCAIIT; reverse dot hybridisation  
KM PCR-microplate hybridisation; PCR-MPH; trinucleotide repeat; TNR;  
KM SCAIIT syndrome; ss.

FH	Key	Location/Qualifiers
FH		
EE		

```
FT      Repeat_region    137..355  
FT  
FT      Repeat_unit     /*tag= a  
FT      137..139  
FT
```

PD 02-SEP-1999.

PR 26-FEB-1998; 98KR-0006278  
XX

PA (SMST) SAMSUNG ETNE CHEM CO LTD

Jin DK:

WPI: 1999-527634/44

PT Diagnosis of spinocerebellar ataxia type III (SCA III) syndrome  
PT using techniques which ensure highly accurate diagnosis

CC The invention relates to the diagnosis of spinocerebellar ataxia type  
CC ii (SCAII) syndrome using reverse dot hybridisation or PCR-microplate  
CC hybridisation (PCR-MH). The method comprises attaching a portion of the  
CC SCAII gene containing 73 copies of the trinucleotide (CA)<sub>n</sub> repeat unit  
CC (the present sequence) to a substrate, and hybridising with amplified  
CC testee genomic DNA containing copies of the trinucleotide units, PCR  
CC amplified with labeled primers (AX98989-99). The new method is useful  
CC for diagnosis of SCAII syndrome, and for determining the severity of  
CC the disease. The present sequence represents the SCAII gene fragment  
CC containing 73 trinucleotide (TNR) repeats.

Query Match	4.48;	Score 51.8;	DB 20;	Length 397;
Best Local Similarity	58.98;	Pred. No. 0.00039;		
Matches 89; Conservative	0;	Mismatches 62;	Indels 0;	Gaps 0

QY 808 GCTGCTGCTGCTGCCGCGCTGTTGTTGGCTGCAACTGCTGCTGCCGCTGTGTTCT 867  
 |||||  
 DB 200 GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1411  
 |||||

868 CCTGTAGAAGAAAAGAGGATTTCGTATTCATTTCAAAGAATCTGA AAAAGAGAGA 922

Db 140 GCTGTTGCTGCTTTTGCTGCTGCTGAACATTCAAAAGTGAAGTATATTAAAAAACAA 81

928 CAACCAAGAACTGAGACAGAAAGTGGAA 958

DB 80 AACCTAAAGAAATAATACACCAIGAGAAA 50

RESULT 14  
ABK10240/C

ID ABK10240 standard; DNA; 403 BP.

AC ABK10240;

DT 20-MAY-2002 (first entry,  
 VY

| DE | Trinucleotide repeat sequence #3 |

spino cerebellar ataxia type ITT: DRPLA: neurosychiatric

KW dentatorubral and pallidum; synucleinopathy; malian

XX  
XX

XXXXXXXXXXXXXXXXXXXXXXXXXXXX

XX

```
FT repeat_region 152..347
```

```

FTT
/rpt_type= TANDEM

```

FT / \*tag= b

22 XX

XX VP30000003004-2  
DN

XX 15-TAN-2000  
PD

25-TTN-1998

25-JUN-1998: 98KR-0024064

PA (SMSU ) SAMSUNG MEDICAL CENT

XX

XX



XX 28-JUN-2001; 2001WO-US20719.  
 XX 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX (AMGE-) AMGEN INC.  
 XX Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 DR WPI; 2002-130881/17.  
 XX P-PSDB; AAU75545.  
 PT New B7-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 XX  
 PS Claim 1; Fig 6; 135pp; English.

CC The invention relates to an isolated B7-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular stenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the coding sequence of mouse B7-L<sub>m2</sub>.

XX  
 XX  
 SQ Sequence 895 BP; 250 A; 223 C; 212 G; 210 T; 0 other;

Query Match 15.8%; Score 186; DB 24; Length 895;  
 Best Local Similarity 71.1%; Pred. No. 3,6e-41;  
 Matches 246; Conservative 0; Mismatches 100; Indels 0; Gaps 0;

QY 24 GAGATGGGGCTTGATTTTCCTCCACGGTTGGCTCGGTAATGAAGTCTAAGAGC 83  
 DB 83 GTCTGGTATCTCGTCTAGCTGACAGCTCCGATCCAGTTCAGTATGAAGT 142  
 QY 84 CCCAGATGCAAGCTCTGGAAGGGCTCCAGGCTCGCTTAACGACCGCTCCAG 143  
 DB 143 CTCACAAATGTATACACTCTTAAGAGCTCAGAGGCTCACTTAAGTCCAGTCTC 202  
 QY 144 GGGTGAAGCTCATGTTGGCTCTCACTGACATGTTGGTCTTAAGCGCTCAGGCCCATG 203  
 DB 203 GCGTGAAGCTTCTCATGTGAGCTTTACCAAAATGGTGTGCTGAGTCTACCAACCA 262

QY 204 GAGCCATCATCACCAGATGACCGCTTACCTCTCAGAGGTACGACAGGGCGGAGCTTC 263  
 DB 263 GGACCATCATCACCAGATGACCGCTTACCTCTCAGAGGTACGACAGGGCGGAGCTTC 322  
 QY 264 ACCTGGAGATGATCATCCACAATGTGAGCGCCAGTATTTGGGGGAACATCAGATGACG 323  
 DB 323 ATCTGGAGATGATCATCCACAATGTGAGCGCCAGTATTTGGGGGAACATCAGATGACG 382  
 QY 324 CTCAGACAGTTCGCTGATGATCTGCTTACCTTACCGTCCAG 369  
 DB 383 CTGCAAGACAGTTCGCTGATGATCTGCTTACCTTACCGTCCAG 428

RESULT 10  
 ABK10239/C  
 ID ABK10239 standard; DNA; 277 BP.  
 XX  
 AC ABK10239;  
 XX  
 DT 20-MAY-2002 (first entry)  
 XX  
 DE Trinucleotide repeat sequence #2.

XX Trinucleotide repeat; fragile X syndrome; ds; DRPLA;  
 KW spinocerebellar ataxia type III; Marfan syndrome;  
 KW hereditary hypertrophic cardiomyopathy; neuropsychiatric;  
 KW dentatorubral and pallidoluysian atrophy;  
 XX spinocerebellar ataxia; X-linked spinobulbar atrophy.

XX Homo sapiens.

XX  
 FH Key Location/Qualifiers  
 FT repeat\_region 152..194  
 FT /\*tag= a  
 FT /rpt\_type= TANDEM  
 FT 152..154  
 FT /\*tag= b  
 FT /note= "CAG type repeat"  
 FT repeat\_region 198..222  
 FT /\*tag= a  
 FT /rpt\_type= TANDEM  
 FT 198..200  
 FT /\*tag= b  
 FT /note= "CAG type repeat"

XX Homo sapiens.

OS KR2000003004-A.

XX 15-JAN-2000.

PD 25-JUN-1998; 98KR-0024064.

XX 25-JUN-1998; 98KR-0024064.

PR 25-JUN-1998; 98KR-0024064.

XX (SMSU ) SAMSUNG MEDICAL CENT.

PA (JIND/) JIN D G.

PI JIN DG;

DR WPI; 2000-662424/64.

XX Plasmid vector arraying neuropsychiatric gene more than copy number

PT containing trinucleotide repeats its use thereof -

XX Disclosure; Page 12; 23pp; Korean.

XX This invention relates to the use of a plasmid vector array

CC containing a neuropsychiatric gene containing trinucleotide repeats.

CC Trinucleotide repeats and their expansion are known to be involved

CC in a number of diseases including fragile X syndrome, spinocerebellar

CC ataxia type III, hereditary hypertrophic, cardiomyopathy, dentatorubral



QY	84	CCGAGAAATGCACAGGCTCCGAGGGCTCCGAGGCTCCGCTTCAATGCACGCTCCGAC	143
Db	143	CTCTGAGATGTAAACAGCTCTTAAAGGACTAGAGGCTCACTTCAACTGCACGCTAC	202
QY	144	GCGTGAAGCTCAATAGTGGGCTCTCAGTGCATGATGGTGGCTAAAGCGTCAGGCCATG	203
Db	203	GGCTGGAAAGCTTCTCAATGTGAGACTTTAAACAAATGGTGGTGTGAGTCTCACCA	262
QY	204	GAGCCCATCATCACCAATGACGGCTTCCACTCTCAGAGGTACGACCAAGGCGGAACTTC	263
Db	263	GGAGCCCATCATCACCAACACCGCTTCCACTTATGGCAGTTTAAACAGCATGACAGCTTC	322
QY	264	ACCTCGAGATGATCATCCCATGTGGAGCCAGATGTGGGGAACATGATGATGACG	323
Db	323	ATCTCGAGATGATCATCCCATGTATGTGACAGCCCATGACTGGGATCCGCTCAATG	382
QY	324	CTCCAGAACAGTGGCGCTGCATGGATCTGCTTACCTTACCGTCCAAATTTATGGGAG	383
Db	383	CTCGAACAAAGCCATGGGTTTGGATCTGGCTTCTCTCTCAGTCAAGTCATGGGAC	442
QY	384	TTCTATTCGCAAGTGTATCTTTGTAAGTCGTGGAATGAACCTTGTGAAGTTACTGTCTA	443
Db	443	AACATTCCTTGACCAACAACCTTATATGCTAGAGGGGAACCTGTAAATGATCTTGAT	502
QY	444	CCCTCACACTGACCCGCGCTCCCGATATTTCTCTGGAGACTGGCTCTCTGATAGCAT	503
Db	503	GCGGTGGGCTGGACCTCACTCCGGATATTTCTCTGGAGACTTGAAGTTC	562
QY	504	TCAAGCTATTTATTTTGTTCGGGAGCCAGCAGACTTCAAAGTGCAGTACATCTGGCT	563
Db	563	TTGAGTTACATTTCTTTTGGAGCCGGGCAACTTATAGGGTCTTAAAGTGTCTGTGAC	622
QY	564	CTGACCCACAGACAACTGGAGCTTTGACTTGGCTGGCTACTGGAAGCTGGAAGCC	623
Db	623	CTCAACACACTGGGCAACGGGACCTTGACTGTGTGCGACACTBAAGACTGTGAGGCC	682
QY	624	CGCAAGTCTGCACCTGTAATCTCAGTGTGATTCGCTGCCAAGACACTGAGAGTGT	683
Db	683	AGCAAGTCTTAACTGCAACCTGACGTGGTGTACCCCTCACTGACAGATTTGGAGAG	742
QY	684	ATTAAATATCCAGGTGTAATATCAAGTTTACGAGTTTGGATTTCAATGGCTACTGG	743
Db	743	GA-----AGGCCACAGCACTGCCACCTGG	766
QY	744	GGCAAAAGTTGCACTTGGACAGCAGCACCATCTTCTAGCCGACAGCTGACTTTACA	803
Db	767	GGCATCACTCTGGGAGAGTGGCTTTCTCTCTCTGATCTGTATGTTTGTAT	826
QY	804	ATACGCTGCTGCTCTGCCCGCTGTGTGTGGCTGCACTGCTGGCTGGCTGTGTGT	863
Db	827	ATAATATCTGTTCTCTGTGT-----GCTCTCAGAGAGGAAGGAAGATC	873
QY	864	TTTGTGCTAGAAAAAAGAGATTTGTAATCAATTTCAAAGAAATCTGAAAAAGAG	923
Db	874	TACTTATCAAAATGAATTAAGGAATCTGCAACATGAGAGACA-----AC	919
QY	924	AAGACAAACAAAGAACTGAGACAGAAAGTGGAAATGAAATCCGGCTACATTTCAAT	983
Db	930	AAAGCAGATCCGGGAGACAAAGTTAAAAAGGGAAGAAACAACTACGGGTCAGTTCGAT	979
QY	984	GAACAAAGACACAGACACCGCTCTCTCCCTCCCAAAATCCGTGAATCACTGATCTCT	1043
Db	980	GAGGCAAAAGCTGCAAGACTGCTCTCTCTCTTAATCTGTCTAAGTCAACGCTTCCA	1039
QY	1044	GAACAAAGAAACAGTACCTGTGGCCCTCTCACACAGCGGGCTGATCAAGTCCACCCAGG	1103
Db	1040	GAAGAAAGCAGCAGTA-----GCTTCTCTTACAGGAATCAATTAACATCAGCCCGT	1093
QY	1104	CCAGCAATCTATCCACAGGCTCTTTTAATCTGGCCAGTCTGAGAAAGTCTAGTAATACA	1163
Db	1094	CCAGCAATCTATCCACAGGTTTCTCTTGAATGCAAGTCTCTCAGAAAGTCTGAAATGTG	1153

QY	1164	ACTGTAGTATA	1174
Db	1154	ACTTTAGTGTA	1164

RESULT 7  
AAI36582  
ID AAI36582 standard; DNA; 401 BP.

DT 17-OCT-2001 (first entry)

DE Probe #5268 used to measure gene expression in human placenta sample.

Probe; microarray; human; placenta; antenatal diagnosis;

genetic disorder

Homo sapiens.

PN W0200157272-A2.

PD 09-AUG-2001.

AA 30-JAN-2001; 2001WO-US006663.  
PF

AA 04-FEB-2000; 2000US-0180312.  
PR

PR	20-MAY-2000; 2000US-0207400.
PR	30-JUN-2000; 2000US-0608408.

PR 03-AUG-2000; 2000US-0632366.  
PR 21-SEP-2000; 2000US-0234687.

PR 2/-SEP-2000; 2000US-0236359.  
PR 04-OCT-2000; 2000GB-0024263.

XX  
PA (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;  
PI

XX  
DR  
WPT: 2001-488897/53.  
DR

XX	PT	Human genome-derived
XX	PT	Human genome-derived

PT analyzing gene expression in human placenta -  
XY

PS Claim 25; SEQ ID No 5268; 654pp; English.  
 YY

**CC** The present invention relates to single exon nucleic acid probes (SENP).  
**CO** The present invention relates to single exon nucleic acid probes (SENP).  
**CP** The present invention relates to single exon nucleic acid probes (SENP).

producing a microarray for predicting, measuring and displaying gene

CC for antenatal diagnosis of human genetic disorders.

Sequence 401 BP; 105 A; 98 C; 111 G; 87 T; 0 other;

Query Match 16.2%; Score 190.4; DB 22; Length 401;

Matches 194; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

42 TTCCTCAGGTTCTGGTCTGTAATGAAGTCATAGAAGGCCCCAGAGATGCAACAGTC 103

Db 202 TACCTTCCAGGTTCTGGGTTCTGGTAATGAAGTCATAGAAAGCCCCCAAAATGCCAAGATC 261

QY 102 CTGAAGGCTCCAGGCTCGCTTCAACTGCACCGTCTCCAGGGCTGGAAGCTCATCATG 161

Db 262 CTGAGGGCTCCCAAGGCTCGCTTCAACTGCACCGTCTCCCAAGGCTGGAAGCTCATCATG 321

162 TGGGCTCTCAGTGACATGGTGGTCTAAGCGTCAGGCCCATGGAGCCCATTCACCAAT 221

Db 322 TGGGCTCTCAGTACATGGTGGTCTAAGCGTCAGGCCCATGGAGCCCATCACC AAT 381

222 GACCGCTCAGCTCTGAG 241

DB 382 GACCGCTTCACTCTCAGAC 401

Db 301 CGGCTCCCGGATATTTCTGGAGCTCGTCTCTGTCAGCCATTCAGCTATATTTT 360  
 QY 519 GTTCCGAGGCCAGGACCTTCAAGTGCAGTGCATCTGCTGACCCACAGAGC 578  
 Db 361 GTTCCGAGGCCAGGACCTTCAAGTGCAGTGCATCTGCTGACCCACAGAGC 420  
 QY 579 AATGGAGCTTGTGCTGGTGCCTACCGTGAAGGCGCCGAGTGTGCAGT 638  
 Db 421 AATGGAGCTTGTGCTGGTGCCTACCGTGAAGGCGCCGAGTGTGCAGT 480  
 QY 639 GTAATCTCAGTGTGCTGGTGCCTACCGTGAAGGCGCCGAGTGTGCAGT 698  
 Db 481 GTAATCTCAGTGTGCTGGTGCCTACCGTGAAGGCGCCGAGTGTGCAGT 540  
 QY 699 GTATTATCAATGTTACGAGTGTGCTGGTGCCTACCGTGAAGGCGCCGAGTGTGCAGT 758  
 Db 541 GTATTATCAATGTTACGAGTGTGCTGGTGCCTACCGTGAAGGCGCCGAGTGTGCAGT 600  
 QY 759 GGACTAGCAGGACCATGCTTCTGACGCGGAGTGTACTTACATACGCTGCTGCTG 818  
 Db 601 GGACTAGCAGGACCATGCTTCTGACGCGGAGTGTACTTACATACGCTGCTGCTG 660  
 QY 819 TGCCGCGCTGCTGTGCTGCTGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 878  
 Db 661 TGCCGCGCTGCTGTGCTGCTGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 720  
 QY 879 AAAGAGATTTTCTATTC----- 897  
 Db 721 AAAGAGATTTTCTATTC----- 897  
 QY 898 -----AATTTCAAAAGAAATCTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAG 948  
 Db 841 CTGATCCATACCGTGGGACGAAATCTGAAAAAGAGAGAGAGAGAGAGAGAGAGAG 900  
 QY 949 AAAGTGGAAATGAAAGTCCGCGTACAAATCAGATGAAGAGAGAGAGAGAGAGAGAGAG 1008  
 Db 901 AAAGTGGAAATGAAAGTCCGCGTACAAATCAGATGAAGAGAGAGAGAGAGAGAGAGAG 960  
 QY 1009 CTCTCCCTCCCAATCTCTGTAATCAGATGCTGTAAGAGAGAGAGAGAGAGAGAGAG 1068  
 Db 961 CTCTCCCTCCCAATCTCTGTAATCAGATGCTGTAAGAGAGAGAGAGAGAGAGAGAG 1020  
 QY 1069 CTCTCCCTCCCAATCTCTGTAATCAGATGCTGTAAGAGAGAGAGAGAGAGAGAGAG 1094  
 Db 1021 CTCTCCCTCCCAATCTCTGTAATCAGATGCTGTAAGAGAGAGAGAGAGAGAGAGAG 1046  
 Db 1021 CTCTCCCTCCCAATCTCTGTAATCAGATGCTGTAAGAGAGAGAGAGAGAGAGAGAG 1046  
 RESULT 6  
 ABK13032  
 ID ABK13032 standard; cDNA, 1195 BP.  
 XX  
 AC ABK13032;  
 XX  
 DT 23-Apr-2002 (first entry)  
 XX  
 DE DNA encoding mouse B7-1-like protein, B7-L<sub>m</sub>.  
 XX  
 KW Mouse: B7-1-like protein; B7-L; antiniferility; gynecological;  
 KW antitumour; cytotatic; immunosuppressive; antitumor; antineoplastic;  
 KW antineoplastic; dermatologic; antiparasitic; antiparasitic;  
 KW antidiabetic; haemostatic; antihypertensive; antidiabetic;  
 KW antidiabetic; nephrotoxic; antibacterial; virucide; tumour; cancer;  
 KW reproductive disorder; graft versus host disease; autoimmune disease;  
 KW toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KW endocrinopathy; lymphoproliferative disorder; gene; ss.  
 XX  
 OS Mus musculus.  
 XX

FH Key Location/Qualifiers  
 FT CDS 53..1165  
 FT /tag="a  
 FT /product="B7-1-like protein, B7-L<sub>m</sub>"  
 PN WO200200710-A2.  
 PD 03-JAN-2002.  
 XX 28-JUN-2001; 2001WO-US20719.  
 XX 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX (AMGE-) AMGEN INC.  
 PA Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 PI WPI; 2002-130881/17.  
 DR P-PSDB; AAU75544.  
 XX  
 PT New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 PS Claim 1, Fig 5; 135pp; English.  
 XX  
 CC The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-1-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility, miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian, testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo-sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions.  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and Wastenhof's syndrome, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the coding sequence of mouse B7-L<sub>m</sub>.  
 XX  
 SQ Sequence 1195 BP; 313 A; 304 C; 291 G; 287 T; 0 other;  
 Query Match 32.4%; Score 381; DB 24; Length 1195;  
 Best Local Similarity 61.9%; Pred. No. 3.4e-95;  
 Matches 712; Conservative 0; Mismatches 370; Indels 69; Gaps 4;  
 QY 24 GAGATGGGCGTGTGATTTCTCCAGGTTCTGGCTGTGTAATGAGTATGAGAGC 83  
 Db 83 GTGCTGTCATCTCGTGCAGTGCAGTGCAGTTCGCGATCCATTTATGATCATGAGAGC 142



Db 270 CAATGTGAGACCCAGTATCGGGGAACATCAGATCCCTCCAGACAGTCGCCGTGCA 329  
 QY 344 TGGATCTGCTTACCTTACCGTCCAAAGTATAGGAGAGCTGTTTCATTCCTCCAGTATATCT 403  
 Db 330 TGGATCTGCTTACCTTACCGTCCAAAGTATAGGAGAGCTGTTTCATTCCTCCAGTATATCT 389  
 QY 404 TGTATGCTGCTGAGATGAACTTGTGAAGTACTTGTCTACCTCCACTGAGACCGGCT 463  
 Db 390 TGTATGCTGCTGAGATGAACTTGTGAAGTACTTGTCTACCTCCACTGAGACCGGCT 449  
 QY 464 CCGGGAATTTCTGGAGAGCTGGTCCGTCGACCACTCAAGTATATTTTGTCC 523  
 Db 450 CCGGGAATTTCTGGAGAGCTGGTCCGTCGACCACTCAAGTATATTTTGTCC 509  
 QY 524 GGAGCCCGAGGACCTTCAAAAGTCACTGAGCATCTGCGTCTGACCCCAAGAGCAATG 583  
 Db 510 GGAGCCCGAGGACCTTCAAAAGTCACTGAGCATCTGCGTCTGACCCCAAGAGCAATG 569  
 QY 584 GACTTGTACTTGGCTGCTACTGAGAGAGCTGAAAGCCCGCAAGTCTGCAACTGTAA 643  
 Db 570 GACTTGTACTTGGCTGCTACTGAGAGAGCTGAAAGCCCGCAAGTCTGCAACTGTAA 629  
 QY 644 TCTCAGCTGATTCGGTGTCCCAAGCACTGAGGTGATTAATATCCAGTGTAT 703  
 Db 630 TCTCAGCTGATTCGGTGTCCCAAGCACTGAGGTGATTAATATCCAGTGTAT 689  
 QY 704 ATCAAGTTTACCGAGTTTATGTTTTCATTCCTTACTTGGGCAAGTTGCACTTGACT 763  
 Db 690 ATCAAGTTTACCGAGTTTATGTTTTCATTCCTTACTTGGGCAAGTTGCACTTGACT 749  
 QY 764 AGCAGCACCAGCTTCTGTGACGCCAGCTGTACTTTCACATATGCTGCTGCTGCCG 823  
 Db 750 AGCAGCACCAGCTTCTGTGACGCCAGCTGTACTTTCACATATGCTGCTGCTGCCG 809  
 QY 824 CCGGCTGTTGTGGGCAACTGCTGCTGCTGCTGTTTGTGTTGTGTAAGAAAGAAAG 883  
 Db 810 CCGGCTGTTGTGGGCAACTGCTGCTGCTGCTGTTTGTGTTGTGTAAGAAAGAAAG 869  
 QY 884 AGGATTTCTGATTCATTTTCAAAAGAAATCTGAAAAAGAGAAAGCAAAAGCAAACTGA 943  
 Db 870 AG-----GAAATGTGAAAAAGAGAAACAAACAAAGAAACTGA 907  
 QY 944 GACAGAAAGTGAATGAAATCTCCGGCTTCAATTCAGATGAAACAAAGCAACACAC 1003  
 Db 908 GACAGAAAGTGAATGAAATCTCCGGCTTCAATTCAGATGAAACAAAGCAACACAC 967  
 QY 1004 CGGCTTCTCCCTCCCAATCTGTGAATCCAGTATCCCTGAACAAAGAAAGCTAGCTG 1063  
 Db 968 CGGCTTCTCCCTCCCAATCTGTGAATCCAGTATCCCTGAACAAAGAAAGCTAGCTG 1027  
 QY 1064 TGGCCCTCTCCACAGCGGGCTGATCAAGCTCCACCCAGCCAGCAAGTATCCACAGGC 1123  
 Db 1028 TGGCCCTCTCCACAGCGGGCTGATCAAGCTCCACCCAGCCAGCAAGTATCCACAGGC 1087  
 QY 1124 TTTCTTTTAACTGGCCAGTCTCTGAGAAAGTCAATATACACTGTGTATTA 1174  
 Db 1088 TTTCTTTTAACTGGCCAGTCTCTGAGAAAGTCAATATACACTGTGTATTA 1138  
 RESULT 5  
 AAS92356 standard; cDNA; 1392 BP.  
 ID AAS92356 standard; cDNA; 1392 BP.  
 AC AAS92356;  
 XX  
 DT 13-FEB-2002 (first entry)  
 XX  
 DE DNA encoding novel human diagnostic protein #28160.  
 XX  
 KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 XX food supplement; medical imaging; diagnostic; genetic disorder; ss.  
 OS Homo sapiens.

XX  
 PN W0200175067-A2.  
 XX  
 PD 11-OCT-2001.  
 XX  
 PP 30-MAR-2001; 2001WO-US08631.  
 PE  
 PR 31-MAR-2000; 2000US-0540217.  
 PR 23-AUG-2000; 2000US-0649167.  
 XX  
 PA (HSE-) HXSEQ INC.  
 XX  
 PI Drmanac RT, Liu C, Tang YT;  
 XX  
 DR WPI; 2001-639362/73.  
 P-PSDB; ABG28169.  
 XX  
 PT New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity -  
 XX  
 PS Claim 1; SEQ ID NO 28160; 103pp; English.  
 CC  
 CC The invention relates to isolated polynucleotide (I) and  
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,  
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
 CC and gene mapping, and in recombinant production of (II). The  
 CC polynucleotides are also used in diagnostics as expressed sequence tags  
 CC for identifying expressed genes. (I) is useful in gene therapy techniques  
 CC to restore normal activity of (II) or to treat disease states involving  
 CC (II). (II) is useful for generating antibodies against it, detecting or  
 CC quantitating a polypeptide in tissue, as molecular weight markers and as  
 CC a food supplement. (II) and its binding partners are useful in medical  
 CC imaging of sites expressing (II). (I) and (II) are useful for treating  
 CC disorders involving aberrant protein expression or biological activity.  
 CC The polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations in  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. AAS64197-AAS94564 represent novel human  
 CC diagnostic coding sequences of the invention.  
 CC Note: The sequence data for this patent did not appear in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequences.  
 XX  
 SQ Sequence 1392 BP; 338 A; 361 C; 341 G; 352 T; 0 other;  
 Query Match 66.3%; Score 779.2; DB 23; Length 1392;  
 Best Local Similarity 87.3%; Pred. No. 1.3e-205;  
 Matches 913; Conservative 0; Mismatches 23; Indels 110; Gaps 1;  
 QY 159 ATGTGGGCTCTCAGTGAATGATGTGGTGTGCTAAGCGTCAAGCCCATGAGCCCATCATCACC 218  
 Db 1 ATGTGGGCTCTCAGTGAATGATGTGGTGTGCTAAGCGTCAAGCCCATGAGCCCATCATCACC 60  
 QY 219 AATGACCGCTTCACTCTCAGAGTAGACACAGGCGGGAACCTTACTCGGAATGATC 278  
 Db 61 AATGACCGCTTCACTCTCAGAGTAGACACAGGCGGGAACCTTACTCGGAATGATC 120  
 QY 279 ATCCACATGTGAGACCCAGCAGTATGCGGGGAACATCAGATCAGAGCTCCACAAAGTCGC 338  
 Db 121 ATCCACATGTGAGACCCAGCAGTATGCGGGGAACATCAGATCAGAGCTCCACAAAGTCGC 180  
 QY 339 CTGATGATCTGCTTACTTACCTCCAGATTATGAGAGAGCTGTTTCATTCAGAGTGT 398  
 Db 181 CTGATGATCTGCTTACTTACCTCCAGATTATGAGAGAGCTGTTTCATTCAGAGTGT 240  
 QY 399 AATCTTGTAGTGTGAGAGTAACCTTGTGAAGTACTTGTCTACCTCAGACTGAGCC 458  
 Db 241 AATCTTGTAGTGTGAGAGTAACCTTGTGAAGTACTTGTCTACCTCAGACTGAGCC 300  
 QY 459 CGGCTCCCGGATATTTCCGTGGAGAGCTCGTCCCTGTCAGACATCAAGTATATTTT 518







PR 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 (AMGB-) AMGEN INC.  
 PI Welcher AA, Sarmiento UM, Schultz HU, Chute HT;  
 DR WPI: 2002-130881/17.  
 XX P-PSDB; AAU75540.  
 XX  
 XX New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 XX  
 XX Claim 1; Fig 1; 135pp: English.  
 XX  
 XX The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-1-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of hematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or all sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the coding sequence of human B7-L.h1.  
 CC  
 CC Sequence 1175 BP; 295 A; 307 C; 286 G; 287 T; 0 other;  
 CC  
 CC Query Match 100.0%; Score 1175; DB 24; Length 1175;  
 CC Best Local Similarity 100.0%; Pred. No. 0;  
 CC Matches 1175; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 181 TGTGCTAAGCGTCAGGCCCATGAGCCCATCATCACCACATGACCGCTTCACCTTCAGA 240  
 QY 241 GGTACACGAGCGCGGGAACCTTCACCTCGAGATGATCATCATCATGAGAGCCAGTG 300  
 DB 241 GGTACGACGAGCGCGGGAACCTTCACCTCGAGATGATCATCATCATGAGAGCCAGTG 300  
 QY 301 ATTGGGGAGACATGATGATGACAGCTCCAGAACAGTCGGCTGATGATCTGCTTACCTTA 360  
 DB 301 ATTGGGGAGACATGATGATGACAGCTCCAGAACAGTCGGCTGATGATCTGCTTACCTTA 360  
 QY 361 CCGTCAAGTTATGGGAGAGAGCTGTTTCATCTCCAGTGTAACTGTTGTCGTCAGATG 420  
 DB 361 CCGTCAAGTTATGGGAGAGAGCTGTTTCATCTCCAGTGTAACTGTTGTCGTCAGATG 420  
 QY 421 AACCTTGAAGTTACTGTTCTACCTCAGACCTGAGACCGGCTCCGAGATATTTCTGGG 480  
 DB 421 AACCTTGAAGTTACTGTTCTACCTCAGACCTGAGACCGGCTCCGAGATATTTCTGGG 480  
 QY 481 AGCTGCTCTCTGCTGACAGCCATTCAGCTATTTATTTGTCGGAGCCGACACTTC 540  
 DB 481 AGCTGCTCTCTGCTGACAGCCATTCAGCTATTTATTTGTCGGAGCCGACACTTC 540  
 QY 541 AAGTGCAGTGCATTCCTGGGCTGACCCCAAGAGCATGGGACTTTGACTTGCCTGG 600  
 DB 541 AAGTGCAGTGCATTCCTGGGCTGACCCCAAGAGCATGGGACTTTGACTTGCCTGG 600  
 QY 601 CTACCTGGAAGACCTGGAAGGCCCGCAAGCTGCAACTGTAATCTCATCTGATTCGGT 660  
 DB 601 CTACCTGGAAGACCTGGAAGGCCCGCAAGCTGCAACTGTAATCTCATCTGATTCGGT 660  
 QY 661 GTCCCAAGACACTGGAGTGTATTAATTTCCAGGTGTATTAATCAAGTTACCGAGTT 720  
 DB 661 GTCCCAAGACACTGGAGTGTATTAATTTCCAGGTGTATTAATCAAGTTACCGAGTT 720  
 QY 721 TAGGTTTTCATTCGCTACTGCTTGGGCAAGTTGACTGCACTAGACGACCAATGCTTC 780  
 DB 721 TAGGTTTTCATTCGCTACTGCTTGGGCAAGTTGACTGCACTAGACGACCAATGCTTC 780  
 QY 781 TGAAGCGGAGCTGTAATCTTCAATATAGCTGCTGCTGCCCGCTGTTGTTGAGCT 840  
 DB 781 TGAAGCGGAGCTGTAATCTTCAATATAGCTGCTGCTGCCCGCTGTTGTTGAGCT 840  
 QY 841 GCAAGCTGCTGCGCGTGTGTTGTTCTGCTGTAAGAGAAAGAGATTTGCTATTCAT 900  
 DB 841 GCAAGCTGCTGCGCGTGTGTTGTTCTGCTGTAAGAGAAAGAGATTTGCTATTCAT 900  
 QY 901 TTCAAAAGAAATCTGAAAAAGAGAAAGACAAACAAAGAAAGTGAAGTGAATG 960  
 DB 901 TTCAAAAGAAATCTGAAAAAGAGAAAGACAAACAAAGAAAGTGAAGTGAATG 960  
 QY 961 AAAACTCCGGCTACAAATTTAGATGAAGAAAGACCAAGACACCGCTTCTCCCTCCCA 1020  
 DB 961 AAAACTCCGGCTACAAATTTAGATGAAGAAAGACCAAGACACCGCTTCTCCCTCCCA 1020  
 QY 1021 AATCTGTGATTCAGTATCTCTGAAACAAAGAGTGTGCTGCTCCTCCTCAGC 1080  
 DB 1021 AATCTGTGATTCAGTATCTCTGAAACAAAGAGTGTGCTGCTCCTCCTCAGC 1080  
 QY 1081 GGGCTGATCAAGCTCCACCGAGCCAGCAAGTCAATCCAGGCTTCTTTAATCTGSCCA 1140  
 DB 1081 GGGCTGATCAAGCTCCACCGAGCCAGCAAGTCAATCCAGGCTTCTTTAATCTGSCCA 1140  
 QY 1141 GTCTTGAGAAAGTCAAGTAATACACTGTAGTAG 1175  
 DB 1141 GTCTTGAGAAAGTCAAGTAATACACTGTAGTAG 1175  
 RESULT 2  
 ABK13030  
 ID ABK13030 standard; cDNA; 1240 BP.  
 XX  
 XX AC ABK13030;  
 XX





```

QY      808  GCTGCTCTCTCTCTGCGCGCGCTTGTGTGGCGGCAACTGCTGCGCCGTTGTTTCT  867
          ||||| |
Db      4785  GCTCTCTCTCTCTGTGTGTGCTGCTGTGCTGCGTCTGCTGCTGCTGCTGCTGCT  4728
          ||||| |
QY      868  GCTGTAGA  875
          ||||| |
Db      4725  GCTGTACA  4718

```

Search completed: April 29, 2003, 10:49:16  
Job time : 88.1906 secs

QY	868	GCTGTAGACAAAAAGAGATTTCGATT	896
Db	2928	GCTGTGCTGCGGATGCAGTGAT	2900

```

RESULT 15
US-08-479-913E-1/c
; Sequence 1, Application US/08479913E
; Patent No. 6416998
; GENERAL INFORMATION:
; APPLICANT: O'Malley, Bert W.
; APPLICANT: Tsai, Ming-Jer
; APPLICANT: Leebur, Harry C.
; APPLICANT: Kittle, Joseph D.
; TITLE OF INVENTION: MODIFIED STEROID HORMONES FOR GENE THERAPY AND METHODS FOR THEIR
; FILE REFERENCE: 212/113
; CURRENT APPLICATION NUMBER: US/08/479,913E
; CURRENT FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: US 07/939,246
; PRIOR FILING DATE: 1992-09-02
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: Microsoft Word 97
; SEQ ID NO 1
; LENGTH: 6177
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; NAME/KEY: misc-feature
; OTHER INFORMATION: Plasmid pGR0403R
; US-08-479-913E-1

```

Query Match	3.5%;	Score 40.8;	DB 4;	Length 6177;
Best Local Similarity	75.0%;	Pred. NO. 0.14;		
Matches	51;	Conservative	0;	Mismatches 17;
			Indels	0;
			Gaps	0;





100

154 TCGTGGCTGCTGATGTTGCTGCTGTTG 129

154 TCGTGGCTGCTGATGTTGCTGCTGTTG 129

LENGTH: 3292 base pairs  
 TYPE: NUCLEIC ACID  
 STRANDEDNESS: double  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA (genomic)  
 ORIGINAL SOURCE:  
 ORGANISM: *Saccharomyces cerevisiae*  
 IMMEDIATE SOURCE:  
 CLONE: lambda ypt  
 FEATURE:  
 NAME/KEY: CDS  
 LOCATION: 1..1626

TELEPHONE: (619) 535-9001  
TELEFAX: (619) 535-8949  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1776 base pairs  
type: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 36..1116  
US-09-041-886-12

Query Match 3.6%; Score 42.8; DB 4; Length 1776;  
Best Local Similarity 61.8%; Pred. No. 0.02; Indels 0; Gaps 0;  
Matches 66; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

OY 808 GCTGCTGCTGCTGCGCCGCTGTTGTTGAGTCGCACTGCTGCTGCTGTTGTTCT 867  
DB 975 GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTTTT 916  
OY 868 GCTGTAGAGAAAAGAGATTTCATTTCATTTCAAAAGAAATCTGAA 917  
DB 915 GCTGCTGTTTTCAAAGTAGGCTTCGCTCTCCGAGCTCTTCTGAA 866

RESULT 5  
US-07-814-964-12/c  
Sequence 12, Application US/07814964  
Patent No. 5359047

## GENERAL INFORMATION:

APPLICANT: Donahue, Brian A.  
APPLICANT: Toney, Jeffrey H.  
APPLICANT: Bruhn, Suzanne L.  
APPLICANT: Pil, Pieter M.  
APPLICANT: Brown, Steven  
APPLICANT: Kellelt, Patti  
APPLICANT: Essigmann, John M.  
APPLICANT: Lippard, Stephen J.  
TITLE OF INVENTION: DNA Structure Specific Recognition  
TITLE OF INVENTION: Protein and Uses Therefor  
NUMBER OF SEQUENCES: 13  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
STREET: 2 Millitia Drive  
CITY: Lexington  
STATE: MA  
COUNTRY: USA  
ZIP: 02173

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/814,964  
FILING DATE: 19911226  
CLASSIFICATION: 435

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/539,906  
FILING DATE: 18-JUN-1990  
ATTORNEY/AGENT INFORMATION:  
NAME: Granahan, Patricia  
REGISTRATION NUMBER: 32,227  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-861-9540  
TELEFAX: 617-861-6240  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 3292 base pairs  
type: NUCLEIC ACID

STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
ORIGINAL SOURCE:  
ORGANISM: Saccharomyces cerevisiae  
IMMEDIATE SOURCE:  
CLONE: lambda yPt  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 1..1626  
US-07-814-964-12

Query Match 3.6%; Score 42.6; DB 1; Length 3292;  
Best Local Similarity 64.9%; Pred. No. 0.031;  
Matches 63; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

OY 804 ATACGCTGCTGCTGCTGCGCCGCTGTTGTTGCTGCACTGCTGCTGCTGTTGT 863  
DB 818 AGATGATGATGTTGTTGAAAGTTGTTGTTGTTGCACTGCTGCTGTTGAGC 759  
OY 864 TTCTGCTAGAGAAAAGAGATTTCATTTCAT 900  
DB 758 TGCTGCTGTTGCTGCACTGCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 722

RESULT 6  
US-08-258-442-12/c  
Sequence 12, Application US/08258442  
Patent No. 5670621

## GENERAL INFORMATION:

APPLICANT: Donahue, Brian A.  
APPLICANT: Toney, Jeffrey H.  
APPLICANT: Bruhn, Suzanne L.  
APPLICANT: Pil, Pieter M.  
APPLICANT: Brown, Steven  
APPLICANT: Kellelt, Patti  
APPLICANT: Essigmann, John M.  
APPLICANT: Lippard, Stephen J.  
TITLE OF INVENTION: DNA Structure Specific Recognition  
TITLE OF INVENTION: Protein and Uses Therefor  
NUMBER OF SEQUENCES: 13  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
STREET: 2 Millitia Drive  
CITY: Lexington  
STATE: MA  
COUNTRY: USA  
ZIP: 02173

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/258,442  
FILING DATE: 19911226  
CLASSIFICATION: 530

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/539,906  
FILING DATE: 18-JUN-1990  
ATTORNEY/AGENT INFORMATION:  
NAME: Granahan, Patricia  
REGISTRATION NUMBER: 32,227  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-861-9540  
TELEFAX: 617-861-6240  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 3292 base pairs  
type: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear

```

Query Matched 4.1%; Score 48.2; DB 2; Length 325;
Best Local Similarity 57.8%; Pred. No. 0.00023;
Matches 100; Conservative 2; Mismatches 70; Indels 1; Gaps 1

QY 792 TGACCTCTCAAAATACGCTGCTGCTGCCGCCGCTGTTGTGTGGCTGCACTGCTGC 851
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 210 TGTCCTATATAGTCCSCCTGCTGCTGCTCTGCTCTGCTGCTGCTGCTGCTGCTG 151

QY 852 TGGCGTGTGTTGCTTGCCTGTAGAA-GAAAAAGAGATTTCGTATTCATTTCAAAAGAA 910
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 150 TGTCTGTGCTGCTTTTGTCTGTCTGTGAACACTTCAAAAGTGAAGTATATTAAAAAACA 91

QY 911 ATCTGAAAAAGACAGACAACAAGAAAGAACTAGACAGACAAGATGAAATGAAA 963
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 90 AACTTAAAAAGATTAATATACACCATGAGAAAAAATTCATTAAGAAAAAATACA 38

RESULT 3
US-08-531-927B-1/c
; Sequence 1, Application US/08531927B
; Patent No. 5840491
; GENERAL INFORMATION:
; APPLICANT: Kakizuka, Akira
; TITLE OF INVENTION: DNA Sequence Encoding the Machado-Joseph
; Patent No. 5840491
; TITLE OF INVENTION: Disease Gene and Uses Thereof
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Millitia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02173-4799
; COMPUTER READABLE FORM:
;

```

Query Match	3.6%	Score 42.8;	DB 2;	Length 1776;
Best Local Similarity	61.8%;	Pred. No. 0.02;		
Matches	68;	Conservative	0;	Mismatches 42; Indels 0; Gaps 0;
OY	808	GCCTGCTGCTGCTCCGCCCTGCTGTTTGGCTGCAATGCTGCTGCTGTTGTTTTC	867	
Db	975	GCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTTTT	916	
OY	868	GCCTGTAAGAAAAGAGATTTGCTATTCAATTTCAAAAGAAATTCGAA	917	
Db	915	GCCTGCTGTTTTCCTCAAGTAGGCTTCGCTCTCTTCCGAAGCTCTTTCGAA	866	

RESULT 4  
US-09-041-886-12/c  
Sequence 12, Application US/09041886  
Patent No. 6235872  
GENERAL INFORMATION:  
APPLICANT: Bredesen, Dale E.  
APPLICANT: Rabizadeh, Sharoz  
TITLE OF INVENTION: Proapoptotic Peptides, Dependence  
TITLE OF INVENTION: Polypeptides and Methods of Use  
NUMBER OF SEQUENCES: 72  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Campbell & Flores LLP  
STREET: 4370 La Jolla Village Drive, Suite 700  
CITY: San Diego  
STATE: California  
COUNTRY: United States  
ZIP: 92122  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/041,886  
FILING DATE:  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Campbell, Cathryn A.  
REGISTRATION NUMBER: 31,815  
REFERENCE/DOCKET NUMBER: P-LJ 2626  
TELECOMMUNICATION INFORMATION:









```

APPLICANT: Penn, Sharon G.
APPLICANT: Rank, David R.
APPLICANT: Hanzel, David K.
APPLICANT: Chen, Weisheng
TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
FILE REFERENCE: Aecmlca-x-1
CURRENT APPLICATION NUMBER: US/09/864,761
PRIORITY FILING DATE: 2001-05-23
PRIORITY APPLICATION NUMBER: US 60/180,312
PRIORITY FILING DATE: 2000-02-04
PRIORITY APPLICATION NUMBER: US 60/207,456
PRIORITY FILING DATE: 2000-05-26
PRIORITY APPLICATION NUMBER: US 09/632,366
PRIORITY FILING DATE: 2000-08-03
PRIORITY APPLICATION NUMBER: GB 24263.6
PRIORITY FILING DATE: 2000-10-04
PRIORITY APPLICATION NUMBER: US 60/236,359
PRIORITY FILING DATE: 2000-09-27
PRIORITY APPLICATION NUMBER: PCT/US01/00666
PRIORITY FILING DATE: 2001-01-30
PRIORITY APPLICATION NUMBER: PCT/US01/00667
PRIORITY FILING DATE: 2001-01-30
PRIORITY APPLICATION NUMBER: PCT/US01/00664
PRIORITY FILING DATE: 2001-01-30
PRIORITY APPLICATION NUMBER: PCT/US01/00669
PRIORITY FILING DATE: 2001-01-30
PRIORITY APPLICATION NUMBER: PCT/US01/00665
PRIORITY FILING DATE: 2001-01-30
PRIORITY APPLICATION NUMBER: PCT/US01/00668
PRIORITY FILING DATE: 2001-01-30
PRIORITY APPLICATION NUMBER: PCT/US01/00663
PRIORITY FILING DATE: 2001-01-30
PRIORITY APPLICATION NUMBER: PCT/US01/00662
PRIORITY FILING DATE: 2001-01-30
PRIORITY APPLICATION NUMBER: PCT/US01/00661
PRIORITY FILING DATE: 2001-01-30
PRIORITY APPLICATION NUMBER: PCT/US01/00670
PRIORITY FILING DATE: 2001-01-30
PRIORITY APPLICATION NUMBER: US 60/234,687
PRIORITY FILING DATE: 2000-09-21
PRIORITY APPLICATION NUMBER: US 09/608,408
PRIORITY FILING DATE: 2000-06-30
PRIORITY APPLICATION NUMBER: US 09/774,203
PRIORITY FILING DATE: 2001-01-29
PRIORITY OF SEQ ID NOS: 49117
SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
SEQ ID NO 18923
LENGTH: 293
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: MAP TO AC009954.1
OTHER INFORMATION: EXPRESSED IN BT474, SIGNAL = 47
OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 53
OTHER INFORMATION: EXPRESSED IN HBL100, SIGNAL = 69
OTHER INFORMATION: EXPRESSED IN HEAT, SIGNAL = 27
OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 16
OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 21
OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 45
OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 33
OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 21
OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 21
OTHER INFORMATION: NT HIT: Z22828.1, EVALUE 9.00e-59
OTHER INFORMATION: SWISSPROT HIT: P53360, EVALUE 4.00e-15
OTHER INFORMATION: EST_HUMAN HIT: AM409956.1, EVALUE 1.00e-58
US-09-864-761-18923

```

	Query Match	3.7%	Score 43.2;	DB 10;	Length 293;
	Best Local Similarity	79.7%;	Pred. No. 0.005;		
	Matches	51;	Conservative	0;	Mismatches 13; Indels 0; Gaps 0;
07	808 GCTCTGCTGCTGCTGCGGCGTGGTGGTGGCTGCACACTGCTGCTGCGTGGCTTTGTTTC 867				

[illegible]

```

1  US-09-864-761-2182/c
2  RESULT 14
3  Sequence 2182, Application US/09864761
4  Patent No. US20020048763A1
5  GENERAL INFORMATION:
6  APPLICANT: Penn, Sharon G.
7  APPLICANT: Rank, David R.
8  APPLICANT: Hanzel, David K.
9  APPLICANT: Chen, Wensheng
10 TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
11 TITLE OF INVENTION: GENE EXPRESSION ANALYSIS BY MICROARRAY
12 FILE REFERENCE: Aecomica-X-1
13 CURRENT APPLICATION NUMBER: US/09/864,761
14 CURRENT FILING DATE: 2001-05-23
15 PRIOR APPLICATION NUMBER: US 60/180,312
16 PRIOR FILING DATE: 2000-02-04
17 PRIOR APPLICATION NUMBER: US 60/207,456
18 PRIOR FILING DATE: 2000-05-26
19 PRIOR APPLICATION NUMBER: US 09/632,366
20 PRIOR FILING DATE: 2000-08-03
21 PRIOR APPLICATION NUMBER: GB 24263.6
22 PRIOR FILING DATE: 2000-10-04
23 PRIOR APPLICATION NUMBER: US 60/236,359
24 PRIOR FILING DATE: 2000-09-27
25 PRIOR APPLICATION NUMBER: PCT/US01/00666
26 PRIOR FILING DATE: 2001-01-30
27 PRIOR APPLICATION NUMBER: PCT/US01/00667
28 PRIOR FILING DATE: 2001-01-30
29 PRIOR APPLICATION NUMBER: PCT/US01/00664
30 PRIOR FILING DATE: 2001-01-30
31 PRIOR APPLICATION NUMBER: PCT/US01/00669
32 PRIOR FILING DATE: 2001-01-30
33 PRIOR APPLICATION NUMBER: PCT/US01/00665
34 PRIOR FILING DATE: 2001-01-30
35 PRIOR APPLICATION NUMBER: PCT/US01/00668
36 PRIOR FILING DATE: 2001-01-30
37 PRIOR APPLICATION NUMBER: PCT/US01/00663
38 PRIOR FILING DATE: 2001-01-30
39 PRIOR APPLICATION NUMBER: PCT/US01/00662
40 PRIOR FILING DATE: 2001-01-30
41 PRIOR APPLICATION NUMBER: PCT/US01/00661
42 PRIOR FILING DATE: 2001-01-30
43 PRIOR APPLICATION NUMBER: PCT/US01/00670
44 PRIOR FILING DATE: 2001-01-30
45 PRIOR APPLICATION NUMBER: US 60/234,687
46 PRIOR FILING DATE: 2000-09-21
47 PRIOR APPLICATION NUMBER: US 09/608,408
48 PRIOR FILING DATE: 2000-06-30
49 PRIOR APPLICATION NUMBER: US 09/774,203
50 PRIOR FILING DATE: 2001-01-29
51 NUMBER OF SEQ ID NOS: 49117
52 SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
53 SEQ ID NO 2182
54 LENGTH: 459
55 TYPE: DNA
56 ORGANISM: Homo sapiens
57 FEATURE:
58 OTHER INFORMATION: MAP TO AC009954.1
59 OTHER INFORMATION: EXPRESSED IN BR474, SIGNAL = 47
60 OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 53
61 OTHER INFORMATION: EXPRESSED IN HBL100, SIGNAL = 69
62 OTHER INFORMATION: EXPRESSED IN HEPL, SIGNAL = 27
63 OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 16
64 OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 21
65 OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 45

```

QY 808 GCTGCTGCTGCTGCCCGCGTGTGTGTGCTGCACTGCTGCTGCCGTTGTGTTCT 867  
 Db 6175 GCTGTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 6116  
 QY 868 GCTGTAGAAGAA 879  
 Db 6115 GCTGCTGCCGCA 6104

## RESULT 10

US-09-728-444-151  
 ; Sequence 151, Application US/09728444  
 ; Patent No. US20020161207A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Friedlich, Glenn  
 ; APPLICANT: Zambrowicz, Brian  
 ; APPLICANT: Sands, Arthur T.  
 ; TITLE OF INVENTION: No. US20020161207A1a1 Murine Polynucleotide Sequences  
 ; TITLE OF INVENTION: and Mutant Cells and Mutant Animals Defined Thereby  
 ; FILE REFERENCE: LEX-0100-USA  
 ; CURRENT APPLICATION NUMBER: US/09/728,444  
 ; PRIOR FILING DATE: 2000-11-30  
 ; PRIOR APPLICATION NUMBER: US 60/168,360  
 ; PRIOR FILING DATE: 1999-12-01  
 ; NUMBER OF SEQ ID NOS: 1206  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 151  
 ; LENGTH: 455  
 ; TYPE: DNA  
 ; ORGANISM: Mus musculus  
 ; FEATURE:  
 ; NAME/KEY: misc\_feature  
 ; LOCATION: (1)..(455)  
 ; OTHER INFORMATION: n = A,T,C or G  
 US-09-728-444-151

Query Match 3.7%; Score 44; DB 9; Length 455;  
 Best Local Similarity 69.4%; Pred. No. 0.0038;  
 Matches 59; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 810 TCGTCTGCTGCCCGCGTGTGTGTGCTGCACTGCTGCTGCCGTTGTGTTCTGC 869  
 Db 162 TCGTCTGCTGCCCGCGTGTGTGTGCTGCACTGCTGCTGCCGTTGTGTTCTGC 221  
 QY 870 TGTAGAAGAAAGAGGATTGCTGA 894  
 Db 222 TCGAAACCTAACCAGAGTGGGA 246

## RESULT 11

US-09-738-626-544  
 ; Sequence 544, Application US/09738626  
 ; Publication No. US20020197605A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: NAKAGAWA, SATOSHI  
 ; APPLICANT: MIZOGUCHI, HIROSHI  
 ; APPLICANT: ANDO, SEIKO  
 ; APPLICANT: HAYASHI, MIKIRO  
 ; APPLICANT: OCHIAI, KEIKO  
 ; APPLICANT: YOKOI, HARUHIKO  
 ; APPLICANT: TATEISHI, NAOKO  
 ; APPLICANT: SENOH, AKIHIRO  
 ; APPLICANT: IKEDA, MASATO  
 ; APPLICANT: OZAKI, AKIO  
 ; TITLE OF INVENTION: NOVEL POLYNUCLEOTIDES  
 ; FILE REFERENCE: 249-125  
 ; CURRENT APPLICATION NUMBER: US/09/738,626  
 ; PRIOR FILING DATE: 2000-12-18  
 ; PRIOR APPLICATION NUMBER: JP 99/377484  
 ; PRIOR FILING DATE: 1999-12-16  
 ; PRIOR APPLICATION NUMBER: JP 00/159162  
 ; PRIOR FILING DATE: 2000-04-07  
 ; PRIOR APPLICATION NUMBER: JP 00/280988

;; PRIOR FILING DATE: 2000-08-03  
 ;; NUMBER OF SEQ ID NOS: 7059  
 ;; SOFTWARE: PatentIn ver. 3.0  
 ;; SEQ ID NO 544  
 ;; LENGTH: 384  
 ;; TYPE: DNA  
 ;; ORGANISM: Corynebacterium glutamicum  
 US-09-738-626-544

Query Match 3.7%; Score 43.4; DB 9; Length 384;  
 Best Local Similarity 64.4%; Pred. No. 0.0052;  
 Matches 65; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

QY 806 ACGTCTGCTGCTGCCCGCGTGTGTGTGCTGCACTGCTGCTGCCGTTGTGTTT 865  
 Db 98 ACGTACCGCAGCTGCTCCAGCTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 157  
 QY 866 CTGCTGTAGAAGAAAGAGGATTGCTATTCATTCAATTCAAA 906  
 Db 158 CTGCTGCAAG 198

## RESULT 12

US-09-738-626-1  
 ; Sequence 1, Application US/09738626  
 ; Publication No. US20020197605A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: NAKAGAWA, SATOSHI  
 ; APPLICANT: MIZOGUCHI, HIROSHI  
 ; APPLICANT: ANDO, SEIKO  
 ; APPLICANT: HAYASHI, MIKIRO  
 ; APPLICANT: OCHIAI, KEIKO  
 ; APPLICANT: YOKOI, HARUHIKO  
 ; APPLICANT: TATEISHI, NAOKO  
 ; APPLICANT: SENOH, AKIHIRO  
 ; APPLICANT: IKEDA, MASATO  
 ; APPLICANT: OZAKI, AKIO  
 ; TITLE OF INVENTION: NOVEL POLYNUCLEOTIDES  
 ; FILE REFERENCE: 249-125  
 ; CURRENT APPLICATION NUMBER: US/09/738,626  
 ; PRIOR FILING DATE: 2000-12-18  
 ; PRIOR APPLICATION NUMBER: JP 99/377484  
 ; PRIOR FILING DATE: 1999-12-16  
 ; PRIOR APPLICATION NUMBER: JP 00/159162  
 ; PRIOR FILING DATE: 2000-04-07  
 ; PRIOR APPLICATION NUMBER: JP 00/280988  
 ; NUMBER OF SEQ ID NOS: 7059  
 ; SOFTWARE: PatentIn ver. 3.0  
 ; SEQ ID NO 1  
 ; LENGTH: 3309400  
 ; TYPE: DNA  
 ; ORGANISM: Corynebacterium glutamicum  
 US-09-738-626-1

Query Match 3.7%; Score 43.4; DB 9; Length 3309400;  
 Best Local Similarity 64.4%; Pred. No. 2.1;  
 Matches 65; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

QY 806 ACGTCTGCTGCTGCCCGCGTGTGTGTGCTGCACTGCTGCTGCCGTTGTGTTT 865  
 Db 510668 ACGTACCGCAGCTGCTCCAGCTTGTGCTGCTGCTGCTGCTGCTGCTGCTG 906  
 QY 866 CTGCTGTAGAAGAAAGAGGATTGCTATTCATTCAATTCAAA 906  
 Db 510748 CTGCTGCAAG 510788

## RESULT 13

US-09-864-761-18923/C  
 ; Sequence 18923, Application US/09864761  
 ; Patent No. US20020048763A1  
 ; GENERAL INFORMATION:



DR WPI; 2000-662424/64.

PT Plasmid vector arraying neuropsychiatric gene more than copy number  
PT containing trinucleotide repeats its use thereof -

PT containing trinucleotide repeats its use therefore

PS Disclosure; Page 12; 23pp; Korean.

CC This invention relates to the use of a plasmid vector array  
CC containing a neuropsychiatric gene containing trinucleotide repeats.  
CC Tri-nucleotide repeats and their expansion are known to be involved  
CC in a number of diseases including fragile X syndrome, spinocerebellar  
CC ataxia type III, hereditary hyperphosphic, cardiomyopathy, dentatorubral  
CC and pallidum degeneration atrophy (DRPA), spinocerebellar ataxia, Marfan  
CC syndrome, x-linked spinobulbar atrophy. The present sequence  
CC represents a nucleotide sequence of the invention showing the  
CC the CAG tri-nucleotide repeats.

Sequence 403 BP; 121 A; 108 C; 105 G; 69 T; 0 other;

Query Match	4.28;	Score 51.8;	DB 21;	Length 403;
Best Local Similarity	58.98;	Pred. No. 0.00042;		
Matches	89;	Conservative	0;	Mismatches 62;
				Indels 0;
				Gaps 0;

873 GCTGCTGCTGCTGCGCGCTGTTGTTGTGGTGCACACTGCTGCTGCCGTTGTTGTTCT 932

[illegible]

933 GCTGTAGAGAAAAAGAGGATTTCTATTCATTTCAAAAGAAATCTGAAAAAGAGA 992

Db 155 GCTGTTGCTGCTTTTGCCTGCTCTGAACATTCAAAAGTGAAGTATATTAAAAACAA 96

993 CAAACAAAGAACTGAGACAGAAAGTGGA 1023

Db 95 AACTTAAAGAATAATACACCATGAGAAA 65

## RESULT 15

ID	standard; CDNA; 742 BP.
AA195221	

AC AA195221;

DT 13-NOV-2001 (first entry)

DE Human neuroblastoma expressed polynucleotide SEQ ID NO 1296.

KW Human; neuroblastoma; malignancy; cancer; tumour marker; N-myc; TrkA; ss

OS Homo sapiens.

PN WO200166719-A1.

PD 13-SEP-2001.  
XY

PE 02-MAR-2001; 2001WO-JP01629.  
YY

PR 07-MAR-2000; 2000JP-0159195.  
YY

PA (CHIB-) CHIBA PREFECTURE.  
PA (HISM) HISAMITSU PHARM CO LTD

XX  
PI Nakagawara A:

XX  
DR WPT: 2001-565

XX Nucleic acids oxidiz

PT Nucleic acids originating in gene expressed in human neuroblastoma,  
PT useful as probe or primer in diagnosing prognosis of human  
PT neuroblastoma, malignancy and susceptibility indicator or tumour marker  
PT for anti-cancer agents -

PS Claim 1; Page 977-978; 2979pp; Japanese

CC The invention relates to novel genes (AAI93926-AAI97963) expressed in

human neuroblastoma. The nucleic acids are applicable as a probe or primer in diagnosing the prognosis of human neuroblastoma, malignancy and susceptibility indicators or tumour markers for anti-cancer agents. The gene information for diagnosing prognosis is related to factors similar to that for N-myc and TrkA genes.

Sequence 742 BP; 180 A; 183 C; 152 G; 219 T; 8 other;

Query Match	4.08;	Score	49.6;	DB	22;	Length	742;
Best Local Similarity	69.88;	Pred.	No. 0.0024;				
Matches	67;	Conservative	0;	Mismatches	29;	Indels	0;
						Caps	0;

23 GTGGATCAGTTTCCTAGGCTGCCATAACAAGCACCATAACCTGGTGTAGAACAAATG 82

Db 343 G T A T A T T A G T T A T A A G G C T C C C A I A A C A A G C A C C A C A G A C T G G G T G G C T I A A A C A A A 402

83 GAAAGGCATTTCCTCACGGTTCAGAGCCTGAGG 118

Db 403 GAAATCTATTTCCTCACAGTCTGGAGGCTAGAAGT 438

Search completed: April 29, 2003, 11:05:46  
Job time : 322.05 secs





XX 28-JUN-2001; 2001WO-US20719.  
 PF  
 XX 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX  
 PA (AMGE-) AMGEN INC.  
 XX  
 PI Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 DR WPI; 2002-130881/17.  
 XX P-PSDB; AAU75545.  
 PT New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 XX  
 PS Claim 1; Fig 6; 135pp; English.

XX The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-1-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of hematopoietic system. B7-L polypeptide  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo-sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the coding sequence of mouse B7-L<sub>m2</sub>.

XX  
 SQ Sequence 895 BP; 250 A; 223 C; 212 G; 210 T; 0 other;

Query Match 15.0%; Score 185.6; DB 24; Length 895;  
 Best Local Similarity 73.8%; Pred. No. 5.8e-41;  
 Matches 236; Conservative 0; Mismatches 84; Indels 0; Gaps 0;

QY 115 AGTTCTGGTCTGTAATGAGTATAGAGGCCCCAGAAATGCAAGTCTGGAAGG 174  
 DB 109 AGCTTCGGGATCCAGTATACATAGAGTCTCTAGAAATGTAACAGTCTTAAGGA 168  
 DB 169 CTAGAGGCTCACTTAAGTGCACCTGAGCTCAAGGCTTCTTATGAGTCT 228  
 QY 175 CTCCAGGCGCTTCAAGTGCACCTCTCCAGGCTTGAAGCTCATATGAGGCTCT 234  
 DB 169 CTAGAGGCTCACTTAAGTGCACCTGAGCTCAAGGCTTCTTATGAGTCT 228  
 QY 235 CAGTGACATGCTGCTAAGCTCAGGCCATGAGCCATCATACCAATGACCGCTT 294  
 DB 229 TAACCAAAATGCTGCTGAGTCTACCAACCAAGAGCCATCATCATCCAAACACGCTT 288

QY 295 CACCTTCAGAGTACAGCAGGCGGGAACCTTACCTCGAGATGATCCCAATGT 354  
 DB 289 CACCTATGCCAGTTACACAGCACTGACAGCTTCACTCGAGATGATCATGATGT 348  
 QY 355 GGAGCCAGTATGCGGGGAACATCAGATGACCTCCAGACAGTGCCTGATGATC 414  
 DB 349 GCAGCCAGTACTCGGATCCGTCAGATGACAGCTGCAAGACGATGGTTGGATC 408  
 QY 415 TGCTTACCTTACCGTCCAG 434  
 DB 409 TGCCTCTCTCAGTGCAG 428

RESULT 10  
 ABK10239/C  
 ID ABK10239 standard; DNA; 277 BP.

XX ABK10239;  
 AC  
 XX 20-MAY-2002 (first entry)  
 DT  
 XX Trinucleotide repeat sequence #2.

XX Trinucleotide repeat; fragile X syndrome; ds; DRPLA;  
 KW spinocerebellar ataxia type III; Marfan syndrome;  
 KW hereditary hypertrophic cardiomyopathy; neuropsychiatric;  
 KW dentatorubral and pallidolysian atrophy;  
 KW spinocerebellar ataxia; X-linked spinobulbar atrophy.

XX Homo sapiens.

XX Key Location/Qualifiers  
 FH repeat\_region 152..194  
 FT /\*tag= a  
 FT /\*rpt\_type= TANDEM  
 FT 152..154  
 FT /\*tag= b  
 FT /\*note= "CAG type repeat"  
 FT 198..222  
 FT /\*tag= a  
 FT /\*rpt\_type= TANDEM  
 FT 198..200  
 FT /\*tag= b  
 FT /\*note= "CAG type repeat"

XX Homo sapiens.  
 OS KR2000003004-A.

XX 15-JAN-2000.  
 PD 25-JUN-1998; 98KR-0024064.  
 PF 25-JUN-1998; 98KR-0024064.  
 XX 25-JUN-1998; 98KR-0024064.

XX (SMSU ) SAMSUNG MEDICAL CENT.  
 PA (JIND/) JIN D. G.

XX JIN DG;  
 DR WPI; 2000-662424/64.

XX Plasmid vector arraying neuropsychiatric gene more than copy number  
 PT containing trinucleotide repeats its use thereof -

XX Disclosure; Page 12; 23pp; Korean.

XX This invention relates to the use of a plasmid vector array  
 CC containing a neuropsychiatric gene containing trinucleotide repeats.  
 CC Trinucleotide repeats and their expansion are known to be involved  
 CC in a number of diseases including fragile X syndrome, spinocerebellar  
 CC ataxia type III, hereditary hypertrophic, cardiomyopathy, dentatorubral

ID	ABK13034	standard; cDNA; 754 BP.
XX	ABK13034;	
XX	23-APR-2002	(first entry)
XX	DNA encoding mouse B7-1-like protein, B7-L <sub>m3</sub> .	
XX	Mouse: B7-1-like protein; B7-L; antinefertility; gynaecological;	
KW	antitumour; cyclostatic; immunosuppressive; antiarthritic; antineumatic;	
KW	antihistaminic; dermatologic; antipruritic; neuroprotective;	
KW	antidiabetic; haemostatic; antihypoid; antulcer; antiallergic;	
KW	antiaesthetic; nephrotoxic; antibacterial; vitruide; tumour; cancer;	
KW	reproductive disorder; graft versus host disease; autoimmune disease;	
KW	toxic shock syndrome; allergy; nephropathy; skin disorder;	
KW	endocrinopathy; lymphoproliferative disorder; gene; ss.	
XX	Mus musculus.	
OS	Mus musculus.	
XX	Key	Location/Qualifiers
PH	CDS	53..724
FT		/*tag= a
FT		/product= "B7-1-like protein, B7-L <sub>m3</sub> "
XX	W0200200710-A2.	
XX	03-JAN-2002.	
XX	28-JUN-2001; 2001WO-US20719.	
XX	28-JUN-2000; 2000US-214512P.	
PR	28-NOV-2000; 2000US-0729264.	
XX	(AMGE-) AMGEN INC.	
PA	Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;	
PI	WPI: 2002-130881/17.	
DR	P-PSDB: AMU75546.	
XX	New B7-1-like polypeptides, polynucleotides and their modulators, useful	
PT	for diagnosing, preventing and treating reproductive, immune and	
PT	proliferative disorders, e.g. cancer and arteriosclerosis	
XX	Claim 1; Fig 7; 135pp; English.	
XX	The invention relates to an isolated B7-1-like (B7-L) polypeptide (I);	
CC	The polypeptide, polynucleotide encoding it and antibody against (I) are	
CC	useful for treating B7-1-like polypeptide-related disease, disorders or	
CC	conditions including reproductive disorders (e.g. infertility,	
CC	miscarriage, preterm labour and delivery and endometriosis) and	
CC	proliferative disorders. Antibodies, soluble proteins comprising	
CC	extracellular domains and other regulators of B7-L polypeptides are	
CC	useful for enhancing the immune response to tumours. (I) plays a role in	
CC	growth and maintenance of cancer cells based on the observation of	
CC	seminal vesicle hyperplasia in transgenic mice overexpressing B7-L	
CC	polypeptide. Hence modulators of (I) are useful for the treatment of	
CC	cancer including seminal vesicle cancer, lung, brain, breast, ovarian,	
CC	testicular cancer and cancers of haematopoietic system. B7-L polypeptide	
CC	pathway can be manipulated to regulate cytotoxic T-lymphocyte response	
CC	in allograft transplantation, graft versus host disease, T-cell	
CC	dependent B-cell mediated diseases and autoimmune diseases. B7-L	
CC	molecules are useful for alleviating the symptoms associated with	
CC	diseases involving chronic immune cell dysfunction or to treat	
CC	autoimmune diseases such as systemic lupus erythematosus, Rheumatoid	
CC	arthritis, multiple sclerosis, diabetes, immune thrombocytopenic	
CC	purpura and psoriasis, chronic inflammatory disease such as	
CC	inflammatory bowel disease (Crohn's disease and ulcerative colitis),	
CC	grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They	
CC	are also useful as immunosuppressive agents for bone marrow and organ	

CC	transplantation or to prolong graft survival. B7-L molecules are also
CC	useful for diagnosis and treatment of diseases involving abnormal cell
CC	proliferation, including arteriosclerosis and vascular restenosis.
CC	Antagonists of B7-L polypeptides are useful for alleviation of toxic
CC	shock syndrome or allosensitisation due to blood transfusions, and for
CC	treatment of allergy, asthma and hypersensitivity reactions,
CC	nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and
CC	pemphigoid), endocrinopathies (Graves' disease), various pneumopathies
CC	(extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,
CC	lymphoproliferative disorders such as multiple myeloma. The present
CC	sequence represents the coding sequence of mouse B7-Lm3.
xx	
SQ	Sequence 754 BP; 220 A; 191 C; 175 G; 168 T; 0 other;
Query Match	15.0%; Score 185.6; DB 24; Length 754;
Best Local Similarity	73.8%; Pred. No. 5.3e-41;
Matches 236:	Conservative 0; Mismatches 84; Indels 0; Gaps 0;
OY	115 AGGTTCTGGGTCTGTGAATGAAGTACATAGAAGGCCCGCAAAATGCACAAGTCCTTGAGGG 174
Dd	109 ACCTTCGGGATCCAGATTATCAGATCATAGAAGTCTCTCAGAAATGTMAAGTCTCTAAGA 168
OY	175 CTCGCCAGGCTCGCTTAATGCACCGCTCCCCAGGGCTGGAAAGCTCATATGAGGGCTGT 234
Dd	169 CTTCAGAGGCTCACTTCATCTGACGCTGACTACCGCTGGAACTTCTATGTGGACTCT 228
OY	235 CAGTGACATATGATGCTGAAGGCTCAGGGCCATGAGCCCATCATCACCAGATGACCGCTT 294
Dd	229 TAACCAAAATGTGTGTCTGTGATCTCACACCCAAAGAGAACATCATCAACAAACCGCTT 288
OY	295 CACCTTCAGAGGTACGACACGAGGGGGGAACCTCAGCTGGAGTAGATCATCCACATGT 354
Dd	289 CACCTTATGCAGTTAAACAAGACACTACAGCTTCACTCATGTGGAATTATCATTCATATGT 348
OY	355 GGAGCCCAAGTATCGGGGAACATCAGATGACAGCTCTCCAGAACATGCGCCTGCATGATC 414
Dd	349 GCAGCCCAAGTATCGGGGATCCGTGAATGACAGCTGACAGAACAGCCATGTGGTTGGATC 408
OY	415 TGCTTACCTTACCCTCCAG 434
Dd	409 TGCCTTCTCTCAGTGCAAG 428
RESULT 9	
ID	ABK13033 standard; cDNA; 895 BP.
XX	ABK13033;
DT	23-APR-2002 (first entry)
XX	
DE	DNA encoding mouse B7-like protein, B7-Lm2.
XX	
KW	Mouse; B7-like protein; B7-L; antinfertility; gynaecological;
KW	antitumor; cytoskeletal; immunosuppressive; antiatheritic; antirheumatic;
KW	antiinflammatory; dermatological; antipsoriatic; neuroprotective;
KW	antidiabetic; haemostatic; antihypoid; anticancer; anti-allergic;
KW	antistimatic; nephrotropic; antibacterial; virucide; tumour; cancer;
KW	reproductive disorder; graft versus host disease; autoimmune disease;
KW	toxic shock syndrome; allergy; nephropathy; skin disorder;
KW	endocrinopathy; lymphoproliferative disorder; gene; ss.
OS	Mus musculus.
XX	
FH	Key Location/Qualifiers
FT	CDS 53..865
FT	/lag= a
PX	/product= "B7-like protein, B7-Lm2"
PN	MO200200710-A2.
XX	
PD	03-JAN-2002



QY 115 AGTTTGGGTCTGTAATGAAGTCAATGAAAGGCCCCAGAAATGCAACAGTCTGAAAGG 174  
 DB 109 AGCTTCGGATCCAGTATATAGATAGAAAGGCTCTCAAAATGTATACAGTCTTAAAGA 168  
 QY 175 CTCCAGAGCTCGTCAACGACGCTCTCCAGAGGCTGGAAGCTCATATGAGGCTCT 234  
 DB 169 CTCAGAGGCTACTTCACTGACGCTGACTCAAGGCTGGAAGCTCTCTGAGACTCT 228  
 QY 235 CAGTACATGAGTGTCTTAAGCCGTCAGAGGCTGAGAGGCTCATCATGACGCTT 294  
 DB 229 TAACCAATAGTGTGTGAGTCTACACACCAAGAGCCATCATCATCAACACCGCTT 288  
 QY 295 CAGCTTCAGAGTACAGCAAGGAGGAGAACTTACCTGAGAGATGATCATCCAAATG 354  
 DB 289 CAGCTATGAGGATACAAACAGCACTGACCTCATCTCGAGAGTGTATCATCATGATG 348  
 QY 355 GAGAGGAGTATGAGGAGAAATCATGATGACCTTCACAAACAGTCCGCTGATGATC 414  
 DB 349 GAGAGGAGTATGAGGAGAAATCATGATGACCTTCACAAACAGTCCGCTGATGATC 408  
 QY 415 TGCTTACCTTACCTGACGTAATGAGAGAGCTTTCATCCAGTGTATCTTGTAGT 474  
 DB 409 TGCTTACCTTACGATGATGAGAGAGCTTTCATCCAGTGTATCTTGTAGT 468  
 QY 475 CAGTACATGAACTTGTGATGATGATGATGATGATGATGATGATGATGATGATG 534  
 DB 469 CAGTACATGAACTTGTGATGATGATGATGATGATGATGATGATGATGATGATG 528  
 QY 535 TATTTCTGGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 594  
 DB 529 TATTTCTGGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 588  
 QY 595 CAGGAGCTTCAAGTGCATGAGTGCATGAGTGCATGAGTGCATGAGTGCATGAGT 654  
 DB 589 GAGCACTTATGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 648  
 QY 655 GAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 714  
 DB 649 GAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 708  
 QY 715 TGTGATCGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 774  
 DB 709 TGTGATCGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 744  
 QY 775 TTTACGAGTATGAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 834  
 DB 745 TTTACGAGTATGAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 792  
 QY 835 CAGCATGCTTGTGAGGCGGAGCGTGTACTCTTACATACGCTGCTGCTGCTGCTGCTG 894  
 DB 793 TTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 843  
 QY 895 TTTGTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 954  
 DB 844 TTTGTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 899  
 QY 955 TCGTATTCATTTCAAAAGAAATCTGAAAAGAAAGAAAGAAAGAAAGAAAGTGA 1014  
 DB 900 CTGCAAAAGTGAAGACAA-----ACAAAGCAGATCCGAGACAAAGTTAA 945  
 QY 1015 AAGTGAATGAAAGTCCGAGCTACATTCAGATGAAACAAAGACACAGAAACCGCTTC 1074  
 DB 946 AAGTGAATGAAAGTCCGAGCTACATTCAGATGAAACAAAGACACAGAAACCGCTTC 1005  
 QY 1075 TCTCCCTCCCAATCTCTGAAATCCAGTATCTGAAACAAAGAAAGTGTGAGCC 1134  
 DB 1006 TCTCCCTCCCAATCTCTGAAATCCAGTATCTGAAACAAAGAAAGTGTGAGCC 1059  
 QY 1135 TCTCCAGAGGCTGATCAACGCTCAACGAGGAGAGTCAATCCAGAGCTTCTT 1194  
 DB 1060 TCTTATTCAGAGAACTCAATTAACATCAGCCGCTGAGCACTCATCCAGGCTTCTT 1119

QY 1195 TATCTGGCCAGTCTGAGAAAGTCAATGAAAGGCTGTAATGAAAGGCTGTAATG 1239  
 DB 1120 TGCATATGCGCACTCTCTGAGAAAGTCAAGAAAGTGTGACTTATGATGTA 1164  
 RESULT 7  
 AAI36582  
 ID AAI36582 standard; DNA; 401 BP.  
 AC AAI36582;  
 XX  
 DT 17-OCT-2001 (first entry)  
 DE Probe #5268 used to measure gene expression in human placenta sample.  
 XX  
 KW Probe; microarray; human; placenta; antenatal diagnosis;  
 XX genetic disorder; ss.  
 OS Homo sapiens.  
 XX  
 PN W0200157272-A2.  
 XX  
 PD 09-AUG-2001.  
 XX  
 PF 30-JAN-2001; 2001WO-US00663.  
 XX  
 PR 04-FEB-2000; 2000US-0180312.  
 XX 26-MAY-2000; 2000US-0207456.  
 PR 30-JUN-2000; 2000US-0608408.  
 PR 03-AUG-2000; 2000US-0632366.  
 PR 21-SEP-2000; 2000US-0234687.  
 PR 27-SEP-2000; 2000US-0236359.  
 PR 04-OCT-2000; 2000GB-0024263.  
 XX  
 PA (MOLE-) MOLECULAR DYNAMICS INC.  
 XX  
 PI Penn SG, Hanzel DK, Chen W, Rank DR;  
 XX  
 DR WPI; 2001-488897/53.  
 XX  
 PT Human genome-derived single exon nucleic acid probes useful for  
 XX analyzing gene expression in human placenta -  
 PS Claim 25; SEQ ID No 5268; 654bp; English.  
 XX  
 CC The present invention relates to single exon nucleic acid probes (SENP).  
 CC The present sequence is one such probe. The probes are useful for  
 CC producing a microarray for predicting, measuring and displaying gene  
 CC expression in samples derived from human placenta. The probes are useful  
 CC for antenatal diagnosis of human genetic disorders.  
 XX  
 SQ Sequence 401 BP; 105 A; 98 C; 111 G; 87 T; 0 other;  
 Query Match 15.2%; Score 188.8; DB 22; Length 401;  
 Best Local Similarity 99.0%; Pred. No. 5e-42;  
 Matches 190; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 115 AGTTTGGGTCTGTAATGAAGTCAATGAAAGGCCCCAGAAATGCAACAGTCTGAAAGG 174  
 DB 210 AGTTTGGGTCTGTAATGAAGTCAATGAAAGGCCCCAGAAATGCAACAGTCTGAAAGG 269  
 QY 175 CTCCAGAGCTCGTCAACGACGCTCTCCAGAGGCTGGAAGCTCATATGAGGCTCT 234  
 DB 270 CTCCAGAGCTCGTCAACGACGCTCTCCAGAGGCTGGAAGCTCATATGAGGCTCT 329  
 QY 235 CAGTACATGAGTGTCTTAAGCCGTCAGAGGCTGAGAGGCTCATCATGACGCTT 294  
 DB 330 CAGTACATGAGTGTCTTAAGCCGTCAGAGGCTGAGAGGCTCATCATGACGCTT 389  
 QY 295 CAGCTTCAGAGTACAGCAAGGAGGAGAACTTACCTGAGAGATGATCATCCAAATG 354  
 DB 390 CAGCTTCAGAGTACAGCAAGGAGGAGAACTTACCTGAGAGATGATCATCCAAATG 389

```

Db 241 AATCTGTGTGCTGAGATGACCTTGTGAAGTTACTTGTCTACCTCCACACAGCAGC 300
      |||
Oy 524 CGGCTCCCGGATATTTCTGGAGCTCGGCTCTCGGTAGCCATTCAAGTATATTTT 583
      |||
Db 301 CGGCTCCCGGATATTTCTGGAGCTCGGCTCTCGGTAGCCATTCAAGTATATTTT 360
      |||
Oy 584 GTTCGGAGCCCGGACCTTCAAATGAGAGACATCCTGGCTGTGACCCACAGC 643
      |||
Db 361 GTTCGGAGCCCGGACCTTCAAATGAGAGACATCCTGGCTGTGACCCACAGC 420
      |||
Oy 644 AATGGACTTGTGCTGCGGTGCTGAGAGAGCCTTAAAGCCCGCAAGTCTGCACT 703
      |||
Db 421 AATGGACTTGTGCTGCGGTGCTGAGAGAGCCTTAAAGCCCGCAAGTCTGCACT 480
      |||
Oy 704 GTAATCTCACTGTGATTCGGTGTCCCAAGACACTGAGAGTGATTTATATTCAGGT 763
      |||
Db 481 GTAATCTCACTGTGATTCGGTGTCCCAAGACACTGAGAGTGATTTATATTCAGGT 540
      |||
Oy 764 GTATTATCAAGTTACCGAGTTAGTTTTCATTTGCTGCTGAGAGAGAGTGGACTT 823
      |||
Db 541 GTATTATCAAGTTACCGAGTTAGTTTTCATTTGCTGCTGAGAGAGAGTGGACTT 600
      |||
Oy 824 GGACTAGCAGCAGCAGCAGTCTTTCAGAGCCGAGCTGACTTTCATTAATAGCTGCTGCTG 883
      |||
Db 601 GGACTAGCAGCAGCAGCAGTCTTTCAGAGCCGAGCTGACTTTCATTAATAGCTGCTGCTG 660
      |||
Oy 884 TGGCCGCGTGTGTGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 943
      |||
Db 661 TGGCCGCGTGTGTGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 720
      |||
Oy 944 AAAAGAGATTTGCTGATTC----- 962
      |||
Db 721 AAAAGAGATTTGCTGATTC----- 962
      |||
Oy 963 ----- 962
      |||
Db 781 AATGGCTCATTTGTGTATCTATTTATGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 840
      |||
Oy 963 -----AATTCAAAAGAAATCTGAAAAGAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 1013
      |||
Db 841 CTGATTCATTCCTGCGCAGCAAAATCTGAAAAGAGAAAGAAAGAAAGAAAGAAAGAAAG 900
      |||
Oy 1014 AATGTGAAATGAAAGAACTCCGCGCTACAAATTCAGATGAAAGAAAGAAAGAAAGAAAGAAAG 1073
      |||
Db 901 AATGTGAAATGAAAGAACTCCGCGCTACAAATTCAGATGAAAGAAAGAAAGAAAGAAAGAAAG 960
      |||
Oy 1074 CTCTCCCTCCCAATCTCTGATTCAGTATCTGAAACAAAGAAAGAAAGAAAGAAAGAAAG 1133
      |||
Db 961 CTCTCCCTCCCAATCTCTGATTCAGTATCTGAAACAAAGAAAGAAAGAAAGAAAGAAAG 1020
      |||
Oy 1134 CTCTCCAGCAGCGGCTGATCAACGT 1159
      |||
Db 1021 CTCTCCAGCAGCAAGAAAGATGACCT 1046
      |||

```

```

RESULT 6
ABK13032
ID ABK13032 standard; cDNA; 1195 BP.
XX
AC ABK13032;
XX
DT 23-APR-2002 (first entry)
XX
DE DNA encoding mouse B7-1-like protein, B7-Lm1.
XX
KW Mouse; B7-1-like protein; B7-Lm1; antinfertility; gynaeological;
KW antitumor; cytostatic; immunosuppressive; antiarthritic; antirheumatic;
KW antiinflammatory; dermatological; antipsoriatic; neuroprotective;
KW antidiabetic; haemostatic; antihypertensive; antitumor; antiallergic;
KW antiautismic; nephropathic; antibacterial; viral; tumor; cancer;
KW reproductively disorder; graft versus host disease; autoimmune disease;
KW toxic shock syndrome; allergy; nephropathy; skin disorder;

```

```

KW endocrinopathy; lymphoproliferative disorder; gene; ss.
XX Mus musculus.
OS
XX Key Location/Qualifiers
XX CDS 53..1165
XX FT /*tag= a
XX FT /product= "B7-1-like protein, B7-Lm1"
XX
XX W0200200710-A2.
XX
XX 03-JAN-2002.
XX
XX 28-JUN-2001; 2001WO-US20719.
XX
XX 28-JUN-2000; 2000US-214512P.
XX 28-NOV-2000; 2000US-0729264.
XX (AMGE-) AMGEN INC.
XX
XX Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;
XX WPI: 2002-130881/17.
XX P-PSDB: AA075544.
XX
XX New B7-1-like polypeptides, polynucleotides and their modulators, useful
XX for diagnosing, preventing and treating reproductive, immune and
XX proliferative disorders, e.g. cancer and arteriosclerosis
XX
XX Claim 1; Fig 5; 135pp; English.
XX
XX The invention relates to an isolated B7-1-like (B7-L) polypeptide (I).
XX The polypeptide, B7-1-like polypeptide-related disease, disorders or
XX useful for treating B7-1-like polypeptide-related disease, disorders or
XX conditions including reproductive disorders (e.g. infertility,
XX miscarriage, preterm labour and delivery and endometriosis) and
XX proliferative disorders. Antibodies, soluble proteins comprising
XX extracellular domains and other regulators of B7-L polypeptides are
XX useful for enhancing the immune response to tumours. (I) plays a role in
XX growth and maintenance of cancer cells based on the observation of
XX seminal vesicle hyperplasia in transgenic mice overexpressing B7-L
XX polypeptide. Hence modulators of (I) are useful for the treatment of
XX cancer including seminal vesicle cancer, lung, brain, breast, ovarian,
XX testicular cancer and cancers of haematopoietic system. B7-L polypeptide
XX pathway can be manipulated to regulate cytotoxic T-lymphocyte response
XX in allograft transplantation, graft versus host disease, T-cell
XX dependent B-cell mediated diseases and autoimmune diseases. B7-L
XX molecules are useful for alleviating the symptoms associated with
XX diseases involving chronic immune cell dysfunction or to treat
XX autoimmune diseases such as systemic lupus erythematosus, rheumatoid
XX arthritis, multiple sclerosis, diabetes, immune thrombocytopenic
XX purpura and psoriasis, chronic inflammatory disease such as
XX inflammatory bowel disease (Crohn's disease and ulcerative colitis),
XX Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They
XX are also useful as immunosuppressive agents for bone marrow and organ
XX transplantation or to prolong graft survival. B7-L molecules are also
XX useful for diagnosis and treatment of diseases involving abnormal cell
XX proliferation, including arteriosclerosis and vascular stenosis.
XX Antagonists of B7-L polypeptides are useful for alleviation of toxic
XX shock syndrome or allosensitisation due to blood transfusions, and for
XX treatment of allergy, asthma and hypersensitivity reactions,
XX nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and
XX pemphigoid), endocrinopathies (Grave's disease), various pneumopathies
XX (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,
XX thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and
XX CC lymphoproliferative disorders such as multiple myeloma. The present
XX sequence represents the coding sequence of mouse B7-Lm1.
XX
XX Sequence 1195 BP; 313 A; 304 C; 291 G; 287 T; 0 other;
XX
XX Query Match 30.7%; Score 380.6; DB 24; Length 1195;
XX Best Local Similarity 62.4%; Pred. No. 7e-95;
XX Matches 702; Conservative 0; Mismatches 354; Indels 69; Gaps 4;

```

Db 207 TGACCGCTTACCTCTCAGAGGTACGACCAAGGGGGAGACCTCCTGGAGATGATCAT 266  
 Qy 346 CCACAAATGTGAGAGCCAGTATTCGGGGAGACATCATGAGCCTCCAGAACAGTGGCC 405  
 Db 267 CCACAAATGTGAGAGCCAGTATTCGGGGAGACATCATGAGCCTCCAGAACAGTGGCC 326  
 Qy 406 GCATGATCTGCTTACCTTACCGTCCAGATTATGGAGAGAGCTGTTCATCCAGTGTAA 465  
 Db 327 GCATGATCTGCTTACCTTACCGTCCAGATTATGGAGAGAGCTGTTCATCCAGTGTAA 386  
 Qy 466 TCTTGATGTGCGAGAAATATACCTGTGAAGTACTGCTACCTCCACACAGAGAGCCG 525  
 Db 387 TCTTGATGTGCGAGAAATATACCTGTGAAGTACTGCTACCTCCACACAGAGAGCCG 446  
 Qy 526 GCTCCCGGATATTTCTGGAGAGCTGGTCTCTGTCAGCAGCATTCAGATATATTTTG 585  
 Db 447 GCTCCCGGATATTTCTGGAGAGCTGGTCTCTGTCAGCAGCATTCAGATATATTTTG 506  
 Qy 586 TCCGAGCCCAAGGAGCCTTAAAGTGAAGTGAAGTATCTGCTGACCCACAGAGCAA 645  
 Db 507 TCCGAGCCCAAGGAGCCTTAAAGTGAAGTGAAGTATCTGCTGACCCACAGAGCAA 566  
 Qy 646 TGGGACTTGTACTGCTGCTGCTACCTGAGAGAGCTGAAGCCCGCAAGTCTCAACTGT 705  
 Db 567 TGGGACTTGTACTGCTGCTGCTACCTGAGAGAGCTGAAGCCCGCAAGTCTCAACTGT 626  
 Qy 706 AATCTGACTGTGATTCGGTGTGCTCCCAAGACACTGAGAGTGTATTAATATTCAGGTGT 765  
 Db 627 AATCTGACTGTGATTCGGTGTGCTCCCAAGACACTGAGAGTGTATTAATATTCAGGTGT 686  
 Qy 766 ATTATCAAGTTTACCGGTTAGTTTTCATGCTTACTGCTGAGGAGGAGTTGGACTTGG 825  
 Db 687 ATTATCAAGTTTACCGGTTAGTTTTCATGCTTACTGCTGAGGAGGAGTTGGACTTGG 746  
 Qy 826 ACTAGAGGACCATGCTTGAAGGCGGAGCTGACTTCAATAGCTGCTGCTGCTG 885  
 Db 747 ACTAGAGGACCATGCTTGAAGGCGGAGCTGACTTCAATAGCTGCTGCTGCTG 806  
 Qy 886 CCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 945  
 Db 807 CCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 866  
 Qy 946 AAGAGATTTGCTATTCATTTCAAAAAGAAATCTGAAAAGAAAGAAACAAACAAAC 1005  
 Db 867 AAGAG-----GAAATTTGAAAAGAAAGAAACAAACAAACAAAC 904  
 Qy 1006 TGAGACAGAAAGTGAATGAAATCTCGGCTACATTCAGATGAGAAAGACACAGAGA 1065  
 Db 905 TGAGACAGAAAGTGAATGAAATCTCGGCTACATTCAGATGAGAAAGACACAGAGA 964  
 Qy 1066 AACCCTCTCTCTCCCTCCCAATCTCTGTGATTCAGTATCTGAAACAAAGAAACAGTAG 1125  
 Db 965 CACCCTCTCTCTCCCTCCCAATCTCTGTGATTCAGTATCTGAAACAAAGAAACAGTAG 1024  
 Qy 1126 CTGTGGCCCTCTCAGCAGGAGGCTGATCAAGCTCCAGCCAGGCGCAGAGTATCCACA 1185  
 Db 1025 CTGTGGCCCTCTCAGCAGGAGGCTGATCAAGCTCCAGCCAGGCGCAGAGTATCCACA 1084  
 Qy 1186 GGCCTCTTTTAAATCTGAGCAGTCTGAGAGGTCAGTAAATACAACTGTAGTATA 1239  
 Db 1085 GGCCTCTTTTAAATCTGAGCAGTCTGAGAGGTCAGTAAATACAACTGTAGTATA 1138  
 RESULT 5  
 AAS92356  
 ID AAS92356 standard; cDNA; 1392 BP.  
 AC AAS92356;  
 XX  
 XX 13-FEB-2002 (first entry)  
 DE DNA encoding novel human diagnostic protein #28160.  
 XX

KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder; ss.  
 OS Homo sapiens.  
 PN WO2001/5067-A2.  
 PD 11-OCT-2001.  
 XX  
 XX  
 PF 30-MAR-2001; 2001WO-US08631.  
 XX  
 XX 31-MAR-2000; 2000US-0540217.  
 PR 23-AUG-2000; 2000US-0649167.  
 XX  
 PA (HYSE-) HYSEQ INC.  
 PI Drmanac RT, Liu C, Tang YT;  
 XX  
 DR WPI: 2001-639362/73.  
 DR P-PSDB; ABG28169.  
 XX  
 PT New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity  
 PS  
 PS Claim 1; SEQ ID No 28160; 103pp; English.

The invention relates to isolated polynucleotide (I) and  
 polypeptide (II) sequences. (I) is useful as hybridisation probes,  
 polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
 and gene mapping, and in recombinant production of (II). The  
 polynucleotides are also used in diagnostics as expressed sequence tags  
 for identifying expressed genes. (I) is useful in gene therapy techniques  
 to restore normal activity of (II) or to treat disease states involving  
 (II). (II) is useful for generating antibodies against it, detecting or  
 quantitating a polypeptide in tissue, as molecular weight markers and as  
 a food supplement. (II) and its binding partners are useful in medical  
 imaging of sites expressing (II). (I) and (II) are useful for treating  
 disorders involving aberrant protein expression or biological activity.  
 The polypeptide and polynucleotide sequences have applications in  
 diagnostics, forensics, gene mapping, identification of mutations  
 responsible for genetic disorders or other traits to assess biodiversity  
 and to produce other types of data and products dependent on DNA and  
 amino acid sequences. AAS64197-AAS94564 represent novel human  
 CC diagnostic coding sequences of the invention.  
 CC Note: The sequence data for this patent did not appear in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pat\_sequences.  
 CC  
 XX

Sequence 1392 BP; 338 A; 361 C; 341 G; 352 T; 0 other;

Query Match 62.7%; Score 777.6; DB 23; Length 1392;  
 Best Local Similarity 87.2%; Pred. No. 9.3e-205;  
 Matches 912; Conservative 0; Mismatches 24; Indels 110; Gaps 1;

Qy 224 ATGTGGCTCTCAGTGAAGTGTGCTTAAGCTCTGAGGCGCCATGAGCCCATCATCACC 283  
 Db 1 ATGTGGCTCTCAGTGAAGTGTGCTTAAGCTCTGAGGCGCCATGAGCCCATCATCACC 60  
 Qy 284 AATGACCGCTTCACTCTCAGATGAGTACAGCAGGCGGGAACCTTCACTCTGGAGATATC 343  
 Db 61 AATGACCGCTTCACTCTCAGATGAGTACAGCAGGCGGGAACCTTCACTCTGGAGATATC 120  
 Qy 344 ATCCAAATGTGAGAGCCAGTATTCGGGAAACATCAGATGACAGCTCCAGAACAGTCCG 403  
 Db 121 ATCCAAATGTGAGAGCCAGTATTCGGGAAACATCAGATGACAGCTCCAGAACAGTCCG 180  
 Qy 404 CTGATGATCTGCTTACCTTACCGTCCAAAGTATGAGAGAGCTGTTCATTCACAGTGT 463  
 Db 181 CTGATGATCTGCTTACCTTACCGTCCAAAGTATGAGAGAGCTGTTCATTCACAGTGT 240  
 Qy 464 AATCTGTAGTGTGAGAAATGAACTTGTGAAGTATCTGTACCTCAACACTGAGACC 523



Db 891 CCGTATTCATTTCAAAAGAAATCTGAAAAAGAGAAACAAAGAAAGAACTGACAGACA 950  
 Qy 1016 AGTGAATGAAAGAACTCCGGCTGACAAATTCAGTAAGAAAGACCAAGAAACCGCTTCT 1075  
 Db 951 AGTGAATGAAAGAACTCCGGCTGACAAATTCAGTAAGAAAGAAAGACCAAGAAACCGCTTCT 1010  
 Qy 1076 CTCCTCCCAAAATCTGTGAATTCAGTAGTATCTGAAACAAAGAAACAGTAGCTGTGCGCT 1135  
 Db 1011 CTCCTCCCAAAATCTGTGAATTCAGTAGTATCTGAAACAAAGAAACAGTAGCTGTGCGCT 1070  
 Qy 1136 CCGTACAGCGGGCTGATCAACGTCACCGGCGGAGCAATGATCCACAGCGCTTCTTTT 1195  
 Db 1071 CCGTACAGCGGGCTGATCAACGTCACCGGCGGAGCAATGATCCACAGCGCTTCTTTT 1130  
 Qy 1196 AATCTGCGGAGTCTGAGAGAGTCAATATCAACTGATATAG 1240  
 Db 1131 AATCTGCGGAGTCTGAGAGAGTCAATATCAACTGATATAG 1175

## RESULT 3

ABK13029

ID ABK13029 standard; cDNA; 1168 BP.

XX ABK13029;

XX 23-APR-2002 (first entry)

XX DNA encoding human B7-1-like protein, B7-L<sub>h2</sub>.

XX Human; B7-1-like protein; B7-L; antifertility; gynecological;  
 XX antitumor; cytostatic; immunosuppressive; antithyroid; antirheumatic;  
 XX antiinflammatory; dermatological; antipsoriatic; neuroprotective;  
 XX antidiabetic; hemostatic; antihypertensive; antiallergic;  
 XX antiautism; nephrotropic; antibacterial; virucide; tumour; cancer;  
 XX reproductive disorder; graft versus host disease; autoimmune disease;  
 XX toxic shock syndrome; allergy; neuropathy; skin disorder;  
 XX endocrinopathy; lymphoproliferative disorder; gene; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

XX CDS 8..1168

XX FT /\*tag- a /product- "B7-1-like protein, B7-L<sub>h2</sub>"

XX PN NC0200200710-A2.

XX PD 03-JAN-2002.

XX PF 28-JUN-2001; 2001MO-US20719.

XX PR 28-JUN-2000; 2000US-214512P.

XX PR 28-NOV-2000; 2000US-0729264.

XX PA (AMGE-) AMGEN INC.

XX PI Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;

XX DR WPI; 2002-130881/17.

XX DR P-PSDB; AADU5541.

XX PT New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 XX for diagnosing, preventing and treating reproductive, immune and  
 XX proliferative disorders, e.g. cancer and arteriosclerosis

XX PS Claim 1; Fig 2; 135p; English.

XX The invention relates to an isolated B7-1-like (B7-L) polypeptide (1).  
 XX The polypeptide, polynucleotide encoding it and antibody against (1) are  
 XX useful for treating B7-1-like polypeptide-related disease, disorders or  
 XX conditions including reproductive disorders (e.g. infertility,  
 XX miscarriage, preterm labour and delivery and endometriosis) and

CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (1) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (1) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of hematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosis and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allsensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the coding sequence of human B7-L<sub>h2</sub>.

SQ Sequence 1168 BP; 299 A; 302 C; 288 G; 279 T; 0 other;

Query Match Best Local Similarity 99.1%; Score 1119; DB 24; Length 1168;

Matches 1125; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 106 AGAAGCTGATAGTCTGAGGCTGTGTAATGAATGAGAGGCCCCAGAAATGCAACAGT 165  
 Db 34 AGACCCACCCGGTCTGAGGCTGTGTAATGAATGAGAGGCCCCAGAAATGCAACAGT 93  
 Qy 166 CCTGAAGGCTCCAGAGCTGCTTAACATGACCGCTGCCAGAGGCTGAAGCTATCAT 225  
 Db 94 CCTGAAGGCTCCAGAGCTGCTTAACATGACCGCTGCCAGAGGCTGAAGCTATCAT 153  
 Qy 226 GTGGGCTCTCACTGACATGAGTGTGCTAAGGCTGAGGCGCCAGTGAAGCCATCACCAG 285  
 Db 154 GTGGGCTCTCACTGACATGAGTGTGCTAAGGCTGAGGCGCCAGTGAAGCCATCACCAG 213  
 Qy 286 TGACCGCTTACCTCTCAGAGGTAGACACGAGGCGGGAATCTCACTGAGATGATCAT 345  
 Db 214 TGACCGCTTACCTCTCAGAGGTAGACACGAGGCGGGAATCTCACTGAGATGATCAT 273  
 Qy 346 CCACAATGTGGAGCCCATGATTTGGGGAACATCATGATGACGCTCCAGAACTGCGCT 405  
 Db 274 CCACAATGTGGAGCCCATGATTTGGGGAACATCATGATGACGCTCCAGAACTGCGCT 333  
 Qy 406 GCATGATCTGCTTACCTTACCGTCAAGTATGAGAGAGTGTCAATGCCAGTGTAA 465  
 Db 334 GCATGATCTGCTTACCTTACCGTCAAGTATGAGAGAGTGTCAATGCCAGTGTAA 393  
 Qy 466 TCTTGTAGCTGCTGAGAAATGAACTTGTGAATGATGTTTACCTCCACACTGAGCCG 525  
 Db 394 TCTTGTAGCTGCTGAGAAATGAACTTGTGAATGATGTTTACCTCCACACTGAGCCG 453  
 Qy 526 GCTCCGATATTTCTGAGAGCTGCTGCTGCTGCTCAACCTCAAGCTATATTTGT 585  
 Db 454 GCTCCGATATTTCTGAGAGCTGCTGCTGCTGCTCAACCTCAAGCTATATTTGT 513  
 Qy 586 TCCGAGGCGGAGCAGCTTCAAGTGAAGAGATGAGATCTGAGTGAAGCCAGAGAGCA 645  
 Db 514 TCCGAGGCGGAGCAGCTTCAAGTGAAGAGATGAGATCTGAGTGAAGCCAGAGAGCA 573

ID ABK13028 standard; CDNA; 1175 BP.  
 XX  
 AC ABK13028;  
 XX  
 DT 23-APR-2002 (first entry)  
 XX  
 DE DNA encoding human B7-1-like protein, B7-L.h1.  
 XX  
 KM Human; B7-1-like protein; B7-L; anti-infectivity; gynaecological;  
 KM antitumour; cytostatic; immunosuppressive; antiarthritic; antineumatic;  
 KM antiinflammatory; dermatological; antiporiatic; neuroprotective;  
 KM antidiabetic; haemostatic; antihypertensive; antileukemic;  
 KM antilactamic; nephrotoxic; antibacterial; virucide; tumour; cancer;  
 KM reproductive disorder; graft versus host disease; autoimmune disease;  
 KM toxic shock syndrome; allergy; nephropathy; skin disorder;  
 KM endocrinopathy; lymphoproliferative disorder; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT 27..1175  
 FT /tag= a  
 FT /product= "B7-1-like protein, B7-L.h1"  
 XX  
 XX MO20000710-A2.  
 PD 03-JAN-2002.  
 XX  
 XX 28-JUN-2001; 2001WO-US20719.  
 PF  
 XX 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 XX  
 XX (AMGE-) AMGEN INC.  
 PA  
 XX Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 PI WPI: 2002-130881/17.  
 DR P-PSDB; AAT075540.  
 XX  
 XX New B7-1-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 PT  
 XX Claim 1; Fig 1; 135pp; English.  
 PS  
 XX The invention relates to an isolated B7-1-like (B7-L) polypeptide (1),  
 CC CC The polypeptide, polynucleotide encoding it and antibody against (1) are  
 CC useful for treating B7-1-like polypeptide-related disease, disorders or  
 CC conditions affecting reproductive disorders (e.g. infertility),  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (1) plays a role in  
 CC growth and maintenance of cancer cells based on the observation of  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (1) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC dependent B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or to prolong graft survival. B7-L molecules are also  
 CC useful for diagnosing and treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.

CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allosensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions.  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various neuropathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the coding sequence of human B7-L.h1.  
 XX  
 SQ Sequence 1175 BP; 295 A; 307 C; 286 G; 287 T; 0 other:  
 XX  
 Query Match 90.6%; Score 1123.4; DB 24; Length 1175;  
 Best Local Similarity 99.9%; Pred. No. 1.6e-300;  
 Matches 1124; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 116 GGTTCGGTCTGTTAATGAATGAAAGGCCCCAGAAATGCAACAGCTGGAAGGCG 175  
 DB 51 GGTTCGGTCTGTTAATGAATGAAAGGCCCCAGAAATGCAACAGCTGGAAGGCG 110  
 QY 176 TCCAGAGCTGCTCAACTGACCGCTCCAGAGGCTGGAAGCTCATCTGCGCTCTC 235  
 DB 111 TCCAGAGCTGCTCAACTGACCGCTCCAGAGGCTGGAAGCTCATCTGCGCTCTC 170  
 QY 236 AGTACATGTTGTTGCTTAAGGCTCAGGCGCCATGAGCCATCATCACCAGTACCGCTTC 295  
 DB 171 AGTACATGTTGTTGCTTAAGGCTCAGGCGCCATGAGCCATCATCACCAGTACCGCTTC 230  
 QY 296 ACCCTCAGAGGTACGACGAGGCGGGAACCTCAGCTGGAGATCATCCACATGTG 355  
 DB 221 ACCCTCAGAGGTACGACGAGGCGGGAACCTCAGCTGGAGATCATCCACATGTG 290  
 QY 356 GAGCCAGTATGTTGGGGAACATGATGACGCTCCAGAACTGCTGCTGATGATCT 415  
 DB 291 GAGCCAGTATGTTGGGGAACATGATGACGCTCCAGAACTGCTGCTGATGATCT 350  
 QY 416 GCTTACCTTACCGTCAAGTTATGAGAGAGCTGTTTATCCAGTGTATCTTGTAGTC 475  
 DB 351 GCTTACCTTACCGTCAAGTTATGAGAGAGCTGTTTATCCAGTGTATCTTGTAGTC 410  
 QY 476 GCTGGAATGAACTTGGAGTTACTGTTACCTCAGCTGAGCCGCTCCCGAT 535  
 DB 411 GCTGGAATGAACTTGGAGTTACTGTTACCTCAGCTGAGCCGCTCCCGAT 470  
 QY 536 ATTTCCTGGAGCTGCTGCTCTGCTGACCCATTCAAGCTATTAATTTTCCGAGCC 595  
 DB 471 ATTTCCTGGAGCTGCTGCTCTGCTGACCCATTCAAGCTATTAATTTTCCGAGCC 530  
 QY 596 AGCGACCTTCAAGTGCAGTGCATCTGCTGCTGACCCCAAGCAATGGACTTTG 655  
 DB 531 AGCGACCTTCAAGTGCAGTGCATCTGCTGCTGACCCCAAGCAATGGACTTTG 590  
 QY 656 ACTTCGTTGCTTACCTGGAAGAGCTGGAAGGCGCCAGTGTGCAACTGTAAATCTCACT 715  
 DB 591 ACTTCGTTGCTTACCTGGAAGAGCTGGAAGGCGCCAGTGTGCAACTGTAAATCTCACT 650  
 QY 716 GTGATTCGGTGTCCCAAGACACTGAGAGTGTATTAATTCAGTGTATCAAGT 775  
 DB 651 GTGATTCGGTGTCCCAAGACACTGAGAGTGTATTAATTCAGTGTATTAATCAAGT 710  
 QY 776 TTACCGAGTTAGTTTTCATGCTTCTGCTGAGGCAAGTTGGACTGGACTGACAGC 835  
 DB 711 TTACCGAGTTAGTTTTCATGCTTCTGCTGAGGCAAGTTGGACTGGACTGACAGC 770  
 QY 836 ACCATGCTTCTGACGCGCAGCGTGTACTCTTACATACGCTGCTGCTGCGCGCTGT 895  
 DB 771 ACCATGCTTCTGACGCGCAGCGTGTACTCTTACATACGCTGCTGCTGCGCGCTGT 830  
 QY 896 TGTGTGCTGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 955  
 DB 831 TGTGTGCTGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 890  
 QY 956 CGTATTCATTTCAAAAGAAATCTGAAGAAAGAAAGAAAGAAAGAAAGAAAGAA 1015

PR 28-JUN-2000; 2000US-214512P.  
 PR 28-NOV-2000; 2000US-0729264.  
 PA (AMGE-) AMGEN INC.  
 PI Welcher AA, Sarmiento UM, Schultz HJ, Chute HT;  
 DR WPI: 2002-130881/17.  
 DR P-PSDB: AAU75542.  
 XX  
 XX  
 XX New B7-like polypeptides, polynucleotides and their modulators, useful  
 PT for diagnosing, preventing and treating reproductive, immune and  
 PT proliferative disorders, e.g. cancer and arteriosclerosis  
 PT  
 XX  
 XX  
 PS Claim 1; Fig 3; 135pp; English.

XX The invention relates to an isolated B7-like (B7-L) polypeptide (I).  
 CC The polypeptide, polynucleotide encoding it and antibody against (I) are  
 CC useful for treating B7-like polypeptide-related disease, disorders or  
 CC conditions including reproductive disorders (e.g. infertility,  
 CC miscarriage, preterm labour and delivery and endometriosis) and  
 CC proliferative disorders. Antibodies, soluble proteins comprising  
 CC extracellular domains and other regulators of B7-L polypeptides are  
 CC useful for enhancing the immune response to tumours. (I) plays a role in  
 CC growth and maintenance of the immune response to tumours. (I) plays a role in  
 CC seminal vesicle hyperplasia in transgenic mice overexpressing B7-L  
 CC polypeptide. Hence modulators of (I) are useful for the treatment of  
 CC cancer including seminal vesicle cancer, lung, brain, breast, ovarian,  
 CC testicular cancer and cancers of haematopoietic system. B7-L polypeptide  
 CC pathway can be manipulated to regulate cytotoxic T-lymphocyte response  
 CC in allograft transplantation, graft versus host disease, T-cell  
 CC mediated B-cell mediated diseases and autoimmune diseases. B7-L  
 CC molecules are useful for alleviating the symptoms associated with  
 CC diseases involving chronic immune cell dysfunction or to treat  
 CC autoimmune diseases such as systemic lupus erythematosus, rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, immune thrombocytopenic  
 CC purpura and psoriasis, chronic inflammatory disease such as  
 CC inflammatory bowel disease (Crohn's disease and ulcerative colitis),  
 CC Grave's disease, Hashimoto's thyroiditis and diabetes mellitus. They  
 CC are also useful as immunosuppressive agents for bone marrow and organ  
 CC transplantation or treatment of diseases involving abnormal cell  
 CC proliferation, including arteriosclerosis and vascular restenosis.  
 CC Antagonists of B7-L polypeptides are useful for alleviation of toxic  
 CC shock syndrome or allo sensitisation due to blood transfusions, and for  
 CC treatment of allergy, asthma and hypersensitivity reactions,  
 CC nephropathies (e.g. glomerulonephritis), skin disorders (pemphigus and  
 CC pemphigoid), endocrinopathies (Grave's disease), various pneumopathies  
 CC (extrinsic alveolitis), vasculopathies, coeliac disease, anaemia,  
 CC thrombocytopenias, Guillain-Barre syndrome and myasthenia gravis, and  
 CC lymphoproliferative disorders such as multiple myeloma. The present  
 CC sequence represents the coding sequence of human B7-L<sub>h3</sub>.  
 XX

Sequence 1240 BP; 318 A; 319 C; 305 G; 298 T; 0 other;

Query Match 100.0%; Score 1240; DB 24; Length 1240;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 1240; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGTGAGTCCAGCCCAAGCTGTGATCGATTCTAGAGCTCCATACAAACACCAT 60  
 DB 1 AGGTGAGTCCAGCCCAAGCTGTGATCGATTCTAGAGCTCCATACAAACACCAT 60  
 QY 61 AACCTGTGCTTGAAGCAATGGAAGGATTTGTCAGAGCTCCAGAGCTTAGTTC 120  
 DB 61 AACCTGTGCTTGAAGCAATGGAAGGATTTGTCAGAGCTCCAGAGCTTAGTTC 120  
 QY 121 TGGGTCTGTAATGAACTAGAAAGCCGCCAGAAATGCAACAGTCTGAAAGGCTCCCA 180  
 DB 121 TGGGTCTGTAATGAACTAGAAAGCCGCCAGAAATGCAACAGTCTGAAAGGCTCCCA 180  
 QY 181 GGCCTGCTTAACTGACGAGCTCCAGAGCTGGAAGCTCATATGTGGCTTCAGTGA 240  
 DB 181 GGCCTGCTTAACTGACGAGCTCCAGAGCTGGAAGCTCATATGTGGCTTCAGTGA 240

DB 181 GGCCTGCTTAACTGACGAGCTCCAGAGCTGGAAGCTCATATGTGGCTTCAGTGA 240  
 QY 241 CATGTGTGCTTAAGCTCAGGCGCCATGAGCCCATCATCACAATGACCGCTTCACTC 300  
 DB 241 CATGTGTGCTTAAGCTCAGGCGCCATGAGCCCATCATCACAATGACCGCTTCACTC 300  
 QY 301 TCAGAGGTACGACGAGGCGGGAACCTTCACCTCGGAGATGATCATCCAAATGTGAGCC 360  
 DB 301 TCAGAGGTACGACGAGGCGGGAACCTTCACCTCGGAGATGATCATCCAAATGTGAGCC 360  
 QY 361 CAGTGATTCGGGGAGACATCAGATGACGCTCCAGAACAGTCCGCTCATGATCTGCTTA 420  
 DB 361 CAGTGATTCGGGGAGACATCAGATGACGCTCCAGAACAGTCCGCTCATGATCTGCTTA 420  
 QY 421 CCTTACCGTCAAGTTATGAGGAGCTGTTCATTTCCAGTGTAACTTTGTAGTCCGTA 480  
 DB 421 CCTTACCGTCAAGTTATGAGGAGCTGTTCATTTCCAGTGTAACTTTGTAGTCCGTA 480  
 QY 481 GAATGAACCTTGTGAGTACTGTCTACCCACACCTGGACCGGCTCCGGATATTTTC 540  
 DB 481 GAATGAACCTTGTGAGTACTGTCTACCCACACCTGGACCGGCTCCGGATATTTTC 540  
 QY 541 CTGGAGCTCGGTCTCTCGTCAAGCAATTCATTAATTTTGTCCGAGCCAGCGA 600  
 DB 541 CTGGAGCTCGGTCTCTCGTCAAGCAATTCATTAATTTTGTCCGAGCCAGCGA 600  
 QY 601 CCTTCAAGTGCAGTACGATCTGTGCTGCTGACCCACAGACCAATGAGACTTTTACCTG 660  
 DB 601 CCTTCAAGTGCAGTACGATCTGTGCTGCTGACCCACAGACCAATGAGACTTTTACCTG 660  
 QY 661 CGTGAGCTCGGTGAGAGGCTGAGGCGCCGCAAGTCTGCACTGTAATCTCATCTGAT 720  
 DB 661 CGTGAGCTCGGTGAGAGGCTGAGGCGCCGCAAGTCTGCACTGTAATCTCATCTGAT 720  
 QY 721 TCGGTCTCCCAAGAGACAGGAGGAGTGTATTAATTCAGAGTATATATCAAGTTTACC 780  
 DB 721 TCGGTCTCCCAAGAGACAGGAGGAGTGTATTAATTCAGAGTATATATCAAGTTTACC 780  
 QY 781 GAGTTAGTGTATTTTCAATTCCTACTTGGGGCAAGTTGGACTGAGCAGCACCAT 840  
 DB 781 GAGTTAGTGTATTTTCAATTCCTACTTGGGGCAAGTTGGACTGAGCAGCACCAT 840  
 QY 841 GCTTTCAGAGCGGAGCTGTACTTCAATACGCTGTCTGCTCCGCGCTGCTTGTG 900  
 DB 841 GCTTTCAGAGCGGAGCTGTACTTCAATACGCTGTCTGCTCCGCGCTGCTTGTG 900  
 QY 901 TGGCTGCAACTGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 960  
 DB 901 TGGCTGCAACTGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 960  
 QY 961 TCAATTTCAAAAGAAATCTGAAAAAGAGAACAAACAAAGAACTGAGACAGAAATGG 1020  
 DB 961 TCAATTTCAAAAGAAATCTGAAAAAGAGAACAAACAAAGAACTGAGACAGAAATGG 1020  
 QY 1021 AATGAAACCTCGGCTCAATTCAGATGAAACAAAGACCAAGAACCGCTTCTCTCC 1080  
 DB 1021 AATGAAACCTCGGCTCAATTCAGATGAAACAAAGACCAAGAACCGCTTCTCTCC 1080  
 QY 1081 TCCCAAAATCTTGAATCAGTATCTGAAACAAAGAAAGAACTGAGCTGCTGCTCA 1140  
 DB 1081 TCCCAAAATCTTGAATCAGTATCTGAAACAAAGAAAGAACTGAGCTGCTGCTCA 1140  
 QY 1141 CCAGGCGGCTGATCAACGTCACCCAGGCGAGCAAGTATCCACAGGCTTTTAACT 1200  
 DB 1141 CCAGGCGGCTGATCAACGTCACCCAGGCGAGCAAGTATCCACAGGCTTTTAACT 1200  
 QY 1201 GGCAGTCTCTGAGAGTCAATATCAATCAAGTATAGTATAG 1240  
 DB 1201 GGCAGTCTCTGAGAGTCAATATCAATCAAGTATAGTATAG 1240

RESULT 2  
 ABK13028







QY 1 AGGTGTAGTCCACCACACAGTGTGATCAGTTTCTAGGCTGCCATTAACAAGCACCAT 60  
|||||  
Db 159444 AGGTGTAGTCCACCACACAGTGTGATCAGTTTCTAGGCTGCCATTAACAAGCACCAT 159503  
|||||  
QY 61 AACCTGGTGGCTTAGAACATGGAAGGCAATTGCTCAGCGTTCCAGAGCTGTAGGTT 119  
|||||  
Db 159504 AACCTGGTGGCTTAGAACATGGAAGGCAATTGCTCAGCGTTCCAGAGCTGTAGGTT 159562  
|||||

Search completed: April 29, 2003, 14:51:53  
Job time : 4716.78 secs

```

/note="GC score = 10.60 (249bp); Region: GC content"
/evidence-not_experimental
repeat_region 15369..16268
/evidence-not_experimental
/rpt_family="MERVL"
complement(16623..16714)
/note="GRAIL, score = 72.000%, comment = good"
/evidence-not_experimental
exon 16661..16730
/note="MZF, score = 93.58"
/evidence-not_experimental
repeat_region 16880..17318
/evidence-not_experimental
/rpt_family="MLTIC"
17326..17436
/evidence-not_experimental
/rpt_family="LIR16C"
complement(17540..17675)
/evidence-not_experimental
/rpt_family="MIR"
complement(17805..17864)
/evidence-not_experimental
/rpt_family="MLTIC"
18076..18098
/note="GRAIL, score = 45.000%, comment = marginal shadow"
/evidence-not_experimental
exon 18219..18349
/note="Genscan, score = 2.998, comment = Internal_exon 131
bp frame: 1 phase: 2"
/evidence-not_experimental
complement(18717..19211)
/evidence-not_experimental
/rpt_family="MLTIC"
complement(19252..19399)
/note="GRAIL, score = 71.000%, comment = good"
/evidence-not_experimental
exon 19269..19350
/note="GRAIL, score = 81.000%, comment = excellent shadow"
/evidence-not_experimental
complement(19379..19399)
/note="Xpound exon prediction, score = 60% (0%)"
/evidence-not_experimental
complement(19501..19881)
/note="MZF, score = 50.6%"
/evidence-not_experimental
19945..20020
/note="homology = 100.00%, score = 38, counts = 2"
/evidence-not_experimental
/rpt_type=tandem
20223..20643
/evidence-not_experimental
/rpt_family="MLTIF"
20645..20910
/evidence-not_experimental
/rpt_family="MLTIF"
20961..21007
/evidence-not_experimental
/rpt_family="MLTIF"
21483..21781
/evidence-not_experimental
/rpt_family="ALUB"
complement(21504..21756)
/note="MZF, score = 79.4%"
/evidence-not_experimental
complement(22325..22806)
/evidence-not_experimental
/rpt_family="MLTIC"

```

Query Match 9.6%; Score 119; DB 9; Length 40205;  
 Best Local Similarity 100.0%; Pred. No. 1.7e-17;  
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Oy 1 AGGTGTGAGTCACGACCACTGTGATCACTTCTAGAGCTGCCATACAAACACCAT 60
|||||
Db 18694 AGGTGTGAGTCACGACCACTGTGATCACTTCTAGAGCTGCCATACAAACACCAT 18753
Oy 61 AACCTGTGGCTTAGAACATGGAAGGCAATTTGCTCAGGTTCCAGAACTGTAGCTT 119
|||||
Db 18754 AACCTGTGGCTTAGAACATGGAAGGCAATTTGCTCAGGTTCCAGAACTGTAGCTT 18812

RESULT 15
AF064860 170121 bp DNA linear PRI 05-MAR-2002
LOCUS AF064860
DEFINITION Homo sapiens chromosome 21 clone PAC 70124 map 21q22.3, complete
sequence.
ACCESSION AF064860
VERSION AF064860.2 GI:18958624
KEYWORDS HTG; HTGS; DRAFT.
SOURCE Homo sapiens.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 170121)
Hattori,M., Fujiyama,A., Taylor,T.D., Matanabe,H., Yada,T.,
Park,H.-S., Toyoda,A., Ishii,K., Totoki,Y., Choi,D.-K., Soeda,E.,
Ohki,M., Takagi,T., Sakaki,Y., Tauden,S., Blechschmidt,K.,
Polley,A., Menzel,U., Delabar,J., Kumpf,K., Lehmann,R.,
Patterson,D., Reichwald,K., Rump,A., Schilhabel,M.B., Schudy,A.,
Zimmermann,W., Rosenthal,A., Kudoh,J., Kawasaki,K., Asakawa,S.,
Shintani,A., Sasaki,T., Nagamine,S., Shimizu,N., Nordiek,G.,
Antonarakis,S.E., Minoshima,S., Shimizu,N., Nordiek,G.,
Honisch,K., Brandt,P., Scharfe,M., Schoen,O., Desario,A.,
Reichelt,J., Kauer,G., Bloeker,H., Ramser,J., Beck,A., Klages,S.,
Hennig,S., Riessmann,L., Dagand,E., Haaf,T., Wehnemeyer,S.,
Borzym,K., Gardiner,K., Nizetic,D., Francis,F., Lehnach,H.,
Reinhardt,R. and Yaspo,M.Laure.
The DNA sequence of human chromosome 21
Nature 405 (6784), 311-319 (2000)
JOURNAL MEDLINE
PUBMED 10830953
REFERENCE 2 (bases 1 to 170121)
Rump,A., Dagand,E., Hildmann,T., Nordiek,G., Drescher,B.,
Weber,J., Schattevoy,R., Yaspo,M.-L. and Rosenthal,A.
Direct Submission
Submitted (12-MAY-1998) Genome Analysis, Institute of Molecular
Biotechnology, Beutenbergstrasse 11, Jena 07745, Germany
JOURNAL 3 (bases 1 to 170121)
Rump,A., Dagand,E., Hildmann,T., Nordiek,G., Drescher,B.,
Weber,J., Schattevoy,R., Yaspo,M.-L., Rosenthal,A., Yaspo,M.-L. and
Rosenthal,A.
Direct Submission
Submitted (27-FEB-2002) Genome Analysis, Institute of Molecular
Biotechnology, Beutenbergstr. 11, Jena 07745, Germany
REFERENCE 4 (bases 1 to 170121)
Rump,A., Dagand,E., Hildmann,T., Nordiek,G., Drescher,B.,
Weber,J., Schattevoy,R., Yaspo,M.-L. and Rosenthal,A.
Direct Submission
Submitted (05-MAR-2002) Genome Analysis, Institute of Molecular
Biotechnology, Beutenbergstr. 11, Jena 07745, Germany
COMMENT On Feb 27, 2002 this sequence version replaced gi:3171153.
FEATURES
source
1..170121
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="21"
/map="21q22.3"
/clone="PAC 70124"
BASE COUNT 45184 a 36756 c 37509 g 50672 t
ORIGIN

```

Query Match 9.6%; Score 119; DB 9; Length 170121;  
 Best Local Similarity 100.0%; Pred. No. 1.8e-17;  
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;







RESULT 10	AX380408	754 bp	DNA	linear	PAT 18-MAR-2002
LOCUS	AX380408				
DEFINITION	Sequence 13 from Patent WO0200710.				
ACCESSION	AX380408				
VERSION	AX380408.1	GI:19575338			
KEYWORDS					
SOURCE	house mouse.				
ORGANISM	Mus musculus				
REFERENCE	1. Welcher, A.A., Sarmiento, U.M., Schuit, H.J. and Chute, H.T.				
AUTHORS	Welcher, A.A., Sarmiento, U.M., Schuit, H.J. and Chute, H.T.				
TITLE	B7-like molecules and uses thereof				
JOURNAL	Patent: WO 0200710-A 13 03-JAN-2002.				
FEATURES	Location/Qualifiers				
source	1..754				
	/organism="Mus musculus"				
	/db_xref="taxon:10090"				
	53..724				
	/note="unnamed protein product"				
	/codon_start=1				
	/protein_id="CAD28222.1"				
	/db_xref="GI:19575339"				
	/translation="MEGSRDVLAVILIAQLTASGSSYIIIEGPONTVLKDEAHF				
	NCVTHGMRKLMTNTLNMVVLSTLQDPIITNNPFYASNSGDSFISLLIHVQPS				
	DSGSVCSLSSHGSPGSAFLSVQESTQNEIIRKSANMRKADPEIKSGKENYGS				
	SDPKKAQVTSLEPPKSAEVSLEPERSSSLFYQELNKHQHPATHPRVPIASQKRV				
	NVTLY"				
BASE COUNT	220 a 191 c 175 g 168 t				
ORIGIN					
Query Match	15.0%: Score 185.6; DB 6; Length 754;				
Best Local Similarity	73.8%: Pred. No. 2.2e-33;				
Matches 236; Conservative	0; Mismatches 84; Indels 0; Gaps 0;				
QY	115 AGTTCTGGGCTCTGGTAATGAGTCATGAGAGGCCCCAGAGATGCACAGCTCTGGAAGG	174			
Db	109 AGCTTCGGGATCCAGTTATCAGATCATGAGAGGTCCTCAGAAATGTAAACAGTCTAAAG	168			
QY	175 CTCGCCAGGCTGCTTCAACTGCACCGTCTCCAGGGCTGGAAAGCTCATCATGTGGGCT	234			
Db	169 CTCAGAGGCTCACTTCAACACTGCACCGTACGTCACGGCTGGAAAGCTTCTCATGTGACTCT	228			
QY	235 CAGTGACATGGTGGGCTGAAGCGTGAAGGCCCATGAGGCCATCATCACAACCGCTT	294			
Db	229 TAACCAATATGTTGGTGTGATGCTCAGCTCACCACCAAGACCAACCATCATCACAACCGCTT	288			
QY	295 CACCTCTCAGAGTAGACGACCAAGGCGGGAACCTTCACCTCGGAGATGATCATCCACAATGT	354			
Db	289 CACCTATGCCAGTTTACACAGACACTGACAGAGTCTATCTCGGGTGTGATCATCCATGATGT	348			
QY	355 GGAGGCCAGTATTCGGGGGAACATCAGATGGAAGCCTCCAGAACAGTACGGCTGCATGATGC	414			
Db	349 GGAGCCCAAGTACTCGGATCCGTGCATATGACGCTTGACAGAACACCATGGGTTTGATC	408			
QY	415 TGCTTACCTTACCGTCAAG	434			
Db	409 TGCTTCTCTCTCAGTCAAG	428			
RESULT 11					
LOCUS	AX380406	895 bp	DNA	linear	PAT 18-MAR-2002
DEFINITION	Sequence 11 from Patent WO0200710.				
ACCESSION	AX380406				
VERSION	AX380406.1	GI:19575336			
KEYWORDS					
ORGANISM	house mouse.				
SOURCE	Mus musculus				

REFERENCE	AUTHORS	TITLE	JOURNAL
1	Welcher, A.A., Sarmiento, U.M., Schultz, H.J., and Chute, H.T.	H7-like molecules and uses thereof	
	Patent: WO 0200710-A 11 03-JAN-2002;		
	Amgen, Inc. (US)		
FEATURES	Location/Qualifiers		
source	1..895		
	/organism="Mus musculus"		
	/db_xref="taxon:10090"		
CDS	53..865		
	/note="unnamed protein product"		
	/codon_start=1		
	/protein_id="CAD28221.1"		
	/db_xref="GI:19575337"		
	/translation="MEGSRBDVLAVLILQLTASGSSQIIIEGPONVTLKSEAF NCVTHQNMKILMTINQMYLISLTGSPITTNRFYASINSDFSELIDVOPS DSGSVQCSLONSHRGFGAFSLSYDSDISEBPALPTMAILLAAVSLILILVLI FCCCAARRKEESTYONELTRKSNMNTINADEETKSKRENYGCSDDAKAQTNS LPPSAVSLSPEKRSSSLPYOELNKHQPGPATHPRVSDIASPOKRVNVLV"		
BASE COUNT	250 a	223 c	212 g
ORIGIN	210 t		
Query Match	15.08;	Score 185.6;	DB: 6; Length 895;
Best Local Similarity	73.88;	Pred. No. 2.2e-33;	
Matches 236;	Conservative 0;	Mismatches 84;	Indels 0; Gaps 0;
OY	115	AGGTTCTGGGTCGTGTATGAAGTCATGTAAGAGGCCCCAGAAATGCACAGTCCTCAAGGG	174
Db	109	AGCTTCGGGATCCACTTATCAGATCATTAAGAGTCTCAGATGTAAACAGTCCTAAAGGA	168
OY	175	CTCCAGGCGTGGCTTCAACTGCACCGCTCTCCAGGGCTGGAAGCTCATATGTGGGCTCT	234
Db	169	CTCAAGAGCTCACTCACTGACCGCTGACACGCGTGAAGGCTTCATGTGACACT	228
OY	235	CAGTACATGTGTGTCTAAGCGTGAAGCCCATGAGGCCCATCATACACATGACCGGCTT	294
Db	229	TAAACCAATGGTGGTGGTCAAGTCTGACCAACCAAGGACCATCATCAACCAACCGCTT	288
OY	295	CACCTTCAGAGATGACGACAGGCGGGGACCTTCCTCGAGATGATCATACCAATGT	354
Db	289	CACCTATGCCAGTTTCAACAGACGACGACGCTTCTCTCGAGTGTATCATCATGATGT	348
OY	355	GGAGCCCAAGTATTCGGGGAACATCATGATGACGCTTCAGAAACAGTCCCTGCATGATC	414
Db	349	GCAGCCCAAGTATTCGGGGAACATCATGATGACGCTTCAGAAACAGTCCCTGCATGATC	408
OY	415	TGCTTAACTTACCGTCAAG	434
Db	409	TGCTTAACTTACCGTCAAG	428
RESULT 12			
LOCUS	BC004806	1556 bp	linear
DEFINITION	Mus musculus, RIKEN cDNA 201003020 gene, clone MGC:7960		
ACCESSION	BC004806		
VERSION	BC004806.1		
KEYWORDS	GI:13435932		
SOURCE	MGC.		
ORGANISM	house mouse.		
REFERENCE	Mus musculus.		
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
TITLE	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus		
JOURNAL	Submitted (21-MAR-2002) National Institutes of Health, Mammalian		
	Gene Collection (MGC), Cancer Genomics Office, National Cancer		
	Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,		
	USA		
REMARK	NIH-MGC Project URL: <a href="http://mgc.nci.nih.gov">http://mgc.nci.nih.gov</a>		

LOCUS AC020851 196900 bp DNA linear HTG 15-JUL-2000  
 DEFINITION Mus musculus clone RP21-467L12, WORKING DRAFT SEQUENCE, 33  
 unorderd pieces.  
 ACCESSION AC020851  
 VERSION AC020851.2 GI:9211212  
 KEYWORDS HTG; HTGS\_PHASE1; HTGS\_DRAFT.  
 SOURCE Mus musculus.  
 ORGANISM Mus musculus.  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE  
 AUTHORS DOE Joint Genome Institute.  
 TITLE Sequencing of Mouse  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 196900)  
 AUTHORS DOE Joint Genome Institute.  
 TITLE Direct Submission  
 JOURNAL Submitted (10-JAN-2000) Production Sequencing Facility, DOE Joint  
 Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA  
 On Jul 15, 2000 this sequence version replaced gi:6686457.  
 COMMENT  
 -----Genome Center  
 Center: Joint Genome Institute  
 Center Code: JGI  
 Web site: <http://www.jgi.doe.gov>  
 -----  
 Project Information  
 Center Project Name: 1437240  
 Center clone name: RP21-467L12  
 -----

Summary Statistics  
 Consensus quality: 164618 bases at least Q40  
 Consensus quality: 180887 bases at least Q30  
 Estimated insert size: 14700; pulse field gel estimation  
 Estimated insert size: 193700; sum-of-contrigs estimation  
 Quality coverage: 5.67 in Q20 bases; pulse field gel estimation  
 Quality coverage: 4.3 in Q20 bases; sum-of-contrigs estimation.  
 \* NOTE: This is a 'working draft' sequence. It currently  
 \* consists of 33 contrigs. The true order of the pieces  
 \* is not known and their order in this sequence record is  
 \* arbitrary. Gaps between the contrigs are represented as  
 \* runs of N, but the exact sizes of the gaps are unknown.  
 \* This record will be updated with the finished sequence  
 \* as soon as it is available and the accession number will  
 \* be preserved.

```

1      1541: contig of 1541 bp in length
*      1542      1641: gap of unknown length
*      1642      3492: contig of 1851 bp in length
*      3493      3592: gap of unknown length
*      3593      4738: contig of 1146 bp in length
*      4739      4838: gap of unknown length
*      4839      7248: contig of 2410 bp in length
*      7249      7348: gap of unknown length
*      7349      9178: contig of 1830 bp in length
*      9179      9278: gap of unknown length
*      9279      11493: contig of 2215 bp in length
*      11494      11593: gap of unknown length
*      11594      13607: contig of 2014 bp in length
*      13608      13707: gap of unknown length
*      13708      15946: contig of 2239 bp in length
*      15947      16046: gap of unknown length
*      16047      18392: contig of 2346 bp in length
*      18393      18492: gap of unknown length
*      18493      21231: contig of 2739 bp in length
*      21232      21331: gap of unknown length
*      21332      24662: contig of 3331 bp in length
*      24663      24762: gap of unknown length
*      24763      27140: contig of 2378 bp in length
*      27141      27240: gap of unknown length
*      27241      29950: contig of 2710 bp in length
*      29951      30050: gap of unknown length
*      30051      32245: contig of 2195 bp in length
*      32246      32345: gap of unknown length

```

```

*      32346      35688: contig of 3343 bp in length
*      35689      35788: gap of unknown length
*      35789      40387: contig of 4599 bp in length
*      40388      40487: gap of unknown length
*      40488      43580: contig of 3093 bp in length
*      43581      43680: gap of unknown length
*      43681      46437: contig of 2757 bp in length
*      46438      46537: gap of unknown length
*      46538      50184: contig of 3647 bp in length
*      50185      50284: gap of unknown length
*      50285      54572: contig of 4288 bp in length
*      54573      54672: gap of unknown length
*      54673      60227: contig of 5555 bp in length
*      60228      60327: gap of unknown length
*      60328      68024: contig of 7697 bp in length
*      68025      68124: gap of unknown length
*      68125      78610: contig of 10486 bp in length
*      78611      78710: gap of unknown length
*      78711      88151: contig of 9441 bp in length
*      88152      88251: gap of unknown length
*      88252      96257: contig of 8006 bp in length
*      96258      96357: gap of unknown length
*      96358      106227: contig of 9870 bp in length
*      106228      106327: gap of unknown length
*      106328      115795: contig of 9468 bp in length
*      115796      115895: gap of unknown length
*      115896      126363: contig of 10468 bp in length
*      126364      126463: gap of unknown length
*      126464      137189: contig of 10726 bp in length
*      137190      137289: gap of unknown length
*      137290      146378: contig of 9089 bp in length
*      146379      146478: gap of unknown length
*      146479      161686: contig of 15208 bp in length
*      161687      161786: gap of unknown length
*      161787      176149: contig of 14363 bp in length
*      176150      176249: gap of unknown length
*      176250      196900: contig of 20651 bp in length.

```

FEATURES  
 source  
 1..196900  
 /organism="Mus musculus"  
 /db\_xref="taxon:10090"  
 /clone="RP21-467L12"  
 /clone\_1bp="RP21 mouse PAC library 21"

BASE COUNT 51456 a 43823 c 44608 g 53666 t 3347 others  
 ORIGIN

Query Match 15.1%; Score 187.4; DB 2; Length 196900;  
 Best Local Similarity 73.5%; Pred. No. 1e-33;  
 Matches 239; Conservative 0; Mismatches 86; Indels 0; Gaps 0;

```

QY 112 TGTAGCTTCTGGCTCTGTAATGAATGAAAGAGCCCAAGATGCAAGTCTGAA 171
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 67442 TCTAGCTTCCGATCCAGTATCAGATCATAGAGGCTCTGATGACGCTTAA 67501

QY 172 GGGCTCCAGGCTGCTCACTCACTGACGCTCCAGGCTGGAAGCTCATAGTGGG 231
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 67502 GGACTCAGAGGCTCACTTCACTGACGCTGACCTGACGCTTCTTCAATGTGAC 67561

QY 232 TCTCAGTGACATGTGTGTCTAAGCTCAGGCCCATGAGGCCATCATCAACATGACCG 291
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 67562 TCTTAACCAATATGAGTGTGAGTGTACACCAACCAAGACCATCATCAACAAACCG 67621

QY 292 CTTACACCTCTAGAGGTACGACGAGGCGGGAACCTTCACTTCGAGATGATCATCCACA 351
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 67622 CTTACACCTATGCCAGTTTACACACACACTGACAGGTTCTATCCGATGATCATTCATGA 67681

QY 352 TGTGAGCCCGATGATTCGAGGAGCATCATGAGAGCTCCAGAGAGTGCCTGCATGG 411
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 67682 TGTGACAGCCGATGATTCGAGGATCCGTCATGATGACCTGACGAGAACCAAGCTGAGTTGG 67741

QY 412 ATCTGCTTACCTTACCGTCAAGTT 436
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 67742 ATCTGCTTACCTTACCGTCAAGTT 67766

```





```

repeat_region      /rpt_family="MER34"
                    complement(17633..17969)
                    /evidence=not_experimental
                    /rpt_family="AluSg1"
repeat_region      /evidence=not_experimental
                    complement(18004..18334)
                    /rpt_family="L1m17"
repeat_region      /evidence=not_experimental
                    complement(18335..18632)
                    /rpt_family="HERV17"
exon                /evidence=not_experimental
                    /note="GRAIL, score = 51.000%, comment = good shadow"
                    /evidence=not_experimental
exon                /note="GRAIL, score = 66.000%, comment = good"
                    /evidence=not_experimental
                    complement(18643..24647)
repeat_region      /evidence=not_experimental
                    /rpt_family="HERV17"
                    complement(19228..19361)
exon                /note="MZF, score = 92.8%"
                    /evidence=not_experimental
                    complement(20900..21135)
exon                /note="MZF, score = 51.4%"
                    /evidence=not_experimental
                    complement(21150..21275)
exon                /note="Xpound exon prediction, score = 74% (0%)"
                    /evidence=not_experimental

```

```

Query Match      25.7%; Score 318.6; DB 9; Length 142742;
Best Local Similarity 98.8%; Pred. No. 7e-65;
Matches 321; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

QY 115 AGGTTCTGGGCTCTGTAATGATGATAGAGAGGCCCCAGAGTCAACAGTCCGAGAGG 174
    |||||||
Db 44273 AGGTTCTGGGCTCTGTAATGATGATAGAGAGGCCCCAGAGTCAACAGTCCGAGAGG 44332
QY 175 CTCCAGGCTCGCTTCACTGACACGCTGCCAGGGCTGGAAGCTCATCATGTGGCTCT 234
    |||||||
Db 44333 CTCCAGGCTCGCTTCACTGACACGCTGCCAGGGCTGGAAGCTCATCATGTGGCTCT 44392
QY 235 CAGTGACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 294
    |||||||
Db 44393 CAGTGACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 44452
QY 295 CACCTCTCAGAGTACAGCAGGCGGGAAGTTCACCTCGAGATGATCATCCACATGT 354
    |||||||
Db 44453 CACCTCTCAGAGTACAGCAGGCGGGAAGTTCACCTCGAGATGATCATCCACATGT 44512
QY 355 GGAGCCAGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 414
    |||||||
Db 44513 GGAGCCAGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 44572
QY 415 TGCTTACCTTACGCTCCAGTATGATGATGATGATGATGATGATGATGATGATGATGATG 439
    |||||||
Db 44573 TGCTTACCTTACGCTCCAGTATGATGATGATGATGATGATGATGATGATGATGATGATG 44597

```

```

RESULT 8
LOCUS      HS21C080      340000 bp      DNA      linear      PRI 24-MAY-2000
DEFINITION Homo sapiens chromosome 21 segment HS21C080.
ACCESSION AL163280 AF001735 BA000005
VERSION    AL163280.2 GI:7717369
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 340000)
AUTHORS    Hattori,M., Fujiyama,A., Taylor,T.D., Watanabe,H., Yada,T.,
            Park,H.S., Toyoda,A., Ishii,K., Totoki,Y., Choi,D.K., Soeda,E.,
            Ohki,M., Takagi,T., Sakaki,Y., Taudien,S., Blechschmidt,K.,

```

# TITLE JOURNAL

## COMMENT

Polley,A., Menzel,U., Delabar,J., Kumpf,K., Lehmann,R.,  
 Patterson,D., Reichwald,K., Rump,A., Schillhabel,M., Schudy,A.,  
 Zimmermann,W., Rosenthal,A., Kudo,H., Shibusaki,K., Kawasaki,K.,  
 Aakawa,S., Shintani,A., Sasaki,T., Nagamine,K., Mitsuyma,S.,  
 Antonarakis,S.E., Minoshima,S., Shimizu,N., Nordstiek,G.,  
 Hornischer,K., Brandt,P., Scharfe,M., Schoen,O., Desario,A.,  
 Reichelt,J., Kauer,G., Bloeker,H., Ranser,J., Beck,A., Klages,S.,  
 Hennig,S., Riesselmann,L., Dagand,E., Wehmeyer,S., Borzym,K.,  
 Gardiner,K., Mizetic,D., Francis,F., Lehrach,H., Reinhardt,R. and  
 Vasp,M.L.

Direct Submission  
 Submitted (05-MAY-2000) The Chromosome 21 Mapping and Sequencing  
 Consortium: \* RIKEN Genomic Sciences Center, Human Genome Research  
 Group \* Institute of Molecular Biotechnology, Genome Analysis \*  
 Keio University School of Medicine, Dept. of Molecular Biology \*  
 GFE, Dept. of Genome Analysis \* Max-Planck Institute for Molecular  
 Genetics (addresses see below)

The Chromosome 21 Mapping and Sequencing Consortium consists of  
 \* RIKEN Genomic Sciences Center, Human Genome Research Group, \*  
 Sagamihara 228-8555, Japan,  
 \* e.mail: sakaki@gsc.riken.go.jp/  
 \* URL: http://hgp.gsc.riken.go.jp/  
 and  
 \* Institute of Molecular Biotechnology, Genome Analysis, \*  
 Beutenbergstrasse 11, D-07745 Jena, Germany,  
 \* e.mail: gscj-submit@genome.imb-jena.de  
 \* URL: http://genome.imb-jena.de/  
 and  
 \* Keio University School of Medicine, Dept. of Molecular Biology, \*  
 Tokyo 160-8582, Japan,  
 \* e.mail: shimizu@mb.med.keio.ac.jp/  
 \* URL: http://adenine.dmb.med.keio.ac.jp/  
 and  
 \* GFE, Dept. of Genome Analysis,  
 Mascheroder Weg 1, D-38124 Braunschweig, Germany, \* e.mail:  
 info.genomegfbf.de  
 \* URL: http://genome.gfbf.de/  
 and  
 \* Max-Planck Institute for Molecular Genetics,  
 Innestrasse 73, D-14195 Berlin, Germany,  
 \* e.mail: info-chr21@molgen.mpg.de  
 \* URL: http://chr21.rz-berlin.mpg.de/  
 Location/Qualifiers  
 1. 340000  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="21"  
 /map="21q22.3"  
 <1.125946  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="21"  
 /map="21q22.3"  
 /clone="P16019, 5' partial"  
 /clone\_lib="RPC11,3-5 PAC library"  
 /note="Accession No. AF121897"  
 73410.243533  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="21"  
 /map="21q22.3"  
 /clone="P70124"  
 /clone\_lib="RPC11,3-5 PAC library"  
 /note="Accession No. AF064860"  
 224137..3340000  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="21"  
 /map="21q22.3"  
 /clone="P206A10, 3' partial"  
 /clone\_lib="RPC11,3-5 PAC library"  
 /note="Accession No. AF121782"  
 286628..3340000

```

repeat_region complement(140. .415)
/rpt_family="MLT2E"
/evidence-not_experimental
repeat_region complement(68. .881)
/evidence-not_experimental
/rpt_family="MER58A"
exon complement(1078. .1162)
/note="GRAIL, score = 86.000%, comment = excellent shadow"
/evidence-not_experimental
repeat_region 1114. .1403
/evidence-not_experimental
/rpt_family="MLT1I"
repeat_region 1481. .1603
/evidence-not_experimental
/rpt_family="L2"
exon 1576. .1710
/note="MZEf, score = 66.1%"
/evidence-not_experimental
1576. .1710
/note="GRAIL, score = 99.000%, comment = excellent"
/evidence-not_experimental
repeat_region complement(1693. .1741)
/evidence-not_experimental
/rpt_family="MIR"
repeat_region complement(1780. .2326)
/evidence-not_experimental
/rpt_family="MLT1E"
exon complement(1834. .1955)
/note="GRAIL, score = 50.000%, comment = good shadow"
/evidence-not_experimental
2629. .2831
/evidence-not_experimental
/rpt_family="AlusX"
repeat_region 3012. .3122
/evidence-not_experimental
/rpt_family="MLT1J"
repeat_region 3123. .3478
/evidence-not_experimental
/rpt_family="MLT1J"
repeat_region 3479. .3618
/evidence-not_experimental
/rpt_family="THE1B"
repeat_region 4674. .4781
/evidence-not_experimental
/rpt_family="MLT1J"
exon complement(3502. .3540)
/note="GRAIL, score = 65.000%, comment = good shadow"
/evidence-not_experimental
4674. .4781
/note="GRAIL, score = 42.000%, comment = marginal"
/evidence-not_experimental
4712. .4749
/note="Xpound exon prediction, score = 70% (0%)"
/evidence-not_experimental
5385. .6104
/evidence-not_experimental
/rpt_family="HERVL"
exon 6682. .6751
/note="MZEf, score = 95.1%"
/evidence-not_experimental
6746. .6751
/note="Genscan, score = 1.83%, comment = Initial_exon 6 bp.
frame: 1 phase: 0"
/evidence-not_experimental
6901. .7339
/evidence-not_experimental
repeat_region 7347. .7457
/rpt_family="MLT1C"
repeat_region 7347. .7457
/evidence-not_experimental
/rpt_family="MLT1C"
repeat_region complement(7561. .7696)
/evidence-not_experimental
/rpt_family="MIR"
repeat_region complement(7819. .8220)
/evidence-not_experimental
/rpt_family="MLT1J"

```

---

```

exon 8097. .8119
/note="GRAIL, score = 45.000%, comment = marginal"
/evidence-not_experimental
repeat_region complement(8738. .9232)
/evidence-not_experimental
/rpt_family="MLT1C"
exon complement(9273. .9420)
/note="GRAIL, score = 71.000%, comment = good"
/evidence-not_experimental
exon 9290. .9371
/note="GRAIL, score = 81.000%, comment = excellent shadow"
/evidence-not_experimental
9966. .10041
/note="homology = 100.00%, score = 38, counts = 2"
/evidence-not_experimental
repeat_region 10244. .10664
/rpt_type=tandem
/rpt_family="MLT1C"
repeat_region 10665. .11028
/evidence-not_experimental
/rpt_family="MLT1F"
repeat_region 11318. .11417
/evidence-not_experimental
/rpt_family="L1MC/D"
repeat_region 11503. .11818
/evidence-not_experimental
/rpt_family="Alus9"
exon complement(11525. .11777)
/note="MZEf, score = 79.4%"
/evidence-not_experimental
repeat_region complement(12346. .12827)
/evidence-not_experimental
/rpt_family="MLT1C"
repeat_region 12902. .13180
/evidence-not_experimental
/rpt_family="Alus9"
exon complement(13057. .13161)
/note="MZEf, score = 76.1%"
/evidence-not_experimental
repeat_region complement(13226. .13364)
/evidence-not_experimental
/rpt_family="L1MC2"
repeat_region complement(13613. .13908)
/evidence-not_experimental
/rpt_family="AlusX"
repeat_region complement(14317. .14614)
/evidence-not_experimental
/rpt_family="L1P3A"
exon complement(14962. .15036)
/note="MZEf, score = 93%"
/evidence-not_experimental
repeat_region 15255. .15299
/evidence-not_experimental
/rpt_family="L1P3A"
exon complement(15469. .15497)
/note="Xpound exon prediction, score = 62% (0%)"
/evidence-not_experimental
16045. .16768
/evidence-not_experimental
/rpt_family="MER21A"
exon complement(16555. .16655)
/note="GRAIL, score = 54.000%, comment = good"
/evidence-not_experimental
repeat_region 16823. .16850
/evidence-not_experimental
/rpt_family="MER34"
repeat_region complement(16851. .17208)
/evidence-not_experimental
/rpt_family="THE1A"
repeat_region 17209. .17632
/evidence-not_experimental

```

```

RESULT 6
AX380404 1195 bp DNA linear PAT 18-MAR-2002
LOCUS Sequence 9 from Patent WO200710.
DEFINITION AX380404
ACCESSION AX380404
VERSION AX380404.1 GI:19575334
KEYWORDS
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1 Welcher, A.A., Sarmiento, U.M., Schultz, H.J. and Chute, H.T.
AUTHORS B7-like molecules and uses thereof
JOURNAL Patent: WO 0200710-A 9 03-JAN-2002;
Amgen, Inc. (US)
FEATURES
source location/Qualifiers
1..1195
CDS
/organism="Mus musculus"
/db_xref="taxon:10090"
53..1165
/note="unnamed protein product"
/protein_start=1
/protein_id="CAD28220.1"
/db_xref="GI:19575335"
/translation="MEGSRDVLAVLIIAQLTASGSSVOIEGPONVLYKDESAH
NCTVTHGWLKMTLNMVYSLTQGPITNNRFTYASNSDSELIIDVOPS
DSGVSQSLONSHGFCGSAFLVQNGTLNPSNNLIVTEGPNCTCYAGMTSLPDI
SMELVPSHSSYNSFLPGNEMRWLVLDLPGLGTLNCAELDLQASKSLTVDL
TYVQPPDSIGSGPALPTMAIILAVAFSLIILIVLITFCSCASRRESESTY
QNEIRKSAMRTKADPETKSKGKENTGSSDEAARATASLPPPSAEVSLPEKSS
SLPYQLNHQHPATHPRVSEDIASPKRVNTLV"
BASE COUNT 313 a 304 c 291 g 287 t
ORIGIN
Query Match 30.7%; Score 380.6; DB 6; Length 1195;
Best Local Similarity 62.4%; Pred. NO. 1.1e-79;
Matches 702; Conservative 0; Mismatches 354; Indels 69; Gaps 4;
QY 115 AGGTTCTGGGCTCTGTAATGATGATGAGAGCCGCCAGATGCAACAGCTGGAAGG 174
DB 109 AGCTCCGGATCCAGTATGATGATGAGAGGCTCTCAGATATTAACAGCTTAAAGGA 168
QY 175 CTCGAGGCTGCTCACTGACGACGCTCCGAGGCTGGAAGCTCATGTGGCTCT 234
DB 169 CTCAGAGGCTCATTCAAGTACGACGCTGACGCTGGAAGCTTCTCATGTGGACTCT 228
QY 235 CAGTGAATGTGTGTGTAAGCGTCAGGCCCATGAGCCCATCTCATCAACATGACCGCTT 294
DB 229 TAACCAATGTGTGTGTGTAAGCTGACACCAAGACCATCATCAACCAACCGCTT 288
QY 295 CACCTTCAGAGTACGACGAGGCGGGAACCTCACTCGAGATGATCATCAATGT 354
DB 289 CACTATGACGATGACGACGACGACGACGACGACGACGACGACGACGACGACGACGAC 348
QY 355 GGAAGCCAGTGTGTGGGGAACATGACGACGCTCCAGAACAGTGGCTGATGATC 414
DB 349 GCAAGCCAGTGTGTGGGGAACGCTGCAATGACGACGCTCCAGAACAGCCTTATGATC 408
QY 415 TGCTTACTTACCTGCAAGTATGAGAGGAGCTTCTCATCTCCAGTGTATCTTGTAGT 474
DB 409 TGCTTACTTCTCACTGCAAGTATGAGAGGAGCTTCTCATCTCCAGTGTATCTTGTAGT 468
QY 475 CGGTGAGATGAGATCTTGAAGTACTTCTCACTCACTCACTCACTCACTCACTCACTCA 534
DB 469 CACTGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 528
QY 535 TATTTCCTGGAGGCTGCTCTCTGCTGACGACATTCAGCTATTTATTTGTTCCGAGCC 594
DB 529 TATTTCCTGGAGGCTGAGGTTCCCTGAGGACATTCAGTATTAATTCCTTCTGAGACC 588

```

```

QY 595 CAGGACCTTCAAGTGCAGTACATCTGCTGTGACCCCAAGAGCAATGGACTTT 654
DB 589 GGGCACTTTATVAGAGGCTTGTGCTGACCTACACACCTGGGCAAGGGACCTT 648
QY 655 GACTTGGGCTGCTACCTGAGAGGCTGAGAGGCGGCAAGCTGCAACTGAAATCTCAC 714
DB 649 GACTTGTGTGCTGAGAGGCTGAGAGGCTGAGAGGCGGCAAGCTGCAACTGAGC 708
QY 715 TGTATTTGGTGTGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGG 774
DB 709 TGTGTTGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAG 744
QY 775 TTTACCGAGTTTACGTTTCTTATTCCTGCTGCTGAGAGGCAAGTGTGACTGACAG 834
DB 745 -----AGGCGAGAGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGG 792
QY 835 CACCATGCTTGTGAGGCGGAGGCTGACTTACATATGAGGCTGAGGCTGAGGCTGAG 894
DB 793 TTTCTGCTGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAG 843
QY 895 TTTGTTGCTGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAG 954
DB 844 -----TTGTCCTGCTGAGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 899
QY 955 TGTATTCATTTTCAAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1014
DB 900 CTGCAAACTAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 945
QY 1015 AAGTGAAGTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1074
DB 946 AAGTGAAGTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1005
QY 1075 TTTCTGCTGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAG 1134
DB 1006 TTTCTGCTGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAG 1059
QY 1135 TTTCTGCTGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAG 1194
DB 1060 TTTCTGCTGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAG 1119
QY 1195 TAAATGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTGAG 1239
DB 1120 TGACATGCGCAGCTGCTGAGAGGCTGAGAGAGTGAATGTGACTTATGTGA 1164

```

RESULT 7  
 AF121782 142742 bp DNA linear PRI 02-FEB-1999  
 LOCUS Homo sapiens chromosome 21q22.3 PAC 206A10, complete sequence.  
 DEFINITION AF121782  
 ACCESSION AF121782.1 GI:4210991  
 VERSION  
 KEYWORDS HTG.  
 SOURCE Homo sapiens.  
 ORGANISM Homo sapiens.  
 Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE  
 1 (bases 1 to 142742)  
 Taubien, S., Dagand, E., Hildmann, T., Nordsiek, G., Drescher, B.,  
 Schatke, R., Weber, J., Schilling, M., Menzel, U., Vespö, M. L. and  
 Rosenthal, A.  
 TITLE Direct Submission  
 JOURNAL Biotechnology, Beutenbergstrasse 11, Jena 07745, Germany  
 FEATURES  
 source location/Qualifiers  
 1..142742  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="21"  
 /map="21q22.3"  
 /clone="PAC 206A10"  
 3..118  
 /evidence="not experimental"  
 /rpt\_family="Mir"

```

Db 694 ATATCAAGTTTACCGAGTTAGTTTTCATTCCTACTGGGGCAAGTGGACTTGG 753
QY 826 ACTAGCAGGACCATGCTTCTGACGCCGAGCTGACTTCAATACGCTGCTGCTG 885
Db 754 ACTAGCAGGACCATGCTTCTGACGCCGAGCTGACTTCAATACGCTGCTGCTG 813
QY 886 CCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 945
Db 814 CCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 873
QY 946 AAGAGATTTGCTATTCATTTCAAAAGAAATCTGAAAAGAGAGCAAAAGAAAC 1005
Db 874 AAGAGATTTGCTATTCATTTCAAAAGAAATCTGAAAAGAGAGCAAAAGAAAC 933
QY 1006 TGAACAGAAAGTGAAGATGAAAACCTCGGCTACATTCAGATGACAAAAGACACAGA 1065
Db 934 TGAACAGAAAGTGAAGATGAAAACCTCGGCTACATTCAGATGACAAAAGACACAGA 993
QY 1066 AACGCTTCCTCCCTCCCAATCTGTGAATCCAGATCCGTAACAAAGAAACAGTAG 1125
Db 994 CACGCTTCCTCCCTCCCAATCTGTGAATCCAGATCCGTAACAAAGAAACAGTAG 1053
QY 1126 CTGTGGCCCTCCTCACCAGCGGCTGATCAACGTCACCCAGGCCACAGTCAATCACA 1185
Db 1054 CTGTGGCCCTCCTCACCAGCGGCTGATCAACGTCACCCAGGCCACAGTCAATCACA 1113
QY 1186 GGCCTTTTAACTGCGCAGCTCTGAGAAAGTCAATATCAACTGTAGTAG 1240
Db 1114 GGCCTTTTAACTGCGCAGCTCTGAGAAAGTCAATATCAACTGTAGTAG 1168

RESULT 5
AX380402 1139 bp DNA linear PAT 18-MAR-2002
LOCUS AX380402
DEFINITION Sequence 7 from Patent WO0200710.
ACCESSION AX380402
VERSION AX380402.1 GI:19575332
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1
AUTHORS Welcher, A.A., Sarmiento, U.M., Schultz, H.J. and Chute, H.T.
TITLE B7-like molecules and uses thereof.
JOURNAL Patent: WO 0200710-A 7 03-JAN-2002;
Amgen, Inc. (US)
FEATURES
source
1. .1139
Location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
1. .1134
CDS
1. .1134
/note="unnamed protein product"
/codon_start=1
/protein_id="CAD28219.1"
/db_xref="GI:19575333"
/translation="MTAGAMENRDPGSSGNVTEGPONARVILKSOARFCTVSOG
WKLIMALSDMYLVSRMEPIITNDRTSQRIDGGLTSEKTIHNPESGNTKRC
SLQNSRLHGSAYLTQVGEELFIPSVNLVAENEPEVCLPSHWRLPDISWELGL
VSHSYTFVPEPESDLOSAYSIATLPOSNGTULCVATWSLAKRSATVNLIVIRPO
DTGGGNGINGVSLPSLSESLPTMGVIGLGLATLLPTCTLTTRCCGCRRCGQ
NCCRCGCCRRKRRGNLKRROTKLRKQVEKGTPTTOMNRPTQPLSLPVPNPV
ILNKETVAVALLSGILNHPGQVTHRLLLIMPVLRNSYIDL"
BASE COUNT 290 a 300 c 283 g 266 t
ORIGIN
Query Match 85.8%; Score 1064; DB 6; Length 1139;
Best Local Similarity 97.2%; Pred. No. 5.4e-242;
Matches 1102; Conservative 0; Mismatches 10; Indels 22; Gaps 1;
QY 106 AGAAGCTGTAGCTTCGGCTGTGTAATGAAGTCAAGAGCCCGACAGTCAACAGT 165
111 1

```

```

Db 27 AGACCCACCCGGGTCTGGGCTGTGTAATGAAGTCAATAGAGGCCCCCAAAATGC.AAGAT 86
QY 166 CCGAAGGGGCTCCCGAGCTCGCTTCACTGACCGCTTCCCGAGGGCTGGAAGCTATATAT 225
Db 87 CCGAAGGGGCTCCCGAGCTCGCTTCACTGACCGCTTCCCGAGGGCTGGAAGCTATATAT 146
QY 226 GTGGGCTCTCAGTGCATGATGTGGTGAAGCTGACAGGCCATGAGGCCATATCATCAACA 285
Db 147 GTGGGCTCTCAGTGCATGATGTGGTGAAGCTGACAGGCCATGAGGCCATATCATCAACA 206
QY 286 TGAACGCTTCACCTCTCAGAGGTACGACAGCGGCGGAACTTCACCTCGAGATGATCAT 345
Db 207 TGAACGCTTCACCTCTCAGAGGTACGACAGCGGCGGAACTTCACCTCGAGATGATCAT 266
QY 346 CCACAAATGTGAGGCCAGTGCATGCGGGGAACTTCAGATGACACCTCCAGAACAGTGGCT 405
Db 267 CCACAAATGTGAGGCCAGTGCATGCGGGGAACTTCAGATGACACCTCCAGAACAGTGGCT 326
QY 406 GCATGATCTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTAA 465
Db 327 GCATGATCTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTAA 386
QY 466 TCTTGTAGTCTGCTGAGAAATGAACCTTGTGAAGTACTTGTACCTCAGACCTGAGACCG 525
Db 387 TCTTGTAGTCTGCTGAGAAATGAACCTTGTGAAGTACTTGTACCTCAGACCTGAGACCG 446
QY 526 GCTCCCGGATATTTCTCTGGGAGCTGGTCTCTGGTCAAGCTTCAAGCTATTTTGT 585
Db 447 GCTCCCGGATATTTCTCTGGGAGCTGGTCTCTGGTCAAGCTTCAAGCTATTTTGT 506
QY 586 TCCGGAGCCGAGGACCTTCAAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAG 645
Db 507 TCCGGAGCCGAGGACCTTCAAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAGTGCAG 566
QY 646 TGGGACTTTGACTTGGTGGTGCCTGAGAGAGCCTGAGAGGCCCGCAAGTGTCAACTGT 705
Db 567 TGGGACTTTGACTTGGTGGTGCCTGAGAGAGCCTGAGAGGCCCGCAAGTGTCAACTGT 626
QY 706 AATCTCACTGTGATTCGGTGTCCCAAGACCTGAGAGTGTATTAATTTCCAGGTGT 765
Db 627 AATCTCACTGTGATTCGGTGTCCCAAGACCTGAGAGTGTATTAATTTCCAGGTGT 686
QY 766 ATATCAAGTTTACCGAGTGTAGTTTTCATTTGCTTACCTTGGGCAAGTGTGACTTGG 825
Db 687 ATATCAAGTTTACCGAGTGTAGTTTTCATTTGCTTACCTTGGGCAAGTGTGACTTGG 746
QY 826 ACTAGCAGGACCATGCTTCTGACGCCGAGCTGACTTCAATACGCTGCTGCTG 885
Db 747 ACTAGCAGGACCATGCTTCTGACGCCGAGCTGACTTCAATACGCTGCTGCTGCTG 806
QY 886 CCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 945
Db 807 CCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 866
QY 946 AAGAGATTTGCTATTCATTTCAAAAGAAATCTGAAAAGAGAGCAAAAGAAAC 1005
Db 867 AAGAG-----GAAATCTGAAAAAGAGAGCAAAAGAAAC 904
QY 1006 TGAACAGAAAGTGAAGATGAAAACCTCGGCTACATTCAGATGACAAAAGACACAGA 1065
Db 905 TGAACAGAAAGTGAAGATGAAAACCTCGGCTACATTCAGATGACAAAAGACACAGA 964
QY 1066 AACGCTTCCTCCCTCCCAATCTGTGAATCCAGATCCGTAACAAAGAAACAGTAG 1125
Db 965 AACGCTTCCTCCCTCCCAATCTGTGAATCCAGATCCGTAACAAAGAAACAGTAG 1024
QY 1126 CTGTGGCCCTCCTCACCAGCGGCTGATCAACGTCACCCAGGCCACAGTCAATCACA 1185
Db 1025 CTGTGGCCCTCCTCACCAGCGGCTGATCAACGTCACCCAGGCCACAGTCAATCACA 1084
QY 1186 GGCCTTTTAACTGCGCAGTCTGAGAAAGTCAATATCAACTGTAGTAG 1239
Db 1085 GGCCTTTTAACTGCGCAGTCTGAGAAAGTCAATATCAACTGTAGTAG 1138

```

QY 356 GAGCCAGTATTTGGGGAGACATGATGACGCTCCAGAACAGTGGCTGCATGATCT 415  
 DB 291 GAGCCAGTATTTGGGGAGACATGATGACGCTCCAGAACAGTGGCTGCATGATCT 350  
 QY 416 GCTTACCTTACCGTCCAGTATGAGAGAGTGTTCATTCCTCCAGTAACTTATCT 475  
 DB 351 GCTTACCTTACCGTCCAGTATGAGAGAGTGTTCATTCCTCCAGTAACTTATCT 410  
 QY 476 GCTGAGATGAACCTTGTGAAGTACTGTCTACCTCCACACTGAGCCGGCTCCGGAT 535  
 DB 411 GCTGAGATGAACCTTGTGAAGTACTGTCTACCTCCACACTGAGCCGGCTCCGGAT 470  
 QY 536 ATTTCCTGGAGCTCGCTCTCTCTGTCAGCCATTCAGCTATTTATTTGTTCCGAGCC 595  
 DB 471 ATTTCCTGGAGCTCGCTCTCTCTGTCAGCCATTCAGCTATTTATTTGTTCCGAGCC 530  
 QY 596 AGCGACCTTCAAAAGTGCAGTGAAGATCTGCTGACCCCAAGAGAGATGGAGCTTTG 655  
 DB 531 AGCGACCTTCAAAAGTGCAGTGAAGATCTGCTGACCCCAAGAGAGATGGAGCTTTG 590  
 QY 656 ACTTGCCTGAGTACCTGTGAAGAGCCTGAAGCCCGCAAGTGTGCAACTGTAACTCACT 715  
 DB 591 ACTTGCCTGAGTACCTGTGAAGAGCCTGAAGCCCGCAAGTGTGCAACTGTAACTCACT 650  
 QY 716 GTGATTCGCTGCTCCCAAGACACTGAGAGTGTATTAATTTCCAGTGTATTCAGT 775  
 DB 651 GTGATTCGCTGCTCCCAAGACACTGAGAGTGTATTAATTTCCAGTGTATTCAGT 710  
 QY 776 TTACCGATTTAGTCTTTTCTATGCTGCTGCTGAGGCAAGTGTGAGTGTGAGTACGACG 835  
 DB 711 TTACCGATTTAGTCTTTTCTATGCTGCTGAGGCAAGTGTGAGTGTGAGTACGACG 770  
 QY 836 ACCATGCTTGTGACGCGCAGCTGTACTTCTACATACGCTGCTGCTGCTGCTGCTGCT 895  
 DB 771 ACCATGCTTGTGACGCGCAGCTGTACTTCTACATACGCTGCTGCTGCTGCTGCTGCT 830  
 QY 896 TGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 955  
 DB 831 TGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 890  
 QY 956 CGTATTCATTTCAAAAGAAATCTGAAGAAAGAGAAAGAAAGAAAGAAAGAAAGAAAG 1015  
 DB 891 CGTATTCATTTCAAAAGAAATCTGAAGAAAGAGAAAGAAAGAAAGAAAGAAAGAAAG 950  
 QY 1016 AGTGAATGAATGAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1075  
 DB 951 AGTGAATGAATGAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1010  
 QY 1076 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1135  
 DB 1011 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1070  
 QY 1136 CCTGACGAGGCGGCTGATCAAGTCAAGCCAGGCGAGCAAGTCAATCCAGAGCTTTCT 1195  
 DB 1071 CCTGACGAGGCGGCTGATCAAGTCAAGCCAGGCGAGCAAGTCAATCCAGAGCTTTCT 1130  
 QY 1196 AATTCGCGAGTCTGTGAAGAGTCAATCAACTGTATATAG 1240  
 DB 1131 AATTCGCGAGTCTGTGAAGAGTCAATCAACTGTATATAG 1175

RESULT 4  
 LOCUS AX380398 1168 bp DNA linear PAT 18-MAR-2002  
 DEFINITION Sequence 3 from Patent WO0200710.  
 ACCESSION AX380398  
 VERSION AX380398.1 GI:19575328  
 KEYWORDS  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
 AUHORS Welcher, A.A., Sarmiento, U.M., Schultz, H.J. and Chute, H.T.  
 TITLE B7-1 like molecules and uses thereof  
 JOURNAL Patent: WO 0200710-A 3 03-JAN-2002;  
 Amgen, Inc. (US)

FEATURES  
 source Location/Qualifiers  
 1..1168  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 8..1168  
 /note="unnamed protein product"  
 /codon\_start=1  
 /protein\_id="CAD28217.1"  
 /db\_xref="GI:19575329"  
 /translation="MVGAMENRDPGSGSNEVIEGPQNAVRLKSGQARFNTVSG  
 WKILMALSDVVLVSVPMIEIITNDFTSORYOGGNTSEMIHNHVPDSGNIC  
 SLONSRLHSAVYLVOYMGELFIPSVNLVYVENEPCVTCIPSHWMLPDI  
 VSHSYFVPEPSPDLSAVSLATIPSONGLITLVATWKSIAKASVNTIVTRCO  
 DTGGGINPGLSLPSLGSFLPTMGVGLAGLMTLLTPTCLTIRCCRRRCGC  
 NCCRCCECCRRKGRFRIQFKSEKERTNKETTESGNSGYSNDEKTTDASLP  
 PKSESSDPEORNSCGPHORADOREPRPASHPOASFNLASPERVNTIV"  
 BASE COUNT 299 a 302 c 288 g 279 t  
 ORIGIN

Query Match 90.2%; Score 1119; DB 6; Length 1168;  
 Best Local Similarity 99.1%; Pred. No. 4,7e-255;  
 Matches 1125; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 106 AGAAGCTGTAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 165  
 DB 34 AGAAGCTGTAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 93  
 QY 166 CCGAAGGCTCCAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 225  
 DB 94 CCGAAGGCTCCAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 153  
 QY 226 GTGGGCTCTGAGTGAATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 285  
 DB 154 GTGGGCTCTGAGTGAATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 213  
 QY 286 TGACCGCTTCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 345  
 DB 214 TGACCGCTTCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 273  
 QY 346 CCACATGTGAGGCCAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 405  
 DB 274 CCACATGTGAGGCCAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 333  
 QY 406 GCATGATCTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCT 465  
 DB 334 GCATGATCTGCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCT 393  
 QY 466 TCTTGTAGTCTGCTGAGTGAACCTTGTGAAGTACTGTCTACCTCCACACTGAGCCG 525  
 DB 394 TCTTGTAGTCTGCTGAGTGAACCTTGTGAAGTACTGTCTACCTCCACACTGAGCCG 453  
 QY 526 GCTCCCGGATATTTCTGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 585  
 DB 454 GCTCCCGGATATTTCTGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 513  
 QY 586 TCCGAGGCCAGGCACTTCAAAAGTGAAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 645  
 DB 514 TCCGAGGCCAGGCACTTCAAAAGTGAAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 573  
 QY 646 TGGGACTTTGACTTGGCGGTGCTACCTGGAAGAGCTGGAAGCCCGCAAGTGTGCAACTGT 705  
 DB 574 TGGGACTTTGACTTGGCGGTGCTACCTGGAAGAGCTGGAAGCCCGCAAGTGTGCAACTGT 633  
 QY 706 AAATCTCACTGTGATGGGTGCTCCCAAGACACTGAGAGTGTATTAATATTCAGAGTGT 765  
 DB 634 AAATCTCACTGTGATGGGTGCTCCCAAGACACTGAGAGTGTATTAATATTCAGAGTGT 693  
 QY 766 ATTATCAAGTTTACCGAGTTTATGCTTTTCTATGCTTACTTGGGCAAAAGTTGCACTTGG 825

FEATURES  
source

Location/Qualifiers  
1..2051  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="PLACE6017788"  
/tissue\_type="placenta"  
/clone\_id="PLACE6"  
/note="cloning vector: PME18SFL3"

BASE COUNT 580 a 463 c 474 g 534 t  
ORIGIN

Query Match 90.8%; Score 1126.4; DB 9; Length 2051;  
Best Local Similarity 99.5%; Pred. No. 8.4e-257;  
Matches 1130; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

105 CAGAGCGTGTGGTCTGGTGTATGAGTATGAGAGGCCCCAGATGACACAG 164  
192 CAGGTGGAGCGTGTGGTGTGTATGAGTATGAGAGGCCCCAGATGACACAG 251  
165 TCCTGAAGGGCTCCAGGCTGCTTCAACTGACCGCTCCAGGGCTGAGAGCTCATCA 224  
252 TCCTGAAGGGCTCCAGGCTGCTTCAACTGACCGCTCCAGGGCTGAGAGCTCATCA 311  
225 TGTGGGCTCTCAGTACATGTTGTTGCTTAAAGCTGAGGCCCATGAGCCCATCATCA 284  
312 TGTGGGCTCTCAGTACATGTTGTTGCTTAAAGCTGAGGCCCATGAGCCCATCATCA 371  
285 ATGACCGGCTTCACTCTCAGAGTACAGACCGAGGGGAGGAGCTTCACTGAGAGTATCA 344  
372 ATGACCGGCTTCACTCTCAGAGTACAGACCGAGGGGAGGAGCTTCACTGAGAGTATCA 431  
345 TCACAAATGTGAGCCAGTATTCGGGGAACATCAGATGACAGCCCTCCAGAACAGTCCG 404  
432 TCACAAATGTGAGCCAGTATTCGGGGAACATCAGATGACAGCCCTCCAGAACAGTCCG 491  
405 TGCATGATCTGCTTACCTTACCTGCAAGTTATGGGAGAGCTGTTATTCCTCAGTCTTA 464  
492 TGCATGATCTGCTTACCTTACCTGCAAGTTATGGGAGAGCTGTTATTCCTCAGTCTTA 551  
465 ATCTGTGATGCTGAGATGAGTAACTTGAAGTACTTGTCTACCCACACAGGAGACC 524  
553 ATCTGTGATGCTGAGATGAGTAACTTGAAGTACTTGTCTACCCACACAGGAGACC 611  
525 GGCCTCCCGGATATTCCTGAGAGTCTGCTCTCTGCTGAGCCATTCAGATTAATTTTG 584  
612 GGCCTCCCGGATATTCCTGAGAGTCTGCTCTCTGCTGAGCCATTCAGATTAATTTTG 671  
585 TTCGAGAGCCAGGAGCTTCAAGTGCAGTGCATCTGCTGACCCACACAGACA 644  
672 TTCGAGAGCCAGGAGCTTCAAGTGCAGTGCATCTGCTGACCCACACAGACA 731  
645 ATGGAGCTTGTGCTGCTGAGTCTGCTGAGAGGCTGAGAGCCCGGCAAGTCTGCAATG 704  
733 ATGGAGCTTGTGCTGAGTCTGCTGAGAGGCTGAGAGCCCGGCAAGTCTGCAATG 791  
705 TAAATCTCAGTGTGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 764  
792 TAAATCTCAGTGTGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 851  
765 TATTAATCAAGTTTACGAGTTTAAAGTTTATTCATGCTTACCTTGGGCAAGTTGACTTG 824  
852 TATTAATCAAGTTTACGAGTTTAAAGTTTATTCATGCTTACCTTGGGCAAGTTGACTTG 911  
825 GACTGAGAGGAGCAGTCTGCTGAGCGGAGCTGAGTCTTACATAGCTGCTGCTGCT 884  
912 GACTGAGAGGAGCAGTCTGCTGAGCGGAGCTGAGTCTTACATAGCTGCTGCTGCT 971  
885 GCGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 944  
972 GCGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1031  
945 AAGAGGATTTCTGATTCATTAATTTCAAAAGAAATCTGAAAAGAGAGCAAAAGAAA 1004

Db 1032 AAGAGGATTTCTGATTCATTAATTTCAAAAGAAATCTGAAAAGAGAGCAAAAGAAA 1091  
1005 CTGAGACAGAAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 1064  
1092 CTGAGACAGAAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 1151  
1065 AAACCGCTTCTCCCTCCCAAAATCTGTAATTCAGTATCTGTAATTCAGTATCTGTAATTC 1124  
1152 AAACCGCTTCTCCCTCCCAAAATCTGTAATTCAGTATCTGTAATTCAGTATCTGTAATTC 1211  
1125 GCTGTGGCCCTCTCAGACAGGCGGTGATCAGCTGACCCAGGCGGAGGAGGAGGAGGAG 1184  
1212 GCTGTGGCCCTCTCAGACAGGCGGTGATCAGCTGACCCAGGCGGAGGAGGAGGAGGAG 1271  
1185 AGGCTTCTTAAATTCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1240  
1272 AGGCTTCTTAAATTCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1327

RESULT 3  
AX380396 1175 bp DNA linear PAT 18-MAR-2002  
LOCUS  
DEFINITION Sequence 1 from Patent WO0200710.  
ACCESSION AX380396  
VERSION AX380396.1 GI:19575326  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE  
1  
AUTHORS Welch A.A., Sarmiento, U.M., Schultz, H.J. and Chute, H.T.  
TITLE B7-like molecules and uses thereof  
JOURNAL Patent: WO 0200710-A 1 03-JAN-2002;  
Amgen, Inc. (US)

FEATURES  
source  
Location/Qualifiers  
1..1175  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
27..1175  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="CAD28216.1"  
/db\_xref="GI:19575327"  
/translation="MGIVFLHSGSGNEVIEPONATVILKSGARFNCYISQGWLI  
MMALSDMVLVSRPMEPIITNDRTSORDOGNFTSEMLIHNEPDSGNIRCSLON  
SRHLSAYITVOYMEELTPSYNLIYAERDEYCLSHWRLLPDISNEIGLIYSHS  
STFVDEPDLDSAVSTIALVTPQSMGTLTCAVTKSLARKSATVNLVIRCPDPTG  
GINPEVLSLPSLPSLPTWGVGLAGTMLLPCTLTIRCCCRRCGCCNCCC  
RCDFCCRRRGRFRIOFKSEKERNKETETESGNSGNSVNDKKTDTASLPKSC  
ESSDEPORSNCGPPIHORADQPPPPASHPOASFNILASPEKVSNTTVV"

BASE COUNT 295 a 307 c 286 g 287 t  
ORIGIN  
Query Match 90.6%; Score 1123.4; DB 6; Length 1175;  
Best Local Similarity 99.9%; Pred. No. 4.3e-256;  
Matches 1124; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

116 GGTCTGGGCTGTGTATGAGTCTATGAGAGGCCCCAGAAATGCAACACTCTCGAAGGCG 175  
51 GGTCTGGGCTGTGTATGAGTCTATGAGAGGCCCCAGAAATGCAACACTCTCGAAGGCG 110  
176 TCCAGAGCTGCTTCAACTGACCGCTGCTCCAGAGGCTGGAAGCTCATCATGTTGGGCTTC 235  
111 TCCAGAGCTGCTTCAACTGACCGCTGCTCCAGAGGCTGGAAGCTCATCATGTTGGGCTTC 170  
236 AGTGACATGTTGTGCTTAAGCTCAGAGCCATGAGAGCCCATCATCAATGACCGCTTC 295  
171 AGTGACATGTTGTGCTTAAGCTCAGAGCCATGAGAGCCCATCATCAATGACCGCTTC 230  
296 ACCTCTCAGAGGATGACGACGAGGCGGAGACTTACCTCGAGATGATCATCCAAATGTG 355  
231 ACCTCTCAGAGGATGACGACGAGGCGGAGACTTACCTCGAGATGATCATCCAAATGTG 290

Amgen, Inc. (US)  
 Location/Qualifiers  
 1.1240  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 80.1240  
 CDS  
 /note="unnamed protein product"  
 /codon\_start=1  
 /protein\_id="CAD28218.1"  
 /db\_xref="GI:19575331"  
 /translation="MERHLITVPEAVGSGSNEYIEGPONATVKGSGQARFNCTVSG  
 WKLMALSDMYLVLSRPMPEITITNDPESRISQRTDQGNFTSEMIHNVEPSDGNIR  
 SLONSRJHGSAYLVIVQVDELTPSVNLVVAENPEVETLPSHMTALPDISWELIL  
 VSHSYTFEPEPSDLOSVAISIALTPDSNGLTCVATWMSLKARKSATLVIVIRCPQ  
 DTGGGINIPGVLSLPSLGFSLPTWVGVLGTLGMLLPTCELTITRCCCRKCGC  
 NCCRCFCCKRRKGFRIQFQKSEKTEKTEKTESGNSGNSGNSDEKTEETASLP  
 PKCESSDPQORNSGCPHQRADORPRASHPQASFNLASPEKVSNTTV"

BASE COUNT 318 a 319 c 305 g 298 t  
 ORIGIN

Query Match 100.0%; Score 1240; DB 6; Length 1240;  
 Best Local Similarity 100.0%; Pred. No. 8.7e-284;  
 Matches 1240; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGGTGTGATCCAGCAACAGTGTGATCACTTCTTCAAGCTGCTCAACAGCAACCAT 60  
 DB 1 AGGTGTGATCCAGCAACAGTGTGATCACTTCTTCAAGCTGCTCAACAGCAACCAT 60  
 OY 61 AACCTGTGCTTGAACAAATGAAAGAGCATTTGCTCAGGTTCCAGAGCTGTAGGTTG 120  
 DB 61 AACCTGTGCTTGAACAAATGAAAGAGCATTTGCTCAGGTTCCAGAGCTGTAGGTTG 120  
 OY 121 TGGGTCTGTATATAGTATAGAGAGCCGCCAGATGCAACAGTCTGAAAGGCTTCCA 180  
 DB 121 TGGGTCTGTATATAGTATAGAGAGCCGCCAGATGCAACAGTCTGAAAGGCTTCCA 180  
 OY 181 GGCCTGCTTCACTGCAACCGCTCCCAAGGGCTGSAAGCTATATATGAGGCTCTCACTGA 240  
 DB 181 GGCCTGCTTCACTGCAACCGCTCCCAAGGGCTGSAAGCTATATATGAGGCTCTCACTGA 240  
 OY 241 CATGTGTGCTTGAAGCTGAGGCCCATGAGCCCATCATCAACATGACCGCTTCACTCT 300  
 DB 241 CATGTGTGCTTGAAGCTGAGGCCCATGAGCCCATCATCAACATGACCGCTTCACTCT 300  
 OY 301 TCAGAGGTAGACAGGGGGGAGAACTTCACTGAGATGATCATCAATGTGGAGCC 360  
 DB 301 TCAGAGGTAGACAGGGGGGAGAACTTCACTGAGATGATCATCAATGTGGAGCC 360  
 OY 361 CAGTATTCGGGGGAAATCATGATGACAGCTCCAGAAACAGTGGCTGATGATCTGCTTA 420  
 DB 361 CAGTATTCGGGGGAAATCATGATGACAGCTCCAGAAACAGTGGCTGATGATCTGCTTA 420  
 OY 421 CCTTACCGTCCAAAGTATGAGAGAGCTTTCATTCAGTGTAACTTGTAGTCTGCTGA 480  
 DB 421 CCTTACCGTCCAAAGTATGAGAGAGCTTTCATTCAGTGTAACTTGTAGTCTGCTGA 480  
 OY 481 GAATGAACCTTGAATTAATCTGTCTACCTGACAGTCCAGCCGCTCCCGGATATTTC 540  
 DB 481 GAATGAACCTTGAATTAATCTGTCTACCTGACAGTCCAGCCGCTCCCGGATATTTC 540  
 OY 541 CTGGAGCTGCTGCTCTGCTGACCAATTCATATATTTTGTTCGGAGCCGACGCA 600  
 DB 541 CTGGAGCTGCTGCTCTGCTGACCAATTCATATATTTTGTTCGGAGCCGACGCA 600  
 OY 601 CCTTCAAGAGTGAAGAGCTCTGCTGCTGACCCCAAGAGCAATGAGACTTTGACTTG 660  
 DB 601 CCTTCAAGAGTGAAGAGCTCTGCTGCTGACCCCAAGAGCAATGAGACTTTGACTTG 660  
 OY 661 CGTGTACTCTGGAAGAGCTGGAAGGCGGCAAGTCTGCAACGTAAATCTCACTGTGAT 720  
 DB 661 CGTGTACTCTGGAAGAGCTGGAAGGCGGCAAGTCTGCAACGTAAATCTCACTGTGAT 720  
 OY 721 TCGGTGTCCCAAGACACTGAGAGTGTATTAATATTCAGAGTGTATTCAGATTAC 780

DB 721 TCGGTGTCCCAAGACACTGAGAGTGTATTAATATTCAGAGTGTATTCAGATTAC 780  
 OY 781 GAGTTTAAAGTTTTCATTTGCTTCACTTGGGCAAGTGTGACTGAGAGGACCAT 840  
 DB 781 GAGTTTAAAGTTTTCATTTGCTTCACTTGGGCAAGTGTGACTGAGAGGACCAT 840  
 OY 841 GCTTTCAGAGCGGAGCTGATACCTTCAATAGCTCTGCTGCGCCGCTTGTG 900  
 DB 841 GCTTTCAGAGCGGAGCTGATACCTTCAATAGCTCTGCTGCGCCGCTTGTG 900  
 OY 901 TGGCTGCAACTGCTGCTGCGCTTGTGTTCTGCTCTGAAGAAAAGAGATTGCTAT 960  
 DB 901 TGGCTGCAACTGCTGCTGCGCTTGTGTTCTGCTCTGAAGAAAAGAGATTGCTAT 960  
 OY 961 TCAATTTCAAAAGAAATCTGAAAAGAGAAAGCAAAAGAACTGAGACAGAAAGTGG 1020  
 DB 961 TCAATTTCAAAAGAAATCTGAAAAGAGAAAGCAAAAGAACTGAGACAGAAAGTGG 1020  
 OY 1021 AATGAAAACCTCGGCTGACAAATTCAGATGACAAAAGACAGAAACCGCTTCTCC 1080  
 DB 1021 AATGAAAACCTCGGCTGACAAATTCAGATGACAAAAGACAGAAACCGCTTCTCC 1080  
 OY 1081 TCCCAATCTCTGTAATCCAGTATCTCTGACAAAGAAACAGTACTGTGCGCTCTCA 1140  
 DB 1081 TCCCAATCTCTGTAATCCAGTATCTCTGACAAAGAAACAGTACTGTGCGCTCTCA 1140  
 OY 1141 CCAGCGGGGTGATCAACGTCACCCAGCCAGCAAGTCAACAGAGCTTTCTTTAATCT 1200  
 DB 1141 CCAGCGGGGTGATCAACGTCACCCAGCCAGCAAGTCAACAGAGCTTTCTTTAATCT 1200  
 OY 1201 GGCAGTCTCTGAGAAGTGTAGTAATACACTGTAGTATAG 1240  
 DB 1201 GGCAGTCTCTGAGAAGTGTAGTAATACACTGTAGTATAG 1240

RESULT 2  
 AK092516  
 LOCUS  
 DEFINITION  
 Homo sapiens cDNA FLJ35197 fls, clone PLACE6017788, highly similar to IGSP5.  
 ACCESSION  
 AK092516  
 VERSION  
 AK092516.1 GI:21751130  
 KEYWORDS  
 Oligo capping; fls (full insert sequence).  
 SOURCE  
 Homo sapiens Placenta cDNA to mRNA, clone\_1lb.PLACE6  
 clone:PLACE6017788.  
 ORGANISM  
 Homo sapiens  
 Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE  
 1  
 Kawakami, B., Sugiyama, A., Takemoto, M., Sugiyama, T., Irie, R., Otsuki, T., Sato, H., Wakamatsu, A., Ishii, S., Yamamoto, J., Isono, Y., Kawai-Hio, Y., Saito, K., Nishikawa, T., Kimura, K., Yamashita, H., Matsuo, K., Nakamura, Y., Sekine, M., Kikuchi, H., Kanda, K., Wagaitsuma, M., Murakawa, K., Kanehori, K., Takahashi-Fujii, A., Oshima, A., Suzuki, Y., Sugano, S., Nagahari, K., Masuno, Y., Negai, K. and Isogai, T.  
 NEDO human cDNA sequencing project  
 TITLE  
 NEDO human cDNA sequencing project  
 JOURNAL  
 Unpublished  
 REFERENCE  
 2 (bases 1 to 2051)  
 Isogai, T. and Yamamoto, J.  
 Direct Submission  
 Submitted (04-JUL-2002) Takao Isogai, FLJ Project(HRI Team); 2-6-7  
 Kazusa-Kamatari, Kisarazu, Chiba 292-0812, Japan  
 (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)  
 NEDO human cDNA sequencing project supported by Ministry of Economy, Trade and Industry of Japan; cDNA full insert sequencing: Research Association for Biotechnology (RAB); cDNA library construction: Helix Research Institute (HRI) (supported by Japan Key Technology Center etc.); 5'- & 3'-end one pass sequencing: RAB, HRI, and Biotechnology Center, National Institute of Technology and Evaluation; clone selection for full insert sequencing: HRI and RAB; annotation: HRI and RAB.

GenCore version 5.1.4\_p5\_4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 28, 2003, 23:25:03 ; Search time 3424.45 Seconds  
(without alignments)

10538.186 million cell updates/sec

Title: US-09-729-264-5

Sequence: 1 agtgtgtgagtcacgccaaca.....gtaatacaactgtagtatag 1240

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 4109280

```
Minimum DB seq length: 0
Maximum DB seq length: 20000000000
```

Post-processing:	Minimum Match	0%
	Maximum Match	100%

Listing first 45 summaries

Database :

1:	gb_ba:	*
2:	gb_hbg:	*
3:	gb_in:	*
4:	gb_dom:	*
5:	gb_ov:	*
6:	gb_pat:	*
7:	gb_ph:	*
8:	gb_pl:	*
9:	gb_pr:	*
10:	gb_ro:	*
11:	gb_rts:	*
12:	gb_sy:	*
13:	gb_un:	*
14:	gb_y1:	*
15:	em_ba:	*
16:	em_fun:	*
17:	em_hum:	*
18:	em_in:	*
19:	em_mu:	*
20:	em_om:	*
21:	em_of:	*
22:	em_ov:	*
23:	em_pat:	*
24:	em_ph:	*
25:	em_pl:	*
26:	em_ro:	*
27:	em_rts:	*
28:	em_un:	*
29:	em_v1:	*
30:	em_hbg_hum:	*
31:	em_hbg_inv:	*
32:	em_hbg_other:	*
33:	em_hbg_mus:	*
34:	em_hbg_pln:	*
35:	em_hbg_rod:	*
36:	em_hbg_mam:	*
37:	em_hbg_vrt:	*
38:	em_sy:	*
39:	em_hbgo_hum:	*
40:	em_hbgo_mus:	*
41:	em_hbgo_other:	*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	1240	100.0	1240	6	AX380400	AX380400 Sequence
2	1126.4	90.8	2051	6	AK092516	AK092516 Homo sapi
3	1123.4	90.6	1175	6	AX380386	AX380386 Sequence
4	1119	90.2	1168	6	AX380398	AX380398 Sequence
5	1064	85.8	1139	6	AX380402	AX380402 Sequence
6	380.6	30.7	1195	6	AX380404	AX380404 Sequence
7	318.6	25.7	142742	9	AF1211782	AF1211782 Homo sapi
8	318.6	25.7	340000	9	HS21C080	AL163280 Homo sapi
9	187.4	15.1	196900	2	AC020851	AC020851 Mus muscu
10	185.6	15.0	754	6	AX380408	AX380408 Sequence
11	185.6	15.0	895	6	AX380406	AX380406 Sequence
12	185.6	15.0	1556	10	BC004606	BC004606 Mus muscu
13	176.4	14.2	175861	2	AC120346	AC120346 Mus muscu
14	119	9.6	40205	9	AF045430	AF045430 Homo sapi
15	119	9.6	170121	9	AF064860	AF064860 Homo sapi
16	100	8.1	199665	9	AF064857	AF064857 Homo sapi
17	58.4	4.7	143266	2	AC067790	AC067790 Homo sapi
18	58.4	4.7	152276	2	AC112649	AC112649 Homo sapi
19	58.2	4.7	186968	2	AC007917	AC007917 Homo sapi
20	58.2	4.7	175861	2	AC120346	AC120346 Mus muscu
21	58.2	4.7	196900	2	AC020851	AC020851 Mus muscu
22	56.6	4.6	16427	9	HS063332	U63332 Human super
23	56.2	4.5	163295	2	AC078808	AC078808 Homo sapi
24	56.2	4.5	205933	3	AC117381	AC117381 Homo sapi
25	55.4	4.5	53908	2	AC120145	AC120145 Mus muscu
26	55	4.4	1061	9	HSCGACG	AJ000501 Homo sapi
27	55	4.4	123576	9	AC015969	AC015969 Homo sapi
28	55	4.4	206059	9	AC127383	AC127383 Homo sapi
29	54.2	4.4	138000	2	AC079127	AC079127 Homo sapi
30	54.2	4.4	157743	2	AC067887	AC067887 Homo sapi
31	54.2	4.4	183000	2	AC025134	AC025134 Homo sapi
32	53.8	4.3	63692	9	AL603750	AL603750 Human DNA
33	53.8	4.3	160541	2	AL359271	AL359271 Homo sapi
34	53.8	4.3	206187	2	AC021172	AC021172 Homo sapi
35	53.4	4.3	73925	2	AP005626	AP005626 Homo sapi
36	53.4	4.3	164235	9	AC016074	AC016074 Homo sapi
37	53	4.3	178052	2	AC118358	AC118358 Rattus no
38	52.8	4.3	138685	2	AC017582	AC017582 Drosophill
39	52.8	4.3	166249	3	AC093502	AC093502 Drosophill
40	52.8	4.3	185404	3	AC104703	AC104703 Drosophill
41	52.8	4.3	341319	3	AE003536	AE003536 Drosophill
42	52.6	4.2	143501	9	AC104383	AC104383 Homo sapi
43	52.6	4.2	146836	9	AC019317	AC019317 Homo sapi
44	52.4	4.2	44768	9	AL589649	AL589649 Human DNA
45	52.4	4.2	166337	9	AC091559	AC091559 Homo sapi

## ALIGNMENTS

RESULT 1	AX380400	LOCUS	AX380400	1240 bp	DNA	linear	PAT 18-MAR-2002
DEFINITION	AX380400	Sequence	5 from Patent WO0200710.				
ACCESSION	AX380400						
VERSION	AX380400.1	GI:19575330					
KEYWORDS							
SOURCE	human.						
ORGANISM	Homo sapiens						
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;						
	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.						
REFERENCE	1	Welcher, A.A., Sarmiento, U. M., Schultze, H.J. and Chute, H.T.					
AUTHORS		B7-like molecules and uses thereof					
TITLE		Patent: WO 0200710-A 5 03-JAN-2002;					
JOURNAL							





